<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<html>
 <body>
  <pmc-articleset>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Clin Microbiol Rev
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Clin. Microbiol. Rev
      </journal-id>
      <journal-id journal-id-type="hwp">
       cmr
      </journal-id>
      <journal-id journal-id-type="pmc">
       cmr
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       CMR
      </journal-id>
      <journal-title-group>
       <journal-title>
        Clinical Microbiology Reviews
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0893-8512
      </issn>
      <issn pub-type="epub">
       1098-6618
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25810418
      </article-id>
      <article-id pub-id-type="pmc">
       4402954
      </article-id>
      <article-id pub-id-type="publisher-id">
       00102-14
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/CMR.00102-14
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Reviews
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East Respiratory Syndrome Coronavirus: Another Zoonotic Betacoronavirus Causing SARS-Like Disease
       </article-title>
       <alt-title alt-title-type="running-head">
        Middle East Respiratory Syndrome Coronavirus
       </alt-title>
       <alt-title alt-title-type="short-authors">
        Chan et al.
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          Jasper F. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e53">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lau
         </surname>
         <given-names>
          Susanna K. P.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e76">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          To
         </surname>
         <given-names>
          Kelvin K. W.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e105">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Vincent C. C.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e131">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Woo
         </surname>
         <given-names>
          Patrick C. Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e151">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          Kwok-Yung
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
        <xref ref-type="bio" rid="d35e171">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        State Key Laboratory of Emerging Infectious Diseases and Research Centre of Infection and Immunology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        Carol Yu Centre for Infection, Department of Microbiology, The University of Hong Kong, Hong Kong Special Administrative Region, China
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Kwok-Yung Yuen,
        <email>
         kyyuen@hku.hk
        </email>
        .
       </corresp>
       <fn fn-type="other">
        <p>
         <bold>
          Citation
         </bold>
         Chan JFW, Lau SKP, To KKW, Cheng VCC, Woo PCY, Yuen K-Y. 25 March 2015. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev doi:
         <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/CMR.00102-14">
          10.1128/CMR.00102-14
         </ext-link>
         .
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        25
       </day>
       <month>
        3
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <month>
        4
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       28
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       465
      </fpage>
      <lpage>
       522
      </lpage>
      <permissions>
       <copyright-statement>
        Copyright © 2015, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri content-type="pdf" xlink:href="zcm002152507465.pdf">
      </self-uri>
      <abstract>
       <title>
        SUMMARY
       </title>
       <p>
        The source of the severe acute respiratory syndrome (SARS) epidemic was traced to wildlife market civets and ultimately to bats. Subsequent hunting for novel coronaviruses (CoVs) led to the discovery of two additional human and over 40 animal CoVs, including the prototype lineage C betacoronaviruses,
        <named-content content-type="genus-species">
         Tylonycteris
        </named-content>
        bat CoV HKU4 and
        <named-content content-type="genus-species">
         Pipistrellus
        </named-content>
        bat CoV HKU5; these are phylogenetically closely related to the Middle East respiratory syndrome (MERS) CoV, which has affected more than 1,000 patients with over 35% fatality since its emergence in 2012. All primary cases of MERS are epidemiologically linked to the Middle East. Some of these patients had contacted camels which shed virus and/or had positive serology. Most secondary cases are related to health care-associated clusters. The disease is especially severe in elderly men with comorbidities. Clinical severity may be related to MERS-CoV's ability to infect a broad range of cells with DPP4 expression, evade the host innate immune response, and induce cytokine dysregulation. Reverse transcription-PCR on respiratory and/or extrapulmonary specimens rapidly establishes diagnosis. Supportive treatment with extracorporeal membrane oxygenation and dialysis is often required in patients with organ failure. Antivirals with potent
        <italic>
         in vitro
        </italic>
        activities include neutralizing monoclonal antibodies, antiviral peptides, interferons, mycophenolic acid, and lopinavir. They should be evaluated in suitable animal models before clinical trials. Developing an effective camel MERS-CoV vaccine and implementing appropriate infection control measures may control the continuing epidemic.
       </p>
      </abstract>
      <counts>
       <fig-count count="10">
       </fig-count>
       <table-count count="12">
       </table-count>
       <equation-count count="0">
       </equation-count>
       <ref-count count="345">
       </ref-count>
       <page-count count="58">
       </page-count>
       <word-count count="46818">
       </word-count>
      </counts>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Ecancermedicalscience
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Ecancermedicalscience
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       ecancermedicalscience
      </journal-id>
      <journal-title-group>
       <journal-title>
        ecancermedicalscience
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1754-6605
      </issn>
      <publisher>
       <publisher-name>
        Cancer Intelligence
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32256705
      </article-id>
      <article-id pub-id-type="pmc">
       7105343
      </article-id>
      <article-id pub-id-type="doi">
       10.3332/ecancer.2020.1022
      </article-id>
      <article-id pub-id-type="publisher-id">
       can-14-1022
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Russell
         </surname>
         <given-names>
          Beth
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Moss
         </surname>
         <given-names>
          Charlotte
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          George
         </surname>
         <given-names>
          Gincy
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Santaolalla
         </surname>
         <given-names>
          Aida
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff5">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Cope
         </surname>
         <given-names>
          Andrew
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Papa
         </surname>
         <given-names>
          Sophie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         2
        </xref>
        <xref ref-type="aff" rid="aff4">
         4
        </xref>
        <xref ref-type="aff" rid="aff6">
         **
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Van Hemelrijck
         </surname>
         <given-names>
          Mieke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         1
        </xref>
        <xref ref-type="aff" rid="aff6">
         **
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        Translational Oncology and Urology Research, King’s College London, London, UK
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        Guy’s and St. Thomas NHS Foundation Trust, London, UK
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        Centre for Rheumatic Diseases, King’s College London, London, UK
       </aff>
       <aff id="aff4">
        <label>
         4
        </label>
        School of Cancer and Pharmaceutical Sciences, King’s College London, London, UK
       </aff>
       <aff id="aff5">
        <label>
         *
        </label>
        All authors contributed equally.
       </aff>
       <aff id="aff6">
        <label>
         **
        </label>
        Both senior authors contributed equally.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="c1-can-14-1022">
        <bold>
         Correspondence to:
        </bold>
        Mieke Van Hemelrijck
        <email>
         mieke.vanhemelrijck@kcl.ac.uk
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        27
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       14
      </volume>
      <elocation-id>
       1022
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © the authors; licensee
        <italic>
         e
        </italic>
        cancermedicalscience.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0">
        <license-p>
         <!--CREATIVE COMMONS-->
         This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0">
          http://creativecommons.org/licenses/by/3.0
         </ext-link>
         ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <sec>
        <title>
         Background
        </title>
        <p>
         Cancer and transplant patients with COVID-19 have a higher risk of developing severe and even fatal respiratory diseases, especially as they may be treated with immune-suppressive or immune-stimulating drugs. This review focuses on the effects of these drugs on host immunity against COVID-19.
        </p>
       </sec>
       <sec sec-type="methods">
        <title>
         Methods
        </title>
        <p>
         Using Ovid MEDLINE, we reviewed current evidence for immune-suppressing or -stimulating drugs: cytotoxic chemotherapy, low-dose steroids, tumour necrosis factorα (TNFα) blockers, interlukin-6 (IL-6) blockade, Janus kinase (JAK) inhibitors, IL-1 blockade, mycophenolate, tacrolimus, anti-CD20 and CTLA4-Ig.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p>
         89 studies were included. Cytotoxic chemotherapy has been shown to be a specific inhibitor for severe acute respiratory syndrome coronavirus in in vitro studies, but no specific studies exist as of yet for COVID-19. No conclusive evidence for or against the use of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of COVID-19 patients is available, nor is there evidence indicating that TNFα blockade is harmful to patients in the context of COVID-19. COVID-19 has been observed to induce a pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, but there is no evidence of the beneficial impact of IL-6 inhibitors on the modulation of COVID-19. Although there are potential targets in the JAK-STAT pathway that can be manipulated in treatment for coronaviruses and it is evident that IL-1 is elevated in patients with a coronavirus, there is currently no evidence for a role of these drugs in treatment of COVID-19.
        </p>
       </sec>
       <sec>
        <title>
         Conclusion
        </title>
        <p>
         The COVID-19 pandemic has led to challenging decision-making about treatment of critically unwell patients. Low-dose prednisolone and tacrolimus may have beneficial impacts on COVID-19. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFα agents are contraindicated. There is clear evidence that IL-6 peak levels are associated with severity of pulmonary complications.
        </p>
       </sec>
      </abstract>
      <kwd-group>
       <kwd>
        immune modulation
       </kwd>
       <kwd>
        immune suppression
       </kwd>
       <kwd>
        cancer
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        adverse events
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec>
     <title>
      Introduction
     </title>
     <p>
      Since the outbreak of severe acute respiratory syndrome (SARS)-CoV-2 or COVID-19 coronavirus started in China in December 2019, there is increasing evidence that those with existing comorbidities, older age or a compromised immune system are at higher risk of developing severe and even fatal respiratory diseases [
      <xref ref-type="bibr" rid="ref1">
       1
      </xref>
      ]. Cancer and transplant patients are also considered to be in this risk group [
      <xref ref-type="bibr" rid="ref2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="ref3">
       3
      </xref>
      ], especially as they may be treated with immune-suppressive or immune-stimulating drugs.
     </p>
     <p>
      The current review focuses on the effects of immune-suppressive or immune-stimulating drugs on the host immunity against COVID-19. Here, we report a short introduction to each drug, followed by a summary of the results from the identified studies for each relative drug.
     </p>
     <p>
      We hypothesise that the drugs selected will likely be categorised into one of two groups: 1) those that may be harmful for patients and put them at risk of increased morbidity/mortality associated with COVID-19 infection and 2) those that may be used to treat the immunopathology associated with severe persistent viral infection. The clinical impact of this review is, thus, twofold. It aims to identify which drugs clinicians should be thinking about taking patients off to protect them from increased harm from COVID-19 and also which drugs could be potentially beneficial in the fight against the disease.
     </p>
     <p>
      This review covers the information available today. As the COVID-19 pandemic progresses, there is an opportunity and responsibility to collect prospective data using established randomised controlled trial involving drugs of interest and cohort-based translational studies.
      <list list-type="order">
       <list-item>
        <p>
         All cytotoxic chemotherapy
        </p>
       </list-item>
       <list-item>
        <p>
         Low-dose steroids and non-steroidal anti-inflammatory drugs (NSAIDs)
        </p>
       </list-item>
       <list-item>
        <p>
         Any tumour necrosis factor (TNF) blocker
        </p>
       </list-item>
       <list-item>
        <p>
         interlukin-6 (IL-6) blockade
        </p>
       </list-item>
       <list-item>
        <p>
         Janus kinase (JAK) inhibitors
        </p>
       </list-item>
       <list-item>
        <p>
         IL-1 blockade
        </p>
       </list-item>
       <list-item>
        <p>
         Mycophenolate
        </p>
       </list-item>
       <list-item>
        <p>
         Tacrolimus
        </p>
       </list-item>
       <list-item>
        <p>
         Anti-CD20
        </p>
       </list-item>
       <list-item>
        <p>
         CTLA4-Ig
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec sec-type="methods">
     <title>
      Methods
     </title>
     <p>
      A search was conducted using Ovid MEDLINE and a total of 89 studies were included in this review for 10 different types of immune-suppressing or immune-stimulating drug groups.
      <xref ref-type="table" rid="table1">
       Table 1
      </xref>
      shows the search terms and the number of studies included in the review.
     </p>
    </sec>
    <sec>
     <title>
      Results
     </title>
     <sec>
      <title>
       All cytotoxic chemotherapy
      </title>
      <p>
       Cytotoxic chemotherapy inhibits cell division through multiple mechanisms. It may have therapeutic activity as compounds against corona viral strains. Moreover, cancer patients who have undergone chemotherapy may be at increased risk of developing symptoms of SARS.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        The search yielded 24 results, of which 18 were included (
        <xref ref-type="table" rid="Stable1">
         Supplementary Table 1
        </xref>
        ). Below are key case-reports of interest to highlight:
        <list list-type="bullet">
         <list-item>
          <p>
           Coronavirus was one of the most common viral pathogens identified in paediatric cancer patients undergoing chemotherapy, second to human rhinovirus [
           <xref ref-type="bibr" rid="ref4">
            4
           </xref>
           ]. Viral co-detection was frequent in patients with cancer and acute respiratory infections.
          </p>
         </list-item>
         <list-item>
          <p>
           A brain biopsy was HCoV-OC43-positive by metagenomic next-generation sequencing in the case of a 1-year-old child with pre-B acute lymphoblastic leukaemia [
           <xref ref-type="bibr" rid="ref5">
            5
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           A case of a young woman with stage IIIA breast cancer from 1999 reported that diagnosis of coronavirus following treatment for cancer using a high-dose chemotherapy regimen and autologous bone marrow and stem cell transplantation. The electron microscopy revealed coronavirus pneumonia [
           <xref ref-type="bibr" rid="ref6">
            6
           </xref>
           ]. Coronavirus should be potentially considered in the differential diagnoses of respiratory failure in patients who have undergone high-dose chemotherapy and autologous bone marrow transplantation.
          </p>
         </list-item>
        </list>
       </p>
       <p>
        In addition, some further observations have been made in relation to specific treatments:
        <list list-type="bullet">
         <list-item>
          <p>
           Although HIV protease inhibitors such as lopinavir has been suggested as a low-micromolar inhibitor of MERS-CoV, the different mechanistic classes that HIV and coronavirus fall under meant that there was low affinity for coronavirus strains compared to HIV [
           <xref ref-type="bibr" rid="ref7">
            7
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           The following compounds have been shown to be active
           <italic>
            in vitro
           </italic>
           against the SARS-CoV virus: TNFα-converting enzyme inhibitor (TAPI-2); IFN-α (B/D, mDEF201 by adenovirus 5 vector, CR3014 humanized monoclonal antibody (a neutralising antibody specific for SARS-CoV), recombinant IFN-α2b and type I IFN-β); Interferon inducers (Ampligen and polyinosinic–polycytidylic); therapeutic antibodies (2978/10, equine anti-SARS-CoV F[ab’] and monoclonal antibody 201); attachment inhibitors (Urtica Dioica lectin and griffithsin); host immune system [
           <xref ref-type="bibr" rid="ref8">
            8
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia and were found to be specific inhibitors for the SARS coronavirus [
           <xref ref-type="bibr" rid="ref9">
            9
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           Carbohydrate-binding agents (CBA) may be able to block enveloped viruses other than HIV in their entry process and coronaviruses and influenza viruses are other examples of enveloped viruses that may be highly susceptible to the antiviral action of CBAs [
           <xref ref-type="bibr" rid="ref10">
            10
           </xref>
           ].
          </p>
         </list-item>
         <list-item>
          <p>
           The genome of SARS-CoV encodes five major proteins: the spike protein (S), the envelope protein (E), the membrane glycoprotein (M), and the nucleocapsid protein (N). M and E may help host cells to induce the production of protective IFN-α to fight against the virus. Bananin 1-[3-hydroxy-5-(hydroxymethyl)-2-methyl-4-pyridinyl]-2,8,9-trioxaadamantane-3,5,7-triol acts as zinc (Zn
           <sup>
            2+
           </sup>
           ) chelator and is therefore of interest to target and inhibit immunodeficiency virus type 1 (HIV-1) zinc finger HIV-1 RNA-binding nucleocapsid protein p7 (NCp7). Bananin is converted to bananin 5’-monophosphate (BNP) which together with B6RA (vitamin A-vitamin B6 conjugate) and could inhibit infectious virion encapsidation. Targets of BNP and B6RA has shown to be present also in SARS-associated coronavirus making them possible therapeutic candidates [
           <xref ref-type="bibr" rid="ref11">
            11
           </xref>
           ].
          </p>
         </list-item>
        </list>
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Coronavirus strains were one of the most common viral pathogens identified in paediatric cancer patients undergoing chemotherapy. Patients with pre-B acute lymphoblastic leukaemia and breast cancer who have undergone chemotherapy have reported cases of coronavirus infection. Cytotoxic therapies used in cancer chemotherapy such as 6MP and 6TG have shown to be specific inhibitors for SARS coronavirus in
        <italic>
         in vitro
        </italic>
        studies. However, further
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        studies are required to confirm this, especially in COVID-19. Currently, there is no scientific evidence of the interaction between methotrexate and COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Low-dose steroids and NSAIDs
      </title>
      <p>
       Since the outbreak of the novel COVID-19 infection, various contradictory information has been circulated regarding the potentially negative effect of treating patients with NSAIDs, non-NSAIDs and corticosteroids. NSAIDs work through inhibition of the cyclooxygenase enzymes (COX-1/COX-2), which are involved in the synthesis of key biological mediators. These mediators in turn control inflammation. Corticosteroids are involved in a number of key physiological processes including the immune response and inflammation and low-dose steroids are often prescribed to cancer patients with suppressed immune systems to prevent the development of related auto-immune diseases.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 58 studies were identified from the search terms, of which 13 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable2">
         Supplementary Table 2
        </xref>
        ). Our search did not identify any strong evidence for or against the use of ibuprofen for treatment of COVID-19 specifically. One study did however link SARS-CoV to the downregulation of angiotensin converting enzyme-2 (ACE2) which is upregulated by ibuprofen [
        <xref ref-type="bibr" rid="ref12">
         12
        </xref>
        ]. The authors of this study were investigating the link between the severity of COVID-19 symptoms in patients with asthma and hypertension.
       </p>
       <p>
        The only other study to investigate a non-steroidal anti-inflammatory drug was one which looked at indomethacin [
        <xref ref-type="bibr" rid="ref13">
         13
        </xref>
        ]. This study suggested that indomethacin exhibited potent antiviral activity against canine coronavirus (dramatically inhibiting virus replication and protecting the host cell from virus-induced damage). This activity was also observed against human SARS-CoV at a concentration dose of 1 mg/kg.
       </p>
       <p>
        In general, there appeared to be a few positive results for the use of corticosteroids in viral infections such as SARS-CoV [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        -
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
        ]. Corticosteroids were widely used during the SARS-CoV outbreak due to their known ability to modulate a variety of involved cytokines (including IL-1, IL-6, IL-8, IL-12 and TNFα) [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="ref16">
         16
        </xref>
        ]. Various studies in humans noted that corticosteroids appeared effective in reducing immunopathological damage but concerns centred around the promotion of viral rebound and association with adverse events (including acute respiratory distress syndrome) [
        <xref ref-type="bibr" rid="ref14">
         14
        </xref>
        ]. One laboratory study which treated porcine respiratory coronavirus infected pigs with dexamethasone suggested that one or two doses of the corticosteroid in the acute phase of infection may effectively alleviate early pro-inflammatory response, but prolonged administration may play a role in enhancing viral replication [
        <xref ref-type="bibr" rid="ref18">
         18
        </xref>
        ]. A separate Chinese study, which separated SARS-CoV patients into 4 treatment groups, identified early high-dose steroids in combination with a quinolone as producing the best patient outcomes [
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
        ]. Nevertheless, one review stated that the WHO does not currently recommend corticosteroids in other viral diseases such as Dengue as the ‘glucocorticoid-mediated stimulation of the hypothalamic-pituitaryadrenal axis can also drive lymphocytopenia, or it may promote exaggerated pro-inflammatory responses that eventually cause a worsening of the pathogenic condition’ [
        <xref ref-type="bibr" rid="ref20">
         20
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        The current literature does not give conclusive evidence for or against the use of NSAIDs in the treatment of COVID-19 patients, though there appears to be some evidence that corticosteroids may be beneficial in the treatment of SARS-CoV. However, it is important to note this is not specific to COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       TNFa blocker
      </title>
      <p>
       TNF family of receptors and cytokines is very large and are often the targets for drugs. One example are TNFa inhibitors, which act by supressing the physiologic response to TNFa. TNFa is a pro-inflammatory cytokine involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma. Inhibitors of TNFa may be used in their treatment.
      </p>
      <p>
       Inhibition of TNFa can be achieved with a monoclonal antibody, such as infliximab (Remicade), adalimumab (Humira), certolizumab pegol (Cimzia) and golimumab (Simponi), or with the receptor fusion protein etanercept (Enbrel).
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of three studies were identified, of which two were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable3">
         Supplementary Table 3
        </xref>
        ). The first study was a research letter that suggested that TNFa has been implicated in the severe immune-based pulmonary injury caused by SARS coronavirus, suggesting that TNFa inhibitors could be a potential treatment for the acute respiratory disease syndrome caused by coronavirus [
        <xref ref-type="bibr" rid="ref21">
         21
        </xref>
        ]
       </p>
       <p>
        The second study utilised 22 piglets to assess the efficacy of an anti-TNFa)therapy for endotoxin respiratory diseases and observed that TNFa blockade was not associated with decrease in disease severity [
        <xref ref-type="bibr" rid="ref22">
         22
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Currently, there is no evidence indicating that TNFa blockade is harmful to patients in the context of COVID-19.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       IL-6 blockade
      </title>
      <p>
       IL-6, promptly and transiently produced in response to infections and tissue injuries, contributes to host defence through the stimulation of acute phase responses, hematopoiesis, and immune reactions. Although its expression is strictly controlled by transcriptional and posttranscriptional mechanisms, dysregulated continual synthesis of IL-6 plays a pathological effect on chronic inflammation and autoimmunity [
       <xref ref-type="bibr" rid="ref23">
        23
       </xref>
       ]. For this reason, tocilizumab, a humanized anti-IL-6 receptor antibody was developed. Other approved anti IL-6 drugs are siltuximab (Sylvant) and sarilumab. Several agents are in clinical trials:olokizumab (CDP6038), elsilimomab, BMS945429(ALD518), sirukumab (CNTO 136), CPSI-2364, ALX-0061, clazakizumab, olokizumab, sarilumab, sirukumab, ARGX-109, FE301 and FM101
       <sup>
        .
       </sup>
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 108 studies were identified from the second search strategy, 23 were suitable for inclusion (
        <xref ref-type="table" rid="Stable4">
         Supplementary Table 4
        </xref>
        ). The first search strategy found no hits.
       </p>
      </sec>
      <sec>
       <title>
        IL6 an actor in the pathogenetic mechanisms of the coronavirus infection
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          COVID-19 induces a pro-inflammatory generation and secretion of cytokines including IL-1b and IL-6 via the toll like receptors (TLR) that causes the production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis. Anti-inflammatory cytokines, such as IL1-Ra, IL-37 or IL-38 could potentially provide relief in both systemic inflammation and fever occurring after infection [
          <xref ref-type="bibr" rid="ref24">
           24
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Cytokine profiles in patients diagnosed with SARS showed marked elevation of T-helper lymphocyte type 1 (Th1) cytokine interferon-gamma (IFN-γ), inflammatory cytokines IL-1β, IL-6 and IL-12 for at least two weeks after disease onset. Children however presented a much milder cytokine and chemokine storm [
          <xref ref-type="bibr" rid="ref16">
           16
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The high levels of IL-6 in the acute stage associated with lung lesions found in SARS patients are activated by the viral nucleocapsid SARS-CoV N protein [
          <xref ref-type="bibr" rid="ref25">
           25
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Over induction of inflammatory cytokine and dysregulation of cytokine signalling has been observed in patients with SARS in comparison with other respiratory viruses including respiratory syncytial virus (RSV), influenza A virus (FluAV), and human parainfluenza virus type 2 (hPIV2). SARS-CoV and RSV induced high levels of IL-6 and RANTES compared with FluAV and hPIV2 [
          <xref ref-type="bibr" rid="ref26">
           26
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The N-protein of SARS-CoV induces pulmonary inflammatory reaction and acute lung injury, which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines. Glucocorticoids could effectively alleviate the pulmonary inflammatory reaction induced by N-protein of SARS-CoV [
          <xref ref-type="bibr" rid="ref15">
           15
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          SARS-CoV does not productively infect human macrophages (Mphi) or dentritic cells (DCs), however it modulates a massive release of IL-6 and IL-12 and compromises the endocytic capacity (e.g., antigen capture capture) of Mphi was significantly compromised [
          <xref ref-type="bibr" rid="ref27">
           27
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS were assessed. The elevation of Th1 cytokine IFN-γ, inflammatory cytokines IL-1, IL-6 and IL-12 and chemokines IL-8, MCP-1 and IP-10 confirmed the activation of Th1 cell-mediated immunity and hyper-innate inflammatory response in SARS through the accumulation of monocytes/macrophages and neutrophils [
          <xref ref-type="bibr" rid="ref17">
           17
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        IL-6 as a potential marker of disease severity in coronavirus infected patients
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          IL-6 blood measurements seem useful to diagnose severe COVID-19 cases. The findings suggest that IL-6 and D-Dimer level can be used to estimate the severity of COVID-19. The optimum critical point of IL-6 in the group was 24.3 pg/ml, which was the upper limit of no severe pneumonia [
          <xref ref-type="bibr" rid="ref28">
           28
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The increased expression of IL-2R and IL-6 in serum is expected to predict the severity of the 2019-nCoV pneumonia and the prognosis of patients [
          <xref ref-type="bibr" rid="ref29">
           29
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The serum levels of IL-6 and CXCL-10 were significantly elevated in MERS-CoV patients who developed severe diseases [
          <xref ref-type="bibr" rid="ref30">
           30
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          A new lethal animal model was characterised for SARS-CoV. Strain v2163 had nine mutations that increased levels of IL-1alpha and IL-6 in mice. The high IL-6 expression was correlated with mortality [
          <xref ref-type="bibr" rid="ref31">
           31
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          SARS vaccination was tested in a murine SARS model. A high level of IL-6 and on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity [
          <xref ref-type="bibr" rid="ref32">
           32
          </xref>
          ]
         </p>
        </list-item>
        <list-item>
         <p>
          Interleukin-6 (IL-6) and IL-8 are key SARS-CoV-induced epithelial cytokines capable of inhibiting the T-cell-priming ability of dendritic cells, a cellular element of the host innate defenses against respiratory infections, leading to an exacerbated inflammatory cascades and severe tissue damage in SARS patients [
          <xref ref-type="bibr" rid="ref33">
           33
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          In patients with a diagnosis of SARS-associated coronavirus infection, there were no significant differences in peak levels of IL-6, IL-8 and TNF
          <bold>
           α
          </bold>
          between patients with and without acute respiratory distress syndrome. However , CRP and TNFα were associated with worse outcomes and might be used as prognostic markers of SARS [
          <xref ref-type="bibr" rid="ref34">
           34
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG were highly elevated in the acute phase sera of Taiwan SARS patients, being IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group. It suggests that an interferon-gamma-related cytokine storm was induced post SARS coronavirus infection [
          <xref ref-type="bibr" rid="ref35">
           35
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          Eight patients with SARS [
          <xref ref-type="bibr" rid="ref36">
           36
          </xref>
          ] were treated with ribavirin, which was not effective in reducing the SARS coronavirus load in three of eight. Elevated levels of interleukin (IL)-6 and IL-8 subsequent to the peak viral load were found in eight and six cases [
          <xref ref-type="bibr" rid="ref37">
           37
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          A cytokine profiling was performed for 110 serum from healthy donors, patients with SARS, patients with severe SARS, and patients with SARS in convalescence. IL6 concentrations were significantly elevated in severe SARS patients, but the IL-6 concentrations were similar in convalescent patients and control subjects which suggested that IL6 is associated with SARS severity [
          <xref ref-type="bibr" rid="ref38">
           38
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          The authors of this study set out to study the inflammatory cytokine profile in children with SARS. They found that the plasma concentrations’ key proinflammatory cytokines, including IL-6, were not substantially increased in any of the patients throughout the course of illness. From this, the authors stated that the cytokine results cast doubt on the liberal use of corticosteroids in paediatric SARS patients [
          <xref ref-type="bibr" rid="ref39">
           39
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Potential targets for therapeutic intervention related to IL6 regulation during infection
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          ADAM-17 regulates IL-6 class switching as a mediator between pro- and anti-inflammatory responses to viral antigenic stimuli in Ebola, SARS-CoV and dengue infections in humans. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery for infections, such as SARS-CoV [
          <xref ref-type="bibr" rid="ref20">
           20
          </xref>
          ]
         </p>
        </list-item>
        <list-item>
         <p>
          SARS-CoV ssRNA is a new therapeutic target given its capacity to cause acute lung injury in mice with a high mortality rate
          <italic>
           in vivo
          </italic>
          experiment suggesting that SARS-CoV specific GU-rich ssRNA plays a very important role in the cytokine storm associated with a dysregulation of the innate immunity [
          <xref ref-type="bibr" rid="ref40">
           40
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p>
          DUSP1 and p38 MAPK are potential therapeutic targets for coronavirus infectious bronchitis virus, given their capability to reduce the production of an excessive amount of IL-6 and IL-8 in the infected cells [
          <xref ref-type="bibr" rid="ref41">
           41
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Potential therapeutic agents that inhibit the infection-induced production of IL6
       </title>
       <list list-type="bullet">
        <list-item>
         <p>
          Pretreatment of primary cultures of human nasal and tracheal epithelial cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E and the infection-induced production of cytokines, including IL-6, IL-8 and IFN-beta. Treatment of the cells with the CD13 inhibitor 2’2’-dipyridyl decreased viral titers. Pretreatment of the cells with a combination of three drugs (glycopyrronium, formoterol and budesonide) exerted additive inhibitory effects on viral titers and cytokine production [
          <xref ref-type="bibr" rid="ref42">
           42
          </xref>
          ].
         </p>
        </list-item>
       </list>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        It has been suggested that the pathogenesis of SARS-CoV is mediated by disproportional immune responses and the ability of the virus to circumvent innate immunity. The COVID-19 infection has also been observed to induce pro-inflammatory cytokine generation and secretion of cytokines, such as IL-6, which dysregulates the local inflammatory responses that have been suggested as partially responsible for the devastating acute respiratory distress syndrome.
       </p>
       <p>
        Moreover, it has been observed that COVID-19 induces high levels of IL-6 for at least 2 weeks after disease onset. Children presented lower levels of cytokine production. IL-6 has been suggested as a potential prognostic marker of COVID-19 disease severity. Different molecules related with the IL6 pathway have been suggested as potential therapeutic targets such as ADAM-17, SARS-CoV ssRNA, DUSP1 and p38 MAPK.
       </p>
       <p>
        Currently, there is no scientific evidence of the beneficial impact of IL-6 inhibitors in the modulation of the COVID-19 infection. Further understanding of the role of IL-6 reduction will be forthcoming as the pandemic progresses and further clinical data becomes available.
        <italic>
         In vitro
        </italic>
        treatment with glycopyrronium, formoterol and budesonide exerted additive inhibitory effects on viral titers and cytokine production human nasal and tracheal epithelial cells.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       JAK inhibitors
      </title>
      <p>
       JAK inhibitors work by inhibiting the activity of one or more of the JAK family of enzymes, including, JAK1, JAK2, JAK3 and TYK3. JAKs interact with signal transducer and activator of transcription proteins (STATs) and the JAK-STAT pathway is central to cellular response to exogenous signals in the immune system. The JAK family of enzymes are responsible for signal transduction and JAK inhibitors play a major role in inhibiting and blocking cytokine release that can contribute to growth of malignant cells in cancer. JAK inhibitors are used in the treatment of cancer and inflammatory diseases such as rheumatoid arthritis [
       <xref ref-type="bibr" rid="ref43">
        43
       </xref>
       ].
      </p>
      <p>
       This review focuses on how the JAK-STAT pathway can be manipulated to reduce viral entry and inflammation in patients with coronavirus. The main targets that the review highlighted were baricitinib (JAK inhibitor), IRE1α (an endoplasmic reticulum stress sensor, leading to an increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3) and combination therapies using tylophorine-based compounds with JAK2 inhibitors.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        Fifteen studies were yielded from the search of which 4 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable5">
         Supplementary Table 5
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <title>
        Baricitinib
       </title>
       <p>
        Baricitinib (Olumiant) is a JAK inhibitor that was approved by the European Medicines Agency in February 2017 for the treatment of moderate-to-severe active rheumatoid arthritis in adults with an inadequate response to one or more disease-modifying anti-rheumatic drugs [
        <xref ref-type="bibr" rid="ref44">
         44
        </xref>
        ]. One study suggested the use of Baricitinib to reduce the viral entry and inflammation caused by 2019-nCoV. Most viruses enter cells through receptor-mediated endocytosis. ACE2, a cell-surface protein expressed on cells in the kidney, blood vessels, heart, and alveola type 2 (AT2) cells in the pulmonary epithelia, may be the receptor that 2019-nCoV uses to infect lung cells. The authors of Richardson
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref45">
         45
        </xref>
        ] suggest that by inhibiting adaptor associated protein kinase 1 (AAK1) receptor that promotes endocytosis involved in ACE2, Baricitinib may reduce both the viral entry and the inflammation in 2019-nCoV patients.
       </p>
      </sec>
      <sec>
       <title>
        IRE1α
       </title>
       <p>
        Inositol-requiring transmembrane kinase/endoribonuclease 1α (IRE1α) is an endoplasmic reticulum stress sensor that leads to increased expression of negative regulators of JAK-STAT, suppressor of cytokine signalling (SOCS)-1 and SOCS-3 [
        <xref ref-type="bibr" rid="ref46">
         46
        </xref>
        ]. Therefore, IRE1α may be a novel target against coronavirus infection requiring further exploration.
       </p>
      </sec>
      <sec>
       <title>
        Tylophorine-based compounds
       </title>
       <p>
        Tylophorine-based compounds are isolated from plants and exert potent anti-coronaviral activities against SARS-CoV and MERS-CoV [
        <xref ref-type="bibr" rid="ref47">
         47
        </xref>
        ]. Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation is a common pro-inflammatory response of host cells to viral infection. Following
        <italic>
         in vitro
        </italic>
        analysis, Yang
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref48">
         48
        </xref>
        ] suggests the use of a combination therapy for SARS-CoV or MERS-CoV, wherein a tylophorine compound known to target transmissible gastroenteritis virus and a JAK2 inhibitor synergise to block the alternative dominant NF-κB activation mediated by JAK2. Therefore, the combination treatment for the inhibition of coronavirus per se, e.g. viral genome replication, and blocking cellular NF-κB activation by coronaviruses, is a promising approach for the development of anti-coronavirals.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Current studies suggest that although there are potential targets in the JAK-STAT pathway that can be manipulated in the treatment for coronaviruses, they are all in early stages and require further
        <italic>
         in vitro
        </italic>
        and
        <italic>
         in vivo
        </italic>
        studies to confirm their therapeutic effects.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       IL-1 blockade
      </title>
      <p>
       IL-1 is a pro-inflammatory cytokine and an important mediator of local and systemic inflammation. Excessive IL-1 release during viral infections can cause lung and tissue inflammation, fever and fibrosis. IL-1 suppression has found to be effective in many inflammatory diseases including rheumatoid arthritis [
       <xref ref-type="bibr" rid="ref24">
        24
       </xref>
       ].
      </p>
      <p>
       It is well established that an over-expression of interleukin-1 is a hallmark of SARS-CoV infection, probably through activation of transcription factor nuclear factor, activator protein 1 and activating factor 2. In COVID-19 specifically, the virus is thought to bind to TLRs which activate the formation of pro-IL-1 and activation of the inflammasome [
       <xref ref-type="bibr" rid="ref24">
        24
       </xref>
       ]. This inflammasome activation is important for the regulation of cells of both the innate and adaptive immune system paving the way for specific immune responses. As part of the inflammasome activation, IL1-b is subsequently produced which mediates the inflammation of the lungs, fever and fibrosis thus causing respiratory complications in the infected host.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 37 studies were identified from the search of which 9 were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable6">
         Supplementary Table 6
        </xref>
        ). Many of the studies were
        <italic>
         in vitro
        </italic>
        studies and repeatedly demonstrated increased IL-1 levels in patients infected with a coronavirus. One study investigated the levels of various inflammatory cytokines in 29, COVID-19 patients in China and compared the levels between general, severe and critically ill groups [
        <xref ref-type="bibr" rid="ref49">
         49
        </xref>
        ]. The authors reported no significant differences in IL-1b levels between the three groups of patients. Another study involving 20 consecutive SARS patients admitted to a Hong Kong hospital identified significantly elevated levels of IL-1β within the first 12, 7 and 5 days following onset of infection [
        <xref ref-type="bibr" rid="ref17">
         17
        </xref>
        ]. Those patients with more severe disease were treated with pulsed methylprednisolone and IL-1β levels returned to normal after 7 days. The seven patients with less severe disease did not receive any dosage of corticosteroids and their cytokine levels returned to normal range levels over the same 7-day time period.
       </p>
       <p>
        A further Chinese study also identified reduced levels of IL-1β following administration of corticosteroids- suggesting inhibition of pro-inflammatory cytokines such as IL-1 may be a beneficial treatment strategy for treatment of SARS [
        <xref ref-type="bibr" rid="ref50">
         50
        </xref>
        ]. A third study, which measured serum cytokine levels in four patient groups including controls, patients with SARS, patients with severe SARS and convalescent SARS patients suggested that longer term treatment (over a period of 7-10 days) with low-dose steroids can alter serum cytokine levels, including IL-1α [
        <xref ref-type="bibr" rid="ref38">
         38
        </xref>
        ].
       </p>
       <p>
        One rat model showed promising results for an IL-1 receptor antagonist which reduced the chemokine expression in infected animals [
        <xref ref-type="bibr" rid="ref51">
         51
        </xref>
        ]. However, this result cannot be generalised for humans. Unfortunately, one study, in which the authors state the ‘demonstrate for the first time that inflammation by coronavirus may be inhibited by anti-inflammatory cytokines belonging to the IL-1 family’, was only available as an abstract [
        <xref ref-type="bibr" rid="ref52">
         52
        </xref>
        ]. Therefore, further evidence or information to back this claim up is not available.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Overall, this review demonstrated that although it is evident that IL-1 is elevated in patients infected with a coronavirus, there is not at present evidence for an established role for IL-1 blockers in the treatment of COVID-19 in humans. The literature did, however, suggest a potential role for low-dose corticosteroids to reduce levels of pro-inflammatory markers, such as IL-1, which are elevated as part of the immune response and may have a role in the severe lung damage associated with human coronaviruses.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Mycophenolate
      </title>
      <p>
       Mycophenolate mofetil (which is a derivative of mycophenolic acid (MPA)) is an immune suppressant, antineoplastic and antiviral mediation. According to the British National Formulary, mycophenolate mofetil is used for the prophylaxis of acute rejection in renal transplantation and is usually used in combination with a corticosteroid and ciclosporin.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        Almost all of the studies investigated MPA as a potential therapy for MERS-CoV due to its anti-viral properties. Six of the 13 selected studies were
        <italic>
         in vitro
        </italic>
        studies, two were
        <italic>
         in vivo,
        </italic>
        one was a clinical example and four were reviews (therefore there was some overlapping of results) (
        <xref ref-type="table" rid="Stable7">
         Supplementary Table 7
        </xref>
        ).
       </p>
      </sec>
      <sec>
       <title>
        In-vitro studies
       </title>
       <p>
        In general, the
        <italic>
         in vitro
        </italic>
        studies looked positive with MPA targeting the papain like proteases of both MERS-CoV and SARS-CoV [
        <xref ref-type="bibr" rid="ref53">
         53
        </xref>
        ,
        <xref ref-type="bibr" rid="ref54">
         54
        </xref>
        ]. The studies found that MPA showed strong inhibition of the virus with a very low IC50 [
        <xref ref-type="bibr" rid="ref55">
         55
        </xref>
        -
        <xref ref-type="bibr" rid="ref57">
         57
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        In vivo study
       </title>
       <p>
        MPA can been used in combination with interferon-beta (IFN-b). One study, which applied this regime in marmosets exhibiting a severe disease resembling human MERS, reported high viral loads with more severe or even fatal disease [
        <xref ref-type="bibr" rid="ref28">
         28
        </xref>
        ]. The authors of this study state that MPA is likely to cause more harm than benefit to MERS patients.
       </p>
      </sec>
      <sec>
       <title>
        Clinical studies
       </title>
       <p>
        According to the review by Mo and Fisher [
        <xref ref-type="bibr" rid="ref58">
         58
        </xref>
        ], MPA monotherapy had not been tested in a clinical setting for the treatment of MERS-CoV. Al Ghamdi
        <italic>
         et al
        </italic>
        [
        <xref ref-type="bibr" rid="ref59">
         59
        </xref>
        ], presented an example where eight patients were treated with MPA for MERS-CoV, seven in combination with IFN-β. All eight of these patients survived, however the review by Mo and Fisher stated that this group of patients had lower Acute Physiology and Chronic Health Evaluation II scores compared with others in the cohort who received a variety of antiviral agents including ribavirin and IFN-a, steroids and antibiotics. Therefore, the results must be interpreted with caution.
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Whilst the
        <italic>
         in vitro
        </italic>
        studies showed promising results for MPA against MERS, the
        <italic>
         in vivo
        </italic>
        studies suggest that its use is likely to cause more harm than benefit and hence is not likely to be useful against coronavirus infections. The clinical studies are too small to confirm or deny any beneficial use for MERS-CoV patients.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Tacrolimus
      </title>
      <p>
       Tacroliumus, also known as fujimycin, envarsus or FK506, is an immunosuppressive drug which is mainly administered after allogeneic organ transplant to lower risk of organ rejection. It’s mechanism of action focusses on inhibition of calcineurin which is involved in the production of IL-2. IL-2 is a cytokine which promotes the development and proliferation of T cells which form a vital component of the human adaptive immune response.
      </p>
      <sec>
       <title>
        Results
       </title>
       <p>
        A total of 18 studies were identified from the search terms, of which three were deemed suitable for inclusion (
        <xref ref-type="table" rid="Stable8">
         Supplementary Table 8
        </xref>
        ).
       </p>
       <p>
        Overall, the literature appeared to suggest a potential role for tacrolimus in the treatment of human coronaviruses. In a case study of two renal transplant recipients who tested positive for MERS CoV, a patient who was being treated with an immunosuppressive regimen of tacrolimus underwent full recovery whilst the other patient (who was not on this treatment regimen) succumbed to the infection [
        <xref ref-type="bibr" rid="ref60">
         60
        </xref>
        ]. The patient who eventually made a full recovery was also treated with antibacterial therapy and a reduced dose of mycophenolate mofetil and it is therefore not possible to conclude that patient recovery due to tacrolimus.
       </p>
       <p>
        The two other included studies were both laboratory studies involving cell line culture. The first investigated pathways of coronavirus viral replication as potential antiviral therapeutic targets [
        <xref ref-type="bibr" rid="ref61">
         61
        </xref>
        ]. Genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identified FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1. Subsequently, the authors investigated whether tacrolimus inhibits viral replication of human coronaviruses. VeroFM cells infected with SARS-CoV and other human coronaviruses were treated with FK506. Results showed that FK506 effectively inhibited viral replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with a reduction in viral titers to undetectable levels. The second study further confirmed this inhibition using novel non-immunosuppressive derivatives of FK506 in the context of HCoV-NL63 at low-micromolar, non-cytotoxic concentrations in cell culture [
        <xref ref-type="bibr" rid="ref62">
         62
        </xref>
        ].
       </p>
      </sec>
      <sec>
       <title>
        Conclusion
       </title>
       <p>
        Overall the small amount of literature available suggests a potential role of FK506 (tacrolimus) as a potent antiviral in the treatment of human coronaviruses. It is important to note, however, that COVID-19 is a novel disease and may have different aetiology and mechanistic action compared to existing strains and to date, this immunosuppressive drug and its derivatives has not been tested in humans. Further study is warranted, both in the clinical setting and laboratory.
       </p>
      </sec>
     </sec>
     <sec>
      <title>
       Anti-CD20
      </title>
      <p>
       No studies were identified for inclusion.
      </p>
     </sec>
     <sec>
      <title>
       CTLA-4 Ig
      </title>
      <p>
       No studies were identified for inclusion.
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      Overall conclusion
     </title>
     <p>
      The rapidly progressing SARS-CoV-2 pandemic has led to challenging decision-making about the treatment of critically unwell patients with the novel viral infection. In parallel, doctors across multiple specialties are making clinical decisions about the appropriate continuation of treatments for patients with chronic illnesses requiring immune-suppressive medication. This systematic review looks to provide guidance from the current available literature.
     </p>
     <p>
      As the COVID-19 pandemic progresses, collective effort to capture data from prospective trials is required. Sponsors of randomized controlled trials recruiting patients randomized to receive immune modulatory drugs that may be affected by COVID-19 should collect data about the disease outcomes and consider interim analysis of potential advantages and disadvantages associated with using one of these medications.
     </p>
     <p>
      Low-dose prednisolone and tacrolimus therapy may have beneficial impacts on the course of SARS-CoV-2. This observation requires further validation. The mycophenolate mofetil picture is less clear, with conflicting data from pre-clinical studies. There is no definitive evidence that specific cytotoxic drugs, low-dose methotrexate for auto-immune disease, NSAIDs, JAK kinase inhibitors or anti-TNFa biological agents are contraindicated. There is evidence that IL-6 peak levels are associated with severity of pulmonary complications. Ongoing studies of blockade of the IL-6 pathway are rational and will hopefully inform practice as the pandemic progresses.
     </p>
    </sec>
    <sec>
     <title>
      Funding declaration
     </title>
     <p>
      We would like to thank our various funders: Guy’s and St Thomas’ Charity, Cancer Research UK (C45074/A26553), and the CRUK King’s Health Partner Centre.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Conflicts of interest
     </title>
     <p>
      The authors have no conflicts of interest to declare.
     </p>
    </sec>
    <back>
     <sec>
      <title>
       Supplementary tables of summarised literature
      </title>
      <table-wrap id="Stable1" position="anchor">
       <label>
        Supplementary Table 1.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19 and cytotoxic chemotherapy.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS1">
            1
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhu
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           COVID-19 complicates the clinical scenario of pulmonary infiltrates in cancer patients. Active treatment against the infection and patient surveillance should be initiated if infectious disease is considered.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS2">
            2
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chemotherapy strategy for colorectal cancer under the outbreak of novel coronavirus pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Li
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Recommendations based on stage of cancer:
           <list list-type="bullet">
            <list-item>
             <p>
              Recurrent metastatic colorectal cancer: low-intensity maintenance therapy
             </p>
            </list-item>
            <list-item>
             <p>
              Patients with tumour changes or higher malignancy still need to receive combined chemotherapy.
             </p>
            </list-item>
            <list-item>
             <p>
              After radical surgery, given the relatively limited benefits of adjuvant chemotherapy, the intensity and duration of treatment can be reduced.
             </p>
            </list-item>
            <list-item>
             <p>
              In the face of patients with febrile tumour chemotherapy, it is necessary to analyse the cause of the fever of the patient.
             </p>
            </list-item>
            <list-item>
             <p>
              Stable disease and good general condition: elect to delay the time of imaging evaluation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS3">
            3
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Nilsson
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sweden
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A one-year-old child with pre-B acute lymphoblastic leukaemia (ALL) developed fatal encephalitis associated with human coronavirus OC43 (HCoV-OC43). During chemotherapy the child had a persistent HCoV-OC43 respiratory infection and later developed progressive encephalitis. Cerebrospinal fluid was negative for pathogens including HCoV-OC43, but a brain biopsy was HCoV-OC43-positive.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS4">
            4
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Barnard and Kumaki
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2011
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-SARS-CoV therapies recently published from 2007 to 2010 reviewed in this paper and the following compounds have been shown to be active in vitro against the virus:
           <break>
           </break>
           TNF-α-converting enzyme inhibitor (TAPI-2); IFN-α (B/D, mDEF201 by adenovirus 5 vector, CR3014 humanised monoclonal antibody, recombinant IFN-α2b and type I IFN-β); Interferon inducers (Ampligen and polyinosinic–polycytidylic);
           <break>
           </break>
           therapeutic antibodies (2978/10, equine anti-SARS-CoV F[ab’] and monoclonal antibody 201); attachment inhibitors (Urtica Dioica lectin and griffithsin); host immune system.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS5">
            5
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A 3-Year Retrospective Study of the Epidemiology of Acute Respiratory Viral Infections in Pediatric Patients With Cancer Undergoing Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Aydin Köker et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Turkey
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Nasopharyngeal aspirates were analysed in patients younger than 21 years with acute respiratory infections.
             </p>
            </list-item>
            <list-item>
             <p>
              Coinfection with 2 viruses was present in 20.5% (45/219) of the episodes.
             </p>
            </list-item>
            <list-item>
             <p>
              Most frequent coinfections of respiratory viruses: 6 cases of HRV+hBoV, 5 of HRV, +AdRV, 4 of PI3+CoV 43, 3 of HRV+CoV 43, 3 of HRV, +IF A/H1N1, 3 of HRV+RSV A/B, and 2 of HRV+EV
             </p>
            </list-item>
            <list-item>
             <p>
              Detected more often in the months of January (16%) and October (15%) than in the other months
             </p>
            </list-item>
            <list-item>
             <p>
              Conclusion: no increase in mortality of cancer patients but cause for significant delays to chemotherapy, which might have an indirect impact on patient survival rates.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS6">
            6
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Frequent Respiratory Viral Infections in Children with Febrile Neutropenia - A Prospective Follow-Up Study
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Söderman
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sweden
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Nasopharyngeal aspirates were collected during 87 episodes of febrile neutropenia in children age 0-18 years
             </p>
            </list-item>
            <list-item>
             <p>
              No symptoms were apparent in four episodes involving RV and one episode involving HCoV
             </p>
            </list-item>
            <list-item>
             <p>
              Persistent HCoV with a median follow-up time of 31 days
             </p>
            </list-item>
            <list-item>
             <p>
              High viral loads were correlated to more symptoms
             </p>
            </list-item>
            <list-item>
             <p>
              Respiratory viruses play an etiologic role in febrile neutropenia in children receiving treatment for a malignancy.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS7">
            7
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Pillaiyar
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The paper focuses on on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003−2015) from all sources, including laboratory synthetic methods, natural products, and virtual screening.
             </p>
            </list-item>
            <list-item>
             <p>
              Conclusion: No coronavirus protease inhibitor has yet successfully completed a preclinical development program
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS8">
            8
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Respiratory Viral Infections in Patients With Cancer or Undergoing Hematopoietic Cell Transplant. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hijano
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Switzerland
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Clinical manifestations vary significantly depending on the type of virus and the type and degree of immunosuppression.
             </p>
            </list-item>
            <list-item>
             <p>
              Risk factors associated with prolonged viral shedding can include viral load, use of steroids, and myeloablative conditioning.
             </p>
            </list-item>
            <list-item>
             <p>
              Mortality associated with coronavirus in HCT recipients was inconclusive. While some studies [
              <xref ref-type="bibr" rid="refS9">
               9
              </xref>
              ] reported no associations, other studies [
              <xref ref-type="bibr" rid="refS10">
               10
              </xref>
              ] reported similar mortality rates in HCT recipients to those observed with other viruses such as RSV, influenza virus, and PIV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS11">
            11
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Progress in Anti-SARS Coronavirus Chemistry, Biology and Chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ghosh et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV proteases are attractive targets for the development of antiviral drugs to reduce viral replication and pathogenicity.
             </p>
            </list-item>
            <list-item>
             <p>
              Glycyrrhizin showed inhibitory activity for SARS-CoV replication but it has high cytotoxicity.
             </p>
            </list-item>
            <list-item>
             <p>
              HIV protease inhibitor nelfinavir, antihelminthic drug niclosamide and antimalarial agent chloroquine have also showed strong inhibitory activity against SARS-CoV replication.
             </p>
            </list-item>
            <list-item>
             <p>
              A human lgG1 form of 80R was found to bind the S1 domain of the SARS-CoV S protein (with a higher affinity comparable to that of ACE2 suggesting that the 80R human monoclonal antibody is a useful viral entry inhibitor for SARS treatment.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS12">
            12
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Alternative screening approaches for discovery of Middle East respiratory syndrome coronavirus inhibitors
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           LaFemina, RL.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Lopinavir is an HIV protease inhibitor.
             </p>
            </list-item>
            <list-item>
             <p>
              Lopinavir has been suggested as a low-micromolar inhibitor of MERS-CoV.
             </p>
            </list-item>
            <list-item>
             <p>
              However, proteases of HIV and coronaviruses fall into different mechanistic classes of proteases.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS13">
            13
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Acute respiratory viral infections in paediatric cancer patients undergoing chemotherapy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Benites
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Brazil
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Paediatric patients with cancer and acute respiratory infection [
              <xref ref-type="bibr" rid="refS14">
               14
              </xref>
              ] and/or fever.
             </p>
            </list-item>
            <list-item>
             <p>
              Coronavirus was identified in 6.8% in the 50 samples of respiratory cases.
             </p>
            </list-item>
            <list-item>
             <p>
              Human rhinovirus (HRV) was the most common viral pathogen, followed by coronavirus, respiratory syncytial virus (RSV), and metapneumovirus, demonstrating the importance of these pathogens in the studied population.
             </p>
            </list-item>
            <list-item>
             <p>
              The prevalence of respiratory viruses was relevant in the infectious episode, with no increase in morbidity and mortality. Viral co-detection was frequent in patients with cancer and ARIs.
             </p>
            </list-item>
            <list-item>
             <p>
              The link of whether severe acute infection was directly related to the type of cancer or viral pathogen was not identified in the study.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS15">
            15
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              6-mercaptopurine (6MP) and 6-thioguanine (6TG) have been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia and were found to be specific inhibitors for the SARS coronavirus.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS14">
            14
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Balzarini, J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Belgium
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Carbohydrate-binding agents (CBA) may be able to block enveloped viruses other than HIV in their entry process and coronaviruses and influenza viruses are other examples of enveloped viruses that may be highly susceptible to the antiviral action of CBAs.
             </p>
            </list-item>
            <list-item>
             <p>
              In HIV, glycan deletions in gp120 delays the spread of virus.
             </p>
            </list-item>
            <list-item>
             <p>
              CBA administration may bring the viral infection under control before glycan deletions occur and the immune system can get involved in the further clearance of the virus.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS16">
            16
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chebotkevich et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Russia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Only abstract available, article in Russian and not accessible.
           <list list-type="bullet">
            <list-item>
             <p>
              Communicable respiratory viruses were investigated in 51 patients as a causative factor of infectious complication in hemoblastosis and myelodepression
             </p>
            </list-item>
            <list-item>
             <p>
              Coronaviruses detected in 13.7%
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS17">
            17
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome [
           <xref ref-type="bibr" rid="refS18">
            18
           </xref>
           ]. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kesel AJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           United Arab Emirates
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              25 test materials including interferon-inducer
             </p>
            </list-item>
            <list-item>
             <p>
              Bananin (BN) was an effective inhibitor of SARS-CoV in cell culture.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS19">
            19
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Huali
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The M and E are play a role in coronaviral particle assembling. Targeting these agents may lead to immune responses by inducing the production of protective IFN-α.
             </p>
            </list-item>
            <list-item>
             <p>
              N, M, and E genes may be used as the targets to prevent SARS-CoV infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS20">
            20
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Keseal AJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Bananin acts as zinc (Zn2+) chelator
             </p>
            </list-item>
            <list-item>
             <p>
              Targets and inhibits zinc finger of HIV-1 RNA-binding nucleocapsid protein p7 (NCp7).
             </p>
            </list-item>
            <list-item>
             <p>
              Bananin is converted to bananin 5’-monophosphate (BNP) which together with B6RA (vitamin A-vitamin B6 conjugate) and could inhibit infectious virion encapsidation.
             </p>
            </list-item>
            <list-item>
             <p>
              Targets of BNP and B6RA have shown to be present also in SARS-associated coronavirus making them possible therapeutic candidates.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS21">
            21
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Coronavirus Pneumonia
           <break>
           </break>
           Following Autologous Bone
           <break>
           </break>
           Marrow Transplantation for
           <break>
           </break>
           Breast Cancer
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Folz and Elkordy
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           1999
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Case report: coronavirus in woman with stage III breast cancer following treatment with hig-dose chemotherapy and autologous bone marrow and stem cell transplant.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable2" position="anchor">
       <label>
        Supplementary Table 2.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and low-dose steroids.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS22">
            22
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fu, Cheng and Wu
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           This review suggests that:
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV S protein can downregulate ACE2
             </p>
            </list-item>
            <list-item>
             <p>
              Loss of pulmonary ACE2 function has been suggested to be associated with acute lung injury; the reduction in ACE2 function can cause dysfunction of the renin-angiotensin system [
              <xref ref-type="bibr" rid="refS23">
               23
              </xref>
              ] and enhance inflammation and vascular permeability.
             </p>
            </list-item>
            <list-item>
             <p>
              ACE2-associated lung injury has been suggested in SARS- CoV infection
             </p>
            </list-item>
            <list-item>
             <p>
              From reading this article the following article was then discovered…
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS24">
            24
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Fang, Karakiulakis and Roth
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Greece
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The expression of ACE2 is substantially increased in patients with type 1 or type 2 diabetes, who are treated with ACE inhibitors and angiotensin II type-I receptor blockers (ARBs). Hypertension is also treated with ACE inhibitors and ARBs, which results in an upregulation of ACE2
           <break>
           </break>
           ACE2 can be increased by thiazolidinediones and ibuprofen. These data suggest that ACE2 expression is increased in diabetes and treatment with ACE inhibitors and ARBs increases ACE2 expression. Consequently, the increased expression of ACE2 would facilitate infection with COVID-19.
           <break>
           </break>
           The authors therefore hypothesise that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS25">
            25
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Drug treatment options for the 2019-new coronavirus (2019- nCoV)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lu
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           No evidence given for or against using ibuprofen only that ‘anti-inflammatory drugs (such as hormones and other molecules)’ are potential therapeutic options for 2019-nCoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS26">
            26
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome: clinical and laboratory manifestations.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lam, Chan, Wong
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Corticosteroid treatment reduced interleukin 8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and IFN-γ-inducible protein-10 (IP-10) concentrations from 5 - 8 days after treatment in SARS patients. These were all inflammatory markers which were remarkably increased in SARS patients. NB. This study is not specifically looking at SARS-CoV2 only at SARS-CoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS27">
            27
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Decoding the enigma of antiviral crisis: Does one target molecule regulate all?
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mahmud-Al-Rafat
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Bangladesh, Germany, Canada, UK and Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           This review article aimed to look at multiple diseases caused by various viruses including Dengue, Ebola and SARS-CoV. They stated that ribavirin (an antiviral) is the most frequently used drug to combat SARS-CoV, and is administered together with corticosteroids.
           <break>
           </break>
           Although immunosuppressive corticosteroid drugs are commonly used in an attempt to reduce fatality rates, the results of clinical trials are not sufficiently satisfactory to approve as an effective class of therapeutic
           <break>
           </break>
           Glucocorticoid-mediated stimulation of the hypothalamic-pituitaryadrenal axis can also drive lymphocytopenia, or it may promote exaggerated pro-inflammatory responses that eventually cause a worsening of the pathogenic condition. (Please note this is not specific for SARS-CoV-19 and is referring to the 3 viral diseases mentioned).
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS28">
            28
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The management of coronavirus infections with particular reference to SARS.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong SS, Yuen KY
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2008
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           HCoV-OC43 and HCoV-229E initial principal pathogens discovered in 1960’s; acute respiratory diseases of less severity and mortality than SARS-CoV which promoted rapid search for effective antiviral treatments.
           <break>
           </break>
           Immunomodulatory agents (primarily corticosteroids) widely used during SARS to avoid excessive tissue damage by cytokine dysregulation but benefit of use not conclusively demonstrated.
           <break>
           </break>
           Multiple studies demonstrated increased plasma viral load with use of corticosteroids (RCT measured plasma viral load at regular intervals in non-intubated cases found higher concentrations of SARS-CoV RNA in week 2/3 of illness compared to patients who received placebo).
           <break>
           </break>
           9.9% of patients in Hong Kong cohort study also suffered opportunitistic infections such as aspergillosis and late sequelae (including avascular osteonecrosis) with corticosteroid use.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS29">
            29
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2008
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Laboratory study which treated porcine respiratory coronavirus infected pigs with corticosteroid dexamethasone as a model for SARS.
           <break>
           </break>
           Goal to define whether corticosteroid treatment altered immunity and lung inflammatory response at cytokine level and how changes correlated with pig lung lesions.
           <break>
           </break>
           Confirmed infection model applicable and resembled SARS.
           <break>
           </break>
           Treatment with dexamethasone suppressed early local IL-6 levels but increased later on in disease. Suggests may decrease inflammation at early infection stage but not later.
           <break>
           </break>
           Results also suggest that dexamethasone induced reduction of IL-6 might play a role in delayed onset of lung lesions but increases of IL-6 at later infection stage may contribute to severity of lung lesions (mimicking delayed onset of disease severity as seen in SARS patients treated with corticosteroids).
           <break>
           </break>
           <bold>
            Overall findings suggest that 1 or 2 doses of dexamethasone in acute phase of infection may effectively alleviate early pro-inflammatory response, but prolonged DEX administration may play role in enhancing viral replication.
           </bold>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS30">
            30
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Indomethacin has a potent antiviral activity against SARS coronavirus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Amici C,
           <break>
           </break>
           Di Caro A, Ciucci A, Chiappa L, Castilletti C, Martella V, Decaro N, Buonavoglia C, Capobianchi MR, Santoro MG
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Italy
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Utilised observation that cyclopentenone cyclooxygenase (COX) metabolites are active against several RNA viruses to investigate effect of COX inhibitor indomethacin on coronavirus replication.
           <break>
           </break>
           Indomethacin is common NSAID.
           <break>
           </break>
           Report describes how indomethacin was unexpectedly found to possess potent antiviral activity against canine coronavirus (dramatically inhibit virus replication and protect the host cell from virus-induced damage).
           <break>
           </break>
           Activity also observed in vivo and against human SARS-CoV.
           <break>
           </break>
           Oral administration of concentration 1mg/kg found to be effective.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS31">
            31
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hao D, He LX, Qu JM, Pan J, Hu BJ, Zhang J, Li ZZ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China (full article only available in Chinese but informative abstract)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Studied pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on inflammatory reaction.
           <break>
           </break>
           Mice treated with dexamethasone.
           <break>
           </break>
           N-protein of SARS-CoV shown to have pathogenicity inducing pulmonary inflammatory reaction and acute lung injury which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines.
           <break>
           </break>
           Glucocorticoids (dexamethasone) demonstrated effectively alleviate pulmonary inflammatory reaction.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS32">
            32
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chihrin S, Loutfy MR
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Canada
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-inflammatory agents heavily utilised during SARS outbreak as it was believed that the development and worsening of the pulmonary disease had inflammatory aetiology and pathogenesis.
           <break>
           </break>
           Immunopathological analysis of 20 SARS patients demonstrated increased Th1 cytokine interferon y and inflammatory cytokines IL-1, IL-6 and IL-12 for &gt; 2 weeks following onset of symptoms.
           <break>
           </break>
           Also observed decrease in viral activity and IgG seroconversion during 2nd week of illness despite general progression of respiratory disease- suggesting respiratory damage is secondary to immune-mediated inflammatory response.
           <break>
           </break>
           Corticosteroids used during SARS outbreak for their ability to module variety of involved cytokines.
           <break>
           </break>
           Numerous papers published outcomes of patients administered corticosteroids (mostly IV hydrocortisone or methylprednisolone) in either early low-dose or pulsed-dose strategies. Most concluded corticosteroids appeared to be effective in reducing immunopathological damage (resulting in improved and rapid resolution of symptoms).
           <break>
           </break>
           Opposition to corticosteroid use centred around use of corticosteroid use in treatment of acute respiratory distress syndrome- concern that corticosteroid treatment may weaken immune response and promote viral rebound. Reports also add evidence to theory.
           <break>
           </break>
           Further opposition includes association with adverse events such as hyperglycaemia, hypokalaemia, hypertension, gastrointestinal haemorrhage and avascular necrosis (AVN).
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS33">
            33
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cinatl J Jr, Michaelis M, Morgenstern B, Doerr HW
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany (needs to be purchased)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Investigated influence of SARS-CoV infection on CXCL8 and CXCL10 in human intestinal epithelial cells.
           <break>
           </break>
           High concentrations of hydrocortisone prevented DNA binding activity of AP-1 and NF-kappabeta and inhibited upregulation of CXCL8 and CXCL10 but did not reduce chemokine expression to basal.
           <break>
           </break>
           Results suggest corticosteroid may be of limited benefit in suppression of chemokine production by SARS-CoV infected cells.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Overproduction of TNF-alpha, IL-1, IL-6 and IL-10 hallmark of viral infection.
           <break>
           </break>
           Investigated inflammatory profiles of patients infected with SARS in Hong Kong hospital.
           <break>
           </break>
           Use of corticosteroids significantly reduced IL-8, MCP-1 and IP-10 concentrations from 5-8 days after treatment.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS35">
            35
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Description and clinical treatment of an early outbreak of severe acute respiratory syndrome [
           <xref ref-type="bibr" rid="refS18">
            18
           </xref>
           ] in Guangzhou, PR China.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, Yin Z, Huang S, Deng Z, Wei M, Xiong J, Hawkey PM
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Patients treated in different methods. 2 groups of 4 received steroids (in form of methyl prednisolone).
           <break>
           </break>
           Early use of high-dose steroids appeared to help recovery from SARS.
           <break>
           </break>
           Early use of high-dose steroids in combination with a quinolone plus azithromycin gave the best outcome with improvement of clinical signs and symptoms, decreased incidence of ARDs and mechanical ventilation as well as mortality.
           <break>
           </break>
           Hypothesised that steroids may help by reducing the damaging effect of the local inflammatory response.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable3" position="anchor">
       <label>
        Supplementary Table 3.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/other coronavirus strains and TNF blockers.
         <italic>
          (continued)
         </italic>
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS36">
            36
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tobinick E.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Clinical and experimental evidence implicate TNF as a possible mediator of the severe immune-based pulmonary injury which can follow infection with H5N1 influenza and SARS coronavirus.
             </p>
            </list-item>
            <list-item>
             <p>
              In humans, anti-TNF therapy utilising etanercept has been reported to be beneficial for treatment of the non-infectious idiopathic pneumonia syndrome which can follow stem-cell transplantation, a pulmonary syndrome that resembles SARS pneumonia in some respect.
             </p>
            </list-item>
            <list-item>
             <p>
              If the SARS coronavirus does indeed lead to massive release of TNF-αf rom alveolar macrophages, then early inhibition of TNF-α might be able to prevent TNF-αmediated immune activation and therefore reduce pulmonary injury in these patients.
             </p>
            </list-item>
            <list-item>
             <p>
              Compared with the use of corticosteroids, the use of biologic TNF inhibitors, including etanercept, has the potential to be a more specific and more effective method of ameliorating the severe alveolar damage which can occur following infection with these agents.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS37">
            37
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Anti-TNF alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Atanasova K; Van Gucht S; Van Reeth K.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Netherlands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2010
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           22 piglets were assessed to to elucidate the role of TNF-α in the development of virus-endotoxin-induced respiratory disease.
           <break>
           </break>
           The study demonstrates that after intratracheal administration etanercept is able to successfully block TNF-α activity in vivo in the lungs of PRCV-LPS inoculated pigs during the first 4–8 HPI.
           <break>
           </break>
           TNF-α reduction, however, was not associated with decrease in disease severity, bronchoalveolar neutrophil infiltration, or altered virus replication and induction of IL-1, IL-6, IL-12/IL-23 or IFN-α in the lungs.
           <break>
           </break>
           There was no obvious difference in macroscopic lung lesions and histopathological findings in the lungs. This data confirms the generally accepted belief that TNF-α, though very important, is not the sole culprit in development of respiratory disease and pathology, and possibly other, yet unidentified, components and mechanisms of the immune system are involved.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable4" position="anchor">
       <label>
        Supplementary Table 4.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and IL-6.
         <italic>
          (continued)
         </italic>
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS38">
            38
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Gao Y; Li T; Han M; Li X; Wu D; Xu Y; Zhu Y; Liu Y; Wang X; Wang L.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They investigated forty‐three adult patients with COVID‐19. The patients were classified into mild group (28 patients) and severe group (15 patients).
             </p>
            </list-item>
            <list-item>
             <p>
              Comparison of the haematological parameters between the mild and severe groups showed significant differences in IL‐6, D‐Dimer, GLU, TT, FIB and CRP (
              <italic>
               p
              </italic>
              &lt;0.05).
             </p>
            </list-item>
            <list-item>
             <p>
              Infection-related biomarkers appeared to differ between the two groups (IL-6).However, the proportion of IL-6 above normal was [36.10(23.00,59.20) pg/mL]in the severe group, which was significantly higher than that in the mild group [10.60(5.13,24.18) pg/mL].
             </p>
            </list-item>
            <list-item>
             <p>
              The AUC of IL-6 which was used to predict the severity of COVID-19 was 0.795 (P&lt;0.0001), which could better predict whetherrCOVID-19 was complicated by severe pneumonia. The optimum critical point of IL-6 in the group was 24.3 pg/ml, which was the upper limit of no severe pneumonia.
             </p>
            </list-item>
            <list-item>
             <p>
              IL‐6 and D‐Dimer were closely related to the occurrence of severe COVID‐19 in the adult patients, and their combined detection had the highest specificity and sensitivity for early prediction of the severity of COVID‐19 patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS39">
            39
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Conti, P; Ronconi, G; Caraffa, A; Gallenga, C; Ross, R; Frydas, I; Kritas, S.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Italy
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              When COVID-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1b and IL-6.
             </p>
            </list-item>
            <list-item>
             <p>
              The binding of COVID-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1b which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1b which is a mediator of lung inflammation, fever and fibrosis.
             </p>
            </list-item>
            <list-item>
             <p>
              Proinflammatory cytokines levels are correlated with COVID-19 replication and disease.
             </p>
            </list-item>
            <list-item>
             <p>
              Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS40">
            40
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yamaya M; Nishimura H; Deng X; Sugawara M; Watanabe O; Nomura K; Shimotai Y; Momma H; Ichinose M; Kawase T.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Netherlands
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Primary human nasal (HNE) and tracheal (HTE) epithelial cell cultures were infected with HCoV-229E coronavirus.
             </p>
            </list-item>
            <list-item>
             <p>
              Pretreatment of HNE and HTE cells with glycopyrronium or formoterol decreased viral RNA levels and/or titers, the expression of the HCoV-229E receptor CD13, the number and fluorescence intensity of acidic endosomes where HCoV-229E RNA enters the cytoplasm, and the infection-induced production of cytokines, including IL-6, IL-8, and IFN-beta.
             </p>
            </list-item>
            <list-item>
             <p>
              IL-6 and IL-8 are related to airway inflammation in COPD and bronchial asthma exacerbation induced by viral infection. The decreased production of IL-6 and IL-8 in cells pretreated with glycopyrronium, formoterol, and budesonide, as well as the increased inhibitory effects of GFB observed in the present study, may be associated with the inhibitory effects of these drugs on COPD and bronchial asthma exacerbation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS41">
            41
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of clinical features of 29 patients with 2019 novel
           <bold>
            coronavirus
           </bold>
           pneumonia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen, L; Liu, H G; Liu, W; Liu, J; Liu, K; Shang, J; Deng, Y; Wei, S.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              29 patients with 2019-ncov admitted to the isolation ward of Tongji hospital ( mild (15 cases), severe (9 cases) and critical (5 cases).
             </p>
            </list-item>
            <list-item>
             <p>
              The expression levels of inflammatory cytokines and other markers in the serum of each group were detected.
             </p>
            </list-item>
            <list-item>
             <p>
              There were statistically significant differences in the expression levels of interleukin-2 receptor (IL-2R) and IL-6
              <bold>
               in the serum of the three groups (
              </bold>
              <italic>
               p
              </italic>
              &lt; 0.05), among which the critical group was higher than the severe group and the severe group was higher than the mild group.
             </p>
            </list-item>
            <list-item>
             <p>
              However, there were no statistically significant differences in serum levels of tumor necrosis factor-alpha (TNF-alpha), IL-1, IL-8, IL-10, hs-CRP, lymphocyte count and LDH among the three groups (P&gt;0.05).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS26">
            26
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome: clinical and laboratory manifestations.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lam, Christopher W K; Chan, Michael H M; Wong, Chun K.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They have investigated daily changes in plasma inflammatory cytokines and chemokines in 20 adult SARS patients [19 men and 1 woman, mean (SD) age 33 (12) years, range 21–58] for 19 consecutive days upon hospital admission (from ≤ 2 days after disease onset).
             </p>
            </list-item>
            <list-item>
             <p>
              The cytokine profile showed marked elevation of T-helper lymphocyte type 1 (Th1) cytokine IFN-γ, inflammatory cytokines IL-1β, IL-6 and IL-12 for at least two weeks after disease onset, but there was no significant increase in inflammatory cytokine TNF-α, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2, and T-helper lymphocyte type 2 (Th2) cytokine IL-4.
             </p>
            </list-item>
            <list-item>
             <p>
              We have also performed serial studies of plasma cytokine and chemokine profiles of 8 children with SARS (5 boys and 3 girls, age 0.3 – 6.2 years) and found that these patients had a much milder cytokine and chemokine storm, rendering the use of corticosteroids more controversial if not unjustified.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="left" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS42">
            42
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection.
           <break>
           </break>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kim ES; Choe PG; Park WB; Oh HS; Kim EJ; Nam EY; Na SH; Kim M; Song KH; Bang JH; Park SW; Kim HB; Kim NJ; Oh MD.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Korea (South)
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              17 patients with laboratory-confirmed MERS-CoV during the 2015 outbreak in Korea were studied.
             </p>
            </list-item>
            <list-item>
             <p>
              The severe group had higher neutrophil counts during week 1 than the mild group (4,500 versus 2,200/muL, P = 0.026). In the second week of illness, the severe group had higher serum levels of IL-6 (54 versus 4 pg/ml,
              <italic>
               p
              </italic>
              = 0.006) and CXCL-10 (2,642 versus 382 pg/ml,
              <italic>
               p
              </italic>
              &lt; 0.001).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS27">
            27
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Decoding the enigma of antiviral crisis: Does one target molecule regulate all?. [Review]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mahmud-Al-Rafat A; Majumder A; Taufiqur Rahman KM; Mahedi Hasan AM; Didarul Islam KM; Taylor-Robinson AW; Billah MM
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              IL-6 Interleukin acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signalling, which might relate to the cytokine storm that is triggered by excessive pro-inflammatory responses to Ebola, SARS-CoV and dengue infections in humans.
             </p>
            </list-item>
            <list-item>
             <p>
              Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling
             </p>
            </list-item>
            <list-item>
             <p>
              The tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli.
             </p>
            </list-item>
            <list-item>
             <p>
              ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS43">
            43
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Li Y; Chen M; Cao H; Zhu Y; Zheng J; Zhou H.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           France
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2013
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They identified a set of SARS-CoV specific GU-rich ssRNA fragments with a high-density distribution in the genome.
             </p>
            </list-item>
            <list-item>
             <p>
              In vitro experiments, the result showed the representative SARS-CoV ssRNAs had powerful immunostimulatory activities to induce considerable level of pro-inflammatory cytokine TNF-a, IL-6 and IL-12 release via the TLR7 and TLR8, almost 2-fold higher than the strong stimulatory ssRNA40 that was found previously from other virus.
             </p>
            </list-item>
            <list-item>
             <p>
              Moreover, SARS-CoV ssRNA was able to cause acute lung injury in mice with a high mortality rate in vivo experiment. It suggests that SARS-CoV specific GU-rich ssRNA plays a very important role in the cytokine storm associated with a dysregulation of the innate immunity and could open a new therapeutic strategy.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS44">
            44
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Liao Y; Wang X; Huang M; Tam JP; Liu DX
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2011
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Characterised cellular mechanisms exploited by coronavirus infectious bronchitis virus (IBV) to regulate the induction of two pro-inflammatory cytokines, interleukin (IL)-6 and IL-8, at the transcriptional level.
             </p>
            </list-item>
            <list-item>
             <p>
              IBV modulates the infection by inducing the expression of dual-specificity phosphatase 1 (DUSP1), a negative regulator of the p38 MAPK, in order to limit the production of an excessive amount of IL-6 and IL-8 in the infected cells.
             </p>
            </list-item>
            <list-item>
             <p>
              DUSP1 and p38 MAPK are possible therapeutic targets for IBV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS45">
            45
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Day CW; Baric R; Cai SX; Frieman M; Kumaki Y; Morrey JD; Smee DF; Barnard DL.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              A new strain of SARS-CoV (strain v2163) was characterised and it was highly lethal in 5- to 6-week-old BALB/c mice. It had nine mutations affecting 10 amino acid residues.
             </p>
            </list-item>
            <list-item>
             <p>
              Strain v2163 increased IL-1alpha, IL-6, MIP-1alpha, MCP-1, and RANTES in mice, and high IL-6 expression correlated with mortality.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS46">
            46
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Neutralising antibody against severe acute respiratory syndrome -coronavirus spike is highly effective for the protection of mice in the murine SARS model.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Australia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The efficacy of three SARS vaccine candidates was tested in a murine SARS model utilising low-virulence Pp and SARS-CoV coinfection.
             </p>
            </list-item>
            <list-item>
             <p>
              Vaccinated mice were protected from severe respiratory disease.
             </p>
            </list-item>
            <list-item>
             <p>
              A high level of IL-6 and on days 2 and 3 after SARS-CoV infection was closely linked to the virus replication and disease severity, suggesting the importance of these cytokines in the lung pathogenicity of SARS-CoV infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS47">
            47
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome (18) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yoshikawa T; Hill T; Li K; Peters CJ; Tseng CT.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2009
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              In highly polarised human lung epithelial Calu-3 cells modelled the cellular bases of the host antiviral innate immunity within the lungs.
             </p>
            </list-item>
            <list-item>
             <p>
              Role of IL-6 as a key SARS-CoV-induced epithelial cytokine capable of inhibiting the T-cell-priming ability of Denditric cells leading to an exacerbated inflammatory cascades and severe tissue damage in SARS patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS48">
            48
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang X; Wu K; Wang D; Yue X; Song D; Zhu Y; Wu J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              High levels of IL6 High levels of interleukin-6 (IL-6) in the acute stage associated with lung lesions were found in SARS patients.
             </p>
            </list-item>
            <list-item>
             <p>
              The viral nucleocapsid SARS-CoV N protein
              <bold>
               activate
              </bold>
              IL-6 expression in the lung cells.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS49">
            49
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Okabayashi T; Kariwa H; Yokota S; Iki S; Indoh T; Yokosawa N; Takashima I; Tsutsumi H; Fujii N.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              They compared the cytokine profile in Caco2 cells after infection of SARS coronavirus (SARS-CoV) with other respiratory viruses including respiratory syncytial virus (RSV), influenza A virus (FluAV), and human parainfluenza virus type 2 (hPIV2).
             </p>
            </list-item>
            <list-item>
             <p>
              Interferon (IFN) system (production and response) was not suppressed by SARS-CoV infection
             </p>
            </list-item>
            <list-item>
             <p>
              SARS-CoV and RSV induced high levels of IL-6 and RANTES compared with FluAV and hPIV2.
             </p>
            </list-item>
            <list-item>
             <p>
              Induction level of suppressor of cytokine signaling-3 (SOCS3) by SARS-CoV was significantly lower than that by RSV in spite of the significant production of IL-6.
             </p>
            </list-item>
            <list-item>
             <p>
              Collectively, overinduction of inflammatory cytokine and dysregulation of cytokine signaling may contribute to the immunopathology associated with “severe” inflammation in SARS.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS31">
            31
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hao D; He LX; Qu JM; Pan J; Hu BJ; Zhang J; Li ZZ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The pulmonary inflammatory reaction in rat models were induced by intratracheal instillation of N-protein of SARS-CoV and glucocorticoids were administrated to one of the groups.
             </p>
            </list-item>
            <list-item>
             <p>
              The N-protein of SARS-CoV presented pathogenicity and could induce pulmonary inflammatory reaction and acute lung injury, which were related to the increase and imbalance of pro-inflammatory and anti-inflammatory cytokines. Glucocorticoids could effectively alleviate the pulmonary inflammatory reaction induced by N-protein of SARS-CoV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS50">
            50
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Sheng WH; Chiang BL; Chang SC; Ho HN; Wang JT; Chen YC; Hsiao CH; Hseuh PR; Chie WC; Yang PC.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Singapore
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Fourteen hospitalised patients with a diagnosis of SARS-associated coronavirus infection.
             </p>
            </list-item>
            <list-item>
             <p>
              There were no significant differences in peak levels of IL-6, IL-8 and TNF-alpha between patients with and without acute respiratory distress syndrome.
             </p>
            </list-item>
            <list-item>
             <p>
              CRP and TNF-alpha are associated with worse outcomes and might be used as prognostic markers of SARS.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS51">
            51
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Tseng CT; Perrone LA; Zhu H; Makino S; Peters CJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              SARS-CoV does not productively infect human macrophages or Dentritic cells, it appears to exert differential effects on Mphi and DC maturation and functions, which might contribute to SARS pathogenesis.
             </p>
            </list-item>
            <list-item>
             <p>
              It modulates a massive release of IL-6 and IL-12. However, the endocytic capacity (e.g., Ag capture) of Mphi was significantly compromised upon exposure to infectious SARS-CoV.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS52">
            52
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           An interferon-gamma-related cytokine storm in SARS patients.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Huang KJ; Su IJ; Theron M; Wu YC; Lai SK; Liu CC; Lei HY.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2005
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Fourteen cytokines or chemokines were analysed on 88 RT-PCR-confirmed severe acute respiratory syndrome [
              <xref ref-type="bibr" rid="refS18">
               18
              </xref>
              ] patients.
             </p>
            </list-item>
            <list-item>
             <p>
              IFN-gamma, IL-18, TGF-beta, IL-6, IP-10, MCP-1, MIG, and IL-8, but not of TNF-alpha, IL-2, IL-4, IL-10, IL-13, or TNFRI, were highly elevated in the acute phase sera of Taiwan SARS patients.
             </p>
            </list-item>
            <list-item>
             <p>
              IL-18, IP-10, MIG, and MCP-1 were significantly higher in the death group than in the survival group
             </p>
            </list-item>
            <list-item>
             <p>
              An interferon-gamma-related cytokine storm was induced post SARS coronavirus infection, and this cytokine storm might be involved in the immunopathological damage in SARS patients.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS53">
            53
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wang WK; Chen SY; Liu IJ; Kao CL; Chen HL; Chiang BL; Wang JT; Sheng WH; Hsueh PR; Yang CF; Yang PC; Chang SC;
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              8 patients with acute respiratory syndrome [
              <xref ref-type="bibr" rid="refS18">
               18
              </xref>
              ], were included to study the link between viral load, ribavirin, proinflammatory cytokines, and clinical progression.
             </p>
            </list-item>
            <list-item>
             <p>
              ribavirin was not effective in reducing the SARS coronavirus load in 3 of 8 probable cases studied
             </p>
            </list-item>
            <list-item>
             <p>
              elevated levels of interleukin (IL)-6 and IL-8 subsequent to the peak viral load were found in 8 and 6 cases, respectively.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS54">
            54
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of serum cytokines in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang Y; Li J; Zhan Y; Wu L; Yu X; Zhang W; Ye L; Xu S; Sun R; Wang Y; Lou J.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           US
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Serum from 110 individuals (healthy donors, patients with SARS, patients with severe SARS, and patients with SARS in convalescence) was collected and cytokine profile was studied.
             </p>
            </list-item>
            <list-item>
             <p>
              The IL-6 concentration was increased in SARS patients and was significantly elevated in severe SARS patients, but the IL-6 concentrations were similar in convalescent patients and control subjects, suggesting that there was a positive relationship between the serum IL-6 concentration and
             </p>
            </list-item>
            <list-item>
             <p>
              SARS severity.
             </p>
            </list-item>
            <list-item>
             <p>
              The concentrations of IL-8 and TGF-beta were decreased in SARS patients and significantly reduced in severe SARS patients, but they were comparable in convalescent SARS patients and control subjects, suggesting that there was a negative relationship between the IL-8 and TGF-beta concentrations and SARS severity.
             </p>
            </list-item>
            <list-item>
             <p>
              The concentrations of IL-1 and TNF-alpha were not significantly different in different groups.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK; Lam CW; Wu AK; Ip WK; Lee NL; Chan IH; Lit LC; Hui DS; Chan MH; Chung SS; Sung JJ.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Changes in plasma T helper (Th) cell cytokines, inflammatory cytokines and chemokines in 20 patients diagnosed with SARS were assessed.
             </p>
            </list-item>
            <list-item>
             <p>
              Th1 cytokine interferon (IFN)-gamma, inflammatory cytokines interleukin (IL)-1, IL-6 and IL-12 was elevated for at least 2 weeks after disease onset, but there was no significant elevation of inflammatory cytokine tumour necrosis factor (TNF)-alpha, anti-inflammatory cytokine IL-10, Th1 cytokine IL-2 and Th2 cytokine IL-4.
             </p>
            </list-item>
            <list-item>
             <p>
              The chemokine profile demonstrated significant elevation of neutrophil chemokine IL-8, monocyte chemoattractant protein-1 (MCP-1), and Th1 chemokine IFN-gamma-inducible protein-10 (IP-10).
             </p>
            </list-item>
            <list-item>
             <p>
              Corticosteroid reduced significantly IL-8, MCP-1 and IP-10 concentrations from 5 to 8 days after treatment (all p &lt; 0.001).
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS55">
            55
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wang and Pang
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              (Abstract only)
             </p>
            </list-item>
            <list-item>
             <p>
              This study observed changed in various serum IL levels in patients with SARS. The authors stated that the mean concentration of serum IL-6 in SARS patients did not differ from the control group in 3-7-day group and 8-14-day group, but became significantly higher in over 14-day group as compared to the control group, 3-7-day group and 8-14-day group (
              <italic>
               p
              </italic>
              &lt; 0.01). The results of the study led the authors to conclude that the immune state of SARS was abnormal. However, as only the abstract was available it is hard to draw upon any more conclusions from this study in relation in IL-6 specifically.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS56">
            56
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Inflammatory Cytokine Profile in Children With Severe Acute Respiratory Syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ng
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              The authors of this study set out to study the inflammatory cytokine profile in children with SARS. They found that the plasma concentrations key proinflammatory cytokines, including IL-6 were not substantially increased in any of the patients throughout the course of illness. From this the authors stated that the cytokine results cast doubt on the liberal use of corticosteroids in paediatric SARS patients, as the host immunologic response did not seem to be as severe as initially anticipated.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable5" position="anchor">
       <label>
        Supplementary Table 5.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and JAK inhibitors
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS57">
            57
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Richardson
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           England
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              ACE2 is a cell-surface protein on lung cells in corona viral infected patients
             </p>
            </list-item>
            <list-item>
             <p>
              AAK1 receptor promoted endocytosis involved in ACE2
             </p>
            </list-item>
            <list-item>
             <p>
              The study suggests the use of Baricitinib to inhibit AAK1 in patients with 2019-nCoV acute respiratory disease, to reduce both the viral entry and the inflammation in patients, using endpoints such as the MuLBSTA score, an early warning model for predicting mortality in viral pneumonia [
              <xref ref-type="bibr" rid="refS58">
               58
              </xref>
              ].
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS59">
            59
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The Coronavirus Transmissible Gastroenteritis Virus Evades the Type I Interferon Response through IRE1α-Mediated Manipulation of the MicroRNA miR-30a-5p/SOCS1/3 Axis
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Ma
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              JAK-signal transducer and activator of transcription (STAT), the suppressor of cytokine signaling protein 1 (SOCS1), and SOCS3.
             </p>
            </list-item>
            <list-item>
             <p>
              IFN-I are major antiviral molecules, and coronaviruses have evolved diverse strategies to counter the IFN-I response during infection.
             </p>
            </list-item>
            <list-item>
             <p>
              This study uses endoplasmic reticulum stress and IFN-I production after infection with transmissible gastroenteritis virus (TGEV) to understand how coronavirus-elicited ER stress is actively involved in viral replication and manipulates the host IFN-I response.
             </p>
            </list-item>
            <list-item>
             <p>
              Increased SOCS1 or SOCS3 expression impaired the IFN-I antiviral response, promoting TGEV replication.
             </p>
            </list-item>
            <list-item>
             <p>
              IRE1α is an endoplasmic reticulum stress sensor, which led to the increased expression of negative regulators of JAK-STAT SOCS1 and SOCS3.
             </p>
            </list-item>
            <list-item>
             <p>
              Therefore, IRE1α may be a novel target against coronavirus infection.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS60">
            60
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Targeting Coronaviral Replication and Cellular JAK2 Mediated Dominant NF-kappaB Activation for Comprehensive and Ultimate Inhibition of Coronaviral Activity
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Yang
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Tylophorine-based compounds exert broad spectral, potent inhibition of coronaviruses.
             </p>
            </list-item>
            <list-item>
             <p>
              NF-
              <bold>
               κB
              </bold>
              activation is a common pro-inflammatory response of host cells to viral infection.
             </p>
            </list-item>
            <list-item>
             <p>
              The combination treatment, wherein a tylophorine compound targets TGEV and a JAK2 inhibitor blocks the alternative dominant NF-
              <bold>
               κB
              </bold>
              activation mediated by JAK2, is more effective and comprehensive than either one alone and constitutes a feasible approach for the treatment of SARS-CoV or MERS-CoV
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS61">
            61
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe Acute Respiratory Syndrome Coronavirus Evades Antiviral Signaling: Role of nsp1 and Rational Design of an Attenuated Strain
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wathelet
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <list list-type="bullet">
            <list-item>
             <p>
              Expression of non-structural protein 1 (nsp1) significantly inhibited the activation of SARS-Cov signaling pathways.
             </p>
            </list-item>
            <list-item>
             <p>
              However, the study results show that SARS-CoV nsp1 does not inhibit JAK phosphorylation.
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable6" position="anchor">
       <label>
        Supplementary Table 6.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and IL-1 blockade.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS62">
            62
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The levels of several inflammatory markers were
           <break>
           </break>
           measured in 29 COVID-19 patients and were compared between general, severe and critically ill groups. The authors reported no significant differences in IL-1b levels between the three groups of patients.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS63">
            63
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Miura
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2007
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors used two rat coronaviruses on alveolar epithelial cells taken from 6-8 weeks old rats. Infection with the viruses caused the increase in expressed of both IL-1a and IL-1b. The authors concluded that the virus-induced chemokine expression was subsequently reduced by the IL-1 receptor antagonist, suggesting that IL-1 produced by infected cells induces uninfected cells to express chemokines.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS64">
            64
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zalinger, Elliott and Weiss
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors used several infectious agents including murine coronavirus to assess the role of the inflammasome and its related cytokines on pathogenesis and host defence during viral infection. The authors concluded that mice lacking IL-1 signalling experienced elevated viral replication but similar survival compared to wild-type controls.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS65">
            65
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Severe Acute Respiratory
           <break>
           </break>
           Syndrome Coronavirus Viroporin 3a Activates the NLRP3
           <break>
           </break>
           Inflammasome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Japan and Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           The authors provide evidence that SARS-CoV 3a protein activates the NLRP3 inflammasome in lipopolysaccharide-primed macrophages and that the ion channel activity of the 3a protein was essential for 3a-mediated IL-1β secretion. The macrophages obtained in this study were from 6-week-old female mice.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS66">
            66
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Kritas
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Greece, Italy and USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2020
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Abstract Only)
           <break>
           </break>
           Infection with coronavirus activates mast cells which in turn causes the generation of pro-inflammatory IL-1 family members. The authors state that they demonstrate for the first time that inflammation by coronavirus may be inhibited by anti-inflammatory cytokines belonging to the IL-1 family. However, as this is only an abstract there is no further information to support this statement.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS67">
            67
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           SARS Immunity and Vaccination.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhu M
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           SARS-CoV binds to host cells via a specific SARS receptor, angiotensin converting enzyme 2 (ACE-2).
           <break>
           </break>
           Following entry into the cell, the virus uncoats, nucleic acid is released and transcription occurs for production of viral proteins. During this course, the host immune system is activated (B and T-cells).
           <break>
           </break>
           Specifically, CD4+ T helper cells recognise antigenic peptides produced by antigen presenting cells and produce cytokines that promote cell mediated and/or humoral immunity.
           <break>
           </break>
           Similarly to avian flu, SARS infection induced similar pro-inflammatory cytokine pattern and might contribute to the severe nature of the virus.
           <break>
           </break>
           Clinical evidence of SARS treatment by corticosteroids where levels of IL-1beta reduced after administration- thus inhibition of inflammatory cytokines such as IL-1 may be beneficial strategy for treatment of SARS.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS54">
            54
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Analysis of serum cytokines in patients with severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Zhang Y, Li J, Zhan Y, Wu L, Yu X, Zhang W, Ye L, Xu S, Sun R, Wang Y, Lou J
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Following the discovery of SARS-CoV, no specific or efficient clinical treatments were available since pathogenesis was not well understood.
           <break>
           </break>
           Acute lung injury associated with SARS can be attributed to complex and multifactorial pathophysiological process involving cytokines. Demonstrated that IL-1 play key role in pathogenesis of acute lung injury. WHO inferred that severe immune response kills SARS patients and that some cytokines may play important role in the process.
           <break>
           </break>
           IL-1 cytokine promotes inflammation by inducing cell injury.
           <break>
           </break>
           Study measured levels of IL-1 in 4 patient groups: controls, patients with SARS, patients with severe SARS and convalescent SARS patients.
           <break>
           </break>
           Study showed that levels of IL-1alpha did not differ between 3 SARS groups or controls.
           <break>
           </break>
           Suggests that host immune response to novel coronavirus may be different from the immune reaction to other pathogens.
           <break>
           </break>
           Overall results suggest that acute lung injury associated with SARS may not be induced by circulating cytokines. HOWEVER some patients had accepted corticosteroids and therefore results consistent with reports that only long term treatment (7-10 days) with a steroid can alter serum cytokine levels.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS34">
            34
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH, Lit LC, Hui DS, Chan MH, Chung SS, Sung JJ
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2004
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Known that over-expression of IL-1beta hallmark of SARS infection probably through activation of transcription factor nuclear factor, activator protein AP1 and activating factor 2. Therefore lung damage associated with SARS postulated to occur through cytokine and chemokine dysregulation.
           <break>
           </break>
           Study involved measurement of cytokines and chemokines including IL-1beta in 20 consecutive patients admitted to Hong Kong hospital.
           <break>
           </break>
           IL-1beta was significantly elevated above normal range within first 12, 7 and 5 days after disease onset.
           <break>
           </break>
           Those patients with more severe disease treated with pulsed methylprednisolone. IL-1beta levels higher in this patient group particularly 3-10 days after onset but returned to normal levels 1 week after disease onset in both sets of patients.
           <break>
           </break>
           IL-1beta can act as early response cytokine to viral infection. IL-1 elevation in SARS can induce hyperinnate inflammatory response leading to recruitment and accumulation of alveolar macrophages and PMN.
           <break>
           </break>
           Higher disease severity associated with more elevated plasma IL-1beta and addition of pulsed steroid controlled rapidly deteriorating clinical condition and attenuated otherwise exaggerated immunological response.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <table-wrap id="Stable7" position="anchor">
       <label>
        Supplementary Table 7.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and Mycophenolate.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS68">
            68
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Interferon-β and mycophenolic acid are potent inhibitors of middle east respiratory syndrome coronavirus in cell-based assays
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hart
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (
           <italic>
            In vitro
           </italic>
           only)
           <break>
           </break>
           MPA showed strong inhibition, with an IC50 of 2.87 mM. This drug may provide an alternative to ribavirin for treatment of MERS-CoV. In conclusion, IFN-b, MPA or a combination of the two may be beneficial in the treatment of MERS-CoV or as a post-exposure intervention in high-risk patients with known exposures to MERS-CoV.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS69">
            69
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Lin
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2018
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro)
           <break>
           </break>
           Note. (PLpros)= Papain-like proteases MERS-CoV and SARS-CoV – act as a potential anti-viral target for drugs
           <break>
           </break>
           Multiple inhibition assays also support a kinetic mechanism by which disulfiram together with 6TG and/or MPA can synergistically inhibit MERS-CoV PLpro, but not, due to its competitive mode of inhibition, SARS-CoV PLpro.
           <break>
           </break>
           Synergistic inhibition of MERS-CoV PLpro by disulfiram and 6-thioguanine or
           <bold>
            mycophenolic acid
           </bold>
           implies the potential for combination treatments using these three clinically available drugs.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS70">
            70
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cheng et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Taiwan
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro)
           <break>
           </break>
           At the time of the study, there were no potent inhibitors that target MERS-CoV PLpro. The authors report that the immunosuppressive drug mycophenolic acid, was able to inhibit MERS-CoV PLpro.
           <break>
           </break>
           MPA is a non-competitive inhibitor of MERS-CoV PLpro.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS71">
            71
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2013
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (
           <italic>
            In vitro
           </italic>
           )
           <break>
           </break>
           The authors assessed the anti-MERS-CoV activities of several compounds. Only mycophenolic acid exhibited low EC50 and high selectivity index.
           <break>
           </break>
           They found that a combination of mycophenolic acid and IFN-b1b lowered the EC50 of each drug by 1-3 times.
           <break>
           </break>
           Mycophenolic acid exhibits a number of attributes that support its practical use in MERS-CoV infection. It is commonly available in two forms, the prodrug mycophenolate mofetil and the salt mycophenolate sodium, and could be given orally.
           <break>
           </break>
           Interferon-b1b with mycophenolic acid should be considered in treatment trials of MERS.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS72">
            72
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Shen
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2019
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           <italic>
            (In vitro)
           </italic>
           <break>
           </break>
           The authors sought to identify potent broad-spectrum inhibitors of corona viruses. They concluded that they had identified seven compounds (lycorine, emetine, monensin sodium,
           <bold>
            mycophenolate mofetil, mycophenolic acid
           </bold>
           , phenazopyridine, and pyrvinium pamoate) as broad-spectrum inhibitors according to their strong inhibition of replication by four CoVs in vitro at low-micromolar concentrations. They all inhibited the replication of all CoVs with EC50 values of 5μm.
           <break>
           </break>
           Mycophenolate mofetil and mycophenolic acid, showed a similar antiviral effect on the four CoVs suggesting that the two drugs might harbour similar core structures and antiviral mechanisms.
           <break>
           </break>
           In vivo antiviral activity is unknown from this study.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS73">
            73
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Cinatl
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2003
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vitro but using clinical samples - Abstract only)
           <break>
           </break>
           The authors assessed the antiviral activities of ribavirin, 6-azauridine, pyrazofurin,
           <bold>
            mycophenolic acid
           </bold>
           , and glycyrrhizin against two clinical isolates of coronavirus (FFM-1 and FFM-2) from patients with SARS admitted to the clinical centre of Frankfurt University, Germany.
           <break>
           </break>
           Mycophenolic acid did not affect replication of the SARS-associated coronaviruses.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS74">
            74
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al Ghamdi et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Clinical example)
           <break>
           </break>
           Eight patients (15.7%) received mycophenolate mofetil, seven of these patients received it in combination with interferon beta. All patients who received mycophenolate mofetil survived. The authors concluded that whilst treatment with beta interferon and mycophenolate mofetil predicted survival (in univariate analysis only), the greatest predictor of survival was the severity of illness on presentation.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS75">
            75
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERSCoV infection in a nonhuman primate model of common marmoset
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (In vivo)
           <break>
           </break>
           The authors assessed 3 repurposed drugs with potent in vitro anti-MERS-CoV activity (mycophenolate mofetil, lopinavir/ritonavir, and interferon-β1b) in common marmosets with severe disease resembling MERS in humans.
           <break>
           </break>
           all MMF-treated animals developed severe and/or fatal disease with higher mean viral loads.
           <break>
           </break>
           The authors concluded that MMF alone may worsen MERS and should not be used.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS76">
            76
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Barnard
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           USA
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2006
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           In vivo study in BALB/c mice (a replication model for SARS infections)
           <break>
           </break>
           In mycophenolic acid-treated mice, the lung virus titers (aka viral load) increased with increasing dosage, although these increases in lung virus titers were not quite significantly different from the lung virus titers in placebo-treated, infected mice.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS77">
            77
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A review of treatment modalities for Middle East Respiratory Syndrome
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Mo and Fisher
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Singapore
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2016
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           Mycophenolic acid also inhibits purine nucleotide synthesis in lymphocytes. This makes it a popular immunosuppressant in solid-organ transplants and autoimmune diseases such as systemic lupus erythematosus.
           <break>
           </break>
           The use of mycophenolic acid monotherapy has not been reported in MERS. IFN-b and mycophenolic acid combination therapy was described in a retrospective observational study in Saudi Arabia involving 51 patients; all of the 8 patients who received IFN-b and mycophenolic acid survived.
           <break>
           </break>
           Corticosteroids, ribavirin monotherapy and mycophenolic acid are likely to cause more harm than benefit.
           <break>
           </break>
           There are no clinical data on the efficacy of mycophenolic acid in SARS or MERS. However, it led to severe and/or fatal disease with higher mean viral loads in an animal model.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS78">
            78
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al-Tawfiq and Memish
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           MPA mechanism of action - Direct and indirect antiviral activity by modulation of IFN response
           <break>
           </break>
           The use of mycophenolate in the common marmoset animal model resulted in higher mortality than untreated animals: Mortality rate was 67% (untreated and MMF treated) at 36 h post inoculation versus 0%–33% (lopinavir/ ritonavir-treated and interferon-β1b- treated
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS79">
            79
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Middle East Respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Chan et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Hong Kong/China
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           The combination of mycophenolic acid and interferon beta 1b shows synergistic activity against MERS-CoV in Vero cells. The desirable pharmacokinetics of mycophenolic acid compared to ribavirin warrants further evaluation, although the potential inhibitory effect on the immune system and therefore neutralising antibody production should be fully assessed in animal models before use in humans.
           <break>
           </break>
           A fatal case of MERS was reported in a renal transplant recipient who was receiving antirejection therapy consisting of prednisone, mycophenolate mofetil, and cyclosporine, but the dosage, serum drug level of mycophenolate mofetil, and resulting lymphocyte count were not reported
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS80">
            80
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Rabaan
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="center" colspan="1" rowspan="1" valign="top">
           2017
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           (Review)
           <break>
           </break>
           Reiteration of the promising results of MPA in an in vitro setting, however, the marmoset animal model resulted in fatal disease and high viral loads. The authors therefore state that MPA should be used with caution for treatment of MERS-CoV.
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          The EC50 is the concentration of a drug that gives half-maximal response. The IC50 is the concentration of an inhibitor where the response (or binding) is reduced by half. These terms are referred to a few times within the summary table.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="Stable8" position="anchor">
       <label>
        Supplementary Table 8.
       </label>
       <caption>
        <title>
         Current studies investigating COVID-19/ other coronavirus strains and Tacrolimus.
        </title>
       </caption>
       <table frame="border" rules="all">
        <thead>
         <tr>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Study Ref
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Title
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Authors
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Country of study
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Year
          </th>
          <th align="center" colspan="1" rowspan="1" valign="middle">
           Summary of results
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS81">
            81
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbajo-Lozoya
           <italic>
            et al
           </italic>
           .
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany/Switzerland
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2012
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Coronaviruses represent the group of RNA viruses with the largest RNA genome to date therefore the development of resistant mutants to targeted drugs remains a concern.
           <break>
           </break>
           Viral replication represents potential antiviral targets.
           <break>
           </break>
           Study performed genome-wide SARS-CoV yeast-two-hybrid interaction screen with human cDNA libraries identifying FK506-binding proteins as interaction partners of SARS-CoV non-structural protein 1 (Nsp1).
           <break>
           </break>
           FK506-binding proteins bind the immunosuppressive drug FK506 (tacrolimus).
           <break>
           </break>
           Since Nsp1 interacts with FK506-binding proteins, investigated whether FK506 inhibits replication of human coronaviruses.
           <break>
           </break>
           VeroFM cells infected with SARS-CoV and other human coronaviruses and treated with FK506.
           <break>
           </break>
           Study found that FK506 inhibits the replication of SARS-CoV, HCoV-NL63 and HCoV-229E at non-toxic, low-micromolar concentrations with reduction in viral titers to undetectable levels.
           <break>
           </break>
           All human coronaviruses sensitive to FK506 indicating the involvement of FK506-binding proteins in viral replication.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS82">
            82
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           MERS CoV infection in two renal transplant recipients: Case report
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Al Ghamdi et al
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Saudi Arabia
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2015
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Pneumonia caused by MERS-CoV associated with severe morbidity and mortality in immunocompromised patients.
           <break>
           </break>
           Data on clinical picture in solid organ transplant recipients and effect of anti-rejection immunosuppressive regimens unclear.
           <break>
           </break>
           30-year old patient with renal transplant on immunosuppressive regimen of tacrolimus.
           <break>
           </break>
           Tested positive for MERS CoV through nasopharyngeal swab.
           <break>
           </break>
           Received antibacterial therapy and mycophenolate mofetil dose reduced and underwent full recovery.
           <break>
           </break>
           Difficult to pinpoint why made full recovery compared to other case study (not on tacrolimus) who died.
          </td>
         </tr>
         <tr>
          <td align="center" colspan="1" rowspan="1" valign="top">
           [
           <xref ref-type="bibr" rid="refS83">
            83
           </xref>
           ]
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Human coronavirus NL63 replication is cyclophilin
           <break>
           </break>
           A-dependent and inhibited by non-immunosuppressive
           <break>
           </break>
           cyclosporine A-derivatives
           <break>
           </break>
           including Alisporivir
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Carbajo-Lozoya
           <italic>
            et al
           </italic>
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Germany
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           2014
          </td>
          <td align="left" colspan="1" rowspan="1" valign="top">
           Previous study shown that FK506 inhibit coronavirus replication.
           <break>
           </break>
           This study further shows that novel non-immunosuppressive derivatives of CsA and FK506 strongly inhibit the growth of human coronavirus HCoV-NL63 at low-micromolar, non-cytotoxic concentrations in cell culture.
           <break>
           </break>
           HCoV-NL63 and HCoV-HKU1 discovered in 2004 and 2005 causing more severe lower respiratory tract
           <break>
           </break>
           infections in younger children.
           <break>
           </break>
           PPIase-independent activities of CsA and FK506 exerted by gain-of-function, result from binary complexes formed by binding of the drugs to FKBPs. Based on inhibition of the protein phosphatase activity of calcineurin, these complexes block the cellular calcineurin/NFAT pathway
           <break>
           </break>
           thereby interfering with T-cell activation and IL-2 production.
           <break>
           </break>
           FK506 analogues (altered by side chain modification)
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <ref-list>
      <title>
       References
      </title>
      <ref id="ref1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref2">
       <label>
        2.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Risk of COVID-19 for patients with cancer
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(20)30149-2
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref3">
       <label>
        3.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Risk of COVID-19 for cancer patients
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S1470-2045(20)30150-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         32142622
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benites
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cabrini
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr (Rio J)
        </source>
        <year>
         2014
        </year>
        <volume>
         90
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         370
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jped.2014.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         24703819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref5">
       <label>
        5.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Edner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
        </article-title>
        <source>
         Infect Dis (Lond)
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Elkordy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer
        </article-title>
        <source>
         Chest
        </source>
        <year>
         1999
        </year>
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.115.3.901
        </pub-id>
        <pub-id pub-id-type="pmid">
         10084516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LaFemina
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alternative screening approaches for discovery of middle east respiratory syndrome coronavirus inhibitors
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4251
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03406-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4135998</pub-id>-->
        <pub-id pub-id-type="pmid">
         24867994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Kumaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
        </article-title>
        <source>
         Future Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         615
        </fpage>
        <lpage>
         631
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/fvl.11.33
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3136164</pub-id>-->
        <pub-id pub-id-type="pmid">
         21765859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020901900402
        </pub-id>
        <pub-id pub-id-type="pmid">
         19374142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balzarini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2007
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020701800101
        </pub-id>
        <pub-id pub-id-type="pmid">
         17354647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         11
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         4599
        </fpage>
        <lpage>
         4613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0968-0896(03)00500-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14527557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref12">
       <label>
        12.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30116-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32171062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amici
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ciucci
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Indomethacin has a potent antiviral activity against SARS coronavirus
        </article-title>
        <source>
         Antivir therapy
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1030
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chihrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome
        </article-title>
        <source>
         Expert Rev Anti Infect Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         251
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14787210.3.2.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         15918782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L-X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]
        </article-title>
        <source>
         Zhonghua nei ke za zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         890
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16409721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MHM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: clinical and laboratory manifestations
        </article-title>
        <source>
         Clin Biochem Rev
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         121
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18458712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         136
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2249.2004.02415.x
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">1808997</pub-id>-->
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Alekseev
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         4420
        </fpage>
        <lpage>
         4428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02190-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2293053</pub-id>-->
        <pub-id pub-id-type="pmid">
         18287230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         Pt 8
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahmud-Al-Rafat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Taufiqur Rahman
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine
        </article-title>
        <source>
         Cytokine
        </source>
        <year>
         2019
        </year>
        <volume>
         115
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cyto.2018.12.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         30616034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobinick
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection
        </article-title>
        <source>
         Curr Med Res Opin
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         39
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="doi">
         10.1185/030079903125002757
        </pub-id>
        <pub-id pub-id-type="pmid">
         14741070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Atanasova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Van Gucht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <year>
         2010
        </year>
        <volume>
         137
        </volume>
        <issue>
         1–2
        </issue>
        <fpage>
         12
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetimm.2010.04.003
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2922464</pub-id>-->
        <pub-id pub-id-type="pmid">
         20466438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Narazaki
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kishimoto
          </surname>
          <given-names>
           T
          </given-names>
         </name>
        </person-group>
        <article-title>
         IL-6 in inflammation, immunity, and disease
        </article-title>
        <source>
         Cold Spring Harb Perspect Biol
        </source>
        <year>
         2014
        </year>
        <volume>
         6
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         a016295
        </fpage>
        <pub-id pub-id-type="doi">
         10.1101/cshperspect.a016295
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4176007</pub-id>-->
        <pub-id pub-id-type="pmid">
         25190079
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <comment>
         pii:1
        </comment>
        <pub-id pub-id-type="pmid">
         32171193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         324
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         17490702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okabayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kariwa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yokota
          </surname>
          <given-names>
           S-I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20556
        </pub-id>
        <pub-id pub-id-type="pmid">
         16482545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C-TK
          </given-names>
         </name>
         <name>
          <surname>
           Perrone
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         174
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         7977
        </fpage>
        <lpage>
         7985
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.174.12.7977
        </pub-id>
        <pub-id pub-id-type="pmid">
         15944304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         203
        </fpage>
        <lpage>
         208
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Korean Medi Sci
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1717
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2016.31.11.1717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         53
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         19291090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3039
        </fpage>
        <lpage>
         3048
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01792-08
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2655569</pub-id>-->
        <pub-id pub-id-type="pmid">
         19004938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           B-L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S-C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Formosan Med Assoc = Taiwan yi zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         104
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         16385373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K-J
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I-J
          </given-names>
         </name>
         <name>
          <surname>
           Theron
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An interferon-gamma-related cytokine storm in SARS patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         185
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20255
        </pub-id>
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B-S
          </given-names>
         </name>
         <name>
          <surname>
           National Research Project for Sars
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="ref37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W-K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423808
        </pub-id>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of serum cytokines in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         2004
        </year>
        <volume>
         72
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4410
        </fpage>
        <lpage>
         4415
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/IAI.72.8.4410-4415.2004
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">470699</pub-id>-->
        <pub-id pub-id-type="pmid">
         15271897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2004
        </year>
        <volume>
         113
        </volume>
        <fpage>
         e7
        </fpage>
        <lpage>
         e14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.113.1.e7
        </pub-id>
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
        </article-title>
        <source>
         Microb Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         88
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2012.10.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2011
        </year>
        <volume>
         420
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2011.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         21959016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref42">
       <label>
        42.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nishimura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
        </article-title>
        <source>
         Respir Investig
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.resinv.2019.12.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kontzias
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Kotlyar
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Laurence
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
        </article-title>
        <source>
         Curr Opin Pharmacol
        </source>
        <year>
         2012
        </year>
        <volume>
         12
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         464
        </fpage>
        <lpage>
         470
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.coph.2012.06.008
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3419278</pub-id>-->
        <pub-id pub-id-type="pmid">
         22819198
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref44">
       <label>
        44.
       </label>
       <element-citation publication-type="webpage">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agency
          </surname>
          <given-names>
           EM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Olumiant (baricitinib)
        </article-title>
        <year>
         2019
        </year>
        <comment>
         [
         <ext-link ext-link-type="uri" xlink:href="https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant">
          https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant
         </ext-link>
         ]
        </comment>
       </element-citation>
      </ref>
      <ref id="ref45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         e30
        </fpage>
        <lpage>
         e1
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus transmissible gastroenteritis virus evades the type I interferon response through IRE1alpha-mediated manipulation of the microRNA miR-30a-5p/SOCS1/3 axis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         22
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00728-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           YZ
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of phenanthroindolizines and phenanthroquinolizidines as novel potent anti-coronaviral agents for porcine enteropathogenic coronavirus transmissible gastroenteritis virus and human severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Antivir Res
        </source>
        <year>
         2010
        </year>
        <volume>
         88
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         160
        </fpage>
        <lpage>
         168
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2010.08.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         20727913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C-W
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           Y-Z
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H-Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04203-9
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5481340</pub-id>-->
        <pub-id pub-id-type="pmid">
         28642467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="ref50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         1
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         193
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16219167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         369
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         288
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.07.030
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2170429</pub-id>-->
        <pub-id pub-id-type="pmid">
         17804032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kritas
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
       </element-citation>
      </ref>
      <ref id="ref53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        <volume>
         150
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.12.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2019
        </year>
        <volume>
         93
        </volume>
        <issue>
         12
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00023-19
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         Pt 3
        </issue>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3929173</pub-id>-->
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East Respiratory Syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         71
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw338
        </pub-id>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Ghamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ghandoora
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         174
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1492-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4839124</pub-id>-->
        <pub-id pub-id-type="pmid">
         27097824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report
        </article-title>
        <source>
         Am J Transplant
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1104
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/ajt.13085
        </pub-id>
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.02.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         22349148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="ref62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma-Lauer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Malesevic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2014
        </year>
        <volume>
         184
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2014.02.010
        </pub-id>
        <pub-id pub-id-type="pmid">
         24566223
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ref-list>
      <title>
       References
      </title>
      <ref id="refS1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           XH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [The differential diagnosis of pulmonary infiltrates in cancer patients during the outbreak of the 2019 novel coronavirus disease]
        </article-title>
        <source>
         Zhonghua Zhong Liu Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         42
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E008
        </fpage>
        <pub-id pub-id-type="pmid">
         32133833
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Chemotherapy strategy for colorectal cancer under the outbreak of novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua Wei Chang Wai Ke Za Zhi
        </source>
        <year>
         2020
        </year>
        <volume>
         23
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E004
        </fpage>
        <pub-id pub-id-type="pmid">
         32100980
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS3">
       <label>
        3.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Edner
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Fatal encephalitis associated with coronavirus OC43 in an immunocompromised child
        </article-title>
        <source>
         Infect Dis (Lond)
        </source>
        <year>
         2020
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         4
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Kumaki
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy
        </article-title>
        <source>
         Future Virol
        </source>
        <year>
         2011
        </year>
        <volume>
         6
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         615
        </fpage>
        <lpage>
         631
        </lpage>
        <pub-id pub-id-type="doi">
         10.2217/fvl.11.33
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3136164</pub-id>-->
        <pub-id pub-id-type="pmid">
         21765859
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aydin Köker
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Demirag
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Tahta
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A 3-year retrospective study of the epidemiology of acute respiratory viral infections in pediatric patients with cancer undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr Hematol Oncol
        </source>
        <year>
         2019
        </year>
        <volume>
         41
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         e242
        </fpage>
        <lpage>
         e246
        </lpage>
        <pub-id pub-id-type="doi">
         10.1097/MPH.0000000000001418
        </pub-id>
        <pub-id pub-id-type="pmid">
         30688827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soderman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Rhedin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tolfvenstam
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Frequent respiratory viral infections in children with febrile neutropenia—a prospective follow-up study
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         e0157398
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0157398
        </pub-id>
        <pub-id pub-id-type="pmid">
         27309354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pillaiyar
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Manickam
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Namasivayam
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy
        </article-title>
        <source>
         J Med Chem
        </source>
        <year>
         2016
        </year>
        <volume>
         59
        </volume>
        <issue>
         14
        </issue>
        <fpage>
         6595
        </fpage>
        <lpage>
         6628
        </lpage>
        <pub-id pub-id-type="doi">
         10.1021/acs.jmedchem.5b01461
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7075650</pub-id>-->
        <pub-id pub-id-type="pmid">
         26878082
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hijano
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Maron
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           RT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Respiratory viral infections in patients with cancer or undergoing hematopoietic cell transplant
        </article-title>
        <source>
         Front Microbiol
        </source>
        <year>
         2018
        </year>
        <volume>
         9
        </volume>
        <fpage>
         3097
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2018.03097
        </pub-id>
        <pub-id pub-id-type="pmid">
         30619176
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Milano
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Campbell
          </surname>
          <given-names>
           AP
          </given-names>
         </name>
         <name>
          <surname>
           Guthrie
          </surname>
          <given-names>
           KA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients
        </article-title>
        <source>
         Blood
        </source>
        <year>
         2010
        </year>
        <volume>
         115
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         2088
        </fpage>
        <lpage>
         2094
        </lpage>
        <pub-id pub-id-type="doi">
         10.1182/blood-2009-09-244152
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2837322</pub-id>-->
        <pub-id pub-id-type="pmid">
         20042728
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ogimi
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Waghmare
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical significance of human coronavirus in bronchoalveolar lavage samples from hematopoietic cell transplant recipients and patients with hematologic malignancies
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2017
        </year>
        <volume>
         64
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1532
        </fpage>
        <lpage>
         1539
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/cid/cix160
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5434339</pub-id>-->
        <pub-id pub-id-type="pmid">
         28329354
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ghosh
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <name>
          <surname>
           Xi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Progress in anti-SARS coronavirus chemistry, biology and chemotherapy
        </article-title>
        <source>
         Annu Rep Med Chem
        </source>
        <year>
         2007
        </year>
        <volume>
         41
        </volume>
        <fpage>
         183
        </fpage>
        <lpage>
         196
        </lpage>
        <!--<pub-id pub-id-type="pmcid">2718771</pub-id>-->
        <pub-id pub-id-type="pmid">
         19649165
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           LaFemina
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alternative screening approaches for discovery of middle east respiratory syndrome coronavirus inhibitors
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        <year>
         2014
        </year>
        <volume>
         58
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4251
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/AAC.03406-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4135998</pub-id>-->
        <pub-id pub-id-type="pmid">
         24867994
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benites
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Cabrini
          </surname>
          <given-names>
           DP
          </given-names>
         </name>
         <name>
          <surname>
           Silva
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute respiratory viral infections in pediatric cancer patients undergoing chemotherapy
        </article-title>
        <source>
         J Pediatr (Rio J)
        </source>
        <year>
         2014
        </year>
        <volume>
         90
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         370
        </fpage>
        <lpage>
         376
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jped.2014.01.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         24703819
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balzarini
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Carbohydrate-binding agents: a potential future cornerstone for the chemotherapy of enveloped viruses?
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2007
        </year>
        <volume>
         18
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         1
        </fpage>
        <lpage>
         11
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020701800101
        </pub-id>
        <pub-id pub-id-type="pmid">
         17354647
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chou
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           GG
          </given-names>
         </name>
        </person-group>
        <article-title>
         Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme
        </article-title>
        <source>
         Antivir Chem Chemother
        </source>
        <year>
         2009
        </year>
        <volume>
         19
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         151
        </fpage>
        <lpage>
         156
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/095632020901900402
        </pub-id>
        <pub-id pub-id-type="pmid">
         19374142
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chebotkevich
          </surname>
          <given-names>
           VN
          </given-names>
         </name>
         <name>
          <surname>
           Bessmel'tsev
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Volkov
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Molecular biology investigation of respiratory viruses as a factor of infectious complications in hemoblastosis and myelodepression]
        </article-title>
        <source>
         Vopr Onkol
        </source>
        <year>
         2006
        </year>
        <volume>
         52
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         421
        </fpage>
        <lpage>
         426
        </lpage>
        <pub-id pub-id-type="pmid">
         17024815
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Synthesis of novel test compounds for antiviral chemotherapy of severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <issue>
         18
        </issue>
        <fpage>
         2095
        </fpage>
        <lpage>
         2162
        </lpage>
        <pub-id pub-id-type="doi">
         10.2174/0929867054637644
        </pub-id>
        <pub-id pub-id-type="pmid">
         16101496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B-S
          </given-names>
         </name>
         <name>
          <surname>
           National Research Project for Sars
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2005
        </year>
        <volume>
         328
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         979
        </fpage>
        <lpage>
         986
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2005.01.048
        </pub-id>
        <pub-id pub-id-type="pmid">
         15707974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kesel
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         A system of protein target sequences for anti-RNA-viral chemotherapy by a vitamin B6-derived zinc-chelating trioxa-adamantane-triol
        </article-title>
        <source>
         Bioorg Med Chem
        </source>
        <year>
         2003
        </year>
        <volume>
         11
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         4599
        </fpage>
        <lpage>
         4613
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0968-0896(03)00500-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         14527557
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Folz
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Elkordy
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pneumonia following autologous bone marrow transplantation for breast cancer
        </article-title>
        <source>
         Chest
        </source>
        <year>
         1999
        </year>
        <volume>
         115
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         901
        </fpage>
        <lpage>
         905
        </lpage>
        <pub-id pub-id-type="doi">
         10.1378/chest.115.3.901
        </pub-id>
        <pub-id pub-id-type="pmid">
         10084516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS22">
       <label>
        22.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools
        </article-title>
        <source>
         Virol Sin
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1007/s12250-020-00207-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7035235</pub-id>-->
        <pub-id pub-id-type="pmid">
         32125642
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Acland
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Gunson
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Gillette
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ulcerative duodenitis in foals
        </article-title>
        <source>
         Vet Pathol
        </source>
        <year>
         1983
        </year>
        <volume>
         20
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         653
        </fpage>
        <lpage>
         661
        </lpage>
        <pub-id pub-id-type="doi">
         10.1177/030098588302000601
        </pub-id>
        <pub-id pub-id-type="pmid">
         6649336
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS24">
       <label>
        24.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/S2213-2600(20)30116-8
        </pub-id>
        <pub-id pub-id-type="pmid">
         32171062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS25">
       <label>
        25.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.5582/bst.2020.01020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           MHM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: clinical and laboratory manifestations
        </article-title>
        <source>
         Clin Biochem Rev
        </source>
        <year>
         2004
        </year>
        <volume>
         25
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         121
        </fpage>
        <lpage>
         132
        </lpage>
        <pub-id pub-id-type="pmid">
         18458712
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mahmud-Al-Rafat
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Taufiqur Rahman
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Decoding the enigma of antiviral crisis: does one target molecule regulate all? Cytokine
        </article-title>
        <source>
         Cytokine
        </source>
        <year>
         2019
        </year>
        <volume>
         115
        </volume>
        <fpage>
         13
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.cyto.2018.12.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         30616034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SSY
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K-Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         The management of coronavirus infections with particular reference to SARS
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2008
        </year>
        <volume>
         62
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         437
        </fpage>
        <lpage>
         441
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkn243
        </pub-id>
        <pub-id pub-id-type="pmid">
         18565970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Alekseev
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2008
        </year>
        <volume>
         82
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         4420
        </fpage>
        <lpage>
         4428
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.02190-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2293053</pub-id>-->
        <pub-id pub-id-type="pmid">
         18287230
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amici
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Di Caro
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Ciucci
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Indomethacin has a potent antiviral activity against SARS coronavirus
        </article-title>
        <source>
         Antivir Ther
        </source>
        <year>
         2006
        </year>
        <volume>
         11
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         1021
        </fpage>
        <lpage>
         1030
        </lpage>
        <pub-id pub-id-type="pmid">
         17302372
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           L-X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J-M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [A study of pulmonary inflammatory reaction induced by N-protein of SARS-CoV in rat models and effects of glucocorticoids on it]
        </article-title>
        <source>
         Zhonghua nei ke za zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         44
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         890
        </fpage>
        <lpage>
         893
        </lpage>
        <pub-id pub-id-type="pmid">
         16409721
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chihrin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome
        </article-title>
        <source>
         Expert Rev Anti-infect Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         251
        </fpage>
        <lpage>
         262
        </lpage>
        <pub-id pub-id-type="doi">
         10.1586/14787210.3.2.251
        </pub-id>
        <pub-id pub-id-type="pmid">
         15918782
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Michaelis
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells
        </article-title>
        <source>
         Int J Mol Med
        </source>
        <year>
         2005
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         323
        </fpage>
        <lpage>
         327
        </lpage>
        <pub-id pub-id-type="pmid">
         15647850
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AKL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Exp Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         136
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         95
        </fpage>
        <lpage>
         103
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1365-2249.2004.02415.x
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">1808997</pub-id>-->
        <pub-id pub-id-type="pmid">
         15030519
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2003
        </year>
        <volume>
         52
        </volume>
        <issue>
         Pt 8
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         720
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.05320-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         12867568
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tobinick
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <article-title>
         TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection
        </article-title>
        <source>
         Curr Med Res Opin
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         39
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="doi">
         10.1185/030079903125002757
        </pub-id>
        <pub-id pub-id-type="pmid">
         14741070
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Atanasova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Van Gucht
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Van Reeth
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-TNF-alpha therapy does not ameliorate disease in a model of acute virus-endotoxin mediated respiratory disease in pigs
        </article-title>
        <source>
         Vet Immunol Immunopathol
        </source>
        <year>
         2010
        </year>
        <volume>
         137
        </volume>
        <issue>
         1–2
        </issue>
        <fpage>
         12
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetimm.2010.04.003
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2922464</pub-id>-->
        <pub-id pub-id-type="pmid">
         20466438
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS38">
       <label>
        38.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25770
        </pub-id>
        <pub-id pub-id-type="pmid">
         32181911
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Conti
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by COVID-19: anti-inflammatory strategies
        </article-title>
        <source>
         J Biol Regul Homeost Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         pii:1
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS40">
       <label>
        40.
       </label>
       <element-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yamaya
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Nishimura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells
        </article-title>
        <source>
         Respir Investig
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1016/j.resinv.2019.12.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         32094077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           ES
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           PG
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical progression and cytokine profiles of middle east respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J Korean Medi Sci
        </source>
        <year>
         2016
        </year>
        <volume>
         31
        </volume>
        <issue>
         11
        </issue>
        <fpage>
         1717
        </fpage>
        <lpage>
         1725
        </lpage>
        <pub-id pub-id-type="doi">
         10.3346/jkms.2016.31.11.1717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response
        </article-title>
        <source>
         Microb Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         15
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         88
        </fpage>
        <lpage>
         95
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.micinf.2012.10.008
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2011
        </year>
        <volume>
         420
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         106
        </fpage>
        <lpage>
         116
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2011.09.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         21959016
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS45">
       <label>
        45.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           SX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2009
        </year>
        <volume>
         395
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         210
        </fpage>
        <lpage>
         222
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2009.09.023
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2787736</pub-id>-->
        <pub-id pub-id-type="pmid">
         19853271
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS46">
       <label>
        46.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ishii
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Hasegawa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Nagata
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model
        </article-title>
        <source>
         Microbiol Immunol
        </source>
        <volume>
         53
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         75
        </fpage>
        <lpage>
         82
        </lpage>
        <pub-id pub-id-type="pmid">
         19291090
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS47">
       <label>
        47.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yoshikawa
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Hill
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2009
        </year>
        <volume>
         83
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         3039
        </fpage>
        <lpage>
         3048
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01792-08
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2655569</pub-id>-->
        <pub-id pub-id-type="pmid">
         19004938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS48">
       <label>
        48.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         365
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         324
        </fpage>
        <lpage>
         335
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.04.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         17490702
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS49">
       <label>
        49.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Okabayashi
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Kariwa
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Yokota
          </surname>
          <given-names>
           S-I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2006
        </year>
        <volume>
         78
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         417
        </fpage>
        <lpage>
         424
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20556
        </pub-id>
        <pub-id pub-id-type="pmid">
         16482545
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W-H
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           B-L
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S-C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations and inflammatory cytokine responses in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         J Formosan Med Assoc = Taiwan yi zhi
        </source>
        <year>
         2005
        </year>
        <volume>
         104
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         715
        </fpage>
        <lpage>
         723
        </lpage>
        <pub-id pub-id-type="pmid">
         16385373
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS51">
       <label>
        51.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C-TK
          </given-names>
         </name>
         <name>
          <surname>
           Perrone
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and the innate immune responses: modulation of effector cell function without productive infection
        </article-title>
        <source>
         J Immunol
        </source>
        <year>
         2005
        </year>
        <volume>
         174
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         7977
        </fpage>
        <lpage>
         7985
        </lpage>
        <pub-id pub-id-type="doi">
         10.4049/jimmunol.174.12.7977
        </pub-id>
        <pub-id pub-id-type="pmid">
         15944304
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS52">
       <label>
        52.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K-J
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           I-J
          </given-names>
         </name>
         <name>
          <surname>
           Theron
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An interferon-gamma-related cytokine storm in SARS patients
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         75
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         185
        </fpage>
        <lpage>
         194
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.20255
        </pub-id>
        <pub-id pub-id-type="pmid">
         15602737
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS53">
       <label>
        53.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W-K
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S-Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2004
        </year>
        <volume>
         39
        </volume>
        <issue>
         7
        </issue>
        <fpage>
         1071
        </fpage>
        <lpage>
         1075
        </lpage>
        <pub-id pub-id-type="doi">
         10.1086/423808
        </pub-id>
        <pub-id pub-id-type="pmid">
         15472864
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analysis of serum cytokines in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         Infect Immun
        </source>
        <year>
         2004
        </year>
        <volume>
         72
        </volume>
        <issue>
         8
        </issue>
        <fpage>
         4410
        </fpage>
        <lpage>
         4415
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/IAI.72.8.4410-4415.2004
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">470699</pub-id>-->
        <pub-id pub-id-type="pmid">
         15271897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS55">
       <label>
        55.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dynamic changes and the meanings of blood cytokines in severe acute respiratory syndrome
        </article-title>
        <source>
         Chin J Tuberc Respir Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         26
        </volume>
        <issue>
         10
        </issue>
        <fpage>
         586
        </fpage>
        <lpage>
         589
        </lpage>
       </element-citation>
      </ref>
      <ref id="refS56">
       <label>
        56.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CWK
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome
        </article-title>
        <source>
         Pediatrics
        </source>
        <year>
         2004
        </year>
        <volume>
         113
        </volume>
        <fpage>
         e7
        </fpage>
        <lpage>
         e14
        </lpage>
        <pub-id pub-id-type="doi">
         10.1542/peds.113.1.e7
        </pub-id>
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS57">
       <label>
        57.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Griffin
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Tucker
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         e30
        </fpage>
        <lpage>
         e1
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS58">
       <label>
        58.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS59">
       <label>
        59.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Xue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The coronavirus transmissible gastroenteritis virus evades the type I interferon response through IRE1alpha-mediated manipulation of the microRNA miR-30a-5p/SOCS1/3 axis
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2018
        </year>
        <volume>
         92
        </volume>
        <issue>
         22
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00728-18
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS60">
       <label>
        60.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           C-W
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           Y-Z
          </given-names>
         </name>
         <name>
          <surname>
           Hsu
          </surname>
          <given-names>
           H-Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting coronaviral replication and cellular JAK2 mediated dominant NF-κB activation for comprehensive and ultimate inhibition of coronaviral activity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4105
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04203-9
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5481340</pub-id>-->
        <pub-id pub-id-type="pmid">
         28642467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS61">
       <label>
        61.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wathelet
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           Orr
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2007
        </year>
        <volume>
         81
        </volume>
        <issue>
         21
        </issue>
        <fpage>
         11620
        </fpage>
        <lpage>
         11633
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00702-07
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2168762</pub-id>-->
        <pub-id pub-id-type="pmid">
         17715225
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS62">
       <label>
        62.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           HG
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia]
        </article-title>
        <source>
         Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chin J Tuberc Respir Dis
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         0
        </issue>
        <fpage>
         E005
        </fpage>
       </element-citation>
      </ref>
      <ref id="refS63">
       <label>
        63.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Miura
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Holmes
          </surname>
          <given-names>
           KV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Rat coronaviruses infect rat alveolar type I epithelial cells and induce expression of CXC chemokines
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2007
        </year>
        <volume>
         369
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         288
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2007.07.030
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">2170429</pub-id>-->
        <pub-id pub-id-type="pmid">
         17804032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS64">
       <label>
        64.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zalinger
          </surname>
          <given-names>
           ZB
          </given-names>
         </name>
         <name>
          <surname>
           Elliott
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           SR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of the inflammasome-related cytokines Il-1 and Il-18 during infection with murine coronavirus
        </article-title>
        <source>
         J Neurovirol
        </source>
        <year>
         2017
        </year>
        <volume>
         23
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         845
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s13365-017-0574-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">5726909</pub-id>-->
        <pub-id pub-id-type="pmid">
         28895072
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS65">
       <label>
        65.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           IY
          </given-names>
         </name>
         <name>
          <surname>
           Moriyama
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           M-F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus viroporin 3a activates the nlrp3 inflammasome
        </article-title>
        <source>
         Front Microbiol
        </source>
        <year>
         2019
        </year>
        <volume>
         10
        </volume>
        <fpage>
         50
        </fpage>
        <pub-id pub-id-type="doi">
         10.3389/fmicb.2019.00050
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">6361828</pub-id>-->
        <pub-id pub-id-type="pmid">
         30761102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS66">
       <label>
        66.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kritas
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Ronconi
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Caraffa
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy
        </article-title>
        <source>
         J Biol Regul Homeostat Agents
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <issue>
         1
        </issue>
       </element-citation>
      </ref>
      <ref id="refS67">
       <label>
        67.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS immunity and vaccination
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        <year>
         2004
        </year>
        <volume>
         1
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         193
        </fpage>
        <lpage>
         198
        </lpage>
        <pub-id pub-id-type="pmid">
         16219167
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS68">
       <label>
        68.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hart
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Dyall
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Postnikova
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays
        </article-title>
        <source>
         J Gen Virol
        </source>
        <year>
         2014
        </year>
        <volume>
         95
        </volume>
        <issue>
         Pt 3
        </issue>
        <fpage>
         571
        </fpage>
        <lpage>
         577
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/vir.0.061911-0
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">3929173</pub-id>-->
        <pub-id pub-id-type="pmid">
         24323636
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS69">
       <label>
        69.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
         <name>
          <surname>
           Moses
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2018
        </year>
        <volume>
         150
        </volume>
        <fpage>
         155
        </fpage>
        <lpage>
         163
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.12.015
        </pub-id>
        <pub-id pub-id-type="pmid">
         29289665
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS70">
       <label>
        70.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2015
        </year>
        <volume>
         115
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         25542975
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS71">
       <label>
        71.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J Infect
        </source>
        <year>
         2013
        </year>
        <volume>
         67
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         606
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jinf.2013.09.029
        </pub-id>
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS72">
       <label>
        72.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2019
        </year>
        <volume>
         93
        </volume>
        <issue>
         12
        </issue>
        <pub-id pub-id-type="doi">
         10.1128/JVI.00023-19
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS73">
       <label>
        73.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Morgenstern
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2003
        </year>
        <volume>
         361
        </volume>
        <issue>
         9374
        </issue>
        <fpage>
         2045
        </fpage>
        <lpage>
         2046
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(03)13615-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         12814717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS74">
       <label>
        74.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Ghamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Alghamdi
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ghandoora
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        <year>
         2016
        </year>
        <volume>
         16
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         174
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12879-016-1492-4
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4839124</pub-id>-->
        <pub-id pub-id-type="pmid">
         27097824
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS75">
       <label>
        75.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J Infect Dis
        </source>
        <year>
         2015
        </year>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/infdis/jiv392
        </pub-id>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS76">
       <label>
        76.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           DL
          </given-names>
         </name>
         <name>
          <surname>
           Day
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Bailey
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2006
        </year>
        <volume>
         71
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         53
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.03.001
        </pub-id>
        <pub-id pub-id-type="pmid">
         16621037
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS77">
       <label>
        77.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fisher
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of treatment modalities for Middle East Respiratory Syndrome
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         71
        </volume>
        <issue>
         12
        </issue>
        <fpage>
         3340
        </fpage>
        <lpage>
         3350
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/jac/dkw338
        </pub-id>
        <pub-id pub-id-type="pmid">
         27585965
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS78">
       <label>
        78.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
        </article-title>
        <source>
         Expert Rev Anti Infect Ther
        </source>
        <year>
         2017
        </year>
        <volume>
         15
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         269
        </fpage>
        <lpage>
         275
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/14787210.2017.1271712
        </pub-id>
        <pub-id pub-id-type="pmid">
         27937060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS79">
       <label>
        79.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease
        </article-title>
        <source>
         Clin Microbiol Rev
        </source>
        <year>
         2015
        </year>
        <volume>
         28
        </volume>
        <issue>
         2
        </issue>
        <fpage>
         465
        </fpage>
        <lpage>
         522
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/CMR.00102-14
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">4402954</pub-id>-->
        <pub-id pub-id-type="pmid">
         25810418
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS80">
       <label>
        80.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rabaan
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Alahmed
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Bazzi
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective
        </article-title>
        <source>
         J Med Microbiol
        </source>
        <year>
         2017
        </year>
        <volume>
         66
        </volume>
        <issue>
         9
        </issue>
        <fpage>
         1261
        </fpage>
        <lpage>
         1274
        </lpage>
        <pub-id pub-id-type="doi">
         10.1099/jmm.0.000565
        </pub-id>
        <!--<pub-id pub-id-type="pmcid">7079582</pub-id>-->
        <pub-id pub-id-type="pmid">
         28855003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS81">
       <label>
        81.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Kallies
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
        </article-title>
        <source>
         Virus Res
        </source>
        <year>
         2012
        </year>
        <volume>
         165
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         112
        </fpage>
        <lpage>
         117
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2012.02.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         22349148
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS82">
       <label>
        82.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report
        </article-title>
        <source>
         Am J Transplant
        </source>
        <year>
         2015
        </year>
        <volume>
         15
        </volume>
        <issue>
         4
        </issue>
        <fpage>
         1101
        </fpage>
        <lpage>
         1104
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/ajt.13085
        </pub-id>
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </element-citation>
      </ref>
      <ref id="refS83">
       <label>
        83.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Carbajo-Lozoya
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ma-Lauer
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Malesevic
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir
        </article-title>
        <source>
         Virus Res
        </source>
        <volume>
         184
        </volume>
        <fpage>
         44
        </fpage>
        <lpage>
         53
        </lpage>
        <pub-id pub-id-type="pmid">
         24566223
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
    <floats-group>
     <table-wrap id="table1" position="float">
      <label>
       Table 1.
      </label>
      <caption>
       <title>
        Search terms and the number of studies included for each investigated drug group.
       </title>
      </caption>
      <table frame="border" rules="all">
       <thead>
        <tr>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Drug group
         </th>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Search terms
         </th>
         <th align="center" colspan="1" rowspan="1" valign="middle">
          Number of studies included
         </th>
        </tr>
       </thead>
       <tbody>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          All cytotoxic
          <break>
          </break>
          chemotherapy
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or Middle East Respiratory Syndrome Coronavirus (MERS-CoV) or SARS-CoV AND
          <break>
          </break>
          chemotherapy)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          24/30
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Low-dose steroids/NSAIDs
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-inflammatory or ibuprofen or isobutylphenylpropionic acid or cortisone or non-steroidal anti-inflammatory)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13/58
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Any TNF blocker
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (TNF blocker or Anti-TNF therapy or TNFα inhibitor or infliximab or etanercept or Certolizumab or Golimumab or adalimumab))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          2/3
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          IL-6 blockade
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Two different search strategies were explored due to the number of agents that block the IL-6:
          <break>
          </break>
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (Anti-IL-6 therapy or anti-interleukin-6 receptor antibody or anti-interlukin-6 therapy or interlukin 6 blockage or interlukin-6 blockage or IL 6 blockage or IL-6 blockage or tocilizumab or siltuximab or Sylvant or sarilumab or olokizumab or CDP6038 or elsilimomab or BMS-945429 or ALD518 or sirukumab or CNTO 136 or CPSI-2364 or ALX-0061 or clazakizumab or olokizumab or sarilumab or sirukumab or ARGX-109 or FE301 or FM101))
          <break>
          </break>
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) and (IL-6 or interlukin 6 or Anti-IL-6 therapy or IL-6 blockage or tocilizumab or siltuximab))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
          <break>
          </break>
          23/108
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          JAK inhibitors
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) and (JAK or JAK1 or JAK2 or TYK3 or tofacitinib or baricitinib or filgotinib or peficitinib or ABT494 or decernotinib))
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          4/15
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          IL-1 blockade
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (Interleukin-1 or IL-1 or IL-1RA or canakinumab or anti-IL-1 or IL-1 antagonists or IL-1 blockers or rilonacept or IL-1 trap or ACZ885 or anakinra)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          9/37
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Mycophenylate
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (mycophenolate mofetil OR mycophenolate OR myfortic)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          13/29
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Tacrolimus
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          (SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (envarsus or tacni or tacrolimus or prograf or FK506)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          3/18
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          Anti-CD20
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (anti-cd20 monoclonal antibodies or anti-cd20 or rituximab or truxima or zevalin or ruxience or rituxan or arzerra or gazyva)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
        <tr>
         <td align="left" colspan="1" rowspan="1" valign="top">
          CTLA4-Ig
         </td>
         <td align="left" colspan="1" rowspan="1" valign="top">
          ((SARS-CoV-2 or coronavirus or COVID or betacoronavirus or MERS-CoV or SARS-CoV) AND (CTLA-4 Ig or CTLA4 or CTLA-4 or Ipilimumab or yervoy)
         </td>
         <td align="center" colspan="1" rowspan="1" valign="top">
          0
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </floats-group>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Autoimmun
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Autoimmun
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Autoimmunity
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0896-8411
      </issn>
      <issn pub-type="epub">
       1095-9157
      </issn>
      <publisher>
       <publisher-name>
        Elsevier Ltd.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32143990
      </article-id>
      <article-id pub-id-type="pmc">
       7126544
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0896-8411(20)30047-0
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.jaut.2020.102434
      </article-id>
      <article-id pub-id-type="publisher-id">
       102434
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au1">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Yongshi
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au2">
        <name>
         <surname>
          Peng
         </surname>
         <given-names>
          Fujun
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au3">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Runsheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         d
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au4">
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          Kai
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au5">
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          Taijiao
         </given-names>
        </name>
        <email>
         taijiao@ibms.pumc.edu.cn
        </email>
        <xref ref-type="aff" rid="aff2">
         b
        </xref>
        <xref ref-type="aff" rid="aff3">
         c
        </xref>
        <xref ref-type="corresp" rid="cor4">
         ∗∗∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au6">
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          Guogang
         </given-names>
        </name>
        <email>
         guogang_xu@qq.com
        </email>
        <xref ref-type="aff" rid="aff5">
         e
        </xref>
        <xref ref-type="corresp" rid="cor3">
         ∗∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au7">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Jinlyu
         </given-names>
        </name>
        <email>
         sunjinlv@pumch.cn
        </email>
        <xref ref-type="aff" rid="aff1">
         a
        </xref>
        <xref ref-type="corresp" rid="cor2">
         ∗∗
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au8">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          Christopher
         </given-names>
        </name>
        <email>
         chrchang@ucdavis.edu
        </email>
        <xref ref-type="aff" rid="aff6">
         f
        </xref>
        <xref ref-type="aff" rid="aff7">
         g
        </xref>
        <xref ref-type="corresp" rid="cor1">
         ∗
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff1">
       <label>
        a
       </label>
       Department of Allergy &amp; Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College &amp; Chinese Academy of Medical Sciences, National Clinical Research Center for Immunologic Diseases, Beijing, 100730, China
      </aff>
      <aff id="aff2">
       <label>
        b
       </label>
       Center for Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, 100005, China
      </aff>
      <aff id="aff3">
       <label>
        c
       </label>
       Suzhou Institute of Systems Medicine, Suzhou, Jiangsu 215123, China
      </aff>
      <aff id="aff4">
       <label>
        d
       </label>
       Department of Respiratory Diseases, The Second Medical Center &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China
      </aff>
      <aff id="aff5">
       <label>
        e
       </label>
       Department of Infection Prevention and Disease Control, The Second Medical Center &amp; National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, 100853, China
      </aff>
      <aff id="aff6">
       <label>
        f
       </label>
       Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA, 95616, USA
      </aff>
      <aff id="aff7">
       <label>
        g
       </label>
       Division of Pediatric Immunology and Allergy, Joe DiMaggio Children's Hospital, Hollywood, FL, USA
      </aff>
      <author-notes>
       <corresp id="cor1">
        <label>
         ∗
        </label>
        Corresponding authors. University of California, Davis, 451 Health Sciences Drive, Suite 6510, Davis, CA 95616, USA.
        <email>
         chrchang@ucdavis.edu
        </email>
       </corresp>
       <corresp id="cor2">
        <label>
         ∗∗
        </label>
        Corresponding author. No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, 100730, China.
        <email>
         sunjinlv@pumch.cn
        </email>
       </corresp>
       <corresp id="cor3">
        <label>
         ∗∗∗
        </label>
        Corresponding authors. No.28 Fuxing Road, Beijing, 100853, China.
        <email>
         guogang_xu@qq.com
        </email>
       </corresp>
       <corresp id="cor4">
        <label>
         ∗∗∗∗
        </label>
        Corresponding author. No.9, Dongdan 3 rd, Dongcheng District, Beijing, 100005, China.
        <email>
         taijiao@ibms.pumc.edu.cn
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p id="ntpara0010">
         Yongshi Yang, Fujun Peng, Runsheng Wang contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       102434
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         19
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         22
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier Ltd. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Elsevier Ltd
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="abs0010">
       <p>
        The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. This viral epidemic in China has led to the deaths of over 1800 people, mostly elderly or those with an underlying chronic disease or immunosuppressed state. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002–2003 and MERS in 2012. While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 may present with varying degrees of severity, from flu-like symptoms to death. It is currently believed that this deadly Coronavirus strain originated from wild animals at the Huanan market in Wuhan, a city in Hubei province. Bats, snakes and pangolins have been cited as potential carriers based on the sequence homology of CoV isolated from these animals and the viral nucleic acids of the virus isolated from SARS-CoV-2 infected patients. Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes, were instituted in January 2020 to prevent spread of the virus, but by that time much of the damage had been done, as human-human transmission became evident. While these quarantine measures are necessary and have prevented a historical disaster along the lines of the Spanish flu, earlier recognition and earlier implementation of quarantine measures may have been even more effective. Lessons learned from SARS resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy. However, it is clear that finding an effective antiviral and developing a vaccine are still significant challenges. The costs of the epidemic are not limited to medical aspects, as the virus has led to significant sociological, psychological and economic effects globally. Unfortunately, emergence of SARS-CoV-2 has led to numerous reports of Asians being subjected to racist behavior and hate crimes across the world.
       </p>
      </abstract>
      <abstract abstract-type="author-highlights" id="abs0015">
       <title>
        Highlights
       </title>
       <p>
        <list id="ulist0010" list-type="simple">
         <list-item id="u0010">
          <p id="p0010">
           •The 2019-nCoV is officially called SARS-CoV-2, and is the cause of the disease named COVID-19.
          </p>
         </list-item>
         <list-item id="u0015">
          <p id="p0015">
           •COVID-19 is the third severe epidemic caused by coronaviruses in the past 20 years.
          </p>
         </list-item>
         <list-item id="u0020">
          <p id="p0020">
           •It is believed that the SARS-CoV-2 virus originated from bats, based on genomic sequencing.
          </p>
         </list-item>
         <list-item id="u0025">
          <p id="p0025">
           •While human strains of Coronavirus are associated with about 15% of cases of the common cold, the SARS-CoV-2 is far more deadly, with a mortality rate around 2.3%.
          </p>
         </list-item>
         <list-item id="u0030">
          <p id="p0030">
           •As of February 19th, 2020, there have been 75,282 confirmed cases and 2012 deaths worldwide.
          </p>
         </list-item>
         <list-item id="u0035">
          <p id="p0035">
           •Lessons learned from SARS in 2003 resulted in faster determination of the nucleic acid sequence and a more robust quarantine strategy.
          </p>
         </list-item>
         <list-item id="u0040">
          <p id="p0040">
           •Extreme quarantine measures, including sealing off large cities, closing borders and confining people to their homes are critical to stemming spread of the virus.
          </p>
         </list-item>
         <list-item id="u0045">
          <p id="p0045">
           •Pyroptosis, a novel form of inflammatory cell death, is a possible mechanism for the increased virulence of the SARS-CoV-2.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <kwd-group id="kwrds0010">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Pneumonia
       </kwd>
       <kwd>
        Flu
       </kwd>
       <kwd>
        Bats
       </kwd>
       <kwd>
        Human to human transmission
       </kwd>
       <kwd>
        Epidemic
       </kwd>
       <kwd>
        Pandemic
       </kwd>
       <kwd>
        Pyroptosis
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0050">
      Coronaviruses (CoVs) are named for the crown-like spikes on their surface and belong to the family Coronaviridae within the order Nidovirales. Coronaviruses broadly infect vertebrates including humans, birds, bats, snakes, mice and other wild animals [
      <xref ref-type="bibr" rid="bib1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib2">
       2
      </xref>
      ]. Since the mid-1960s, seven known human coronaviruses (HCoVs) have been identified [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib4">
       4
      </xref>
      ]. Four commonly detected HCoVs are 229E, OC43, NL63 and HKU1. In one study, 229E and OC43 accounted for approximately 15–29% of respiratory pathogens with relatively low virulence in humans [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib5">
       5
      </xref>
      ]. Another epidemiological study in adults estimates that coronavirus causes about 15% of common colds [
      <xref ref-type="bibr" rid="bib6">
       6
      </xref>
      ]. Other significant causes of upper respiratory infections include influenza virus, rhinovirus, parainfluenza virus, Group A Streptococci, EBV and respiratory syncytial virus (RSV).
     </p>
     <p id="p0055">
      The three other strains of HCoVs, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have a different pathogenicity and lead to higher mortality rates in human populations. MERS-CoV was isolated from a male patient who died from acute pneumonia and renal failure in Saudi Arabia in 2012 [
      <xref ref-type="bibr" rid="bib7">
       7
      </xref>
      ], and was subsequently responsible for 2494 cases and 858 deaths from 27 different countries (case-fatality rate: 34.4%) [
      <xref ref-type="bibr" rid="bib8">
       8
      </xref>
      ]. Both SARS-CoV and SARS-CoV-2 were first recognized in China. SARS-CoV caused a total of 8422 probable SARS cases, 919 SARS-related deaths (case-fatality rate: 11%) and spread to 32 different countries or regions between November 2002 and August 2003 [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ]. Since December 2019, the SARS-CoV-2 has infected 73,230 people and caused 1871 deaths (case-fatality rate: 2.6%) and has spread to 25 countries, according to the State Council Information Office in Beijing, China (updated as of Feb. 17, 2020) [
      <xref ref-type="bibr" rid="bib10">
       10
      </xref>
      ]. As of this date, the number of confirmed and suspected cases is still increasing, as is the number of deaths, although there is a significant increase in the number of recovered patients as well.
     </p>
     <p id="p0060">
      Coronaviruses were first identified in the 1960s. It is not known for how long they have existed. Most of the time they are associated with mild disease, but every few years a highly virulent strain appears. The pathogenesis of these deadly epidemics is unclear. An examination of the structure of the viruses and the mechanism of infection may help elucidate and provide information for the development of effective treatment and possibly vaccines. Our purpose of this review is to provide a brief summary of the epidemiology and history of SARS, as well as the lessons learned. The other aim is to review the epidemiology, pathogenesis, clinical characteristics, diagnosis and management of patients infected with SARS-CoV-2 to better understand this deadly coronavirus and suggest prevention, treatment and management strategies.
     </p>
    </sec>
    <sec id="sec2">
     <label>
      2
     </label>
     <title>
      Characteristics of coronaviruses and coronavirus infections
     </title>
     <sec id="sec2.1">
      <label>
       2.1
      </label>
      <title>
       Biology of the coronaviruses
      </title>
      <p id="p0065">
       CoVs are enveloped with a non-segmented, positive-sense, single-strand RNA, with size ranging from 26,000 to 37,000 bases. This is the largest known genome among RNA viruses [
       <xref ref-type="bibr" rid="bib11">
        11
       </xref>
       ]. The genomic structure of CoVs is as follows: 5′-leader-UTR-replicase-S (Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail. There are accessory genes interspersed within the structural genes at the 3′ end of genome [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ], some of which have been shown to play an important roles in viral pathogenesis [
       <xref ref-type="bibr" rid="bib13">
        13
       </xref>
       ]. The S protein is responsible for receptor-binding and subsequent viral entry into host cells, the M and E proteins play important roles in viral assembly, and the N protein is necessary for RNA synthesis [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib14">
        14
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.2">
      <label>
       2.2
      </label>
      <title>
       Coronavirus transmission
      </title>
      <p id="p0070">
       CoVs can transmit across species barriers. SARS-CoV originated from bats of the Hipposideridae family, using palm civets as intermediary hosts before dissemination to humans [
       <xref ref-type="bibr" rid="bib15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib16">
        16
       </xref>
       ]. The earliest patients infected with SARS-CoV-2 in Wuhan ultimately caused the epidemic known as COronaVIrus Disease 2019 (COVID-2019). Some of these patients had a history of contact with a wholesale seafood market in the early stages, suggesting animal-to-person spread. Subsequently, a large number of patients reportedly did not have exposure to the markets, suggesting the development of person-to-person spread [
       <xref ref-type="bibr" rid="bib17">
        [17]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib18">
        [18]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib19">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib20">
        [20]
       </xref>
       ].
      </p>
      <p id="p0075">
       There are three primary ways to transmit the virus, including close person-to-person contact, aerosol transmission, and transmission by touch [
       <xref ref-type="bibr" rid="bib21">
        [21]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        [22]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib23">
        [23]
       </xref>
       ]. The virus is thought to be transmitted to other people by respiratory droplets during coughing or sneezing. Droplet spread can occur when an infected person sneezes or coughs, whereupon virus containing droplets are propelled up to 3 feet through the air and are deposited on the mucous membranes of the mouth, nose, or eyes of persons who are nearby. A recent report suggests that transmission through the ocular surface is also possible [
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ]. The other avenues for the spread of the virus are shaking hands with an infected person, touching an infected object/surface, frequent touching of the nose or mouth or coming into contact with a patient's excreta. Another avenue is through “hidden transmission” [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ], in which asymptomatic infected individuals or carriers unknowingly transmit the virus to unsuspecting contacts.
      </p>
     </sec>
     <sec id="sec2.3">
      <label>
       2.3
      </label>
      <title>
       Variability of clinical presentation
      </title>
      <p id="p0080">
       Before the first outbreak of SARS, a limited number of HCoVs such as HCoV-229E were frequently found to infect humans, and were widely circulating in human populations causing only mild illnesses like the common cold [
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ]. However, SARS, MERS and SARS-CoV-2 present with a spectrum of disease severity ranging from flu-like symptoms to acute respiratory distress syndrome [
       <xref ref-type="bibr" rid="bib25">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. Early on, these patients are usually treated with conventional medications which had no clinical benefit, resulting in spread to health care personnel. For those with flu-like symptoms or even more severe disease, it would not be immediately evident that this is an atypical and virulent form of a coronavirus. For comparison, influenza has an estimated mortality rate of 0.07%–0.2%. A high index of suspicion is helpful but not foolproof.
      </p>
     </sec>
     <sec id="sec2.4">
      <label>
       2.4
      </label>
      <title>
       Genetic diversity
      </title>
      <p id="p0085">
       The various CoVs of animal origin undergo evolution and genetic recombination, thereby resulting in mutated CoVs that may be highly pathogenic and potentially be more deadly to humans [
       <xref ref-type="bibr" rid="bib3">
        3
       </xref>
       ,
       <xref ref-type="bibr" rid="bib27">
        27
       </xref>
       ]. For SARS-CoV, the mutation rate in the SARS-CoV genome was estimated to be 0.80–2.38 × 10
       <sup>
        −3
       </sup>
       nucleotide substitutions per site per year, and the nonsynonymous and synonymous substitution rates were estimated to be 1.16–3.30 × 10
       <sup>
        −3
       </sup>
       and 1.67–4.67 × 10
       <sup>
        −3
       </sup>
       per site per year, respectively, which are similar to that of other RNA viruses [
       <xref ref-type="bibr" rid="bib28">
        28
       </xref>
       ]. The various CoVs of animal origin undergo evolution and genetic recombination either within the host species or upon jumping from one species to another. Such changes thus have the potential to lead to variants that have high pathogenic potential when transmitted to humans [
       <xref ref-type="bibr" rid="bib29">
        [29]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib30">
        [30]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib31">
        [31]
       </xref>
       ]. Recently, two mutations of the S protein and N protein SARS-CoV-2 may explain its zoonotic transmission [
       <xref ref-type="bibr" rid="bib32">
        32
       </xref>
       ]. Genomic alignment of 54 SARS-CoV-2 genomes identified two hotspots of hypervariability at positions 8789 (synonymous variant) and 28,151(Ser/Leu change), located in the polyprotein and ORF8 genes respectively [
       <xref ref-type="bibr" rid="bib33">
        33
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.5">
      <label>
       2.5
      </label>
      <title>
       Comorbidities
      </title>
      <p id="p0090">
       Most patients who have died from the virus had other chronic medical conditions, were elderly patients or were immunocompromised. One study reported that 6.7% of SARS patients had acute renal impairment and 84.6% had proteinuria [
       <xref ref-type="bibr" rid="bib34">
        34
       </xref>
       ]. Hematological abnormalities such as thrombocytopenia and lymphopenia were frequently observed in SARS [
       <xref ref-type="bibr" rid="bib35">
        35
       </xref>
       ,
       <xref ref-type="bibr" rid="bib36">
        36
       </xref>
       ]. Complications encountered for SARS-CoV-2 include acute respiratory distress syndrome (29%,12/41), anemia (15%, 6/41), acute cardiac injury (12%, 5/41) and secondary infection (10%, 4/41) [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. In a SARS-CoV-2 descriptive study, 11 of 99 patients died of multiple organ failure, and seven were older than 60 years [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec2.6">
      <label>
       2.6
      </label>
      <title>
       Lack of effective treatment
      </title>
      <p id="p0095">
       To date, there is no anti-viral therapeutics that specifically targets human coronaviruses, so treatment is only supportive.
       <italic>
        In vitro
       </italic>
       , interferons (IFNs) are only partially effective against coronaviruses [
       <xref ref-type="bibr" rid="bib38">
        38
       </xref>
       ].
       <italic>
        In vivo
       </italic>
       , the effectiveness of IFNs combined with ribavirin requires further evaluation [
       <xref ref-type="bibr" rid="bib39">
        39
       </xref>
       ]. A variety of other agents, including antiviral peptides and corticosteroids have been shown to be effective
       <italic>
        in vitro
       </italic>
       and/or in animal models [
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ,
       <xref ref-type="bibr" rid="bib41">
        41
       </xref>
       ]. However, clinical evidence does not support the use of corticosteroid treatment for SARS-CoV-2 lung injury [
       <xref ref-type="bibr" rid="bib42">
        42
       </xref>
       ]. Vaccines that have been developed are either not effective, or in some cases have been reported to be involved in the selection of novel pathogenic CoVs via recombination of circulating strains [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib22">
        22
       </xref>
       ,
       <xref ref-type="bibr" rid="bib40">
        40
       </xref>
       ]. Vaccine development can be a challenge. It is noteworthy that almost 20 years after SARS, there is still no vaccine for coronavirus.
      </p>
     </sec>
    </sec>
    <sec id="sec3">
     <label>
      3
     </label>
     <title>
      A historical review of the epidemiology of SARS and how it was contained
     </title>
     <p id="p0100">
      It has been 17 years since the outbreak of severe acute respiratory syndrome (SARS) caused by the SARS coronavirus (SARS-CoV) [
      <xref ref-type="bibr" rid="bib43">
       43
      </xref>
      ]. This highly contagious atypical pneumonia first appeared in Guangdong Province, China, in November 2002. The initial cases were animal handlers in Guangzhou city having close contact with wild game food. It was suggested that civets could serve as an intermediate amplification host. Three months later, the SARS pandemic was rapidly and globally disseminated due to person-to-person transmission of the virus. On the February 21, 2003, a medical professor from Foshan in Guangdong province who was considered a “super-spreader” went to Hong Kong to visit his relatives. During his stay in Hong Kong, he transmitted the virus to 2 family members, 4 health care workers (HCWs) and 12 other nearby residents. Because of international travel and transmission to HCWs, these patients spread the SARS-CoV to Hong Kong and other countries including Vietnam, Singapore and Canada. Eventually, 8422 people were infected in 32 countries and 919 (11%) died [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ]. In China, 5328 cases were reported and 349 (6.5%) perished between November 16, 2002 and June 3, 2003 [
      <xref ref-type="bibr" rid="bib9">
       9
      </xref>
      ].
     </p>
     <p id="p0105">
      At the beginning of the outbreaks in Hong Kong, mainland China and other areas, we were unfamiliar with the deadly SARS-CoV. It took about 3 months to complete the sequencing of this coronavirus [
      <xref ref-type="bibr" rid="bib44">
       44
      </xref>
      ]. The global success in the fight against SARS was partly based on epidemiological and biological characteristics of the infectious agent SARS-CoV. An understanding of transmission patterns and the ability to diagnose and confirm affected patients ultimately led to effective containment measures and a slowdown in the spread of the disease. Due to the lack of medications or a vaccine, the options for early intervention were limited to public health measures [
      <xref ref-type="bibr" rid="bib45">
       45
      </xref>
      ].
     </p>
     <p id="p0110">
      The steps that led to the containment of SARS can be illustrated by the events that occurred in Beijing. Beijing experienced the largest outbreak of SARS beginning on the March 5, 2003. The outbreak peaked within 6 weeks on the April 25, 2003 when 173 newly suspected SARS cases were hospitalized daily [
      <xref ref-type="bibr" rid="bib46">
       46
      </xref>
      ]. On the June 20, 2003, the last batch of 18 SARS patients recovered and were discharged from hospital, signaling the end of the pandemic in Beijing. The prompt resolution of the outbreak in Beijing was attributed to the rapid adoption of a series of effective control measures.
      <list id="olist0010" list-type="simple">
       <list-item id="o0010">
        <label>
         1.
        </label>
        <p id="p0115">
         Thousands of local and military health workers were deployed for emergency management of the outbreak. Large quantities of emergency supplies including personal protective equipment (PPE) and medical apparat were sent to front-line medical sectors. These people and materials were key to winning the war against SARS.
        </p>
       </list-item>
       <list-item id="o0015">
        <label>
         2.
        </label>
        <p id="p0120">
         More than 100 fever clinics were set up in all secondary and tertiary hospitals in Beijing. People visiting the fever clinics had a physical examination including body temperature, white blood cell count and chest radiograph. Fever clinics played an important role in screening and triage.
        </p>
       </list-item>
       <list-item id="o0020">
        <label>
         3.
        </label>
        <p id="p0125">
         All actively ill patients with SARS were concentrated in designated hospital wards. On the May 1, 2003, a new 1000-bed SARS hospital (Xiaotangshan Hospital, Beijing) was built and put into operation immediately. The advantages of having such a facility was that it was more conducive to the centralized management of SARS patients, and at the same time, it reduced transmission of the virus to healthy people.
        </p>
       </list-item>
       <list-item id="o0025">
        <label>
         4.
        </label>
        <p id="p0130">
         During the period of the SARS outbreak, more than 60,000 HCWs received medical training in the management of patients with SARS, infection control and the use of PPE.
        </p>
       </list-item>
       <list-item id="o0030">
        <label>
         5.
        </label>
        <p id="p0135">
         Multiple measures were taken to reduce person-to-person transmission, including isolation of patients with SARS, tracing and quarantine of close contacts, transit site surveillance and closing poorly maintained facilities that could enhance spread of the virus.
        </p>
       </list-item>
       <list-item id="o0035">
        <label>
         6.
        </label>
        <p id="p0140">
         Information dissemination was critical. Timely and accurate reporting of the status of the epidemic and scientific guidance on prevention and infection control played important roles in stabilizing people and overcoming the epidemic [
         <xref ref-type="bibr" rid="bib45">
          [45]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib46">
          [46]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib47">
          [47]
         </xref>
         ,
         <xref ref-type="bibr" rid="bib48">
          [48]
         </xref>
         ].
        </p>
       </list-item>
      </list>
     </p>
    </sec>
    <sec id="sec4">
     <label>
      4
     </label>
     <title>
      Lessons learned from the 2003 SARS pandemic
     </title>
     <p id="p0145">
      SARS was the very first coronavirus pandemic with the ability to spread from people to people mainly by droplets, but it would not be the last [
      <xref ref-type="bibr" rid="bib49">
       49
      </xref>
      ]. This section presents lessons learned from the SARS pandemic. Although the SARS-CoV rapidly spread throughout the world and caused great damages to human health, the global success in the fight against SARS ultimately demonstrated that containment was possible [
      <xref ref-type="bibr" rid="bib50">
       50
      </xref>
      ].
     </p>
     <sec id="sec4.1">
      <label>
       4.1
      </label>
      <title>
       Animal source containment
      </title>
      <p id="p0150">
       Early on, there were clues suggesting the link between SARS-CoV and civets, bred for food in China [
       <xref ref-type="bibr" rid="bib51">
        51
       </xref>
       ]. Strengthening the monitoring of these wild animal sources was an important factor in controlling emergence of these virus and their spread in humans. Some scholars advocated that the trading of wild animals in wet markets in Southern China should be banned [
       <xref ref-type="bibr" rid="bib52">
        52
       </xref>
       ]. In fact, the Chinese government had issued bans on rearing, trading, transporting and slaughtering wild animals for dietary purposes over 10 years ago [
       <xref ref-type="bibr" rid="bib53">
        53
       </xref>
       ]. This however, did not stop the practice of illegal trading of wild animals.
      </p>
     </sec>
     <sec id="sec4.2">
      <label>
       4.2
      </label>
      <title>
       Early detection and diagnosis
      </title>
      <p id="p0155">
       The nonspecific symptoms and signs of SARS and the long incubation period accentuated the transmission to HCWs and people in close communities [
       <xref ref-type="bibr" rid="bib54">
        54
       </xref>
       ]. Early identification of suspect cases is the key to inhibiting the spread of the virus. Rapid identification of the viral genome and the development of rapid diagnostic tests will facilitate the isolation of those who are confirmed as infected [
       <xref ref-type="bibr" rid="bib50">
        50
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4.3">
      <label>
       4.3
      </label>
      <title>
       Rigorous infection control
      </title>
      <p id="p0160">
       <list id="olist0015" list-type="simple">
        <list-item id="o0040">
         <label>
          a)
         </label>
         <p id="p0165">
          Environmental hygiene in medical sectors and personal hygiene of health care workers should be maintained [
          <xref ref-type="bibr" rid="bib55">
           55
          </xref>
          ,
          <xref ref-type="bibr" rid="bib56">
           56
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0045">
         <label>
          b)
         </label>
         <p id="p0170">
          Contact tracing, strict isolation of actively ill patients and quarantine of close contacts should be implemented early [
          <xref ref-type="bibr" rid="bib54">
           54
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0050">
         <label>
          c)
         </label>
         <p id="p0175">
          Training in the use of personal protective equipment protects the safety of HCWs [
          <xref ref-type="bibr" rid="bib57">
           57
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0055">
         <label>
          d)
         </label>
         <p id="p0180">
          Establishing fever clinics, setting up designated hospital wards and SARS hospitals reduced human-to-human transmission [
          <xref ref-type="bibr" rid="bib58">
           58
          </xref>
          ].
         </p>
        </list-item>
        <list-item id="o0060">
         <label>
          e)
         </label>
         <p id="p0185">
          Education of the public on communicable diseases and what measures to take on a personal basis to prevent spread.
         </p>
        </list-item>
       </list>
      </p>
     </sec>
     <sec id="sec4.4">
      <label>
       4.4
      </label>
      <title>
       Timely case report and rapid information dissemination
      </title>
      <p id="p0190">
       A number of studies have shown that clear and timely dissemination of information is essential in handling an outbreak [
       <xref ref-type="bibr" rid="bib54">
        54
       </xref>
       ]. Infection control is based on rapid information dissemination. Since SARS in 2003, China has implemented legislation on the surveillance, reporting and early warning system of infectious diseases, requiring the regular release of information during public health emergencies. There is a clearly defined procedure and schedule for reporting public health emergencies which requires designated medical centers to submit relevant information online. If confirmed, reports on SARS and other infectious diseases can be submitted and received directly within two hours through the Internet [
       <xref ref-type="bibr" rid="bib53">
        53
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec4.5">
      <label>
       4.5
      </label>
      <title>
       Vaccine development
      </title>
      <p id="p0195">
       After SARS, development of a vaccine appeared to be the best approach to prevent future SARS-CoV epidemics. However, there were many obstacles in SARS vaccine development. Firstly, researchers did not have a comprehensive understanding of the pathogenic mechanism of SARS-CoV. Secondly, animal models of SARS-CoV infection could not simulate human disease because of an incongruent pathogenesis. Thirdly, in order to test the efficacy, many people must be tested in areas where the virus is endemic. Once the SARS epidemic ended, human trials were not possible [
       <xref ref-type="bibr" rid="bib59">
        59
       </xref>
       ]. Although several candidate vaccines against SARS-CoV have been produced and tested, at present, unfortunately, there is no FDA approved vaccine against SARS.
      </p>
     </sec>
    </sec>
    <sec id="sec5">
     <label>
      5
     </label>
     <title>
      The current SARS-CoV-2 infection in China
     </title>
     <sec id="sec5.1">
      <label>
       5.1
      </label>
      <title>
       The origin of SARS-CoV-2
      </title>
      <p id="p0200">
       A cluster of cases of viral pneumonia of unknown etiology, now known as SARS-CoV-2 pneumonia, occurred in Wuhan, Hubei Province and were reported to health authorities on the December 29, 2019 [
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       ]. This outbreak was associated with a large seafood and animal market [
       <xref ref-type="bibr" rid="bib61">
        61
       </xref>
       ]. Further investigations are ongoing to determine the origin of the infection. To date, many reports have described possible original and intermediate hosts (
       <xref ref-type="fig" rid="fig1">
        Fig. 1
       </xref>
       ). Researchers found that the SARS-CoV-2 showed a higher sequence homology to Bat-CoV-RaTG13 that was previously detected in
       <italic>
        Rhinolophus affinis
       </italic>
       from Yunnan Province than Bat-SL-CoVZC21 and Bat-SL-CoVZC45, which suggested that the Chinese chrysanthemum bat is the origin of SARS-CoV-2. More recently, the pangolin was believed to be the likely intermediate host due to the fact that there appeared to be approximately 99% sequence homology between SARS-Co V-2 and the consensus sequence derived from &gt;1000 metagenomic samples from the pangolin species [
       <xref ref-type="bibr" rid="bib62">
        62
       </xref>
       ].
       <fig id="fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          The origin and inter-host timeline of SARS-CoV-2. All the information is derived from published data. Journal name: (a) Emerging Microbes &amp; Infections, (b) bioRvix, (c) J Med Virol, (d) The Lancet, (e) the New England Journal of Medicine, (f) J Virol, (g) Chin Med J (Engl), (h)
          <ext-link ext-link-type="uri" id="intref0115" xlink:href="https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm">
           https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm
          </ext-link>
          . Bat-ZC21: Bat-SL-CoVZC21, GenBank Accession MG772934; Bat-ZC45: Bat-SL-CoVZC45, GenBank Accession MG772933; Bat-RaTG13: yun-nan-Bat-CoV-RaTG13, GISAID accession EPI_ISL_402,131.
         </p>
        </caption>
        <alt-text id="alttext0010">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec5.2">
      <label>
       5.2
      </label>
      <title>
       New epidemiological developments
      </title>
      <p id="p0205">
       Currently, person to person transmission from patients with pneumonia or even asymptomatic patients during the incubation period are the main conduits for the spread of the infection [
       <xref ref-type="bibr" rid="bib63">
        63
       </xref>
       ]. Respiratory droplets are the main route of transmission, but the virus can also be transmitted through contact or through the fecal-oral route based on a study which demonstrated the presence of the virus in rectal swabs [
       <xref ref-type="bibr" rid="bib64">
        64
       </xref>
       ]. Fifteen health care workers in a Wuhan hospital were infected while caring for patients with confirmed or suspected infection [
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ,
       <xref ref-type="bibr" rid="bib66">
        66
       </xref>
       ]. As of February 11, 2020, a total of 1716 health care workers have become infected and 5 have died (0.3%) [
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ]. A study of a family cluster reported that five members of a family of six traveled to Wuhan, and four were infected with the SARS-CoV-2. The family member who did not travel became infected with the virus after several days of contact with the four infected members [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ].
      </p>
      <p id="p0210">
       Li et al. [
       <xref ref-type="bibr" rid="bib65">
        65
       </xref>
       ] showed that human-to-human transmission among close contacts has been occurring since the middle of December 2019. Further dissemination has continued rapidly over the ensuing months. The authors estimated that the reproduction number (R
       <sub>
        0
       </sub>
       ) for SARS-CoV-2 is 2.2, meaning that every infected person can infect a mean of 2.2 people. In another study, the reproduction number of the SARS-CoV-2 was 2.68 with an epidemic doubling time of 6.4 days [
       <xref ref-type="bibr" rid="bib68">
        68
       </xref>
       ]. It is worth noting that a nucleic acid fragment of the SARS-CoV-2 was detected by Guangzhou Centers for Disease Control and Prevention (CDC) on a doorknob touched by a confirmed patient [
       <xref ref-type="bibr" rid="bib69">
        69
       </xref>
       ]. China Daily reported that scientists have discovered that stool samples from patients infected with the SARS-CoV-2 have also tested positive for the virus [
       <xref ref-type="bibr" rid="bib70">
        70
       </xref>
       ], and that the virus was also detected in the loose stool of the first patient in the US infected with the virus [
       <xref ref-type="bibr" rid="bib71">
        71
       </xref>
       ], meaning the virus has the potential to be spread through contaminated fecal material.
      </p>
      <p id="p0215">
       On the January 22, 2020, a member of the national expert panel on pneumonia reported that he was infected by SARS-CoV-2 during an inspection in Wuhan. He had worn an N95 mask but did not wear eye protection. Several days before the onset of pneumonia, he complained of redness of the eyes. Unprotected exposure of the eyes to SARS-CoV-2 in the Wuhan Fever Clinic may have allowed the virus to enter his body [
       <xref ref-type="bibr" rid="bib24">
        24
       </xref>
       ].
      </p>
      <p id="p0220">
       The situation with SARS-CoV-2 is evolving rapidly. According to the National Health Commission (NHC) of China update on February 17, 2020 [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ], a total of 72,436 cases were confirmed in the Chinese mainland, including 11,741 severe cases and 1868 deaths. A total of 12,552 patients have recovered and have been discharged. An additional total of 6242 suspected cases remain. Most patients (59,989 cases) have been in Hubei province, where the outbreak began, including 10,970 severe cases and 1789 deaths. The Hong Kong and Macao Special Administrative Regions as well as Taiwan reported 92 confirmed cases of the disease, including 2 deaths and 9 patients who have recovered. There are significantly more SARS-CoV-2 cases than SARS cases during the 2003 outbreak. The current spread of the epidemic in China is shown in
       <xref ref-type="fig" rid="fig2">
        Fig. 2
       </xref>
       ,
       <xref ref-type="fig" rid="fig3">
        Fig. 3
       </xref>
       ,
       <xref ref-type="fig" rid="fig4">
        Fig. 4
       </xref>
       .
       <fig id="fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Confirmed cases of SARS-CoV-2, February 17, 2020. (Data from the government website of China's National Health Commission).
         </p>
        </caption>
        <alt-text id="alttext0015">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
       <fig id="fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Numbers of suspected, confirmed and severe cases of SARS-CoV-2 in China and Hubei province, February 17, 2020. (Data from the government website of China's National Health Commission. Since February 12, 2020, Hubei Province has included the number of clinical diagnosis cases into the number of confirmed cases).
         </p>
        </caption>
        <alt-text id="alttext0020">
         Fig. 3
        </alt-text>
        <graphic xlink:href="gr3_lrg">
        </graphic>
       </fig>
       <fig id="fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Numbers of deaths and recovered cases of SARS-CoV-2 in China and Hubei, February 17, 2020. (Data from the government website of China's National Health Commission).
         </p>
        </caption>
        <alt-text id="alttext0025">
         Fig. 4
        </alt-text>
        <graphic xlink:href="gr4_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0225">
       According to World Health Organization (WHO) SARS-CoV-2 Situation Report [
       <xref ref-type="bibr" rid="bib72">
        72
       </xref>
       ], additional cases have been identified in a growing number of other international locations, including 25 countries outside China (
       <xref ref-type="fig" rid="fig5">
        Fig. 5
       </xref>
       ). There are now three deaths that have been reported outside of China (one in the Philippines, one in Japan and one in France). The WHO declared the SARS-CoV-2 epidemic a Public Health Emergency of International Concern (PHEIC) on January 30, 2020, citing that human-to-human infections have been confirmed in multiple countries [
       <xref ref-type="bibr" rid="bib73">
        73
       </xref>
       ].
       <fig id="fig5">
        <label>
         Fig. 5
        </label>
        <caption>
         <p>
          Countries, territories or areas with reported confirmed cases of SARS-CoV-2, February 17, 2020. (Data from the WHO Coronavirus disease 2019 (COVID-19) Situation Report-28).
         </p>
        </caption>
        <alt-text id="alttext0030">
         Fig. 5
        </alt-text>
        <graphic xlink:href="gr5_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0230">
       According to Fang et al. [
       <xref ref-type="bibr" rid="bib74">
        74
       </xref>
       ], fifteen cases of childhood infection had been identified as of January 30, 2020, including 8 boys and 7 girls, ranging in age from 8 months to 12 years. Of the 15 pediatric cases, 13 had a clear history of family clustering in Wuhan. At present, several confirmed pregnant women in Wuhan have given birth during the illness. On February 2, 2020, Wuhan local media reported that a confirmed pregnant woman gave birth to a newborn by cesarean section under strict level three protection, but the newborn's throat swab was positive for the nucleic acid virus test [
       <xref ref-type="bibr" rid="bib75">
        75
       </xref>
       ]. However, Chen et al. tested the SARS-CoV-2 in amniotic fluid, cord blood, neonatal throat swab, and breastmilk samples from six confirmed SARS-CoV-2 pregnant women, and all samples tested negative for the virus, which suggests that there is currently no evidence for intrauterine infection caused by vertical transmission in women who develop COVID-19 pneumonia in late pregnancy [
       <xref ref-type="bibr" rid="bib76">
        76
       </xref>
       ]. No cases of newborns or child deaths have been reported. The NHC has called for close monitoring of outbreaks in children and pregnant women [
       <xref ref-type="bibr" rid="bib77">
        77
       </xref>
       ].
      </p>
      <p id="p0235">
       The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team of the Chinese CDC reported the epidemiology characteristics of 44,672 confirmed cases as of February 11, 2020. Among the confirmed 44,672 cases (74.7% in Hubei Province), 51.4% were male, and 80.9% were mild or moderate cases. The majority of the cases were between 30 and 69 years old (77.8%), while 0-9 year-olds and 10-19 year-olds accounted for 0.9% and 1.2% respectively. Hypertension (12.8%), diabetes (5.3%), cardiovascular disease (4.2%) were the most common underlying diseases. A total of 1023 deaths occurred among confirmed cases for an overall case-fatality rate of 2.3%, and 81% of the deaths were over 60 years old. The mortality rates of those aged 60–69, 70–79 and over 80 years were 3.6%, 8.0%, and 14.8%, respectively. The mortality rate of critical cases was 49% [
       <xref ref-type="bibr" rid="bib67">
        67
       </xref>
       ].
      </p>
      <p id="p0240">
       Based on this evidence, the current SARS-CoV-2 is easily transmissible in humans, even in children and pregnant women. It should also be noted that most patients have a good prognosis. The symptoms in children are relatively mild, and only a minority are in critical condition. The death cases involved mostly the elderly and those with a chronic underlying disease. This fact, however, does not diminish the seriousness of the epidemic.
      </p>
      <p id="p0245">
       During the early stages of the epidemic, several hospitals, including Wuhan Union Hospital, Wuhan Tongji Hospital, and Peking Union Medical College Hospital, had created different diagnosis and treatment programs [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       ]. The WHO and the NHC of China have since then published guidelines for the diagnosis and clinical management of SARS-CoV-2 pneumonia [
       <xref ref-type="bibr" rid="bib81">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec6">
     <label>
      6
     </label>
     <title>
      Clinical presentation
     </title>
     <sec id="sec6.1">
      <label>
       6.1
      </label>
      <title>
       Clinical manifestations
      </title>
      <p id="p0250">
       According to the guidelines published by the NHC and based on current epidemiological studies, the incubation period is typically 3–7 days, with a maximum of 14 days [
       <xref ref-type="bibr" rid="bib82">
        82
       </xref>
       ]. Common symptoms of COVID-19 include fever, fatigue, and dry cough. A few patients have symptoms such as nasal congestion, runny nose, sore throat, and diarrhea. Some patients only have a low fever, mild fatigue, and no pneumonia. In severe cases, the infection can cause pneumonia, shortness of breath and breathing difficulties occurring more than one week after infection. Critical patients may progress rapidly to acute respiratory distress syndrome (ARDS), septic shock, metabolic acidosis, coagulation dysfunction, and even death. It is worth noting that during the course of severe and critical patients, there can be moderate to low-grade fever or even no obvious fever.
      </p>
      <p id="p0255">
       Huang et al. provided first-hand data regarding COVID-19 [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ]. Their study reported the clinical features of the first 41 patients admitted to the designated hospital in Wuhan who were laboratory-confirmed COVID-19 by January 2, 2020. Twenty-seven (66%) of the 41 patients had been exposed to the Huanan seafood market. Common symptoms at the onset of illness were fever (98%), cough (76%), and myalgia or fatigue (44%). Less common symptoms were sputum production, headache, hemoptysis, and diarrhea. Dyspnea developed in 22 (55%) of 40 patients and 26 (63%) of 41 patients had lymphopenia. The median time from onset of symptoms to first hospital admission was 7.0 days, to shortness of breath was 8.0 days, and to ARDS was 9.0 days. Almost a third of patients developed ARDS requiring intensive care, 5 patients had acute cardiac injury, and 4 patients required assisted ventilation. Eventually 28 patients were discharged, 13 patients were admitted to the intensive care unit (ICU) and 6 patients died.
      </p>
      <p id="p0260">
       Chen et al. reported 99 patients with SARS-CoV-2 pneumonia admitted to the Jinyintan Hospital in Wuhan [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ]. Forty-nine (49%) patients had a history of exposure to the local Huanan seafood market and 50 patients (51%) had chronic underlying diseases. Patients had clinical manifestations of fever (83%), cough (82%), shortness of breath (31%), muscle aches (11%), confusion (9%), headache (8%), sore throat (5%), rhinorrhea (4%), chest pain (2%), and diarrhea (2%). Eighty-nine (90%) patients had more than one symptom. According to their study, many cases presented with organ function damage, including 17 cases with ARDS, 8 cases with acute respiratory injury, 3 cases with acute renal injury, 4 cases with septic shock, and 1 case with ventilator-associated pneumonia. Eventually 31 patients were discharged, 11 patients died, and the remaining 57 patients were still in hospital.
      </p>
      <p id="p0265">
       At Zhongnan Hospital of Wuhan University in Wuhan, Wang et al. [
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       ] enrolled 138 hospitalized patients with SARS-CoV-2 pneumonia. Common symptoms included fever (98.6%), fatigue (69.6%), dry cough (59.4%), myalgia (34.8%), and dyspnea (31.2%). The median time from first symptom to dyspnea was 5.0 days, to hospital admission was 7.0 days, and to ARDS was 8.0 days. Major complications during hospitalization included ARDS, arrhythmia, and shock. Of the 138 hospitalized patients, 47 recovered and have been discharged, 36 patients were admitted to the ICU and 6 patients have died.
      </p>
      <p id="p0270">
       Chang et al. [
       <xref ref-type="bibr" rid="bib84">
        84
       </xref>
       ] reported 13 confirmed patients outside of Wuhan, including 2 children (aged 2 years and 15 years). Twelve patients (92%) had fever before hospitalization. Other symptoms included upper airway congestion (62%), cough (46%), myalgia (23%), and headache (23%). All the patients recovered.
      </p>
      <p id="p0275">
       Guan et al. [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ] reported 1099 confirmed patients from 552 hospitals in the whole of China as of January 29, 2020. The most common symptoms including fever (87.9%) and cough (67.7%), whereas diarrhea (3.7%) and vomiting (5.0%) were rare. They also pointed out that only 43.8% of the patients had fever on presentation but 87.9% developed fever after being hospitalized. Moreover, compared with non-severe cases, any underlying diseases were significantly more common in severe cases. The most common complication was pneumonia (79.1%), ARDS (3.4%) and shock (1.0%). Of the 1099 patients, 55 patients were admitted to the ICU, and 15 patients died.
      </p>
      <p id="p0280">
       There were therefore a total of 41, 99 and 138 (total 278) cases of SARS-CoV pneumonia admitted in the 3 regional hospitals closest to the Huanan Seafood Market that resulted in 6, 11 and 6 deaths (23 deaths) or a case fatality rate of 0.82%.
      </p>
     </sec>
     <sec id="sec6.2">
      <label>
       6.2
      </label>
      <title>
       Laboratory tests
      </title>
      <p id="p0285">
       In the early stages of the disease, the total number of leukocytes in peripheral blood is normal or decreased, the lymphocyte count is decreased, and some patients show increases in liver enzymes, muscle enzymes, and myoglobin. The C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are increased in most patients, and procalcitonin is normal. In severe cases, D-dimer increases, and peripheral blood lymphocytes decrease progressively. Coronavirus nucleic acid can be detected in the throat, sputum, lower respiratory tract secretions, blood and tool.
      </p>
      <p id="p0290">
       In Huang's study [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ], the blood counts of patients on admission showed leucopenia and lymphopenia. Prothrombin time and D-dimer levels on admission were higher in ICU patients. Compared with non-ICU patients, ICU patients had higher plasma levels of IL-2, IL-7, IL-10, G-SCF, IP-10, MCP-1, MIP-1α, and TNFα. In Chen's study [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ], all patients were tested for nine respiratory pathogens and nucleic acids of influenza viruses A and B, as well as bacteria and fungi. No other respiratory viruses were detected, but 4 cases of fungal and 1 case of bacterial infection were found. The absolute number of leukocytes was decreased in 9 patients and increased in 24 patients. The absolute neutrophil count was increased in 38 patients and the absolute lymphocyte count was decreased in 35 patients. Forty-three patients had varying degrees of liver dysfunction, seven patients had varying degrees of renal dysfunction, and most patients had abnormal myocardial zymograms. Seventy-three patients were tested for C-reactive protein which was increased in 63 patients. In Guan's study, 82.1%, 36.2%, and 33.7% of the patients had lymphopenia, thrombocytopenia, and leukopenia, respectively. Compared with non-severe cases, severe cases had more prominent laboratory abnormalities [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec6.3">
      <label>
       6.3
      </label>
      <title>
       Imaging studies
      </title>
      <p id="p0295">
       In Huang's study [
       <xref ref-type="bibr" rid="bib26">
        26
       </xref>
       ], all 41 patients had pneumonia with abnormal findings on chest computed tomography (CT) and 40 (98%) had bilateral involvement. The ICU patients on admission had bilateral multiple lobular and subsegmental areas of consolidation. The non-ICU patients had bilateral ground-glass opacity and subsegmental areas of consolidation. Subsequent chest CT images showed bilateral ground-glass opacity, whereas the consolidation was resolved. In Chen's study [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ], imaging showed that 74 patients had bilateral pneumonia, 14 patients had multiple mottled and ground-glass opacities, and 1 patient had a pneumothorax. In Wang's study [
       <xref ref-type="bibr" rid="bib83">
        83
       </xref>
       ], imaging showed that 138 patients had bilateral patchy shadows or ground-glass opacity. In Guan's study, 840 of 1099 patients received chest CT on admission which showed that 76.4% had pneumonia, but 23.9% of severe cases had no radiologic abnormality on initial presentation. Ground-glass opacity (50.0%) and bilateral patchy shadow (46.0%) were the most common findings [
       <xref ref-type="bibr" rid="bib85">
        85
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec7">
     <label>
      7
     </label>
     <title>
      Diagnosis
     </title>
     <p id="p0300">
      The earliest cases of SARS-CoV-2 were identified as “pneumonia of unknown etiology”, which was defined as an illness of unknown etiology with 1. Fever with or without a recorded temperature 2. Radiographic evidence of pneumonia 3. Low or normal leukocyte count or low lymphocyte count during the early stage of disease and 4. No improvement or worsening symptoms after 3–5 days of antimicrobial treatment per standard clinical guidelines [
      <xref ref-type="bibr" rid="bib61">
       61
      </xref>
      ]. With increasing research and knowledge of the disease, diagnosis and treatment guidelines have been continuously updated. At present, the NHC has issued the fifth edition of the guidelines. However, because of a shortage of diagnostic reagents for SARS-CoV-2 detection, different guidelines or programs emphasized comprehensive analysis based on epidemiological history, clinical manifestations and imaging examinations in diagnosis.
     </p>
     <sec id="sec7.1">
      <label>
       7.1
      </label>
      <title>
       Diagnostic criteria [
       <xref ref-type="bibr" rid="bib37">
        37
       </xref>
       ,
       <xref ref-type="bibr" rid="bib78">
        [78]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib79">
        [79]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib80">
        [80]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib81">
        [81]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib82">
        [82]
       </xref>
       ]
      </title>
      <p id="p0305">
       The diagnostic criteria of suspected and confirmed cases were summarized in
       <xref ref-type="table" rid="tbl1">
        Table 1
       </xref>
       .
       <table-wrap id="tbl1" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          The diagnostic criteria for suspected and confirmed cases [
          <xref ref-type="bibr" rid="bib37">
           37
          </xref>
          ,
          <xref ref-type="bibr" rid="bib77">
           [77]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib78">
           [78]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib79">
           [79]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib80">
           [80]
          </xref>
          ,
          <xref ref-type="bibr" rid="bib81">
           [81]
          </xref>
          ].
         </p>
        </caption>
        <alt-text id="alttext0060">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <tbody>
          <tr>
           <td align="left">
            Case
           </td>
           <td align="left">
            Diagnostic criteria
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="3">
            Suspected case
           </td>
           <td align="left">
            Anyone with a history of epidemiology and any two of the clinical manifestations or anyone without epidemiological history and three of the clinical manifestations is considered to be a suspected case:
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0020" list-type="simple">
             <list-item id="o0065">
              <label>
               (1)
              </label>
              <p id="p0540">
               Epidemiological history:
               <list id="olist0025" list-type="simple">
                <list-item id="o0070">
                 <label>
                  1)
                 </label>
                 <p id="p0545">
                  within 14 days before the disease onset, there is a travel history or living history in Wuhan or other areas with local cases
                 </p>
                </list-item>
                <list-item id="o0075">
                 <label>
                  2)
                 </label>
                 <p id="p0550">
                  within 14 days before the disease onset, there is contact with patients who had fever or respiratory symptoms from Wuhan or other areas with local cases
                 </p>
                </list-item>
                <list-item id="o0080">
                 <label>
                  3)
                 </label>
                 <p id="p0555">
                  a clustering of patients or a contact with patients infected with the SARS-CoV-2
                 </p>
                </list-item>
               </list>
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0030" list-type="simple">
             <list-item id="o0085">
              <label>
               (2)
              </label>
              <p id="p0560">
               Clinical manifestations:
               <list id="olist0035" list-type="simple">
                <list-item id="o0090">
                 <label>
                  1)
                 </label>
                 <p id="p0565">
                  fever and/or respiratory symptoms
                 </p>
                </list-item>
                <list-item id="o0095">
                 <label>
                  2)
                 </label>
                 <p id="p0570">
                  with the above-mentioned imaging characteristics of pneumonia
                 </p>
                </list-item>
                <list-item id="o0100">
                 <label>
                  3)
                 </label>
                 <p id="p0575">
                  the total number of leukocytes in the early stage of the disease is normal or decreased, or the lymphocyte count is decreased
                 </p>
                </list-item>
               </list>
              </p>
             </list-item>
            </list>
           </td>
          </tr>
          <tr>
           <td align="left" rowspan="2">
            Confirmed case
           </td>
           <td align="left">
            Any suspected case with one of the following pathogenic features is reclassified as a confirmed case:
           </td>
          </tr>
          <tr>
           <td align="left">
            <list id="olist0040" list-type="simple">
             <list-item id="o0105">
              <label>
               (1)
              </label>
              <p id="p0580">
               Positive results of SARS-CoV-2 nucleic acids by RT-PCR of respiratory or blood specimens
              </p>
             </list-item>
             <list-item id="o0110">
              <label>
               (2)
              </label>
              <p id="p0585">
               DNA highly homologous to SARS-CoV-2 by genetic sequencing of viral genes in respiratory or blood specimens
              </p>
             </list-item>
            </list>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn>
          <p>
           RT-PCR: real-time reverse-transcriptase polymerase-chain-reaction.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="sec7.2">
      <label>
       7.2
      </label>
      <title>
       Differential diagnosis
      </title>
      <p id="p0310">
       The SARS-CoV-2 needs to be distinguished from other known viral pneumonias including influenza virus, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, SARS coronavirus, MERS coronavirus, as well as
       <italic>
        Mycoplasma pneumoniae
       </italic>
       , chlamydia pneumonia, and bacterial pneumonias. For patients with underlying diseases, attention should be paid to the detection of invasive fungal infections. The differential diagnosis also includes non-infectious diseases such as vasculitis, dermatomyositis, and organizing pneumonia. It should be noted that often patients with viral pneumonia may test positive to multiple viruses, and the potential lethality of a combined SARS-CoV-2/influenza virus infection should not be ignored.
      </p>
     </sec>
    </sec>
    <sec id="sec8">
     <label>
      8
     </label>
     <title>
      The effectiveness of SARS-CoV-2 rapid diagnosis in preventing spread of disease
     </title>
     <p id="p0315">
      Several rapid and sensitive detection tests have been developed for the prevention and control of the SARS-CoV-2 outbreak. At present, seven products including the SARS-CoV-2 nucleic acid detection kit (fluorescent PCR method) and the SARS-CoV-2 nucleic acid sequencing system have been approved on an emergency basis by the National Medical Products Administration. Biological product companies have expanded production of detection kits for the new coronavirus. The use of detection kits can accelerate accurate diagnosis of patients, help to determine quarantine and isolation requirements, assist in determining the treatment of patients and save limited medical resources. However, the rapidity of spread of the disease has led to an insufficient supply of detection kits.
     </p>
     <p id="p0320">
      It is worth noting that there have been confirmed patients whose viral nucleic acid tests are negative multiple times in the early stages, and there have also been confirmed cases whose throat swabs were negative for the viral nucleic acid test but positive in alveolar lavage fluid. Correlation of Chest CT and RT-PCR testing of 1014 cases showed that CT had a 88% had a positive CT scan but only 59% had positive RT-PCR. [
      <xref ref-type="bibr" rid="bib86">
       86
      </xref>
      ]. The poor sensitivity of the current tests makes diagnosis and epidemic control more challenging. Sampling techniques, extraction and detection of viral nucleic acids, and diagnostic reagents may affect the test results. More attention should be paid to the sensitivity and specificity of diagnostic reagents, and diagnostic decisions should rely on comprehensive judgment based on the clinical manifestations, laboratory results and imaging examinations of patients. According to the latest guideline of the NHC [
      <xref ref-type="bibr" rid="bib82">
       82
      </xref>
      ], if the suspected cases in Hubei Province have imaging characteristic of pneumonia, the CT image results can be used as a basis for “clinical diagnosis cases”.
     </p>
    </sec>
    <sec id="sec9">
     <label>
      9
     </label>
     <title>
      The pathogenesis of COVID-19
     </title>
     <p id="p0325">
      Current understanding of the pathogenesis of HCoVs infection is still limited, especially for SARS-CoV-2. Before 2019, there were six CoVs that could infect humans and cause respiratory disease. HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 are sometimes attributed to the “common cold”, but in rare cases can cause severe infections in infants, young children and elderly people. On the other hand, SARS-CoV and MERS-CoV can infect the lower respiratory tract and cause a severe respiratory syndrome in human [
      <xref ref-type="bibr" rid="bib3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ]. The new coronavirus SARS-CoV-2 is similar to SARS-CoV and MERS-CoV and can infect lower respiratory tract and cause severe pneumonia.
     </p>
     <p id="p0330">
      The origin of SARS-CoV-2 was thought to be wild animals in the Huanan Seafood Market in Wuhan. However, not all cases have an apparent connection with the Wuhan Huanan Seafood Wholesale Market. It is evident now that SARS-CoV-2 is capable of person-person transmission. We list the major pathogenic CoVs in
      <xref ref-type="table" rid="tbl2">
       Table 2
      </xref>
      for better understanding of the pathogenesis of HCoV [
      <xref ref-type="bibr" rid="bib87">
       87
      </xref>
      ].
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Partial list of important pathogenic human coronaviruses [
         <xref ref-type="bibr" rid="bib87">
          87
         </xref>
         ].
        </p>
       </caption>
       <alt-text id="alttext0065">
        Table 2
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Virus
          </th>
          <th>
           Genus
          </th>
          <th>
           Symptoms
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left">
           HCoV-229E
          </td>
          <td align="left">
           <italic>
            alpha
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-NL63
          </td>
          <td align="left">
           <italic>
            alpha
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-OC43
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           mild respiratory tract infections
          </td>
         </tr>
         <tr>
          <td align="left">
           HCoV-HKU1
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           pneumonia
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 11% mortality rate
          </td>
         </tr>
         <tr>
          <td align="left">
           MERS-CoV
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 34% mortality rate
          </td>
         </tr>
         <tr>
          <td align="left">
           SARS-CoV-2
          </td>
          <td align="left">
           <italic>
            beta
           </italic>
          </td>
          <td align="left">
           severe acute respiratory syndrome, 2.6% mortality rate
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="p0335">
      The term “cell pyroptosis” was first proposed in 2001 [
      <xref ref-type="bibr" rid="bib88">
       88
      </xref>
      ]. In recent decades, there has been increasing evidence suggesting that “pyroptosis” is a novel inflammatory form of programmed cell death. In 2019, Chen et al. found that SARS-CoV Viroporin 3a triggered the activation of the NLRP3 inflammasome and the secretion of IL-1β in bone marrow-derived macrophages, suggesting SARS-CoV induced cell pyroptosis [
      <xref ref-type="bibr" rid="bib89">
       89
      </xref>
      ]. Studies have shown that patients infected with SARS-CoV-2 have increased IL-1β in the serum [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ]. As the rise of IL-1β is a downstream indicator of cell pyroptosis, this may suggest that cell pyroptotic activity is likely to be activated and involved in the pathogenesis of COVID-19 patients. Nevertheless, as both classical and non-classical pyroptosis signaling can induce the release of IL-1β, it is unclear which pathway is involved in COVID-19. Based on existing data, SARS-CoV-2 is likely to cause cell pyroptosis, especially in lymphocytes, through the activation of NLRP3 inflammasome. The pathways involved in the activation of the signaling between NLRP3m IL-1β, IL-18 and GSDMD are illustrated in
      <xref ref-type="fig" rid="fig6">
       Fig. 6
      </xref>
      and are a subject of study in samples from SARS-CoV-2 patients [
      <xref ref-type="bibr" rid="bib90">
       90
      </xref>
      ].
      <fig id="fig6">
       <label>
        Fig. 6
       </label>
       <caption>
        <p>
         A hypothesis of the relationship between SARS-CoV-2 and cell pyroptosis. The COVID-19 may be linked to cell pyroptosis, especially in lymphocytes through the activation of the NLRP3 inflammasome. Morphological changes in lymphocytes and macrophages, nucleic acid and protein levels in classical and non-classical cells, detection of NLRP3 and GSDMD, and the role of inflammatory cytokines IL-1β and IL-18 requires further research.
        </p>
       </caption>
       <alt-text id="alttext0035">
        Fig. 6
       </alt-text>
       <graphic xlink:href="gr6_lrg">
       </graphic>
      </fig>
     </p>
     <sec id="sec9.1">
      <label>
       9.1
      </label>
      <title>
       The genomic structure of SARS-CoV-2
      </title>
      <p id="p0340">
       The rapid sequencing of the nearly 30,000 nucleotide SARS-CoV-2 genome was accomplished in approximately 3 weeks from the time of the first hospitalized patient on the December 12, 2019 by Zhang's group and several others in China [
       <xref ref-type="bibr" rid="bib91">
        91
       </xref>
       ]. The genomic structure is shown in
       <xref ref-type="fig" rid="fig7">
        Fig. 7
       </xref>
       and shows greater than 99.9% consistency [
       <xref ref-type="bibr" rid="bib19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib94">
        [94]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib95">
        [95]
       </xref>
       ].
       <fig id="fig7">
        <label>
         Fig. 7
        </label>
        <caption>
         <p>
          Schematic diagram of the SARS-CoV-2 genome [
          <xref ref-type="bibr" rid="bib95">
           95
          </xref>
          ]. The genomic structure of SARS-CoV-2 is 5′-UTR-orf1a-orf1ab-S (Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-3′UTRpoly (A) tail. Accessory genes are interspersed within the structural genes at the 3′ end of genome. The pp1a protein encoded by the orf1a gene and the pp1ab protein encoded by the orf1ab gene contains 10 nsps (nsp1-nsp10). The pp1ab protein also includes nsp12-nsp16.
         </p>
        </caption>
        <alt-text id="alttext0040">
         Fig. 7
        </alt-text>
        <graphic xlink:href="gr7_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0345">
       The SARS-CoV-2 genome was found to possess 14 ORFs encoding 27 proteins. The orf1ab and orf1a genes are located at the 5′-terminus of the genome and encode 15 non-structural proteins (nsps) from nsp1 to nsp10, and from nsp12 to nsp16. The 3′-terminus of the genome contains 4 structural proteins (S, E, M and N) and 8 accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b and orf14). At the amino acid level, the SARS-CoV-2 is quite similar to that of SARS-CoV, but there are some notable differences. For example, the 8a protein is present in SARS-CoV and absent in SARS-CoV-2; the 3b protein is 154 amino acids in SARS-CoV but shorter in SARS-CoV-2 with only 22 amino acids. Further studies are needed to characterize how these differences affect the functionality and pathogenesis of SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib95">
        95
       </xref>
       ].
      </p>
      <p id="p0350">
       The phylogenetic tree based on whole genomes showed that SARS-CoV-2 is most closely related to bat SARS-like coronavirus bat-SL-CoVZC21 (NCBI accession number MG772934) and bat-SL-CoVZC45 (NCBI accession number MG772933), which share ~89% sequence homology [
       <xref ref-type="bibr" rid="bib91">
        [91]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib92">
        [92]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib93">
        [93]
       </xref>
       ]. Their genomic organization is typical of a lineage B beta coronavirus. Further phylogenetic analysis has posited that SARS-CoV-2 is a product of recombination with previously identified bat coronaviruses, but a recent report has subsequently identified a bat CoVs sequence, RaTG13, with 92–96% sequence identity with the novel virus, demonstrating that RaTG13 is the closest relative of the SARS-CoV-2 and forms a distinct lineage from other SARS-CoVs. This rejects the hypothesis of emergence as a result of a recombination event [
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ,
       <xref ref-type="bibr" rid="bib96">
        96
       </xref>
       ]. Even though there are high similarities between SARS-CoV-2 S and RaTG13 S, there are two distinct differences: one is an “RRAR” furin recognition site formed by an insertion residues in the S1/S2 protease cleavage site in SARS-CoV-2, rather than the single Arginine in SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        [97]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib98">
        [98]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib99">
        [99]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib100">
        [100]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib101">
        [101]
       </xref>
       ]; the other difference is the presence of 29 variant residues between SARS-CoV-2 S and RaTG13 S, 17 of which mapped to the receptor binding domain (RBD) [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0355">
       The identities of 5′- and 3′-UTR sequences are more than 83.6% consistent between SARS-CoV-2 and other β-CoVs, such as SARS-CoV [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. The replicase polyproteins ppla and pp1ab encoded by the largest genes orf1ab are proteolytic and have been reported to function in the replication of CoVs by regulatory elements located within the non-structural proteins [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. Four structural proteins (S, E, M and N) contribute to virion assembly and infection of CoVs. The spike protein located on the surface of viral particles is made up of homotrimers of S proteins and is the key for the viral attachment to host receptors [
       <xref ref-type="bibr" rid="bib103">
        103
       </xref>
       ,
       <xref ref-type="bibr" rid="bib104">
        104
       </xref>
       ].
      </p>
      <p id="p0360">
       Spike glycoprotein consists of S1 and S2 subunits. The S1 subunit contains a signal peptide, an N-terminal domain (NTD) and RBD, while the S2 subunit includes the conserved fusion peptide (FP), heptad repeat 1 and 2 (HR1 and HR2), transmembrane domain (TM), and cytoplasmic domain (CP) [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ,
       <xref ref-type="bibr" rid="bib105">
        105
       </xref>
       ]. Furthermore, the S2 subunit of SARS-CoV-2 is highly conserved and shares 99% similarity with those of Bat-SL-CoVZC45, Bat-SL-CoVZC21 and human SARS-CoV [
       <xref ref-type="bibr" rid="bib102">
        102
       </xref>
       ]. The S2 subunit is therefore targeted when screening broad spectrum antiviral peptides, which is an important piece of information that can be used to develop preventive and treatment measures. Most recently, the 3D structure of S protein was elucidated using Cryo-electron microscopy (Cryo-EM), and the RBD structure of the S protein is closer to the central location of SARS-CoV-2 compared to SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0365">
       The E protein plays a role in virus assembly and release, and is required for pathogenesis [
       <xref ref-type="bibr" rid="bib106">
        106
       </xref>
       ,
       <xref ref-type="bibr" rid="bib107">
        107
       </xref>
       ]. The N protein contains two domains, both of which can bind virus RNA genomes via different mechanisms. It has been reported that the N protein can bind nsp3 protein to help tether the genome to replicase-transcriptase complex (RTC) and package the encapsulated genome into virions [
       <xref ref-type="bibr" rid="bib12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="bib108">
        108
       </xref>
       ,
       <xref ref-type="bibr" rid="bib109">
        109
       </xref>
       ]. The N protein is also an antagonist of interferon and viral encoded repressor (VSR) of RNA interference (RNAi), which benefits viral replication [
       <xref ref-type="bibr" rid="bib110">
        110
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec9.2">
      <label>
       9.2
      </label>
      <title>
       Entry into host cell
      </title>
      <p id="p0370">
       Cell entry is an essential component of cross-species transmission, especially for the β-CoVs. All CoVs encode a surface glycoprotein, spike, which binds to the host receptor and mediates viral entry [
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ]. For β-CoVs, the RBD of the spike protein mediates the interaction with host receptor. Upon binding the receptor, the spike protein is cleaved by nearby host proteases and releases the signal peptide to facilitate virus entry into host cells [
       <xref ref-type="bibr" rid="bib112">
        [112]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib113">
        [113]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib114">
        [114]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib115">
        [115]
       </xref>
       ].
      </p>
      <p id="p0375">
       Angiotensin converting enzyme 2 (ACE2) and dipeptidyl peptidase 4 (DPP4) are known host receptors for the β-CoVs SARS-CoV and MERS-CoV, respectively [
       <xref ref-type="bibr" rid="bib116">
        116
       </xref>
       ,
       <xref ref-type="bibr" rid="bib117">
        117
       </xref>
       ]. In similar fashion to SARS-CoV, SARS-CoV-2 also uses ACE2 to gain entry into host cells. Hoffmann et al. found that the cellular protease MPRSS2 blocks entry by cleaving the spike protein and may constitute a treatment option [
       <xref ref-type="bibr" rid="bib118">
        118
       </xref>
       ]. Zhou et al. also confirmed that SARS-CoV-2 is able to use all but mouse ACE2 as an entry receptor for ACE2-expressing cells, but not cells without ACE2, indicating that the cell receptor for SARS-CoV-2 could be ACE2, and not other coronavirus receptors such as aminopeptidase N and dipeptidyl peptidase 4 [
       <xref ref-type="bibr" rid="bib94">
        94
       </xref>
       ]. Huang also showed that the affinity of the SARS-CoV-2 S-RBD binding to ACE2 is less than that of SARS-CoV through Monte Carlo algorithm [
       <xref ref-type="bibr" rid="bib119">
        119
       </xref>
       ]. However, Wrapp et al. found that SARS-CoV-2 S binding to ACE2 has approximately 10- to 20- fold higher affinity than SARS-CoV S, which can provide one explanation why SARS-CoV-2 has more human-to human spread compared to SARS-CoV [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0380">
       The combination of SARS-CoV-2 S and ACE2 of host cells is similar to the combination of SARS-CoV and ACE2, indicating that they have the same mechanism to entry into host cells [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ]. The S protein of metastable prefusion conformation undergoes a series of structural rearrangements to combine with the viral membrane of host cells [
       <xref ref-type="bibr" rid="bib111">
        111
       </xref>
       ,
       <xref ref-type="bibr" rid="bib120">
        120
       </xref>
       ]. This process consists of the S1 subunit binding to the host cell receptor, triggering of the prefusion trimer's instability, and shedding of the S1 subunit, resulting in a highly stable post-fusion conformation of the S2 subunit [
       <xref ref-type="bibr" rid="bib121">
        121
       </xref>
       ]. During the binding of the subunit S1 to its cognate receptor, it is important to note that the S1 subunit exists in 2 different states, a “down” conformation and an “up” conformation state, which corresponds to a receptor-inaccessible state and an unstable receptor-accessible state, respectively [
       <xref ref-type="bibr" rid="bib122">
        [122]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib123">
        [123]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib124">
        [124]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib125">
        [125]
       </xref>
       ]. Unfortunately, there are significant conformational differences between SARS-CoV and SARS-CoV-2 such that the commercially available monoclonal antibodies against SARS-CoV do not react with SARS-CoV-2 [
       <xref ref-type="bibr" rid="bib97">
        97
       </xref>
       ].
      </p>
      <p id="p0385">
       SARS-CoV-2 may directly bind to ACE2 positive cholangiocytes but not necessarily hepatocytes via specific expression of ACE2 in healthy liver tissues using cell RNA-seq data of two independent cohorts [
       <xref ref-type="bibr" rid="bib126">
        126
       </xref>
       ]. Though the respiratory systems is a primary target of SARS-CoV-2, bioinformatic analysis of single-cell transcriptomes datasets of lung, esophagus, gastric, ileum and colon reveal that the digestive system is also a potential route of entry for COVID-19, as ACE2 was not only highly expressed in lung AT2 cells, esophagus upper and stratified epithelial cells but also in absorptive enterocytes from the ileum and colon [
       <xref ref-type="bibr" rid="bib127">
        127
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec10">
     <label>
      10
     </label>
     <title>
      Recommendations
     </title>
     <sec id="sec10.1">
      <label>
       10.1
      </label>
      <title>
       Preventing the spread of disease
      </title>
      <p id="p0390">
       In response to the outbreak of pneumonia caused by the SARS-CoV-2, China has activated Level I public health emergency response for the entire country. This activates the most comprehensive and rigorous prevention and control measures for health and safety. A team of professionals from the NHC and China CDC was sent to conduct field investigations and implement disease control and prevention measures. The virus was quickly isolated and sequenced. On January 3, 2020, the first complete genome of the SARS-CoV-2 was determined and shared internationally, which led to the rapid development and deployment of diagnostic tests [
       <xref ref-type="bibr" rid="bib60">
        60
       </xref>
       ]. The NHC announced that preventive and control measures of category A infectious diseases would be implemented to effectively fight SARS-CoV-2 and has also introduced public education campaigns. At the same time, all medical expenses of confirmed patients would be covered by central and local financial institutions.
      </p>
     </sec>
     <sec id="sec10.2">
      <label>
       10.2
      </label>
      <title>
       Quarantine
      </title>
      <p id="p0395">
       Quarantine is a traditional but very effective measure to counter a deadly epidemic, but quarantine protocols can be hard to enforce. The local government in Wuhan announced the suspension of public transportation, with closure of airports, railway stations, and highways in the city, to prevent further disease transmission on January 23, 2020. Subsequently, the Chinese government imposed travel bans on several Chinese cities near Wuhan. At the same time, the Chinese government extended the Lunar New Year holidays and postponed the reopening of schools and factories to keep the nationwide migration of the population to a minimum. Travelers from Wuhan and other epidemic areas were advised to report their travel history and to self-quarantine for two weeks to prevent community transmission. In addition, most local governments required that all passengers must wear medical surgical masks or N95 masks when accessing public places, taxis or subways. Temperature screening checkpoints have been set up at subway stations, railway stations, high-speed rail exits and airports to screen passengers in an effort to curb the spread of the novel coronavirus.
      </p>
     </sec>
     <sec id="sec10.3">
      <label>
       10.3
      </label>
      <title>
       Mobilize resources
      </title>
      <p id="p0400">
       With the rapid spread of the epidemic, more designated treatment hospitals and health care workers were needed to meet the growing number of patients. On January 24, 2020, the local government in Wuhan announced the construction of a 1000-bed infirmary, named Huoshenshan hospital, and a 1500-bed infirmary, named Leishenshan hospital within 10 days, to ease the shortage of beds and treat people diagnosed with the SARS-CoV-2. These facilities are specialty hospitals for infectious diseases, rather than simply units to receive and quarantine patients. Wuhan has also been building 11 mobile Fangcang hospitals (a Chinese name which came from Noah's Ark) and creating tens of thousands of beds, to centralize quarantine and provide medical treatment for confirmed patients with mild symptoms, suspected patients and those who need observation. The new facilities further enhance the local public health capacities. Hospitals offer online consultants and medical services to symptomatic patients and suspected patients, which help reduce the frequency that patients go to hospitals and thereby reduce the risk of being infected. Health care workers, including military medical teams, from across the Chinese mainland arrived in Hubei to provide much needed assistance. At present, more than 30,000 health care workers have arrived in Hubei to help fight the novel coronavirus epidemic. In order to prevent health care workers from being infected, the NHC ensured enough supplies of isolation gowns, gloves and masks and issued a technical guideline for the prevention and control of infection caused by the novel coronavirus [
       <xref ref-type="bibr" rid="bib128">
        128
       </xref>
       ].
      </p>
     </sec>
     <sec id="sec10.4">
      <label>
       10.4
      </label>
      <title>
       Disseminate information
      </title>
      <p id="p0405">
       The NHC also formulated a community prevention and control program for SARS-CoV-2 pneumonia to strengthen community-level epidemic prevention measures to control the spread of the outbreak [
       <xref ref-type="bibr" rid="bib129">
        129
       </xref>
       ]. All communities screen patients with fever within the community and monitor and report suspected cases with COVID-19. Various forms of health education have been carried out in the community to disseminate knowledge of epidemic prevention and control, such as using masks and washing hands correctly. The NHC issued guidelines for the protection of people at different levels of risk for COVID-19 [
       <xref ref-type="bibr" rid="bib130">
        130
       </xref>
       ].
      </p>
     </sec>
    </sec>
    <sec id="sec11">
     <label>
      11
     </label>
     <title>
      Treatment and management
     </title>
     <p id="p0410">
      There is no clear, unified and effective treatment plan for COVID-19. Most guidelines emphasize early identification, early isolation, early diagnosis, and early treatment. The treatment and management of SARS-CoV-2 pneumonia mainly include the following aspects (
      <xref ref-type="fig" rid="fig8">
       Fig. 8
      </xref>
      ) [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ,
      <xref ref-type="bibr" rid="bib78">
       [78]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib79">
       [79]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib80">
       [80]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib81">
       [81]
      </xref>
      ,
      <xref ref-type="bibr" rid="bib82">
       [82]
      </xref>
      ].
      <fig id="fig8">
       <label>
        Fig. 8
       </label>
       <caption>
        <p>
         The treatment and management of COVID-19 pneumonia. ICU: intensive care unit; ECMO: extracorporeal membrane oxygenation.
        </p>
       </caption>
       <alt-text id="alttext0045">
        Fig. 8
       </alt-text>
       <graphic xlink:href="gr8_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0415">
      Suspected and confirmed cases should be isolated and treated in designated hospitals with effective isolation and protective conditions as soon as possible. Suspected cases should be isolated in a single room. WHO suggests that patients with mild symptoms and without underlying chronic diseases (such as lung or heart disease, renal failure, or immunodeficiency) may be cared for in the home environment in isolation [
      <xref ref-type="bibr" rid="bib131">
       131
      </xref>
      ]. However, severe cases should be hospitalized, and critical cases should be admitted to the ICU as soon as possible.
     </p>
     <p id="p0420">
      Supportive therapy includes bedrest, adequate nutrition, monitoring vital signs and oxygen saturation, prevention of dehydration and maintaining water, electrolyte, and acid-base balance. For severe cases, it may be necessary to proactively prevent complications and secondary infections, treat underlying diseases and provide organ function support according to the patients’ condition such as that reported by Chen et all that involved the administration of intravenous immunoglobulin therapy to 27 of such patients [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ].
     </p>
     <p id="p0425">
      Supplemental oxygen should be administered to patients with decreased oxygen saturation. In Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], four (10%) patients needed invasive mechanical ventilation, and two received extracorporeal membrane oxygenation (ECMO). In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 75 of 99 patients received oxygen therapy, 13 patients required non-invasive mechanical ventilation, four patients needed an invasive ventilator to assist ventilation, and three patients were treated with ECMO. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], of the 36 patients in the ICU, four patients received high-flow oxygen therapy, 15 patients received non-invasive ventilation, and 17 patients received invasive ventilation (four patients switched to ECMO). In Guan's study, 418 of 1099 patients received oxygen therapy, 67 patients received mechanical ventilation, and ECMO was adopted in 5 severe cases [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0430">
      Due to lack of valid evidence and possible adverse effects, routine use of corticosteroid should be avoided unless for specific reasons. Baillie JK et al. [
      <xref ref-type="bibr" rid="bib42">
       42
      </xref>
      ] suggested that corticosteroid should not be used for the treatment of SARS-CoV-2-induced lung injury or shock, because of the lack of evidence that patients with COVID-19 will benefit from corticosteroid. In the first 41 patients, only 22% (9/41) patients were given corticosteroid, with six of these in the ICU [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ]. Chen et al. reported that 19% (19/99) patients received corticosteroid treatment for 3–15 days [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ]. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], 45% (62/138) patients received corticosteroid treatment. In Guan's study, 18.6% (204/1099) of patients were given systemic corticosteroids [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0435">
      Indiscriminate or inappropriate antimicrobial treatment, especially the combination of broad-spectrum antibiotics, should be avoided. However, in Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], all his 41 patients received antibiotic therapy. In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 70 patients were given antibiotic treatment, among whom 25 patients were treated with a single antibiotic and 45 patients were given combination therapy. The duration of antibiotic treatment was 3–17 days. In addition, there were 15 patients who received antifungal treatment. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], the 138 hospitalized patients all received antibacterial therapy, including moxifloxacin (64.4%), ceftriaxone (24.6%), azithromycin (18.1%). In Guan's study, 632 patients were given intravenous antibiotics, and 30 patients were given antifungal medications [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ].
     </p>
     <p id="p0440">
      At present, there is no evidence-based medicine to support the effectiveness of antiviral drugs for COVID-19. The previous experience of treating SARS-CoV, MERS-CoV or influenza infections guides the selection of antiviral agents for COVID-19. The current guideline of the NHC recommends IFN-α, lopinavir/ritonavir, and ribavirin as antiviral therapy. In Huang's study [
      <xref ref-type="bibr" rid="bib26">
       26
      </xref>
      ], 38 of 41 patients were given antiviral therapy. The Jinyintan hospital has launched a randomized, controlled trial of the anti-HIV drug combination of lopinavir and ritonavir. In Chen's study [
      <xref ref-type="bibr" rid="bib37">
       37
      </xref>
      ], 75 patients received antiviral treatment, including oseltamivir, ganciclovir, and lopinavir/ritonavir, and the duration of antiviral treatment was 3–14 days. In Wang's study [
      <xref ref-type="bibr" rid="bib83">
       83
      </xref>
      ], there were 89.9% (124/138) patients who received oseltamivir. And in Guan's study, 35.8% (393/1099) of patients received oseltamivir [
      <xref ref-type="bibr" rid="bib85">
       85
      </xref>
      ]. The anti-viral drug remdesivir (Gilead®) is in clinical trials to treat COVID-19 in Wuhan [
      <xref ref-type="bibr" rid="bib132">
       132
      </xref>
      ]. Chloroquine phosphate has also been shown to be effective in some patients.
     </p>
     <p id="p0445">
      Identifying or developing novel drug treatment options as soon as possible is critical for the response to the SARS-CoV-2 outbreak. Based on the structural information of clinical effective medicines for SARS-CoV-2, Liu et al. predicted 10 commercial medicines which may function as inhibitors of SARS-CoV-2, including colistin, valrubicin, icatibant, bepotastine, epirubicin, etc. Some of these may be more resistant to viral mutation than lopinavir/ritonavir [
      <xref ref-type="bibr" rid="bib133">
       133
      </xref>
      ]. Stebbing et al. suggested that baricitinib may reduce both the viral entry and inflammation [
      <xref ref-type="bibr" rid="bib134">
       134
      </xref>
      ].
     </p>
     <p id="p0450">
      Lu reported that remdesivir may have the greatest potential for the successful treatment of SARS-CoV-2, but the efficacy and safety of remdesivir in COVID-19 needs further evaluation [
      <xref ref-type="bibr" rid="bib135">
       135
      </xref>
      ]. The antiviral efficiency of five FAD-approved drugs and two well-known broad-spectrum antiviral drugs have been studied and it has been found that remdesivir and chloroquine effectively inhibit SARS-CoV-2
      <italic>
       in vitro
      </italic>
      [
      <xref ref-type="bibr" rid="bib136">
       136
      </xref>
      ]. The New England Journal of Medicine reported that the first case of COVID-19 confirmed in the United States was treated with intravenous remdesivir and demonstrated clinical improvement [
      <xref ref-type="bibr" rid="bib71">
       71
      </xref>
      ]. At present, a randomized, double-blind, placebo-controlled phase III clinical trial of remdesivir has been launched and already 761 confirmed cases have been enrolled [
      <xref ref-type="bibr" rid="bib132">
       132
      </xref>
      ]. Lu also pointed out that there is no direct evidence that oseltamivir is effective in the treatment of SARS-CoV-2 [
      <xref ref-type="bibr" rid="bib135">
       135
      </xref>
      ]. However, we found that oral oseltamivir or abidol has been used for suspected or confirmed SARS-CoV-2 cases.
     </p>
     <p id="p0455">
      Favilavir, formerly known as Fapilavir, was the first anti-novel coronavirus drug that has been approved for marketing by the National Medical Products Administration since the outbreak. The drug was developed by Zhejiang Hisun Pharmaceutical Company and is expected to play an important role in preventing and treating the epidemic [
      <xref ref-type="bibr" rid="bib137">
       137
      </xref>
      ].
     </p>
     <p id="p0460">
      The role of intestinal microecological regulators that can be used to maintain intestinal microecological balance and prevent secondary bacterial infections is unclear. Chinese traditional medicine suggests Shufengjiedu and Lianhuaqingwen, which have played a role in the prevention and treatment of new infectious respiratory diseases, may be of benefit [
      <xref ref-type="bibr" rid="bib138">
       138
      </xref>
      ,
      <xref ref-type="bibr" rid="bib139">
       139
      </xref>
      ].
     </p>
     <p id="p0465">
      Anxiety and fear often exist in suspected or confirmed patients. Emergency psychological crisis intervention [
      <xref ref-type="bibr" rid="bib140">
       140
      </xref>
      ], and the implementation of classified intervention for different groups of people, is helpful in order to strengthen psychological counseling and reduce the psychological damage caused by the epidemic. Mass hysteria has also led to incidences of racial discrimination against Asians, particularly in non-Asian countries.
     </p>
    </sec>
    <sec id="sec12">
     <label>
      12
     </label>
     <title>
      Development of vaccines for coronavirus
     </title>
     <p id="p0470">
      Research institutions and pharmaceutical companies worldwide are stepping up research and development for a coronavirus vaccine. Virus strains have been isolated from patients’ samples and provide the basis for research and development of a vaccine for the novel coronavirus. Although vaccines have been developed for SARS-CoV and MERS-CoV, these are not commercially available [
      <xref ref-type="bibr" rid="bib12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib14">
       14
      </xref>
      ,
      <xref ref-type="bibr" rid="bib141">
       141
      </xref>
      ]. Since the emergence of SARS-CoV and MERS-CoV, basic research on coronaviruses and advances in vaccine preparation technology can significantly shorten the development time of new coronavirus vaccines. However, the difficulties and challenges of developing an effective vaccine have been discussed earlier, and the key to a successful vaccine program is to vaccinate people before an outbreak occurs, not begin to develop the vaccine during the outbreak. Development of animal models that faithfully mimic SARS-CoV-2 infection in humans is critical not only in providing a more refined understanding of the pathogenic mechanisms involved but also to serve as a screening model for potential chemotherapeutic agents and vaccines.
     </p>
    </sec>
    <sec id="sec13">
     <label>
      13
     </label>
     <title>
      Guidelines for the future
     </title>
     <p id="p0475">
      Recommendations for the prevention and management of coronavirus epidemics are summarized in
      <xref ref-type="fig" rid="fig9">
       Fig. 9
      </xref>
      . Since both SARS and SARS-CoV-2 appear to have an exotic animal origin, the purchase, trafficking, and sale of wild animals should be banned, and illegal activities should be prosecuted. Early recognition of the problem, early identification of infected patients and early mobilization of healthcare resources are critical in limiting morbidity and mortality. When an outbreak occurs, it is very important to rapidly identify and characterize the pathogen, in order to be able to develop diagnostic assays. In the early stage of the disease epidemic, summarizing the clinical characteristics and treatment efficacy, formulating the diagnosis procedures, defining suspected cases and locations, determining transmission patterns, isolating contagious patients and formulating the appropriate quarantine strategy are all necessary and need to be implemented promptly.
      <fig id="fig9">
       <label>
        Fig. 9
       </label>
       <caption>
        <p>
         Keys to the control of future hCoV epidemics. Lessons learned from both the SARS and SARS-CoV-2 epidemics.
        </p>
       </caption>
       <alt-text id="alttext0050">
        Fig. 9
       </alt-text>
       <graphic xlink:href="gr9_lrg">
       </graphic>
      </fig>
     </p>
     <p id="p0480">
      The strict control of cross-infection in medical institutions is also key to preventing the further spread of the epidemic. In addition, actively mobilizing the population to participate in epidemic prevention and control is critical, and this can be achieved by accurate information dissemination and ongoing updates. Real-time updating the information of the epidemic situation can help to alleviate panic and reduce societal anxiety. A strong public health surveillance system to guide the response to the outbreak is important in the face of a lack of effective therapeutics or vaccines. Big data and artificial intelligence systems are tools that can be used to fully integrate the information, conduct comprehensive research and analyze public health risks. Last but not least, use of the Internet and the media to conduct health education for the people, publicize the correct knowledge of prevention, and offer online consultation to guide patients to seek medical treatment correctly are additional strategies that can be implemented to achieve viral containment.
     </p>
    </sec>
    <sec id="sec14">
     <label>
      14
     </label>
     <title>
      Discussion
     </title>
     <sec id="sec14.1">
      <label>
       14.1
      </label>
      <title>
       <italic>
        The differences between SARS and
       </italic>
       SARS-CoV-2
      </title>
      <p id="p0485">
       Although SARS-CoV-2 and SARS-CoV have certain similarities in biological, epidemiological and pathological characteristics, there are some important differences. First, the most fundamental difference between the two viruses lies in their gene sequence. Second, during the SARS epidemic, a total of 8422 patients worldwide were infected with SARS-CoV, of whom 919 died, with a mortality rate of 9.5% [
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ]. A total of 5328 patients in China were infected with SARS-CoV, of whom 349 died, with a mortality rate of 6.5% [
       <xref ref-type="bibr" rid="bib9">
        9
       </xref>
       ]. As of February 17, 2020, there were 72,436 confirmed cases of 2019-nCoV in China, of whom 1868 have died, with a mortality rate of 2.6% [
       <xref ref-type="bibr" rid="bib10">
        10
       </xref>
       ]. Compared to SARS, there are more confirmed cases, suspected cases and deaths of SARS-CoV-2, but the mortality rate is lower than that of SARS.
      </p>
      <p id="p0490">
       From 2017 to 2018, influenza ravaged the world, affecting up to 45 million people and killing about 95,000 people, with a reported mortality rate of about 0.2%. Every year millions of people are infected by influenza despite the existence of a yearly vaccine. According to the United States CDC weekly report, the number of childhood deaths in the United States so far from influenza during this flu season alone is 105. Compared with influenza, the number of patients who have died of coronavirus infection is less, but the virulence and mortality rate of coronavirus is significantly higher.
      </p>
      <p id="p0495">
       Clinically, the patients with COVID-19 have no upper respiratory symptoms (such as runny nose, sneezing, sore throat). In 2003, a large number of medical personnel were infected, and iatrogenic transmission occurred in SARS. In contrast, although there are cases of nosocomial infection in SARS-CoV-2, most of them are out-of-hospital infections.
      </p>
     </sec>
     <sec id="sec14.2">
      <label>
       14.2
      </label>
      <title>
       What can we learn from the 2020 nCoV epidemic in China?
      </title>
      <p id="p0500">
       The SARS-CoV-2 epidemic of 2020 in China is an international crisis, affecting human lives, the global economy, societal views and lifestyle. During times of crisis, misinformation, blame and conspiracy theories abound. It is probably prudent to not entirely trust the media, whether local, regional or international, as each most likely has their own agenda. On the other hand, it is the responsibility of doctors and scientists to evaluate the events to ascertain whether or not more effective management of the crisis could have been attained. This comes with its own set of challenges, as hindsight is always 20/20.
      </p>
      <p id="p0505">
       The quarantining of an entire country has been extreme, astounding and unprecedented. This not only involves quarantining measures within China but also internationally, as countries canceled flights into China, quarantined their own nationals as they returned from China and installed thermal scanners to detect ill people. But the quarantine measures inside China are certainly eye-opening. The entire city of Wuhan was shut off, and this was extended to every other city in China. In effect, the entire country was told to stay home, creating an enormous impact on the economy and on people's daily lives. Roads and stores became deserted (
       <xref ref-type="fig" rid="fig10">
        Fig. 10
       </xref>
       ). In Ningbo, each household was only permitted to send one person out for groceries every other day. Schools were closed till the end of March. Everyone wears masks. The objective was to starve the virus, to eliminate hosts. Yet even with these measures, new cases continued to appear. The quarantine measures in China have obviously come under a great deal of scrutiny, with so called “experts” weighing in, some saying that it will not work, that isolating a city deprives it of medical resources. Whatever the criticism, it is humbling to think of what may have happened without these draconian measures. It is also difficult to comprehend if such measures could actually take place in other parts of the world, or if the implementation of these changes could have taken place as quickly. For example, hand shaking is not part of Chinese culture, but it is almost automatic in other parts of the world, and it is normally done without even thinking. This is the first thing that would have to stop to help contain the virus.
       <fig id="fig10">
        <label>
         Fig. 10
        </label>
        <caption>
         <p>
          Life in China in Beijing and Hubei during quarantine measures. Quarantine measures have led to empty streets and shopping centers.
         </p>
        </caption>
        <alt-text id="alttext0055">
         Fig. 10
        </alt-text>
        <graphic xlink:href="gr10_lrg">
        </graphic>
       </fig>
      </p>
      <p id="p0510">
       Then there is the matter of the ophthalmologist and others who voiced concerns in the media about a cluster of cases of a flu-like illness near the end of December. At the present time, it is difficult to say whether or not the response could have been faster than it actually was, as this corresponds to the time when work began on viral sequencing. It is possible that medical teams were already working on the sequence at that time. It is also quite possible that officials did not initially sound the alarm publicly because they did not want to cause a panic. Perhaps this was the wrong decision, but these decisions are difficult in times of crisis and it is of course easy to second guess. It is easy to understand that this can be perceived as withholding information and why the public would be frustrated. The lesson here is that dissemination of accurate and validated information and establishing guidelines to prevent the spread of infections is critical.
      </p>
      <p id="p0515">
       There are many “heroes” in these crises, people who have risked their lives and made incredible sacrifices to help society rid itself of this scourge, including those who work on the front lines, epidemiologists, scientists, doctors, first responders, and members of the public. Unfortunately, these events also bring out the worst in people. Numerous accounts of racial discrimination have been perpetrated against Asians across the world, many rising to the level of hate crimes. One must not forget the psychological impact of an infection such as this on people who are not even infected or who will never encounter an infected person.
      </p>
      <p id="p0520">
       The emergence of SARS-CoV, MERS-CoV, and now SARS-CoV-2, suggests that coronavirus will pose a lasting threat to human beings. The epidemic will eventually be contained, and people's memory of the coronavirus may gradually blur. But we must not forget the lessons learned from this crisis, and already begin to take measures to prevent the next new outbreak of Coronavirus or some other virus from appearing in the future. If it does appear, how will we respond to it? What if it does not happen in China? Will other countries have the fortitude to implement even more drastic measures and mobilize resources to prevent the spread of the virus and to care for the sick?
      </p>
      <p id="p0525">
       We can always improve on the handling of global pandemics or epidemics. From the lessons learned during the SARS and now the SARS-CoV-2 epidemics, we can nearly provide a roadmap for the response to future outbreaks. The development of a vaccine for coronavirus is a critical step in prevention, but it may not be effective for future strains, and we must be ready for the next epidemic.
      </p>
     </sec>
    </sec>
    <sec id="sec15">
     <title>
      Funding
     </title>
     <p id="p0530">
      <funding-source id="gs1">
       Beijing Municipal Natural Science Foundation
      </funding-source>
      General Program (7,192,197).
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of competing interest
     </title>
     <p id="p0535">
      The authors declare no conflict of interest.
     </p>
    </sec>
    <back>
     <ref-list id="cebib0010">
      <title>
       References
      </title>
      <ref id="bib1">
       <label>
        1
       </label>
       <element-citation id="sref1" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Leibowitz
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis
        </article-title>
        <source>
         Adv. Virus Res.
        </source>
        <volume>
         81
        </volume>
        <year>
         2011
        </year>
        <fpage>
         85
        </fpage>
        <lpage>
         164
        </lpage>
        <pub-id pub-id-type="pmid">
         22094080
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib2">
       <label>
        2
       </label>
       <element-citation id="sref2" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Balasuriya
          </surname>
          <given-names>
           U.B.R.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         List of contributors
        </chapter-title>
        <person-group person-group-type="editor">
         <name>
          <surname>
           MacLachlan
          </surname>
          <given-names>
           N.J.
          </given-names>
         </name>
         <name>
          <surname>
           Dubovi
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <source>
         Fenner's Veterinary Virology
        </source>
        <edition>
         fifth ed.
        </edition>
        <year>
         2017
        </year>
        <publisher-name>
         Academic Press
        </publisher-name>
        <publisher-loc>
         Boston
        </publisher-loc>
        <fpage>
         xvii
        </fpage>
        <lpage>
         xviii
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib3">
       <label>
        3
       </label>
       <element-citation id="sref3" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         24
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         490
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib4">
       <label>
        4
       </label>
       <element-citation id="sref4" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         N Engl J Med
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib5">
       <label>
        5
       </label>
       <element-citation id="sref5" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology of coronavirus respiratory infections
        </article-title>
        <source>
         Arch. Dis. Child.
        </source>
        <volume>
         58
        </volume>
        <issue>
         7
        </issue>
        <year>
         1983
        </year>
        <fpage>
         500
        </fpage>
        <lpage>
         503
        </lpage>
        <pub-id pub-id-type="pmid">
         6307189
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib6">
       <label>
        6
       </label>
       <element-citation id="sref6" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on human rhinovirus and coronavirus infections
        </article-title>
        <source>
         Semin. Respir. Crit. Care Med.
        </source>
        <volume>
         37
        </volume>
        <issue>
         4
        </issue>
        <year>
         2016
        </year>
        <fpage>
         555
        </fpage>
        <lpage>
         571
        </lpage>
        <pub-id pub-id-type="pmid">
         27486736
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib7">
       <label>
        7
       </label>
       <element-citation id="sref7" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib8">
       <label>
        8
       </label>
       <element-citation id="sref8" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV)
        </article-title>
        <comment>
         [cited Jan 30, 2020; Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0010" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
         http://www.who.int/emergencies/mers-cov/en/
        </ext-link>
        <year>
         2019 Jan 30
        </year>
       </element-citation>
      </ref>
      <ref id="bib9">
       <label>
        9
       </label>
       <element-citation id="sref9" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Summary table of SARS cases by country, November 1, 2002-August 7, 2003
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0015" xlink:href="http://www.who.int/csr/sars/country/2003_08_15/en/">
         http://www.who.int/csr/sars/country/2003_08_15/en/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib10">
       <label>
        10
       </label>
       <element-citation id="sref10" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Update on the Novel Coronavirus Pneumonia Outbreak
        </chapter-title>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0020" xlink:href="http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml">
         http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib11">
       <label>
        11
       </label>
       <element-citation id="sref11" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Weiss
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Navas-Martin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Microbiol. Mol. Biol. Rev.
        </source>
        <volume>
         69
        </volume>
        <issue>
         4
        </issue>
        <year>
         2005
        </year>
        <fpage>
         635
        </fpage>
        <lpage>
         664
        </lpage>
        <pub-id pub-id-type="pmid">
         16339739
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib12">
       <label>
        12
       </label>
       <element-citation id="sref12" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <volume>
         1282
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         23
        </lpage>
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib13">
       <label>
        13
       </label>
       <element-citation id="sref13" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <volume>
         11
        </volume>
        <issue>
         6
        </issue>
        <year>
         2012
        </year>
        <fpage>
         607
        </fpage>
        <lpage>
         616
        </lpage>
        <pub-id pub-id-type="pmid">
         22704621
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib14">
       <label>
        14
       </label>
       <element-citation id="sref14" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         From SARS to MERS, thrusting coronaviruses into the spotlight
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         11
        </volume>
        <issue>
         1
        </issue>
        <year>
         2019
        </year>
        <fpage>
         59
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib15">
       <label>
        15
       </label>
       <element-citation id="sref15" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         6
        </issue>
        <year>
         2010
        </year>
        <fpage>
         2808
        </fpage>
        <lpage>
         2819
        </lpage>
        <pub-id pub-id-type="pmid">
         20071579
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib16">
       <label>
        16
       </label>
       <element-citation id="sref16" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <volume>
         310
        </volume>
        <issue>
         5748
        </issue>
        <year>
         2005
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib17">
       <label>
        17
       </label>
       <element-citation id="sref17" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Stratton
          </surname>
          <given-names>
           C.W.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         402
        </lpage>
        <comment>
         Epub 2020 Feb 12
        </comment>
        <pub-id pub-id-type="pmid">
         31950516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib18">
       <label>
        18
       </label>
       <element-citation id="sref18" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross-species transmission of the newly identified coronavirus 2019-nCoV
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         433
        </fpage>
        <lpage>
         440
        </lpage>
        <pub-id pub-id-type="pmid">
         31967321
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib19">
       <label>
        19
       </label>
       <element-citation id="sref19" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
        <comment>
         Epub 2020 Jan 24
        </comment>
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib20">
       <label>
        20
       </label>
       <element-citation id="sref20" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Akhmetzhanov
          </surname>
          <given-names>
           A.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initial cluster of novel coronavirus (2019-nCoV) infections in wuhan, China is consistent with substantial human-to-human transmission
        </article-title>
        <source>
         J. Clin. Med.
        </source>
        <volume>
         9
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         E488
        </fpage>
        <pub-id pub-id-type="pmid">
         32054045
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib21">
       <label>
        21
       </label>
       <mixed-citation id="sref21" publication-type="other">
        Organization, W.H., Consensus Document on the Epidemiology of Severe Acute Respiratory Syndrome (SARS). 2003, World Health Organization: Geneva.
       </mixed-citation>
      </ref>
      <ref id="bib22">
       <label>
        22
       </label>
       <element-citation id="sref22" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Maier
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Bickerton
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Britton
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses: Methods and Protocols
        </chapter-title>
        <year>
         2015
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         282
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib23">
       <label>
        23
       </label>
       <element-citation id="sref23" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus: current knowledge and future considerations
        </article-title>
        <source>
         EMHJ-Eastern Mediterranean Health J.
        </source>
        <volume>
         22
        </volume>
        <issue>
         7
        </issue>
        <year>
         2016
        </year>
        <fpage>
         533
        </fpage>
        <lpage>
         542
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib24">
       <label>
        24
       </label>
       <element-citation id="sref24" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         2019-nCoV transmission through the ocular surface must not be ignored
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020 Feb 22
        </year>
        <fpage>
         e39
        </fpage>
        <comment>
         Epub 2020 Feb 6
        </comment>
        <pub-id pub-id-type="pmid">
         32035510
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib25">
       <label>
        25
       </label>
       <element-citation id="sref25" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wunderink
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS, SARS and other coronaviruses as causes of pneumonia
        </article-title>
        <source>
         Respirology
        </source>
        <volume>
         23
        </volume>
        <issue>
         2
        </issue>
        <year>
         2018
        </year>
        <fpage>
         130
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="pmid">
         29052924
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib26">
       <label>
        26
       </label>
       <element-citation id="sref26" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <comment>
         Epub 2020 Jan 24
        </comment>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib27">
       <label>
        27
       </label>
       <element-citation id="sref27" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <issue>
         6268
        </issue>
        <year>
         2016
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib28">
       <label>
        28
       </label>
       <element-citation id="sref28" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Moderate mutation rate in the SARS coronavirus genome and its implications
        </article-title>
        <source>
         BMC Evol. Biol.
        </source>
        <volume>
         4
        </volume>
        <year>
         2004
        </year>
        <fpage>
         21
        </fpage>
        <pub-id pub-id-type="pmid">
         15222897
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib29">
       <label>
        29
       </label>
       <element-citation id="sref29" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections
        </article-title>
        <source>
         Curr. Opin. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         5
        </issue>
        <year>
         2006
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         407
        </lpage>
        <pub-id pub-id-type="pmid">
         16940861
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib30">
       <label>
        30
       </label>
       <element-citation id="sref30" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus diversity, phylogeny and interspecies jumping
        </article-title>
        <source>
         Exp. Biol. Med.
        </source>
        <volume>
         234
        </volume>
        <issue>
         10
        </issue>
        <year>
         2009
        </year>
        <fpage>
         1117
        </fpage>
        <lpage>
         1127
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib31">
       <label>
        31
       </label>
       <element-citation id="sref31" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         80
        </volume>
        <issue>
         14
        </issue>
        <year>
         2006
        </year>
        <fpage>
         7136
        </fpage>
        <lpage>
         7145
        </lpage>
        <pub-id pub-id-type="pmid">
         16809319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib32">
       <label>
        32
       </label>
       <element-citation id="sref32" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Benvenuto
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The 2019-new coronavirus epidemic: evidence for virus evolution
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         455
        </fpage>
        <lpage>
         459
        </lpage>
        <comment>
         Epub 2020 Feb 7
        </comment>
        <pub-id pub-id-type="pmid">
         31994738
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib33">
       <label>
        33
       </label>
       <element-citation id="sref33" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ceraolo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Giorgi
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic variance of the 2019-nCoV coronavirus
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib34">
       <label>
        34
       </label>
       <element-citation id="sref34" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute renal impairment in coronavirus-associated severe acute respiratory syndrome
        </article-title>
        <source>
         Kidney Int.
        </source>
        <volume>
         67
        </volume>
        <issue>
         2
        </issue>
        <year>
         2005
        </year>
        <fpage>
         698
        </fpage>
        <lpage>
         705
        </lpage>
        <pub-id pub-id-type="pmid">
         15673319
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib35">
       <label>
        35
       </label>
       <element-citation id="sref35" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9371
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1767
        </fpage>
        <lpage>
         1772
        </lpage>
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib36">
       <label>
        36
       </label>
       <element-citation id="sref36" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Booth
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <volume>
         289
        </volume>
        <issue>
         21
        </issue>
        <year>
         2003
        </year>
        <fpage>
         2801
        </fpage>
        <lpage>
         2809
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib37">
       <label>
        37
       </label>
       <element-citation id="sref37" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: a Descriptive Study
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Lancet
        </publisher-name>
        <publisher-loc>
         London, England)
        </publisher-loc>
        <comment>
         S0140-6736(20)30211-7
        </comment>
       </element-citation>
      </ref>
      <ref id="bib38">
       <label>
        38
       </label>
       <element-citation id="sref38" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cinatl
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of SARS with human interferons
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         362
        </volume>
        <issue>
         9380
        </issue>
        <year>
         2003
        </year>
        <fpage>
         293
        </fpage>
        <lpage>
         294
        </lpage>
        <pub-id pub-id-type="pmid">
         12892961
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib39">
       <label>
        39
       </label>
       <element-citation id="sref39" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        <source>
         PLoS Med.
        </source>
        <volume>
         3
        </volume>
        <issue>
         9
        </issue>
        <year>
         2006
        </year>
        <fpage>
         e343
        </fpage>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib40">
       <label>
        40
       </label>
       <element-citation id="sref40" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib41">
       <label>
        41
       </label>
       <element-citation id="sref41" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
        </article-title>
        <source>
         J. Clin. Virol.
        </source>
        <volume>
         31
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         304
        </fpage>
        <lpage>
         309
        </lpage>
        <pub-id pub-id-type="pmid">
         15494274
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib42">
       <label>
        42
       </label>
       <element-citation id="sref42" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Russell
          </surname>
          <given-names>
           C.D.
          </given-names>
         </name>
         <name>
          <surname>
           Millar
          </surname>
          <given-names>
           J.E.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         The Lancet
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib43">
       <label>
        43
       </label>
       <element-citation id="sref43" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus as a possible cause of severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         361
        </volume>
        <issue>
         9366
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1325
        </lpage>
        <pub-id pub-id-type="pmid">
         12711465
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib44">
       <label>
        44
       </label>
       <element-citation id="sref44" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NS
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           GQ
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Our strategies for fighting severe acute respiratory syndrome (SARS)
        </article-title>
        <source>
         Am. J. Respir. Crit. Care Med.
        </source>
        <volume>
         168
        </volume>
        <issue>
         1
        </issue>
        <year>
         2003
        </year>
        <fpage>
         7
        </fpage>
        <lpage>
         9
        </lpage>
        <pub-id pub-id-type="pmid">
         12773318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib45">
       <label>
        45
       </label>
       <element-citation id="sref45" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           R.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic
        </article-title>
        <source>
         Phil. Trans. Roy. Soc. Lond. B Biol. Sci.
        </source>
        <volume>
         359
        </volume>
        <issue>
         1447
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1091
        </fpage>
        <lpage>
         1105
        </lpage>
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib46">
       <label>
        46
       </label>
       <element-citation id="sref46" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        <source>
         JAMA, 2003
        </source>
        <volume>
         290
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3215
        </fpage>
        <lpage>
         3221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib47">
       <label>
        47
       </label>
       <element-citation id="sref47" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Centers for Disease
          </surname>
         </name>
        </person-group>
        <article-title>
         C. and Prevention, Efficiency of quarantine during an epidemic of severe acute respiratory syndrome-Beijing, China
        </article-title>
        <source>
         MMWR. Morbidity Mortality Weekly Rep.
        </source>
        <volume>
         52
        </volume>
        <issue>
         43
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1040
        </lpage>
        <comment>
         2003
        </comment>
       </element-citation>
      </ref>
      <ref id="bib48">
       <label>
        48
       </label>
       <element-citation id="sref48" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breiman
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of China in the quest to define and control severe acute respiratory syndrome
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1037
        </fpage>
        <lpage>
         1041
        </lpage>
        <pub-id pub-id-type="pmid">
         14519236
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib49">
       <label>
        49
       </label>
       <element-citation id="sref49" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sampathkumar
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology, clinical presentation, management, and infection control measures
        </article-title>
        <source>
         Mayo Clin. Proc.
        </source>
        <volume>
         78
        </volume>
        <issue>
         7
        </issue>
        <year>
         2003
        </year>
        <fpage>
         882
        </fpage>
        <lpage>
         890
        </lpage>
        <pub-id pub-id-type="pmid">
         12839084
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib50">
       <label>
        50
       </label>
       <element-citation id="sref50" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Christian
          </surname>
          <given-names>
           M.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Clin. Infect. Dis.
        </source>
        <volume>
         38
        </volume>
        <issue>
         10
        </issue>
        <year>
         2004
        </year>
        <fpage>
         1420
        </fpage>
        <lpage>
         1427
        </lpage>
        <pub-id pub-id-type="pmid">
         15156481
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib51">
       <label>
        51
       </label>
       <element-citation id="sref51" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           N
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Learning from the sars outbreak
        </article-title>
        <source>
         Curr. Biol. : CB
        </source>
        <volume>
         14
        </volume>
        <issue>
         3
        </issue>
        <year>
         2004
        </year>
        <fpage>
         R91
        </fpage>
        <lpage>
         R93
        </lpage>
        <pub-id pub-id-type="pmid">
         14986624
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib52">
       <label>
        52
       </label>
       <element-citation id="sref52" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome and coronavirus
        </article-title>
        <source>
         Infect. Dis. Clin.
        </source>
        <volume>
         24
        </volume>
        <issue>
         3
        </issue>
        <year>
         2010
        </year>
        <fpage>
         619
        </fpage>
        <lpage>
         638
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib53">
       <label>
        53
       </label>
       <element-citation id="sref53" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NS
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           GQ
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pandemic planning in China: applying lessons from severe acute respiratory syndrome
        </article-title>
        <source>
         Respirology
        </source>
        <year>
         2008
        </year>
        <fpage>
         S33
        </fpage>
        <lpage>
         S35
        </lpage>
        <pub-id pub-id-type="pmid">
         18366527
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib54">
       <label>
        54
       </label>
       <element-citation id="sref54" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AS
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Lessons from the severe acute respiratory syndrome outbreak in Hong Kong
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         9
        </volume>
        <issue>
         9
        </issue>
        <year>
         2003
        </year>
        <fpage>
         1042
        </fpage>
        <lpage>
         1045
        </lpage>
        <pub-id pub-id-type="pmid">
         14519237
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib55">
       <label>
        55
       </label>
       <element-citation id="sref55" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           RP
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           MB
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Listening to SARS: lessons for infection control
        </article-title>
        <source>
         Ann. Intern. Med.
        </source>
        <volume>
         139
        </volume>
        <issue>
         7
        </issue>
        <year>
         2003
        </year>
        <fpage>
         592
        </fpage>
        <lpage>
         593
        </lpage>
        <pub-id pub-id-type="pmid">
         14530231
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib56">
       <label>
        56
       </label>
       <element-citation id="sref56" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical management and infection control of SARS: lessons learned
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         100
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         407
        </fpage>
        <lpage>
         419
        </lpage>
        <pub-id pub-id-type="pmid">
         23994190
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib57">
       <label>
        57
       </label>
       <element-citation id="sref57" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Parashar
          </surname>
          <given-names>
           U.D.
          </given-names>
         </name>
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: review and lessons of the 2003 outbreak
        </article-title>
        <source>
         Int. J. Epidemiol.
        </source>
        <volume>
         33
        </volume>
        <issue>
         4
        </issue>
        <year>
         2004
        </year>
        <fpage>
         628
        </fpage>
        <lpage>
         634
        </lpage>
        <pub-id pub-id-type="pmid">
         15155694
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib58">
       <label>
        58
       </label>
       <element-citation id="sref58" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of control measures implemented in the severe acute respiratory syndrome outbreak in Beijing
        </article-title>
        <source>
         JAMA, 2003
        </source>
        <volume>
         290
        </volume>
        <issue>
         24
        </issue>
        <year>
         2003
        </year>
        <fpage>
         3215
        </fpage>
        <lpage>
         3221
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib59">
       <label>
        59
       </label>
       <element-citation id="sref59" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DR
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Obstacles and advances in SARS vaccine development
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         24
        </volume>
        <issue>
         7
        </issue>
        <year>
         2006
        </year>
        <fpage>
         863
        </fpage>
        <lpage>
         871
        </lpage>
        <pub-id pub-id-type="pmid">
         16191455
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib60">
       <label>
        60
       </label>
       <element-citation id="sref60" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wenjie
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus genome identified in a cluster of pneumonia cases — wuhan, China 2019−2020
        </article-title>
        <source>
         China CDC Weekly
        </source>
        <volume>
         2
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020
        </year>
        <fpage>
         61
        </fpage>
        <lpage>
         62
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib61">
       <label>
        61
       </label>
       <element-citation id="sref61" publication-type="journal">
        <comment>
         The -nCo, V.O.J.F.E.I.T.
        </comment>
        <person-group person-group-type="author">
         <name>
          <surname>
           Qun
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An outbreak of NCIP (2019-nCoV) infection in China — wuhan, Hubei province, 2019−2020
        </article-title>
        <source>
         China CDC Weekly
        </source>
        <volume>
         2
        </volume>
        <issue>
         5
        </issue>
        <year>
         2020
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         80
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib62">
       <label>
        62
       </label>
       <element-citation id="sref62" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           University
          </surname>
          <given-names>
           S.C.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pangolin was found to be a potential intermediate-host of new coronavirus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0025" xlink:href="https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm">
         https://www.scau.edu.cn/2020/0207/c1300a219015/page.htm
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib63">
       <label>
        63
       </label>
       <element-citation id="sref63" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rothe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission of 2019-nCoV infection from an asymptomatic contact in Germany
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020 Jan 30
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib64">
       <label>
        64
       </label>
       <element-citation id="sref64" publication-type="journal">
        <article-title>
         Clinical updates in women's health care summary: liver disease: reproductive considerations
        </article-title>
        <source>
         Obstet. Gynecol.
        </source>
        <volume>
         129
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         236
        </fpage>
        <pub-id pub-id-type="pmid">
         28002308
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib65">
       <label>
        65
       </label>
       <element-citation id="sref65" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib66">
       <label>
        66
       </label>
       <element-citation id="sref66" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paules
          </surname>
          <given-names>
           C.I.
          </given-names>
         </name>
         <name>
          <surname>
           Marston
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Fauci
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus infections-more than just the common cold
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib67">
       <label>
        67
       </label>
       <element-citation id="sref67" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Novel Coronavirus Pneumonia Emergency Response Epidemiology
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China
        </article-title>
        <source>
         Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
        </source>
        <volume>
         41
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
        <fpage>
         145
        </fpage>
        <lpage>
         151
        </lpage>
        <pub-id pub-id-type="pmid">
         32064853
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib68">
       <label>
        68
       </label>
       <element-citation id="sref68" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Nowcasting and Forecasting the Potential Domestic and International Spread of the 2019-nCoV Outbreak Originating in Wuhan, China: a Modelling Study
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Lancet
        </publisher-name>
        <publisher-loc>
         London, England)
        </publisher-loc>
        <comment>
         S0140-6736(20)30260-9
        </comment>
       </element-citation>
      </ref>
      <ref id="bib69">
       <label>
        69
       </label>
       <element-citation id="sref69" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Prevention
          </surname>
         </name>
        </person-group>
        <article-title>
         G.C.f.D.C.a. The virus on the doorknob is not a live virus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0030" xlink:href="http://www.gd.xinhuanet.com/newscenter/2020-02/04/c_1125528591.htm">
         http://www.gd.xinhuanet.com/newscenter/2020-02/04/c_1125528591.htm
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib70">
       <label>
        70
       </label>
       <element-citation id="sref70" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           ZH
          </surname>
         </name>
        </person-group>
        <article-title>
         Z. Fecal matter of patients tests positive for coronavirus
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0035" xlink:href="https://www.chinadaily.com.cn/a/202002/02/WS5e35b026a310128217274206.html">
         https://www.chinadaily.com.cn/a/202002/02/WS5e35b026a310128217274206.html
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib71">
       <label>
        71
       </label>
       <element-citation id="sref71" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First case of 2019 novel coronavirus in the United States
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib72">
       <label>
        72
       </label>
       <element-citation id="sref72" publication-type="other">
        <person-group person-group-type="author">
         <collab>
          Organization, W.H. Novel Coronavirus
         </collab>
        </person-group>
        <article-title>
         (2019-nCoV) situation reports to data
        </article-title>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0040" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib73">
       <label>
        73
       </label>
       <element-citation id="sref73" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         W.H. Statement on the Second Meeting of the International Health Regulations (2005) Emergency Committee Regarding the Outbreak of Novel Coronavirus (2019-nCoV). . 2020
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         World Health Organization
        </publisher-name>
        <publisher-loc>
         Geneva
        </publisher-loc>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0045" xlink:href="https://www.who.int/newsroom/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-healthregulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov">
         https://www.who.int/newsroom/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-healthregulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib74">
       <label>
        74
       </label>
       <element-citation id="sref74" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Z.D.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Diagnosis and prevention of 2019-nCoV virus infection/pneumonia in children
        </article-title>
        <comment>
         (in Chinese) Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0050" xlink:href="https://www.cma.org.cn/art/2020/1/29/art_1822_32177.html">
         https://www.cma.org.cn/art/2020/1/29/art_1822_32177.html
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib75">
       <label>
        75
       </label>
       <element-citation id="sref75" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Technology
          </surname>
         </name>
        </person-group>
        <chapter-title>
         T.H.T.M.C.H.U.o.S.a. Be Alert to the Risk of Mother-To-Child Vertical Transmission and the First New Coronavirus Infection of a Newborn Was Diagnosed in Tongji Hospital
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         ChuTian Metropolis Daily
        </publisher-name>
        <fpage>
         2020
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib76">
       <label>
        76
       </label>
       <element-citation id="sref76" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         The Lancet
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib77">
       <label>
        77
       </label>
       <element-citation id="sref77" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Notice on prevention and control of pneumonia in children and pregnant women with new coronavirus infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0055" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202002/de2d62a5711c41ef9b2c4b6f4d1f2136.shtml
        </ext-link>
        <comment>
         2020; Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib78">
       <label>
        78
       </label>
       <mixed-citation id="sref78" publication-type="other">
        Technology, M.e.g.o.T.h.a.t.T.M.C.o.H.U.o.S.a. A rapid guideline for the diagnosis and treatment of pneumonia with new coronavirus infection (Third edition). . Herald of Medicine 2020 1004-0781,CN 42-1293/R]; Available from:
        <ext-link ext-link-type="uri" id="intref0060" xlink:href="http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html">
         http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html
        </ext-link>
        .
       </mixed-citation>
      </ref>
      <ref id="bib79">
       <label>
        79
       </label>
       <element-citation id="sref79" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Union Hospital
          </surname>
         </name>
        </person-group>
        <article-title>
         T.M.C., Huazhong University of Science and Technology., Wuhan union hospital manage the 2019 new coronavirus infection strategies and instructions
        </article-title>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0065" xlink:href="https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q">
         https://mp.weixin.qq.com/s/d7btF9g1wMhNgFnHy5vY1Q
        </ext-link>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib80">
       <label>
        80
       </label>
       <element-citation id="sref80" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yinghui Jing
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Zhenshui
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Hong
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Diagnosis and Clinical Management of 2019 Novel Coronavirus (2019-nCoV) Infection: an Operational Recommendation of Peking Union Medical College Hospital. (In Chinese)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Medical Journal of Chinese People's Liberation Army
        </publisher-name>
        <comment>
         0577-7402,CN 11-1056/R
        </comment>
       </element-citation>
      </ref>
      <ref id="bib81">
       <label>
        81
       </label>
       <element-citation id="sref81" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
         </name>
        </person-group>
        <chapter-title>
         W.H., Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (nCoV) Infection Is Suspected
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib82">
       <label>
        82
       </label>
       <element-citation id="sref82" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         New Coronavirus Pneumonia Prevention and Control Program
        </chapter-title>
        <edition>
         fifth ed.
        </edition>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission, 2020
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0070" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202002/3b09b894ac9b4204a79db5b8912d4440.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib83">
       <label>
        83
       </label>
       <element-citation id="sref83" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib84">
       <label>
        84
       </label>
       <element-citation id="sref84" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside wuhan, China
        </article-title>
        <source>
         J. Am. Med. Assoc.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib85">
       <label>
        85
       </label>
       <element-citation id="sref85" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.-j.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Clinical Characteristics of 2019 Novel Coronavirus Infection in China
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         medRxiv
        </publisher-name>
        <comment>
         2020.02.06.20020974
        </comment>
       </element-citation>
      </ref>
      <ref id="bib86">
       <label>
        86
       </label>
       <element-citation id="sref86" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of
         <bold>
          1014
         </bold>
         Cases.
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020 Feb 26
        </year>
        <object-id pub-id-type="publisher-id">
         200642
        </object-id>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib87">
       <label>
        87
       </label>
       <element-citation id="sref87" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging coronaviruses: genome structure, replication, and pathogenesis
        </article-title>
        <source>
         J. Med. Virol.
        </source>
        <volume>
         92
        </volume>
        <issue>
         4
        </issue>
        <year>
         2020 Apr
        </year>
        <fpage>
         418
        </fpage>
        <lpage>
         423
        </lpage>
        <comment>
         Epub 2020 Feb 7. Review
        </comment>
        <pub-id pub-id-type="pmid">
         31967327
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib88">
       <label>
        88
       </label>
       <element-citation id="sref88" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cookson
          </surname>
          <given-names>
           B.T.
          </given-names>
         </name>
         <name>
          <surname>
           Brennan
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pro-inflammatory programmed cell death
        </article-title>
        <source>
         Trends Microbiol.
        </source>
        <volume>
         9
        </volume>
        <issue>
         3
        </issue>
        <year>
         2001
        </year>
        <fpage>
         113
        </fpage>
        <lpage>
         114
        </lpage>
        <pub-id pub-id-type="pmid">
         11303500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib89">
       <label>
        89
       </label>
       <element-citation id="sref89" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           I.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus Viroporin 3a activates the NLRP3 inflammasome
        </article-title>
        <source>
         Front. Microbiol.
        </source>
        <volume>
         10
        </volume>
        <year>
         2019
        </year>
        <fpage>
         50
        </fpage>
        <pub-id pub-id-type="pmid">
         30761102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib90">
       <label>
        90
       </label>
       <element-citation id="sref90" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Cell Pyroptosis, a Potential Pathogenic Mechanismof 2019 nCoV Infection
        </chapter-title>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib91">
       <label>
        91
       </label>
       <element-citation id="sref91" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           V.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         12
        </volume>
        <issue>
         2
        </issue>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib92">
       <label>
        92
       </label>
       <element-citation id="sref92" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10224
        </issue>
        <year>
         2020
        </year>
        <fpage>
         565
        </fpage>
        <lpage>
         574
        </lpage>
        <comment>
         Epub 2020 Jan 30
        </comment>
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib93">
       <label>
        93
       </label>
       <element-citation id="sref93" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A new coronavirus associated with human respiratory disease in China
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020 Feb 3
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib94">
       <label>
        94
       </label>
       <element-citation id="sref94" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib95">
       <label>
        95
       </label>
       <element-citation id="sref95" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China
        </article-title>
        <source>
         Cell Host Microbe
        </source>
        <year>
         2020 Feb 7
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </element-citation>
      </ref>
      <ref id="bib96">
       <label>
        96
       </label>
       <element-citation id="sref96" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paraskevis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <volume>
         79
        </volume>
        <year>
         2020
        </year>
        <fpage>
         104212
        </fpage>
        <pub-id pub-id-type="pmid">
         32004758
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib97">
       <label>
        97
       </label>
       <element-citation id="sref97" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.11.944462
        </comment>
       </element-citation>
      </ref>
      <ref id="bib98">
       <label>
        98
       </label>
       <element-citation id="sref98" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         426
        </volume>
        <issue>
         6965
        </issue>
        <year>
         2003
        </year>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib99">
       <label>
        99
       </label>
       <element-citation id="sref99" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bartelink
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Rottier
          </surname>
          <given-names>
           P.J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         82
        </volume>
        <issue>
         17
        </issue>
        <year>
         2008
        </year>
        <fpage>
         8887
        </fpage>
        <lpage>
         8890
        </lpage>
        <pub-id pub-id-type="pmid">
         18562523
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib100">
       <label>
        100
       </label>
       <element-citation id="sref100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         106
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib101">
       <label>
        101
       </label>
       <element-citation id="sref101" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         9
        </issue>
        <year>
         2011
        </year>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib102">
       <label>
        102
       </label>
       <element-citation id="sref102" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan
        </article-title>
        <source>
         Emerg. Microb. Infect.
        </source>
        <volume>
         9
        </volume>
        <issue>
         1
        </issue>
        <year>
         2020
        </year>
        <fpage>
         221
        </fpage>
        <lpage>
         236
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib103">
       <label>
        103
       </label>
       <element-citation id="sref103" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Assembly of coronavirus spike protein into trimers and its role in epitope expression
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         64
        </volume>
        <issue>
         11
        </issue>
        <year>
         1990
        </year>
        <fpage>
         5367
        </fpage>
        <lpage>
         5375
        </lpage>
        <pub-id pub-id-type="pmid">
         2170676
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib104">
       <label>
        104
       </label>
       <element-citation id="sref104" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Beniac
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Architecture of the SARS coronavirus prefusion spike
        </article-title>
        <source>
         Nat. Struct. Mol. Biol.
        </source>
        <volume>
         13
        </volume>
        <issue>
         8
        </issue>
        <year>
         2006
        </year>
        <fpage>
         751
        </fpage>
        <lpage>
         752
        </lpage>
        <pub-id pub-id-type="pmid">
         16845391
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib105">
       <label>
        105
       </label>
       <element-citation id="sref105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
        </article-title>
        <source>
         Cell. Mol. Immunol.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib106">
       <label>
        106
       </label>
       <element-citation id="sref106" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <issue>
         4
        </issue>
        <year>
         2007
        </year>
        <fpage>
         1701
        </fpage>
        <lpage>
         1713
        </lpage>
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib107">
       <label>
        107
       </label>
       <element-citation id="sref107" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nieto-Torres
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <issue>
         5
        </issue>
        <year>
         2014
        </year>
        <object-id pub-id-type="publisher-id">
         e1004077
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib108">
       <label>
        108
       </label>
       <element-citation id="sref108" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modular organization of SARS coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Biomed. Sci.
        </source>
        <volume>
         13
        </volume>
        <issue>
         1
        </issue>
        <year>
         2006
        </year>
        <fpage>
         59
        </fpage>
        <lpage>
         72
        </lpage>
        <pub-id pub-id-type="pmid">
         16228284
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib109">
       <label>
        109
       </label>
       <element-citation id="sref109" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hurst
          </surname>
          <given-names>
           K.R.
          </given-names>
         </name>
         <name>
          <surname>
           Koetzner
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           P.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         7221
        </fpage>
        <lpage>
         7234
        </lpage>
        <pub-id pub-id-type="pmid">
         19420077
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib110">
       <label>
        110
       </label>
       <element-citation id="sref110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The nucleocapsid protein of coronaviruses acts as a viral suppressor of RNA silencing in mammalian cells
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         17
        </issue>
        <year>
         2015
        </year>
        <fpage>
         9029
        </fpage>
        <lpage>
         9043
        </lpage>
        <pub-id pub-id-type="pmid">
         26085159
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib111">
       <label>
        111
       </label>
       <element-citation id="sref111" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure, function, and evolution of coronavirus spike proteins
        </article-title>
        <source>
         Annu. Rev. Virol.
        </source>
        <volume>
         3
        </volume>
        <issue>
         1
        </issue>
        <year>
         2016
        </year>
        <fpage>
         237
        </fpage>
        <lpage>
         261
        </lpage>
        <pub-id pub-id-type="pmid">
         27578435
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib112">
       <label>
        112
       </label>
       <element-citation id="sref112" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Belouzard
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           V.C.
          </given-names>
         </name>
         <name>
          <surname>
           Whittaker
          </surname>
          <given-names>
           G.R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         106
        </volume>
        <issue>
         14
        </issue>
        <year>
         2009
        </year>
        <fpage>
         5871
        </fpage>
        <lpage>
         5876
        </lpage>
        <pub-id pub-id-type="pmid">
         19321428
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib113">
       <label>
        113
       </label>
       <element-citation id="sref113" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         84
        </volume>
        <issue>
         24
        </issue>
        <year>
         2010
        </year>
        <fpage>
         12658
        </fpage>
        <lpage>
         12664
        </lpage>
        <pub-id pub-id-type="pmid">
         20926566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib114">
       <label>
        114
       </label>
       <element-citation id="sref114" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         85
        </volume>
        <issue>
         24
        </issue>
        <year>
         2011
        </year>
        <fpage>
         13363
        </fpage>
        <lpage>
         13372
        </lpage>
        <pub-id pub-id-type="pmid">
         21994442
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib115">
       <label>
        115
       </label>
       <element-citation id="sref115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simmons
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Proteolytic activation of the SARS-coronavirus spike protein: cutting enzymes at the cutting edge of antiviral research
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         100
        </volume>
        <issue>
         3
        </issue>
        <year>
         2013
        </year>
        <fpage>
         605
        </fpage>
        <lpage>
         614
        </lpage>
        <pub-id pub-id-type="pmid">
         24121034
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib116">
       <label>
        116
       </label>
       <element-citation id="sref116" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuhn
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus
        </article-title>
        <source>
         Cell. Mol. Life Sci. : CMLS
        </source>
        <volume>
         61
        </volume>
        <issue>
         21
        </issue>
        <year>
         2004
        </year>
        <fpage>
         2738
        </fpage>
        <lpage>
         2743
        </lpage>
        <pub-id pub-id-type="pmid">
         15549175
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib117">
       <label>
        117
       </label>
       <element-citation id="sref117" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <issue>
         7440
        </issue>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib118">
       <label>
        118
       </label>
       <element-citation id="sref118" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Novel Coronavirus 2019 (2019-nCoV) Uses the SARS-Coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry into Target Cells
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.31.929042
        </comment>
       </element-citation>
      </ref>
      <ref id="bib119">
       <label>
        119
       </label>
       <element-citation id="sref119" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Herrmann
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Fast Assessment of Human Receptor-Binding Capability of 2019 Novel Coronavirus (2019-nCoV)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.01.930537
        </comment>
       </element-citation>
      </ref>
      <ref id="bib120">
       <label>
        120
       </label>
       <element-citation id="sref120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bosch
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         77
        </volume>
        <issue>
         16
        </issue>
        <year>
         2003
        </year>
        <fpage>
         8801
        </fpage>
        <lpage>
         8811
        </lpage>
        <pub-id pub-id-type="pmid">
         12885899
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib121">
       <label>
        121
       </label>
       <element-citation id="sref121" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         114
        </volume>
        <issue>
         42
        </issue>
        <year>
         2017
        </year>
        <fpage>
         11157
        </fpage>
        <lpage>
         11162
        </lpage>
        <pub-id pub-id-type="pmid">
         29073020
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib122">
       <label>
        122
       </label>
       <element-citation id="sref122" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         27
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         129
        </lpage>
        <pub-id pub-id-type="pmid">
         28008928
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib123">
       <label>
        123
       </label>
       <element-citation id="sref123" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pallesen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A
        </source>
        <volume>
         114
        </volume>
        <issue>
         35
        </issue>
        <year>
         2017
        </year>
        <fpage>
         E7348
        </fpage>
        <lpage>
         E7357
        </lpage>
        <pub-id pub-id-type="pmid">
         28807998
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib124">
       <label>
        124
       </label>
       <element-citation id="sref124" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <volume>
         8
        </volume>
        <year>
         2017
        </year>
        <comment>
         15092-15092
        </comment>
       </element-citation>
      </ref>
      <ref id="bib125">
       <label>
        125
       </label>
       <element-citation id="sref125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unexpected receptor functional mimicry elucidates activation of coronavirus fusion
        </article-title>
        <source>
         Cell
        </source>
        <volume>
         176
        </volume>
        <issue>
         5
        </issue>
        <year>
         2019
        </year>
        <comment>
         1026-1039.e15
        </comment>
       </element-citation>
      </ref>
      <ref id="bib126">
       <label>
        126
       </label>
       <element-citation id="sref126" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chai
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage after 2019-nCoV Infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.02.03.931766
        </comment>
       </element-citation>
      </ref>
      <ref id="bib127">
       <label>
        127
       </label>
       <element-citation id="sref127" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         The Digestive System Is a Potential Route of 2019-nCov Infection: a Bioinformatics Analysis Based on Single-Cell Transcriptomes
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.30.927806
        </comment>
       </element-citation>
      </ref>
      <ref id="bib128">
       <label>
        128
       </label>
       <element-citation id="sref128" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Technical Guideline in Medical Institutions for the Prevention and Control of Infection with the Novel Coronavirus
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0080" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/b91fdab7c304431eb082d67847d27e14.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib129">
       <label>
        129
       </label>
       <element-citation id="sref129" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Community Prevention and Control Program for the 2019-nCoV Infected Pneumonia
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0085" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/dd1e502534004a8d88b6a10f329a3369.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/dd1e502534004a8d88b6a10f329a3369.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib130">
       <label>
        130
       </label>
       <element-citation id="sref130" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Commission
          </surname>
          <given-names>
           C.N.H.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         A Guideline for the Protection of People at Different Risk of New Coronavirus Infection
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0090" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/a3a261dabfcf4c3fa365d4eb07ddab34.shtml
        </ext-link>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib131">
       <label>
        131
       </label>
       <element-citation id="sref131" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Organization
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Home care for patients with suspected novel coronavirus (nCoV) infection presenting with mild symptoms and management of contacts: interim Guidance
        </article-title>
        <comment>
         (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0095" xlink:href="https://www.who.int/publications-detail/home-carefor-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-withmild-symptoms-and-management-of-contacts">
         https://www.who.int/publications-detail/home-carefor-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-withmild-symptoms-and-management-of-contacts
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib132">
       <label>
        132
       </label>
       <element-citation id="sref132" publication-type="other">
        <comment>
         China., M.o.S.a.T.o.t.P.s.R.o. Clinical trial of antiviral drug remdesivir starts in Wuhan. (in Chinese)
        </comment>
        <ext-link ext-link-type="uri" id="intref0100" xlink:href="http://www.most.gov.cn/kjbgz/202002/t20200206_151440.htm">
         http://www.most.gov.cn/kjbgz/202002/t20200206_151440.htm
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib133">
       <label>
        133
       </label>
       <element-citation id="sref133" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.-J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Potential Inhibitors for 2019-nCoV Coronavirus M Protease from Clinically Approved Medicines
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         bioRxiv
        </publisher-name>
        <comment>
         2020.01.29.924100
        </comment>
       </element-citation>
      </ref>
      <ref id="bib134">
       <label>
        134
       </label>
       <element-citation id="sref134" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Richardson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <year>
         2020 Feb 15
        </year>
        <fpage>
         e30
        </fpage>
        <lpage>
         e31
        </lpage>
        <comment>
         Epub 2020 Feb 4
        </comment>
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib135">
       <label>
        135
       </label>
       <element-citation id="sref135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci. Trends
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib136">
       <label>
        136
       </label>
       <element-citation id="sref136" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         Cell research
        </publisher-name>
       </element-citation>
      </ref>
      <ref id="bib137">
       <label>
        137
       </label>
       <element-citation id="sref137" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Daily
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First antiviral drug approved to fight coronavirus
        </article-title>
        <comment>
         Feb.17,2002]
        </comment>
        <ext-link ext-link-type="uri" id="intref0105" xlink:href="http://global.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html">
         http://global.chinadaily.com.cn/a/202002/17/WS5e49efc2a310128217277fa3.html
        </ext-link>
        <year>
         2020
        </year>
        <comment>
         Available from:
        </comment>
       </element-citation>
      </ref>
      <ref id="bib138">
       <label>
        138
       </label>
       <element-citation id="sref138" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Unique synergistic antiviral effects of Shufeng Jiedu Capsule and oseltamivir in influenza A viral-induced acute exacerbation of chronic obstructive pulmonary disease
        </article-title>
        <source>
         Biomed. Pharmacotherapy = Biomed. Pharmacotherapie
        </source>
        <volume>
         121
        </volume>
        <year>
         2020
        </year>
        <comment>
         109652-109652
        </comment>
       </element-citation>
      </ref>
      <ref id="bib139">
       <label>
        139
       </label>
       <element-citation id="sref139" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
        </article-title>
        <source>
         BMC Compl. Alternative Med.
        </source>
        <volume>
         17
        </volume>
        <issue>
         1
        </issue>
        <year>
         2017
        </year>
        <comment>
         130-130
        </comment>
       </element-citation>
      </ref>
      <ref id="bib140">
       <label>
        140
       </label>
       <element-citation id="sref140" publication-type="book">
        <person-group person-group-type="author">
         <collab>
          Commission, C.N.H
         </collab>
        </person-group>
        <chapter-title>
         Guiding Principles for the Intervention of Acute Psychological Crisis in Pneumonia Cases with New Coronavirus Infection. (In Chinese)
        </chapter-title>
        <year>
         2020
        </year>
        <publisher-name>
         China National Health Commission
        </publisher-name>
        <publisher-loc>
         Beijing
        </publisher-loc>
        <comment>
         Available from:
        </comment>
        <ext-link ext-link-type="uri" id="intref0110" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/6adc08b966594253b2b791be5c3b9467.shtml">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/6adc08b966594253b2b791be5c3b9467.shtml
        </ext-link>
       </element-citation>
      </ref>
      <ref id="bib141">
       <label>
        141
       </label>
       <element-citation id="sref141" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options
        </article-title>
        <source>
         Nat. Rev. Drug Discov.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2016
        </year>
        <fpage>
         327
        </fpage>
        <lpage>
         347
        </lpage>
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Pediatr Infect Dis J
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Pediatr. Infect. Dis. J
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       INF
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Pediatric Infectious Disease Journal
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0891-3668
      </issn>
      <issn pub-type="epub">
       1532-0987
      </issn>
      <publisher>
       <publisher-name>
        Williams &amp; Wilkins
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7158880
      </article-id>
      <article-id pub-id-type="art-access-id">
       00001
      </article-id>
      <article-id pub-id-type="doi">
       10.1097/INF.0000000000002660
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Special Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Coronavirus Infections in Children Including COVID-19
       </article-title>
       <subtitle>
        An Overview of the Epidemiology, Clinical Features, Diagnosis, Treatment and Prevention Options in Children
       </subtitle>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Zimmermann
         </surname>
         <given-names>
          Petra
         </given-names>
        </name>
        <degrees>
         MD, PhD
        </degrees>
        <xref ref-type="aff" rid="aff1">
         *
        </xref>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Curtis
         </surname>
         <given-names>
          Nigel
         </given-names>
        </name>
        <degrees>
         FRCPCH, PhD
        </degrees>
        <xref ref-type="aff" rid="aff2">
         †
        </xref>
        <xref ref-type="aff" rid="aff3">
         ‡
        </xref>
        <xref ref-type="aff" rid="aff4">
         §
        </xref>
       </contrib>
       <aff id="aff1">
        From the
        <label>
         *
        </label>
        Department of Paediatrics, Fribourg Hospital HFR and Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
       </aff>
       <aff id="aff2">
        <label>
         †
        </label>
        Department of Paediatrics, The University of Melbourne
       </aff>
       <aff id="aff3">
        <label>
         ‡
        </label>
        Infectious Diseases Research Group, Murdoch Children’s Research Institute
       </aff>
       <aff id="aff4">
        <label>
         §
        </label>
        Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia.
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="c1">
        Address for correspondence: Petra Zimmermann, MD, PhD, Faculty of Science and Medicine, University of Fribourg, Route des Arsenaux 41, 1700 Fribourg, Switzerland. E-mail:
        <email xlink:href="petra.zimmermann@unifr.ch">
         petra.zimmermann@unifr.ch
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       39
      </volume>
      <issue>
       5
      </issue>
      <fpage>
       355
      </fpage>
      <lpage>
       368
      </lpage>
      <history>
       <date date-type="accepted">
        <day>
         03
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <license license-type="open-access">
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
       <license license-type="NIH OGC">
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="inf-39-355.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        Coronaviruses (CoVs) are a large family of enveloped, single-stranded, zoonotic RNA viruses. Four CoVs commonly circulate among humans: HCoV2-229E, -HKU1, -NL63 and -OC43. However, CoVs can rapidly mutate and recombine leading to novel CoVs that can spread from animals to humans. The novel CoVs severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012. The 2019 novel coronavirus (SARS-CoV-2) is currently causing a severe outbreak of disease (termed COVID-19) in China and multiple other countries, threatening to cause a global pandemic. In humans, CoVs mostly cause respiratory and gastrointestinal symptoms. Clinical manifestations range from a common cold to more severe disease such as bronchitis, pneumonia, severe acute respiratory distress syndrome, multi-organ failure and even death. SARS-CoV, MERS-CoV and SARS-CoV-2 seem to less commonly affect children and to cause fewer symptoms and less severe disease in this age group compared with adults, and are associated with much lower case-fatality rates. Preliminary evidence suggests children are just as likely as adults to become infected with SARS-CoV-2 but are less likely to be symptomatic or develop severe symptoms. However, the importance of children in transmitting the virus remains uncertain. Children more often have gastrointestinal symptoms compared with adults. Most children with SARS-CoV present with fever, but this is not the case for the other novel CoVs. Many children affected by MERS-CoV are asymptomatic. The majority of children infected by novel CoVs have a documented household contact, often showing symptoms before them. In contrast, adults more often have a nosocomial exposure. In this review, we summarize epidemiologic, clinical and diagnostic findings, as well as treatment and prevention options for common circulating and novel CoVs infections in humans with a focus on infections in children.
       </p>
      </abstract>
      <kwd-group>
       <kwd>
        severe acute respiratory syndrome coronavirus
       </kwd>
       <kwd>
        Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        severe acute respiratory syndrome coronavirus 2
       </kwd>
       <kwd>
        epidemiology
       </kwd>
       <kwd>
        symptoms
       </kwd>
       <kwd>
        laboratory
       </kwd>
       <kwd>
        imaging
       </kwd>
       <kwd>
        treatment
       </kwd>
       <kwd>
        vaccines
       </kwd>
       <kwd>
        prevention
       </kwd>
       <kwd>
        treatment
       </kwd>
       <kwd>
        vaccines
       </kwd>
       <kwd>
        prevention
       </kwd>
       <kwd>
        SARS-CoV
       </kwd>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        SARS-CoV-2
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Coronaviruses (CoVs) comprise a large family of enveloped, single-stranded, zoonotic RNA viruses belonging to the family
     <italic>
      Coronaviridae
     </italic>
     , order
     <italic>
      Nidovirales
     </italic>
     (Fig.
     <xref ref-type="fig" rid="F1">
      1
     </xref>
     ).
     <sup>
      <xref ref-type="bibr" rid="R1">
       1
      </xref>
     </sup>
     They can infect a variety of animals (including livestock, companion animals and birds), in which they can cause serious respiratory, enteric, cardiovascular and neurologic disease.
     <sup>
      <xref ref-type="bibr" rid="R2">
       2
      </xref>
      ,
      <xref ref-type="bibr" rid="R3">
       3
      </xref>
     </sup>
     In humans, CoVs mostly cause respiratory and gastrointestinal symptoms ranging from the common cold to more severe disease such as bronchitis, pneumonia, severe acute respiratory distress syndrome (ARDS), coagulopathy, multi-organ failure and death.
     <sup>
      <xref ref-type="bibr" rid="R4">
       4
      </xref>
      –
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
     </sup>
     Human coronaviruses (HCoVs) have also been associated with exacerbations of chronic obstructive pulmonary disease,
     <sup>
      <xref ref-type="bibr" rid="R9">
       9
      </xref>
     </sup>
     cystic fibrosis
     <sup>
      <xref ref-type="bibr" rid="R10">
       10
      </xref>
     </sup>
     and asthma.
     <sup>
      <xref ref-type="bibr" rid="R11">
       11
      </xref>
      ,
      <xref ref-type="bibr" rid="R12">
       12
      </xref>
     </sup>
    </p>
    <fig id="F1" position="float">
     <label>
      FIGURE 1.
     </label>
     <caption>
      <p>
       Summary of coronavirus diseases. COVID-19 indicates coronavirus disease 2019.
      </p>
     </caption>
     <graphic xlink:href="inf-39-355-g001">
     </graphic>
    </fig>
    <p>
     CoVs are classified into
     <italic>
      Alphacoronaviruses
     </italic>
     and
     <italic>
      Betacoronaviruses
     </italic>
     (which are mainly found in mammals such as bats, rodents, civets and humans) and
     <italic>
      Gammacoronaviruses
     </italic>
     and
     <italic>
      Deltacoronaviruses
     </italic>
     (which are mainly found in birds).
     <sup>
      <xref ref-type="bibr" rid="R8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="R13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="R14">
       14
      </xref>
     </sup>
     Four CoVs commonly circulate among humans: HCoV2-229E, -HKU1, -NL63 and -OC43.
     <sup>
      <xref ref-type="bibr" rid="R15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="R16">
       16
      </xref>
     </sup>
     These viruses are believed to have originally derived from bats (NL63, 229E),
     <sup>
      <xref ref-type="bibr" rid="R17">
       17
      </xref>
      ,
      <xref ref-type="bibr" rid="R18">
       18
      </xref>
     </sup>
     dromedary camels (229E)
     <sup>
      <xref ref-type="bibr" rid="R19">
       19
      </xref>
     </sup>
     and cattle (OC43).
     <sup>
      <xref ref-type="bibr" rid="R20">
       20
      </xref>
     </sup>
     The origin of HCoV-HKU1 remains unknown. Several CoVs are known to circulate in animals (with bats acting as the main reservoir) but have not been associated with human infection.
     <sup>
      <xref ref-type="bibr" rid="R3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="R21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="R22">
       22
      </xref>
     </sup>
     CoVs are capable of rapid mutation and recombination leading to novel CoVs that can spread from animals to humans. This occurred in China in 2002 when the novel CoV severe acute respiratory syndrome coronavirus (SARS-CoV) emerged, thought to have been transmitted from civet cats or bats to humans.
     <sup>
      <xref ref-type="bibr" rid="R22">
       22
      </xref>
      –
      <xref ref-type="bibr" rid="R25">
       25
      </xref>
     </sup>
     Another novel CoVs emerged in Saudi Arabia in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV), which is transmitted from dromedary camels to humans.
     <sup>
      <xref ref-type="bibr" rid="R26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="R27">
       27
      </xref>
     </sup>
     The 2019 novel CoV (SARS-CoV-2), which originated in China and is currently causing outbreaks globally, is a novel
     <italic>
      Betacoronavirus
     </italic>
     belonging to the lineage B or subgenus sarbecovirus, which includes SARS-CoV.
     <sup>
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
     </sup>
     Sequencing shows that the genome is most closely related (87%–89% nucleotide identity) to the bat SARS-related CoV found in Chinese horseshoe bats (bat-SL-CoVZC45).
     <sup>
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="R29">
       29
      </xref>
     </sup>
     The outbreak of SARS-CoV-2 started in Wuhan city, Hubei province, China, where The Health Commission of Hubei province first announced a cluster of adults with pneumonia of unexplained etiology on December 31, 2019. A local seafood and animal market was identified as a potential source. However, the main driver of the outbreak is symptomatic and asymptomatic humans infected with SARS-CoV-2 from whom the virus can spread to others through respiratory droplets or direct contact.
     <sup>
      <xref ref-type="bibr" rid="R28">
       28
      </xref>
     </sup>
     From Wuhan city SARS-CoV-2 has spread to other Chinese cities and internationally, threating to cause a global pandemic. The term COVID-19 is used for the clinical disease caused by SARS-CoV-2.
     <sup>
      <xref ref-type="bibr" rid="R30">
       30
      </xref>
     </sup>
    </p>
    <p>
     In this review, we summarize epidemiologic, clinical and diagnostic findings, as well as treatment and prevention options for common circulating and novel CoVs infections in humans with a focus on infections in children.
    </p>
    <sec>
     <title>
      EPIDEMIOLOGY
     </title>
     <sec>
      <title>
       Common Circulating HCoVs
      </title>
      <p>
       Common circulating HCoVs can be isolated from 4% to 6% of children hospitalized for acute respiratory tract infections
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R31">
         31
        </xref>
       </sup>
       and from 8% of children in an ambulatory setting (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R33">
         33
        </xref>
       </sup>
       Children under the age of 3 years and children with heart disease are the most frequently affected.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
       Reinfections later in life are common
       <sup>
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R115">
         115
        </xref>
        ,
        <xref ref-type="bibr" rid="R116">
         116
        </xref>
       </sup>
       despite the fact that most individuals seroconvert to HCoVs during childhood.
       <sup>
        <xref ref-type="bibr" rid="R117">
         117
        </xref>
        –
        <xref ref-type="bibr" rid="R120">
         120
        </xref>
       </sup>
       In contrast to other respiratory tract viruses [eg, respiratory syncytial virus (RSV)], there is no decrease in the relative prevalence of HCoVs infections with increasing age.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
      </p>
      <table-wrap id="T1" position="float">
       <label>
        TABLE 1.
       </label>
       <caption>
        <p>
         Characteristics of Human Coronaviruses
        </p>
       </caption>
       <graphic xlink:href="inf-39-355-g002">
       </graphic>
      </table-wrap>
      <p>
       In 11%–46% of cases, common circulating HCoVs are found as coinfections with other respiratory viruses such as adeno-, boca-, rhino-, RSV, influenza or parainfluenza virus.
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="R31">
         31
        </xref>
        –
        <xref ref-type="bibr" rid="R33">
         33
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
        ,
        <xref ref-type="bibr" rid="R79">
         79
        </xref>
        ,
        <xref ref-type="bibr" rid="R81">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="R121">
         121
        </xref>
        ,
        <xref ref-type="bibr" rid="R122">
         122
        </xref>
       </sup>
       Symptomatic children whose only detectable respiratory virus is a HCoV are reported to more likely suffer from an underlying chronic disease compared with children coinfected with other respiratory viruses.
       <sup>
        <xref ref-type="bibr" rid="R31">
         31
        </xref>
       </sup>
      </p>
      <p>
       Of the 4 common circulating HCoVs, NL63 and OC43 are the most frequently isolated species.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
       Cyclical patterns have been observed for 229E and OC43, with outbreaks occurring every 2–4 years.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R35">
         35
        </xref>
        ,
        <xref ref-type="bibr" rid="R82">
         82
        </xref>
        ,
        <xref ref-type="bibr" rid="R116">
         116
        </xref>
        ,
        <xref ref-type="bibr" rid="R119">
         119
        </xref>
       </sup>
       Seasonal patterns have also been observed: in the Northern Hemisphere, common circulating HCoVs mostly cause infections in humans between December and May, and in the Southern Hemisphere between March and November with peaks in late winter/early spring for 229E and OC43 and in autumn for NL63.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
        ,
        <xref ref-type="bibr" rid="R123">
         123
        </xref>
       </sup>
       HCoV-HKU1 has been reported to mainly occur in spring and summer in Hong Kong,
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R124">
         124
        </xref>
       </sup>
       but in winter and spring in the United Kingdom and Brazil.
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R15">
         15
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV and MERS-CoV
      </title>
      <p>
       SARS-CoV is a novel group 2b
       <italic>
        Betacoronavirus
       </italic>
       which initially emerged in Guangdong province, south China in 2002,
       <sup>
        <xref ref-type="bibr" rid="R23">
         23
        </xref>
        –
        <xref ref-type="bibr" rid="R25">
         25
        </xref>
       </sup>
       then spread to Hong Kong and from there rapidly to many other countries.
       <sup>
        <xref ref-type="bibr" rid="R125">
         125
        </xref>
       </sup>
       It caused severe lower respiratory tract infection with a severe morbidity and a high case-fatality rate (approaching 50% in individuals over 60 years of age, overall 10%).
       <sup>
        <xref ref-type="bibr" rid="R63">
         63
        </xref>
        ,
        <xref ref-type="bibr" rid="R106">
         106
        </xref>
        ,
        <xref ref-type="bibr" rid="R107">
         107
        </xref>
        ,
        <xref ref-type="bibr" rid="R126">
         126
        </xref>
       </sup>
       Person-to-person transmission of SARS-CoV is well established.
       <sup>
        <xref ref-type="bibr" rid="R55">
         55
        </xref>
       </sup>
       The virus has spread to 29 countries and has been estimated to have caused more than 8000 infections and 774 deaths worldwide (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R52">
         52
        </xref>
       </sup>
      </p>
      <p>
       MERS-CoV is a novel group 2c
       <italic>
        Betacoronavirus
       </italic>
       which first appeared in Saudi Arabia in 2012.
       <sup>
        <xref ref-type="bibr" rid="R26">
         26
        </xref>
        ,
        <xref ref-type="bibr" rid="R27">
         27
        </xref>
        ,
        <xref ref-type="bibr" rid="R127">
         127
        </xref>
       </sup>
       It can spread from person-to-person
       <sup>
        <xref ref-type="bibr" rid="R128">
         128
        </xref>
       </sup>
       and can cause severe lower respiratory tract infections with a case-fatality rate of 20% to 40%.
       <sup>
        <xref ref-type="bibr" rid="R67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="R106">
         106
        </xref>
        ,
        <xref ref-type="bibr" rid="R108">
         108
        </xref>
        –
        <xref ref-type="bibr" rid="R112">
         112
        </xref>
       </sup>
       Apart from being endemic in the Middle East, there was a nosocomial outbreak of MERS-CoV in South Korea in 2014, involving 16 hospitals and 186 patients, caused by a medical doctor returning from the Middle East.
       <sup>
        <xref ref-type="bibr" rid="R49">
         49
        </xref>
        ,
        <xref ref-type="bibr" rid="R68">
         68
        </xref>
       </sup>
       MERS-CoV spread to 27 countries causing an estimated 2494 infections and 858 deaths (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R53">
         53
        </xref>
       </sup>
      </p>
      <p>
       The overall reproductive number (R0) for SARS-CoV was estimated to be 0.3–2.9
       <sup>
        <xref ref-type="bibr" rid="R37">
         37
        </xref>
        ,
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R40">
         40
        </xref>
        ,
        <xref ref-type="bibr" rid="R42">
         42
        </xref>
        ,
        <xref ref-type="bibr" rid="R43">
         43
        </xref>
        ,
        <xref ref-type="bibr" rid="R47">
         47
        </xref>
       </sup>
       and for MERS-CoV to be 0.5–3.5 (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R46">
         46
        </xref>
        ,
        <xref ref-type="bibr" rid="R48">
         48
        </xref>
       </sup>
       R0s largely depend on geographic location, stage of the outbreak and inclusion of only nosocomial versus general transmission. Both viruses have been associated with early super-spreading events with R0s of up to 22 for SARS-CoV
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R40">
         40
        </xref>
        ,
        <xref ref-type="bibr" rid="R43">
         43
        </xref>
       </sup>
       and up to 30 for MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R49">
         49
        </xref>
       </sup>
       These large numbers of secondary infections have been mostly associated with nosocomial outbreaks: 30% of all SARS-CoV cases (mostly health care workers) and 44%–100% of all MERS-CoV cases (mostly patients) occurred from nosocomial transmissions.
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
        ,
        <xref ref-type="bibr" rid="R55">
         55
        </xref>
        ,
        <xref ref-type="bibr" rid="R56">
         56
        </xref>
       </sup>
       These super-spreading events were followed by reduced spread in the following generations of viruses with a decrease in the R0s to 0.8 for SARS-CoV
       <sup>
        <xref ref-type="bibr" rid="R39">
         39
        </xref>
       </sup>
       and to 0.7 for MERS-CoV (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R128">
         128
        </xref>
       </sup>
       Therefore, both SARS-CoV and MERS-CoV have low potential for long-term sustained community transmission. No human SARS-CoV infections have been detected since July 2003. However, SARS-CoV-like viruses can be found in bats, which are known to be able infect human cells without adaptation, making it possible for SARS-CoVs to reemerge
       <sup>
        <xref ref-type="bibr" rid="R84">
         84
        </xref>
       </sup>
       (as has now happened with SARS-CoV-2). The zoonotic transmission of MERS-CoV to humans has continued, attributed to the role of dromedary camels as a reservoir and their close contact with humans (in contrast to human-bat-interactions).
       <sup>
        <xref ref-type="bibr" rid="R21">
         21
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Early in the SARS-CoV-2 outbreak, it was shown that person-to-person transmission was the main driver.
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
       The R0 for SARS-CoV-2 is currently estimated at 2.7.
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
       </sup>
       The incubation period is estimated at 5–6 days, which is similar to that for SARS-CoV and MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
        ,
        <xref ref-type="bibr" rid="R63">
         63
        </xref>
        –
        <xref ref-type="bibr" rid="R65">
         65
        </xref>
        ,
        <xref ref-type="bibr" rid="R67">
         67
        </xref>
        –
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       The serial interval is estimated to be 8 days, also similar to the other novel CoVs (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
        ,
        <xref ref-type="bibr" rid="R45">
         45
        </xref>
        ,
        <xref ref-type="bibr" rid="R48">
         48
        </xref>
        ,
        <xref ref-type="bibr" rid="R70">
         70
        </xref>
       </sup>
       By March 2020, the World Health Organization reported that SARS-CoV-2 had spread to over 100 countries and caused over 100,000 infections and over 3500 deaths.
       <sup>
        <xref ref-type="bibr" rid="R54">
         54
        </xref>
       </sup>
       At that time the case-fatality rate was uncertain but estimated at 0.9%–3%,
       <sup>
        <xref ref-type="bibr" rid="R54">
         54
        </xref>
        ,
        <xref ref-type="bibr" rid="R113">
         113
        </xref>
        ,
        <xref ref-type="bibr" rid="R114">
         114
        </xref>
       </sup>
       which is much lower than for SARS-CoV and MERS-CoV (6%–17% and 20%–40%, respectively).
       <sup>
        <xref ref-type="bibr" rid="R63">
         63
        </xref>
        ,
        <xref ref-type="bibr" rid="R67">
         67
        </xref>
        ,
        <xref ref-type="bibr" rid="R106">
         106
        </xref>
        –
        <xref ref-type="bibr" rid="R112">
         112
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      SYMPTOMS
     </title>
     <sec>
      <title>
       Common HCoVs
      </title>
      <p>
       In children, common circulating HCoVs can cause common cold symptoms such as fever,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
       </sup>
       rhinitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       otitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
       </sup>
       pharyngitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       laryngitis
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
       </sup>
       and headache,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R16">
         16
        </xref>
        ,
        <xref ref-type="bibr" rid="R81">
         81
        </xref>
       </sup>
       but also bronchitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       bronchiolitis,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       wheezing,
       <sup>
        <xref ref-type="bibr" rid="R4">
         4
        </xref>
        ,
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R32">
         32
        </xref>
       </sup>
       pneumonia,
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        ,
        <xref ref-type="bibr" rid="R81">
         81
        </xref>
        ,
        <xref ref-type="bibr" rid="R82">
         82
        </xref>
       </sup>
       and, in up to 57% of cases, gastrointestinal symptoms (which are more common in children than adults).
       <sup>
        <xref ref-type="bibr" rid="R5">
         5
        </xref>
        –
        <xref ref-type="bibr" rid="R7">
         7
        </xref>
       </sup>
       In a study including children and adults, fatigue, headache, myalgia and sore throat were more common in HCoV-infected patients compared with RSV-infected patients, while fever, cough and dyspnea were more frequent in the later.
       <sup>
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
       Fewer patients infected with HCoVs had fever compared with those infected with RSV or influenza.
       <sup>
        <xref ref-type="bibr" rid="R36">
         36
        </xref>
       </sup>
      </p>
      <p>
       In children, HCoV-NL63 has been associated with conjunctivitis,
       <sup>
        <xref ref-type="bibr" rid="R78">
         78
        </xref>
       </sup>
       croup,
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R79">
         79
        </xref>
        ,
        <xref ref-type="bibr" rid="R80">
         80
        </xref>
       </sup>
       asthma exacerbations,
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
        ,
        <xref ref-type="bibr" rid="R12">
         12
        </xref>
       </sup>
       febrile seizures
       <sup>
        <xref ref-type="bibr" rid="R11">
         11
        </xref>
       </sup>
       and HCoV-HKU1 with febrile seizures.
       <sup>
        <xref ref-type="bibr" rid="R7">
         7
        </xref>
       </sup>
       Rare cases of neurologic diseases have also been described (eg, the detection of HCoV in cerebrospinal fluid in a child presenting with acute disseminated encephalomyelitis
       <sup>
        <xref ref-type="bibr" rid="R83">
         83
        </xref>
       </sup>
       or in cerebrospinal fluid of adults with multiple sclerosis.)
       <sup>
        <xref ref-type="bibr" rid="R129">
         129
        </xref>
        ,
        <xref ref-type="bibr" rid="R130">
         130
        </xref>
       </sup>
       A suspected association between HCoVs and Kawasaki disease could not be confirmed.
       <sup>
        <xref ref-type="bibr" rid="R131">
         131
        </xref>
        ,
        <xref ref-type="bibr" rid="R132">
         132
        </xref>
       </sup>
       Common HCoVs can be isolated from asymptomatic individuals.
       <sup>
        <xref ref-type="bibr" rid="R16">
         16
        </xref>
       </sup>
       During an infection, the viral load is high in the first 2 days and decreases thereafter.
       <sup>
        <xref ref-type="bibr" rid="R29">
         29
        </xref>
       </sup>
       A correlation between viral load and severity of disease has not been observed
       <sup>
        <xref ref-type="bibr" rid="R29">
         29
        </xref>
       </sup>
       This contrasts with SARS-CoV for which a higher initial viral load is independently associated with a worse prognosis, including a higher case-fatality rate.
       <sup>
        <xref ref-type="bibr" rid="R133">
         133
        </xref>
        ,
        <xref ref-type="bibr" rid="R134">
         134
        </xref>
       </sup>
       Virus particles can be isolated from nasopharyngeal secretions up to 14 days after the onset of infection.
       <sup>
        <xref ref-type="bibr" rid="R135">
         135
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV
      </title>
      <p>
       There are 3 case series that report a total of 41 children who were affected by SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       The virus was associated with milder disease in children compared with adults, and no deaths have been reported in children.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
        ,
        <xref ref-type="bibr" rid="R86">
         86
        </xref>
       </sup>
       Symptomatic children with SARS-CoV infection were reported to have fever (91%–100%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       myalgia (10%–40%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="R58">
         58
        </xref>
       </sup>
       rhinitis (33%–60%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       sore throat (5%–30%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       cough (43%–80%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       dyspnea (10%–14%),
       <sup>
        <xref ref-type="bibr" rid="R38">
         38
        </xref>
        ,
        <xref ref-type="bibr" rid="R84">
         84
        </xref>
       </sup>
       headache (14%–40%)
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       and, less commonly, vomiting (20%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        ,
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       abdominal pain (10%),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
       </sup>
       diarrhea (10%)
       <sup>
        <xref ref-type="bibr" rid="R58">
         58
        </xref>
        ,
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       and febrile seizures (10%).
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
       </sup>
       In total, 50%–80% of children had other family members who were infected
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       and 30% had a nosocomial contact with SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
       </sup>
       Most children recover quickly from an infection with SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R86">
         86
        </xref>
       </sup>
       However, abnormalities on chest computed tomography (CT) can persist for several months (eg, air trapping and ground-glass opacifications).
       <sup>
        <xref ref-type="bibr" rid="R136">
         136
        </xref>
       </sup>
      </p>
      <p>
       There is no evidence that SARS-CoV can be vertically transmitted to the fetus.
       <sup>
        <xref ref-type="bibr" rid="R137">
         137
        </xref>
       </sup>
       However, SARS-CoV infections during pregnancy have been associated with possible miscarriage, intrauterine growth retardation and preterm delivery.
       <sup>
        <xref ref-type="bibr" rid="R137">
         137
        </xref>
        ,
        <xref ref-type="bibr" rid="R138">
         138
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       MERS-CoV
      </title>
      <p>
       Most case series of patients infected with MERS-CoV report a low proportion (0.1%–4%) of children.
       <sup>
        <xref ref-type="bibr" rid="R34">
         34
        </xref>
        ,
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
        ,
        <xref ref-type="bibr" rid="R109">
         109
        </xref>
        ,
        <xref ref-type="bibr" rid="R110">
         110
        </xref>
        ,
        <xref ref-type="bibr" rid="R139">
         139
        </xref>
        ,
        <xref ref-type="bibr" rid="R140">
         140
        </xref>
       </sup>
       In a large case series of 2235 children with acute respiratory tract infection who presented to a tertiary hospital in Saudi Arabia during the MERS-CoV epidemic (2012–2013), none tested positive for MERS-CoV (Table
       <xref ref-type="table" rid="T1">
        1
       </xref>
       ).
       <sup>
        <xref ref-type="bibr" rid="R34">
         34
        </xref>
       </sup>
       There are 2 small case series of children infected with MERS-CoV: one including 31 children with a mean age of 10 years
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
       and the other one only 7 children.
       <sup>
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       In both studies, 42% of children were asymptomatic.
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       In the case series of 7 children, 57% suffered from fever, 28% from vomiting and diarrhea and 14% from cough and shortness of breath.
       <sup>
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       Two children required oxygen supplementation and one mechanical ventilation.
       <sup>
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
       </sup>
       In the other case series, 2 died (6%).
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
       The main sources of MERS-CoV infection in children were household (32%) and other contacts (23%), followed by nosocomial transmission (19%).
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
      </p>
      <p>
       Eight cases of MERS-CoV maternal infections during pregnancy have been reported (occurring between 20 and 28 weeks of pregnancy), three of the affected infants died.
       <sup>
        <xref ref-type="bibr" rid="R141">
         141
        </xref>
        –
        <xref ref-type="bibr" rid="R144">
         144
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Different case definitions for COVID-19 cases in adults and children from authoritive sources as of March 2020 are detailed in Table
       <xref ref-type="table" rid="T2">
        2
       </xref>
       . Children are less commonly affected by SARS-CoV-2, the Chinese Centers for Disease Control and Prevention reports that of the 72,314 cases reported as of February 11, 2020, only 2% were in individuals of less than 19 years of age.
       <sup>
        <xref ref-type="bibr" rid="R114">
         114
        </xref>
       </sup>
       There are 3 case series of children who have been infected with SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
        ,
        <xref ref-type="bibr" rid="R77">
         77
        </xref>
       </sup>
       The first included 20 children up to January 31, 2020, in the Province of Zhejiang,
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       the second 34 children between January 19, 2020, and February 7, 2020, in the Province of Shenzhen,
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       and the third 9 infants from different provinces in China.
       <sup>
        <xref ref-type="bibr" rid="R77">
         77
        </xref>
       </sup>
       The case series with 34 children provides the most clinical details: none of the children had an underlying disease, 65% had common respiratory symptoms, 26% had mild disease and 9% were asymptomatic.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       The most common symptoms were fever (50%) and cough (38%).
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       In the case series of 20 children, presentation was with low to moderate or no fever, rhinitis, cough, fatigue, headache, diarrhea and, in more severe cases, with dyspnea, cyanosis and poor feeding, but the numbers were not specified.
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       In the series of 9 infants, only 4 were reported to have fever. One infant was asymptomatic.
       <sup>
        <xref ref-type="bibr" rid="R77">
         77
        </xref>
       </sup>
       Additional asymptomatic children infected with SARS-CoV-2 outside these case series have also been described (eg, a 10-year-old asymptomatic child with radiologic ground-glass lung opacities on chest CT).
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
       Most infected children recover 1–2 weeks after the onset of symptoms and no deaths from SARS-CoV-2 had been reported by February 2020.
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
      </p>
      <table-wrap id="T2" position="float">
       <label>
        TABLE 2.
       </label>
       <caption>
        <p>
         Case Definitions for SARS-CoV-2 Infections in Adults and Children (as of February 2020)
        </p>
       </caption>
       <graphic xlink:href="inf-39-355-g003">
       </graphic>
      </table-wrap>
      <p>
       From these series, it appears that children have milder clinical symptoms than adults
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       (as has been reported for SARS-CoV and MERS-CoV infections),
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
        ,
        <xref ref-type="bibr" rid="R76">
         76
        </xref>
        ,86
       </sup>
       which could mean children might not be tested for SARS-CoV-2 as frequently as adults. It has therefore been suggested that asymptomatic or mildly symptomatic children might transmit the disease.
       <sup>
        <xref ref-type="bibr" rid="R147">
         147
        </xref>
       </sup>
       However, the majority of children infected with SARS-CoV-2 thus far have been part of a family cluster outbreak [100% in the infants series, in which other family member had symptoms before the infants in all cases; 82% in the case series of 34 children;
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       and the majority in the one with 20 children (exact number not specified)].
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
       This is similar to SARS-CoV, in which 50%–80%
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       of children were reported to have an affected household contact
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
       and to MERS-CoV in which it was 32%.
       <sup>
        <xref ref-type="bibr" rid="R60">
         60
        </xref>
       </sup>
      </p>
      <p>
       A study prepublished in early March 2020 suggests that children are just as likely as adults to become infected with SARS-CoV-2 but are less likely to be symptomatic or develop severe symptoms.
       <sup>
        <xref ref-type="bibr" rid="R246">
         246
        </xref>
       </sup>
       However, the importance of children in transmitting the virus remains uncertain.
      </p>
      <p>
       From a small case series of 9 mothers who were infected with SARS-CoV-2, there is, to date, no evidence that SARS-CoV-2 can be vertically transmitted to the infant.
       <sup>
        <xref ref-type="bibr" rid="R148">
         148
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      LABORATORY FINDINGS
     </title>
     <p>
      Laboratory findings from children are similar with infections caused by different novel CoVs (Table
      <xref ref-type="table" rid="T1">
       1
      </xref>
      ). The white blood cell count is typically normal or reduced with decreased neutrophil
      <sup>
       <xref ref-type="bibr" rid="R85">
        85
       </xref>
      </sup>
      and/or lymphocyte counts.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,86
      </sup>
      Thrombocytopenia may occur.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R76">
        76
       </xref>
       ,86
      </sup>
      C-reactive protein and procalcitonin levels are often normal.
      <sup>
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
      </sup>
      In severe cases, elevated liver enzymes,
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,86
      </sup>
      lactate dehydrogenase levels,
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
      </sup>
      as well as a abnormal coagulation and elevated
      <sc>
       d
      </sc>
      -dimers have been reported.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,86
      </sup>
     </p>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       The same laboratory findings has above have been observed for children infected with SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       In the case series of 34 children, the white blood cell count was normal in 83%, neutropenia and lymphopenia were each found in 1 case (3%). The lactate dehydrogenase level was elevated in 30% of cases.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       C-reactive protein and procalcitonin levels were each elevated in 1 case only (3%).
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      RADIOLOGIC FINDINGS
     </title>
     <p>
      Similar to the laboratory findings, radiologic findings from children are also similar across infections with different novel CoVs (Table
      <xref ref-type="table" rid="T1">
       1
      </xref>
      ). On chest radiography, children mostly show bilateral patchy airspace consolidations often at the periphery of the lungs, peribronchial thickening and ground-glass opacities.
      <sup>
       <xref ref-type="bibr" rid="R57">
        57
       </xref>
       –
       <xref ref-type="bibr" rid="R59">
        59
       </xref>
       ,
       <xref ref-type="bibr" rid="R76">
        76
       </xref>
       ,86,87
      </sup>
      Chest CT mostly shows airspace consolidations and ground-glass opacities.
      <sup>
       <xref ref-type="bibr" rid="R89">
        89
       </xref>
      </sup>
     </p>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       CT changes observed in children infected with SARS-CoV-2 include bilateral multiple patchy, nodular ground-glass opacities, speckled ground-glass opacities and/or infiltrating shadows in the middle and outer zone of the lung or under the pleura.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
        ,
        <xref ref-type="bibr" rid="R88">
         88
        </xref>
       </sup>
       These findings are unspecific and milder compared with those in adults.
       <sup>
        <xref ref-type="bibr" rid="R88">
         88
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      DIAGNOSIS
     </title>
     <p>
      The main basis for diagnosis of infections with HCoVs is real-time polymerase chain reaction (RT-PCR) on upper or lower respiratory secretions.
      <sup>
       <xref ref-type="bibr" rid="R5">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="R15">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="R90">
        90
       </xref>
       –
       <xref ref-type="bibr" rid="R96">
        96
       </xref>
      </sup>
      For SARS-CoV, MERS-CoV and SARS-CoV-2, higher viral loads have been detected in samples from the lower respiratory tract compared with the upper respiratory tract.
      <sup>
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="R149">
        149
       </xref>
      </sup>
      Therefore, in clinically suspected cases with an initially negative result on nasopharyngeal or throat swab, repeat testing of upper respiratory tract samples or (preferably) testing of lower respiratory tract samples should be done. RT-PCRs on stool samples can be positive for HCoVs but is not used for routine diagnosis.
      <sup>
       <xref ref-type="bibr" rid="R91">
        91
       </xref>
       ,
       <xref ref-type="bibr" rid="R98">
        98
       </xref>
       ,
       <xref ref-type="bibr" rid="R99">
        99
       </xref>
      </sup>
      For SARS-CoV and SARS-CoV-2, rare cases with positive PCRs in blood have been reported.
      <sup>
       <xref ref-type="bibr" rid="R28">
        28
       </xref>
       ,
       <xref ref-type="bibr" rid="R150">
        150
       </xref>
      </sup>
      Serology has been used to diagnose infections with SARS-CoV and MERS-CoV, but is not useful in the acute phase of the infection.
      <sup>
       <xref ref-type="bibr" rid="R100">
        100
       </xref>
       –
       <xref ref-type="bibr" rid="R103">
        103
       </xref>
      </sup>
      Cross-reactivities between antibodies against SARS-CoV and common CoVs have been observed.
      <sup>
       <xref ref-type="bibr" rid="R151">
        151
       </xref>
      </sup>
     </p>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Whole genome sequencing allowed the rapid development of molecular diagnostic tests for SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
       RT-PCR for genes encoding the internal RNA-dependent RNA polymerase and surface spike glycoprotein are commonly used.
       <sup>
        <xref ref-type="bibr" rid="R28">
         28
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      TREATMENT
     </title>
     <p>
      Supportive treatment including sufficient fluid and calorie intake, and additional oxygen supplementation should be used in the treatment of children infected with HCoVs. The aim is to prevent ARDS, organ failure and secondary nosocomial infections. If bacterial infection is suspected broad-spectrum antibiotics such as second or third generation cephalosporins may be used.
     </p>
     <sec>
      <title>
       SARS-CoV
      </title>
      <p>
       In the absence of specific antiviral drugs for CoVs, broad-spectrum antiviral drugs, such as interferon alpha and beta or ribavirin were used for the treatment of SARS-CoV, including in children.
       <sup>
        <xref ref-type="bibr" rid="R57">
         57
        </xref>
        –
        <xref ref-type="bibr" rid="R59">
         59
        </xref>
       </sup>
       Ribavirin was subsequently shown to be ineffective or even harmful because it can cause hemolytic anemia or liver dysfunction.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       In adults, interferon-alpha alone or together with ribavirin also did not consistently improve outcomes.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
        ,
        <xref ref-type="bibr" rid="R153">
         153
        </xref>
       </sup>
       There is some evidence that intravenous corticosteroids led to clinical and radiologic improvement in SARS-CoV-infected individuals.
       <sup>
        <xref ref-type="bibr" rid="R58">
         58
        </xref>
       </sup>
       However, a systematic review showed that the evidence for this is inconclusive and corticosteroids might also be harmful (delayed viral clearance, avascular necrosis, osteoporosis, new onset of diabetes).
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       There is some evidence from adult studies that lopinavir/ritonavir (Kaletra) started early during infection is associated with improved clinical outcomes (decreased intubation, ARDS and death rates).
       <sup>
        <xref ref-type="bibr" rid="R154">
         154
        </xref>
        ,
        <xref ref-type="bibr" rid="R155">
         155
        </xref>
       </sup>
       However, a systematic review found inconclusive results for the use of lopinavir/ritonavir because of a possible selection bias in many of the studies.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       Inconclusive results were also found for intravenous immunoglobulins because studies did not account for comorbidities, stage of illness and effect of other treatments.
       <sup>
        <xref ref-type="bibr" rid="R152">
         152
        </xref>
       </sup>
       There is no evidence for the use of monoclonal antibodies against tumor necrosis factor alpha.
       <sup>
        <xref ref-type="bibr" rid="R156">
         156
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       MERS-CoV
      </title>
      <p>
       There are no studies on treatment outcomes for MERS-CoV in children. In adults, as for SARS-CoV, interferon or ribavirin alone or in combination have not been shown to have a clear benefit.
       <sup>
        <xref ref-type="bibr" rid="R157">
         157
        </xref>
        –
        <xref ref-type="bibr" rid="R159">
         159
        </xref>
       </sup>
       Mycophenolate mofetil, which inhibits guanine (and therefore RNA) synthesis, was identified as a potential anti-MERS-CoV drug in vitro.
       <sup>
        <xref ref-type="bibr" rid="R160">
         160
        </xref>
       </sup>
       However, animal studies showed that the drug leads to worse outcomes with higher viral loads in lung and extrapulmonary tissues.
       <sup>
        <xref ref-type="bibr" rid="R161">
         161
        </xref>
       </sup>
       Consistent with this, renal transplant patients on mycophenolate mofetil have been reported to develop severe and sometimes fatal MERS-CoV infections.
       <sup>
        <xref ref-type="bibr" rid="R162">
         162
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       SARS-CoV-2
      </title>
      <p>
       Until the results of on-going clinical trials become available, there is no definitive evidence on which to base treatment of patients infected with SARS-CoV-2. The only treatment recommendation for children, published by the Zhejiang University School of Medicine, suggests the use of nebulized interferon alpha-2b and oral lopinavir/ritonavir together with corticosteroids for complications (ARDS, encephalitis, hemophagocytic syndrome or septic shock) and intravenous immunoglobulin for severe cases.
       <sup>
        <xref ref-type="bibr" rid="R72">
         72
        </xref>
       </sup>
      </p>
      <p>
       However, as none of these therapies have shown a clear benefit in the treatment of other novel CoVs, it is questionable whether they will be beneficial in the treatment of SARS-CoV-2. Neither the World Health Organization nor the US Centers for Disease Control and Prevention recommends any specific treatment in children or adults.
       <sup>
        <xref ref-type="bibr" rid="R97">
         97
        </xref>
        ,
        <xref ref-type="bibr" rid="R163">
         163
        </xref>
       </sup>
       Despite this, in the previously mentioned case series of the 34 children infected with SARS-CoV-2, 59% were treated with lopinavir/ritonavir.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
       None of the children received glucocorticoids or immunoglobulins.
       <sup>
        <xref ref-type="bibr" rid="R61">
         61
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Other Therapeutic Options
      </title>
      <sec>
       <title>
        Monoclonal Antibodies
       </title>
       <p>
        Despite their diversity, CoVs share many proteins among different species, which is helpful for the design of new drugs. One of them is the surface structural spike glycoprotein S, which is responsible for virus-cell interaction.
        <sup>
         <xref ref-type="bibr" rid="R164">
          164
         </xref>
        </sup>
        Monoclonal antibodies (from convalescent human plasma, animal plasma or manufactured) against the spike glycoprotein S have been shown to inhibit fusion of CoVs with human cells and to decrease mortality rate in SARS-CoV-infected patients.
        <sup>
         <xref ref-type="bibr" rid="R165">
          165
         </xref>
         –
         <xref ref-type="bibr" rid="R171">
          171
         </xref>
        </sup>
        A protein, which also inhibits the spike glycoprotein S, although it is not a monoclonal antibody, has been isolated from a red alga called Griffithsia.
        <sup>
         <xref ref-type="bibr" rid="R172">
          172
         </xref>
        </sup>
        However, to date, it has only been tested in animal studies.
        <sup>
         <xref ref-type="bibr" rid="R172">
          172
         </xref>
        </sup>
       </p>
       <p>
        Angiotensin-converting enzyme 2, dipeptidyl peptidase 4, aminopeptidase N, O-acetylated sialic acid are further host receptors for HCoVs and monoclonal antibodies against these proteins might be useful in treatment of infections.
        <sup>
         <xref ref-type="bibr" rid="R173">
          173
         </xref>
         –
         <xref ref-type="bibr" rid="R176">
          176
         </xref>
        </sup>
        However, rapid mutation of CoVs poses a potential problem, which might be diminished by using several monoclonal antibodies targeting different epitopes.
        <sup>
         <xref ref-type="bibr" rid="R166">
          166
         </xref>
        </sup>
       </p>
      </sec>
      <sec>
       <title>
        Protease Inhibitors
       </title>
       <p>
        Endosomal and nonendosomal virus entry into cells can be reduced by inhibiting responsible proteases.
        <sup>
         <xref ref-type="bibr" rid="R177">
          177
         </xref>
         –
         <xref ref-type="bibr" rid="R179">
          179
         </xref>
        </sup>
        Papain-like proteases (PLpro) are involved in viral replication in CoVs and are further potential targets for treatment. Numerous PLpro inhibitors have been identified. However, none of them has been validated in in vivo studies.
        <sup>
         <xref ref-type="bibr" rid="R180">
          180
         </xref>
         ,
         <xref ref-type="bibr" rid="R181">
          181
         </xref>
        </sup>
        Moreover, PLpro enzymes differ between CoVs species, making PLpro inhibitors narrow-spectrum antiviral drugs against CoVs.
        <sup>
         <xref ref-type="bibr" rid="R182">
          182
         </xref>
        </sup>
       </p>
       <p>
        A further protein involved in viral replication is CoV main proteinase, which is inhibited by lopinavir. However, as previously mentioned, lopinavir (plus ritonavir) has been shown to be effective against CoVs in animal and nonrandomized studies of SARS-CoV-infected humans.
        <sup>
         <xref ref-type="bibr" rid="R154">
          154
         </xref>
         ,
         <xref ref-type="bibr" rid="R161">
          161
         </xref>
        </sup>
        However, as previously mentioned, these results are considered inconclusive because of potential selection bias.
        <sup>
         <xref ref-type="bibr" rid="R152">
          152
         </xref>
        </sup>
       </p>
       <sec>
        <title>
         Chloroquine
        </title>
        <p>
         Chloroquine, which is commonly used against malaria and autoimmune diseases, increases the endosomal pH thereby inhibiting virus-cell fusion, and is therefore a potential broad-spectrum antiviral drug.
         <sup>
          <xref ref-type="bibr" rid="R183">
           183
          </xref>
         </sup>
         It also interferes with glycosylation of cellular receptors of SARS-CoV.
         <sup>
          <xref ref-type="bibr" rid="R184">
           184
          </xref>
         </sup>
         In addition, in vitro studies show that chloroquine inhibits entry and postentry stages of SARS-CoV-2 into cells.
         <sup>
          <xref ref-type="bibr" rid="R185">
           185
          </xref>
         </sup>
         Moreover, chloroquine possesses immune-modulating activity, which might enhance its antiviral effect in vivo.
         <sup>
          <xref ref-type="bibr" rid="R185">
           185
          </xref>
         </sup>
        </p>
       </sec>
      </sec>
      <sec>
       <title>
        RNA Synthesis Inhibitors
       </title>
       <p>
        As previously mentioned, ribavirin, a guanosine analog has been shown to be ineffective or even harmful against SARS-CoV
        <sup>
         <xref ref-type="bibr" rid="R152">
          152
         </xref>
        </sup>
        and MERS-CoV.
        <sup>
         <xref ref-type="bibr" rid="R157">
          157
         </xref>
         –
         <xref ref-type="bibr" rid="R159">
          159
         </xref>
        </sup>
        Immucillin-A, a new adenosine analog that has recently been developed, inhibits the viral RNA polymerase of a wide range of RNA viruses, including SARS-CoV and MERS-CoV,
        <sup>
         <xref ref-type="bibr" rid="R186">
          186
         </xref>
        </sup>
        and might be useful in the treatment of other HCoVs. Furthermore, inhibitors of helicase (which are proteins unwinding double-stranded RNA into single strands during replication) might be useful in treatment of CoVs.
        <sup>
         <xref ref-type="bibr" rid="R187">
          187
         </xref>
        </sup>
        RNA synthesis inhibitors, which reduce the formation of double-membrane vesicles, a hallmark of CoV2 replication, have been identified as potential antiviral drugs.
        <sup>
         <xref ref-type="bibr" rid="R188">
          188
         </xref>
         ,
         <xref ref-type="bibr" rid="R189">
          189
         </xref>
        </sup>
        A double-stranded RNA activated caspase oligomerizer (DRACO) that targets long viral double-stranded RNA and induces apoptosis of infected cells, but spares healthy cells, might also be useful in the treatment of CoVs.
        <sup>
         <xref ref-type="bibr" rid="R190">
          190
         </xref>
        </sup>
       </p>
      </sec>
     </sec>
    </sec>
    <sec>
     <title>
      VACCINES
     </title>
     <p>
      Several vaccines against HCoVs are in development with the aim of preventing infection, reducing disease severity and viral shedding. The main antigens for vaccine development are the structural spike glycoprotein S or its receptor-binding domain (RBD).
      <sup>
       <xref ref-type="bibr" rid="R191">
        191
       </xref>
      </sup>
      However, the propensity of CoVs to rapidly mutate and recombine poses a potential problem for vaccine development.
      <sup>
       <xref ref-type="bibr" rid="R192">
        192
       </xref>
       –
       <xref ref-type="bibr" rid="R194">
        194
       </xref>
      </sup>
      Furthermore, the enhanced disease after viral challenges postvaccination has been observed in animal models after several different vaccines.
      <sup>
       <xref ref-type="bibr" rid="R195">
        195
       </xref>
       –
       <xref ref-type="bibr" rid="R197">
        197
       </xref>
      </sup>
     </p>
     <sec>
      <title>
       Live-attenuated Vaccines
      </title>
      <p>
       The advantage of live-attenuated vaccines is that they usually induce a robust and long-lasting immune response, including cellular and humoral immunity to many different antigens. In SARS-CoV animal studies, attenuated mutants with deletion of the structural E gene have been shown to induce neutralizing antibodies, reduce viral loads and protect from clinical symptoms of SARS-CoV infection.
       <sup>
        <xref ref-type="bibr" rid="R198">
         198
        </xref>
        –
        <xref ref-type="bibr" rid="R200">
         200
        </xref>
       </sup>
       In contrast, deletion of open reading frames had little or no effect on viral loads in vitro and in vivo.
       <sup>
        <xref ref-type="bibr" rid="R201">
         201
        </xref>
       </sup>
       Other strategies under development for live-attenuated vaccines against CoVs are genome rearrangement or gene knockouts.
       <sup>
        <xref ref-type="bibr" rid="R202">
         202
        </xref>
        –
        <xref ref-type="bibr" rid="R204">
         204
        </xref>
       </sup>
       These have the advantage that the vaccine virus cannot recombine with wild viruses.
      </p>
     </sec>
     <sec>
      <title>
       Inactivated Vaccines
      </title>
      <p>
       In mouse models, inactivated vaccines successfully induce cellular and humoral immunity (with many different neutralization antibodies) against SARS-CoV
       <sup>
        <xref ref-type="bibr" rid="R191">
         191
        </xref>
        ,
        <xref ref-type="bibr" rid="R205">
         205
        </xref>
        –
        <xref ref-type="bibr" rid="R207">
         207
        </xref>
       </sup>
       and humoral immunity against MERS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R208">
         208
        </xref>
        ,
        <xref ref-type="bibr" rid="R209">
         209
        </xref>
       </sup>
       In a human phase 1 trial, inactivated vaccines against SARS-CoV were well tolerated and elicited neutralizing antibodies.
       <sup>
        <xref ref-type="bibr" rid="R210">
         210
        </xref>
       </sup>
       However, no challenge studies have been done in humans, and in monkey challenge studies, no clear evidence of protection was shown despite the induction of strong cellular and humoral responses.
       <sup>
        <xref ref-type="bibr" rid="R211">
         211
        </xref>
       </sup>
       Moreover, concerns have been raised that inactivated vaccines against SARS-CoV and MERS-CoV may lead to harmful immune and/or inflammatory responses postchallenge.
       <sup>
        <xref ref-type="bibr" rid="R195">
         195
        </xref>
        ,
        <xref ref-type="bibr" rid="R209">
         209
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Subunit and Recombinant Vaccines
      </title>
      <p>
       Subunit vaccines are purified antigens, usually combined with adjuvants and are the most popular method in the development of vaccines against novel CoVs. For SARS-CoV and MERS-CoV, these are mostly developed from spike glycoprotein S, RBD or nucleocapsid protein.
       <sup>
        <xref ref-type="bibr" rid="R212">
         212
        </xref>
        –
        <xref ref-type="bibr" rid="R216">
         216
        </xref>
       </sup>
       Some studies show that subunit vaccines given intranasally might induce stronger immune responses and mucosal immunity.
       <sup>
        <xref ref-type="bibr" rid="R217">
         217
        </xref>
       </sup>
       Several subunit vaccines have shown to be successful in animal challenging studies.
       <sup>
        <xref ref-type="bibr" rid="R218">
         218
        </xref>
        –
        <xref ref-type="bibr" rid="R220">
         220
        </xref>
       </sup>
      </p>
      <p>
       In a study in monkeys, recombinant RBD protein was used to successfully reduce viral loads in lungs and oropharynx and to prevent MERS-CoV pneumonia.
       <sup>
        <xref ref-type="bibr" rid="R218">
         218
        </xref>
       </sup>
       In mice, similar results were achieved using recombinant RBD protein vaccines from SARS-CoV.
       <sup>
        <xref ref-type="bibr" rid="R221">
         221
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       Viral Vectors Vaccines
      </title>
      <p>
       Adenovirus-based vectors encoding SARS proteins (eg, nucleocapsid protein, spike glycoprotein S and other membrane proteins) have been shown to be immunogenic in mice and rhesus macaques in whom they induced humoral and cellular vaccine responses.
       <sup>
        <xref ref-type="bibr" rid="R222">
         222
        </xref>
        ,
        <xref ref-type="bibr" rid="R223">
         223
        </xref>
       </sup>
       Adenovirus-based vaccines carrying parts MERS-CoV have been shown to reduce morbidity and mortality (undetectable or reduced pulmonary viral loads) in mouse models.
       <sup>
        <xref ref-type="bibr" rid="R196">
         196
        </xref>
        ,
        <xref ref-type="bibr" rid="R224">
         224
        </xref>
       </sup>
       Initially, pulmonary hemorrhages were observed postviral challenge.
       <sup>
        <xref ref-type="bibr" rid="R196">
         196
        </xref>
       </sup>
       However, adding a CD40 ligand to the vaccine enhanced immunogenicity and efficacy, and also prevented inadvertent pulmonary pathology, which makes this vaccine a promising strategy.
       <sup>
        <xref ref-type="bibr" rid="R196">
         196
        </xref>
       </sup>
       Nonetheless, preexisting immunity against adenovirus might reduce efficacy. This might be addressed by giving a viral-based vaccine followed by a recombinant vaccine as a booster.
       <sup>
        <xref ref-type="bibr" rid="R225">
         225
        </xref>
       </sup>
       A adenovirus-based MERS-CoV vaccine has moved into a phase I clinical trial.
       <sup>
        <xref ref-type="bibr" rid="R226">
         226
        </xref>
       </sup>
      </p>
      <p>
       One study, comparing an inactivated SARS-CoV vaccine with an adenovirus-based vaccine against SARS-CoV, found that the first led to higher humoral responses.
       <sup>
        <xref ref-type="bibr" rid="R227">
         227
        </xref>
       </sup>
       Adenovirus-based vaccines administered intranasally led to immunoglobulin A antibody production which has been associated with superior protection from virus replication in lungs.
       <sup>
        <xref ref-type="bibr" rid="R227">
         227
        </xref>
       </sup>
       This indicates that measuring serum neutralizing antibodies might not be a sufficient way of assessing vaccine efficacy for HCoV as mucosal immunity might be more important.
      </p>
      <p>
       For SARS-CoV, a poxvirus has also been used as a vector for an intranasally and intramuscularly administered vaccine. This vaccine-induced neutralizing antibodies and reduced viral loads in the respiratory tract of challenged mice.
       <sup>
        <xref ref-type="bibr" rid="R228">
         228
        </xref>
       </sup>
       However, a similar vaccine used in ferrets led to increased liver damage after SARS-CoV challenge.
       <sup>
        <xref ref-type="bibr" rid="R197">
         197
        </xref>
       </sup>
      </p>
      <p>
       Further vector vaccines for SARS-CoV that have been tested in animals are based on recombinant parainfluenza virus,
       <sup>
        <xref ref-type="bibr" rid="R229">
         229
        </xref>
        ,
        <xref ref-type="bibr" rid="R230">
         230
        </xref>
       </sup>
       live-attenuated recombinant measles virus,
       <sup>
        <xref ref-type="bibr" rid="R231">
         231
        </xref>
       </sup>
       attenuated rabies virus
       <sup>
        <xref ref-type="bibr" rid="R232">
         232
        </xref>
       </sup>
       and attenuated
       <italic>
        Salmonella
       </italic>
       .
       <sup>
        <xref ref-type="bibr" rid="R233">
         233
        </xref>
       </sup>
      </p>
     </sec>
     <sec>
      <title>
       DNA Vaccines
      </title>
      <p>
       Vaccines containing DNA encoding the spike glycoprotein seem to induce a more robust response of neutralizing antibodies against MERS-CoV than vaccines only containing the RBD protein. They have been shown to protect rhesus macaques from MERS-CoV pneumonia.
       <sup>
        <xref ref-type="bibr" rid="R234">
         234
        </xref>
        ,
        <xref ref-type="bibr" rid="R235">
         235
        </xref>
       </sup>
       Three DNA vaccines against MERS-CoV have advanced into clinical trials.
       <sup>
        <xref ref-type="bibr" rid="R236">
         236
        </xref>
        –
        <xref ref-type="bibr" rid="R238">
         238
        </xref>
       </sup>
      </p>
     </sec>
    </sec>
    <sec>
     <title>
      OTHER STRATEGIES FOR CONTROLLING EMERGING CORONAVIRUSES
     </title>
     <p>
      After quickly spreading across the globe, SARS-CoV was contained in 2003 after a highly effective global public health response. This highlights the urgent need for rapid and effectful strategies of infection control. One of the main challenges with novel CoVs is the high potential for nosocomial transmission.
      <sup>
       <xref ref-type="bibr" rid="R239">
        239
       </xref>
      </sup>
      Health care settings seem to increase the risk of viral transmission due to aerosol-generating procedures such as intubation and bronchoscopy. Appropriate hospital hygiene practices are therefore crucial to limit nosocomial outbreaks. The main aims are to effectively triage patients with fever, respiratory symptoms and a contact history
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
      </sup>
      and to apply stringent infection control measures such as isolating patients and quarantine contacts as early as possible. Ideally, each patient is placed in a single negative pressure room. If this is not possible, patients and health care workers should be cohorted.
      <sup>
       <xref ref-type="bibr" rid="R241">
        241
       </xref>
      </sup>
      Protective gear should include water-resistant gowns, disposable gloves, N95 masks and goggles or face shields.
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
      </sup>
      Only suction catheters and mechanical respirators with a closed-circuit system and viral filters should be used.
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
      </sup>
      In contrasts, nebulizers, oxygen masks or nasal continuous positive airway pressure systems should not be used on an open ward.
      <sup>
       <xref ref-type="bibr" rid="R240">
        240
       </xref>
       ,
       <xref ref-type="bibr" rid="R241">
        241
       </xref>
      </sup>
      Needless to say, strict hand hygiene needs to be applied and visitors should be avoided or limited to an absolute minimum. HCoVs have been shown to persist on dry surfaces for up to 9 days.
      <sup>
       <xref ref-type="bibr" rid="R242">
        242
       </xref>
       –
       <xref ref-type="bibr" rid="R244">
        244
       </xref>
      </sup>
      The persistence depends on temperature (shorter duration at 30–40°C) and humidity (longer at higher humidity).
      <sup>
       <xref ref-type="bibr" rid="R245">
        245
       </xref>
      </sup>
      HCoVs, including novel CoVs, can be inactivated by heating to 56°C for 30 minutes or by using lipid solvents such as ethanol (&gt;75%), isopropanol (&gt;70%), formaldehyde (&gt;0.7%), povidone-iodine (&gt;0.23%), sodium hypochlorite (&gt;0.21%), hydrogen peroxide (&gt;0.5%), but not chlorhexidine.
      <sup>
       <xref ref-type="bibr" rid="R72">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="R244">
        244
       </xref>
      </sup>
     </p>
    </sec>
    <sec>
     <title>
      SUMMARY
     </title>
     <p>
      SARS-CoV, MERS-CoV and SARS-CoV-2 infections seem to affect children less commonly and less severely as compared with adults. This might be because children are less frequently exposed to the main sources of transmission (which until now has been disproportionally nosocomial) or because they are less exposed to animals. However, it could also be that children are less frequently symptomatic or have less severe symptoms and are therefore less often tested, leading to an underestimate of the true numbers infected. In relation to SARS-CoV-2, a study prepublished in early March 2020 suggests that children are just as likely as adults to become infected with this virus but are less likely to be symptomatic or develop severe symptoms.
      <sup>
       <xref ref-type="bibr" rid="R246">
        246
       </xref>
      </sup>
      However, the importance of children in transmitting the virus remains uncertain. The majority of children infected by a novel CoVs reported thus far have a documented household contact, often showing symptoms before them, suggesting the possibility that children are not an important reservoir for novel CoVs. The clinical, laboratory and radiologic features in children are similar for all novel CoVs, except more children infected with SARS-CoV presented with fever compared with SARS-CoV-2 or MERS-CoV. To date, no deaths in children have been reported for SARS-CoV or SARS-CoV-2, except (in the case of the former) for infants of mothers who were infected during pregnancy.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="financial-disclosure">
       <p>
        P.Z. is supported by a Fellowship from the European Society for Paediatric Infectious Diseases.
       </p>
      </fn>
      <fn fn-type="COI-statement">
       <p>
        The authors have no conflicts of interest to disclose.
       </p>
      </fn>
      <fn fn-type="equal">
       <p>
        P.Z. drafted the initial article. N.C. critically revised the article and both authors approved the final article as submitted.
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <title>
       REFERENCES
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: an overview of their replication and pathogenesis.
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         1282
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         23
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25720466
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Amer
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Bovine-like coronaviruses in domestic and wild ruminants.
        </article-title>
        <source>
         Anim Health Res Rev
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         113
        </fpage>
        –
        <lpage>
         124
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30683171
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome?
        </article-title>
        <source>
         Rev Sci Tech
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         643
        </fpage>
        –
        <lpage>
         660
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15702725
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cabeça
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Granato
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Bellei
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical features of human coronavirus infections among different subsets of patients.
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         1040
        </fpage>
        –
        <lpage>
         1047
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23462106
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mourez
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Gouarin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         An outbreak of coronavirus OC43 respiratory infection in Normandy, France.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         985
        </fpage>
        –
        <lpage>
         989
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12684910
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Esper
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           YT
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronaviruses are uncommon in patients with gastrointestinal illness.
        </article-title>
        <source>
         J Clin Virol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         48
        </volume>
        :
        <fpage>
         131
        </fpage>
        –
        <lpage>
         133
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20362494
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dina
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gouarin
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of the new human coronavirus HKU1: a report of 6 cases.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         42
        </volume>
        :
        <fpage>
         634
        </fpage>
        –
        <lpage>
         639
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16447108
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         884
        </fpage>
        –
        <lpage>
         895
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15613317
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gorse
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           O’Connor
          </surname>
          <given-names>
           TZ
          </given-names>
         </name>
         <name>
          <surname>
           Hall
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         199
        </volume>
        :
        <fpage>
         847
        </fpage>
        –
        <lpage>
         857
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19239338
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           da Silva Filho
          </surname>
          <given-names>
           LV
          </given-names>
         </name>
         <name>
          <surname>
           Zerbinati
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Tateno
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The differential clinical impact of human coronavirus species in children with cystic fibrosis.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         206
        </volume>
        :
        <fpage>
         384
        </fpage>
        –
        <lpage>
         388
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22459737
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         40
        </volume>
        :
        <fpage>
         1721
        </fpage>
        –
        <lpage>
         1729
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15909257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ellis
          </surname>
          <given-names>
           EF
          </given-names>
         </name>
         <name>
          <surname>
           Hoffman
          </surname>
          <given-names>
           LS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The association of viral and bacterial respiratory infections with exacerbations of wheezing in young asthmatic children.
        </article-title>
        <source>
         J Pediatr
        </source>
        .
        <year>
         1973
        </year>
        ;
        <volume>
         82
        </volume>
        :
        <fpage>
         578
        </fpage>
        –
        <lpage>
         590
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4349062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         3995
        </fpage>
        –
        <lpage>
         4008
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         3076
        </fpage>
        –
        <lpage>
         3092
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25552712
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gaunt
          </surname>
          <given-names>
           ER
          </given-names>
         </name>
         <name>
          <surname>
           Hardie
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Claas
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         48
        </volume>
        :
        <fpage>
         2940
        </fpage>
        –
        <lpage>
         2947
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         20554810
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Foxman
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronaviruses and other respiratory infections in young adults on a university campus: prevalence, symptoms, and shedding.
        </article-title>
        <source>
         Influenza Other Respir Viruses
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         582
        </fpage>
        –
        <lpage>
         590
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29660826
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huynh
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evidence supporting a zoonotic origin of human coronavirus strain NL63.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         12816
        </fpage>
        –
        <lpage>
         12825
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22993147
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Oppong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Drexler
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Distant relatives of severe acute respiratory syndrome coronavirus and close relatives of human coronavirus 229E in bats, Ghana.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         1377
        </fpage>
        –
        <lpage>
         1384
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19788804
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <name>
          <surname>
           Eckerle
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Link of a ubiquitous human coronavirus to dromedary camels.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         113
        </volume>
        :
        <fpage>
         9864
        </fpage>
        –
        <lpage>
         9869
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27528677
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Moës
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         1595
        </fpage>
        –
        <lpage>
         1604
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15650185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS and MERS: recent insights into emerging coronaviruses.
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         523
        </fpage>
        –
        <lpage>
         534
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27344959
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         A review of studies on animal reservoirs of the SARS coronavirus.
        </article-title>
        <source>
         Virus Res
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         133
        </volume>
        :
        <fpage>
         74
        </fpage>
        –
        <lpage>
         87
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17451830
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Günther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1967
        </fpage>
        –
        <lpage>
         1976
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS-CoV infection in a restaurant from palm civet.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         1860
        </fpage>
        –
        <lpage>
         1865
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16485471
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           HKH
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular epidemiology, evolution and phylogeny of SARS coronavirus.
        </article-title>
        <source>
         Infect Genet Evol
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         71
        </volume>
        :
        <fpage>
         21
        </fpage>
        –
        <lpage>
         30
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30844511
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Groot
          </surname>
          <given-names>
           RJ
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         7790
        </fpage>
        –
        <lpage>
         7792
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23678167
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ommeh
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zohaib
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genetic evidence of Middle East respiratory syndrome coronavirus (MERS-Cov) and widespread seroprevalence among camels in Kenya.
        </article-title>
        <source>
         Virol Sin
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         33
        </volume>
        :
        <fpage>
         484
        </fpage>
        –
        <lpage>
         492
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30570714
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         514
        </fpage>
        –
        <lpage>
         523
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         727
        </fpage>
        –
        <lpage>
         733
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200221-sitrep-32-covid-19.pdf?sfvrsn=4802d089_2">
          https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200221-sitrep-32-covid-19.pdf?sfvrsn=4802d089_2
         </ext-link>
         . Accessed March 2, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <name>
          <surname>
           Heugel
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical disease in children associated with newly described coronavirus subtypes.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         119
        </volume>
        :
        <fpage>
         e70
        </fpage>
        –
        <lpage>
         e76
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17130280
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Uddin
          </surname>
          <given-names>
           SMI
          </given-names>
         </name>
         <name>
          <surname>
           Englund
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kuypers
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Burden and risk factors for coronavirus infections in infants in rural Nepal.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         67
        </volume>
        :
        <fpage>
         1507
        </fpage>
        –
        <lpage>
         1514
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29668900
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Taylor
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lopez
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Weckx
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory viruses and influenza-like illness: epidemiology and outcomes in children aged 6 months to 10 years in a multi-country population sample.
        </article-title>
        <source>
         J Infect
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         74
        </volume>
        :
        <fpage>
         29
        </fpage>
        –
        <lpage>
         41
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27667752
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Garbati
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Hasan
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Acute viral respiratory infections among children in MERS-endemic Riyadh, Saudi Arabia, 2012-2013.
        </article-title>
        <source>
         J Med Virol
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         195
        </fpage>
        –
        <lpage>
         201
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27430485
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Tuo
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           XB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou.
        </article-title>
        <source>
         PLoS One
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         e0191789
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29377913
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Friedman
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Alter
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Hindiyeh
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human
        </article-title>
        <article-title>
         coronavirus infections in Israel: epidemiology, clinical symptoms and summer seasonality of HCoV-HKU1.
        </article-title>
        <source>
         Viruses
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peak
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Childs
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <name>
          <surname>
           Grad
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparing nonpharmaceutical interventions for containing emerging epidemics.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         114
        </volume>
        :
        <fpage>
         4023
        </fpage>
        –
        <lpage>
         4028
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28351976
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         395
        </volume>
        :
        <fpage>
         689
        </fpage>
        –
        <lpage>
         697
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32014114
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Abdirizak
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study.
        </article-title>
        <source>
         BMC Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         210
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26336062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lloyd-Smith
          </surname>
          <given-names>
           JO
          </given-names>
         </name>
         <name>
          <surname>
           Schreiber
          </surname>
          <given-names>
           SJ
          </given-names>
         </name>
         <name>
          <surname>
           Kopp
          </surname>
          <given-names>
           PE
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Superspreading and the effect of individual variation on disease emergence.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         438
        </volume>
        :
        <fpage>
         355
        </fpage>
        –
        <lpage>
         359
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16292310
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Rivers
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Lofgren
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Estimation of MERS-coronavirus reproductive number and case fatality rate for the spring 2014 Saudi Arabia outbreak: insights from publicly available data.
        </article-title>
        <source>
         PLoS Curr
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Teunis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures.
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         160
        </volume>
        :
        <fpage>
         509
        </fpage>
        –
        <lpage>
         516
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15353409
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Castillo-Chavez
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Fenimore
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Model parameters and outbreak control for SARS.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1258
        </fpage>
        –
        <lpage>
         1263
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15324546
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Riley
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Donnelly
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission dynamics of the etiological agent of SARS in Hong Kong: impact of public health interventions.
        </article-title>
        <source>
         Science
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         300
        </volume>
        :
        <fpage>
         1961
        </fpage>
        –
        <lpage>
         1966
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12766206
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lipsitch
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission dynamics and control of severe acute respiratory syndrome.
        </article-title>
        <source>
         Science
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         300
        </volume>
        :
        <fpage>
         1966
        </fpage>
        –
        <lpage>
         1970
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12766207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         14
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26132768
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Predictive models of control strategies involved in containing indoor airborne infections.
        </article-title>
        <source>
         Indoor Air
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         481
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17100668
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cauchemez
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nouvellet
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cori
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Unraveling the drivers of MERS-CoV transmission.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         113
        </volume>
        :
        <fpage>
         9081
        </fpage>
        –
        <lpage>
         9086
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27457935
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           JE
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS transmission and risk factors: a systematic review.
        </article-title>
        <source>
         BMC Public Health
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         574
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29716568
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Ran
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak.
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         92
        </volume>
        :
        <fpage>
         214
        </fpage>
        –
        <lpage>
         217
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         32007643
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cyranoski
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mystery deepens over animal source of coronavirus.
        </article-title>
        <year>
         2020
        </year>
        <comment>
         Accessed March 4, 2020. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/d41586-020-00548-w">
          https://www.nature.com/articles/d41586-020-00548-w
         </ext-link>
         .
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization.
        </collab>
        .
        <comment>
         Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2004. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/sars/country/table2004_04_21/en/">
          https://www.who.int/csr/sars/country/table2004_04_21/en/
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R53">
       <label>
        53.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         Middle East respiratory syndrome coronavirus (MERS-CoV), MERS Monthly Summary, November 2019.
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/mers-cov/en/">
          https://www.who.int/emergencies/mers-cov/en/
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R54">
       <label>
        54.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report – 48. 2020. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4">
          https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200308-sitrep-48-covid-19.pdf?sfvrsn=16f7ccef_4
         </ext-link>
         . Accessed March 9, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R55">
       <label>
        55.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           NS
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         362
        </volume>
        :
        <fpage>
         1353
        </fpage>
        –
        <lpage>
         1358
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14585636
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R56">
       <label>
        56.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hunter
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Aden
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         647
        </fpage>
        –
        <lpage>
         656
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26981708
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R57">
       <label>
        57.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hon
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           WT
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical presentations and outcome of severe acute respiratory syndrome in children.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1701
        </fpage>
        –
        <lpage>
         1703
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12767737
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R58">
       <label>
        58.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <name>
          <surname>
           Cheung
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome in children: experience in a regional hospital in Hong Kong.
        </article-title>
        <source>
         Pediatr Crit Care Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         279
        </fpage>
        –
        <lpage>
         283
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12831407
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R59">
       <label>
        59.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bitnun
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           U
          </given-names>
         </name>
         <name>
          <surname>
           Heurter
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         Other Members of the Hospital for Sick Children SARS Investigation Team
        </collab>
        .
        <article-title>
         Children hospitalized with severe acute respiratory syndrome-related illness in Toronto.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         112
        </volume>
        :
        <fpage>
         e261
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         14523209
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R60">
       <label>
        60.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Kattan
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia.
        </article-title>
        <source>
         World J Clin Pediatr
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         391
        </fpage>
        –
        <lpage>
         396
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27872828
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R61">
       <label>
        61.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           XF
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen].
        </article-title>
        <source>
         Zhonghua Er Ke Za Zhi
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         E008
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32062875
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R62">
       <label>
        62.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lessler
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           NG
          </given-names>
         </name>
         <name>
          <surname>
           Brookmeyer
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Incubation periods of acute respiratory viral infections: a systematic review.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         291
        </fpage>
        –
        <lpage>
         300
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19393959
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R63">
       <label>
        63.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Hedley
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           LM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients.
        </article-title>
        <source>
         Ann Intern Med
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         141
        </volume>
        :
        <fpage>
         662
        </fpage>
        –
        <lpage>
         673
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15520422
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R64">
       <label>
        64.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Rayner
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           MH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Does SARS-CoV-2 has a longer incubation period than SARS and MERS?
        </article-title>
        <source>
         J Med Virol
        </source>
        .
        <year>
         2020
        </year>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         3
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         31502247
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R65">
       <label>
        65.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           EH
          </given-names>
         </name>
         <name>
          <surname>
           Hsiung
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         50
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         20205928
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R66">
       <label>
        66.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan-Yeung
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: epidemiology.
        </article-title>
        <source>
         Respirology
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         8
        </volume>
        (
        <issue>
         suppl
        </issue>
        ):
        <fpage>
         S9
        </fpage>
        –
        <lpage>
         S14
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15018127
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R67">
       <label>
        67.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Rabeeah
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         752
        </fpage>
        –
        <lpage>
         761
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23891402
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R68">
       <label>
        68.
       </label>
       <mixed-citation publication-type="journal">
        <collab>
         Korea Centers for Disease Control and Prevention
        </collab>
        .
        <article-title>
         Middle East respiratory syndrome coronavirus outbreak in the republic of Korea, 2015.
        </article-title>
        <source>
         Osong Public Health Res Perspect
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         269
        </fpage>
        –
        <lpage>
         278
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26473095
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R69">
       <label>
        69.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         386
        </volume>
        :
        <fpage>
         995
        </fpage>
        –
        <lpage>
         1007
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26049252
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R70">
       <label>
        70.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         7
        </fpage>
        –
        <lpage>
         13
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R71">
       <label>
        71.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Virlogeux
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparison of incubation period distribution of human infections with MERS-CoV in South Korea and Saudi Arabia.
        </article-title>
        <source>
         Sci Rep
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         35839
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         27775012
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R72">
       <label>
        72.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           ZM
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Shu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Diagnosis
        </article-title>
        <article-title>
         and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus.
        </article-title>
        <source>
         World J Pediatr
        </source>
        .
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R73">
       <label>
        73.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Martin
          </surname>
          <given-names>
           ET
          </given-names>
         </name>
         <name>
          <surname>
           Fairchok
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <name>
          <surname>
           Stednick
          </surname>
          <given-names>
           ZJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology of multiple respiratory viruses in childcare attendees.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         207
        </volume>
        :
        <fpage>
         982
        </fpage>
        –
        <lpage>
         989
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23288925
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R74">
       <label>
        74.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           RM
          </given-names>
         </name>
         <name>
          <surname>
           Fraser
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Ghani
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, transmission dynamics and control of SARS: the 2002-2003 epidemic.
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         359
        </volume>
        :
        <fpage>
         1091
        </fpage>
        –
        <lpage>
         1105
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15306395
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R75">
       <label>
        75.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         HKU/UCH SARS Study Group
        </collab>
        .
        <article-title>
         Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         361
        </volume>
        :
        <fpage>
         1767
        </fpage>
        –
        <lpage>
         1772
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12781535
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R76">
       <label>
        76.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alfaraj
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Altuwaijri
          </surname>
          <given-names>
           TA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in pediatrics: a report of seven cases from Saudi Arabia.
        </article-title>
        <source>
         Front Med
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         126
        </fpage>
        –
        <lpage>
         130
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29623560
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R77">
       <label>
        77.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel coronavirus infection in hospitalized infants under 1 year of age in China.
        </article-title>
        <source>
         JAMA
        </source>
        .
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R78">
       <label>
        78.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a new human coronavirus.
        </article-title>
        <source>
         Nat Med
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         368
        </fpage>
        –
        <lpage>
         373
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15034574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R79">
       <label>
        79.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Sure
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Ihorst
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Croup is associated with the novel coronavirus NL63.
        </article-title>
        <source>
         PLoS Med
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e240
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16104827
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R80">
       <label>
        80.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pyrc
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel human coronaviruses NL63 and HKU1.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        :
        <fpage>
         3051
        </fpage>
        –
        <lpage>
         3057
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17079323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R81">
       <label>
        81.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Greenberg
          </surname>
          <given-names>
           SB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Update on human rhinovirus and coronavirus infections.
        </article-title>
        <source>
         Semin Respir Crit Care Med
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         555
        </fpage>
        –
        <lpage>
         571
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27486736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R82">
       <label>
        82.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           McIntosh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kapikian
          </surname>
          <given-names>
           AZ
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           HC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Seroepidemiologic studies of coronavirus infection in adults and children.
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        .
        <year>
         1970
        </year>
        ;
        <volume>
         91
        </volume>
        :
        <fpage>
         585
        </fpage>
        –
        <lpage>
         592
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4315625
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R83">
       <label>
        83.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           ME
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of coronavirus in the central nervous system of a child with acute disseminated encephalomyelitis.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         1 pt 1
        </issue>
        ):
        <fpage>
         e73
        </fpage>
        –
        <lpage>
         e76
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14702500
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R84">
       <label>
        84.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         503
        </volume>
        :
        <fpage>
         535
        </fpage>
        –
        <lpage>
         538
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24172901
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R85">
       <label>
        85.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           FW
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           WK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A case-control study of SARS versus community acquired pneumonia.
        </article-title>
        <source>
         Arch Dis Child
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         747
        </fpage>
        –
        <lpage>
         749
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15970619
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R86">
       <label>
        86.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Kwan
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome among children.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         113
        </volume>
        :
        <fpage>
         e535
        </fpage>
        –
        <lpage>
         e543
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15173534
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R87">
       <label>
        87.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Babyn
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           WC
          </given-names>
         </name>
         <name>
          <surname>
           Tsou
          </surname>
          <given-names>
           IY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS): chest radiographic features in children.
        </article-title>
        <source>
         Pediatr Radiol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         47
        </fpage>
        –
        <lpage>
         58
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14624321
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R88">
       <label>
        88.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Yun
          </surname>
          <given-names>
           YX
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           XF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Analysis of CT features of 15 children with 2019 novel coronavirus infection].
        </article-title>
        <source>
         Zhonghua Er Ke Za Zhi
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         E007
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         32061200
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R89">
       <label>
        89.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome (SARS) in neonates and children.
        </article-title>
        <source>
         Arch Dis Child Fetal Neonatal Ed
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         90
        </volume>
        :
        <fpage>
         F461
        </fpage>
        –
        <lpage>
         F465
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16244207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R90">
       <label>
        90.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vabret
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Mouthon
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Mourez
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Direct diagnosis of human respiratory coronaviruses 229E and OC43 by the polymerase chain reaction.
        </article-title>
        <source>
         J Virol Methods
        </source>
        .
        <year>
         2001
        </year>
        ;
        <volume>
         97
        </volume>
        :
        <fpage>
         59
        </fpage>
        –
        <lpage>
         66
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11483217
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R91">
       <label>
        91.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           PK
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           LK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         1699
        </fpage>
        –
        <lpage>
         1700
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15158632
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R92">
       <label>
        92.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chim
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           RW
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic sequencing of the severe acute respiratory syndrome-coronavirus.
        </article-title>
        <source>
         Methods Mol Biol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         336
        </volume>
        :
        <fpage>
         177
        </fpage>
        –
        <lpage>
         194
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16916263
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R93">
       <label>
        93.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chim
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           YK
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomic sequencing of a SARS coronavirus isolate that predated the Metropole Hotel case cluster in Hong Kong.
        </article-title>
        <source>
         Clin Chem
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         50
        </volume>
        :
        <fpage>
         231
        </fpage>
        –
        <lpage>
         233
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14709660
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R94">
       <label>
        94.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           BS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of a Real-Time Reverse Transcription-PCR (RT-PCR) assay for detection of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in clinical samples from an outbreak in South Korea in 2015.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         55
        </volume>
        :
        <fpage>
         2554
        </fpage>
        –
        <lpage>
         2555
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28566313
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R95">
       <label>
        95.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           MN
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Seong
          </surname>
          <given-names>
           MW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Analytical and clinical validation of six commercial Middle East respiratory syndrome coronavirus RNA detection kits based on real-time reverse-transcription PCR.
        </article-title>
        <source>
         Ann Lab Med
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         36
        </volume>
        :
        <fpage>
         450
        </fpage>
        –
        <lpage>
         456
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27374710
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R96">
       <label>
        96.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al Johani
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Hajeer
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV diagnosis: an update.
        </article-title>
        <source>
         J Infect Public Health
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         216
        </fpage>
        –
        <lpage>
         219
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27106390
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R97">
       <label>
        97.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/iris/handle/10665/330893">
          https://apps.who.int/iris/handle/10665/330893
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R98">
       <label>
        98.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jevšnik
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Steyer
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Zrim
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Detection of human coronaviruses in simultaneously collected stool samples and nasopharyngeal swabs from hospitalized children with acute gastroenteritis.
        </article-title>
        <source>
         Virol J
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         46
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         23379823
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R99">
       <label>
        99.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Sci Adv
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         eaao4966
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29152574
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R100">
       <label>
        100.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Serology of severe acute respiratory syndrome: implications for surveillance and outcome.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         189
        </volume>
        :
        <fpage>
         1158
        </fpage>
        –
        <lpage>
         1163
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15031782
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R101">
       <label>
        101.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Heinen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Iturriza-Gómara
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Laboratory diagnosis of SARS.
        </article-title>
        <source>
         Philos Trans R Soc Lond B Biol Sci
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         359
        </volume>
        :
        <fpage>
         1083
        </fpage>
        –
        <lpage>
         1089
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15306394
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R102">
       <label>
        102.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           LQ
          </given-names>
         </name>
         <name>
          <surname>
           Qian
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           RN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         [Serological analysis of SARS coronavirus in children diagnosed clinically as severe acute respiratory syndrome cases during SARS epidemic in Beijing].
        </article-title>
        <source>
         Zhonghua Er Ke Za Zhi
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         262
        </fpage>
        –
        <lpage>
         266
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16780645
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R103">
       <label>
        103.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           VM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         559
        </fpage>
        –
        <lpage>
         564
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R104">
       <label>
        104.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oosterhof
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Christensen
          </surname>
          <given-names>
           CB
          </given-names>
         </name>
         <name>
          <surname>
           Sengeløv
          </surname>
          <given-names>
           H
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fatal lower respiratory tract disease with human corona virus NL63 in an adult haematopoietic cell transplant recipient.
        </article-title>
        <source>
         Bone Marrow Transplant
        </source>
        .
        <year>
         2010
        </year>
        ;
        <volume>
         45
        </volume>
        :
        <fpage>
         1115
        </fpage>
        –
        <lpage>
         1116
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19820731
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R105">
       <label>
        105.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cabeça
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Bellei
          </surname>
          <given-names>
           N
          </given-names>
         </name>
        </person-group>
        <article-title>
         Human coronavirus NL-63 infection in a Brazilian patient suspected of H1N1 2009 influenza infection: description of a fatal case.
        </article-title>
        <source>
         J Clin Virol.
        </source>
        <year>
         2012
        </year>
        ;
        <volume>
         53
        </volume>
        :
        <fpage>
         82
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21978613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R106">
       <label>
        106.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Koopmans
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus emerging in China - key questions for impact assessment.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2020
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         692
        </fpage>
        –
        <lpage>
         694
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         31978293
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R107">
       <label>
        107.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           LQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Case fatality of SARS in mainland China and associated risk factors.
        </article-title>
        <source>
         Trop Med Int Health
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         14
        </volume>
        (
        <issue>
         suppl 1
        </issue>
        ):
        <fpage>
         21
        </fpage>
        –
        <lpage>
         27
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19508439
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R108">
       <label>
        108.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nassar
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Bakhrebah
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Meo
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics.
        </article-title>
        <source>
         Eur Rev Med Pharmacol Sci
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         4956
        </fpage>
        –
        <lpage>
         4961
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30070331
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R109">
       <label>
        109.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Aleanizy
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Mohmed
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Alqahtani
          </surname>
          <given-names>
           FY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Outbreak of Middle East respiratory syndrome coronavirus in Saudi Arabia: a retrospective study.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         23
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         28056850
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R110">
       <label>
        110.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alhamlan
          </surname>
          <given-names>
           FS
          </given-names>
         </name>
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Brownstein
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Case characteristics among Middle East respiratory syndrome coronavirus outbreak and non-outbreak cases in Saudi Arabia from 2012 to 2015.
        </article-title>
        <source>
         BMJ Open
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         e011865
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R111">
       <label>
        111.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         World Health Organization. Disease outbreak news. 24 February 2020. Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/">
          https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R112">
       <label>
        112.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           WB
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: what we learned from the 2015 outbreak in the Republic of Korea.
        </article-title>
        <source>
         Korean J Intern Med
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         33
        </volume>
        :
        <fpage>
         233
        </fpage>
        –
        <lpage>
         246
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29506344
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R113">
       <label>
        113.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         National Health Commission
        </collab>
        <collab>
         of the People’s Republic of China
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqtb/202002/6c305f6d70f545d59548ba17d79b8229.shtml">
          http://www.nhc.gov.cn/xcs/yqtb/202002/6c305f6d70f545d59548ba17d79b8229.shtml
         </ext-link>
         . Accessed February 15 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R114">
       <label>
        114.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention.
        </article-title>
        <source>
         JAMA
        </source>
        .
        <year>
         2020
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R115">
       <label>
        115.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Isaacs
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Flowers
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           JR
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology of coronavirus respiratory infections.
        </article-title>
        <source>
         Arch Dis Child
        </source>
        .
        <year>
         1983
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         500
        </fpage>
        –
        <lpage>
         503
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         6307189
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R116">
       <label>
        116.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Monto
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Tecumseh study of respiratory illness. VI. Frequency of and relationship between outbreaks of coronavirus infection.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         1974
        </year>
        ;
        <volume>
         129
        </volume>
        :
        <fpage>
         271
        </fpage>
        –
        <lpage>
         276
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         4816305
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R117">
       <label>
        117.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Jebbink
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           El Idrissi
          </surname>
          <given-names>
           NB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 and 229E seroconversion in children.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         46
        </volume>
        :
        <fpage>
         2368
        </fpage>
        –
        <lpage>
         2373
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18495857
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R118">
       <label>
        118.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hasony
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Macnaughton
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence of human coronavirus antibody in the population of southern Iraq.
        </article-title>
        <source>
         J Med Virol
        </source>
        .
        <year>
         1982
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         209
        </fpage>
        –
        <lpage>
         216
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         7097257
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R119">
       <label>
        119.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kaye
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Marsh
          </surname>
          <given-names>
           HB
          </given-names>
         </name>
         <name>
          <surname>
           Dowdle
          </surname>
          <given-names>
           WR
          </given-names>
         </name>
        </person-group>
        <article-title>
         Seroepidemiologic survey of coronavirus (strain OC 43) related infections in a children’s population.
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        .
        <year>
         1971
        </year>
        ;
        <volume>
         94
        </volume>
        :
        <fpage>
         43
        </fpage>
        –
        <lpage>
         49
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         5556222
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R120">
       <label>
        120.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           WY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology and clinical presentations of human coronavirus NL63 infections in hong kong children.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         47
        </volume>
        :
        <fpage>
         3486
        </fpage>
        –
        <lpage>
         3492
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19759228
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R121">
       <label>
        121.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           RF
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           ZP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Newly identified respiratory viruses associated with acute lower respiratory tract infections in children in Lanzou, China, from 2006 to 2009.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         18
        </volume>
        :
        <fpage>
         74
        </fpage>
        –
        <lpage>
         80
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         21767329
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R122">
       <label>
        122.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Berkhout
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical manifestations of human coronavirus NL63 infection in children in Taiwan.
        </article-title>
        <source>
         Eur J Pediatr
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         167
        </volume>
        :
        <fpage>
         75
        </fpage>
        –
        <lpage>
         80
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17297612
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R123">
       <label>
        123.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lina
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Valette
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Foray
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Surveillance of community-acquired viral infections due to respiratory viruses in Rhone-Alpes (France) during winter 1994 to 1995.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         1996
        </year>
        ;
        <volume>
         34
        </volume>
        :
        <fpage>
         3007
        </fpage>
        –
        <lpage>
         3011
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         8940439
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R124">
       <label>
        124.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronavirus HKU1 and other coronavirus infections in Hong Kong.
        </article-title>
        <source>
         J Clin Microbiol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         44
        </volume>
        :
        <fpage>
         2063
        </fpage>
        –
        <lpage>
         2071
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16757599
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R125">
       <label>
        125.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Molecular epidemiology of the novel coronavirus that causes severe acute respiratory syndrome.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         99
        </fpage>
        –
        <lpage>
         104
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14726162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R126">
       <label>
        126.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Ho
          </surname>
          <given-names>
           PL
          </given-names>
         </name>
         <name>
          <surname>
           Ooi
          </surname>
          <given-names>
           GC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A cluster of cases of severe acute respiratory syndrome in Hong Kong.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         348
        </volume>
        :
        <fpage>
         1977
        </fpage>
        –
        <lpage>
         1985
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12671062
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R127">
       <label>
        127.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mackay
          </surname>
          <given-names>
           IM
          </given-names>
         </name>
         <name>
          <surname>
           Arden
          </surname>
          <given-names>
           KE
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS coronavirus: diagnostics, epidemiology and transmission.
        </article-title>
        <source>
         Virol J
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         222
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26695637
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R128">
       <label>
        128.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Breban
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Riou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Fontanet
          </surname>
          <given-names>
           A
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         382
        </volume>
        :
        <fpage>
         694
        </fpage>
        –
        <lpage>
         699
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23831141
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R129">
       <label>
        129.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cristallo
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Gambaro
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Biamonti
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus polyadenylated RNA sequences in cerebrospinal fluid from multiple sclerosis patients.
        </article-title>
        <source>
         New Microbiol
        </source>
        .
        <year>
         1997
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         105
        </fpage>
        –
        <lpage>
         114
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9208420
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R130">
       <label>
        130.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dessau
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name>
          <surname>
           Lisby
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Frederiksen
          </surname>
          <given-names>
           JL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses in spinal fluid of patients with acute monosymptomatic optic neuritis.
        </article-title>
        <source>
         Acta Neurol Scand
        </source>
        .
        <year>
         1999
        </year>
        ;
        <volume>
         100
        </volume>
        :
        <fpage>
         88
        </fpage>
        –
        <lpage>
         91
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         10442448
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R131">
       <label>
        131.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shimizu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Shike
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Baker
          </surname>
          <given-names>
           SC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         192
        </volume>
        :
        <fpage>
         1767
        </fpage>
        –
        <lpage>
         1771
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16235175
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R132">
       <label>
        132.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           LY
          </given-names>
         </name>
         <name>
          <surname>
           Chiang
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         Kawasaki Disease Research Group
        </collab>
        .
        <article-title>
         Lack of association between infection with a novel human coronavirus (HCoV), HCoV-NH, and Kawasaki disease in Taiwan.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         193
        </volume>
        :
        <fpage>
         283
        </fpage>
        –
        <lpage>
         286
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16362893
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R133">
       <label>
        133.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           LL
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Initial viral load and the outcomes of SARS.
        </article-title>
        <source>
         CMAJ
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         171
        </volume>
        :
        <fpage>
         1349
        </fpage>
        –
        <lpage>
         1352
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15557587
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R134">
       <label>
        134.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         42
        </volume>
        :
        <fpage>
         1561
        </fpage>
        –
        <lpage>
         1569
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16652313
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R135">
       <label>
        135.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Elden
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           van Loon
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Alphen
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Frequent detection of human coronaviruses in clinical specimens from patients with respiratory tract infection by use of a novel real-time reverse-transcriptase polymerase chain reaction.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         189
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         657
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14767819
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R136">
       <label>
        136.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           HK
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Radiological and pulmonary function outcomes of children with SARS.
        </article-title>
        <source>
         Pediatr Pulmonol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         38
        </volume>
        :
        <fpage>
         427
        </fpage>
        –
        <lpage>
         433
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15514972
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R137">
       <label>
        137.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shek
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Fung
          </surname>
          <given-names>
           GP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infants born to mothers with severe acute respiratory syndrome.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         112
        </volume>
        :
        <fpage>
         e254
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         14523207
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R138">
       <label>
        138.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Chow
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome.
        </article-title>
        <source>
         Am J Obstet Gynecol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         191
        </volume>
        :
        <fpage>
         292
        </fpage>
        –
        <lpage>
         297
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15295381
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R139">
       <label>
        139.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saeed
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Alzahrani
          </surname>
          <given-names>
           AG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Surveillance and testing for Middle East respiratory syndrome coronavirus, Saudi Arabia, April 2015-February 2016.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         682
        </fpage>
        –
        <lpage>
         685
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28322710
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R140">
       <label>
        140.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         469
        </fpage>
        –
        <lpage>
         474
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24460984
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R141">
       <label>
        141.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Payne
          </surname>
          <given-names>
           DC
          </given-names>
         </name>
         <name>
          <surname>
           Iblan
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           Alqasrawi
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         Jordan MERS-CoV Investigation Team
        </collab>
        .
        <article-title>
         Stillbirth during infection with Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         209
        </volume>
        :
        <fpage>
         1870
        </fpage>
        –
        <lpage>
         1872
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24474813
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R142">
       <label>
        142.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alserehi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Wali
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Alshukairi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Impact of Middle East respiratory syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome.
        </article-title>
        <source>
         BMC Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         105
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26936356
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R143">
       <label>
        143.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Malik
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           El Masry
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Ravi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         515
        </fpage>
        –
        <lpage>
         517
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26890613
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R144">
       <label>
        144.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Assiri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Abedi
          </surname>
          <given-names>
           GR
          </given-names>
         </name>
         <name>
          <surname>
           Al Masri
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         63
        </volume>
        :
        <fpage>
         951
        </fpage>
        –
        <lpage>
         953
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27358348
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R145">
       <label>
        145.
       </label>
       <mixed-citation publication-type="other">
        <comment>
         Centers for Disease Control and Prevention CfDCaP. Evaluating and reporting persons under investigation (PUI). 2020. Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html">
          https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html
         </ext-link>
         . Accessed March 5, 2020.
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R146">
       <label>
        146.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         World Health Organization
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)">
          https://www.who.int/publications-detail/global-surveillance-for-human-infection-with-novel-coronavirus-(2019-ncov)
         </ext-link>
         and
         <ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov">
          https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infection-novel-coronavirus-2019-ncov
         </ext-link>
         . Accessed March 5, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R147">
       <label>
        147.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           WJ
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           CQ
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           JX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical Characteristics of Coronavirus Disease 2019 in China.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2020
        </year>
       </mixed-citation>
      </ref>
      <ref id="R148">
       <label>
        148.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.
        </article-title>
        <source>
         The Lancet
        </source>
        .
        <year>
         2020
        </year>
        :
        <fpage>
         1
        </fpage>
        –
        <lpage>
         7
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R149">
       <label>
        149.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           ZA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Makhdoom
          </surname>
          <given-names>
           HQ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         210
        </volume>
        :
        <fpage>
         1590
        </fpage>
        –
        <lpage>
         1594
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24837403
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R150">
       <label>
        150.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           AK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Viral loads in clinical specimens and SARS manifestations.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1550
        </fpage>
        –
        <lpage>
         1557
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15498155
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R151">
       <label>
        151.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Che
          </surname>
          <given-names>
           XY
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           LW
          </given-names>
         </name>
         <name>
          <surname>
           Liao
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         191
        </volume>
        :
        <fpage>
         2033
        </fpage>
        –
        <lpage>
         2037
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15897988
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R152">
       <label>
        152.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           LJ
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects.
        </article-title>
        <source>
         PLoS Med
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         3
        </volume>
        :
        <fpage>
         e343
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R153">
       <label>
        153.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           KK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical management and infection control of SARS: lessons learned.
        </article-title>
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         100
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         419
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23994190
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R154">
       <label>
        154.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           ST
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study.
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         399
        </fpage>
        –
        <lpage>
         406
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14660806
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R155">
       <label>
        155.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VC
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <collab>
         HKU/UCH SARS Study Group
        </collab>
        .
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.
        </article-title>
        <source>
         Thorax
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         59
        </volume>
        :
        <fpage>
         252
        </fpage>
        –
        <lpage>
         256
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R156">
       <label>
        156.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           CW
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inflammatory cytokine profile in children with severe acute respiratory syndrome.
        </article-title>
        <source>
         Pediatrics
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         113
        </volume>
        (
        <issue>
         1 pt 1
        </issue>
        ):
        <fpage>
         e7
        </fpage>
        –
        <lpage>
         e14
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14702488
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R157">
       <label>
        157.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Omrani
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Saad
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Baig
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         1090
        </fpage>
        –
        <lpage>
         1095
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25278221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R158">
       <label>
        158.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Farahat
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Al-Jiffri
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.
        </article-title>
        <source>
         J Antimicrob Chemother
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         70
        </volume>
        :
        <fpage>
         2129
        </fpage>
        –
        <lpage>
         2132
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25900158
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R159">
       <label>
        159.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Momattin
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Dib
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study.
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         42
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24406736
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R160">
       <label>
        160.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
         <name>
          <surname>
           Kao
          </surname>
          <given-names>
           RY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         J Infect
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         67
        </volume>
        :
        <fpage>
         606
        </fpage>
        –
        <lpage>
         616
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24096239
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R161">
       <label>
        161.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        :
        <fpage>
         1904
        </fpage>
        –
        <lpage>
         1913
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R162">
       <label>
        162.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           AlGhamdi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Mushtaq
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Awn
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS CoV infection in two renal transplant recipients: case report.
        </article-title>
        <source>
         Am J Transplant
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         1101
        </fpage>
        –
        <lpage>
         1104
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25716741
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R163">
       <label>
        163.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Centers for Disease Control and Prevention CfDCaP
        </collab>
        .
        <year>
         2020
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html">
          https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
         </ext-link>
         . Accessed February 21, 2010
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R164">
       <label>
        164.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Coronaviruses - drug discovery and therapeutic options.
        </article-title>
        <source>
         Nat Rev Drug Discov
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         327
        </fpage>
        –
        <lpage>
         347
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26868298
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R165">
       <label>
        165.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           YO
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Use of convalescent plasma therapy in SARS patients in Hong Kong.
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         44
        </fpage>
        –
        <lpage>
         46
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15616839
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R166">
       <label>
        166.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zuo
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein.
        </article-title>
        <source>
         Sci Transl Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         234ra59
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R167">
       <label>
        167.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ying
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Ju
          </surname>
          <given-names>
           TW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         7796
        </fpage>
        –
        <lpage>
         7805
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24789777
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R168">
       <label>
        168.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           XC
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothram
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Jiao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         111
        </volume>
        :
        <fpage>
         E2018
        </fpage>
        –
        <lpage>
         E2026
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24778221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R169">
       <label>
        169.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         212
        </volume>
        :
        <fpage>
         1894
        </fpage>
        –
        <lpage>
         1903
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26164863
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R170">
       <label>
        170.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           YO
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients.
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         676
        </fpage>
        –
        <lpage>
         678
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15214887
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R171">
       <label>
        171.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective humoral responses to severe acute respiratory syndrome-associated coronavirus: implications for the design of an effective protein-based vaccine.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         85
        </volume>
        (
        <issue>
         pt 10
        </issue>
        ):
        <fpage>
         3109
        </fpage>
        –
        <lpage>
         3113
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15448374
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R172">
       <label>
        172.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barton
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Kouokam
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Lasnik
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models.
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         120
        </fpage>
        –
        <lpage>
         127
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24145548
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R173">
       <label>
        173.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         426
        </volume>
        :
        <fpage>
         450
        </fpage>
        –
        <lpage>
         454
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R174">
       <label>
        174.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           VS
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         495
        </volume>
        :
        <fpage>
         251
        </fpage>
        –
        <lpage>
         254
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R175">
       <label>
        175.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Milewska
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         89
        </volume>
        :
        <fpage>
         7202
        </fpage>
        –
        <lpage>
         7213
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25926653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R176">
       <label>
        176.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Keyaerts
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Zlateva
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of six new polymorphisms in the human coronavirus 229E receptor gene (aminopeptidase N/CD13).
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         217
        </fpage>
        –
        <lpage>
         222
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15234325
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R177">
       <label>
        177.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Matsuyama
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         87
        </volume>
        :
        <fpage>
         12552
        </fpage>
        –
        <lpage>
         12561
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R178">
       <label>
        178.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Vedantham
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protease inhibitors targeting coronavirus and filovirus entry.
        </article-title>
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         116
        </volume>
        :
        <fpage>
         76
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R179">
       <label>
        179.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kawase
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Shirato
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           van der Hoek
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         86
        </volume>
        :
        <fpage>
         6537
        </fpage>
        –
        <lpage>
         6545
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         22496216
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R180">
       <label>
        180.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Báez-Santos
          </surname>
          <given-names>
           YM
          </given-names>
         </name>
         <name>
          <surname>
           St John
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Mesecar
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
        </article-title>
        <source>
         Antiviral Res
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         115
        </volume>
        :
        <fpage>
         21
        </fpage>
        –
        <lpage>
         38
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25554382
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R181">
       <label>
        181.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ratia
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Pegan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Takayama
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         105
        </volume>
        :
        <fpage>
         16119
        </fpage>
        –
        <lpage>
         16124
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18852458
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R182">
       <label>
        182.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Santarsiero
          </surname>
          <given-names>
           BD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV.
        </article-title>
        <source>
         ACS Chem Biol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         1456
        </fpage>
        –
        <lpage>
         1465
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25746232
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R183">
       <label>
        183.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Savarino
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Di Trani
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Donatelli
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         New insights into the antiviral effects of chloroquine.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         67
        </fpage>
        –
        <lpage>
         69
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16439323
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R184">
       <label>
        184.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.
        </article-title>
        <source>
         Virol J
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         69
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R185">
       <label>
        185.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
        </article-title>
        <source>
         Cell Res
        </source>
        .
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R186">
       <label>
        186.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Warren
          </surname>
          <given-names>
           TK
          </given-names>
         </name>
         <name>
          <surname>
           Wells
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Panchal
          </surname>
          <given-names>
           RG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.
        </article-title>
        <source>
         Nature
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         508
        </volume>
        :
        <fpage>
         402
        </fpage>
        –
        <lpage>
         405
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24590073
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R187">
       <label>
        187.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adedeji
          </surname>
          <given-names>
           AO
          </given-names>
         </name>
         <name>
          <surname>
           Singh
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Kassim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses.
        </article-title>
        <source>
         Antimicrob Agents Chemother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         58
        </volume>
        :
        <fpage>
         4894
        </fpage>
        –
        <lpage>
         4898
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24841268
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R188">
       <label>
        188.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lundin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Bergström
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus.
        </article-title>
        <source>
         PLoS Pathog
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         e1004166
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         24874215
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R189">
       <label>
        189.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rappe
          </surname>
          <given-names>
           JCF
          </given-names>
         </name>
         <name>
          <surname>
           de Wilde
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Di
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Antiviral activity of K22 against members of the order Nidovirales.
        </article-title>
        <source>
         Virus Res
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         246
        </volume>
        :
        <fpage>
         28
        </fpage>
        –
        <lpage>
         34
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29337162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R190">
       <label>
        190.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rider
          </surname>
          <given-names>
           TH
          </given-names>
         </name>
         <name>
          <surname>
           Zook
          </surname>
          <given-names>
           CE
          </given-names>
         </name>
         <name>
          <surname>
           Boettcher
          </surname>
          <given-names>
           TL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broad-spectrum antiviral therapeutics.
        </article-title>
        <source>
         PLoS One
        </source>
        .
        <year>
         2011
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         e22572
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         21818340
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R191">
       <label>
        191.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         5498
        </fpage>
        –
        <lpage>
         5508
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16725238
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R192">
       <label>
        192.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses.
        </article-title>
        <source>
         Trends Microbiol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         490
        </fpage>
        –
        <lpage>
         502
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R193">
       <label>
        193.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           DW
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Variations in spike glycoprotein gene of MERS-CoV, South Korea, 2015.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         100
        </fpage>
        –
        <lpage>
         104
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26691200
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R194">
       <label>
        194.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sohrab
          </surname>
          <given-names>
           SS
          </given-names>
         </name>
         <name>
          <surname>
           Azhar
          </surname>
          <given-names>
           EI
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia.
        </article-title>
        <source>
         J Infect Public Health
        </source>
        .
        <year>
         2019
        </year>
        <comment>
         [Epub ahead of print]
        </comment>
       </mixed-citation>
      </ref>
      <ref id="R195">
       <label>
        195.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Siddiqui
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         325
        </volume>
        :
        <fpage>
         445
        </fpage>
        –
        <lpage>
         452
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15530413
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R196">
       <label>
        196.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hashem
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A highly immunogenic, protective, and safe adenovirus-based vaccine expressing Middle East respiratory syndrome coronavirus S1-CD40L fusion protein in a transgenic human dipeptidyl peptidase 4 mouse model.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         220
        </volume>
        :
        <fpage>
         1558
        </fpage>
        –
        <lpage>
         1567
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         30911758
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R197">
       <label>
        197.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Weingartl
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Czub
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         2273
        </fpage>
        –
        <lpage>
         2279
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15755610
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R198">
       <label>
        198.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         81
        </volume>
        :
        <fpage>
         1701
        </fpage>
        –
        <lpage>
         1713
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17108030
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R199">
       <label>
        199.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         82
        </volume>
        :
        <fpage>
         7721
        </fpage>
        –
        <lpage>
         7724
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18463152
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R200">
       <label>
        200.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dediego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Pewe
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Alvarez
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         376
        </volume>
        :
        <fpage>
         379
        </fpage>
        –
        <lpage>
         389
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18452964
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R201">
       <label>
        201.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           RS
          </given-names>
         </name>
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           AC
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         79
        </volume>
        :
        <fpage>
         14909
        </fpage>
        –
        <lpage>
         14922
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16282490
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R202">
       <label>
        202.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Haan
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <name>
          <surname>
           Masters
          </surname>
          <given-names>
           PS
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2002
        </year>
        ;
        <volume>
         296
        </volume>
        :
        <fpage>
         177
        </fpage>
        –
        <lpage>
         189
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12036329
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R203">
       <label>
        203.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Almazán
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           DeDiego
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Sola
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate.
        </article-title>
        <source>
         mBio
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         4
        </volume>
        :
        <fpage>
         e00650
        </fpage>
        –
        <lpage>
         e00613
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24023385
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R204">
       <label>
        204.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Mitchell
          </surname>
          <given-names>
           HD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis.
        </article-title>
        <source>
         mSphere
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         e00346
        </fpage>
        –
        <lpage>
         e00417
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         29152578
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R205">
       <label>
        205.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           YF
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunogenicity of SARS inactivated vaccine in BALB/c mice.
        </article-title>
        <source>
         Immunol Lett
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         95
        </volume>
        :
        <fpage>
         139
        </fpage>
        –
        <lpage>
         143
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15388253
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R206">
       <label>
        206.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Takasuka
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Fujii
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Takahashi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice.
        </article-title>
        <source>
         Int Immunol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         1423
        </fpage>
        –
        <lpage>
         1430
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15314040
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R207">
       <label>
        207.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Spruth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Kistner
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Savidis-Dacho
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         24
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         661
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16214268
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R208">
       <label>
        208.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         60
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29618723
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R209">
       <label>
        209.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           AS
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Algaissi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus.
        </article-title>
        <source>
         Hum Vaccin Immunother
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         2351
        </fpage>
        –
        <lpage>
         2356
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27269431
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R210">
       <label>
        210.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.
        </article-title>
        <source>
         Antivir Ther
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         12
        </volume>
        :
        <fpage>
         1107
        </fpage>
        –
        <lpage>
         1113
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18018769
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R211">
       <label>
        211.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         23
        </volume>
        :
        <fpage>
         3202
        </fpage>
        –
        <lpage>
         3209
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15837221
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R212">
       <label>
        212.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jaume
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Kam
          </surname>
          <given-names>
           YW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement.
        </article-title>
        <source>
         Hong Kong Med J
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         18
        </volume>
        (
        <issue>
         suppl 2
        </issue>
        ):
        <fpage>
         31
        </fpage>
        –
        <lpage>
         36
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R213">
       <label>
        213.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The spike protein of SARS-CoV–a target for vaccine and therapeutic development.
        </article-title>
        <source>
         Nat Rev Microbiol
        </source>
        .
        <year>
         2009
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         226
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R214">
       <label>
        214.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas.
        </article-title>
        <source>
         Viruses
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         11
        </volume>
        :
        <fpage>
         E212
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         30832356
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R215">
       <label>
        215.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.
        </article-title>
        <source>
         Hum Vaccin Immunother
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         1615
        </fpage>
        –
        <lpage>
         1624
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         28277821
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R216">
       <label>
        216.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection.
        </article-title>
        <source>
         Virology
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         499
        </volume>
        :
        <fpage>
         375
        </fpage>
        –
        <lpage>
         382
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27750111
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R217">
       <label>
        217.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines.
        </article-title>
        <source>
         Vaccine.
        </source>
        <year>
         2014
        </year>
        ;
        <volume>
         32
        </volume>
        :
        <fpage>
         2100
        </fpage>
        –
        <lpage>
         2108
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24560617
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R218">
       <label>
        218.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lan
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge.
        </article-title>
        <source>
         EBioMedicine
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         1438
        </fpage>
        –
        <lpage>
         1446
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26629538
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R219">
       <label>
        219.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jiaming
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Yanfeng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         35
        </volume>
        :
        <fpage>
         10
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         27899228
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R220">
       <label>
        220.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         Cell Mol Immunol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         13
        </volume>
        :
        <fpage>
         180
        </fpage>
        –
        <lpage>
         190
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         25640653
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R221">
       <label>
        221.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           WH
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Chag
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.
        </article-title>
        <source>
         Hum Vaccin Immunother
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         648
        </fpage>
        –
        <lpage>
         658
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         24355931
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R222">
       <label>
        222.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zakhartchouk
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Viswanathan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mahony
          </surname>
          <given-names>
           JB
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         86
        </volume>
        (
        <issue>
         pt 1
        </issue>
        ):
        <fpage>
         211
        </fpage>
        –
        <lpage>
         215
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15604448
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R223">
       <label>
        223.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Soloff
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Effects of a SARS-associated coronavirus vaccine in monkeys.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         362
        </volume>
        :
        <fpage>
         1895
        </fpage>
        –
        <lpage>
         1896
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         14667748
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R224">
       <label>
        224.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           VJ
          </given-names>
         </name>
         <name>
          <surname>
           Wells
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Lambe
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model.
        </article-title>
        <source>
         NPJ Vaccines
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         2
        </volume>
        :
        <fpage>
         28
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         29263883
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R225">
       <label>
        225.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rocha
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Caetano
          </surname>
          <given-names>
           BC
          </given-names>
         </name>
         <name>
          <surname>
           Machado
          </surname>
          <given-names>
           AV
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Recombinant viruses as tools to induce protective cellular immunity against infectious diseases.
        </article-title>
        <source>
         Int Microbiol
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         83
        </fpage>
        –
        <lpage>
         94
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15248156
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R226">
       <label>
        226.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Hill, A
        </collab>
        .
        <year>
         2018
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT03399578">
          https://clinicaltrials.gov/ct2/show/study/NCT03399578
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R227">
       <label>
        227.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           See
          </surname>
          <given-names>
           RH
          </given-names>
         </name>
         <name>
          <surname>
           Zakhartchouk
          </surname>
          <given-names>
           AN
          </given-names>
         </name>
         <name>
          <surname>
           Petric
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         87
        </volume>
        (
        <issue>
         pt 3
        </issue>
        ):
        <fpage>
         641
        </fpage>
        –
        <lpage>
         650
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16476986
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R228">
       <label>
        228.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bisht
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         101
        </volume>
        :
        <fpage>
         6641
        </fpage>
        –
        <lpage>
         6646
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15096611
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R229">
       <label>
        229.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           UJ
          </given-names>
         </name>
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         101
        </volume>
        :
        <fpage>
         9804
        </fpage>
        –
        <lpage>
         9809
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15210961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R230">
       <label>
        230.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bukreyev
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           Buchholz
          </surname>
          <given-names>
           UJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS.
        </article-title>
        <source>
         Lancet
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         363
        </volume>
        :
        <fpage>
         2122
        </fpage>
        –
        <lpage>
         2127
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15220033
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R231">
       <label>
        231.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liniger
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zuniga
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tamin
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses.
        </article-title>
        <source>
         Vaccine
        </source>
        .
        <year>
         2008
        </year>
        ;
        <volume>
         26
        </volume>
        :
        <fpage>
         2164
        </fpage>
        –
        <lpage>
         2174
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         18346823
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R232">
       <label>
        232.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Faber
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Lamirande
          </surname>
          <given-names>
           EW
          </given-names>
         </name>
         <name>
          <surname>
           Roberts
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         2005
        </year>
        ;
        <volume>
         86
        </volume>
        (
        <issue>
         pt 5
        </issue>
        ):
        <fpage>
         1435
        </fpage>
        –
        <lpage>
         1440
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15831955
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R233">
       <label>
        233.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.
        </article-title>
        <source>
         Clin Vaccine Immunol
        </source>
        .
        <year>
         2007
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         990
        </fpage>
        –
        <lpage>
         997
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17596427
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R234">
       <label>
        234.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Joyce
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Evaluation of candidate vaccine approaches for MERS-CoV.
        </article-title>
        <source>
         Nat Commun.
        </source>
        <year>
         2015
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <fpage>
         7712
        </fpage>
        .
        <pub-id pub-id-type="pmid">
         26218507
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R235">
       <label>
        235.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muthumani
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Reuschel
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.
        </article-title>
        <source>
         Sci Transl Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <fpage>
         301ra132
        </fpage>
        .
       </mixed-citation>
      </ref>
      <ref id="R236">
       <label>
        236.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Modjarrad, K
        </collab>
        .
        <year>
         2016
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02670187?term=GLS-5300">
          https://clinicaltrials.gov/ct2/show/NCT02670187?term=GLS-5300
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R237">
       <label>
        237.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Maslow, J
        </collab>
        .
        <year>
         2018
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03721718">
          https://clinicaltrials.gov/ct2/show/NCT03721718
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R238">
       <label>
        238.
       </label>
       <mixed-citation publication-type="other">
        <collab>
         Addo, M
        </collab>
        .
        <year>
         2018
        </year>
        <comment>
         Available at:
         <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures">
          https://clinicaltrials.gov/ct2/show/NCT03615911#outcomemeasures
         </ext-link>
         . Accessed February 22, 2020
        </comment>
        .
       </mixed-citation>
      </ref>
      <ref id="R239">
       <label>
        239.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bin
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Heo
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Environmental contamination and viral shedding in MERS patients during MERS-CoV outbreak in South Korea.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         62
        </volume>
        :
        <fpage>
         755
        </fpage>
        –
        <lpage>
         760
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26679623
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R240">
       <label>
        240.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           So
          </surname>
          <given-names>
           KW
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection control for SARS in a tertiary neonatal centre.
        </article-title>
        <source>
         Arch Dis Child Fetal Neonatal Ed
        </source>
        .
        <year>
         2003
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         F405
        </fpage>
        –
        <lpage>
         F409
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         12937045
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R241">
       <label>
        241.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           TF
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           PC
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           FW
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Infection control for SARS in a tertiary paediatric centre in Hong Kong.
        </article-title>
        <source>
         J Hosp Infect
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         56
        </volume>
        :
        <fpage>
         215
        </fpage>
        –
        <lpage>
         222
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15003670
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R242">
       <label>
        242.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dowell
          </surname>
          <given-names>
           SF
          </given-names>
         </name>
         <name>
          <surname>
           Simmerman
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           DD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus on hospital surfaces.
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        .
        <year>
         2004
        </year>
        ;
        <volume>
         39
        </volume>
        :
        <fpage>
         652
        </fpage>
        –
        <lpage>
         657
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         15356778
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R243">
       <label>
        243.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Donskey
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination.
        </article-title>
        <source>
         J Hosp Infect
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         92
        </volume>
        :
        <fpage>
         235
        </fpage>
        –
        <lpage>
         250
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         26597631
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R244">
       <label>
        244.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Todt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pfaender
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Persistence of coronaviruses on inanimate surfaces and its inactivation with biocidal agents.
        </article-title>
        <source>
         J Hosp Infect
        </source>
        .
        <year>
         2020
        </year>
        <fpage>
         246
        </fpage>
        –
        <lpage>
         251
        </lpage>
        .
        <comment>
         [Epub ahead of print]
        </comment>
        <pub-id pub-id-type="pmid">
         32035997
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R245">
       <label>
        245.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ijaz
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Brunner
          </surname>
          <given-names>
           AH
          </given-names>
         </name>
         <name>
          <surname>
           Sattar
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Survival characteristics of airborne human coronavirus 229E.
        </article-title>
        <source>
         J Gen Virol
        </source>
        .
        <year>
         1985
        </year>
        ;
        <volume>
         66
        </volume>
        (
        <issue>
         pt 12
        </issue>
        ):
        <fpage>
         2743
        </fpage>
        –
        <lpage>
         2748
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         2999318
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R246">
       <label>
        246.
       </label>
       <mixed-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bi
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Mei
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <comment>
         Epidemiology and transmission of COVID-19 in Shenzhen China: analysis of 391 cases and 1,286 of their close contacts. medRxiv 2020. Available at:
        </comment>
        <pub-id pub-id-type="doi">
         10.1101/2020.03.03.20028423
        </pub-id>
        <comment>
         . Accessed March 4, 2020.
        </comment>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="news" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       ACS Cent Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       ACS Cent Sci
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       oc
      </journal-id>
      <journal-id journal-id-type="coden">
       acscii
      </journal-id>
      <journal-title-group>
       <journal-title>
        ACS Central Science
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2374-7943
      </issn>
      <issn pub-type="epub">
       2374-7951
      </issn>
      <publisher>
       <publisher-name>
        American Chemical Society
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32226821
      </article-id>
      <article-id pub-id-type="pmc">
       7094090
      </article-id>
      <article-id pub-id-type="doi">
       10.1021/acscentsci.0c00272
      </article-id>
      <article-categories>
       <subj-group>
        <subject>
         In Focus
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Research and Development on Therapeutic Agents and Vaccines for COVID-19
and Related Human Coronavirus Diseases
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes" id="ath1">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Cynthia
         </given-names>
        </name>
        <xref ref-type="other" rid="cor1">
         *
        </xref>
       </contrib>
       <contrib contrib-type="author" id="ath2">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Qiongqiong
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath3">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Yingzhu
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath4">
        <name>
         <surname>
          Garner
         </surname>
         <given-names>
          Linda V.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath5">
        <name>
         <surname>
          Watkins
         </surname>
         <given-names>
          Steve P.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath6">
        <name>
         <surname>
          Carter
         </surname>
         <given-names>
          Linda J.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath7">
        <name>
         <surname>
          Smoot
         </surname>
         <given-names>
          Jeffrey
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath8">
        <name>
         <surname>
          Gregg
         </surname>
         <given-names>
          Anne C.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath9">
        <name>
         <surname>
          Daniels
         </surname>
         <given-names>
          Angela D.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath10">
        <name>
         <surname>
          Jervey
         </surname>
         <given-names>
          Susan
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" id="ath11">
        <name>
         <surname>
          Albaiu
         </surname>
         <given-names>
          Dana
         </given-names>
        </name>
       </contrib>
       <aff id="AFF-d7e118-autogenerated">
        <institution>
         CAS, a division of the American Chemical Society
        </institution>
        , Columbus, Ohio 43210,
        <country>
         United States
        </country>
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Email:
        <email>
         cliu@cas.org
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        12
       </day>
       <month>
        03
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <day>
        25
       </day>
       <month>
        03
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       6
      </volume>
      <issue>
       3
      </issue>
      <fpage>
       315
      </fpage>
      <lpage>
       331
      </lpage>
      <history>
       <date date-type="received">
        <day>
         06
        </day>
        <month>
         03
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         09
        </day>
        <month>
         03
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         09
        </day>
        <month>
         03
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2020 American
Chemical Society
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        American
Chemical Society
       </copyright-holder>
       <license license-type="open-access">
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted RESEARCH re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         document-id-old-9
        </meta-name>
        <meta-value>
         oc0c00272
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         document-id-new-14
        </meta-name>
        <meta-value>
         oc0c00272
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         ccc-price
        </meta-name>
        <meta-value>
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="sec1">
     <title>
      Background
     </title>
     <p>
      The outbreak of the novel coronavirus disease,
COVID-19, caused by the new coronavirus 2019-nCoV that is now officially
designated as severe acute respiratory syndrome-related coronavirus
SARS-CoV-2, represents a pandemic threat to global public health.
      <sup>
       <xref ref-type="bibr" rid="ref1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="ref2">
        2
       </xref>
      </sup>
      Although the epicenter of the COVID-19 outbreak in December of 2019
was located in Wuhan, China, this disease has spread to more than
100 countries (
      <xref ref-type="fig" rid="fig1">
       Figure
       <xref ref-type="fig" rid="fig1">
        1
       </xref>
      </xref>
      ) with over 100 000 confirmed cases and over 3,800 confirmed
deaths worldwide (
      <xref ref-type="fig" rid="fig2">
       Figure
       <xref ref-type="fig" rid="fig2">
        2
       </xref>
      </xref>
      ) as of March 9, 2020.
      <sup>
       <xref ref-type="bibr" rid="ref3">
        3
       </xref>
      </sup>
      In addition,
millions of people’s lives have been affected as a result of
mandatory isolations/quarantines. The ripple effect of the COVID-19
outbreak could potentially bring major challenges to worldwide health
systems and have far-reaching consequences on the global economy if
the spread of the virus is not effectively controlled.
      <sup>
       <xref ref-type="bibr" rid="ref1">
        1
       </xref>
       ,
       <xref ref-type="bibr" rid="ref2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="ref4">
        4
       </xref>
      </sup>
     </p>
     <fig id="fig1" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <p>
        Global distribution of confirmed COVID-19
cases. (Map was reproduced from WHO Coronavirus Disease (COVID-2019)
Situation Reports.
        <sup>
         <xref ref-type="bibr" rid="ref3">
          3
         </xref>
        </sup>
        Used with permission
from ref (
        <xref ref-type="bibr" rid="ref3">
         3
        </xref>
        ). Copyright
2020 World Health Organization.)
       </p>
      </caption>
      <graphic id="gr1" position="float" xlink:href="oc0c00272_0001" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
     <fig id="fig2" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <p>
        Global trend of confirmed
COVID-19 cases and associated deaths from January 23 through March
9, 2020. (Data were obtained from WHO Coronavirus Disease (COVID-2019)
Situation Reports
        <sup>
         <xref ref-type="bibr" rid="ref3">
          3
         </xref>
        </sup>
        ).
       </p>
      </caption>
      <graphic id="gr2" position="float" xlink:href="oc0c00272_0002" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
     <p>
      Coronaviruses (CoVs) are relatively large viruses containing a single-stranded
positive-sense RNA genome encapsulated within a membrane envelope.
The viral membrane is studded with glycoprotein spikes that give coronaviruses
their crown-like appearance (
      <xref ref-type="fig" rid="fig3">
       Figure
       <xref ref-type="fig" rid="fig3">
        3
       </xref>
      </xref>
      ). While coronaviruses infect both humans and animals,
certain types of animals such as bats that host the largest variety
of coronaviruses appear to be immune to coronavirus-induced illness.
      <sup>
       <xref ref-type="bibr" rid="ref5">
        5
       </xref>
      </sup>
      There are four classes of coronaviruses designated
as alpha, beta, gamma, and delta. The betacoronavirus class includes
severe acute respiratory syndrome (SARS) virus (SARS-CoV), Middle
East respiratory syndrome (MERS) virus (MERS-CoV), and the COVID-19
causative agent SARS-CoV-2. Similar to SARS-CoV and MERS-CoV, SARS-CoV-2
attacks the lower respiratory system to cause viral pneumonia, but
it may also affect the gastrointestinal system, heart, kidney, liver,
and central nervous system leading to multiple organ failure.
      <sup>
       <xref ref-type="bibr" rid="ref6">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="ref7">
        7
       </xref>
      </sup>
      Current information indicates that SARS-CoV-2 is more transmissible/contagious
than SARS-CoV.
      <sup>
       <xref ref-type="bibr" rid="ref8">
        8
       </xref>
      </sup>
     </p>
     <fig id="fig3" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <p>
        Cartoon illustration
of the coronavirus structure and viral receptor ACE2 on the host cell
surface. (Image was reproduced with permission from ref (
        <xref ref-type="bibr" rid="ref9">
         9
        </xref>
        ),
        <ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/nrmicro2090" xmlns:xlink="http://www.w3.org/1999/xlink">
         Nature Reviews
Microbiology 7(3), 226–236
        </ext-link>
        . Copyright 2009 Springer
Nature.)
       </p>
      </caption>
      <graphic id="gr3" position="float" xlink:href="oc0c00272_0003" xmlns:xlink="http://www.w3.org/1999/xlink">
      </graphic>
     </fig>
     <p>
      The betacoronavirus genome encodes
several structural proteins, including the glycosylated spike (S)
protein that functions as a major inducer of host immune responses.
This S protein mediates host cell invasion by both SARS-CoV and SARS-CoV-2
via binding to a receptor protein called angiotensin-converting enzyme
2 (ACE2) located on the surface membrane of host cells.
      <sup>
       <xref ref-type="bibr" rid="ref9">
        9
       </xref>
       −
       <xref ref-type="bibr" rid="ref11">
        11
       </xref>
      </sup>
      A recent study also revealed that this invasion process requires S
protein priming which is facilitated by the host cell-produced serine
protease TMPRSS211. In addition, the viral genome also encodes several
nonstructural proteins including RNA-dependent RNA polymerase (RdRp),
coronavirus main protease (3CLpro), and papain-like protease (PLpro).
      <sup>
       <xref ref-type="bibr" rid="ref12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="ref13">
        13
       </xref>
      </sup>
      Upon entrance to the host cells, the viral genome is released as
a single-stranded positive RNA. Subsequently, it is translated into
viral polyproteins using host cell protein translation machinery,
which are then cleaved into effector proteins by viral proteinases
3CLpro and PLpro.
      <sup>
       <xref ref-type="bibr" rid="ref12">
        12
       </xref>
       ,
       <xref ref-type="bibr" rid="ref13">
        13
       </xref>
      </sup>
      PLpro also behaves as a deubiquitinase
that may deubiquinate certain host cell proteins, including interferon
factor 3 and NF-κB, resulting in immune suppression.
      <sup>
       <xref ref-type="bibr" rid="ref13">
        13
       </xref>
       ,
       <xref ref-type="bibr" rid="ref14">
        14
       </xref>
      </sup>
      RdRp synthesizes a full-length negative-strand RNA template to be
used by RdRp to make more viral genomic RNA.
     </p>
     <p>
      The interaction
between viral S protein and ACE2 on the host cell surface is of significant
interest since it initiates the infection process. Cryo-EM structure
analysis has revealed that the binding affinity of SARS-CoV-2 S protein
to ACE2 is about 10–20 times higher than that of SARS-CoV S
protein.
      <sup>
       <xref ref-type="bibr" rid="ref10">
        10
       </xref>
       ,
       <xref ref-type="bibr" rid="ref15">
        15
       </xref>
      </sup>
      It is speculated that this may contribute
to the reported higher transmissibility and contagiousness of SARS-CoV-2
as compared to SARS-CoV.
      <sup>
       <xref ref-type="bibr" rid="ref8">
        8
       </xref>
      </sup>
     </p>
     <p>
      The prospect
also exists for discovery of therapeutic agents targeting the highly
conserved proteins associated with both SARS-CoV and SARS-CoV-2.
      <sup>
       <xref ref-type="bibr" rid="ref15">
        15
       </xref>
       −
       <xref ref-type="bibr" rid="ref18">
        18
       </xref>
      </sup>
      RdRp and 3CLpro protease of SARS-CoV-2 share over 95% of sequence
similarity with those of SARS-CoV despite the fact that these two
viruses demonstrate only 79% sequence similarity at the genome level.
      <sup>
       <xref ref-type="bibr" rid="ref15">
        15
       </xref>
       −
       <xref ref-type="bibr" rid="ref18">
        18
       </xref>
      </sup>
      On the basis of sequence alignment and homology modeling, SARS-CoV
and SARS-CoV-2 share a highly conserved receptor-binding domain (RBD),
a domain of S protein, and 76% of sequence similarity in their S proteins.
      <sup>
       <xref ref-type="bibr" rid="ref15">
        15
       </xref>
       −
       <xref ref-type="bibr" rid="ref18">
        18
       </xref>
      </sup>
      In addition, although the PLpro sequences of SARS-CoV-2 and SARS-CoV
are only 83% similar, they share similar active sites.
      <sup>
       <xref ref-type="bibr" rid="ref16">
        16
       </xref>
      </sup>
     </p>
     <p>
      To date, there are no SARS-CoV-2-specific
antiviral agents. Researchers have been racing to find possible treatments
to save lives and produce vaccines for future prevention. To support
research and development efforts to discover effective therapeutic
and preventive agents for COVID-19, CAS, a division of the American
Chemical Society specializing in scientific information solutions,
has analyzed scientific data related to the development of therapeutic
agents and vaccines for human coronaviruses since 2003. The analyses
presented in this report are based on the CAS content collection,
a scientist-curated data collection covering published scientific
literature and patents from over 60 patent authorities worldwide.
For a subset of the analyses, both CAS and MEDLINE data were collectively
analyzed.
     </p>
    </sec>
    <sec id="sec2">
     <title>
      Scientific Literature and Patents Related to COVID-19, SARS,
and MERS
     </title>
     <sec id="sec2.1">
      <title>
       Trend in Scientific Publications Related to COVID-19
      </title>
      <p>
       Since the outbreak of COVID-19, this new disease and its causative
virus have drawn major global attention. Scientists and physicians
worldwide have been conducting a major campaign to understand this
new emergent disease and its epidemiology in an effort to uncover
possible treatment regimens, discover effective therapeutic agents,
and develop vaccines.
       <xref ref-type="fig" rid="fig4">
        Figure
        <xref ref-type="fig" rid="fig4">
         4
        </xref>
       </xref>
       shows the total number of journal articles related to COVID-19
or SARS-CoV-2 published each week from the last week of 2019 through
the week of February 24, 2020. Over 500 journal articles were published
electronically or in print during this period, and the number of published
articles has increased each week since the week of January 13, 2020.
Although a large portion of these articles are about clinical manifestations
and treatment options, an increasing number of studies are focused
on elucidation of virus structure, virus transmission mechanisms/dynamics,
as well as identification of antiviral agents and accurate diagnostics
for virus detection. These trends reflect immense interest and desire
from the scientific community, including both academic and industrial
organizations as well as clinicians, to identify new methods to halt
the progression of this epidemic disease and to prevent infection
and transmission in the future.
      </p>
      <fig id="fig4" position="float">
       <label>
        Figure 4
       </label>
       <caption>
        <p>
         Number of journal articles related to
COVID-19 published each week.
        </p>
       </caption>
       <graphic id="gr4" position="float" xlink:href="oc0c00272_0004" xmlns:xlink="http://www.w3.org/1999/xlink">
       </graphic>
      </fig>
     </sec>
     <sec id="sec2.2">
      <title>
       Notable Journal Articles Related to COVID-19 and SARS-CoV-2
      </title>
      <p>
       <xref ref-type="other" rid="tbl1">
        Table
        <xref ref-type="other" rid="tbl1">
         1
        </xref>
       </xref>
       lists some
journal articles published from December 30, 2019 through February 23,
2020. These articles were selected based on collective use of factors
such as journal impact factor, citation, and type of study. For example,
the No. 8 article listed about the characterization of the SARS-CoV-2
genome has greatly facilitated the global effort to develop a vaccine
for prevention of COVID-19. Also shown in this table are journal articles
pertaining to potential antiviral drug candidates such as remdesivir, baricitinib, and chloroquine for the treatment of this disease.
      </p>
      <table-wrap id="tbl1" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Notable Journal Articles on COVID-19
and/or SARS-CoV-2 Published as of February 23, 2020
         <xref ref-type="table-fn" rid="t1fn1">
          a
         </xref>
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           no.
          </th>
          <th align="center" style="border:none;">
           journal
          </th>
          <th align="center" style="border:none;">
           paper title
          </th>
          <th align="center" style="border:none;">
           publication date
          </th>
          <th align="center" style="border:none;">
           organization
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           1
          </td>
          <td align="left" style="border:none;">
           The New England Journal of Medicine
          </td>
          <td align="left" style="border:none;">
           A novel coronavirus from patients with pneumonia in China,
2019
          </td>
          <td align="left" style="border:none;">
           January 24, 2020
          </td>
          <td align="left" style="border:none;">
           NHC Key Laboratory
of Biosafety, China, and National Institute for Viral Disease Control,
Chinese Center for Disease Control and Prevention, Beijing, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           2
          </td>
          <td align="left" style="border:none;">
           Lancet
          </td>
          <td align="left" style="border:none;">
           Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China
          </td>
          <td align="left" style="border:none;">
           January 24, 2020
          </td>
          <td align="left" style="border:none;">
           Department of Pulmonary and Critical
Care Medicine, China-Japan Friendship Hospital, Beijing, China; NHC
Key Laboratory of Systems Biology of Pathogens and Christophe Merieux
Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical
Sciences and Peking Union Medical College, Beijing, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           3
          </td>
          <td align="left" style="border:none;">
           The New England Journal of Medicine
          </td>
          <td align="left" style="border:none;">
           Early transmission dynamics in Wuhan, China, of novel coronavirus-infected
pneumonia
          </td>
          <td align="left" style="border:none;">
           January 29, 2020
          </td>
          <td align="left" style="border:none;">
           Chinese Center
for Disease Control and Prevention, Beijing, China; School of Public
Health, University of Hong Kong, Hong Kong; Hubei Center for Disease
Control and Prevention, Wuhan, Hubei, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           5
          </td>
          <td align="left" style="border:none;">
           Journal of Virology
          </td>
          <td align="left" style="border:none;">
           Receptor recognition by novel
coronavirus from Wuhan: An analysis based on decade-long structural
studies of SARS
          </td>
          <td align="left" style="border:none;">
           January 29, 2020
          </td>
          <td align="left" style="border:none;">
           Department
of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           6
          </td>
          <td align="left" style="border:none;">
           Lancet
          </td>
          <td align="left" style="border:none;">
           Epidemiological
and clinical characteristics of 99 cases of 2019 novel coronavirus
pneumonia in Wuhan, China: a descriptive study
          </td>
          <td align="left" style="border:none;">
           January
30, 2020
          </td>
          <td align="left" style="border:none;">
           Tuberculosis and Respiratory Department, Wuhan
Jinyintan Hospital, Wuhan, China
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           7
          </td>
          <td align="left" style="border:none;">
           The New England Journal of Medicine
          </td>
          <td align="left" style="border:none;">
           First case
of 2019 novel coronavirus in the United States
          </td>
          <td align="left" style="border:none;">
           January
31, 2020
          </td>
          <td align="left" style="border:none;">
           The Washington State Department of Health Public
Health Laboratories, WA, USA
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           8
          </td>
          <td align="left" style="border:none;">
           Lancet
          </td>
          <td align="left" style="border:none;">
           Genomic characterisation and epidemiology of 2019 novel coronavirus:
implications for virus origins and receptor binding
          </td>
          <td align="left" style="border:none;">
           January 30, 2020
          </td>
          <td align="left" style="border:none;">
           NHC Key Laboratory of Biosafety, National
Institute for Viral Disease Control and Prevention, Chinese Center
for Disease Control and Prevention, Beijing, China, Central Theater,
People’s Liberation Army General Hospital, Wuhan, China, Center
for Biosafety Mega-Science, Chinese Academy of Sciences, Beijing, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           9
          </td>
          <td align="left" style="border:none;">
           Lancet
          </td>
          <td align="left" style="border:none;">
           Nowcasting and forecasting
the potential domestic and international spread of the 2019-nCoV outbreak
originating in Wuhan, China: a modelling study
          </td>
          <td align="left" style="border:none;">
           January
31, 2020
          </td>
          <td align="left" style="border:none;">
           School of Public Health, Li Ka Shing Faculty
of Medicine, University of Hong Kong, Hong Kong, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           10
          </td>
          <td align="left" style="border:none;">
           Nature
          </td>
          <td align="left" style="border:none;">
           A new coronavirus associated with human
respiratory disease in China
          </td>
          <td align="left" style="border:none;">
           February 3, 2020
          </td>
          <td align="left" style="border:none;">
           Shanghai Public Health Clinical Center &amp; School of Public
Health, Fudan University, Shanghai, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           11
          </td>
          <td align="left" style="border:none;">
           Nature
          </td>
          <td align="left" style="border:none;">
           A pneumonia outbreak associated with a
new coronavirus of probable bat origin
          </td>
          <td align="left" style="border:none;">
           February 3, 2020
          </td>
          <td align="left" style="border:none;">
           Key Laboratory of Special Pathogens, Wuhan Institute of Virology,
Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           12
          </td>
          <td align="left" style="border:none;">
           Lancet
          </td>
          <td align="left" style="border:none;">
           Baricitinib as potential
treatment for 2019-nCoV acute respiratory disease
          </td>
          <td align="left" style="border:none;">
           February
4, 2020
          </td>
          <td align="left" style="border:none;">
           BenevolentAI, London, UK and Department of Surgery
and Cancer, Imperial College London, UK
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           13
          </td>
          <td align="left" style="border:none;">
           Cell Research
          </td>
          <td align="left" style="border:none;">
           Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
          </td>
          <td align="left" style="border:none;">
           February 4, 2020
          </td>
          <td align="left" style="border:none;">
           State Key Laboratory of Virology,
Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese
Academy of Sciences, Wuhan, China, and National Engineering Research
Center for the Emergency Drug, Beijing Institute of Pharmacology and
Toxicology, Beijing, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           14
          </td>
          <td align="left" style="border:none;">
           Emerging Microbes &amp; Infections
          </td>
          <td align="left" style="border:none;">
           RNA based
mNGS approach identifies a novel human coronavirus from two individual
pneumonia cases in 2019 Wuhan outbreak
          </td>
          <td align="left" style="border:none;">
           February 5, 2020
          </td>
          <td align="left" style="border:none;">
           State Key Laboratory of Virology, Modern Virology Research
Center, College of Life Sciences, Wuhan University, Wuhan, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           15
          </td>
          <td align="left" style="border:none;">
           The Journal of the American Medical Association
          </td>
          <td align="left" style="border:none;">
           Clinical characteristics of 138 hospitalized patients with
2019 novel coronavirus-infected pneumonia in Wuhan, China
          </td>
          <td align="left" style="border:none;">
           February 7, 2020
          </td>
          <td align="left" style="border:none;">
           Department of Critical Care Medicine,
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           16
          </td>
          <td align="left" style="border:none;">
           Cell Host &amp; Microbe
          </td>
          <td align="left" style="border:none;">
           Genome composition and divergence of the novel
coronavirus (2019-nCoV) originating in China
          </td>
          <td align="left" style="border:none;">
           February
7, 2020
          </td>
          <td align="left" style="border:none;">
           National Institute for Viral Disease Control
and Prevention, China CDC, Beijing, China; Department of Microbiology,
Immunology and Molecular Genetics, University of California, Los Angeles,
USA; Center for Systems Medicine, Institute of Basic Medical Sciences
&amp; Peking Union Medical College, Beijing, China
           <xref ref-type="table-fn" rid="t1fn2">
            b
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           17
          </td>
          <td align="left" style="border:none;">
           Cellular &amp; Molecular Immunology
          </td>
          <td align="left" style="border:none;">
           Fusion mechanism of 2019-nCoV and fusion inhibitors targeting
HR1 domain in spike protein
          </td>
          <td align="left" style="border:none;">
           February 11, 2020
          </td>
          <td align="left" style="border:none;">
           Key Laboratory of Medical Molecular Virology, School of Basic
Medical Sciences, Fudan-Jinbo Joint Research Center, Fudan University,
Shanghai, China
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="t1fn1">
         <label>
          a
         </label>
         <p>
          Note: The publication date is the
date for electronic publication.
         </p>
        </fn>
        <fn id="t1fn2">
         <label>
          b
         </label>
         <p>
          Only corresponding organization(s) is/are listed for papers published
by multiple organizations.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec id="sec2.3">
      <title>
       Distribution
of patents related to SARS and MERS
      </title>
      <p>
       As mentioned earlier,
COVID-19 is caused by SARS-CoV-2, a new type of coronavirus in the
same genus as SARS-CoV and MERS-CoV. Viral proteins responsible for
SARS-CoV-2 entry into host cells and replication are structurally
similar to those associated with SARS-CoV. Thus, research and development
on SARS and MERS may offer insights that would be beneficial to the
development of therapeutic and preventive agents for COVID-19. This
report identified pertinent data from patents related to these two
coronaviruses.
       <xref ref-type="fig" rid="fig5">
        Figure
        <xref ref-type="fig" rid="fig5">
         5
        </xref>
       </xref>
       shows the distribution of patents in the CAS content collection
related to SARS (A) and MERS (B). The number of patents related to
SARS is almost 12 times the number related to MERS, probably because
the SARS outbreak occurred about 10 years before the MERS outbreak.
Among SARS patents, about 80% are related to the development of therapeutics,
35% are related to vaccines, and 28% are related to diagnostic agents
or methods. Because an individual patent may cover any two or more
areas, the sum of percentage values is greater than 100%. A similar
distribution pattern was also observed for patents related to MERS.
Thus, for both diseases, more patents have been devoted to the development
of therapeutic agents as opposed to diagnostic methods and vaccines.
      </p>
      <fig id="fig5" position="float">
       <label>
        Figure 5
       </label>
       <caption>
        <p>
         Distribution
of patents related to SARS (A) and MERS (B) based on application purpose.
        </p>
       </caption>
       <graphic id="gr5" position="float" xlink:href="oc0c00272_0005" xmlns:xlink="http://www.w3.org/1999/xlink">
       </graphic>
      </fig>
     </sec>
    </sec>
    <sec id="sec3">
     <title>
      RESEARCH AND DEVELOPMENT IN SMALL MOLECULE
ANTIVIRAL AGENTS FOR COVID-19 AND RELATED CORONAVIRUS DISEASES
     </title>
     <sec id="sec3.1">
      <title>
       Key Proteins
and Their Roles in Viral Infection
      </title>
      <p>
       Identification of targets
is important for identifying drugs with high target specificity and/or
uncovering existing drugs that could be repurposed to treat SARS-CoV-2
infection.
       <xref ref-type="other" rid="tbl2">
        Table
        <xref ref-type="other" rid="tbl2">
         2
        </xref>
       </xref>
       lists
potential targets, their roles in viral infection, and representative
existing drugs or drug candidates that reportedly act on the corresponding
targets in similar viruses and thus are to be assessed for their effects
on SARS-CoV-2 infection. 3CLpro and PLpro are two viral proteases
responsible for the cleavage of viral peptides into functional units
for virus replication and packaging within the host cells. Thus, drugs
that target these proteases in other viruses such as HIV drugs, lopinavir
and ritonavir, have been explored.
       <sup>
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
       </sup>
       RdRp
is the RNA polymerase responsible for viral RNA synthesis that may
be blocked by existing antiviral drugs or drug candidates, such as
remdesivir.
       <sup>
        <xref ref-type="bibr" rid="ref19">
         19
        </xref>
       </sup>
       Conceivably, the interaction
of viral S protein with its receptor ACE2 on host cells, and subsequent
viral endocytosis into the cells, may also be a viable drug target.
For example, the broad-spectrum antiviral drug Arbidol, which functions
as a virus-host cell fusion inhibitor to prevent viral entry into
host cells against influenza virus,
       <sup>
        <xref ref-type="bibr" rid="ref20">
         20
        </xref>
       </sup>
       has
entered into a clinical trial for treatment of SARS-CoV-2.
       <sup>
        <xref ref-type="bibr" rid="ref21">
         21
        </xref>
        ,
        <xref ref-type="bibr" rid="ref22">
         22
        </xref>
       </sup>
       The protease TMPRSS2 produced by the host cells plays an important
role in proteolytic processing of S protein priming to the receptor
ACE2 binding in human cells.
       <sup>
        <xref ref-type="bibr" rid="ref11">
         11
        </xref>
       </sup>
       It has been
shown that camostat mesylate, a clinically approved TMPRSS2 inhibitor,
was able to block SARS-CoV-2 entry to human cells, indicating its
potential as a drug for COVID-19.
       <sup>
        <xref ref-type="bibr" rid="ref11">
         11
        </xref>
       </sup>
      </p>
      <table-wrap id="tbl2" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <title>
         Key Proteins and Their Roles during the Viral Infection
Process
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           target candidate
          </th>
          <th align="center" style="border:none;">
           full name
          </th>
          <th align="center" style="border:none;">
           role during viral infection
          </th>
          <th align="center" style="border:none;">
           drug candidate
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           3CLpro
          </td>
          <td align="left" style="border:none;">
           coronavirus main protease 3CLpro
          </td>
          <td align="left" style="border:none;">
           a protease for the proteolysis of viral polyprotein into functional
units
          </td>
          <td align="left" style="border:none;">
           lopinavir
           <sup>
            <xref ref-type="bibr" rid="ref19">
             19
            </xref>
            ,
            <xref ref-type="bibr" rid="ref30">
             30
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           PLpro
          </td>
          <td align="left" style="border:none;">
           papain-like
protease PLpro
          </td>
          <td align="left" style="border:none;">
           a protease for the proteolysis of viral
polyprotein into functional units
          </td>
          <td align="left" style="border:none;">
           lopinavir
           <sup>
            <xref ref-type="bibr" rid="ref19">
             19
            </xref>
            ,
            <xref ref-type="bibr" rid="ref30">
             30
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           RdRp
          </td>
          <td align="left" style="border:none;">
           RNA-dependent
RNA polymerase
          </td>
          <td align="left" style="border:none;">
           an RNA-dependent RNA polymerase for replicating
viral genome
          </td>
          <td align="left" style="border:none;">
           remdesivir,
           <sup>
            <xref ref-type="bibr" rid="ref19">
             19
            </xref>
            ,
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
            ,
            <xref ref-type="bibr" rid="ref32">
             32
            </xref>
           </sup>
           ribavirin
           <sup>
            <xref ref-type="bibr" rid="ref16">
             16
            </xref>
            ,
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
            ,
            <xref ref-type="bibr" rid="ref31">
             31
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           S protein
          </td>
          <td align="left" style="border:none;">
           viral spike
glycoprotein
          </td>
          <td align="left" style="border:none;">
           a viral surface protein for binding to
host cell receptor ACE2
          </td>
          <td align="left" style="border:none;">
           Arbidol
           <sup>
            <xref ref-type="bibr" rid="ref20">
             20
            </xref>
            ,
            <xref ref-type="bibr" rid="ref22">
             22
            </xref>
            ,
            <xref ref-type="bibr" rid="ref33">
             33
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t2fn1">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           TMPRSS2
          </td>
          <td align="left" style="border:none;">
           transmembrane protease, serine 2
          </td>
          <td align="left" style="border:none;">
           a host cell-produced protease that primes S protein to facilitate its binding to ACE2
          </td>
          <td align="left" style="border:none;">
           camostat mesylate
           <sup>
            <xref ref-type="bibr" rid="ref11">
             11
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           ACE2
          </td>
          <td align="left" style="border:none;">
           angiotensin-converting enzyme 2
          </td>
          <td align="left" style="border:none;">
           a viral receptor protein on
the host cells which binds to viral S protein
          </td>
          <td align="left" style="border:none;">
           Arbidol
           <sup>
            <xref ref-type="bibr" rid="ref20">
             20
            </xref>
            ,
            <xref ref-type="bibr" rid="ref22">
             22
            </xref>
            ,
            <xref ref-type="bibr" rid="ref33">
             33
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t2fn1">
            a
           </xref>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           AT2
          </td>
          <td align="left" style="border:none;">
           angiotensin AT2 receptor
          </td>
          <td align="left" style="border:none;">
           an important effector involved in the regulation of blood pressure
and volume of the cardiovascular system
          </td>
          <td align="left" style="border:none;">
           L-163491
           <sup>
            <xref ref-type="bibr" rid="ref28">
             28
            </xref>
           </sup>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="t2fn1">
         <label>
          a
         </label>
         <p>
          An inhibitor of viral entry to host cells. Its direct action on S protein and ACE2 is yet to be confirmed.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <p>
       ACE2 involvement with coronavirus infection is of further interest
since ACE2 is a potent negative regulator restraining overactivation
of the renin-angiotensin system (RAS) that may be involved in elicitation
of inflammatory lung disease in addition to its well-known role in
regulation of blood pressure and balance of body fluid and electrolytes.
       <sup>
        <xref ref-type="bibr" rid="ref23">
         23
        </xref>
        ,
        <xref ref-type="bibr" rid="ref24">
         24
        </xref>
       </sup>
       It catalyzes degradation of angiotensin II to angiotensin (1–7).
The balance between angiotensin II and angiotensin (1–7) is
critical since angiotensin II binds to angiotensin AT1 receptor to
cause vasoconstriction, whereas angiotensin (1–7) elicits vasodilation
mediated by AT2.
       <sup>
        <xref ref-type="bibr" rid="ref25">
         25
        </xref>
        −
        <xref ref-type="bibr" rid="ref27">
         27
        </xref>
       </sup>
       Although the notion that ACE2 mediates coronavirus
invasion is largely accepted, it remains unclear how the levels or
activities of ACE2, AT1 receptors, and AT2 receptors are altered in
coronavirus-induced diseases due to the limited number of studies.
       <sup>
        <xref ref-type="bibr" rid="ref23">
         23
        </xref>
        ,
        <xref ref-type="bibr" rid="ref24">
         24
        </xref>
       </sup>
       Therefore, it is yet to be determined whether some drugs or compounds
that target any of these proteins (e.g., L-163491 as a partial antagonist
of AT1 receptor and partial agonist of AT2 receptor) may alleviate
coronavirus-induced lung injury.
       <sup>
        <xref ref-type="bibr" rid="ref28">
         28
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="sec3.2">
      <title>
       Patents and Potential Drug
Candidates Related to Key Protein Targets
      </title>
      <p>
       The CAS content
collection contains patents related to coronavirus key proteins listed
above.
       <xref ref-type="other" rid="tbl3">
        Table
        <xref ref-type="other" rid="tbl3">
         3
        </xref>
       </xref>
       lists
the number of patents related to each protein target and associated
therapeutic compounds with a CAS Registry Number (CAS RN) reported
in these patents. CAS data show that targets 3CLpro and RdRp attracted
more attention than other targets, and more compounds with therapeutic
potential were identified for these targets, probably due to the work
done for SARS-CoV which also contains 3CLpro and RdRp.
      </p>
      <table-wrap id="tbl3" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <title>
         Key Protein Targets and Related Patents in the CAS Content Collection
and Potential Drug Candidates in CAS REGISTRY of Chemical Substances
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="char" char="."/>
         <col align="char" char="."/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           target
          </th>
          <th align="center" char="." style="border:none;">
           no. of patents
          </th>
          <th align="center" char="." style="border:none;">
           no. of
potential drug candidates
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           3CLpro
          </td>
          <td align="char" char="." style="border:none;">
           49
          </td>
          <td align="char" char="." style="border:none;">
           2178
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           PLpro
          </td>
          <td align="char" char="." style="border:none;">
           4
          </td>
          <td align="char" char="." style="border:none;">
           189
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           RdRp
          </td>
          <td align="char" char="." style="border:none;">
           26
          </td>
          <td align="char" char="." style="border:none;">
           570
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           S protein
          </td>
          <td align="char" char="." style="border:none;">
           46
          </td>
          <td align="char" char="." style="border:none;">
           333
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           ACE2
          </td>
          <td align="char" char="." style="border:none;">
           5
          </td>
          <td align="char" char="." style="border:none;">
           97
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           AT2
          </td>
          <td align="char" char="." style="border:none;">
           2
          </td>
          <td align="char" char="." style="border:none;">
           38
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <sec id="sec3.3">
      <title>
       Existing Drugs with Potential
Therapeutic Applications for COVID-19
      </title>
      <p>
       Since SARS-CoV-2 is
a newly discovered pathogen, no specific drugs have been identified
or are currently available. An economic and efficient therapeutic
strategy is to repurpose existing drugs. On the basis of genomic sequence
information coupled with protein structure modeling, the scientific
community has been able to rapidly respond with a suggested list of
existing drugs with therapeutic potential for COVID-19.
       <xref ref-type="other" rid="tbl4">
        Table
        <xref ref-type="other" rid="tbl4">
         4
        </xref>
       </xref>
       provides a summary of such
drugs together with potential mechanisms of actions for their activities.
Barcitinib was proposed because of its anti-inflammatory effect and
possible ability to reduce viral entry.
       <sup>
        <xref ref-type="bibr" rid="ref35">
         35
        </xref>
       </sup>
       A fixed dose of the anti-HIV combination, lopinavir–ritonavir,
is currently in clinical trials with Arbidol or ribavirin.
       <sup>
        <xref ref-type="bibr" rid="ref22">
         22
        </xref>
       </sup>
       Remdesivir, developed by Gilead Sciences Inc.,
was previously tested in humans with Ebola virus disease and has shown
promise in animal models for MERS and SARS.
       <ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/news-events/remdesivir-prevents-mers-coronavirus-disease-monkeys" xmlns:xlink="http://www.w3.org/1999/xlink">
        The drug is currently being studied in phase III clinical trials
in both China and the USA
       </ext-link>
       . Favipiravir, a purine nucleoside
leading to inaccurate viral RNA synthesis,
       <sup>
        <xref ref-type="bibr" rid="ref36">
         36
        </xref>
       </sup>
       was originally developed by Toyama Chemical of Japan, and has recently
been approved for a clinical trial as a drug to treat COVID-19.
       <sup>
        <xref ref-type="bibr" rid="ref30">
         30
        </xref>
       </sup>
       Chloroquine, an antimalarial drug, has proven
effective in treating coronavirus in China.
       <sup>
        <xref ref-type="bibr" rid="ref32">
         32
        </xref>
       </sup>
       In addition to the above-mentioned, many other antiviral drugs are
also listed.
      </p>
      <table-wrap id="tbl4" position="float">
       <label>
        Table 4
       </label>
       <caption>
        <title>
         Existing Drugs with Therapeutic Potentials
for COVID-19 (Drug Repurposing)
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           drug candidate
          </th>
          <th align="center" style="border:none;">
           CAS RN
          </th>
          <th align="center" style="border:none;">
           target
          </th>
          <th align="center" style="border:none;">
           possible mechanism of action on COVID-19
          </th>
          <th align="center" style="border:none;">
           disease indication
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           baricitinib
           <sup>
            <xref ref-type="bibr" rid="ref35">
             35
            </xref>
           </sup>
          </td>
          <td align="left" style="border:none;">
           1187594-09-7
          </td>
          <td align="left" style="border:none;">
           JAK kinase
          </td>
          <td align="left" style="border:none;">
           a JAK inhibitor that may
interfere with the inflammatory processes
          </td>
          <td align="left" style="border:none;">
           approved drug
for rheumatoid arthritis
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           lopinavir
           <sup>
            <xref ref-type="bibr" rid="ref19">
             19
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn2">
            a
           </xref>
          </td>
          <td align="left" style="border:none;">
           192725-17-0
          </td>
          <td align="left" style="border:none;">
           viral
proteases: 3CLpro or PLpro
          </td>
          <td align="left" style="border:none;">
           protease inhibitors that
may inhibit the viral proteases: 3CLpro or PLpro
          </td>
          <td align="left" style="border:none;">
           lopinavir
and ritonavir are approved drug combination for HIV infection
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           ritonavir
           <sup>
            <xref ref-type="bibr" rid="ref19">
             19
            </xref>
            ,
            <xref ref-type="bibr" rid="ref37">
             37
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn4">
            c
           </xref>
          </td>
          <td align="left" style="border:none;">
           155213-67-5
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           darunavir
           <sup>
            <xref ref-type="bibr" rid="ref33">
             33
            </xref>
           </sup>
          </td>
          <td align="left" style="border:none;">
           206361-99-1
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           approved drug for HIV infection
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           favipiravir (favilavir)
           <sup>
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
            ,
            <xref ref-type="bibr" rid="ref36">
             36
            </xref>
           </sup>
          </td>
          <td align="left" style="border:none;">
           259793-96-9
          </td>
          <td align="left" style="border:none;">
           RdRp
          </td>
          <td align="left" style="border:none;">
           a purine nucleoside that acts as an alternate substrate leading
to inaccurate viral RNA synthesis
          </td>
          <td align="left" style="border:none;">
           viral infections
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           remdesivir
           <sup>
            <xref ref-type="bibr" rid="ref19">
             19
            </xref>
            ,
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
            ,
            <xref ref-type="bibr" rid="ref32">
             32
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn2">
            a
           </xref>
          </td>
          <td align="left" style="border:none;">
           1809249-37-3
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           a nucleotide analogue that may block viral nucleotide
synthesis to stop viral replication
          </td>
          <td align="left" style="border:none;">
           Ebola virus infection
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           ribavirin
           <sup>
            <xref ref-type="bibr" rid="ref16">
             16
            </xref>
            ,
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
            −
            <xref ref-type="bibr" rid="ref31">
             31
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn2">
            a
           </xref>
          </td>
          <td align="left" style="border:none;">
           36791-04-5
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           RSV infection, hepatitis C, some viral hemorrhagic fevers
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           galidesivir
           <sup>
            <xref ref-type="bibr" rid="ref34">
             34
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn3">
            b
           </xref>
          </td>
          <td align="left" style="border:none;">
           249503-25-1
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           hepatitis C, Ebola virus, Marburg virus
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           BCX-4430 (salt form of galidesivir)
           <sup>
            <xref ref-type="bibr" rid="ref34">
             34
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn3">
            b
           </xref>
          </td>
          <td align="left" style="border:none;">
           222631-44-9
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           hepatitis C, Ebola
virus, Marburg virus
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           Arbidol
           <sup>
            <xref ref-type="bibr" rid="ref22">
             22
            </xref>
            ,
            <xref ref-type="bibr" rid="ref33">
             33
            </xref>
           </sup>
           <xref ref-type="table-fn" rid="t4fn2">
            a
           </xref>
          </td>
          <td align="left" style="border:none;">
           131707-23-8
          </td>
          <td align="left" style="border:none;">
           S protein/ACE2
           <xref ref-type="table-fn" rid="t4fn5">
            d
           </xref>
          </td>
          <td align="left" style="border:none;">
           an inhibitor that may disrupt the binding of
viral envelope protein to host cells and prevent viral entry to the
target cell
          </td>
          <td align="left" style="border:none;">
           influenza antiviral drug
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           chloroquine
           <sup>
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
            ,
            <xref ref-type="bibr" rid="ref32">
             32
            </xref>
           </sup>
          </td>
          <td align="left" style="border:none;">
           54-05-7
          </td>
          <td align="left" style="border:none;">
           endosome/ACE2
          </td>
          <td align="left" style="border:none;">
           a drug that can elevate endosomal pH
and interfere with ACE2 glycosylation
          </td>
          <td align="left" style="border:none;">
           malarial parasite
infection
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           nitazoxanide
           <sup>
            <xref ref-type="bibr" rid="ref29">
             29
            </xref>
           </sup>
          </td>
          <td align="left" style="border:none;">
           55981-09-4
          </td>
          <td align="left" style="border:none;">
           N/A
          </td>
          <td align="left" style="border:none;">
           a drug that
may inhibit viral protein expression
          </td>
          <td align="left" style="border:none;">
           various helminthic,
protozoal, and viral infection-caused diarrhea
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn id="t4fn2">
         <label>
          a
         </label>
         <p>
          Drugs under clinical trials for treating COVID-19 (repurposing).
         </p>
        </fn>
        <fn id="t4fn3">
         <label>
          b
         </label>
         <p>
          Drugs under clinical trials
for other virus-induced diseases.
         </p>
        </fn>
        <fn id="t4fn4">
         <label>
          c
         </label>
         <p>
          Ritonavir is a pharmacokinetic profile enhancer that may potentiate
the effects of other protease inhibitors due to its ability to attenuate
the degradation of those drugs by the liver enzyme CYP3A4 and thus
is used in combination with antivirial Lopinavir.
          <sup>
           <xref ref-type="bibr" rid="ref37">
            37
           </xref>
          </sup>
         </p>
        </fn>
        <fn id="t4fn5">
         <label>
          d
         </label>
         <p>
          An inhibitor of viral entry to host cells. Its direct action on S protein and ACE2 is yet to be confirmed.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec id="sec3.4">
      <title>
       Selected Patents Related
to Promising Small Molecule Drug Candidates
      </title>
      <p>
       <xref ref-type="other" rid="tbl5">
        Table
        <xref ref-type="other" rid="tbl5">
         5
        </xref>
       </xref>
       shows selected patents associated
with the aforementioned potential drugs, together with patents disclosing
small molecules for treatment of SARS or MERS. The selection was based
on the presence of important terms in CAS-indexed patents as well
as the presence of the synthetic preparation role assigned by CAS
scientists during document indexing. Patent applications WO2009114512
and WO2014028756 disclose preparation of compounds active as JAK inhibitors,
one of which was later named as baricitinib and developed for reducing
inflammation in rheumatoid arthritis. Patent application JP5971830
discloses preparation of polycyclic pyridone compounds and their use
as endonuclease inhibitors. Patent applications US20160122374 and US20170071964 disclose
preparation of the nucleotide analog drug remdesivir that was later
developed as a therapeutic agent for Ebola and Marburg virus infections
(Patent US20170071964). Because of its promising results in at least
two COVID-19 patients, remdesivir has now entered into phase III clinical
trials.
      </p>
      <table-wrap id="tbl5" position="float">
       <label>
        Table 5
       </label>
       <caption>
        <title>
         Selected Patents Associated with Potential
Drugs (Repurposing) for COVID-19 or Small Molecules for Treatment
of SARS or MERS
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           patent no.
          </th>
          <th align="center" style="border:none;">
           priority date
          </th>
          <th align="center" style="border:none;">
           title
          </th>
          <th align="center" style="border:none;">
           organization
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           WO2009114512
          </td>
          <td align="left" style="border:none;">
           20080311
          </td>
          <td align="left" style="border:none;">
           Preparation of azetidine and cyclobutane derivatives as JAK
inhibitors
          </td>
          <td align="left" style="border:none;">
           Incyte Corporation, USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2014028756
          </td>
          <td align="left" style="border:none;">
           20140220
          </td>
          <td align="left" style="border:none;">
           Deuterated baricitinib
          </td>
          <td align="left" style="border:none;">
           Concert Pharmaceuticals,
Inc., USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           JP5971830
          </td>
          <td align="left" style="border:none;">
           20150428
          </td>
          <td align="left" style="border:none;">
           Preparation of polycyclic pyridone
derivatives as cap-dependent endonuclease (CEN) inhibitors and prodrugs
thereof
          </td>
          <td align="left" style="border:none;">
           Shionogi and Co., Ltd., Japan
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           US20160122374
          </td>
          <td align="left" style="border:none;">
           20141029
          </td>
          <td align="left" style="border:none;">
           Preparation of nucleosides and methods for
treating Filoviridae virus infections
          </td>
          <td align="left" style="border:none;">
           Gilead Sciences, Inc., USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           US20170071964
          </td>
          <td align="left" style="border:none;">
           20160916
          </td>
          <td align="left" style="border:none;">
           Preparation of amino acid-containing
nucleotides and methods for treating arenaviridae and coronaviridae
virus infections
          </td>
          <td align="left" style="border:none;">
           Gilead Sciences, Inc., USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2007075145
          </td>
          <td align="left" style="border:none;">
           20070704
          </td>
          <td align="left" style="border:none;">
           Preparation of benzopyranone derivatives as
anti-coronaviral agents
          </td>
          <td align="left" style="border:none;">
           Singapore Polytechnic, Singapore;
Shanghai Institute of Materia Medica Chinese Academy of Sciences,
China
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2005021518
          </td>
          <td align="left" style="border:none;">
           20050310
          </td>
          <td align="left" style="border:none;">
           Preparation of 3,4-dihydro-2
           <italic>
            H
           </italic>
           -1,4-benzoxazine-2-carboxylic acid derivatives as cysLT2
receptor antagonists for treatment of respiratory diseases
          </td>
          <td align="left" style="border:none;">
           Ono Pharmaceutical Co., Ltd., Japan
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2007120160
          </td>
          <td align="left" style="border:none;">
           20071025
          </td>
          <td align="left" style="border:none;">
           Preparation of N-heterocyclic acetamides useful for viral inhibition
          </td>
          <td align="left" style="border:none;">
           Novartis AG, USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2009119167
          </td>
          <td align="left" style="border:none;">
           20091001
          </td>
          <td align="left" style="border:none;">
           Aniline derivative having anti-RNA
viral activity
          </td>
          <td align="left" style="border:none;">
           KinoPharma, Inc., Japan
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2013049382
          </td>
          <td align="left" style="border:none;">
           20130404
          </td>
          <td align="left" style="border:none;">
           Broad-spectrum antivirals against 3c or 3c-like proteases of
picornavirus-like supercluster: picornaviruses, caliciviruses and
coronaviruses
          </td>
          <td align="left" style="border:none;">
           Kansas State University Research Foundation;
The Ohio State University; Wichita State University - all in USA
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2018042343
          </td>
          <td align="left" style="border:none;">
           20180308
          </td>
          <td align="left" style="border:none;">
           Preparation of peptides that inhibit 3C and 3CL proteases and methods
of use thereof
          </td>
          <td align="left" style="border:none;">
           GlaxoSmithKline, UK
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2007067515
          </td>
          <td align="left" style="border:none;">
           20070614
          </td>
          <td align="left" style="border:none;">
           Five-membered iminocyclitol derivatives as selective and potent
glycosidase inhibitors: new structures for antivirals and osteoarthritis
therapeutics
          </td>
          <td align="left" style="border:none;">
           Academia Sinica, Taiwan
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <p>
       Patent application WO2013049382 discloses both structures
and syntheses of compounds from various structure classes (peptidyl
aldehydes, peptidyl α-ketoamides, peptidyl bisulfite salts,
and peptidyl heterocycles), as well as certain formulation compositions,
developed to inhibit viral 3C protease or 3C-like protease (i.e.,
3CLpro).
      </p>
      <p>
       Patent application WO2018042343 presents both preparation
methods and biological assay results for compounds capable of inhibiting
the SARS virus proteases. These compounds appeared to exhibit good
enzyme-inhibiting activity (pIC
       <sub>
        50
       </sub>
       ≈ 7 or IC
       <sub>
        50
       </sub>
       ≈ 0.1 μM) and antiviral activity, which was
assessed by host cell viability using cultured human lung fibroblast
MRC-5 cells infected with a specified virus (e.g., MERS virus) expressing
the viral S protein. Drug administration routes were also mentioned
in this patent.
      </p>
     </sec>
     <sec id="sec3.5">
      <title>
       Small Molecule Compounds in Research and
Development with Potential Effects on Key Protein Targets for Human
Coronavirus-Induced Diseases
      </title>
      <p>
       Besides various commercialized
antiviral drugs, there are also small molecule compounds currently
in research and development that have shown significant inhibitory
effects on many key proteins from similar coronaviruses such as SARS-CoV
and MERS-CoV (
       <xref ref-type="other" rid="tbl6">
        Table
        <xref ref-type="other" rid="tbl6">
         6
        </xref>
       </xref>
       ). These drug candidates mostly inhibit viral enzymes including proteases
and components for RdRp. Since 3CLpro protease has a high level of
sequence homology between SARS-CoV and SARS-CoV-2, inhibitors against
3CLpro of SARS-CoV may also be applicable to SARS-CoV-2. Compounds,
including benzopurpurin B, C-467929, C-473872, NSC-306711 and N-65828,
which may inhibit the activity of viral NSP15, poly(U)-specific endoribonuclease,
were tested for reduced SARS-CoV infectivity in cultured cells with
IC
       <sub>
        50
       </sub>
       of 0.2–40 μM.
       <sup>
        <xref ref-type="bibr" rid="ref38">
         38
        </xref>
       </sup>
       Compound C-21 and CGP-42112A are two AT2 agonists, whereas L-163491
has dual functions as a partial agonist for AT2 receptor and a partial
antagonist of AT1 receptor. Since AT1 and AT2 are important effectors
in the RAS system to which ACE2 belongs, it has been speculated that
these compounds may be used to adjust the balance between AT1 and
AT2, which may be affected by coronavirus infection and to alleviate
viral-induced lung injury during the infection.
       <sup>
        <xref ref-type="bibr" rid="ref24">
         24
        </xref>
       </sup>
      </p>
      <table-wrap id="tbl6" position="float">
       <label>
        Table 6
       </label>
       <caption>
        <title>
         Small Molecule Compounds in Research and Development with Therapeutic
Potential for COVID-19
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           CAS RN
          </th>
          <th align="center" style="border:none;">
           small molecule compound
          </th>
          <th align="center" style="border:none;">
           target
          </th>
          <th align="center" style="border:none;">
           possible mechanism of action
on COVID-19
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           4431-00-9
          </td>
          <td align="left" style="border:none;">
           aurine tricarboxylic acid
          </td>
          <td align="left" style="border:none;">
           RNA-dependent RNA polymerase (RdRp)
          </td>
          <td align="left" style="border:none;">
           an inhibitor
that may bind to viral RdRp, as tested against SARS-CoV in cell culture
           <sup>
            <xref ref-type="bibr" rid="ref16">
             16
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           502960-90-9
          </td>
          <td align="left" style="border:none;">
           4-methyl-
           <italic>
            N
           </italic>
           -[(1
           <italic>
            S
           </italic>
           )-2-oxo-2 [[(1
           <italic>
            S
           </italic>
           ,2
           <italic>
            E
           </italic>
           )-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propen-1-yl]amino]-1-(phenylmethyl)ethyl]-
1-piperazinecarboxamide
          </td>
          <td align="left" style="border:none;">
           viral proteases: 3CLpro and
PLpro
          </td>
          <td align="left" style="border:none;">
           an inhibitor that may disrupt the function of
3CLpro and PLpro, which was tested against SARS-CoV
           <sup>
            <xref ref-type="bibr" rid="ref16">
             16
            </xref>
            ,
            <xref ref-type="bibr" rid="ref39">
             39
            </xref>
            ,
            <xref ref-type="bibr" rid="ref40">
             40
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           1851279-09-8
          </td>
          <td align="left" style="border:none;">
           4-(1,1-dimethylethyl)-
           <italic>
            N
           </italic>
           -[(1
           <italic>
            S
           </italic>
           )-2-oxo-2-[[(1
           <italic>
            S
           </italic>
           ,2
           <italic>
            E
           </italic>
           )-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propen-1-yl]amino]-1-(phenylmethyl)ethyl]-
1-piperazinecarboxamide
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           1851280-00-6
          </td>
          <td align="left" style="border:none;">
           4-(2-methoxyethyl)-
           <italic>
            N
           </italic>
           -[(1
           <italic>
            S
           </italic>
           )-2-oxo-2-[[(1
           <italic>
            S
           </italic>
           ,2
           <italic>
            E
           </italic>
           )-1-(2-phenylethyl)-3-(phenylsulfonyl)-2-propen-1-yl]amino]-1-(phenylmethyl)ethyl]-
1-piperazinecarboxamide
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           223537-30-2
          </td>
          <td align="left" style="border:none;">
           rupintrivir
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           a cysteine protease inhibitor that may disrupt
the function of 3CLpro and PLpro
           <sup>
            <xref ref-type="bibr" rid="ref41">
             41
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           2409054-43-7
          </td>
          <td align="left" style="border:none;">
           (α
           <italic>
            R
           </italic>
           )-α-[[3-(4-chloro-2-fluorophenyl)-1-oxo-2-propen-1-yl]amino]-
           <italic>
            N
           </italic>
           -[(1
           <italic>
            R
           </italic>
           )-1-methyl-2-(2-oxo-3-pyrrolidinyl)ethyl]-
benzenepropanamide
          </td>
          <td align="left" style="border:none;">
           viral proteases: 3CLpro or PLpro
          </td>
          <td align="left" style="border:none;">
           an inhibitor that may disrupt the function of 3CLpro or PLpro,
as tested against SARS-CoV or MERS-CoV
           <sup>
            <xref ref-type="bibr" rid="ref39">
             39
            </xref>
            ,
            <xref ref-type="bibr" rid="ref40">
             40
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           452088-38-9
          </td>
          <td align="left" style="border:none;">
           5-[(4-methyl-1-piperidinyl)sulfonyl]-1
           <italic>
            H
           </italic>
           -indole-2,3-dione
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           2409054-44-8
          </td>
          <td align="left" style="border:none;">
           3-hydroperoxy-4-[2-hydroxy-3-[3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-6-methoxyphenyl]-2-butanone
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           41137-87-5
          </td>
          <td align="left" style="border:none;">
           hirsutenone
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           992-59-6
          </td>
          <td align="left" style="border:none;">
           benzopurpurin B
          </td>
          <td align="left" style="border:none;">
           NSP15
(poly(U)-specific endoribonuclease)
          </td>
          <td align="left" style="border:none;">
           chemical inhibitors
that may suppress viral infectivity by inhibiting endoribonuclease
NSP15, as tested against SARS-CoV in cultured cells
           <sup>
            <xref ref-type="bibr" rid="ref38">
             38
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           351891-58-2
          </td>
          <td align="left" style="border:none;">
           C-467929
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           331675-78-6
          </td>
          <td align="left" style="border:none;">
           C-473872
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           813419-93-1
          </td>
          <td align="left" style="border:none;">
           NSC-306711
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           501444-06-0
          </td>
          <td align="left" style="border:none;">
           N-65828
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           477775-14-7
          </td>
          <td align="left" style="border:none;">
           C-21
          </td>
          <td align="left" style="border:none;">
           AT2
          </td>
          <td align="left" style="border:none;">
           an angiotensin AT2 receptor agonist
that may alleviate the virus-induced lung injury
           <sup>
            <xref ref-type="bibr" rid="ref24">
             24
            </xref>
           </sup>
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           127060-75-7
          </td>
          <td align="left" style="border:none;">
           CGP-42112A
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           170969-73-0
          </td>
          <td align="left" style="border:none;">
           L-163491
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           a dual-property molecule that functions
as angiotensin AT1 partial antagonist and AT2 agonist which may alleviate
the virus-induced lung injury
           <sup>
            <xref ref-type="bibr" rid="ref24">
             24
            </xref>
           </sup>
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
     <sec id="sec3.6">
      <title>
       Small Molecules Identified by Structure Similarity, Lipinski’s
Rule of 5, and CAS-Indexed Pharmacological Activity and/or Therapeutic
Usage
      </title>
      <p>
       Besides the aforementioned antiviral drugs, there may
be additional small molecule compounds with therapeutic or pharmacological
potential against viruses such as SARS-CoV and MERS-CoV. Compounds
listed in
       <xref ref-type="other" rid="tbl4">
        Tables
        <xref ref-type="other" rid="tbl4">
         4
        </xref>
       </xref>
       and
       <xref ref-type="other" rid="tbl6">
        6
       </xref>
       were subjected to a Tanimoto similarity search
in CAS REGISTRY using CAS proprietary fingerprints.
       <xref ref-type="fn" rid="fn1">
        a
       </xref>
       Those substances with at least 60% structural similarity
match and meeting Lipinski’s rule of 5 were identified.
       <xref ref-type="other" rid="tbl7">
        Table
        <xref ref-type="other" rid="tbl7">
         7
        </xref>
       </xref>
       lists selected compounds
that were also identified to have a pharmacological activity or therapeutic
usage role. Compound name and CAS RN are provided for each compound.
The second column lists the number of compounds that met the structure
similarity and Lipinski’s rule criteria. Although more work
remains to be done in this regard, the methodology and results mentioned
here point to a strategy that may help streamline the process of drug
discovery for COVID-19.
      </p>
      <table-wrap id="tbl7" position="float">
       <label>
        Table 7
       </label>
       <caption>
        <title>
         Examples of Similar
Molecules with Possible Therapeutic Effects Identified by Structural
Similarity, Lipinski’s Rule of 5, and Pharmacology/Therapeutic
Role Assigned by CAS Scientists during Document Indexing
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           query substance name (CAS RN)
          </th>
          <th align="center" style="border:none;">
           no. of substances with &gt;60% similarity
          </th>
          <th align="center" style="border:none;">
           example of selected similar substance
          </th>
          <th align="center" style="border:none;">
           Registry Number of selected similar substance
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           ribavirin (36791-04-5)
          </td>
          <td align="left" style="border:none;">
           1520
          </td>
          <td align="left" style="border:none;">
           viramidine
          </td>
          <td align="left" style="border:none;">
           119567-79-2
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           galidesivir (249503-25-1)
          </td>
          <td align="left" style="border:none;">
           502
          </td>
          <td align="left" style="border:none;">
           (2
           <italic>
            R
           </italic>
           ,3
           <italic>
            S
           </italic>
           ,5
           <italic>
            R
           </italic>
           )-5-(4-amino-5
           <italic>
            H
           </italic>
           -pyrrolo[3,2-
           <italic>
            d
           </italic>
           ]pyrimidin-7-yl)-3-hydroxy-2-pyrrolidinemethanol
          </td>
          <td align="left" style="border:none;">
           1610426-50-0
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           (2
           <italic>
            S
           </italic>
           ,4
           <italic>
            R
           </italic>
           ,5
           <italic>
            S
           </italic>
           )-5-(4-amino-5
           <italic>
            H
           </italic>
           -pyrrolo[3,2-
           <italic>
            d
           </italic>
           ]pyrimidin-7-yl)-4-hydroxy-2-pyrrolidinemethanol
          </td>
          <td align="left" style="border:none;">
           872534-76-4
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           (2
           <italic>
            R
           </italic>
           ,3
           <italic>
            R
           </italic>
           ,4
           <italic>
            S
           </italic>
           ,5
           <italic>
            S
           </italic>
           )-5-(4-amino-5
           <italic>
            H
           </italic>
           -pyrrolo[3,2-
           <italic>
            d
           </italic>
           ]pyrimidin-7-yl)-3-hydroxy-4-methoxy-2-pyrrolidinemethanol
          </td>
          <td align="left" style="border:none;">
           1610426-51-1
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           chloroquine (54-05-7)
          </td>
          <td align="left" style="border:none;">
           21176
          </td>
          <td align="left" style="border:none;">
           hydroxychloroquine
          </td>
          <td align="left" style="border:none;">
           118-42-3
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           (±)-chloroquine diphosphate
          </td>
          <td align="left" style="border:none;">
           50-63-5
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           chloroquine hydrochloride
          </td>
          <td align="left" style="border:none;">
           3545-67-3
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           chloroquine
sulfate
          </td>
          <td align="left" style="border:none;">
           132-73-0
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           favipiravir (259793-96-9)
          </td>
          <td align="left" style="border:none;">
           309
          </td>
          <td align="left" style="border:none;">
           6-bromo-3,4-dihydro-3-oxo-2-pyrazine-5-d-carboxamide
          </td>
          <td align="left" style="border:none;">
           1476773-04-2
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
          </td>
          <td align="left" style="border:none;">
           6-fluoro-3,4-dihydro-3-oxo-2-pyrazine-5-d-carboxamide
          </td>
          <td align="left" style="border:none;">
           1492021-26-7
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           2-butanone, 3-hydroperoxy-4-[2-hydroxy-3-[3-(4-hydroxyphenyl)-1-oxo-2-propen-1-yl]-6-methoxyphenyl]
(2409054-44-8)
          </td>
          <td align="left" style="border:none;">
           63195
          </td>
          <td align="left" style="border:none;">
           xanthoangelol D
          </td>
          <td align="left" style="border:none;">
           132998-83-5
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </sec>
    </sec>
    <sec id="sec4">
     <title>
      BIOLOGICS FOR
CORONAVIRUS-ASSOCIATED DISEASES
     </title>
     <sec id="sec4.1">
      <title>
       Distribution of Biologics Patents Related
to SARS and MERS
      </title>
      <p>
       The new coronavirus SARS-CoV-2 related to
SARS and MERS viruses is causing serious and ongoing epidemiological
problems around the world. Since there is limited clinical and basic
research information at this time, treatment options for COVID-19
currently comprise investigational drugs and management of symptoms.
As biologics have the potential to broaden the spectrum of the treatment
options for coronavirus-induced diseases, leveraging prior knowledge
and practices used to address the SARS and MERS outbreaks provides
a practical strategy for developing new target-specific therapeutic
agents for SARS-CoV-2. To this end, an analysis of biologics from
patents contained in the CAS content collection was performed. The
patent analysis included information related to therapeutic antibodies,
cytokines, interfering and other therapeutic RNAs, and vaccines for
potential treatment and/or prevention of SARS-related diseases from
patents published from 2003 to the present.
       <xref ref-type="fig" rid="fig6">
        Figure
        <xref ref-type="fig" rid="fig6">
         6
        </xref>
       </xref>
       shows more than 500 patents that disclose
the use of these four biologics classes to treat and prevent SARS
and MERS. Of these patents, vaccine development was the largest class
(363), followed by therapeutic antibodies (99), interfering RNAs (35),
and cytokines (22). Given the indispensable role of vaccines in viral
disease prevention, detailed analysis of vaccines will be presented
in a later section.
      </p>
      <fig id="fig6" position="float">
       <label>
        Figure 6
       </label>
       <caption>
        <p>
         Distribution of biologics patents related to SARS and
MERS.
        </p>
       </caption>
       <graphic id="gr6" position="float" xlink:href="oc0c00272_0006" xmlns:xlink="http://www.w3.org/1999/xlink">
       </graphic>
      </fig>
     </sec>
     <sec id="sec4.2">
      <title>
       Antibodies
      </title>
      <p>
       Ninety-nine
patents containing information about antibodies with therapeutic and/or
diagnostic potential for SARS and MERS were identified. Of these,
61 patents claimed preparation of SARS-specific antibodies (23), MERS-specific
antibodies (17), or antibodies with diagnostic application (21). Similar
to SARS-CoV, the receptor-binding domain (RBD) in the S protein of
SARS-CoV-2 binds to human ACE2 receptor in order to gain access into
host cells.
       <sup>
        <xref ref-type="bibr" rid="ref42">
         42
        </xref>
       </sup>
       In viral infection, the S
protein, but not the other structural proteins, M, E, and N in SARS-CoV,
elicits an immune response.
       <sup>
        <xref ref-type="bibr" rid="ref43">
         43
        </xref>
       </sup>
       <xref ref-type="other" rid="tbl8">
        Table
        <xref ref-type="other" rid="tbl8">
         8
        </xref>
       </xref>
       shows the target
analysis of patents related to development of therapeutic antibodies
for SARS. Over 90% of these antibodies are directed against S protein
including its RBD. The data indicate that the S protein is a putative
target for SARS-CoV-2 antibody development.
      </p>
      <table-wrap id="tbl8" position="float">
       <label>
        Table 8
       </label>
       <caption>
        <title>
         Target
Analysis of Patents on Developing Therapeutic Antibodies for SARS
        </title>
       </caption>
       <table border="0" frame="hsides" rules="groups">
        <colgroup>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
         <col align="left"/>
        </colgroup>
        <thead>
         <tr>
          <th align="center" style="border:none;">
           patent number
          </th>
          <th align="center" style="border:none;">
           antigen of SARS antibody
          </th>
          <th align="center" style="border:none;">
           patent title
          </th>
          <th align="center" style="border:none;">
           organization
          </th>
          <th align="center" style="border:none;">
           priority date
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td align="left" style="border:none;">
           EP2112164
          </td>
          <td align="left" style="border:none;">
           lipid attachment signals or GPI
          </td>
          <td align="left" style="border:none;">
           Antiviral peptides linked to a lipid attachment signals or
GPI against enveloped virus such as HIV, avian flu, SARS or Ebola
virus
          </td>
          <td align="left" style="border:none;">
           Institute Pasteur of Shanghai
          </td>
          <td align="left" style="border:none;">
           20080229
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2009128963
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Cross-neutralizing human monoclonal antibodies to SARS-CoV
and methods of use thereof
          </td>
          <td align="left" style="border:none;">
           Institute for Research In
Biomedicine
          </td>
          <td align="left" style="border:none;">
           20080117
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2009128963
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Cross-neutralizing human monoclonal
antibodies to spike protein of SARS coronavirus and methods of use
thereof
          </td>
          <td align="left" style="border:none;">
           Humab, LLC
          </td>
          <td align="left" style="border:none;">
           20080117
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2008035894
          </td>
          <td align="left" style="border:none;">
           viral infection
          </td>
          <td align="left" style="border:none;">
           Preparation of antiviral antibody 3D8 fragments and their use in treatment
of viral infection
          </td>
          <td align="left" style="border:none;">
           Sung Kyun Kwan University; Ajou University;
Invitroplant Co., Ltd.
          </td>
          <td align="left" style="border:none;">
           20060919
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2008060331
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Antibodies
to SARS coronavirus
          </td>
          <td align="left" style="border:none;">
           Amgen Inc.
          </td>
          <td align="left" style="border:none;">
           20060519
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2007044695
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Neutralizing monoclonal anti-spike protein antibodies for diagnosis
and treatment of SARS-coronavirus-associated disease and screening
of vaccine or anti-SARS agent
          </td>
          <td align="left" style="border:none;">
           Dana-Farber Cancer Institute
          </td>
          <td align="left" style="border:none;">
           20051007
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           CN1911963
          </td>
          <td align="left" style="border:none;">
           RBD
of S protein
          </td>
          <td align="left" style="border:none;">
           Method for
preparing neutralizing monoclonal antibody against severe acute respiratory
syndrome coronavirus and its application
          </td>
          <td align="left" style="border:none;">
           Chinese Academy
of Sciences
          </td>
          <td align="left" style="border:none;">
           20050810
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           CN1903878
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Fab fragment of human antibody
IgG against SARS coronavirus
          </td>
          <td align="left" style="border:none;">
           Fudan University
          </td>
          <td align="left" style="border:none;">
           20050726
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2006095180
          </td>
          <td align="left" style="border:none;">
           S2 protein
          </td>
          <td align="left" style="border:none;">
           Human monoclonal antibodies against SARS-associated
coronavirus and treatment of patients with SARS
          </td>
          <td align="left" style="border:none;">
           Ultra
Biotech Ltd.; University of California
          </td>
          <td align="left" style="border:none;">
           20050310
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2006086561
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Neutralizing monoclonal antibodies against severe acute respiratory
syndrome-associated coronavirus
          </td>
          <td align="left" style="border:none;">
           New York Blood Center,
Inc.
          </td>
          <td align="left" style="border:none;">
           20050208
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           CN1664100
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Preparation of heavy chain and
light chain variable regions of anti-SARS coronavirus antigen antibodies
and their diagnostic and therapeutic uses thereof
          </td>
          <td align="left" style="border:none;">
           Chen
Zhinan
          </td>
          <td align="left" style="border:none;">
           20050204
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           CN1660912
          </td>
          <td align="left" style="border:none;">
           IL-8
          </td>
          <td align="left" style="border:none;">
           Sequences
of monoclonal antibodies against human interleukin 8 and therapeutic use
          </td>
          <td align="left" style="border:none;">
           Ye Qingwei
          </td>
          <td align="left" style="border:none;">
           20041208
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2006051091
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Compositions against SARS-coronavirus
and uses thereof
          </td>
          <td align="left" style="border:none;">
           Crucell Holland BV
          </td>
          <td align="left" style="border:none;">
           20041111
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2006051091
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Compositions against SARS-coronavirus comprising at least two
immunoglobulins reacting with non-competing epitopes, and therapeutic
and diagnostic uses thereof
          </td>
          <td align="left" style="border:none;">
           Crucell Holland BV
          </td>
          <td align="left" style="border:none;">
           20041111
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           CN1673231
          </td>
          <td align="left" style="border:none;">
           spike
protein
          </td>
          <td align="left" style="border:none;">
           Monoclonal antibody of SARS coronavirus N protein and its use in treatment of SARS virus
infections
          </td>
          <td align="left" style="border:none;">
           Chinese Academy of Sciences
          </td>
          <td align="left" style="border:none;">
           20040715
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           US20060240551
          </td>
          <td align="left" style="border:none;">
           spike
protein
          </td>
          <td align="left" style="border:none;">
           Neutralizing monoclonal antibodies against severe
acute respiratory syndrome-associated coronavirus
          </td>
          <td align="left" style="border:none;">
           New
York Blood Center, Inc.
          </td>
          <td align="left" style="border:none;">
           20040602
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2005054469
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Anti-SARS-coronavirus
monoclonal antibodies, and diagnostic, therapeutic and vaccine preparation
uses
          </td>
          <td align="left" style="border:none;">
           Health Canada
          </td>
          <td align="left" style="border:none;">
           20031205
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2005060520
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Antibodies specific to SARS-CoV spike protein for diagnosis and therapy
of SARS and for screening of epitopic vaccines or anti-SARS therapeutics
          </td>
          <td align="left" style="border:none;">
           Dana-Farber Cancer Institute, Inc.
          </td>
          <td align="left" style="border:none;">
           20031125
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           US20050106563
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Epitope profiles of SARS coronavirus for use in antigen detection,
antibody production, and defense against infection
          </td>
          <td align="left" style="border:none;">
           Genesis
Biotech Inc.
          </td>
          <td align="left" style="border:none;">
           20030908
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           US20050069869
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           SARS coronavirus codon-optimized
sequences for spike (S) protein expression, anti-S human monoclonal antibodies, and therapeutic and diagnostic uses
thereof
          </td>
          <td align="left" style="border:none;">
           University of Massachusetts
          </td>
          <td align="left" style="border:none;">
           20030804
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2005012360
          </td>
          <td align="left" style="border:none;">
           S and N proteins
          </td>
          <td align="left" style="border:none;">
           Antibody binding molecules
specific for SARS coronavirus
          </td>
          <td align="left" style="border:none;">
           Crucell Holland BV
          </td>
          <td align="left" style="border:none;">
           20030722
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           CN1566155
          </td>
          <td align="left" style="border:none;">
           S, N, and M proteins
          </td>
          <td align="left" style="border:none;">
           Antibody library-derived
human monoclonal anti-SARS virus antibodies for treating severe acute
respiratory syndrome
          </td>
          <td align="left" style="border:none;">
           Igcon Therapeutics Co., Ltd.; Genetastix
Corporation
          </td>
          <td align="left" style="border:none;">
           20030710
          </td>
         </tr>
         <tr>
          <td align="left" style="border:none;">
           WO2005007671
          </td>
          <td align="left" style="border:none;">
           spike protein
          </td>
          <td align="left" style="border:none;">
           Compositions and methods for treating
SARS using peptides derived from SARS virus E2 N-terminal-alpha helix
or C-terminal-alpha helix and related monoclonal antibody
          </td>
          <td align="left" style="border:none;">
           Epitomics, Inc.
          </td>
          <td align="left" style="border:none;">
           20030429
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
      <p>
       An additional 38 patents contained
information pertaining to other types of antiviral antibodies that
were useful for SARS and MERS therapies. These included neutralizing
antibodies or antibodies designed to target proteins such as IL-6/IL-6R,
TLR3 (Toll-like receptor 3), CD16, ITAM (immunoreceptor tyrosine-based
activation motif), DC-SIGN (dendritic cell-specific intercellular
adhesion molecule-grabbing nonintegrin), ICAM-3 (intercellular adhesion
molecule 3), or IP-10/CXCL10 (interferon γ-inducible protein
10). Cytokine storm has been reported to correlate with disease severity
in SARS-CoV-2 infection. Patients admitted to an ICU had higher concentrations
of proinflammatory cytokines and chemokines, particularly G-CSF, IP-10/CXCL10,
MCP1 (monocyte chemoattractant protein 1), and TNFα, as well
as elevated cytokines from T helper 2 cells such as IL-4 and IL-10.
       <sup>
        <xref ref-type="bibr" rid="ref44">
         44
        </xref>
       </sup>
       Patent application WO2005058815 discloses human
anti-IP-10 antibodies, including bispecific molecules and immunoconjugates
that bind to IP-10 with high affinity, for treating inflammation,
autoimmune disease, neurodegenerative disease, bacterial infection,
and viral infection. Patent application WO2017095875 discloses the
preparation of human antibodies and immunoconjugates specifically
targeting chemokine IP-10, including an anti-IP-10 antibody shown
to suppress free serum IP-10 in about 3 days at 0.5 mg/kg and in approximately
10 days at 10 mg/kg in Cynomolgus macaques.
      </p>
      <p>
       In addition, DC-SIGN/CD209,
a type II transmembrane adhesion molecule with C-type lectin function,
is mainly expressed on interstitial dendritic cells and lung alveolar
macrophages.
       <sup>
        <xref ref-type="bibr" rid="ref45">
         45
        </xref>
       </sup>
       DC-SIGN functions as an
entry cofactor in transferring SARS-CoV to susceptible cells such
as pneumocytes.
       <sup>
        <xref ref-type="bibr" rid="ref46">
         46
        </xref>
       </sup>
       Patent application WO200505824
claims the production of a humanized anti-DC-SIGN antibody that interfered
with the interaction of DC-SIGN with its receptor, ICAM-3. The antibody
effectively blocked viral binding, infection, and transmission for
viral infections/diseases, including SARS.
      </p>
     </sec>
     <sec id="sec4.3">
      <title>
       Cytokines
      </title>
      <p>
       Cytokines are low-molecular-weight
proteins that act as chemical signals in the immune response to pathogen
invasion. The production of various cytokines in response to an invading
pathogen such as a virus contributes to the host organism’s
ability to eliminate the pathogen. Specific types of cytokines, including
chemokines, interferons (IFNs), interleukins, and lymphokines, have
been reported and characterized in the literature over the past 40
years. By early 2020, the CAS Lexicon contained over 700 terms for
specific types of cytokines associated with 76 724 documents,
including 11 837 patents.
      </p>
      <p>
       During a viral infection, the
most prominent cytokines produced are IFNs, which interfere with viral
replication. IFNs are classified as type I (IFN-α, IFN-β,
IFN-δ, IFN-ε, IFN-κ, IFN-ν, IFN-τ, and
IFN-ω), type II (IFN-γ), or type III (IFN-λ) based
on the receptor complex used for signaling as well as sequence homology.
       <sup>
        <xref ref-type="bibr" rid="ref47">
         47
        </xref>
       </sup>
       Because of their ability to interfere with viral
replication, interferons and interferon fusion proteins have been
utilized as therapeutic agents for treatment of viral infections for
the past 20 years. A few patents disclosing these proteins and their
use for treating SARS are described below.
      </p>
      <sec id="sec4.3.1">
       <title>
        rSIFN-co
       </title>
       <p>
        Patent
applications WO2011072487 and WO2016180335 describe the cloning of
a recombinant interferon (rSIFN-co, CAS RN 2043378-94-3) as well as
a method for determining its potency that was effective for treating
various viral infections/diseases, including SARS. The invention relates
that rSIFN-co has an identical amino acid sequence to Infergen (118390-30-0),
but it has an altered spatial conformation and different biological
potency. The rSIFN-co not only has an antiviral activity that is 20
times stronger than the clinically available interferon, but also
has significantly stronger antitumor properties against breast cancer
and cervical cancer than other recombinant human α-interferons.
The invention further relates that rSIFN has reduced toxic and side
effects and can be safely used in large doses (each dose can be &gt;10
million IU), making it possible to successfully treat some viral diseases
or tumors that require large doses of interferon.
       </p>
      </sec>
      <sec id="sec4.3.2">
       <title>
        IFN-ω
       </title>
       <p>
        Patent application WO2004096852 discloses the amino acid sequence
for recombinant human interferon ω (rhIFN-ω) (RN 791910-34-4)
that was shown to have an anti-SARS viral activity similar to that
of IFN-β. IFN-ω effectively decreased disease severity
and inhibited proliferation of coronavirus strain BJ01 in monkeys.
       </p>
      </sec>
      <sec id="sec4.3.3">
       <title>
        IL-28A (IFN-λ2), IL-28B (IFN-λ3), and IL-29 (IFN-λ1)
Variants
       </title>
       <p>
        Patent application WO2005097165 claims a method
for treating SARS viral infection using IL-28A, IL-28B, and IL-29
cysteine variants conjugated to polymers (e.g., polyethylene glycol)
and discloses the amino acid and nucleic acid sequences for these
cysteine variants. Of these variants, MetIL-29C172S-PEG (RN 867228-40-8)
was specifically shown to inhibit viral replication.
       </p>
      </sec>
      <sec id="sec4.3.4">
       <title>
        Interferon-Human
Serum Albumin Fusion Protein
       </title>
       <p>
        Patents applications US20090053173
and CN101942026 both disclose long-lasting fusion proteins (HSA-IFN)
with each of them being composed of an interferon fused with human
serum albumin-binding peptide for treatment of a wide range of diseases,
including SARS. Specific HSA-IFN fusion proteins were constructed
using five different interferons (IFN-α1b, IFN-α2b, IFN-β,
IFN-ω, IFN-γ) with corresponding CAS RNs 1122730-20-4,
1122730-23-7, 1122730-25-9, 1122730-27-1, and 1122730-29-3, respectively.
These HSA-IFN fusion proteins significantly lengthened the plasma
half-life of interferons (e.g., from 10 h to 12 days for HSA-IFN-α2b)
due to slower free interferon release into the plasma and thus may
prolong the effects of interferon for each injection.
       </p>
      </sec>
     </sec>
     <sec id="sec4.4">
      <title>
       RNA Therapies
      </title>
      <p>
       RNA interference (RNAi) is a biological process wherein small complementary
RNA duplexes target and neutralize specific mRNA molecules,
resulting in inhibition of gene expression or genetic translation.
Interfering RNAs include microRNAs and small interfering RNAs (siRNAs)
that are generally about 21–25 nucleotides in length. Short
hairpin RNAs (shRNAs) are artificial synthetic RNA molecules designed
to fold into a tight hairpin conformation that allows them to silence
their target genes, and can serve as precursors of siRNAs. The expression
of shRNAs in cells is typically accomplished by their delivery via
plasmids or viral or bacterial vectors.
       <sup>
        <xref ref-type="bibr" rid="ref48">
         48
        </xref>
       </sup>
       Although microRNAs are noncoding and naturally found in plants,
animals, and some viruses, synthetic versions are currently being
used to silence a variety of genes.
       <sup>
        <xref ref-type="bibr" rid="ref49">
         49
        </xref>
       </sup>
       The
ability to chemically synthesize modified analogues of microRNAs as
well as siRNAs, which are capable of altering disease-related gene
expression or inhibiting pathogen gene expression, has created a host
of new therapeutic options.
       <sup>
        <xref ref-type="bibr" rid="ref50">
         50
        </xref>
       </sup>
      </p>
      <p>
       In
contrast to the microRNAs and siRNAs, antisense RNAs are single-stranded
RNAs which are naturally occurring or synthetic and usually around
19–23 nucleotides in length with a sequence complementary to
that of a protein coding mRNA, allowing it to hybridize and block
protein translation.
       <sup>
        <xref ref-type="bibr" rid="ref48">
         48
        </xref>
       </sup>
      </p>
      <p>
       Since the
discovery of RNAi in the late 1990s, it has become a well-known method
for silencing/suppressing target genes associated with virulence and
pathogenesis. Thirty-five patents in the CAS content collection disclose
the use of RNAi in treating SARS, with 28 patents using siRNA molecules,
three patents using antisense oligonucleotides, two patents using
RNA aptamers, one patent using a ribozyme, and one patent using a
microRNA inhibitor. Supporting Information
       <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00272/suppl_file/oc0c00272_si_001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        Table S1
       </ext-link>
       provides a high-level view of these 35 patents including
the specific RNAi targets. A few of these patents are further discussed
below.
      </p>
      <sec id="sec4.4.1">
       <title>
        siRNAs Targeting Coronavirus Proteins M, N, or E
       </title>
       <p>
        Patent
application CN101173275 discloses two double-stranded RNAs (dsRNAs)
designed to specifically target two separate regions of the SARS protein
M mRNA. The siRNA-M1 sequences targeting the 220–241 region
of protein M mRNA correspond to CAS RNs 1023405-01-7 and 1023405-02-8,
while siRNA-M2 sequences targeting the 460–480 region correspond
to CAS RNs 1023405-03-9 and 1023405-04-0. The interference efficiency
of these two siRNAs on SARS M protein gene expression was greater
than 70%.
       </p>
       <table-wrap id="tbl9" position="float">
        <label>
         Table 9
        </label>
        <caption>
         <title>
          Representative siRNA Data from Chinese
Patent CN1648249
         </title>
        </caption>
        <table border="0" frame="hsides" rules="groups">
         <colgroup>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
         </colgroup>
         <thead>
          <tr>
           <th align="center" style="border:none;">
            siRNA
           </th>
           <th align="center" style="border:none;">
            sense strand (CAS RN)
           </th>
           <th align="center" style="border:none;">
            antisense strand (CAS RN)
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" style="border:none;">
            No. 8*
           </td>
           <td align="left" style="border:none;">
            5′-cgucgcagcguguaggcacu
            <bold>
             a
            </bold>
            -3′
           </td>
           <td align="left" style="border:none;">
            5′-cagugccuacacgcugcgacg-3′
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
           </td>
           <td align="left" style="border:none;">
            (RN 874840-18-3)
           </td>
           <td align="left" style="border:none;">
            (RN 874840-32-1)
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            No. 51*
           </td>
           <td align="left" style="border:none;">
            5′-aacgguuuacgucuacucgc
            <bold>
             a-
            </bold>
            3′
           </td>
           <td align="left" style="border:none;">
            5′-cgcgaguagacguaaaccguu-3′
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
           </td>
           <td align="left" style="border:none;">
            (RN 874840-19-4)
           </td>
           <td align="left" style="border:none;">
            (RN 874840-47-8)
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            No. 56*
           </td>
           <td align="left" style="border:none;">
            5′-aacguacugccacaaaacag
            <bold>
             c-
            </bold>
            3′
           </td>
           <td align="left" style="border:none;">
            5′-acuguuuuguggcaguacguu-3′
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
           </td>
           <td align="left" style="border:none;">
            (RN 874840-20-7)
           </td>
           <td align="left" style="border:none;">
            (RN 874840-46-7)
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </sec>
      <sec id="sec4.4.2">
       <title>
        siRNAs Targeting Replicase
and RNA Polymerase Region
       </title>
       <table-wrap id="tbl10" position="float">
        <label>
         Table 10
        </label>
        <caption>
         <title>
          Representative
siRNA Data from US20050004063
         </title>
        </caption>
        <table border="0" frame="hsides" rules="groups">
         <colgroup>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
         </colgroup>
         <thead>
          <tr>
           <th align="center" style="border:none;">
            siRNA
           </th>
           <th align="center" style="border:none;">
            sense strand
           </th>
           <th align="center" style="border:none;">
            CAS
RN
           </th>
           <th align="center" style="border:none;">
            target region or gene
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" style="border:none;">
            SARSi-1
           </td>
           <td align="left" style="border:none;">
            5′-gugaacucacucgugagcuctt-3′
           </td>
           <td align="left" style="border:none;">
            821121-35-1
           </td>
           <td align="left" style="border:none;">
            512–531 bp of replicase
A1 region
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-2
           </td>
           <td align="left" style="border:none;">
            5′-guacccucuugauugcauctt-3′
           </td>
           <td align="left" style="border:none;">
            821121-36-2
           </td>
           <td align="left" style="border:none;">
            586–604 bp of replicase
A1 region
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-3
           </td>
           <td align="left" style="border:none;">
            5′-gagucgaagagaggugucutt-3′
           </td>
           <td align="left" style="border:none;">
            821121-37-3
           </td>
           <td align="left" style="border:none;">
            916–934 bp of replicase
A1 region
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-4
           </td>
           <td align="left" style="border:none;">
            5′-gcacuugucuaccuugaugtt-3′
           </td>
           <td align="left" style="border:none;">
            821121-38-4
           </td>
           <td align="left" style="border:none;">
            1194–1213 of replicase
A1 region
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-5
           </td>
           <td align="left" style="border:none;">
            5′-ccuccagaugaggaagaagtt-3′
           </td>
           <td align="left" style="border:none;">
            821121-39-5
           </td>
           <td align="left" style="border:none;">
            3028–3046 bp of replicase
A region
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-6
           </td>
           <td align="left" style="border:none;">
            5′-gguguuuccauuccaugugtt-3′
           </td>
           <td align="left" style="border:none;">
            821121-40-8
           </td>
           <td align="left" style="border:none;">
            5024–5042 bp of replicase
A region
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-7
           </td>
           <td align="left" style="border:none;">
            5′-cacugauuccguucgagauctt-3′
           </td>
           <td align="left" style="border:none;">
            821121-41-9
           </td>
           <td align="left" style="border:none;">
            S gene
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-8
           </td>
           <td align="left" style="border:none;">
            5′-cguuucggaagaaacagguactt-3′
           </td>
           <td align="left" style="border:none;">
            821121-42-0
           </td>
           <td align="left" style="border:none;">
            E gene
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-9
           </td>
           <td align="left" style="border:none;">
            5′-caagccucuucucgcuccuctt-3′
           </td>
           <td align="left" style="border:none;">
            821121-43-1
           </td>
           <td align="left" style="border:none;">
            N gene
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-10
           </td>
           <td align="left" style="border:none;">
            5′-guggcuuagcuacuucguugtt-3′
           </td>
           <td align="left" style="border:none;">
            821121-44-2
           </td>
           <td align="left" style="border:none;">
            M gene
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            SARSi-11
           </td>
           <td align="left" style="border:none;">
            5′-ugcuugcugcugucuacagtt-3′
           </td>
           <td align="left" style="border:none;">
            821121-45-3
           </td>
           <td align="left" style="border:none;">
            M gene
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
       <p>
        The authors demonstrated that SARSi-2,
SARSi-3, SARSi-4, and SARSi-7-11 inhibited coronavirus infection and
replication in FRhk-4 cells. SARSi-4 was the most effective with nearly
complete inhibition, followed by SARSi-2 and SARSi-3.
       </p>
       <p>
        Patent
application CN1569233 discloses siRNAs, shown in
        <xref ref-type="other" rid="tbl11">
         Table
         <xref ref-type="other" rid="tbl11">
          11
         </xref>
        </xref>
        , that target SARS genes encoding
RNA-dependent RNA polymerase, helicase, nucleoprotein N, and proteolytic
enzymes. These siRNAs were able to inhibit or kill 50–90% of
the SARS virus BJ01 strain, with the proteolytic enzyme-targeting
siRNAs being the most effective.
       </p>
       <table-wrap id="tbl11" position="float">
        <label>
         Table 11
        </label>
        <caption>
         <title>
          Representative siRNA
Data from CN1569233
         </title>
        </caption>
        <table border="0" frame="hsides" rules="groups">
         <colgroup>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
          <col align="left"/>
         </colgroup>
         <thead>
          <tr>
           <th align="center" style="border:none;">
            sequence
           </th>
           <th align="center" style="border:none;">
            CAS RN
           </th>
           <th align="center" style="border:none;">
            gene target
           </th>
           <th align="center" style="border:none;">
            % inhibition of
SARS virus
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" style="border:none;">
            5′-caucauccggugaugcuac-3′
           </td>
           <td align="left" style="border:none;">
            872062-80-1
           </td>
           <td align="left" style="border:none;">
            RNA-dependent
RNA polymerase
           </td>
           <td align="left" style="border:none;">
            ∼50
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            5′-uaguguauacggcaugcuc-3′
           </td>
           <td align="left" style="border:none;">
            872062-81-2
           </td>
           <td align="left" style="border:none;">
            helicase
           </td>
           <td align="left" style="border:none;">
            ∼70
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            5′-gugcgugcagacgguucgu-3′
           </td>
           <td align="left" style="border:none;">
            872062-82-3
           </td>
           <td align="left" style="border:none;">
            nucleoprotein N
           </td>
           <td align="left" style="border:none;">
            ∼95
           </td>
          </tr>
          <tr>
           <td align="left" style="border:none;">
            5′-cguagucgcgguaauucaa-3′
           </td>
           <td align="left" style="border:none;">
            872067-98-6
           </td>
           <td align="left" style="border:none;">
            proteolytic enzyme
           </td>
           <td align="left" style="border:none;">
            ∼90
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </sec>
      <sec id="sec4.4.3">
       <title>
        RNA Aptamers
       </title>
       <p>
        Two Korean patents
describe the use of RNA aptamers for inhibition of SARS viruses. Patent
application KR2009128837 identifies RNA aptamers as anti-SARS agents
capable of binding to and inhibiting the double-stranded DNA unwinding
of the SARS virus helicase. Related patent application KR 2012139512
describes RNA aptamers with distinct affinity for the nucleocapsid
of SARS-CoV for potential pharmaceutical use.
       </p>
      </sec>
      <sec id="sec4.4.4">
       <title>
        Ribozymes
       </title>
       <p>
        Patent application JP2007043942 describes a therapeutic RNA/DNA
chimeric ribozyme designed to recognize and cleave conserved common
regions and regions with loop structures in the genes of coronaviruses,
including SARS. This ribozyme specifically recognizes the GUC in viral
genes with loop conformations.
       </p>
      </sec>
      <sec id="sec4.4.5">
       <title>
        Antisense Oligonucleotides
       </title>
       <p>
        Antisense oligonucleotides have also been developed to reduce the
severity of SARS virus infections and to prevent or treat SARS virus-associated
disease, to detect the virus in human samples, and to diagnose SARS
virus-associated diseases. Patent application WO2005023083 published
by Ionis Pharmaceuticals describes hybrid DNA/RNA antisense oligonucleotides
designed to disrupt the pseudoknot in the frameshift site of the SARS
coronavirus RNA. In addition to directly targeting the virus, antisense
oligonucleotides may be used to target disease-related proteins involved
in the inflammatory process.
       </p>
      </sec>
     </sec>
    </sec>
    <sec id="sec5">
     <title>
      Vaccines
     </title>
     <p>
      It is
crucial to develop safe and effective vaccines to control the COVID-19
pandemic, eliminate its spread, and ultimately prevent its future
recurrence. Since the SARS-CoV-2 virus shares significant sequence
homology with two other lethal coronaviruses, SARS and MERS, the vaccines
identified in these patents related to SARS and MERS viruses could
potentially facilitate the design of anti-SARS-CoV-2 vaccines.
     </p>
     <sec id="sec5.1">
      <title>
       Distribution
of Patents Related to SARS and MERS among Vaccine Types
      </title>
      <p>
       Antiviral
vaccines generally fall into one of the following types: inactive
or live-attenuated viruses, virus-like particle (VLP), viral vectors,
protein-based, DNA-based, and mRNA-based vaccines. There are 363 patents
in the CAS content collection related to vaccine development to prevent
viral disorders/diseases, including SARS and MERS. Of these, 175 patents
disclose vaccines for non-coronaviruses that may have relevance to
SARS and MERS, while 188 patents are directly associated with anti-SARS
and anti-MERS vaccines with a demonstrated immune response. Supporting
Information
       <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00272/suppl_file/oc0c00272_si_001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        Table S2
       </ext-link>
       contains additional
information on these SARS/MERS vaccine-related patents.
      </p>
      <p>
       <xref ref-type="fig" rid="fig7">
        Figure
        <xref ref-type="fig" rid="fig7">
         7
        </xref>
       </xref>
       reveals the distribution
of patents among these vaccine types related to SARS and MERS. As
can be seen, 15 patents disclose information about inactive and live-attenuated
virus vaccines, 28 patents describe DNA vaccines, 21 patents disclose
information on viral vector vaccines, 13 patents disclose information
on VLP vaccines, and three patents are focused on mRNA vaccines.
      </p>
      <fig id="fig7" position="float">
       <label>
        Figure 7
       </label>
       <caption>
        <p>
         Distribution of vaccine-related patent
associated to SARS and MERS.
        </p>
       </caption>
       <graphic id="gr7" position="float" xlink:href="oc0c00272_0007" xmlns:xlink="http://www.w3.org/1999/xlink">
       </graphic>
      </fig>
      <p>
       It was reported that viral S protein subunit vaccines produced higher
neutralizing antibody titers and more complete protection than live-attenuated
SARS-CoV, full-length S protein, and DNA-based S protein vaccines.
       <sup>
        <xref ref-type="bibr" rid="ref51">
         51
        </xref>
       </sup>
       Unsurprisingly, about half of the patents focused
on protein vaccines comprising the S protein subunit vaccine and vaccines
specifically targeting the receptor binding domain (RBD) of the S1
subunit of the viral S protein. Collectively, S protein/gene is the
preferred target site in SARS/MERS vaccine development, and the same
strategy can be potentially useful in developing SARS-CoV-2 vaccines.
A condensed report on several patents that describe vaccines for generating
immunity to SARS and MERS follows.
      </p>
     </sec>
     <sec id="sec5.2">
      <title>
       Attenuated Virus Vaccines
      </title>
      <p>
       Patent application US20060039926
discloses live attenuated coronavirus or torovirus vaccines. Introduction
of a mutation (Y6398H) into the Orf1a/b polyprotein (p59/nsp14/ExoN)
was shown to completely attenuate virulence of mouse coronavirus (MHV-A59).
The attenuated MHV virus exhibited reduced replication in mice at
day five following intracerebral inoculation.
      </p>
     </sec>
     <sec id="sec5.3">
      <title>
       DNA-Based Vaccines
      </title>
      <p>
       Patent application WO2005081716 discloses compositions and methods
for inducing/enhancing immune responses, particularly antigen-specific
CD8+ T cell-mediated responses, against antigens of the SARS coronavirus.
An enhancement of the immune response involving particularly cytotoxic
T cell immune responses is induced in vivo by chimeric nucleic acids
that encode an endoplasmic reticulum chaperone polypeptide (e.g.,
calreticulin) linked to at least one antigenic polypeptide or peptide
from SARS-CoV. Using gene gun delivery of DNA-coated gold particles,
vaccination of mice against a calreticulin–nucleocapsid fusion
protein resulted in potent nucleocapsid-specific humoral and T cell-mediated
immune responses. Vaccinated animals were capable of significantly
reducing the titer of a challenging vaccinia vector expressing the
N protein of the SARS virus.
      </p>
      <p>
       Patent application WO2015081155
discloses immunogens, which comprise consensus proteins derived from
the MERS-CoV spike protein, for use in DNA-based vaccines targeting
MERS-CoV. The consensus spike protein significantly induced both humoral
and cellular immune responses, including increased titers of IgG and
neutralizing antibodies. The induced cellular immune response involved
increased CD3+CD4+ and CD3+CD8+ T cell responses that produced IFN-γ,
TNF-α, IL-2, or both IFN-γ and TNF-α. On March 3,
2020, Inovio Pharmaceutical, Inc. announced they had designed the
DNA vaccine called INO-4800 to be planned for human trials in the
United States in April.
       <sup>
        <xref ref-type="bibr" rid="ref57">
         57
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="sec5.4">
      <title>
       Protein-Based
Vaccines
      </title>
      <p>
       Patent application WO2010063685 by GlaxoSmithKline
(GSK) discloses a vaccine capable of provoking a protective immune
response against SARS. The vaccine comprises an S protein immunogen
and an oil-in-water emulsion adjuvant. An engineered ectodomain immunogen
(soluble S protein), in combination with the emulsion adjuvant, GSK2,
induced high levels of anti-SARS-CoV IgG2a or IgG2b antibody responses
and neutralizing antibody responses in animal models. In late February
2020, GSK announced a collaboration with Chinese firm Clover Biopharmaceuticals
to assess a coronavirus (COVID-19) vaccine candidate.
       <sup>
        <xref ref-type="bibr" rid="ref52">
         52
        </xref>
       </sup>
       This collaboration will involve the use of Clover’s
protein-based coronavirus vaccine candidate (COVID-19 S-Trimer) with
GSK’s adjuvant system. By applying their Trimer-Tag technology,
Clover has manufactured an S-Trimer subunit vaccine using a rapid
mammalian cell culture-based expression system. The Trimer-Tag is
an advanced drug development platform, which enables the production
of novel, covalently trimerized fusion proteins that can better target
previous undruggable pathways.
      </p>
      <p>
       Patent application US20070003577
discloses immunogenic compositions and vaccines associated with the
S protein of SARS coronavirus. A TriSpike SARS coronavirus vaccine
was prepared from a recombinant full-length trimeric S protein. The
recombinant protein was shown to (1) exhibit native antigenicity as
shown by reactivity with convalescent SARS patient sera; (2) exhibit
specific binding to soluble ACE2 receptor; (3) promote antibody-dependent
viral entry in otherwise refractory human Raji B cells; and (4) elicit
protection against a challenge infection in an animal model.
      </p>
      <p>
       Patent application US20060002947 (Antigen Express, Inc., a subsidiary
of Generex) discloses the preparation of hybrid peptides composed
of three elements, including (a) an invariant chain (Ii) key peptide
for antigen presentation enhancing activity, (b) a chemical structure
linking the Ii to the antigenic epitope, and (c) an antigenic epitope
that binds to a MHC class II molecule. The methodology was used to
create Ii-Key/MHC II SARS hybrids. Recently, Generex announced that
it is developing a COVID-19 vaccine following a contractual agreement
with a Chinese consortium comprised of China Technology Exchange,
Beijing Zhonghua Investment Fund Management, Biology Institute of
Shandong Academy of Sciences, and Sinotek-Advocates International
Industry Development. The company will utilize its Ii-Key immune system
activation technology to produce a COVID-19 viral peptide for human
clinical trials.
       <sup>
        <xref ref-type="bibr" rid="ref53">
         53
        </xref>
       </sup>
      </p>
     </sec>
     <sec id="sec5.5">
      <title>
       Virus-like Particle Vaccines
      </title>
      <p>
       In 2015, patent application WO2015042373 by Novavax disclosed an
immunogenic composition composed of MERS-CoV nanoparticle VLPs containing
at least one trimer of a S protein, produced by baculovirus overexpression
in Sf9 cells. This VLP preparation induced a neutralizing antibody
response in mice and transgenic cattle, when administered along with
their proprietary adjuvant Matrix M (RN 1235341-17-9). In addition,
preparations of sera from vaccinated cattle (SAB-300 or SAB-301) were
injected into Ad5-hDPP4 transduced BALB/c mice prior to challenge
with MERS-CoV. Both SAB-300 and SAB-301 were able to protect these
mice from MERS-CoV infection with a single prophylactic injection.
Novavax announced on February 26, 2020
       <sup>
        <xref ref-type="bibr" rid="ref54">
         54
        </xref>
       </sup>
       that it was beginning animal testing on potential COVID-19 vaccine
candidates due to their previous experiences working with other coronaviruses,
including both MERS and SARS. Their COVID-19 candidate vaccines targeting
the S protein of SARS-CoV-2 were developed using their recombinant
nanoparticle vaccine technology along with their proprietary adjuvant
Matrix-M.
      </p>
     </sec>
     <sec id="sec5.6">
      <title>
       mRNA-Based Vaccines
      </title>
      <p>
       The potential advantages of an
mRNA approach to prophylactic vaccines include the ability to mimic
natural infection to stimulate a more potent immune response as well
as the ability to combine multiple mRNAs into a single vaccine. Patent
application WO2017070626 by Moderna discloses mRNA vaccines composed
of mRNAs encoding antigenic viral full-length S, S1, or S2 proteins
from SARS-CoV and MERS-CoV virus, formulated in cationic lipid nanoparticles.
They show that mice vaccinated with mRNA encoding coronavirus full-length
S protein generated much higher neutralizing antibody titers compared
to mRNA encoding the S protein S2 subunit. New Zealand white rabbits
immunized with MERS-CoV mRNA vaccine encoding
the full-length S protein reduced more than 90% of the viral load
in the lungs of the rabbits and induced a significant amount of neutralizing
antibody against MERS-CoV. Moderna announced on February 24, 2020
       <sup>
        <xref ref-type="bibr" rid="ref55">
         55
        </xref>
       </sup>
       that it has released the first batch of mRNA-1273
against SARS-CoV-2 for use in humans, prepared using methods and strategies
outlined in their previous patents. Vials of mRNA-1273 have been shipped
to the National Institute of Allergy and Infectious Diseases (NIAID),
a division of the National Institutes of Health (NIH), to be used
in the planned Phase 1 study in the United States. Moderna reports
that mRNA-1273 is an mRNA vaccine targeting a
       <ext-link ext-link-type="uri" xlink:href="https://www.niaid.nih.gov/news-events/atomic-structure-novel-coronavirus-protein" xmlns:xlink="http://www.w3.org/1999/xlink">
        prefusion-stabilized
       </ext-link>
       form of the S protein associated
with SARS-CoV-2, which was selected by Moderna in collaboration with
investigators at the NIAID Vaccine Research Center. Manufacture of
this batch was funded by the Coalition for Epidemic Preparedness Innovations.
      </p>
      <p>
       Patent application WO2018115527 describes vaccines comprising mRNA
encoding at least one antigen of a MERS coronavirus, preferably a
S protein or a S protein fragment (S1), an envelope protein (E), a
membrane protein (M), or a nucleocapsid protein (N), all of which
were effective in inducing an antigen-specific immune response. Intradermal
administration into mice of a lipid nanoparticle (LNP)-encapsulated
mRNA mixture encoding MERS-CoV S proteins was shown to result in translation
in vivo and induction of humoral immune responses.
      </p>
     </sec>
    </sec>
    <sec id="sec6">
     <title>
      SUMMARY AND PERSPECTIVES
     </title>
     <p>
      This report provides an overview of published information on global
research and development of coronavirus-related therapeutic agents
and preventive vaccines based on the extensive CAS content collection,
with a focus on patents. It includes an overview of coronavirus morphology,
biology, and pathogenesis with a particular focus on antiviral strategies
involving small molecule drugs, as well as biologics targeting complex
molecular interactions involved in coronavirus infection and replication.
The drug-repurposing effort summarized in this report is focused primarily
on agents currently known to be effective against other RNA viruses
including SARS-CoV, MERS-CoV, influenza, HCV, and Ebola as well as
anti-inflammatory drugs. The potential impact of biologics for treatment
of coronavirus infections is promising and includes a wide variety
of options including bioengineered and vectored antibodies, cytokines,
and nucleic acid-based therapies targeting virus gene expression as
well as various types of vaccines.
     </p>
     <p>
      The information provided
in this report provides a strong intellectual groundwork for support
of ongoing research and development for discovery and development
of therapeutic agents and vaccines for treatment of COVID-19 and coronavirus-related
diseases. Because of limited space, this report devotes minimal attention
to current efforts involved in advancing more efficient and accurate
COVID-19 diagnosis methods and products.
     </p>
     <p>
      Novel infectious diseases
resulting from RNA viruses subject to mutation and genetic recombination,
as well as cross-species transmission, will continue to present a
serious global health threat, as exemplified by COVID-19. Despite
two former major outbreaks of coronavirus infections causing the SARS
and MERS respiratory illnesses, the world remains underprepared to
effectively manage the current COVID-19 outbreak, as evidenced by
the fact that COVID-19 has resulted in thousands of deaths worldwide.
     </p>
     <p>
      A concerted effort to develop effective drugs and vaccines against
existing and potential future coronavirus infections and other highly
pathogenic virus outbreaks is necessary to reduce overwhelming impacts
on human life and worldwide healthcare systems. Given the costly and
arduous process involved with clinical drug development, the outbreak
of COVID-19 further highlights the value of developing relatively
broad-spectrum antiviral drugs and the importance of applying innovative
approaches such as artificial intelligence to facilitate drug discovery.
Given the lengthy process of new drug development, the current strategy
of drug repurposing has become one of the chosen solutions for immediate
treatment of SARS-CoV-2 infected individuals. Long-term drug development
goals for the pharmaceutical industry include identification of inhibitors
aimed at the replication or infection processes associated with SARS-CoV-2
or other related coronaviruses, as well as the symptomatic results
of their infections leading to severe disease and/or death. The summarized
lists, contained in this report, of small molecule compounds, and
additional descriptions of biologics with properties suitable for
inhibiting several key coronavirus proteins, could serve as information
starting points for drug development. Since vaccines are crucial for
prevention of coronavirus-related epidemic diseases in the future,
it is reassuring that a number of innovative strategies are already
being deployed. Four MERS coronavirus DNA vaccine candidates began
phase 1 clinical trials in September of 2019,
      <sup>
       <xref ref-type="bibr" rid="ref56">
        56
       </xref>
      </sup>
      and Moderna Inc. released its first batch of mRNA-1273 in February
of 2020, which is an mRNA vaccine against SARS-CoV-2 ready for phase
1 study in the United States.
      <sup>
       <xref ref-type="bibr" rid="ref55">
        55
       </xref>
      </sup>
     </p>
     <p>
      Additional
collaboration in the areas of antiviral discovery processes and clinical
trial performance will enhance patients’ access to drug candidates
with improved therapeutic potential and ideally reduce the amount
of time required to bring these drugs to market. The abundance of publications and the
rapid publication rate associated with the SARS-CoV-2 virus-related
disease outbreak, as illustrated in this report, are indicative
of the intense effort by research institutes and pharmaceutical
industries to address both molecular mechanisms and therapeutic routes
useful for treating current and future coronavirus outbreaks.
     </p>
    </sec>
    <back>
     <notes id="notes1" notes-type="si">
      <title>
       Supporting Information Available
      </title>
      <p>
       The Supporting Information is available free of charge at
       <ext-link ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acscentsci.0c00272?goto=supporting-info" xmlns:xlink="http://www.w3.org/1999/xlink">
        https://pubs.acs.org/doi/10.1021/acscentsci.0c00272
       </ext-link>
       .
       <list id="silist" list-type="simple">
        <list-item>
         <p>
          Tables of distribution
of RNAi patents related to SARS and MERS in the CAS content collection
and distribution of vaccine patents related to SARS and MERS in the
CAS content collection (
          <ext-link ext-link-type="uri" xlink:href="http://pubs.acs.org/doi/suppl/10.1021/acscentsci.0c00272/suppl_file/oc0c00272_si_001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
           PDF
          </ext-link>
          )
         </p>
        </list-item>
       </list>
      </p>
     </notes>
     <sec sec-type="supplementary-material">
      <title>
       Supplementary Material
      </title>
      <supplementary-material content-type="local-data" id="sifile1">
       <media xlink:href="oc0c00272_si_001.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
        <caption>
         <p>
          oc0c00272_si_001.pdf
         </p>
        </caption>
       </media>
      </supplementary-material>
     </sec>
     <notes id="NOTES-d7e2651-autogenerated" notes-type="COI-statement">
      <p>
       The authors
declare no competing financial interest.
      </p>
     </notes>
     <ack>
      <title>
       Acknowledgments
      </title>
      <p>
       We would like to thank Dr. Gilles George
for his encouragement and support for this work. We are grateful to
Cristina Tomeo for her advice, and Andrey Sharkov and Cinda Harold
for their useful input.
      </p>
     </ack>
     <fn-group>
      <fn id="fn1">
       <label>
        a
       </label>
       <p>
        To learn more about CAS proprietary fingerprints:
        <uri xlink:href="https://www.cas.org/resources/case-studies/data-quality-impacts-machine-learning" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://www.cas.org/resources/case-studies/data-quality-impacts-machine-learning
        </uri>
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <title>
       References
      </title>
      <ref id="ref1">
       <mixed-citation id="cit1" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Gorbalenya
          </surname>
          <given-names>
           A. E.
          </given-names>
         </name>
        </person-group>
        <etal>
        </etal>
        <article-title>
         The species severe acute respiratory syndrome-related coronavirus:
classifying 2019-nCoV and naming it SARS-CoV-2
        </article-title>
        .
        <source>
         Nature Microbiology
        </source>
        <year>
         2020
        </year>
        ,
        <pub-id pub-id-type="doi">
         10.1038/s41564-020-0695-z
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref2">
       <mixed-citation id="cit2" publication-type="journal">
        <name>
         <surname>
          Kupferschmidt
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Cohen
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <article-title>
         Will novel virus go
pandemic or be contained?
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         367
        </volume>
        (
        <issue>
         6478
        </issue>
        ),
        <fpage>
         610
        </fpage>
        –
        <lpage>
         611
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.367.6478.610
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32029604
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref3">
       <mixed-citation id="cit3" publication-type="report">
        <source>
         Coronavirus Disease
(COVID-2019) Situation Reports 1–45
        </source>
        ;
        <publisher-name>
         World Health Organization
        </publisher-name>
        ,
        <year>
         2020
        </year>
        .
        <uri xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref4">
       <mixed-citation id="cit4" publication-type="weblink">
        <article-title>
         Coronavirus is now expected to curb global
economic growth by 0.3% in 2020
        </article-title>
        .
        <uri xlink:href="https://www.forbes.com/sites/sergeiklebnikov/2020/02/11/coronavirus-is-now-expected-to-curb-global-economic-growth-by-03-in-2020/#5de149ad16da" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://www.forbes.com/sites/sergeiklebnikov/2020/02/11/coronavirus-is-now-expected-to-curb-global-economic-growth-by-03-in-2020/#5de149ad16da
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref5">
       <mixed-citation id="cit5" publication-type="journal">
        <name>
         <surname>
          Anthony
         </surname>
         <given-names>
          S. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Johnson
         </surname>
         <given-names>
          C. K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Greig
         </surname>
         <given-names>
          D. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kramer
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Che
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wells
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hicks
         </surname>
         <given-names>
          A. L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Joly
         </surname>
         <given-names>
          D. O.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wolfe
         </surname>
         <given-names>
          N. D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Daszak
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Karesh
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lipkin
         </surname>
         <given-names>
          W. I.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Morse
         </surname>
         <given-names>
          S. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Mazet
         </surname>
         <given-names>
          J. A. K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Goldstein
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        <article-title>
         Global patterns
in coronavirus diversity
        </article-title>
        .
        <source>
         Virus Evol
        </source>
        <year>
         2017
        </year>
        ,
        <volume>
         3
        </volume>
        (
        <issue>
         1
        </issue>
        ),
        <fpage>
         vex012
        </fpage>
        <pub-id pub-id-type="doi">
         10.1093/ve/vex012
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         28630747
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref6">
       <mixed-citation id="cit6" publication-type="journal">
        <name>
         <surname>
          Su
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wong
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lai
         </surname>
         <given-names>
          A. C.K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bi
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          G. F.
         </given-names>
        </name>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis
of coronaviruses
        </article-title>
        .
        <source>
         Trends Microbiol.
        </source>
        <year>
         2016
        </year>
        ,
        <volume>
         24
        </volume>
        (
        <issue>
         6
        </issue>
        ),
        <fpage>
         490
        </fpage>
        –
        <lpage>
         502
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2016.03.003
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         27012512
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref7">
       <mixed-citation id="cit7" publication-type="journal">
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          N.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Niu
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhan
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          G. F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        <article-title>
         A novel coronavirus from patients with pneumonia in China, 2019
        </article-title>
        .
        <source>
         N. Engl. J. Med.
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         382
        </volume>
        (
        <issue>
         8
        </issue>
        ),
        <fpage>
         727
        </fpage>
        –
        <lpage>
         733
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2001017
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref8">
       <mixed-citation id="cit8" publication-type="journal">
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bragazzi
         </surname>
         <given-names>
          N. L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          Q.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Tang
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xiao
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <article-title>
         An updated estimation
of the risk of transmission of the novel coronavirus (2019-nCov)
        </article-title>
        .
        <source>
         Infect Dis Model
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         5
        </volume>
        ,
        <fpage>
         248
        </fpage>
        –
        <lpage>
         255
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.idm.2020.02.001
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32099934
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref9">
       <mixed-citation id="cit9" publication-type="journal">
        <name>
         <surname>
          Du
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          He
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zheng
         </surname>
         <given-names>
          B.-J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        <article-title>
         The spike protein of SARS-CoV - A target for vaccine and therapeutic
development
        </article-title>
        .
        <source>
         Nat. Rev. Microbiol.
        </source>
        <year>
         2009
        </year>
        ,
        <volume>
         7
        </volume>
        (
        <issue>
         3
        </issue>
        ),
        <fpage>
         226
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nrmicro2090
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         19198616
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref10">
       <mixed-citation id="cit10" publication-type="journal">
        <name>
         <surname>
          Wrapp
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          N.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Corbett
         </surname>
         <given-names>
          K. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Goldsmith
         </surname>
         <given-names>
          J. A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hsieh
         </surname>
         <given-names>
          C.-L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Abiona
         </surname>
         <given-names>
          O.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Graham
         </surname>
         <given-names>
          B. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          McLellan
         </surname>
         <given-names>
          J. S.
         </given-names>
        </name>
        <article-title>
         Cryo-EM structure of the 2019-nCoV Spike in the prefusion
conformation
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2020
        </year>
        ,
        <fpage>
         eabb2507
        </fpage>
        <pub-id pub-id-type="doi">
         10.1126/science.abb2507
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="ref11">
       <mixed-citation id="cit11" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Kruger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Erichsen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Schiergens
          </surname>
          <given-names>
           T. S.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           N.-H.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M. A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV-2
Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically
Proven Protease Inhibitor
        </article-title>
        .
        <source>
         Cell
        </source>
        <year>
         2020
        </year>
        ,
        <pub-id pub-id-type="doi">
         10.1016/j.cell.2020.02.052
        </pub-id>
        . [Epub ahead of print].
       </mixed-citation>
      </ref>
      <ref id="ref12">
       <mixed-citation id="cit12" publication-type="journal">
        <name>
         <surname>
          Gorbalenya
         </surname>
         <given-names>
          A. E.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Snijder
         </surname>
         <given-names>
          E. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ziebuhr
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <article-title>
         Virus-encoded proteinases and proteolytic processing
in the Nidovirales
        </article-title>
        .
        <source>
         J. Gen. Virol.
        </source>
        <year>
         2000
        </year>
        ,
        <volume>
         81
        </volume>
        (
        <issue>
         4
        </issue>
        ),
        <fpage>
         853
        </fpage>
        –
        <lpage>
         879
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1099/0022-1317-81-4-853
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10725411
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref13">
       <mixed-citation id="cit13" publication-type="journal">
        <name>
         <surname>
          Baez-Santos
         </surname>
         <given-names>
          Y. M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          St. John
         </surname>
         <given-names>
          S. E.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Mesecar
         </surname>
         <given-names>
          A. D.
         </given-names>
        </name>
        <article-title>
         The SARS-coronavirus
papain-like protease: structure, function and inhibition by designed
antiviral compounds
        </article-title>
        .
        <source>
         Antiviral Res.
        </source>
        <year>
         2015
        </year>
        ,
        <volume>
         115
        </volume>
        ,
        <fpage>
         21
        </fpage>
        –
        <lpage>
         38
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2014.12.015
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25554382
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref14">
       <mixed-citation id="cit14" publication-type="journal">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          T.-W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Cherney
         </surname>
         <given-names>
          M. M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Huitema
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          James
         </surname>
         <given-names>
          K. E.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Powers
         </surname>
         <given-names>
          J. C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Eltis
         </surname>
         <given-names>
          L. D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          James
         </surname>
         <given-names>
          M. N.G.
         </given-names>
        </name>
        <article-title>
         Crystal
structures of the main peptidase from the SARS coronavirus inhibited
by a substrate-like aza-peptide epoxide
        </article-title>
        .
        <source>
         J.
Mol. Biol.
        </source>
        <year>
         2005
        </year>
        ,
        <volume>
         353
        </volume>
        (
        <issue>
         5
        </issue>
        ),
        <fpage>
         1137
        </fpage>
        –
        <lpage>
         1151
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.jmb.2005.09.004
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16219322
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref15">
       <mixed-citation id="cit15" publication-type="journal">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Niu
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          N.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bi
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhan
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Meng
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lin
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xie
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ma
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          W. J
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Holmes
         </surname>
         <given-names>
          E. C
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          G. F
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Tan
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        <article-title>
         Genomic characterization
and epidemiology of 2019 novel coronavirus: implications for virus
origins and receptor binding
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         395
        </volume>
        ,
        <fpage>
         565
        </fpage>
        –
        <lpage>
         574
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30251-8
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32007145
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref16">
       <mixed-citation id="cit16" publication-type="journal">
        <name>
         <surname>
          Morse
         </surname>
         <given-names>
          J. S.
         </given-names>
        </name>
        ; et al.
        <article-title>
         Learning from the past: possible urgent prevention and treatment
options for severe acute respiratory infections caused by 2019-nCoV
        </article-title>
        .
        <source>
         ChemBioChem
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         21
        </volume>
        (
        <issue>
         5
        </issue>
        ),
        <fpage>
         730
        </fpage>
        –
        <lpage>
         738
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1002/cbic.202000047
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32022370
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref17">
       <mixed-citation id="cit17" publication-type="journal">
        <name>
         <surname>
          Chan
         </surname>
         <given-names>
          J. F.-W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kok
         </surname>
         <given-names>
          K.-H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          To
         </surname>
         <given-names>
          K. K.-W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yuan
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yuen
         </surname>
         <given-names>
          K.-Y.
         </given-names>
        </name>
        <article-title>
         Genomic characterization
of the 2019 novel human-pathogenic coronavirus isolated from a patient
with atypical pneumonia after visiting Wuhan
        </article-title>
        .
        <source>
         Emerging Microbes Infect.
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         9
        </volume>
        (
        <issue>
         1
        </issue>
        ),
        <fpage>
         221
        </fpage>
        –
        <lpage>
         236
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1080/22221751.2020.1719902
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="ref18">
       <mixed-citation id="cit18" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        ,
        <etal>
        </etal>
        <article-title>
         Genomic and protein structure modelling analysis depicts the origin
and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia
outbreak in Wuhan, China
        </article-title>
        ,
        <source>
         bioRxiv
        </source>
        <year>
         2020
        </year>
        ,
        <pub-id pub-id-type="doi">
         10.1101/2020.01.20.913368
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="ref19">
       <mixed-citation id="cit19" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Sheahan
          </surname>
          <given-names>
           T. P.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Sims
          </surname>
          <given-names>
           A. C.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Leist
          </surname>
          <given-names>
           S. R.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Schafer
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Won
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           A. J.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           S. A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Hogg
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Babusis
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Clarke
          </surname>
          <given-names>
           M. O.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Spahn
          </surname>
          <given-names>
           J. E.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Bauer
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Sellers
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Porter
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J. Y.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Cihlar
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Jordan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Denison
          </surname>
          <given-names>
           M. R.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R. S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative therapeutic efficacy of remdesivir and
combination lopinavir, ritonavir, and interferon beta against MERS-CoV
        </article-title>
        <source>
         Nat. Commun.
        </source>
        <year>
         2020
        </year>
        , Ahead of Print.
        <pub-id pub-id-type="doi">
         10.1038/s41467-019-13940-6
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref20">
       <mixed-citation id="cit20" publication-type="journal">
        <name>
         <surname>
          Kadam
         </surname>
         <given-names>
          R. U.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wilson
         </surname>
         <given-names>
          I. A.
         </given-names>
        </name>
        <article-title>
         Structural basis
of influenza virus fusion inhibition by the antiviral drug Arbidol
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <year>
         2017
        </year>
        ,
        <volume>
         114
        </volume>
        (
        <issue>
         2
        </issue>
        ),
        <fpage>
         206
        </fpage>
        –
        <lpage>
         214
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1617020114
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         28003465
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref21">
       <mixed-citation id="cit21" publication-type="weblink">
        <article-title>
         Therapeutic options for the 2019 novel coronavirus
(2019-nCoV)
        </article-title>
        .
        <uri xlink:href="https://www.nature.com/articles/d41573-020-00016-0" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://www.nature.com/articles/d41573-020-00016-0
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref22">
       <mixed-citation id="cit22" publication-type="weblink">
        <article-title>
         The Efficacy of Lopinavir Plus Ritonavir
and Arbidol Against Novel Coronavirus Infection (ELACOI)
        </article-title>
        .
        <uri xlink:href="https://clinicaltrials.gov/ct2/show/NCT04252885" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://clinicaltrials.gov/ct2/show/NCT04252885
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref23">
       <mixed-citation id="cit23" publication-type="journal">
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          I.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Herzog
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Pfefferle
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Steffen
         </surname>
         <given-names>
          I.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Muench
         </surname>
         <given-names>
          M. O.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Simmons
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hofmann
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kuri
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Weber
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Eichler
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Pohlmann
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        <article-title>
         Differential downregulation of ACE2
by the spike proteins of severe acute respiratory syndrome coronavirus
and human coronavirus NL63
        </article-title>
        .
        <source>
         Journal of Virology
        </source>
        <year>
         2010
        </year>
        ,
        <volume>
         84
        </volume>
        (
        <issue>
         2
        </issue>
        ),
        <fpage>
         1198
        </fpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.01248-09
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         19864379
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref24">
       <mixed-citation id="cit24" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Compensation of ACE2 function
for possible clinical management
        </article-title>
        .
        <source>
         Virol. Sin.
        </source>
        <year>
         2020
        </year>
        ,
        <pub-id pub-id-type="doi">
         10.1007/s12250-020-00205-6
        </pub-id>
        . [Epub ahead of print].
       </mixed-citation>
      </ref>
      <ref id="ref25">
       <mixed-citation id="cit25" publication-type="journal">
        <name>
         <surname>
          Donoghue
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hsieh
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Baronas
         </surname>
         <given-names>
          E.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Godbout
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gosselin
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Stagliano
         </surname>
         <given-names>
          N.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Donovan
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Woolf
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Robison
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Jeyaseelan
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Breitbart
         </surname>
         <given-names>
          R. E.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Acton
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2)
converts angiotensin I to angiotensin 1–9
        </article-title>
        .
        <source>
         Circ. Res.
        </source>
        <year>
         2000
        </year>
        ,
        <volume>
         87
        </volume>
        (
        <issue>
         5
        </issue>
        ),
        <fpage>
         426
        </fpage>
        <pub-id pub-id-type="doi">
         10.1161/01.RES.87.5.e1
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="ref26">
       <mixed-citation id="cit26" publication-type="journal">
        <name>
         <surname>
          Imai
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kuba
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Rao
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Huan
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Guo
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Guan
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Sarao
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wada
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Leong-Poi
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Crackower
         </surname>
         <given-names>
          M. A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Fukamizu
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hui
         </surname>
         <given-names>
          C.-C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hein
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Uhlig
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Slutsky
         </surname>
         <given-names>
          A. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Penninger
         </surname>
         <given-names>
          J. M.
         </given-names>
        </name>
        <article-title>
         Angiotensin-converting enzyme 2 protects from severe
acute lung failure
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2005
        </year>
        ,
        <volume>
         436
        </volume>
        (
        <issue>
         7047
        </issue>
        ),
        <fpage>
         112
        </fpage>
        –
        <lpage>
         116
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nature03712
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16001071
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref27">
       <mixed-citation id="cit27" publication-type="journal">
        <name>
         <surname>
          Tipnis
         </surname>
         <given-names>
          S. R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hooper
         </surname>
         <given-names>
          N. M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hyde
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Karran
         </surname>
         <given-names>
          E.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Christie
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Turner
         </surname>
         <given-names>
          A. J.
         </given-names>
        </name>
        <article-title>
         A human homolog
of angiotensin-converting enzyme. Cloning and functional expression
as a captopril-insensitive carboxypeptidase
        </article-title>
        .
        <source>
         J. Biol. Chem.
        </source>
        <year>
         2000
        </year>
        ,
        <volume>
         275
        </volume>
        (
        <issue>
         43
        </issue>
        ),
        <fpage>
         33238
        </fpage>
        –
        <lpage>
         33243
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1074/jbc.M002615200
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref28">
       <mixed-citation id="cit28" publication-type="journal">
        <name>
         <surname>
          De Witt
         </surname>
         <given-names>
          B. J
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Garrison
         </surname>
         <given-names>
          E. A
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Champion
         </surname>
         <given-names>
          H. C
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kadowitz
         </surname>
         <given-names>
          P. J.
         </given-names>
        </name>
        <article-title>
         L-163,491 is a partial angiotensin AT(1) receptor agonist
in the hindquarters vascular bed of the cat
        </article-title>
        .
        <source>
         Eur. J. Pharmacol.
        </source>
        <year>
         2000
        </year>
        ,
        <volume>
         404
        </volume>
        (
        <issue>
         1-2
        </issue>
        ),
        <fpage>
         213
        </fpage>
        –
        <lpage>
         219
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0014-2999(00)00612-9
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         10980281
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref29">
       <mixed-citation id="cit29" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Old weapon for new enemy: drug
repurposing for treatment of newly emerging viral diseases
        </article-title>
        .
        <source>
         Virol. Sin.
        </source>
        <year>
         2020
        </year>
        ,
        <pub-id pub-id-type="doi">
         10.1007/s12250-020-00204-7
        </pub-id>
        . [Epub ahead of print].
       </mixed-citation>
      </ref>
      <ref id="ref30">
       <mixed-citation id="cit30" publication-type="journal">
        <name>
         <surname>
          Maxmen
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        <article-title>
         More than 80 clinical trials launch
to test coronavirus treatments
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         578
        </volume>
        (
        <issue>
         7795
        </issue>
        ),
        <fpage>
         347
        </fpage>
        –
        <lpage>
         348
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/d41586-020-00444-3
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32071447
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref31">
       <mixed-citation id="cit31" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y. M
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al-Omari
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al Qasim
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Jose
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Almotairi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al Khatib
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Abdulmomen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Qushmaq
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Sindi
          </surname>
          <given-names>
           A. A
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Mady
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Solaiman
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al-Raddadi
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Maghrabi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Ragab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al Mekhlafi
          </surname>
          <given-names>
           G. A
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H. H
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al Harthy
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Kharaba
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Gramish
          </surname>
          <given-names>
           J. A
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al-Aithan
          </surname>
          <given-names>
           A. M
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Al-Dawood
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Merson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F. G
          </given-names>
         </name>
         ;
         <name>
          <surname>
           Fowler
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Ribavirin and Interferon Therapy
for Critically Ill Patients With Middle East Respiratory Syndrome:
A Multicenter Observational Study
        </article-title>
        .
        <source>
         Clin. Infect.
Dis.
        </source>
        <year>
         2019
        </year>
        , DOI:
        <pub-id pub-id-type="doi">
         10.1093/cid/ciz544
        </pub-id>
        . [Epub ahead of print].
       </mixed-citation>
      </ref>
      <ref id="ref32">
       <mixed-citation id="cit32" publication-type="journal">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Cao
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Shi
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhong
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xiao
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged
novel coronavirus (2019-nCoV) in vitro
        </article-title>
        .
        <source>
         Cell
Res.
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         30
        </volume>
        ,
        <fpage>
         269
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41422-020-0282-0
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref33">
       <mixed-citation id="cit33" publication-type="weblink">
        <article-title>
         Kangji Xinguangzhuang Bingdu Feiyan Zhuanli
Xinxi Yanbao
        </article-title>
        .
        <uri xlink:href="https://tech.sina.cn/2020-02-17/detail-iimxxstf2046715.d.html" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://tech.sina.cn/2020-02-17/detail-iimxxstf2046715.d.html
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref34">
       <mixed-citation id="cit34" publication-type="journal">
        <name>
         <surname>
          Warren
         </surname>
         <given-names>
          T. K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wells
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Panchal
         </surname>
         <given-names>
          R. G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Stuthman
         </surname>
         <given-names>
          K. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Garza
         </surname>
         <given-names>
          N. L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Van Tongeren
         </surname>
         <given-names>
          S. A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Dong
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Retterer
         </surname>
         <given-names>
          C. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Eaton
         </surname>
         <given-names>
          B. P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Pegoraro
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Honnold
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bantia
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kotian
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Taubenheim
         </surname>
         <given-names>
          B. R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Welch
         </surname>
         <given-names>
          L. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Minning
         </surname>
         <given-names>
          D. M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Babu
         </surname>
         <given-names>
          Y. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Sheridan
         </surname>
         <given-names>
          W. P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bavari
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        <article-title>
         Protection Against Filovirus Diseases
by a Novel Broad-Spectrum Nucleoside Analogue BCX4430
        </article-title>
        .
        <source>
         Nature
        </source>
        <year>
         2014
        </year>
        ,
        <volume>
         508
        </volume>
        (
        <issue>
         7496
        </issue>
        ),
        <fpage>
         402
        </fpage>
        –
        <lpage>
         405
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1038/nature13027
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         24590073
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref35">
       <mixed-citation id="cit35" publication-type="journal">
        <name>
         <surname>
          Richardson
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Griffin
         </surname>
         <given-names>
          I.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Tucker
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Smith
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Oechsle
         </surname>
         <given-names>
          O.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Phelan
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Stebbing
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        <article-title>
         Baricitinib
as potential treatment for 2019-nCoV acute respiratory disease
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         395
        </volume>
        (
        <issue>
         10223
        </issue>
        ),
        <fpage>
         e30
        </fpage>
        –
        <lpage>
         e31
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30304-4
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         32032529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref36">
       <mixed-citation id="cit36" publication-type="journal">
        <name>
         <surname>
          Mifsud
         </surname>
         <given-names>
          E. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hayden
         </surname>
         <given-names>
          F. G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hurt
         </surname>
         <given-names>
          A. C.
         </given-names>
        </name>
        <article-title>
         Antivirals
targeting the polymerase complex of influenza viruses
        </article-title>
        .
        <source>
         Antiviral Res.
        </source>
        <year>
         2019
        </year>
        ,
        <volume>
         169
        </volume>
        ,
        <fpage>
         104545
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2019.104545
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         31247246
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref37">
       <mixed-citation id="cit37" publication-type="journal">
        <name>
         <surname>
          Zeldin
         </surname>
         <given-names>
          R. K.
         </given-names>
        </name>
        <article-title>
         Pharmacological
and therapeutic properties of ritonavir-boosted protease inhibitor
therapy in HIV-infected patients
        </article-title>
        .
        <source>
         J. Antimicrob.
Chemother.
        </source>
        <year>
         2003
        </year>
        ,
        <volume>
         53
        </volume>
        (
        <issue>
         1
        </issue>
        ),
        <fpage>
         4
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/jac/dkh029
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         14657084
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref38">
       <mixed-citation id="cit38" publication-type="journal">
        <name>
         <surname>
          Ortiz-Alcantara
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ; et al.
        <article-title>
         Small molecule inhibitors of the SARS-CoV NSP15 endoribonuclease
        </article-title>
        .
        <source>
         Virus Adapt. Treat.
        </source>
        <year>
         2010
        </year>
        ,
        <volume>
         2
        </volume>
        ,
        <fpage>
         125
        </fpage>
        –
        <lpage>
         133
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.2147/VAAT.S12733
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="ref39">
       <mixed-citation id="cit39" publication-type="journal">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Vedantham
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Agudelo
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Carrion
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Nunneley
         </surname>
         <given-names>
          J. W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Barnard
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Pohlmann
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          McKerrow
         </surname>
         <given-names>
          J. H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Renslo
         </surname>
         <given-names>
          A. R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Simmons
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        <article-title>
         Protease inhibitors targeting coronavirus
and filovirus entry
        </article-title>
        .
        <source>
         Antiviral Res.
        </source>
        <year>
         2015
        </year>
        ,
        <volume>
         116
        </volume>
        ,
        <fpage>
         76
        </fpage>
        –
        <lpage>
         84
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2015.01.011
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         25666761
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref40">
       <mixed-citation id="cit40" publication-type="journal">
        <name>
         <surname>
          Kumar
         </surname>
         <given-names>
          V.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Shin
         </surname>
         <given-names>
          J. S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Shie
         </surname>
         <given-names>
          J.-J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ku
         </surname>
         <given-names>
          K. B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Go
         </surname>
         <given-names>
          Y. Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          K.-F.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liang
         </surname>
         <given-names>
          P.-H.
         </given-names>
        </name>
        <article-title>
         Identification and evaluation of potent Middle East
respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors
        </article-title>
        .
        <source>
         Antiviral Res.
        </source>
        <year>
         2017
        </year>
        ,
        <volume>
         141
        </volume>
        ,
        <fpage>
         101
        </fpage>
        –
        <lpage>
         106
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2017.02.007
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         28216367
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref41">
       <mixed-citation id="cit41" publication-type="journal">
        <name>
         <surname>
          Anand
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        <article-title>
         Coronavirus Main Proteinase (3CLpro)
Structure: Basis for Design of Anti-SARS Drugs
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        ,
        <volume>
         300
        </volume>
        (
        <issue>
         5626
        </issue>
        ),
        <fpage>
         1763
        </fpage>
        –
        <lpage>
         1767
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.1085658
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         12746549
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref42">
       <mixed-citation id="cit42" publication-type="journal">
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          F.
         </given-names>
        </name>
        <article-title>
         Structure
of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
        </article-title>
        .
        <source>
         Science
        </source>
        <year>
         2005
        </year>
        ,
        <volume>
         309
        </volume>
        (
        <issue>
         5742
        </issue>
        ),
        <fpage>
         1864
        </fpage>
        –
        <lpage>
         1868
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.1116480
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref43">
       <mixed-citation id="cit43" publication-type="journal">
        <name>
         <surname>
          Bisht
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Roberts
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Vogel
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Subbarao
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Moss
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        <article-title>
         Neutralizing antibody and protective
immunity to SARS coronavirus infection of mice induced by a soluble
recombinant polypeptide containing an N-terminal segment of the spike
glycoprotein
        </article-title>
        .
        <source>
         Virology
        </source>
        <year>
         2005
        </year>
        ,
        <volume>
         334
        </volume>
        (
        <issue>
         2
        </issue>
        ),
        <fpage>
         160
        </fpage>
        –
        <lpage>
         165
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2005.01.042
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         15780866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref44">
       <mixed-citation id="cit44" publication-type="journal">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ren
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Fan
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xu
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gu
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yu
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xia
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wei
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xie
         </surname>
         <given-names>
          X.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yin
         </surname>
         <given-names>
          W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xiao
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Guo
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Xie
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gao
         </surname>
         <given-names>
          Z.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Jin
         </surname>
         <given-names>
          Q.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Cao
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        <article-title>
         Clinical features of patients infected
with 2019 novel coronavirus in Wuhan
        </article-title>
        .
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         395
        </volume>
        ,
        <fpage>
         497
        </fpage>
        –
        <lpage>
         506
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30183-5
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref45">
       <mixed-citation id="cit45" publication-type="journal">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Z.-Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          Y.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Ganesh
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Leung
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kong
         </surname>
         <given-names>
          W.-P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Schwartz
         </surname>
         <given-names>
          O.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Subbarao
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Nabel
         </surname>
         <given-names>
          G. J.
         </given-names>
        </name>
        <article-title>
         pH-dependent entry
of severe acute respiratory syndrome coronavirus is mediated by the
spike glycoprotein andenhanced by dendritic cell transfer through
DC-SIGN
        </article-title>
        .
        <source>
         J. Virol.
        </source>
        <year>
         2004
        </year>
        ,
        <volume>
         78
        </volume>
        ,
        <fpage>
         5642
        </fpage>
        –
        <lpage>
         5650
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.11.5642-5650.2004
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         15140961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref46">
       <mixed-citation id="cit46" publication-type="journal">
        <name>
         <surname>
          Marzi
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Gramberg
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Simmons
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Moller
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Rennekamp
         </surname>
         <given-names>
          A. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Krumbiegel
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Geier
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Eisemann
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Turza
         </surname>
         <given-names>
          N.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Saunier
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Steinkasserer
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Becker
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bates
         </surname>
         <given-names>
          P.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Hofmann
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Pohlmann
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        <article-title>
         DC-SIGN and DCSIGNR interact with the glycoprotein
of Marburg virus and the S protein of severe acute respiratory syndrome
coronavirus
        </article-title>
        .
        <source>
         J. Virol
        </source>
        <year>
         2004
        </year>
        ,
        <volume>
         78
        </volume>
        ,
        <fpage>
         12090
        </fpage>
        –
        <lpage>
         12095
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.21.12090-12095.2004
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         15479853
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref47">
       <mixed-citation id="cit47" publication-type="weblink">
        <article-title>
         The overview of Interferon
        </article-title>
        .
        <uri xlink:href="https://www.cusabio.com/c-20629.html" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://www.cusabio.com/c-20629.html
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref48">
       <mixed-citation id="cit48" publication-type="journal">
        <person-group>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cross Kingdom
small RNAs among Animals, Plants and Microbes
        </article-title>
        <source>
         Cells
        </source>
        <year>
         2019
        </year>
        ,
        <volume>
         8
        </volume>
        ( (
        <issue>
         4
        </issue>
        ), )
        <fpage>
         371
        </fpage>
        ,
        <pub-id pub-id-type="doi">
         10.3390/cells8040371
        </pub-id>
        .
       </mixed-citation>
      </ref>
      <ref id="ref49">
       <mixed-citation id="cit49" publication-type="journal">
        <name>
         <surname>
          Yan
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        <article-title>
         microRNAs in Cardiovascular Disease:
Small Molecules but Big Roles
        </article-title>
        .
        <source>
         Current Topics
in Medicinal Chemistry
        </source>
        <year>
         2019
        </year>
        ,
        <volume>
         19
        </volume>
        (
        <issue>
         21
        </issue>
        ),
        <fpage>
         1918
        </fpage>
        –
        <lpage>
         1947
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.2174/1568026619666190808160241
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         31393249
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref50">
       <mixed-citation id="cit50" publication-type="journal">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Guo
         </surname>
         <given-names>
          B.
         </given-names>
        </name>
        <article-title>
         RNA-based therapeutics
for colorectal cancer: Updates and future Directions
        </article-title>
        .
        <source>
         Pharmacol. Res.
        </source>
        <year>
         2020
        </year>
        ,
        <volume>
         152
        </volume>
        ,
        <fpage>
         104550
        </fpage>
        <pub-id pub-id-type="doi">
         10.1016/j.phrs.2019.104550
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         31866285
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref51">
       <mixed-citation id="cit51" publication-type="journal">
        <name>
         <surname>
          Buchholz
         </surname>
         <given-names>
          U. J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bukreyev
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          L.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lamirande
         </surname>
         <given-names>
          E. W.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Murphy
         </surname>
         <given-names>
          B. R.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Subbarao
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Collins
         </surname>
         <given-names>
          P. L.
         </given-names>
        </name>
        <article-title>
         Contributions of
the structural proteins of severe acute respiratory syndrome coronavirus
to protective immunity
        </article-title>
        .
        <source>
         Proc. Natl. Acad. Sci.
U. S. A.
        </source>
        <year>
         2004
        </year>
        ,
        <volume>
         101
        </volume>
        (
        <issue>
         26
        </issue>
        ),
        <fpage>
         9804
        </fpage>
        –
        <lpage>
         9809
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.0403492101
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         15210961
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref52">
       <mixed-citation id="cit52" publication-type="weblink">
        <article-title>
         GlaxoSmithKline press release on 2/24/20
        </article-title>
        .
        <uri xlink:href="https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://www.gsk.com/en-gb/media/press-releases/clover-and-gsk-announce-research-collaboration-to-evaluate-coronavirus-covid-19-vaccine-candidate-with-pandemic-adjuvant-system
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref53">
       <mixed-citation id="cit53" publication-type="weblink">
        <article-title>
         Generex press release on 2/27/20
        </article-title>
        .
        <uri xlink:href="https://storage.googleapis.com/wzukusers/user-26831283/documents/5e57ed391b286sVf68Kq/PR_Generex_Coronavirus_Update_2_27_2020.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://storage.googleapis.com/wzukusers/user-26831283/documents/5e57ed391b286sVf68Kq/PR_Generex_Coronavirus_Update_2_27_2020.pdf
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref54">
       <mixed-citation id="cit54" publication-type="weblink">
        <article-title>
         Novavax press release on 2/26/20
        </article-title>
        .
        <uri xlink:href="http://ir.novavax.com/news-releases/news-release-details/novavax-advances-development-novel-covid-19-vaccine" xmlns:xlink="http://www.w3.org/1999/xlink">
         http://ir.novavax.com/news-releases/news-release-details/novavax-advances-development-novel-covid-19-vaccine
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref55">
       <mixed-citation id="cit55" publication-type="weblink">
        <article-title>
         Moderna press release on 2/24/2020
        </article-title>
        .
        <uri xlink:href="https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273" xmlns:xlink="http://www.w3.org/1999/xlink">
         https://investors.modernatx.com/news-releases/news-release-details/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273
        </uri>
        .
       </mixed-citation>
      </ref>
      <ref id="ref56">
       <mixed-citation id="cit56" publication-type="journal">
        <name>
         <surname>
          Modjarrad
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Roberts
         </surname>
         <given-names>
          C. C
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Mills
         </surname>
         <given-names>
          K. T
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Castellano
         </surname>
         <given-names>
          A. R
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Paolino
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Muthumani
         </surname>
         <given-names>
          K.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Reuschel
         </surname>
         <given-names>
          E. L
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Robb
         </surname>
         <given-names>
          M. L
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Racine
         </surname>
         <given-names>
          T.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Oh
         </surname>
         <given-names>
          M.-d.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lamarre
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Zaidi
         </surname>
         <given-names>
          F. I
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Boyer
         </surname>
         <given-names>
          J.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kudchodkar
         </surname>
         <given-names>
          S. B
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Jeong
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Darden
         </surname>
         <given-names>
          J. M
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          Y. K
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Scott
         </surname>
         <given-names>
          P. T
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Remigio
         </surname>
         <given-names>
          C.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Parikh
         </surname>
         <given-names>
          A. P
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Wise
         </surname>
         <given-names>
          M. C
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Patel
         </surname>
         <given-names>
          A.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Duperret
         </surname>
         <given-names>
          E. K
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          K. Y
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Choi
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          White
         </surname>
         <given-names>
          S.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Bagarazzi
         </surname>
         <given-names>
          M.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          May
         </surname>
         <given-names>
          J. M
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kane
         </surname>
         <given-names>
          D.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          H.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Kobinger
         </surname>
         <given-names>
          G.
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Michael
         </surname>
         <given-names>
          N. L
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Weiner
         </surname>
         <given-names>
          D. B
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Thomas
         </surname>
         <given-names>
          S. J
         </given-names>
        </name>
        ;
        <name>
         <surname>
          Maslow
         </surname>
         <given-names>
          J. N
         </given-names>
        </name>
        <article-title>
         Safety and immunogenicity of an anti-Middle East respiratory
syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm,
dose-escalation trial
        </article-title>
        .
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2019
        </year>
        ,
        <volume>
         19
        </volume>
        (
        <issue>
         9
        </issue>
        ),
        <fpage>
         1013
        </fpage>
        –
        <lpage>
         1022
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(19)30266-X
        </pub-id>
        .
        <pub-id pub-id-type="pmid">
         31351922
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="ref57">
       <mixed-citation id="cit57" publication-type="weblink">
        <article-title>
         Inovio
Accelerates Timeline for COVID-19 DNA Vaccine INO-4800
        </article-title>
        .
        <uri xlink:href="http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx" xmlns:xlink="http://www.w3.org/1999/xlink">
         http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Accelerates-Timeline-for-COVID-19-DNA-Vaccine-INO-4800/default.aspx
        </uri>
        .
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cardiovasc Pathol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cardiovasc. Pathol
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cardiovascular Pathology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1054-8807
      </issn>
      <issn pub-type="epub">
       1879-1336
      </issn>
      <publisher>
       <publisher-name>
        Published by Elsevier Inc.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7162778
      </article-id>
      <article-id pub-id-type="publisher-id">
       S1054-8807(20)30032-6
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.carpath.2020.107228
      </article-id>
      <article-id pub-id-type="publisher-id">
       107228
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Pathophysiological Characteristics and Therapeutic Approaches for Pulmonary Injury and Cardiovascular Complications of Coronavirus Disease 2019
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Geng
         </surname>
         <given-names>
          Yong-Jian
         </given-names>
        </name>
        <email>
         yong-jian.geng@uth.tmc.edu
        </email>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Wei
         </surname>
         <given-names>
          Zhi-Yao
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Qian
         </surname>
         <given-names>
          Hai-Yan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          Ji
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Lodato
         </surname>
         <given-names>
          Robert
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0006">
        <name>
         <surname>
          Castriotta
         </surname>
         <given-names>
          Richard J.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0004">
         d
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       Department of Internal Medicine, McGovern School of Medicine, University of Texas Health Science Center at Houston, Texas, USA
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       Center for Coronary Heart Disease, Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, State Key Laboratory of Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China
      </aff>
      <aff id="aff0004">
       <label>
        d
       </label>
       Division of Pulmonary, Critical and Sleep Medicine, University of South California Keck School of Medicine, Los Angeles, California, USA
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        Corresponding author: Yong-Jian Geng, MD, PhD, Professor and Director, The Center for Cardiovascular Biology and Atherosclerosis Research, McGovern Medical School University of Texas Health Science at Houston (UTHealth), Houston, Texas, USA, Telephone: 713-500-6590.
        <email>
         yong-jian.geng@uth.tmc.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        17
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       107228
      </elocation-id>
      <permissions>
       <copyright-statement>
        © 2020 Published by Elsevier Inc.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0001">
       <title>
        Highlights
       </title>
       <p>
        <list id="celist0001" list-type="simple">
         <list-item id="celistitem0001">
          <label>
           •
          </label>
          <p id="para0001">
           The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major health crisis, with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) having infected over a million people around the world within a few months of its identification as a human pathogen.
          </p>
         </list-item>
         <list-item id="celistitem0002">
          <label>
           •
          </label>
          <p id="para0002">
           Initially, SARS-CoV-2 infects cells in the respiratory system and causes inflammation and cell death.
          </p>
         </list-item>
         <list-item id="celistitem0003">
          <label>
           •
          </label>
          <p id="para0003">
           Subsequently, the virus spreads out and damages other vital organs and tissues, triggering a complicated spectrum of pathophysiological changes and symptoms, including cardiovascular complications.
          </p>
         </list-item>
         <list-item id="celistitem0004">
          <label>
           •
          </label>
          <p id="para0004">
           Acting as the receptor for SARS-CoV entering mammalian cells, angiotensin converting enzyme-2 (ACE2) plays a pivotal role in the regulation of cardiovascular cell function.
          </p>
         </list-item>
         <list-item id="celistitem0005">
          <label>
           •
          </label>
          <p id="para0005">
           Diverse clinical manifestations and laboratory abnormalities occur in patients with cardiovascular injury in COVID-19, characterizing the development of this complication, as well as providing clues to diagnosis and treatment.
          </p>
         </list-item>
         <list-item id="celistitem0006">
          <label>
           •
          </label>
          <p id="para0006">
           This review provides a summary of the rapidly appearing laboratory and clinical evidence for the pathophysiology and therapeutic approaches to COVID-19 pulmonary and cardiovascular complications.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0002">
       <p>
        The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a major health crisis, with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) having infected over a million people around the world within a few months of its identification as a human pathogen. Initially, SARS-CoV-2 infects cells in the respiratory system and causes inflammation and cell death. Subsequently, the virus spreads out and damages other vital organs and tissues, triggering a complicated spectrum of pathophysiological changes and symptoms, including cardiovascular complications. Acting as the receptor for SARS-CoV entering mammalian cells, angiotensin converting enzyme-2 (ACE2) plays a pivotal role in the regulation of cardiovascular cell function. Diverse clinical manifestations and laboratory abnormalities occur in patients with cardiovascular injury in COVID-19, characterizing the development of this complication, as well as providing clues to diagnosis and treatment. This review provides a summary of the rapidly appearing laboratory and clinical evidence for the pathophysiology and therapeutic approaches to COVID-19 pulmonary and cardiovascular complications.
       </p>
      </abstract>
      <abstract abstract-type="graphical" id="abs0003">
       <title>
        Graphical abstract
       </title>
       <p>
        <fig id="fig0003" position="anchor">
         <alt-text id="alttx001">
          Image, graphical abstract
         </alt-text>
         <graphic xlink:href="fx1_lrg">
         </graphic>
        </fig>
       </p>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Lung
       </kwd>
       <kwd>
        Heart
       </kwd>
       <kwd>
        Blood vessels
       </kwd>
       <kwd>
        Infection
       </kwd>
       <kwd>
        Injury
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p id="para9001">
     <def-list>
      <def-item>
       <term id="dt0001">
        α-HBDH
       </term>
       <def>
        <p id="para0007">
         α-hydroxybutyrate dehydrogenase
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0002">
        ARDS
       </term>
       <def>
        <p id="para0008">
         acute respiratory distress syndrome
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0003">
        CCL2
       </term>
       <def>
        <p id="para0009">
         C-C motif chemokine ligand 2
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0004">
        COVID-19
       </term>
       <def>
        <p id="para0010">
         Coronavirus disease 2019
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0005">
        EAT
       </term>
       <def>
        <p id="para0011">
         epicardial adipose tissue
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0006">
        MERS-CoV
       </term>
       <def>
        <p id="para0012">
         middle east respiratory syndrome coronavirus
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0007">
        RAS
       </term>
       <def>
        <p id="para0013">
         renin–angiotensin system
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0008">
        SARS-CoV-2
       </term>
       <def>
        <p id="para0014">
         severe acute respiratory syndrome coronavirus 2
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0009">
        SARS-CoV
       </term>
       <def>
        <p id="para0015">
         severe acute respiratory syndrome coronavirus
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0010">
        TACE
       </term>
       <def>
        <p id="para0016">
         Tumor Necrosis Factor-α-converting enzyme
        </p>
       </def>
      </def-item>
      <def-item>
       <term id="dt0011">
        TMPRSS2
       </term>
       <def>
        <p id="para0017">
         type II transmembrane serine proteases
        </p>
       </def>
      </def-item>
     </def-list>
    </p>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="para0018">
      Since December 2019, an acute severe viral infectionivolving primarily the respiratory system has emerged with rapid transmission around the world to over a million people within a few months. Named
      <italic>
       coronavirus disease 2019 (COVID-19)
      </italic>
      by the World health organization
      <xref ref-type="bibr" rid="bib0001">
       [1]
      </xref>
      , the disease pandemic has resulted in a major health crisis. The pathogen of COVID-19 has been attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel beta coronavirus closely related to severe acute respiratory syndrome coronavirus (SARS-CoV)
      <xref ref-type="bibr" rid="bib0002">
       [2]
      </xref>
      . COVID-19 has resulted in many infections and death throughout the world
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      . Unlike those seen in influenza, the morbidity and transmission modality of COVID-19 appear more severe and uncontrollable
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      . The primary pulmonary injury and subsequent cardiovascular complications constitute the key pathophysiology of this deadly disease. This review updates and summarizes the pathophysiological features, possible underlying mechanisms, and clinical characteristics of pulmonary and cardiovascular injury of COVID-19.
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Pathogen(s) of COVID-19
     </title>
     <p id="para0019">
      The highly contagious virus, SARS-CoV-2, has been identified as the primary pathogen responsible for the development of COVID-19. It belongs to the Coronaviridae family
      <xref ref-type="bibr" rid="bib0005">
       [5]
      </xref>
      . Structurally and functionally similar to most members of the Betacoranavirus Subgroup B, SARS-CoV-2 (
      <xref ref-type="fig" rid="fig0001">
       Fig. 1
      </xref>
      ) has thought to be descended from a bat gene pool as the seventh member of coronavirus family known to infect humans, and comprises a positive-sense single-stranded RNA with 50–200nm in size
      <xref ref-type="bibr" rid="bib0006">
       [6]
      </xref>
      . Among the other 6 coronaviruses capable of causing illnesses, only SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) reportedly cause severe disease and fatalities
      <xref ref-type="bibr" rid="bib0007">
       [7]
      </xref>
      . Infection by the other 4 coronaviruses remains asymptomatic or mildly symptomatic in normal people. According to the full-length genome sequencing, SARS-CoV-2 is 79.5% homologous with SARS-CoV. Like SARS-CoV, SARS‐CoV‐2 infects lung alveolar epithelial cells by receptor-mediated endocytosis in association with angiotensin converting enzyme II (ACE2)
      <xref ref-type="bibr" rid="bib0008">
       [8]
      </xref>
      . An epidemiological study enrolling 44672 confirmed cases in China has indicated that the overall case-fatality rate of SARS-CoV-2 was about 2.3%
      <xref ref-type="bibr" rid="bib0009">
       [9]
      </xref>
      , whereas it was 9.6% (774/8096) in the SARS-CoV epidemic
      <xref ref-type="bibr" rid="bib0010">
       [10]
      </xref>
      and 34.4% (858/2494) in the MERS-CoV outbreak
      <xref ref-type="bibr" rid="bib0011">
       [11]
      </xref>
      . Mortality in Italy, Spain and France may be higher and closer to that of SARS-CoV. This may be due to strain variation, yet to be determined. However, in consideration of rapidly increasing numbers of confirmed cases and evidence of human-to-human transmission [
      <xref ref-type="bibr" rid="bib0012">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0013">
       13
      </xref>
      ], the SARS-CoV-2 infectivity seems to be stronger than SARS-CoV and MERS-CoV. Ultrastructural examination of SARS-CoV-2 by cryo-electron microscopy has demonstrated that the binding affinity of SARS-CoV-2 to ACE2 appears approximately 10- to 20-fold higher than SARS-CoV, structurally explaining why SARS-CoV-2 has a high contagiousness
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      .
      <fig id="fig0001">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Schematic representation of the COVID-19 pathogenic virus, SARS-CoV2, invasion and triggering organ injury and symptoms. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ACE2, angiotensin converting enzyme II.
        </p>
       </caption>
       <alt-text id="alt0001">
        Fig 1
       </alt-text>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para0020">
      In spite of the fact that SARS-CoV-2 has infected more than a million individuals it is largely unknown how and when the virus has been evolving and interacts with other microorganisms (
      <xref ref-type="table" rid="tbl0001">
       Table 1
      </xref>
      ) in the lung and other vital organs, such as heart and brain. Shen, et al.
      <xref ref-type="bibr" rid="bib0015">
       [15]
      </xref>
      has recently reported a genomic diversity of SARS-Cov-2 in patients with COVID-19. They observed, by meta-transcriptomal sequencing for the bronchoalveolar lavage fluid samples from of COVID-19, community-acquired pneumonia, and healthy individuals. They observed a limited polymorphism and diversity in the intra-host setting, and a substantial proportion of bacteria in several COVID-19 patients, similar to other patients with non-coronaviral pneumonia. As a common complication of viral infection, especially for respiratory viruses, secondary bacterial infection often results in a significant increase in morbidity or even mortality. Indeed, in the retrospective observational study of 85 fatal cases of COVID-19, Du, et al.
      <xref ref-type="bibr" rid="bib0016">
       [16]
      </xref>
      reported that in addition to SARS-Cov-2 infection, simultaneously or secondarily, other pathogens may participate in the COVID-19 development and complications, contributing to the severity and mortality of COVID-19. Thus, co-infection of other pathogens certainly complicates the pathogenesis and management of COVID-19.
      <table-wrap id="tbl0001" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Co-pathogens of COVID-19*.
        </p>
       </caption>
       <alt-text id="alt0003">
        Table 1
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th valign="top">
           <italic>
            Virus
           </italic>
          </th>
          <th valign="top">
           <italic>
            % cases
           </italic>
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td valign="top">
           Sars-CoV2
          </td>
          <td valign="top">
           100%
          </td>
         </tr>
         <tr>
          <td valign="top">
           Respiratory syncytial virus
          </td>
          <td valign="top">
           33.3%
          </td>
         </tr>
         <tr>
          <td valign="top">
           Influenza A virus
          </td>
          <td valign="top">
           9.1%
          </td>
         </tr>
         <tr>
          <td valign="top">
           Influenza B virus
          </td>
          <td valign="top">
           5.3%
          </td>
         </tr>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Other microorganisms
            </italic>
           </bold>
          </td>
          <td valign="top">
          </td>
         </tr>
         <tr>
          <td valign="top">
           Mycoplasma
          </td>
          <td valign="top">
           26.5%
          </td>
         </tr>
         <tr>
          <td valign="top">
           Chlamydia
          </td>
          <td valign="top">
           34.1%
          </td>
         </tr>
         <tr>
          <td valign="top">
           Fungus
          </td>
          <td valign="top">
           33.3%
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Note. *, Reference: Du, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. Am J Respir Crit Care Med, 2020
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
    </sec>
    <sec id="sec0003">
     <label>
      3
     </label>
     <title>
      Diagnosis of COVID-19
     </title>
     <p id="para0021">
      As recommended by WHO, most countries, including the United States, have adapted similar diagnostic procedures for COVID-19 and harvest certain clinical and epidemiologic information for diagnosis (
      <xref ref-type="table" rid="tbl0002">
       Table 2
      </xref>
      ). In the United States, criteria have been developed for persons under investigation (PUI) for COVID-19. People with confirmed COVID-19 usually develop fever and/or symptoms of acute respiratory illness (e.g., cough, difficulty breathing). For the PUI individuals, health care providers should immediately put him or her under infection control and prevention measures. Initially, testing for all other sources of respiratory infection is implemented while assessing epidemiologic factors to assist their diagnosis, including the information as to whether the person has had close contact with a patient with laboratory-confirmed COVID-19 within 14 days of symptom onset or a history of travel from affected geographic areas or epicenters within 14 days.
      <table-wrap id="tbl0002" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Criteria implemented for assessment and diagnosis of COVID-19.
        </p>
       </caption>
       <alt-text id="alt0004">
        Table 2
       </alt-text>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Epidemiological evidence
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td valign="top">
           History of travel or residence in the epicenter city and surrounding areas, or other communities where COVID-19 cases had been reported in the last 14 days before symptom onset.
          </td>
         </tr>
         <tr>
          <td valign="top">
           History of contact with SARS-CoV-2 infectious cases (with positive nucleic acid test).
          </td>
         </tr>
         <tr>
          <td valign="top">
           History of contacting with patients with fever or respiratory symptoms from the COVID-19 epicenter of city and surrounding areas, or other communities where COVID-19 had been reported in the last 14 days before symptom onset.
          </td>
         </tr>
         <tr>
          <td valign="top">
           History of contacting with a cluster of confirmed cases (≥ 2 cases with fever and/or respiratory symptoms occurred within 2 weeks in small areas, such as home, office, class of school, etc).
          </td>
         </tr>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Clinical Symptoms
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td valign="top">
           General discomforts, typically fever, fatigue, headache, muscle ache, diarrhea, etc.
          </td>
         </tr>
         <tr>
          <td valign="top">
           Signs and symptoms of lung and airway abnormalities, typically cough and dyspnea.
          </td>
         </tr>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Laboratory Evidence
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td valign="top">
           Total white blood cell counts showing normal, decreased, or reduced lymphocyte count in the early onset stage, and increased neutrophils in more advanced cases.
          </td>
         </tr>
         <tr>
          <td valign="top">
           Real-time PCR test positive for SARS-CoV-2.
          </td>
         </tr>
         <tr>
          <td valign="top">
           Viral sequencing showing high homogeneity to SARS-CoV-2.
          </td>
         </tr>
         <tr>
          <td valign="top">
           Serum test positive for SARS-CoV-2 specific IgM and IgG.
          </td>
         </tr>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Chest Imaging Evidence
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td valign="top">
           Chest radiography or CT scan showing multiple mottling and ground-glass opacities with or without consolidation in the lung periphery.
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="para0022">
      Diagnosis of COVID-19 requires collecting specimens from both the upper respiratory tract (naso- and oropharyngeal samples) and lower respiratory tract, including the expectorated sputum, endotracheal aspirate, or bronchoalveolar lavage. The samples need to be processed quickly and stored at four degrees celsius. The reverse polymerase chain reaction (RT-PCR) assays are a standard procedure for viral genomic sequence identification, which involves the synthesis of a double-stranded DNA molecule from the RNA template. If patients are confirmed COVID-19 positively, their laboratory evaluation should be repeated to evaluate for viral clearance prior to being released from quarantine. Patients with the early stage of COVID-19 may have a normal or decreased total white blood cell count and a decreased lymphocyte count. Subsequently, neutrophils arise wit lymphopenia, and the increased ratio of neutriophils vs. lymphocytes is considered a negative prognostic factor. Patients may have increased values of LDH, muscle enzymes, and C-reactive protein. In critical patients, the thrombogenic biomarker D-dimer may increase, the counts of blood lymphocytes decline persistently, and laboratory alterations in biomarkers of multi-organ injury become prominent.
     </p>
     <p id="para0023">
      The clinical profiles and diagnosis for COVID-19 have been well documented to date. However, new evidence is now emerging that this deadly disease is far more mystery than previously thought as many cases appeared atypical and easily misdiagnostic
      <xref ref-type="bibr" rid="bib0017">
       [17]
      </xref>
      . According to the seventh edition (3 March 2020) of COVID-19 guideline by the General Office of National Health Committee, and Office of State Administration of Traditional Chinese Medicine, China (The notice on the issuance of program for the diagnosis and treatment of COVID-19, Trial Version 7, 2020), diagnosis of suspected case needs to combine any one item of epidemiological history features with two items of clinical manifestations to make a comprehensive analysis, or needs to meet three items of clinical manifestations with or without clear epidemiological history (
      <xref ref-type="table" rid="tbl0002">
       Table 2
      </xref>
      ). Wang et al.
      <xref ref-type="bibr" rid="bib0018">
       [18]
      </xref>
      suggest that diagnosing the confirmed case should base on suspected case with any one item of pathogenic or serological evidence as following: (1) real-time PCR test positive for SARS-CoV-2; (2) viral whole genome sequencing showing high homogeneity to the known novel coronaviruses; (3) positive for the specific IgM antibody and IgG antibody to SARS-CoV-2 in serum test; or a change of the SARS-CoV-2-specific IgG antibody from negative to positive, or titer rising ≥4 times in the recovery phase above that in the acute phase.
     </p>
    </sec>
    <sec id="sec0004">
     <label>
      4
     </label>
     <title>
      Pulmonary and Cardiac Injury Caused by COVID-19
     </title>
     <p id="para0024">
      SARS-CoV-2 mainly attacks the respiratory system, clinically characterized by the rapid development of pneumonia, and in severe cases, the acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
      <italic>
       .
      </italic>
      The death rate remains high in those admitted to the intensive care and on ventilator due to complications of respiratory and cardiac failure
      <xref ref-type="bibr" rid="bib0016">
       [16]
      </xref>
      . Even though the lung is the primary organ damaged by the virus, COVID-19 is now regarded as a systemic disease, involving a broad range of other vital organs, such as heart, liver and kidney
      <xref ref-type="bibr" rid="bib0020">
       [20]
      </xref>
      . However, it remains largely unclear whether the organ and tissue injury in patients with COVID-19 is the direct or indirect consequence of the virus infection. ACE2, a known protein binding to SARS-CoV-2, is expressed widely in various organs and tissues, including the cardiovascular, digestive and urogenital systems beside the respiratory tract [
      <xref ref-type="bibr" rid="bib0021">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0022">
       22
      </xref>
      ]. Theoretically the virus may target those organs and tissues with positive expression of ACE2. Cardiovascular cells are known to express ACE2 at high levels, which serves as a key regulator of blood pressure and cardiac contractility
      <xref ref-type="bibr" rid="bib0023">
       [23]
      </xref>
      . Moreover, the virus infection may trigger a drastic immune response which leads to production of large quantities of cytokines, i.e. “cytokine storm”, which may indiscriminately injure vital organs
      <xref ref-type="bibr" rid="bib0024">
       [24]
      </xref>
      . For instance, SARS-CoV-2 infection injures the myocardium, leading to elevated levels of myocardial biomarkers (eg, troponin I &gt; 28 pg/mL) and certain abnormalities in electrocardiography and echocardiography
      <xref ref-type="bibr" rid="bib0025">
       [25]
      </xref>
      . Increasing clinical evidence indicates that virus infection-associated cardiac dysfunction worsen COVID-19 patient's clinical conditions usually in association with the poor prognosis [
      <xref ref-type="bibr" rid="bib0026">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0027">
       27
      </xref>
      ]. In spite of the observation that myocardial injury occurs frequently in COVID-19 patients
      <xref ref-type="bibr" rid="bib0028">
       [28]
      </xref>
      , the underlying mechanisms remains largely unclear. Several lines of clinical evidence point to the possibility of viral infection directly occurring in the myocardium. Both direct and indirect pathogenic impacts of the virus infection may cause injury of the pulmonary and myocardial tissues (
      <xref ref-type="fig" rid="fig0002">
       Fig. 2
      </xref>
      ).
      <fig id="fig0002">
       <label>
        Fig. 2
       </label>
       <caption>
        <p>
         Schematic demonstration of the viral injury to the lung and heart triggering the “Lung-Heart” syndromes with a combination of the respiratory and cardiovascular adverse events and conditions.
        </p>
       </caption>
       <alt-text id="alt0002">
        Fig 2
       </alt-text>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para0025">
      In epidemiology, high prevalence of cardiovascular dysfunction has been recently reported in COVID-19 patients, especially those with critical medical conditions
      <xref ref-type="bibr" rid="bib0029">
       [29]
      </xref>
      . In a study of 138 COVID-19 patients, 10 patients (7.2%) were diagnosed as acute myocardial injury based on the elevation of high-sensitivity cardiac troponin I (hs-cTnI), and 8 of them admitted into the intensive care unit (ICU)
      <xref ref-type="bibr" rid="bib0012">
       [12]
      </xref>
      . In another retrospective study, cardiac troponin I (cTnI) was significantly elevated in 33.3% of severe and 100.0% of critical patients
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . Huang et al. also revealed increased numbers of COVID-19 patients with acute myocardial injury and in the critical conditions leading to admission into ICU
      <xref ref-type="bibr" rid="bib0019">
       [19]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0005">
     <label>
      5
     </label>
     <title>
      Pathological characteristics of Pulmonary and Cardiovascular Injury in COVID-19
     </title>
     <p id="para0026">
      Recent autopsy reports have demonstrated several anatomical features of COVID-19-induced pulmonary and myocardial injury. The early lung of COVID-19 patients exhibited edema, proteinaceous exudate, focal reactive hyperplasia of pneumocytes with patchy inflammatory cellular infiltration, and multinucleated giant cells
      <xref ref-type="bibr" rid="bib0031">
       [31]
      </xref>
      . Liu et al. showed that the lung and cardiac tissues contain significant amounts of inflammatory infiltrates, indicating the inflammatory nature of tissue damage by SARS-CoV-2 infection
      <xref ref-type="bibr" rid="bib0026">
       [26]
      </xref>
      . Patients with a medical history of coronary heart disease are prone to the cardiac injury caused by COVID-19. Although there was no evidence that the acute episode of cardiac injury was caused by coronary events in this patient, one may not rule out the possibility that the underlying medical condition might have made the patient more vulnerable to the hypoxia- and cytokine storm-induced cardiac ischemia
      <xref ref-type="bibr" rid="bib0032">
       [32]
      </xref>
      . Moreover, post-mortem examinations showed moderate pericardial effusion with light yellow and clear liquid and mild epicardial edema indicative of myocardial inflammation, further suggesting that a peri-cardiac inflammatory response contributes to the myocardial dysfunction in COVID-19 patients. In a pilot study, Xu et al.
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      failed to find evidence of myocardial injury in a histopathologic case by autopsy, in which there were only a few interstitial mononuclear inflammatory infiltrates without other substantial damage in the cardiac tissue. This paradoxical result may be attributed to the small sample size and absent clinical evidence of myocardial injury in this case. Overall, future research is needed to enroll more cases with definite clinical evidence of myocardial injury to further investigate histopathologic characteristics of COVID-19-related myocardial injury. The viral infection induces an excessive immune reaction in the host, which in turn generates a 'cytokine storm', comprising released by proinflammatory cytokines known to act on cardiovascular cells [
      <xref ref-type="bibr" rid="bib0034">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0035">
       35
      </xref>
      ]. One of the protagonists in the cytokine storm is interleukin 6 (IL-6), which is produced and released by activated leukocytes and acts on a large number of cells and tissues. IL-6 promotes the differentiation and activation of B lymphocytes, and stimulates the production of acute phase proteins.
     </p>
     <p id="para0027">
      The severity and lethality of COVID-19 may be, at least in part, due to the viral injury to the myocardium and blood vessels. This serves as a major challenge for successful management and care of COVID-19 patients. In an observational study of 52 critical sick adult COVID-19 patients, 19 patients suffered from acute myocardial injury, and 9 of them (75%) died
      <xref ref-type="bibr" rid="bib0029">
       [29]
      </xref>
      , suggesting a higher mortality in COVID-19 patients with cardiovascular complications. Analysis of COVID-19 related death cases has confirmed that myocardial injury was one of the major causes of death. In a review of 25 death cases with COVID-19, Xun et al. found that the serum cTnI were significantly increased in 18 cases, and more COVID-19 cases with heart injury than other organ injuries except for the lung. Zhang et al. reported that 89% of 82 death cases were observed with myocardial injury, which was second only to death cases with pulmonary injury
      <xref ref-type="bibr" rid="bib0036">
       [36]
      </xref>
      . Moreover, in a study of 416 COVID-19 patients, myocardial injury was independently associated with higher risk of in-hospital mortality
      <xref ref-type="bibr" rid="bib0027">
       [27]
      </xref>
      . Hence, early myocardial injury in COVID-19 leads to a poor prognosis in COVID-19 patients.
     </p>
    </sec>
    <sec id="sec0006">
     <label>
      6
     </label>
     <title>
      Laboratory Evidence for Inflammation and Organ Injury
     </title>
     <p id="para0028">
      Changes of cardiac-specific biomarkers in the peripheral blood have been reported in patients with COVID-19. As stated above, hs-cTnI acts as one of the specific biomarkers of myocardial injury
      <xref ref-type="bibr" rid="bib0037">
       [37]
      </xref>
      . Other non- or less-specific myocardial biomarkers may elevate in COVID-19 cardiovascular complications as well, such as creatine kinase (CK), creatine kinase MB isoenzyme (CK-MB) and lactate dehydrogenase (LDH). However, the biomarkers may not always change in the same pattern. For instance, in a study of 99 COVID-19 patients, only 13 patients had elevation of CK while 75 patients showed LDH elevation
      <xref ref-type="bibr" rid="bib0038">
       [38]
      </xref>
      . The measurements of myocardial biomarkers are believed to possess prognostic values. In the first multi-center study
      <xref ref-type="bibr" rid="bib0039">
       [39]
      </xref>
      which enrolled 1,099 patients with laboratory-confirmed COVID-19 from 552 hospitals in China, 675 patients had measurements of serum LDH, and 277 of them showed elevated LDH levels, accounting for 58.1% of total severe cases. Moreover, increased LDH and CK were also observed in the blood of patients at the composite endpoints (the admission to ICU, mechanical ventilation, and death). The elevation of myocardial biomarkers in COVID-19 patients may offer the prognostic information useful for assessing the disease progression, and development of adverse events. Since some of the biomarkers are not specific to the myocardium, the increased nonspecific biomarkers during the development of adverse events of COVID-19 patients may reflect not only the injury to the myocardium but also other vital organs or tissues.
     </p>
     <sec id="sec0007">
      <label>
       6.1
      </label>
      <title>
       Invasion through ACE2
      </title>
      <p id="para0029">
       SARS-CoV-2 may directly invade cardiomyocytes and subsequently result in viral myocarditis and corresponding injury. Structurally, the SARS-CoV-2 particle has an ACE2-binding domain
       <xref ref-type="bibr" rid="bib0040">
        [40]
       </xref>
       . The virus binds to human ACE2 with high affinity, and uses it as an entry receptor to invade target cells. Cryo-electron microscopy reveals the structure of the SARS-CoV-2 spike glycoprotein in two distinct conformations, along with inhibition of spike-mediated entry by SARS-CoV polyclonal antibodies, providing a blueprint for the design of vaccines and therapeutics. Although the main target is the epithelium of respiratory system, the virus may use the ACE2 path to invade cardiomyocytes directly as many cardiovascular cells express ACE2 (
       <xref ref-type="fig" rid="fig0002">
        Figure 2
       </xref>
       ). SARS-CoV-2 may trigger ACE2 activation and upregulate ACE2 downstream signal transduction, including the activation of Ras-ERK–AP-1 pathway
       <xref ref-type="bibr" rid="bib0041">
        [41]
       </xref>
       . Consequently, this may induce myocardial inflammation and fibrosis and exacerbate cardiac dysfunction.
      </p>
      <p id="para0030">
       As the cellular receptor for the entry of SARS-CoV-2, ACE2 is a monocarboxylase highly expressed in cardiac tissue
       <xref ref-type="bibr" rid="bib0042">
        [42]
       </xref>
       , and exhibits cardio-protective roles as a potent negative regulator of the renin–angiotensin system (RAS) by counterbalancing functions of ACE
       <xref ref-type="bibr" rid="bib0043">
        [43]
       </xref>
       . As a membrane protein, it can also initiate outside-in signaling
       <xref ref-type="bibr" rid="bib0044">
        [44]
       </xref>
       . SARS
       <bold>
        -
       </bold>
       CoV have been previously demonstrated to induce myocarditis in a ACE2-dependent manner
       <xref ref-type="bibr" rid="bib0045">
        [45]
       </xref>
       . The trimers of the SARS-CoV spike protein initially extends into a hydrophobic pocket of ACE2 catalytic domain
       <xref ref-type="bibr" rid="bib0046">
        [46]
       </xref>
       , which consequentially leads to the endocytosis of SARS-CoV particles and fusion of virus to cardiomyocytes with the help of type II transmembrane serine proteases (TMPRSS2)
       <xref ref-type="bibr" rid="bib0047">
        [47]
       </xref>
       , finally downregulating ACE2 expression in cardiomyocytes [
       <xref ref-type="bibr" rid="bib0048">
        48
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0049">
        49
       </xref>
       ]. When RAS is over-activated further myocardial injury is a consequence in SARS patients. Moreover, downregulation of ACE2 may be, at least partly, caused by the shedding of ACE2 ectodomain, mediated by TNF-α-converting enzyme (TACE) in coupling with the production of TNF-α, a well-known pro-fibrotic and myocardial impairing factor
       <xref ref-type="bibr" rid="bib0050">
        [50]
       </xref>
       . The binding between SARS-CoV spike protein and ACE2 on the cardiomyocyte surface also triggers the Ras-ERK–AP-1 pathway and activates the C-C motif chemokine ligand 2 (CCL2, a pro-fibrosis factor)
       <xref ref-type="bibr" rid="bib0041">
        [41]
       </xref>
       . The above theories are supported by an autopsy report of heart samples from SARS patients, in which the presence of SARS-CoV in the heart was associated with marked down-regulation of ACE2 expression as well as a significant increase in macrophage infiltration and interstitial fibrosis, verifying ACE2 inhibition is involved in SARS-CoV-driven myocardial injury
       <xref ref-type="bibr" rid="bib0049">
        [49]
       </xref>
       .
      </p>
      <p id="para0031">
       The specific cellular mechanism for SARS-CoV-2 invading and damaging cardiomyocytes has not been clearly demonstrated yet, but it is probable that SARS-CoV-2 shares the similar mechanism with its relative SARS-CoV. A recent study investigated ultrastructure of full-length human ACE2 with cryo-EM
       <xref ref-type="bibr" rid="bib0051">
        [51]
       </xref>
       , indicating that SARS-CoV-2 also invaded host cells via spike protein trimers binding to an ACE2 homodimer. In addition, the interface between the receptor binding domains of spike proteins on SARS-CoV-2 is quite similar to that between the SARS-CoV and ACE2. Furthermore, the serine protease TMPRSS2 is also indispensable for the entry of SARS-CoV-2
       <xref ref-type="bibr" rid="bib0052">
        [52]
       </xref>
       . Given that the high similarity of cellular entry with that of SARS-CoV, it is reasonable to speculate that SARS-CoV-2 interferes in ACE2 expression in the same way. However, this needs to be verified in cardiomyocytes in the further study.
      </p>
     </sec>
     <sec id="sec0008">
      <label>
       6.2
      </label>
      <title>
       Hypoxia and Ischemic Injury
      </title>
      <p id="para0032">
       Myocardial oxygen supply is determined by coronary blood flow and its oxygen carrying capacity while myocardial oxygen demand is determined by systolic wall tension, contractility, and heart rate
       <xref ref-type="bibr" rid="bib0053">
        [53]
       </xref>
       . This physiological mechanism may be involved in SARS-CoV-2-induced myocardial injury. As is well-known, pulmonary dysfunction is the primary insult of SARS-CoV-2, which induces hypoxemia, hypotension and, in some cases, shock [
       <xref ref-type="bibr" rid="bib0020">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0039">
        39
       </xref>
       ]. As a consequencet, an insufficient oxygen supply may occur in multiple organs including the heart. Concomitantly, myocardial oxygen demand is increased in virus-infection states, as high metabolic rate induces an augmented burden on the myocardium
       <xref ref-type="bibr" rid="bib0054">
        [54]
       </xref>
       , further causing the imbalance between myocardial oxygen supply and demand. Along with disease progression, this imbalance is increasingly aggravated, which may result in myocardial injury in COVID-2019 patients, especially for those with cardiovascular disorders who have already exhausted myocardial reserve capacity on the supply side. Other systemic contributors may include, in addition to hypoxia, respiratory and/or metabolic acidosis, fluid or electrolyte disorders and an activated neuro-humoral system following severe infection may also lead to myocardial stunning and injury, even inducing malignant arrhythmia and sudden death.
      </p>
     </sec>
     <sec id="sec0009">
      <label>
       6.3
      </label>
      <title>
       Cytokine Storm and Inflammation
      </title>
      <p id="para0033">
       Previous studies have confirmed that the immune abnormality is related to the pathogenesis of SARS-CoV infection
       <xref ref-type="bibr" rid="bib0045">
        [45]
       </xref>
       . Specifically, cytokine storm, an excessive and uncontrollable cytokines production in response to infection, is suggested to be the main contributor, as numerous studies have found that the expression levels of pro-inflammatory cytokines [eg, Interleukin-1β (IL-1β), IL-6, interferon-γ (IFN-γ), IFNγ inducible protein-10 (IP-10), monocyte chemoattractant protein-1(MCP-1), granulocyte colony-stimulating factor (G-CSF), macrophage inflammatory protein-1α (MIP-1α), tumor necrosis factor-α (TNF-α)] are significantly increased in COVID-19 patients, associated with disease progression [
       <xref ref-type="bibr" rid="bib0055">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0056">
        56
       </xref>
       ]. Among so many cytokines, IL-6 serves as the core of cytokine storm, given that IL-6 not only amplifies cytokine storm by stimulating production of other pro-inflammatory cytokines, but also results in vascular leakage, interstitial edema
       <xref ref-type="bibr" rid="bib0057">
        [57]
       </xref>
       . Moreover, IL-6 has also been shown to weaken papillary muscle contraction, which causes myocardial dysfunction
       <xref ref-type="bibr" rid="bib0058">
        [58]
       </xref>
       . In addition, IFNγ is also regarded as a marker of cytokine storm, causing cell apoptosis through regulating JAK/STAT1 axis and p38-MAPK1
       <xref ref-type="bibr" rid="bib0059">
        [59]
       </xref>
       . However, anti-inflammatory cytokines such as IL-4 and IL-10 are also increased in COVID-19 patients, and their levels are also related to disease severity [
       <xref ref-type="bibr" rid="bib0055">
        55
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0056">
        56
       </xref>
       ], demonstrating the close relation between pro- and anti-inflammation. Cytokine storm is a clear contributor to COVID-19-related myocardial injury, demonstrated by a study that revealed that increased levels of IL-6 were significantly associated with high hs-TnI levels
       <xref ref-type="bibr" rid="bib0026">
        [26]
       </xref>
       , a cardiac-selective biomarker of myocardial infarction and injury
       <xref ref-type="bibr" rid="bib0037">
        [37]
       </xref>
       . Further studies are needed to explore the cytokine expression in cardiomyocytes, which will promote a better understanding for SARS-CoV-2-induced inflammation in cardiac tissue.
      </p>
      <p id="para0034">
       Overall, direct infection through ACE2, the imbalance between myocardial oxygen supply and demand, and the abnormal immune response constitute the most plausible explanations for myocardial injury associated with COVID-19. To be noted, however, the above speculation is mostly based on clinical observation of COVID-19. Therefore, more in-depth research is required to understand the pathophysiology of SARS-CoV-2-induced myocardial injury in order to contribute to the future development of effective treatment.
      </p>
     </sec>
    </sec>
    <sec id="sec0010">
     <label>
      7
     </label>
     <title>
      Clinical Symptoms and Profiles
     </title>
     <p id="para0035">
      The general clinical symptoms found in COVID-19 patients with cardiac dysfunction are similar to those observed in influenza, such as fever (87.9%), cough (67.7%), fatigue (38.1%) , expectoration (33.4%)
      <xref ref-type="bibr" rid="bib0039">
       [39]
      </xref>
      . Additionally, confirmed cases of COVID-19 show several more-specific symptoms, such as anosmia, dysgeusia, chest pain [
      <xref ref-type="bibr" rid="bib0026">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0038">
       38
      </xref>
      ] and palpitation
      <xref ref-type="bibr" rid="bib0060">
       [60]
      </xref>
      . Electro physiologically, COVID-19 patients are prone to the development of arrhythmia, especially tachycardia, indicative for myocardial injury. In a study of 138 COVID-19 patients, 23 patients (16.7%) presented with arrhythmia, and other evidence for myocardial injury
      <xref ref-type="bibr" rid="bib0012">
       [12]
      </xref>
      . Indeed, the COVID-19 patients with tachycardia were often in severe or critical situations. For a better understanding of the etiology of cardiac dysfunction in patients with COVID-19, researchers analyzed body temperature in different groups (mild, light, severe and critical groups), given the fact that high fever caused by the virus infection and inflammation can elevate the heart rate. The result showed that there was no significant difference in the body temperature correlation with arrhythmia between the mild and severe/critical groups. Many COVID-19 patients with tachycardia are severely ill and need critical care, as tachycardia represents a sign of a failing heart
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      .
     </p>
     <p id="para0036">
      With regard to the imaging features of cardiac injury, the epicardial adipose tissue (EAT) density, a measurement for inflammation, between the bifurcation of pulmonary artery and diaphragm as determined by lung CT scan may serve as a specific indicator for COVID-19-induced myocardial injury. Hui et al. reported that the mean EAT density of critical/severe groups in chest CT scan were significantly lower than patients in the light/mild groups (-98.77 /-96.08 HU vs -69.37/-84.76 HU), suggesting that myocardial inflammation occurred in COVID-19 patients
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . As the cytokine storm and consequent inflammatory response are suggested to be the mechanisms contributing to myocardial injury, low EAT density showed in chest CT scan appears to be a high-risk factor for myocardial injury. However, low EAT density is not the optimal imaging parameter of COVID-19-related myocardial injury since it is an indirect sign of inflammation and may be substantively influenced by subjective factors in clinical practice. Other imaging modalities with high sensitivity and specificity such as echocardiography and myocardial magnetic resonance imaging should be preferentially chosen if appropriate.
     </p>
    </sec>
    <sec id="sec0011">
     <label>
      8
     </label>
     <title>
      Management and Treatment of COVID-19
     </title>
     <sec id="sec0012">
      <label>
       8.1
      </label>
      <title>
       Pre-exiting condition management
      </title>
      <p id="para0037">
       Treatment of COVID-19 has been mostly restricted to supportive measures as there has been, to date, no specific therapy available to treat this disease. Pre-existing poor-health conditions increase the risk of cardiovascular comorbidity, with poorer prognosis. Patients at age above 60 years old and those with diabetes are more susceptible to COVID-19 induced myocardial injury. They should be prioritized for treatment. In terms of diagnostic criteria, the dynamic change of myocardial biomarkers especially hs-TnI is the main criteria to identify COVID-19 patients with myocardial injury. However, the levels of myocardial biomarkers may be affected by other factors such as the status of infection, hypoxemia, and renal insufficiency, which are commonly observed in COVID-19 patients. Thus comprehensive assessments combining electrocardiography, imaging and histopathology should be performed in clinical practice.
      </p>
     </sec>
     <sec id="sec0013">
      <label>
       8.2
      </label>
      <title>
       Anti-virus therapy
      </title>
      <p id="para0038">
       Since the outbreak of COVID-19 several anti-virus agents have been proposed and currently are under intensive clinical investigation. Remdesivir is a broad-spectrum investigational antiviral agent which decreased SARS-Cov-2 RNA transcription with
       <italic>
        in vitro
       </italic>
       experiments
       <xref ref-type="bibr" rid="bib0061">
        [61]
       </xref>
       . The agent was originally developed for treating Ebola virus infection but was not shown to have satisfactory efficacy in clinical trials
       <xref ref-type="bibr" rid="bib0062">
        [62]
       </xref>
       . A few COVID-19 patients recovered soon after administering remdesivir [
       <xref ref-type="bibr" rid="bib0063">
        63
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0064">
        64
       </xref>
       ], though its safety and efficacy have not been demonstrated in randomized controlled trials (RCTs)
       <xref ref-type="bibr" rid="bib0065">
        [65]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0066">
        [66]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0067">
        [67]
       </xref>
       . Another antiviral treatment, lopinavir/ritonavir, the protease inhibitor combination used in HIV, was previously given great expectation for treating COVID-19 but failed to show significant benefit in the first RCT. Other antiviral agents are now in RCTs after showing some promise with small numbers of patients during the initial wave of COVID-19 infections in China.
      </p>
     </sec>
     <sec id="sec0014">
      <label>
       8.3
      </label>
      <title>
       Anti-inflammatory and immunoregulatory agents
      </title>
      <p id="para0039">
       Hydroxychloroquine and chloroquine are traditional anti-malarial and autoimmune disease drugs. They have been shown to control the SARS-Cov-2 infection
       <italic>
        in vitro
       </italic>
       [
       <xref ref-type="bibr" rid="bib0061">
        61
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0068">
        68
       </xref>
       ]. The underlying mechanism may involve the increase in the endosomal pH required for virus/cell fusion, interference with the glycosylation of ACE2
       <xref ref-type="bibr" rid="bib0069">
        [69]
       </xref>
       and inactivation of IL-6 and TNF-α
       <xref ref-type="bibr" rid="bib0070">
        [70]
       </xref>
       . A small sample size study showed that hydroxychloroquine treatment was significantly associated with viral load reduction/disappearance in COVID-19 patients
       <xref ref-type="bibr" rid="bib0071">
        [71]
       </xref>
       , but this conclusion still has not been verified by ongoing RCTs [
       <xref ref-type="bibr" rid="bib0072">
        72
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0073">
        73
       </xref>
       ]. The cardiotoxicity of hydroxychloroquine and chloroquine should not be neglected. They may prolong QT interval and induce ventricular arrhythmia
       <xref ref-type="bibr" rid="bib0074">
        [74]
       </xref>
       . Thus, they should be used very cautiously (if at all) to treat COVID-19 patients with cardiovascular comorbidities or uncorrected electrolyte disorder. Given the pivotal role of immunologic overresponse in COVID-19, anti-inflammatory therapy is also promising for treating COVID-19. Corticosteroids were used during the SARV-Cov and MERS-Cov outbreaks and have also been used for patients with COVID-19. However, previous studies on whether corticosteroids exert protective [
       <xref ref-type="bibr" rid="bib0075">
        75
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0076">
        76
       </xref>
       ] or adverse
       <xref ref-type="bibr" rid="bib0077">
        [77]
       </xref>
       effect in SARV-Cov and MERS-Cov infection came to conflicting conclusions, since it might induce in-hospital secondary infection and long-term complications while inhibiting inflammation-related organ injury. With lack of conclusive evidence, the use of corticosteroids may be prudently considered in critical COVID-19 patients with clear evidence of immune overreaction, but their use is not generally recommended by the World Health Organization (WHO) or Centers for Disease Control (CDC). Some have advocated against non-steroidal anti-inflammatory agents (NSAIDs), notably ibruprofen, which may be associated with worse outcome with COVID-19, based on anecdotal reports. Targeted agents such as tocilizumab are also regarded as potential therapy. Tocilizumab was shown to facilitate chimeric antigen receptor-T cell (CAR-T) therapy because it can inhibit IL-6, the core cytokine of cytokine storm syndrome
       <xref ref-type="bibr" rid="bib0078">
        [78]
       </xref>
       . Several clinical observations demonstrated a predominant increase of IL-6 in COVID-19 patients, which is associated with severe conditions [
       <xref ref-type="bibr" rid="bib0038">
        38
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0079">
        79
       </xref>
       ], so inhibiting IL-6 activation may ease the overreacting immune system. Future well-designed RCTs are expected to clarify tocilizumab's efficiency and its applicable patients.
      </p>
     </sec>
     <sec id="sec0015">
      <label>
       8.4
      </label>
      <title>
       ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB)
      </title>
      <p id="para0040">
       The structural evidence of SARS-Cov-2 invasion of cells via ACE2 has led to the hypothesis that ACEI/ARB treatment potentially induces overexpression of ACE2, which subsequently increases the susceptibility of host cells to SARS-Cov-2 invasion and the risk of infection or worsening the severity of disease
       <xref ref-type="bibr" rid="bib0080">
        [80]
       </xref>
       . For cardiovascular patients under regular anti-hypertensive treatment, it has been suggested that they should discontinue ACE inhibitors (ACEI) or angiotensin receptor blocker (ARB) medications. However, ACEI/ARB play a protective role in COVID-19, given that ACE2 shedding caused by SARS-Cov-2 invasion may result in its downregulation, following the activation of RAS axis which is partly responsible for severe organ injury in COVID-19
       <xref ref-type="bibr" rid="bib0048">
        [48]
       </xref>
       . Thus far, there have been no clinical data supporting the case for ACEI/ARB discontinuation in COVID-19 patients. According to WHO's guideline, changing the routine antihypertensive therapy under the COVID-19 pandemic to avoid potential harm or pursue potential benefits is not recommended before any compelling evidence published.
      </p>
     </sec>
     <sec id="sec0016">
      <label>
       8.5
      </label>
      <title>
       Neutralizing anti-virus plasma, stem cell transplantation, traditional herbal remedies and anti-ischemic therapy
      </title>
      <p id="para0041">
       Other therapies with less evidence-based foundation are also worth mentioning. Plasma treatment means transfusing convalescent plasma containing anti-virus polyclonal antibodies, and were proved to be effective in treating SARS patients and COVID-19 patients in observational studies [
       <xref ref-type="bibr" rid="bib0081">
        81
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0082">
        82
       </xref>
       ]. Although the number of patients so treated is small, this does make scientific sense. Dilated horse anti-SARS-CoV-2 serum could cross-neutralize SARS-CoV-2 in an in vitro study
       <xref ref-type="bibr" rid="bib0008">
        [8]
       </xref>
       . Some traditional herbal therapies against coronavirus infection were found to be effective during SARS outbreak and are widely used in current practice in China
       <xref ref-type="bibr" rid="bib0083">
        [83]
       </xref>
       . Mesenchymal stem cell transplantation has shown both efficiency and safety in treating ARDS
       <xref ref-type="bibr" rid="bib0084">
        [84]
       </xref>
       . All the above therapies need more verification by RCTs
       <xref ref-type="bibr" rid="bib0085">
        [85]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0086">
        [86]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0087">
        [87]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0088">
        [88]
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0089">
        [89]
       </xref>
       . Due to the widespread cardiac injury in COVID-19 patients, new or worsening heart failure is common especially in those with poor prognosis
       <xref ref-type="bibr" rid="bib0079">
        [79]
       </xref>
       . After recognizing the onset of heart failure, causes leading to decompensation should be evaluated first, especially those should which could be managed and corrected immediately such as acute coronary syndrome and severe rapid arrhythmias. Hypoxemia following pneumonia and ARDS is common in COVID-19 patients and will be worsened by heart failure. Thus oxygen therapy and mechanical ventilation should be more rigorously used in COVID-19 patients with heart failure than those without. Diuretics should be considered under the evidence of volume overload, as well as renal replacement therapy which can simultaneously eliminate excessive cytokines. Rehydration should be more prudently prescribed in shock patients with COVID-19 than normal shock counterparts, considering that pulmonary edema following rapid fluid resuscitation will further impair alveolar ventilation. Mechanical assist devices such as intra-aortic balloon pump and extracorporeal membrane oxygenation (ECMO) may help patients get through critical periods and should be considered when necessary.
      </p>
     </sec>
    </sec>
    <sec id="sec0017">
     <label>
      9
     </label>
     <title>
      Conclusion
     </title>
     <p id="para0042">
      COVID-19 causes not only pulmonary injury but also severe cardiac complications, in particular in those with pre-existing medical conditions. Although the precise mechanism for the development of myocardial injury associated with COVID-19 is not fully understood, a combination of direct and indirect pathogenic factors, such as ACE2-mediated SARS-CoV-2 infection of cardiomyocytes, hypoxia and cytokine storm, may contribute to the development of myocardial injury and other adverse events which aggravate conditions and increase mortality (
      <xref ref-type="table" rid="tbl0003">
       Table 3
      </xref>
      ). Close and careful monitoring of cardiac function should be emphasized in order to early identify COVID-19-related myocardial injury.
      <table-wrap id="tbl0003" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Major signs and biomarkers for pulmonary and myocardiac injury in COVID-19.
        </p>
       </caption>
       <alt-text id="alt0005">
        Table 3
       </alt-text>
       <table frame="hsides" rules="groups">
        <tbody>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Pulmonary Injury
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td valign="top">
           Respiratory rate, &gt; 24 breaths per min
          </td>
         </tr>
         <tr>
          <td valign="top">
           Hypoxemia (PaO2 decline, PaO
           <sub>
            2
           </sub>
           :FiO
           <sub>
            2
           </sub>
           ratio &lt; 100–150 mm Hg; SaO2 &lt; 95%)
          </td>
         </tr>
         <tr>
          <td valign="top">
           Hypercapnia and acidosis (P
           <sub>
            aCO2
           </sub>
           elevation, respiratory, metabolic or combined)
          </td>
         </tr>
         <tr>
          <td valign="top">
           Pulmonary hypertension
          </td>
         </tr>
         <tr>
          <td valign="top">
           <bold>
            <italic>
             Myocardiac Injury
            </italic>
           </bold>
          </td>
         </tr>
         <tr>
          <td valign="top">
           Lactate dehydrogenase, &gt; 245 U/L
          </td>
         </tr>
         <tr>
          <td valign="top">
           Creatinine, &gt;133 μmol/L
          </td>
         </tr>
         <tr>
          <td valign="top">
           Creatine kinase, &gt;185 U/L
          </td>
         </tr>
         <tr>
          <td valign="top">
           Creatine kinase–MB fraction, &gt; 2 ng/mL
          </td>
         </tr>
         <tr>
          <td valign="top">
           High-sensitivity cardiac troponin I, &gt; 28 pg/mL
          </td>
         </tr>
         <tr>
          <td valign="top">
           Myoblobin, &gt;30 μg/L
          </td>
         </tr>
         <tr>
          <td valign="top">
           N-terminal pro-brain natriuretic peptide (NT-proBNP), &gt;300 pg/mL
          </td>
         </tr>
         <tr>
          <td valign="top">
           <italic>
            Inflammation
           </italic>
          </td>
         </tr>
         <tr>
          <td valign="top">
           High-sensitivity C-reactive protein (hs-CRP), &gt; 3.0 mg/L
          </td>
         </tr>
         <tr>
          <td valign="top">
           Interleukin-6 (IL-6), &gt; 1 pg/mL
          </td>
         </tr>
         <tr>
          <td valign="top">
           Ratio of neutrophils vs. lymphocytes, &gt; 5-10
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of Competing Interest
     </title>
     <p id="para0045">
      All the co-authors have no conflict of interest to be declared.
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <mixed-citation id="othref0001" publication-type="other">
        Organization WH. Coronavirus disease (COVID-19) outbreak. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Pan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Understanding of COVID-19 based on current evidence
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25722
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <mixed-citation id="othref0002" publication-type="other">
        prevention Ccfdca. Epidemic Report for Coronavirus Disease 2019 (COVID-19). 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madjid
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Safavi-Naeini
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Solomon
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Vardeny
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential Effects of Coronaviruses on the Cardiovascular System: A Review
        </article-title>
        <source>
         JAMA Cardiol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <element-citation id="sbref0003" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <collab>
          China Novel Coronavirus I and Research T
         </collab>
        </person-group>
        <article-title>
         A Novel Coronavirus from Patients with Pneumonia in China, 2019
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         727
        </fpage>
        <lpage>
         733
        </lpage>
        <pub-id pub-id-type="pmid">
         31978945
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Hao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
        </article-title>
        <source>
         Sci China Life Sci
        </source>
        <volume>
         63
        </volume>
        <year>
         2020
        </year>
        <fpage>
         457
        </fpage>
        <lpage>
         460
        </lpage>
        <pub-id pub-id-type="pmid">
         32009228
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Forni
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cagliani
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Clerici
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sironi
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Molecular Evolution of Human Coronavirus Genomes
        </article-title>
        <source>
         Trends Microbiol
        </source>
        <volume>
         25
        </volume>
        <year>
         2017
        </year>
        <fpage>
         35
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="pmid">
         27743750
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Si
          </surname>
          <given-names>
           H.R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           R.D.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           X.R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.J.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           F.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <mixed-citation id="othref0003" publication-type="other">
        Organization WH. Cumulative Number of Reported Probable Cases of Severe Acute Respiratory Syndrome (SARS). 2003.
       </mixed-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <mixed-citation id="othref0004" publication-type="other">
        Organization WH. Middle East respiratory syndrome coronavirus (MERS‐CoV). 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K.-H.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           C.C.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           R.W.-S.
          </given-names>
         </name>
         <name>
          <surname>
           Tsoi
          </surname>
          <given-names>
           H.-W.
          </given-names>
         </name>
         <name>
          <surname>
           Lo
          </surname>
          <given-names>
           S.K.-F.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           V.K.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           W.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Ip
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           J.-P.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           V.C.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           C.K.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.-Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Abiona
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Graham
          </surname>
          <given-names>
           B.S.
          </given-names>
         </name>
         <name>
          <surname>
           McLellan
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
        </article-title>
        <source>
         Science
        </source>
        <year>
         2020
        </year>
        <fpage>
         eabb2507
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genomic diversity of SARS-CoV-2 in Coronavirus Disease 2019 patients
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ping
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study
        </article-title>
        <source>
         Am J Respir Crit Care Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Q.D.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           Z.S.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status
        </article-title>
        <source>
         Mil Med Res
        </source>
        <volume>
         7
        </volume>
        <year>
         2020
        </year>
        <fpage>
         11
        </fpage>
        <pub-id pub-id-type="pmid">
         32169119
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           X.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           X.T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Zhongnan Hospital of Wuhan University Novel Coronavirus M and Research T. Updating the diagnostic criteria of COVID-19 "suspected case" and "confirmed case" is necessary
        </article-title>
        <source>
         Mil Med Res
        </source>
        <volume>
         7
        </volume>
        <year>
         2020
        </year>
        <fpage>
         17
        </fpage>
        <pub-id pub-id-type="pmid">
         32245396
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yin
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan
        </article-title>
        <source>
         China
        </source>
        <year>
         2020
        </year>
        <comment>
         2020.02.19.20025239
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tipnis
          </surname>
          <given-names>
           S.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           N.M.
          </given-names>
         </name>
         <name>
          <surname>
           Hyde
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Karran
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Christie
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Turner
          </surname>
          <given-names>
           A.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase
        </article-title>
        <source>
         J Biol Chem
        </source>
        <volume>
         275
        </volume>
        <year>
         2000
        </year>
        <fpage>
         33238
        </fpage>
        <lpage>
         33243
        </lpage>
        <pub-id pub-id-type="pmid">
         10924499
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hamming
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Timens
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bulthuis
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Lely
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Navis
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           van Goor
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
        </article-title>
        <source>
         J Pathol
        </source>
        <volume>
         203
        </volume>
        <year>
         2004
        </year>
        <fpage>
         631
        </fpage>
        <lpage>
         637
        </lpage>
        <pub-id pub-id-type="pmid">
         15141377
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Backx
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The role of ACE2 in cardiovascular physiology
        </article-title>
        <source>
         Trends Cardiovasc Med
        </source>
        <volume>
         13
        </volume>
        <year>
         2003
        </year>
        <fpage>
         93
        </fpage>
        <lpage>
         101
        </lpage>
        <pub-id pub-id-type="pmid">
         12691672
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0024">
       <label>
        24
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Sutter
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Trilling
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        25
       </label>
       <element-citation id="sbref0021" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thygesen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Alpert
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Jaffe
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Chaitman
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bax
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Morrow
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           White
          </surname>
          <given-names>
           H.D.
          </given-names>
         </name>
         <collab>
          Group ESCSD
         </collab>
        </person-group>
        <article-title>
         Fourth universal definition of myocardial infarction (2018)
        </article-title>
        <source>
         Eur Heart J
        </source>
        <volume>
         40
        </volume>
        <year>
         2019
        </year>
        <fpage>
         237
        </fpage>
        <lpage>
         269
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0026">
       <label>
        26
       </label>
       <mixed-citation id="othref0005" publication-type="other">
        Wu C., Hu X., Song J., Du C., Xu J., Yang D., Chen D., Zhong M., Jiang J., Xiong W., Lang K., Zhang Y., Shi G., Xu L., Song Y., Zhou X., Wei M. and Zheng J.Heart injury signs are associated with higher and earlier mortality in coronavirus disease 2019 (COVID-19). 2020:2020.02.26.20028589.
       </mixed-citation>
      </ref>
      <ref id="bib0027">
       <label>
        27
       </label>
       <element-citation id="sbref0022" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
        </article-title>
        <source>
         JAMA Cardiology
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0028">
       <label>
        28
       </label>
       <element-citation id="sbref0023" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)
        </article-title>
        <source>
         JAMA Cardiol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0029">
       <label>
        29
       </label>
       <mixed-citation id="othref0006" publication-type="other">
        X Y., Y Y., J X., H S., J X., H L., Y W., L Z., Z Y., M F., T Y., Y W., S P., X Z., S Y. and medicine SYJTLR. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0030">
       <label>
        30
       </label>
       <mixed-citation id="othref0007" publication-type="other">
        Hui H., Zhang Y., Yang X., Wang X., He B., Li L., Li H., Tian J. and Chen Y.Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. 2020:2020.02.24.20027052.
       </mixed-citation>
      </ref>
      <ref id="bib0031">
       <label>
        31
       </label>
       <element-citation id="sbref0024" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer
        </article-title>
        <source>
         J Thorac Oncol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0032">
       <label>
        32
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baroldi
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anatomy and quantification of myocardial cell death
        </article-title>
        <source>
         Methods Achiev Exp Pathol
        </source>
        <volume>
         13
        </volume>
        <year>
         1988
        </year>
        <fpage>
         87
        </fpage>
        <lpage>
         113
        </lpage>
        <pub-id pub-id-type="pmid">
         3045498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0033">
       <label>
        33
       </label>
       <element-citation id="sbref0026" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathological findings of COVID-19 associated with acute respiratory distress syndrome
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0034">
       <label>
        34
       </label>
       <element-citation id="sbref0027" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Muszynski
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hansson
          </surname>
          <given-names>
           G.K.
          </given-names>
         </name>
         <name>
          <surname>
           Libby
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta
        </article-title>
        <source>
         Arterioscler Thromb Vasc Biol
        </source>
        <volume>
         16
        </volume>
        <year>
         1996
        </year>
        <fpage>
         19
        </fpage>
        <lpage>
         27
        </lpage>
        <pub-id pub-id-type="pmid">
         8548421
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <label>
        35
       </label>
       <element-citation id="sbref0028" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Geng
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Azuma
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.X.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Muszynski
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Libby
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kwiatkowski
          </surname>
          <given-names>
           D.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Caspase-3-induced gelsolin fragmentation contributes to actin cytoskeletal collapse, nucleolysis, and apoptosis of vascular smooth muscle cells exposed to proinflammatory cytokines
        </article-title>
        <source>
         Eur J Cell Biol
        </source>
        <volume>
         77
        </volume>
        <year>
         1998
        </year>
        <fpage>
         294
        </fpage>
        <lpage>
         302
        </lpage>
        <pub-id pub-id-type="pmid">
         9930654
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0036">
       <label>
        36
       </label>
       <mixed-citation id="othref0008" publication-type="other">
        Zhang B., Zhou X., Qiu Y., Feng F., Feng J., Jia Y., Zhu H., Hu K., Liu J., Liu Z., Wang S., Gong Y., Zhou C., Zhu T., Cheng Y., Liu Z., Deng H., Tao F., Ren Y., Cheng B., Gao L., Wu X., Yu L., Huang Z., Mao Z., Song Q., Zhu B. and Wang J.Clinical characteristics of 82 death cases with COVID-19. 2020:2020.02.26.20028191.
       </mixed-citation>
      </ref>
      <ref id="bib0037">
       <label>
        37
       </label>
       <element-citation id="sbref0029" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Buja
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Zehr
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lelenwa
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Ogechukwu
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Dasgupta
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Barth
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinicopathological complexity in the application of the universal definition of myocardial infarction
        </article-title>
        <source>
         Cardiovasc Pathol
        </source>
        <volume>
         44
        </volume>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         107153
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0038">
       <label>
        38
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0039">
       <label>
        39
       </label>
       <element-citation id="sbref0031" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.J.
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ou
          </surname>
          <given-names>
           C.Q.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           J.X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shan
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Lei
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           Z.J.
          </given-names>
         </name>
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           S.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           C.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.S.
          </given-names>
         </name>
         <collab>
          China Medical Treatment Expert Group for C
         </collab>
        </person-group>
        <article-title>
         Clinical Characteristics of Coronavirus Disease 2019 in China
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2020
        </year>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa2002032
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        40
       </label>
       <element-citation id="sbref0032" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Walls
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
         <name>
          <surname>
           Tortorici
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           McGuire
          </surname>
          <given-names>
           A.T.
          </given-names>
         </name>
         <name>
          <surname>
           Veesler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
        </article-title>
        <source>
         Cell
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0041">
       <label>
        41
       </label>
       <element-citation id="sbref0033" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           I.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           H.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chien
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         84
        </volume>
        <year>
         2010
        </year>
        <fpage>
         7703
        </fpage>
        <lpage>
         7712
        </lpage>
        <pub-id pub-id-type="pmid">
         20484496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0042">
       <label>
        42
       </label>
       <element-citation id="sbref0034" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Godbout
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Gosselin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Stagliano
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Donovan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Woolf
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robison
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jeyaseelan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Breitbart
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Acton
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         87
        </volume>
        <year>
         2000
        </year>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0043">
       <label>
        43
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ohto-Nakanishi
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters
        </article-title>
        <source>
         Pharmacol Ther
        </source>
        <volume>
         128
        </volume>
        <year>
         2010
        </year>
        <fpage>
         119
        </fpage>
        <lpage>
         128
        </lpage>
        <pub-id pub-id-type="pmid">
         20599443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0044">
       <label>
        44
       </label>
       <element-citation id="sbref0036" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kohlstedt
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Brandes
          </surname>
          <given-names>
           R.P.
          </given-names>
         </name>
         <name>
          <surname>
           Muller-Esterl
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Busse
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fleming
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         94
        </volume>
        <year>
         2004
        </year>
        <fpage>
         60
        </fpage>
        <lpage>
         67
        </lpage>
        <pub-id pub-id-type="pmid">
         14615289
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <label>
        45
       </label>
       <element-citation id="sbref0037" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Kong
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yip
          </surname>
          <given-names>
           G.W.
          </given-names>
         </name>
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           Y.O.
          </given-names>
         </name>
         <name>
          <surname>
           Chiu
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiovascular complications of severe acute respiratory syndrome
        </article-title>
        <source>
         Postgrad Med J
        </source>
        <volume>
         82
        </volume>
        <year>
         2006
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         144
        </lpage>
        <pub-id pub-id-type="pmid">
         16461478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0046">
       <label>
        46
       </label>
       <element-citation id="sbref0038" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Farzan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Harrison
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of SARS coronavirus spike receptor-binding domain complexed with receptor
        </article-title>
        <source>
         Science
        </source>
        <volume>
         309
        </volume>
        <year>
         2005
        </year>
        <fpage>
         1864
        </fpage>
        <lpage>
         1868
        </lpage>
        <pub-id pub-id-type="pmid">
         16166518
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0047">
       <label>
        47
       </label>
       <element-citation id="sbref0039" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Glowacka
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Bertram
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Soilleux
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Pfefferle
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Steffen
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Tsegaye
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gnirss
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Niemeyer
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Schneider
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        <source>
         J Virol
        </source>
        <volume>
         85
        </volume>
        <year>
         2011
        </year>
        <fpage>
         4122
        </fpage>
        <lpage>
         4134
        </lpage>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0048">
       <label>
        48
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kuba
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Imai
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Rao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Huan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chappell
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Leibbrandt
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wada
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Slutsky
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
        </article-title>
        <source>
         Nat Med
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         875
        </fpage>
        <lpage>
         879
        </lpage>
        <pub-id pub-id-type="pmid">
         16007097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0049">
       <label>
        49
       </label>
       <element-citation id="sbref0041" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           G.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kassiri
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Penninger
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Butany
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS
        </article-title>
        <source>
         Eur J Clin Invest
        </source>
        <volume>
         39
        </volume>
        <year>
         2009
        </year>
        <fpage>
         618
        </fpage>
        <lpage>
         625
        </lpage>
        <pub-id pub-id-type="pmid">
         19453650
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        50
       </label>
       <element-citation id="sbref0042" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haga
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Nakai-Murakami
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Osawa
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tokunaga
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sata
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yamamoto
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Sasazuki
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ishizaka
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         105
        </volume>
        <year>
         2008
        </year>
        <fpage>
         7809
        </fpage>
        <lpage>
         7814
        </lpage>
        <pub-id pub-id-type="pmid">
         18490652
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0051">
       <label>
        51
       </label>
       <element-citation id="sbref0043" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2
        </article-title>
        <source>
         science
        </source>
        <year>
         2020
        </year>
        <fpage>
         eabb2762
        </fpage>
       </element-citation>
      </ref>
      <ref id="bib0052">
       <label>
        52
       </label>
       <element-citation id="sbref0044" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Schroeder
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Kruger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Erichsen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Schiergens
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Herrler
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pohlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
        </article-title>
        <source>
         Cell
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0053">
       <label>
        53
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Braunwald
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         50th anniversary historical article. Myocardial oxygen consumption: the quest for its determinants and some clinical fallout
        </article-title>
        <source>
         J Am Coll Cardiol
        </source>
        <volume>
         35
        </volume>
        <year>
         2000
        </year>
        <fpage>
         45B
        </fpage>
        <lpage>
         48B
        </lpage>
        <pub-id pub-id-type="pmid">
         10636257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0054">
       <label>
        54
       </label>
       <element-citation id="sbref0046" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Heusch
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Myocardial Ischemia: Lack of Coronary Blood Flow or Myocardial Oxygen Supply/Demand Imbalance?
        </article-title>
        <source>
         Circ Res
        </source>
        <volume>
         119
        </volume>
        <year>
         2016
        </year>
        <fpage>
         194
        </fpage>
        <lpage>
         196
        </lpage>
        <pub-id pub-id-type="pmid">
         27390331
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        55
       </label>
       <element-citation id="sbref0047" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           J
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           S
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           J
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pang
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Weng
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Jie
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Dittmer
          </surname>
          <given-names>
           U.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
        <comment>
         2020.02.16.20023671
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0056">
       <label>
        56
       </label>
       <element-citation id="sbref0048" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Lang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Qiang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)
        </article-title>
        <source>
         medRxiv
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0057">
       <label>
        57
       </label>
       <element-citation id="sbref0049" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tanaka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Narazaki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kishimoto
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Immunotherapeutic implications of IL-6 blockade for cytokine storm
        </article-title>
        <source>
         Immunotherapy
        </source>
        <volume>
         8
        </volume>
        <year>
         2016
        </year>
        <fpage>
         959
        </fpage>
        <lpage>
         970
        </lpage>
        <pub-id pub-id-type="pmid">
         27381687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0058">
       <label>
        58
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pathan
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Hemingway
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Alizadeh
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Stephens
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Boldrick
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Oragui
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           McCabe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Welch
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Whitney
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           O'Gara
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Nadel
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Relman
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
         <name>
          <surname>
           Harding
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
         <name>
          <surname>
           Levin
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock
        </article-title>
        <source>
         The Lancet
        </source>
        <volume>
         363
        </volume>
        <year>
         2004
        </year>
        <fpage>
         203
        </fpage>
        <lpage>
         209
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0059">
       <label>
        59
       </label>
       <element-citation id="sbref0051" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chousterman
          </surname>
          <given-names>
           B.G.
          </given-names>
         </name>
         <name>
          <surname>
           Swirski
          </surname>
          <given-names>
           F.K.
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           G.F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cytokine storm and sepsis disease pathogenesis
        </article-title>
        <source>
         Semin Immunopathol
        </source>
        <volume>
         39
        </volume>
        <year>
         2017
        </year>
        <fpage>
         517
        </fpage>
        <lpage>
         528
        </lpage>
        <pub-id pub-id-type="pmid">
         28555385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        60
       </label>
       <element-citation id="sbref0052" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           Y.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.C.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           H.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province
        </article-title>
        <source>
         Chin Med J (Engl)
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0061">
       <label>
        61
       </label>
       <element-citation id="sbref0053" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <volume>
         30
        </volume>
        <year>
         2020
        </year>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0062">
       <label>
        62
       </label>
       <element-citation id="sbref0054" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mulangu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Dodd
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Davey
          </surname>
          <given-names>
           R.T.
          </given-names>
          <suffix>
           Jr.
          </suffix>
         </name>
         <name>
          <surname>
           Tshiani Mbaya
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Proschan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Mukadi
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Lusakibanza Manzo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Nzolo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tshomba Oloma
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ibanda
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ali
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Coulibaly
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Levine
          </surname>
          <given-names>
           A.C.
          </given-names>
         </name>
         <name>
          <surname>
           Grais
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Diaz
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lane
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Muyembe-Tamfum
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Sivahera
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Camara
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kojan
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Walker
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Dighero-Kemp
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Mukumbayi
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Mbala-Kingebeni
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Ahuka
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Albert
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Bonnett
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Crozier
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Duvenhage
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Proffitt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Teitelbaum
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Moench
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Aboulhab
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Barrett
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Cahill
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Cone
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Eckes
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Hensley
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Herpin
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Higgs
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Ledgerwood
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pierson
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Smolskis
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Sow
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tierney
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sivapalasingam
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Holman
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Gettinger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Vallée
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Nordwall
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         381
        </volume>
        <year>
         2019
        </year>
        <fpage>
         2293
        </fpage>
        <lpage>
         2303
        </lpage>
        <pub-id pub-id-type="pmid">
         31774950
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0063">
       <label>
        63
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Spitters
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Ericson
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wilkerson
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Tural
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Diaz
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Cohn
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fox
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           S.I.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lindstrom
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Pallansch
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Weldon
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Biggs
          </surname>
          <given-names>
           H.M.
          </given-names>
         </name>
         <name>
          <surname>
           Uyeki
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pillai
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <collab>
          Washington State -nCo VCIT
         </collab>
        </person-group>
        <article-title>
         First Case of 2019 Novel Coronavirus in the United States
        </article-title>
        <source>
         N Engl J Med
        </source>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <fpage>
         929
        </fpage>
        <lpage>
         936
        </lpage>
        <pub-id pub-id-type="pmid">
         32004427
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0064">
       <label>
        64
       </label>
       <element-citation id="sbref0056" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sanville
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Pidcock
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Hardin
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Sebat
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           M.-V.
          </given-names>
         </name>
         <name>
          <surname>
           Thompson
          </surname>
          <given-names>
           G.R.
          </given-names>
          <suffix>
           III
          </suffix>
         </name>
         <name>
          <surname>
           Haczku
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Schivo
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Community Transmitted Case of Severe Acute Respiratory Distress Syndrome due to SARS CoV2 in the United States
        </article-title>
        <source>
         Clinical Infectious Diseases
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        65
       </label>
       <mixed-citation id="othref0009" publication-type="other">
        ClinicalTrials.gov. Severe 2019-nCoV Remdesivir RCT. Identifier:NCT04257656. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0066">
       <label>
        66
       </label>
       <mixed-citation id="othref0010" publication-type="other">
        ClinicalTrials.gov. Mild/Moderate 2019-nCoV Remdesivir RCT. Identifier: NCT04252664. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0067">
       <label>
        67
       </label>
       <mixed-citation id="othref0011" publication-type="other">
        ClinicalTrials.gov. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19). Identifier:NCT04292899. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0068">
       <label>
        68
       </label>
       <element-citation id="sbref0057" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cui
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clinical infectious diseases: an official publication of the Infectious Diseases Society of America
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0069">
       <label>
        69
       </label>
       <element-citation id="sbref0058" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vincent
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bergeron
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Benjannet
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Erickson
          </surname>
          <given-names>
           B.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rollin
          </surname>
          <given-names>
           P.E.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Seidah
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Nichol
          </surname>
          <given-names>
           S.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
        </article-title>
        <source>
         Virology journal
        </source>
        <volume>
         2
        </volume>
        <year>
         2005
        </year>
        <fpage>
         69
        </fpage>
        <pub-id pub-id-type="pmid">
         16115318
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        70
       </label>
       <element-citation id="sbref0059" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           BE
          </surname>
          <given-names>
           V.D.B.
          </given-names>
         </name>
         <name>
          <surname>
           BA
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           HH
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           S
          </surname>
          <given-names>
           L.C.
          </given-names>
         </name>
         <name>
          <surname>
           CL
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells
        </article-title>
        <source>
         The Journal of rheumatology
        </source>
        <volume>
         24
        </volume>
        <year>
         1997
        </year>
        <fpage>
         55
        </fpage>
        <lpage>
         60
        </lpage>
        <pub-id pub-id-type="pmid">
         9002011
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0071">
       <label>
        71
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gautret
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Lagier
          </surname>
          <given-names>
           J.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Parola
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hoang
          </surname>
          <given-names>
           V.T.
          </given-names>
         </name>
         <name>
          <surname>
           Meddeb
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Mailhe
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Doudier
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Courjon
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Giordanengo
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Vieira
          </surname>
          <given-names>
           V.E.
          </given-names>
         </name>
         <name>
          <surname>
           Dupont
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Honoré
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Colson
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Chabrière
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           La Scola
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Rolain
          </surname>
          <given-names>
           J.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Brouqui
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Raoult
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
        </article-title>
        <source>
         International Journal of Antimicrobial Agents
        </source>
        <year>
         2020
        </year>
        <object-id pub-id-type="publisher-id">
         105949
        </object-id>
       </element-citation>
      </ref>
      <ref id="bib0072">
       <label>
        72
       </label>
       <mixed-citation id="othref0012" publication-type="other">
        ClinicalTrials.gov. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV). Identifier:NCT04261517. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0073">
       <label>
        73
       </label>
       <mixed-citation id="othref0013" publication-type="other">
        ClinicalTrials.gov. Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting (COPCOV). Identifier:NCT04303507. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0074">
       <label>
        74
       </label>
       <element-citation id="sbref0061" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           NJ
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cardiotoxicity of antimalarial drugs
        </article-title>
        <source>
         The Lancet Infectious diseases
        </source>
        <volume>
         7
        </volume>
        <year>
         2007
        </year>
        <fpage>
         549
        </fpage>
        <lpage>
         558
        </lpage>
        <pub-id pub-id-type="pmid">
         17646028
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <label>
        75
       </label>
       <element-citation id="sbref0062" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           Y.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mandourah
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Hameed
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Sindi
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Almekhlafi
          </surname>
          <given-names>
           G.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hussein
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Jose
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Pinto
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Omari
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kharaba
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Almotairi
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Al Khatib
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Shalhoub
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Abdulmomen
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Qushmaq
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Mady
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Solaiman
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Aithan
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Raddadi
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Ragab
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.H.
          </given-names>
         </name>
         <name>
          <surname>
           Al Harthy
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Deeb
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al Mutairi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Dawood
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Merson
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           F.G.
          </given-names>
         </name>
         <name>
          <surname>
           Fowler
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
        </article-title>
        <source>
         American journal of respiratory and critical care medicine
        </source>
        <volume>
         197
        </volume>
        <year>
         2018
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         767
        </lpage>
        <pub-id pub-id-type="pmid">
         29161116
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0076">
       <label>
        76
       </label>
       <element-citation id="sbref0063" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stockman
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Bellamy
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Garner
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: systematic review of treatment effects
        </article-title>
        <source>
         PLoS medicine
        </source>
        <volume>
         3
        </volume>
        <year>
         2006
        </year>
        <fpage>
         e343
        </fpage>
        <pub-id pub-id-type="pmid">
         16968120
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0077">
       <label>
        77
       </label>
       <element-citation id="sbref0064" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.P.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           Z.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           J.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience
        </article-title>
        <source>
         Chest
        </source>
        <volume>
         129
        </volume>
        <year>
         2006
        </year>
        <fpage>
         1441
        </fpage>
        <lpage>
         1452
        </lpage>
        <pub-id pub-id-type="pmid">
         16778260
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0078">
       <label>
        78
       </label>
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           C
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           D
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           DT
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
        </article-title>
        <source>
         Expert review of clinical immunology
        </source>
        <volume>
         15
        </volume>
        <year>
         2019
        </year>
        <fpage>
         813
        </fpage>
        <lpage>
         822
        </lpage>
        <pub-id pub-id-type="pmid">
         31219357
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0079">
       <label>
        79
       </label>
       <element-citation id="sbref0066" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        <source>
         The Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <label>
        80
       </label>
       <element-citation id="sbref0067" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           CM
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           J
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           MC
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           DB
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           KB
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           EA
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           DI
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           PE
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2
        </article-title>
        <source>
         Circulation
        </source>
        <volume>
         111
        </volume>
        <year>
         2005
        </year>
        <fpage>
         2605
        </fpage>
        <lpage>
         2610
        </lpage>
        <pub-id pub-id-type="pmid">
         15897343
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0081">
       <label>
        81
       </label>
       <element-citation id="sbref0068" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           K.-M.
          </given-names>
         </name>
         <name>
          <surname>
           Chiueh
          </surname>
          <given-names>
           T.-S.
          </given-names>
         </name>
         <name>
          <surname>
           Siu
          </surname>
          <given-names>
           L.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lin
          </surname>
          <given-names>
           J.-C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           M.-Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           H.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J.-H.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.-S.
          </given-names>
         </name>
         <name>
          <surname>
           Perng
          </surname>
          <given-names>
           C.-L.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           J.-J.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           F.-Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital
        </article-title>
        <source>
         Journal of Antimicrobial Chemotherapy
        </source>
        <volume>
         56
        </volume>
        <year>
         2005
        </year>
        <fpage>
         919
        </fpage>
        <lpage>
         922
        </lpage>
        <pub-id pub-id-type="pmid">
         16183666
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0082">
       <label>
        82
       </label>
       <element-citation id="sbref0069" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Xing
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Qing
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0083">
       <label>
        83
       </label>
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           N
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Management and prevention of SARS in China
        </article-title>
        <source>
         Philosophical transactions of the Royal Society of London Series B, Biological sciences
        </source>
        <volume>
         359
        </volume>
        <year>
         2004
        </year>
        <fpage>
         1115
        </fpage>
        <lpage>
         1116
        </lpage>
        <pub-id pub-id-type="pmid">
         15306397
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0084">
       <label>
        84
       </label>
       <element-citation id="sbref0071" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           M
          </surname>
          <given-names>
           L.-P.
          </given-names>
         </name>
         <name>
          <surname>
           C
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           PRM
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           P
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current understanding of the therapeutic benefits of mesenchymal stem cells in acute respiratory distress syndrome
        </article-title>
        <source>
         J Cell biology toxicology
        </source>
        <volume>
         36
        </volume>
        <year>
         2020
        </year>
        <fpage>
         83
        </fpage>
        <lpage>
         102
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <label>
        85
       </label>
       <mixed-citation id="othref0014" publication-type="other">
        ClinicalTrials.gov. Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19. Identifier:NCT04292340. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0086">
       <label>
        86
       </label>
       <mixed-citation id="othref0015" publication-type="other">
        ClinicalTrials.gov. Hyperimmune Plasma for Critical Patients With COVID-19 (COV19-PLASMA). Identifier:NCT04321421. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0087">
       <label>
        87
       </label>
       <mixed-citation id="othref0016" publication-type="other">
        ClinicalTrials.gov. NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia (HOPE). Identifier:NCT04315987. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0088">
       <label>
        88
       </label>
       <mixed-citation id="othref0017" publication-type="other">
        ClinicalTrials.gov. Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease2019(COVID-19). Identifier:NCT04288102. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0089">
       <label>
        89
       </label>
       <mixed-citation id="othref0018" publication-type="other">
        ClinicalTrials.gov. Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection. Identifier:NCT04251871. 2020.
       </mixed-citation>
      </ref>
     </ref-list>
     <ack id="ack0001">
      <sec id="sec0018">
       <title>
        Acknowledgment
       </title>
       <p id="para0043">
        This work was supported in part by grants from the National Institutes of Health (NIH) and Hermann Research Foundation (Y.J. Geng), National Natural Science Foundation of China (H. Qian, 81670337) and from the Clinical and Translational Medicine Research Foundation of Chinese Academy of Medical Sciences (H. Qian, 2019XK320061).
       </p>
      </sec>
      <sec id="sec0019">
       <title>
        Disclosure
       </title>
       <p id="para0044">
        The authors report no competing interests.
       </p>
      </sec>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Sci Rep
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Sci Rep
      </journal-id>
      <journal-title-group>
       <journal-title>
        Scientific Reports
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2045-2322
      </issn>
      <publisher>
       <publisher-name>
        Nature Publishing Group UK
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       29654248
      </article-id>
      <article-id pub-id-type="pmc">
       5899083
      </article-id>
      <article-id pub-id-type="publisher-id">
       24407
      </article-id>
      <article-id pub-id-type="doi">
       10.1038/s41598-018-24407-x
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Detection and characterisation of coronaviruses in migratory and non-migratory Australian wild birds
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chamings
         </surname>
         <given-names>
          Anthony
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          Tiffanie M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Vibin
         </surname>
         <given-names>
          Jessy
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wille
         </surname>
         <given-names>
          Michelle
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Klaassen
         </surname>
         <given-names>
          Marcel
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">
         http://orcid.org/0000-0002-5039-3178
        </contrib-id>
        <name>
         <surname>
          Alexandersen
         </surname>
         <given-names>
          Soren
         </given-names>
        </name>
        <address>
         <email>
          soren.alexandersen@deakin.edu.au
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        Geelong Centre for Emerging Infectious Diseases, Geelong, Victoria Australia
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 0526 7079
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.1021.2
         </institution-id>
         <institution>
          Deakin University, School of Medicine,
         </institution>
        </institution-wrap>
        Geelong, Victoria Australia
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.483778.7
         </institution-id>
         <institution>
          WHO Collaborating Centre for Reference and Research on Influenza,
         </institution>
         <institution>
          the Peter Doherty Institute for Infection and Immunity,
         </institution>
        </institution-wrap>
        Melbourne, Victoria Australia
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0001 0526 7079
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.1021.2
         </institution-id>
         <institution>
          Centre for Integrative Ecology,
         </institution>
         <institution>
          School of Life and Environmental Sciences, Deakin University,
         </institution>
        </institution-wrap>
        Geelong, Victoria Australia
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        <institution-wrap>
         <institution-id institution-id-type="ISNI">
          0000 0000 8560 4604
         </institution-id>
         <institution-id institution-id-type="GRID">
          grid.415335.5
         </institution-id>
         <institution>
          Barwon Health,
         </institution>
         <institution>
          University Hospital Geelong,
         </institution>
        </institution-wrap>
        Geelong, Victoria Australia
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        13
       </day>
       <month>
        4
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        13
       </day>
       <month>
        4
       </month>
       <year>
        2018
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2018
       </year>
      </pub-date>
      <volume>
       8
      </volume>
      <elocation-id>
       5980
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         12
        </day>
        <month>
         1
        </month>
        <year>
         2018
        </year>
       </date>
       <date date-type="accepted">
        <day>
         26
        </day>
        <month>
         3
        </month>
        <year>
         2018
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2018
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         .
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        We evaluated the presence of coronaviruses by PCR in 918 Australian wild bird samples collected during 2016–17. Coronaviruses were detected in 141 samples (15.3%) from species of ducks, shorebirds and herons and from multiple sampling locations. Sequencing of selected positive samples found mainly gammacoronaviruses, but also some deltacoronaviruses. The detection rate of coronaviruses was improved by using multiple PCR assays, as no single assay could detect all coronavirus positive samples. Sequencing of the relatively conserved Orf1 PCR amplicons found that Australian duck gammacoronaviruses were similar to duck gammacoronaviruses around the world. Some sequenced shorebird gammacoronaviruses belonged to Charadriiformes lineages, but others were more closely related to duck gammacoronaviruses. Australian duck and heron deltacoronaviruses belonged to lineages with other duck and heron deltacoronaviruses, but were almost 20% different in nucleotide sequence to other deltacoronavirus sequences available. Deltacoronavirus sequences from shorebirds formed a lineage with a deltacoronavirus from a ruddy turnstone detected in the United States. Given that Australian duck gammacoronaviruses are highly similar to those found in other regions, and Australian ducks rarely come into contact with migratory Palearctic duck species, we hypothesise that migratory shorebirds are the important vector for moving wild bird coronaviruses into and out of Australia.
       </p>
      </abstract>
      <kwd-group kwd-group-type="npg-subject">
       <title>
        Subject terms
       </title>
       <kwd>
        Ecological epidemiology
       </kwd>
       <kwd>
        Viral infection
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2018
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1" sec-type="introduction">
     <title>
      Introduction
     </title>
     <p id="Par2">
      Coronaviruses (CoV) are the causative agents of significant diseases resulting in substantial impact on human and animal health. Both severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) have caused a significant burden on human health, including a number of deaths, and have had significant socioeconomic impacts on the countries in which people were infected
      <sup>
       <xref ref-type="bibr" rid="CR1">
        1
       </xref>
       –
       <xref ref-type="bibr" rid="CR3">
        3
       </xref>
      </sup>
      . Coronavirus infections of livestock, such as porcine epidemic diarrhoea virus (PEDV) and more recently porcine deltacoronavirus (PDCoV) in pigs and infectious bronchitis virus (IBV) and turkey coronavirus in poultry, have significant impacts on animal health and cause considerable economic costs to producers
      <sup>
       <xref ref-type="bibr" rid="CR4">
        4
       </xref>
       –
       <xref ref-type="bibr" rid="CR7">
        7
       </xref>
      </sup>
      .
     </p>
     <p id="Par3">
      Interspecies spill-over of coronaviruses into new hosts occurs frequently, with SARS-CoV and MERS-CoV being the most notable examples of spill-over into humans
      <sup>
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
       –
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
      </sup>
      . Bovine coronavirus, canine respiratory coronavirus, dromedary camel coronavirus and even human coronavirus OC43 all potentially come from the same common ancestor, illustrating substantive host flexibility
      <sup>
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       –
       <xref ref-type="bibr" rid="CR13">
        13
       </xref>
      </sup>
      . SARS-CoV likely originated in bats while PDCoV interestingly is likely to have originated in birds
      <sup>
       <xref ref-type="bibr" rid="CR6">
        6
       </xref>
       ,
       <xref ref-type="bibr" rid="CR8">
        8
       </xref>
       ,
       <xref ref-type="bibr" rid="CR9">
        9
       </xref>
      </sup>
      . Consequently, there is significant interest in assessing wild animals for CoV’s.
     </p>
     <p id="Par4">
      Wild birds are ubiquitous and highly mobile potential hosts capable of moving viruses over large distances and across geographical and political borders. Wild birds have been implicated in the spread of highly pathogenic H5Nx avian influenza viruses
      <sup>
       <xref ref-type="bibr" rid="CR14">
        14
       </xref>
      </sup>
      and bird migration patterns describe phylogenetic patterns in the matrix gene of low pathogenic influenza virus
      <sup>
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
      </sup>
      . Coronaviruses have been detected in a range of species of wild birds on all continents except for Australia and Antarctica
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       –
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
      </sup>
      . It is likely that CoV’s are present in wild birds on all continents. However, a recent survey in Australia of 409 birds failed to detect coronaviruses
      <sup>
       <xref ref-type="bibr" rid="CR22">
        22
       </xref>
      </sup>
      .
     </p>
     <p id="Par5">
      Studies in which wild bird coronaviruses have been successfully detected, have commonly sampled aquatic bird species such as Anseriformes (ducks, geese and swans) and Charadriiformes (gulls, migratory shorebirds and waders)
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
      </sup>
      . This prompted our study to look for coronaviruses in Australian birds that notably belong to these two orders.
     </p>
     <p id="Par6">
      Given that the genetic diversity of CoV’s in Australian wild birds was unknown it was decided to use a combination of PCR assays to maximise the probability of detecting positive individuals. Coronavirus positive samples were genetically sequenced and phylogenetic analysis performed to compare these sequences to coronavirus sequences from previous surveys of wild and domestic birds across the globe.
     </p>
    </sec>
    <sec id="Sec2" sec-type="results">
     <title>
      Results
     </title>
     <sec id="Sec3">
      <title>
       PCR assay comparison
      </title>
      <p id="Par7">
       The 5′ UTR detected 66/912 or 7.2% (95% CI: 5.6–8.9%) of samples positive for coronavirus, the nested PCR 100/916 samples or 10.9% (95% CI: 8.9–13.0%) and the modified pancoronavirus PCR 109/915 samples or 11.9% (95% CI: 9.8–14%). By combining the results from the three PCRs, 141/918 or 15.3% (95% CI: 13–17.7%) of all samples tested positive for coronaviruses in at least one PCR assay. Nine hundred and eight samples were tested with all three PCRs. Ten samples had insufficient RNA to allow testing with all three assays. Nine of these samples were negative in the assays with which they were tested. One (Ruddy turnstone CoV-9614–2016/11/19-CM/TAS) was positive in the nested PCR, negative in the 5′ UTR PCR but could not be tested with the modified PCR. These ten samples were excluded from the PCR assay comparison.
      </p>
      <p id="Par8">
       When compared to the combined results, the sensitivities for the UTR, nested and modified PCRs were 46.8%, 70.9% and 77.3% respectively. McNemar’s test revealed no statistical difference in the coronavirus detection abilities of the modified and nested PCRs (χ
       <sup>
        2
       </sup>
       = 2.38, p = 0.12) but a statistical difference was detected between the results of the UTR PCR and the nested PCR (χ
       <sup>
        2
       </sup>
       = 13.96, p = 0.0002) and the UTR and modified PCR (χ
       <sup>
        2
       </sup>
       = 21.25, p = 4 × 10
       <sup>
        −6
       </sup>
       ).
      </p>
      <p id="Par9">
       From the subset of 66 samples where the Orf1/polymerase PCR amplicon was sequenced and genus of coronavirus identified (excluding the one positive pooled sample which contained both a gamma-CoV and delta-CoV (see later)), the 5′ UTR PCR did not detect any delta-CoV’s and only 50% of the gamma-CoV’s (27/54). The nested PCR detected 75% (9/12) of the delta-CoV’s and 85% (46/54) of the gamma-CoV’s. The modified PCR detected 75% (9/12) of the delta-CoV’s and 87% (47/54) of gamma-CoV’s. No PCR was able to detect all positive samples. The 5′ UTR PCR, despite having the lowest sensitivity, detected 19 samples which were declared negative by the other two PCRs. Similarly, both the nested and modified PCRs detected 3 delta-CoV’s the other missed, despite targeting exactly the same region of the CoV genome.
      </p>
      <p id="Par10">
       Coronavirus positive samples produced a peak in the melt curve analysis of the modified polymerase real-time PCR with delta-CoV positive samples producing a peak between 80.6 °C and 81.8 °C and gamma-CoV positive samples producing a peak between 80.4 °C and 85.6 °C. No obvious pattern between melt curve peak temperature (T
       <sub>
        M
       </sub>
       ) or shape was apparent, which could be used to determine the genus of the coronavirus. Samples which produced a visible band of the expected size on the agarose gel also produced a strong peak on the melt curve. However, some negative samples produced small non-specific peaks in the melt curve within, and slightly above, the temperature range in which the positive samples produced peaks. These were small and readily differentiated from strong positive samples. However, without running a gel, these peaks would make it difficult to determine if a sample was weak positive or a non-specific reactor. When present, these non-specific peaks were associated with a ~300 bp band on the agarose gel that was readily differentiated from the target band of size 600 bp. During optimisation of this PCR on known negative and known positive samples, the non-specific band disappeared with forward and reverse primer concentrations of 0.5 µM as opposed to the 1 µM used in this study. This, however, had the impact of increasing the C
       <sub>
        T
       </sub>
       of positive samples by about 3 (an approximately 8-fold decrease in PCR amplification) and it was decided to go for increased PCR sensitivity over the removal of the small non-specific product as all positive samples could be confirmed by gel analysis.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Detection of coronaviruses in Australian wild birds
      </title>
      <p id="Par11">
       Coronaviruses were detected in 141 of the 918 samples tested (15.3%). Positive samples were found in eight out of the 15 bird species tested (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ). Negative species had very low sample sizes (&lt;30 individuals). Positive species included 4 species of ducks (Order Anseriformes): Pacific black duck (18/48), grey teal (19/63), radjah shelduck (1/3) and Australian wood duck (1/16); three shorebirds (Order Charadriiformes): curlew sandpiper (8/34), red-necked stint (42/534) and ruddy turnstone (47/157); and one species of heron (Order Pelecaniformes): pied heron (5/7). The coronavirus sample prevalence in Anseriformes was 26.7%, 13.3% in the Charadriiformes and 71.4% in the Pelecaniformes. Coronaviruses were only found in apparently healthy birds with none of the dead birds positive for CoV. Coronavirus positive birds were found in all states where sampling was conducted. Details of positive samples are presented in Supplementary Table
       <xref ref-type="media" rid="MOESM1">
        S1
       </xref>
       .
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          The bird species sampled in this study and the proportion of coronavirus positive samples.
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Avian Order/Family
           </th>
           <th align="left">
            Species
           </th>
           <th align="left">
            Common Name
           </th>
           <th align="left">
            coronavirus + ve/Total
           </th>
           <th align="left">
            Coronavirus Genus
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            <italic>
             Anseriformes, Anatidae
            </italic>
           </td>
           <td>
            <italic>
             Anas gracilis
            </italic>
           </td>
           <td>
            Grey teal
           </td>
           <td>
            19/63
           </td>
           <td>
            Gamma (11)
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Anas superciliosa
            </italic>
           </td>
           <td>
            Pacific black duck
           </td>
           <td>
            18/48
           </td>
           <td>
            Gamma (18), Delta (1)*
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Tadorna radjah
            </italic>
           </td>
           <td>
            Radjah shelduck
           </td>
           <td>
            1/3
           </td>
           <td>
            Gamma (1)
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Chenonetta jubata
            </italic>
           </td>
           <td>
            Australian wood duck
           </td>
           <td>
            1/16
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Tadorna tadornoides
            </italic>
           </td>
           <td>
            Australian shelduck
           </td>
           <td>
            0/5
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Anas castanea
            </italic>
           </td>
           <td>
            Chestnut teal
           </td>
           <td>
            0/11
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             Pelecaniformes, Ardeidae
            </italic>
           </td>
           <td>
            <italic>
             Ardea picata
            </italic>
           </td>
           <td>
            Pied heron
           </td>
           <td>
            5/7
           </td>
           <td>
            Delta (5)
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             Charadriiformes, Scolopacidae
            </italic>
           </td>
           <td>
            <italic>
             Caladris ferruginea
            </italic>
           </td>
           <td>
            Curlew sandpiper
           </td>
           <td>
            8/34
           </td>
           <td>
            Gamma (3), Delta (1)
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Caladris ruficolis
            </italic>
           </td>
           <td>
            Red-necked stint
           </td>
           <td>
            42/534
           </td>
           <td>
            Gamma (9), Delta (2)
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Calidris acuminata
            </italic>
           </td>
           <td>
            Sharp-tailed sandpiper
           </td>
           <td>
            0/3
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
           </td>
           <td>
            <italic>
             Arenaria interpres
            </italic>
           </td>
           <td>
            Ruddy turnstone
           </td>
           <td>
            47/157
           </td>
           <td>
            Gamma (20), Delta (5)
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             Procellariiformes
            </italic>
           </td>
           <td>
            <italic>
             Ardenna tenuirostris
            </italic>
           </td>
           <td>
            Short-tailed shearwater
           </td>
           <td>
            0/30
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             Acciptriformes
            </italic>
           </td>
           <td>
            <italic>
             Milvus migrans
            </italic>
           </td>
           <td>
            Black kite
           </td>
           <td>
            0/1
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             Columbiformes
            </italic>
           </td>
           <td>
            <italic>
             Streptopelia chinensis
            </italic>
           </td>
           <td>
            Spotted turtle dove
           </td>
           <td>
            0/1
           </td>
           <td>
           </td>
          </tr>
          <tr>
           <td>
            <italic>
             Passeriformes
            </italic>
           </td>
           <td>
            <italic>
             Corvus mellori
            </italic>
           </td>
           <td>
            Little Raven
           </td>
           <td>
            0/4
           </td>
           <td>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          *One pooled sample contained both a gammacoronavirus and deltacoronavirus.
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="Par12">
       Of the 141 positive samples, 67 were sequenced to identify the genus of CoV present. Samples for sequencing were a subset of samples which were positive in either the nested and/or modified PCRs targeting the polymerase gene. Approximately 25–50% of positive samples per species were sequenced, except in the species for which very few samples were tested (e.g. the pied herons and the radjah shelduck). In these species with small sample sizes, all positive samples were sequenced. Gamma-CoV’s (n = 54) were more frequently identified than delta-CoV’s (n = 13). The pooled sample from juvenile Pacific black ducks contained both a gamma- and a delta-CoV. This was the only sample in which two coronaviruses were detected. In the order Anseriformes, 22 gamma-CoV’s (grey teals (11), Pacific black ducks (10) and radjah shelduck (1)) and one delta-CoV (Pacific black duck) were identified. In the order Charadriiformes, 32 gamma-CoV’s (curlew sandpipers (3), red-necked stints (9), ruddy turnstones (20)) and 8 delta-CoV’s (curlew sandpiper (1), red-necked stints (2), ruddy turnstones (5)) were identified. In order Pelecaniformes, 5 delta-CoV’s were sequenced (pied herons (5)) and no gamma-CoV’s were identified.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Phylogenetic analysis of gammacoronaviruses
      </title>
      <p id="Par13">
       Gammacoronavirus sequences from this study were more related to gamma-CoV’s from ducks and wild birds (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       ) than to IBV-like gamma-CoV’s including IBVs from Australia (Supplementary Figure
       <xref ref-type="media" rid="MOESM1">
        S1
       </xref>
       ). All Australian duck gamma-CoV’s grouped on two branches within a predominantly duck lineage of gamma-CoV’s. Bootstrap support for the branches containing the Australian sequences was less than 75%. There was no apparent host duck species, temporal or geographical pattern to the Australian duck gamma-CoV’s distribution within the phylogenetic tree.
       <fig id="Fig1">
        <label>
         Figure 1
        </label>
        <caption>
         <p>
          Maximum likelihood phylogenetic tree of the 277 nt fragment of the polymerase gene of gammacoronaviruses from wild birds including the sequences obtained in this study. Bootstrap confidence of each branch was calculated from 1000 replicates. The region where each sequence was obtained is indicated with colour. Australia (red), Madagascar (teal), China, Hong Kong and Korea (dark blue), Bering Strait (green), United States of America (light blue) and Sweden (pink). The sampling location and state of each Australian sample is identified with a two letter code and the state: New South Wales (NSW): MM-Moulamein; Northern Territory (NT): HD-Humpty Doo; South Australia (SA): BP-Boatswain Point, NV-Nene Valley; Tasmania (TAS): BB-Borges Bay, King Island, CM-Central Manuka, King Island, DW-Dripping Wells, King Island, Tasmania; Victoria (VIC): BI-Barrallier Island, CR-Carlisle River, LC-Lake Connewarre, PV-Paynesville, WS-Werribee South. Some branches have been collapsed if all sequences came from the same region. The complete tree is shown in Supplementary Figure
          <xref ref-type="media" rid="MOESM1">
           S1
          </xref>
          .
         </p>
        </caption>
        <graphic id="d29e726" xlink:href="41598_2018_24407_Fig1_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par14">
       Gamma-CoV’s from shorebirds grouped on branches with other shorebird gamma-CoV’s sequences obtained in this study or from the “
       <italic>
        Beringia
       </italic>
       ” study of wild birds around the Bering Strait
       <sup>
        <xref ref-type="bibr" rid="CR20">
         20
        </xref>
       </sup>
       . With the exception of curlew sandpiper gamma-CoV’s, these branches had 75% or greater bootstrap support in the phylogenetic analysis. There was sequence diversity in the gamma-CoV sequences in all shorebird species except the curlew sandpipers. The majority of the ruddy turnstone gamma-CoV’s grouped with gamma-CoV’s from gulls sampled in 2005 during the Beringia study. One ruddy turnstone gamma-CoV grouped with gamma-CoV’s from rock sandpipers from the Beringia study. Red-necked stint gamma-CoV’s sequences grouped on their own branch. The three curlew sandpiper gamma-CoV sequences were identical, and were most similar to CoV sequences from ducks sampled in Sweden during 2011
       <sup>
        <xref ref-type="bibr" rid="CR25">
         25
        </xref>
       </sup>
       .
      </p>
      <p id="Par15">
       The amino acid ML tree of the gamma-CoV separated the majority of the shorebird gamma-CoV’s and gull gamma-CoV’s from the duck-CoV’s (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       , Supplementary Figure
       <xref ref-type="media" rid="MOESM1">
        S2
       </xref>
       ). However the three curlew sandpiper CoV’s and one ruddy turnstone CoV (Ruddy Turnstone CoV-9564-2016/11/19-BB/TAS) were identical in amino acid sequence to several Australian duck gamma-CoV’s, as well as many domestic and wild duck gamma-CoV sequences from Asia, Africa, Europe and North America.
       <fig id="Fig2">
        <label>
         Figure 2
        </label>
        <caption>
         <p>
          Maximum likelihood phylogenetic tree of the 92 amino acid sequence of the gammacoronaviruses from wild birds. Bootstrap confidence of each branch was calculated from 500 replicates. Some branches have been collapsed for clarity. The region where each sequence was obtained is indicated with colour. Australia (red), Madagascar (teal), China, Hong Kong and Korea (dark blue), Bering Strait (green), United States of America (light blue) and Sweden (pink). The sampling location and state of each Australian sample is identified with a two letter code and the state: New South Wales (NSW): MM-Moulamein; Northern Territory (NT): HD-Humpty Doo; South Australia (SA): BP-Boatswain Point, NV-Nene Valley; Tasmania (TAS): BB-Borges Bay, King Island, CM-Central Manuka, King Island, DW-Dripping Wells, King Island, Tasmania; Victoria (VIC): BI-Barrallier Island, CR-Carlisle River, LC-Lake Connewarre, PV-Paynesville, WS-Werribee South. Some branches have been collapsed if all sequences came from the same region. The complete tree is shown in Supplementary Figure
          <xref ref-type="media" rid="MOESM1">
           S2
          </xref>
          .
         </p>
        </caption>
        <graphic id="d29e759" xlink:href="41598_2018_24407_Fig2_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Phylogenetic analysis of deltacoronaviruses
      </title>
      <p id="Par16">
       Deltacoronavirus sequences from this study were spread across three lineages in the ML phylogenetic analysis (Fig.
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       , Supplementary Figure
       <xref ref-type="media" rid="MOESM1">
        S3
       </xref>
       ). Delta-CoV’s from ruddy turnstones, red-necked stints and curlew sandpipers (all from order Charadriiformes) formed a lineage with a delta-CoV sequence from a ruddy turnstone sampled in the United States. The single Australian duck delta-CoV belonged to a duck lineage with duck delta-CoV’s detected in Hong Kong but was 18.6% different to its nearest relative. The pied heron delta-CoV sequences were all identical, and belonged to a lineage which included delta-CoV’s from species from avian orders Pelecaniformes (Herons), Suliformes (Cormorants) and Anseriformes (Ducks) from Hong Kong and Cambodia. The pied heron delta-CoV was 17.7% different to the next most similar sequence. The genetic diversity in the Charadriiformes delta-CoV lineage was low (1.9–3.2% nucleotide differences) compared to the other lineages (duck lineage 18.6–30.9%; heron/cormorant lineage 17.7–22.8%). The inter-lineage genetic variation was high between wild bird delta-CoV’s. For example the Australian duck delta-CoV was 31.8–34.4% different to the delta-CoV’s within the Heron/Cormorant lineage and 29.6–31.8% different to sequences within the Chardriiforme lineage.
       <fig id="Fig3">
        <label>
         Figure 3
        </label>
        <caption>
         <p>
          Maximum likelihood phylogenetic tree of the 311 nt fragment of the polymerase gene of deltacoronaviruses from wild birds, including the sequences obtained in this study. Bootstrap confidence of each branch was calculated from 1000 replicates. The region where each sequence was obtained is indicated with colour. Australia (red), Madagascar (teal), China, Hong Kong and Korea (dark blue), Bering Strait region (green), United States of America (light blue) and Sweden (pink). The sampling location and state of each Australian sample is identified with a two letter code and the state: New South Wales (NSW): MM-Moulamein; Northern Territory (NT): HD-Humpty Doo; South Australia (SA): BP-Boatswain Point, NV-Nene Valley; Tasmania (TAS): BB-Borges Bay, King Island, CM-Central Manuka, King Island, DW-Dripping Wells, King Island, Tasmania; Victoria (VIC): BI-Barrallier Island, CR-Carlisle River, LC-Lake Connewarre, PV-Paynesville, WS-Werribee South. Some branches have been collapsed if all sequences came from the same region. The complete tree is shown in Supplementary Figure
          <xref ref-type="media" rid="MOESM1">
           S3
          </xref>
          .
         </p>
        </caption>
        <graphic id="d29e782" xlink:href="41598_2018_24407_Fig3_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec7" sec-type="discussion">
     <title>
      Discussion
     </title>
     <p id="Par17">
      This study is the first to demonstrate the presence of coronaviruses in wild birds in Australia. Coronaviruses were distributed across multiple species and geographical locations, with an average coronavirus positive prevalence of 15.3%. In bird orders with over 50 individuals sampled, coronaviruses were most frequently detected in Anseriformes (26.7%) followed by Charadriiformes (13.3%). Gammacoronaviruses were found in 100% of sequenced samples from ducks, while duck deltacoronaviruses were much less common (in only one sample). Shorebirds were positive for gamma-CoV’s most commonly (80% of sequenced samples), but delta-CoV’s were also present in these species (20% of sequenced samples). Herons were positive for delta-CoV’s exclusively; however, with the caveat that only 7 samples were included in this study. While the patterns of predominantly gammacoronaviruses in ducks and deltacoronaviruses in herons have been described in previous surveys
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ,
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      , the detection of both gamma- and delta-CoV’s in the same populations of Charadriiformes at the same time is unique to this study.
     </p>
     <p id="Par18">
      DNA sequencing of 67 of the 141 PCR positive samples confirmed that the PCRs were in fact amplifying coronavirus cDNA, although it was evident that no single PCR assay could detect all coronavirus positive samples. The use of multiple PCR assays to screen wild bird samples increased the overall sensitivity for detecting coronaviruses. Compared to the 5′ UTR PCR, nested and modified PCRs alone, the detection rate of coronaviruses increased 2.1, 1.4 and 1.3 fold respectively when all PCRs were used together. Had only one assay been used in this study, a number of coronaviruses in individual species would not have been detected. For example, only the modified PCR detected delta-CoV’s in the curlew sandpipers and the red-necked stints, while the nested PCR was able to detect more delta-CoV’s in ruddy turnstones and pied herons. None of the PCRs described in this study detected the deltacoronavirus in the pooled duck sample. Amplicon sequencing from this sample found that the PCRs were preferentially amplifying the gammacoronavirus present. However next generation sequencing data from this sample (Vibin
      <italic>
       et al
      </italic>
      ., 2018 (submitted)) found deltacoronavirus sequences were more abundant than those of the gammacoronavirus. Therefore the current pan-coronavirus PCRs may favour detection of gammacoronaviruses over deltacoronaviruses and this may explain why studies to date have found many more gammacoronaviruses in wild birds. It is possible that there are many more genetically diverse coronaviruses circulating in wild birds which are currently outside the detection abilities of the current published pancoronavirus PCRs, and it will be interesting to see how our understanding of coronavirus diversity improves as the use of non-targeted next generation sequencing techniques becomes more common.
     </p>
     <p id="Par19">
      The small fragment of the coronavirus genome sequenced in this study is one of the most conserved regions of the viral polymerase gene
      <sup>
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
      </sup>
      . It is the most sequenced genomic region of coronaviruses from wild bird hosts, with many studies using PCRs targeting this region to detect avian coronaviruses
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       ,
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
      </sup>
      . The fragment analysed in this study represents about 1% of the coronavirus genome, and therefore any interpretation of relationships in the phylogenetic tree should be made cautiously. With these caveats in mind, no temporal or spatial patterns in coronavirus sequences was observed in either the gamma- or deltacoronavirus phylogenetic analyses. However, some clustering by host species/order was observed, and this was strongest in the deltacoronaviruses, similar to the situation observed by Chu,
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      in Hong Kong and Cambodia who observed similar host species lineages. There was a Charadriiformes delta-CoV lineage observed which was strongly supported by the bootstrap analysis. All seven Australian shorebird delta-CoV’s from three different host species clustered with the single previously characterised shorebird delta-CoV from a ruddy turnstone sampled on the East Coast of the United States
      <sup>
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
      </sup>
      . The one Australian duck deltacoronavirus belonged to a duck lineage of deltacoronaviruses, but itself was 18.6% different to its closest relative sequence from a Eurasian teal in Hong Kong
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      . Similarly, the Australian heron deltacoronaviruses were within the lineage containing other herons but were genetically different to heron sequences seen elsewhere.
     </p>
     <p id="Par20">
      There were Charadriiformes lineages within the gammacoronavirus phylogenetic tree, and the majority of the Australian Charadriiform gamma-CoV’s grouped on branches with other gamma-CoV’s from host species within this order. However some Charadriiform gammacoronaviruses were highly similar in nucleotide sequence to gammacoronaviruses from ducks, e.g. the curlew sandpiper gammacoronaviruses contained a single nucleotide difference to mallard gammacoronavirus sequences identified in Sweden
      <sup>
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
      </sup>
      . Even within the Charadriiformes lineages, the degree of genetic difference to duck sequences was much less than that seen in the deltacoronavirus phylogeny. The phylogeny based on the amino acid sequence of the gammacoronaviruses separated the majority of the duck and Charadriiform gammacoronaviruses into separate branches, however both the curlew sandpiper gammacoronaviruses and a single ruddy turnstone gamma-CoV were identical in amino acid homology to duck Australian duck gamma-CoV’s as well as duck gamma-CoV’s identified in other investigations
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
       ,
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="CR27">
        27
       </xref>
      </sup>
      . These results again suggest that migratory Charadriiformes may share gammacoronaviruses with other avian species
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      and are therefore important vectors and reservoir of coronaviruses. Hughes,
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      and Chu,
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      identified similar gammacoronavirus sequences between Charadriiformes and Anseriformes, while Lima,
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      found similar gammacoronaviruses in Charadriiformes and Gruiformes in Madagascar. Interestingly, Hughes,
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
      </sup>
      identified their similar sequences by a PCR targeting the 3′ UTR, while Lima,
      <italic>
       et al
      </italic>
      .
      <sup>
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
      </sup>
      identified similar sequences with the same nested PCR used in this investigation
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
      </sup>
      .
     </p>
     <p id="Par21">
      Regular spill-over of coronaviruses from Charadriiformes to Anseriformes could explain why many Australian duck gammacoronaviruses were similar to the duck gammacoronaviruses from Asia and more distant regions. Australian duck species rarely come into direct contact with Palearctic waterfowl
      <sup>
       <xref ref-type="bibr" rid="CR28">
        28
       </xref>
      </sup>
      . Some degree of geographical gammacoronavirus lineage formation might therefore have been expected, if this was the only means of transmission of duck gamma-CoV’s, due to the high rate of mutation and recombination observed in other avian gamma-CoV’s
      <sup>
       <xref ref-type="bibr" rid="CR29">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="CR30">
        30
       </xref>
      </sup>
      . However, such isolation was not observed, which suggests that movement of coronaviruses between these populations of ducks occurs frequently. Given that millions of Charadriiformes migrate to Australia to spend their non-breeding season in Australia
      <sup>
       <xref ref-type="bibr" rid="CR31">
        31
       </xref>
      </sup>
      , Australian ducks would be much more likely to come into direct contact with Palearctic Charadriiformes than Anseriformes. It is also likely that there are many opportunities for individuals within the migrating shorebird populations to acquire and transmit coronaviruses to/from ducks as they move north-south, as coronaviruses are prevalent in both Charadriiformes and Anseriformes along the East Asian-Australasian Flyway
      <sup>
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ,
       <xref ref-type="bibr" rid="CR32">
        32
       </xref>
      </sup>
      and these species forage and breed in similar habitats
      <sup>
       <xref ref-type="bibr" rid="CR33">
        33
       </xref>
      </sup>
      .
     </p>
     <p id="Par22">
      This study further highlights the need for greater genetic characterisation of wild bird coronaviruses from all regions of the world to better understand the dispersal and host spill-over dynamics of these important pathogens. Further work to obtain more sequence data from the Australian wild bird coronaviruses is currently underway.
     </p>
    </sec>
    <sec id="Sec8" sec-type="materials|methods">
     <title>
      Materials and Methods
     </title>
     <sec id="Sec9">
      <title>
       Sample collection and storage
      </title>
      <p id="Par23">
       Samples tested in this investigation (918) originated from two sources, avian influenza A surveillance by Deakin University (912) and a few dead birds submitted through the Wildlife Health Surveillance Victoria program (6) at the University of Melbourne’s Faculty of Veterinary and Agricultural Science, Werribee, Victoria. Most samples were taken from birds within avian families Anatidae (Anatinae and Tadorninae; Order Anseriformes – 146 samples), Scolopacidae (Order Charadriiformes - 728 samples), Procellariidae (Order Procellariiformes – 30 samples) and Ardeidae (Order Pelecaniformes – 7 samples). Birds were sampled between April 2016 and January 2017 at multiple locations in south eastern Australia and the Northern Territory. Birds were caught either by hand, cannon netting or baited walk-in traps
       <sup>
        <xref ref-type="bibr" rid="CR34">
         34
        </xref>
       </sup>
       . Some duck samples were obtained from hunter-killed animals. All samples were taken from single individuals and consisted of a combined cloacal and oropharyngeal swab, except for one sample (Pacific Black Duck CoV-G0001–2016/12/21-LC/VIC), which was a pool of faeces collected from a group of 6 juvenile Pacific black ducks trapped together. No birds sampled as part of the influenza surveillance were showing any clinical signs of disease. Capture and sampling of birds were carried out in accordance with all relevant guidelines and regulations and under animal ethics permits B37-2013 and B43-2016 issued by Deakin University Animal Ethics Committee.
      </p>
      <p id="Par24">
       Oropharyngeal and cloacal swabs from birds belonging to other families (Accipitridae (Order Accipitriformes) Columbidae (Order Columbiformes), Corvidae (Order Passeriformes)) were collected from six dead birds. Post mortem revealed the cause of death in the four little ravens (
       <italic>
        Corvus mellori
       </italic>
       ) and one black kite (
       <italic>
        Milvus migrans
       </italic>
       ) as physical trauma. Only the spotted turtle dove (
       <italic>
        Streptopelia chinensis
       </italic>
       ) showed clinical signs of disease (diarrhoea and depression) and had been euthanised by a veterinarian (no post mortem was performed on this bird).
      </p>
      <p id="Par25">
       Oropharyngeal and cloacal swabs were pooled in viral transport media (brain heart infusion [BHI] broth based medium [Oxoid] with 0.3 mg/ml penicillin, 5 mg/ml streptomycin, 0.1 mg/ml gentamicin, and 2.5 g/ml amphotericin B). Swabs were placed in viral transport media at the collection sites, transported at 4 °C to the laboratory and stored at −80 °C until the nucleic acid extraction was performed.
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Extraction of RNA
      </title>
      <p id="Par26">
       Total viral nucleic acids from captured wild bird samples was extracted using the Nucleomag Vet Viral DNA/RNA isolation Kit (Scientifix, Australia) and a Kingfisher™ Flex extraction robot (Life Technologies) as per the manufacturer’s instructions, with an elution volume of 50 ul. RNA from the six samples collected from the dead birds was extracted using the Viral RNA mini-prep kit (Qiagen, Australia) as per the manufacturer’s instructions. Extracted RNA was stored at −80 °C. RNA from infectious bronchitis virus (IBV) N1/62 cultured in specified pathogen free chicken eggs (allantoic fluid, passage 7) was extracted using the Viral RNA mini-prep kit and used as a PCR positive control in this investigation. The RNA of each sample was then used in three separate PCR assays as described below.
      </p>
     </sec>
     <sec id="Sec11">
      <title>
       5′ Untranslated region (UTR) coronavirus real-time PCR
      </title>
      <p id="Par27">
       A real-time TaqMan PCR, originally developed to detect IBV in commercial poultry
       <sup>
        <xref ref-type="bibr" rid="CR35">
         35
        </xref>
       </sup>
       , and later used to screen wild birds for the presence of coronaviruses
       <sup>
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
       </sup>
       , was adapted into a real-time SYBR Green PCR assay using the Power SYBR Green RNA-to-C
       <sub>
        T
       </sub>
       1 step kit (Applied Biosystems, California, USA). The PCR amplified a 142 bp product from the 5′ UTR of gammacoronaviruses using primers IBV5′GU391 (5′-GCT TTT GAG CCT AGC GTT-3′) and IBV5′GL533 (5′-GCC ATG TTG TCA CTG TCT ATT G-3′). 2 µl of sample RNA was added to 1 × Power SYBR Green RT-PCR Mix, 1 uM of each primer, 1 × RT-Enzyme Mix and RNase free water to make a total reaction volume of 10 µl. The reaction was conducted in a QuantStudio™ Flex 6 real-time thermal cycler at 48 °C for 30 min, 95 °C for 10 min, 40 cycles of 95 °C for 15 sec, 60 °C for 10 sec, 72 °C for 20 sec and a final 72 °C step for 3 min. A melt curve analysis was performed immediately post PCR with the reaction conditions of 95 °C for 15 sec, then 60 °C for 1 min followed by a continuous temperature ramp between 60 °C and 95 °C increasing at 0.05 °C/sec. The IBV positive control produced a single peak melt curve with a peak melt temperature (T
       <sub>
        M
       </sub>
       ) of 80.25 ± 0.3 °C. If a sample produced a melt curve with a T
       <sub>
        M
       </sub>
       within 0.3 °C of the IBV positive control, 5 µl was then run on a 2% agarose gel. A sample was declared positive if it produced a single peak melt curve consistent with the IBV positive control and produced a 140 bp product on the agarose gel.
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Pancoronavirus polymerase nested PCR
      </title>
      <p id="Par28">
       A nested pancoronavirus PCR
       <sup>
        <xref ref-type="bibr" rid="CR36">
         36
        </xref>
       </sup>
       originally developed to detect coronaviruses in bats and later modified and used to detect gammacoronaviruses and deltacoronaviruses in wild birds
       <sup>
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
       </sup>
       was used to detect coronaviruses in this investigation. The primers used in the initial PCR were: Chu-RdRp-N1-F (5′-GGK TGG GAY TAY CCK AAR TG-3′) and Chu-RdRp-N1-R (5′-TGY TGT SWR CAR AAY TCR TG-3′) and amplified a 602 bp product from the polymerase gene of coronaviruses. cDNA synthesis was performed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Waltham, MA, USA) using 1 × random hexamers as per the manufacturer’s protocol. The initial PCR reaction was made with 2 µl of cDNA, 1 × AmpliTaq Gold 360 PCR Mix (Applied Biosystems, California USA), 0.5 µM of each primer, 3 mM MgCl
       <sub>
        2
       </sub>
       and nuclease free water in a total volume of 10 µl. The nested PCR used primers Chu-RdRp-N2-F (5′-GGT TGG GAC TAT CCT AAG TGT GA-3′) and Chu-RdRp-N2-R (5′-CCA TCA TCA GAT AGA ATC ATC AT-3′) and amplified a 440 bp product within the first PCR. The PCR reaction mixture was made with 1 µl of the first PCR reaction, 1 × AmpliTaq Gold 360 PCR Mix, 0.5 µM of each primer, 3 mM MgCl
       <sub>
        2
       </sub>
       and RNase free water in a total volume of 10 µl. PCR reactions were conducted in a thermal cycler at 95 °C for 10 min, then 40 cycles of 95 °C for 30 sec, 48 °C for 30 sec, 72 °C for 50 sec followed by a final step of 72 °C for 3 min. 5 µl of each PCR was then run on a 1.6% agarose gel. A sample was declared positive if a band of the expected size was seen on the gel from either PCR.
      </p>
     </sec>
     <sec id="Sec13">
      <title>
       Modified pancoronavirus polymerase real-time PCR
      </title>
      <p id="Par29">
       A non-nested touchdown real-time PCR was developed and evaluated against the nested pancoronavirus PCR to see if it could be used as a replacement for the nested assay in future studies. Primers were designed incorporating all current coronavirus polymerase gene sequences and looking for the most conserved regions. Primer candidates were then evaluated in PerlPrimer
       <sup>
        <xref ref-type="bibr" rid="CR37">
         37
        </xref>
       </sup>
       . The selected primers, AC-CoV-F (5′-GGT TGG GAT TAT CCW AAR TGT G-3′) and AC-CoV-R (5′-TGY TGT GAR CAA AAY TCR TG-3′), were less degenerate than Chu-RdRp-N1-F and Chu-RdRp-N1-R described above and targeted the same conserved sites in the polymerase gene of coronaviruses producing a PCR product of 602 bp. cDNA synthesis was performed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Waltham, MA, USA) as per the manufacturer’s instructions but using 100 pM of the reverse primer AC-CoV-R in place of the 1 × random hexamers. The PCR reaction was performed using 2 µl of cDNA, 1 × AmpliTaq Gold 360 PCR Mix, 1 µM of each primer, 3 mM MgCl
       <sub>
        2
       </sub>
       , 2 µM Syto 9 (Thermo Fisher, Waltham, MA, USA) and molecular grade water to a final volume of 10 µl. The reaction was conducted in a QuantStudio™ Flex 6 real-time thermal cycler at 95 °C for 10 min, 45 cycles of 95 °C for 30 sec, annealing temperature for 30 sec, 72 °C for 45 sec and a final 72 °C step for 3 min. The touchdown annealing temperature started at 60 °C for 3 cycles, then decreased by 2 °C every 3 cycles until 48 °C which was used for the final 30 reaction cycles.
      </p>
      <p id="Par30">
       A melt curve analysis was performed immediately post PCR with reactions subjected to 95 °C for 15 sec, then 60 °C for 1 min followed by a continuous temperature ramp between 60 °C and 95 °C increasing at 0.05 °C/sec. 5 µl of the PCR product was then run on a 1.6% agarose gel and a sample was declared positive if a band of the expected size was seen.
      </p>
     </sec>
     <sec id="Sec14">
      <title>
       PCR product sequencing and phylogenetic analysis
      </title>
      <p id="Par31">
       A selection of 67 PCR products from coronavirus Orf1/polymerase PCR positive samples were gel purified using the 2% Size Select E-Gel System (Thermo Fisher, Waltham, MA, USA) and sequenced using the Big Dye Terminator Cycle v3.1 on a Hitachi 3500xl genetic analyser (Applied Biosystems, Foster City, California, USA). As a result of PCR product sequencing conducted during the preliminary PCR testing and optimisation, the pooled duck sample (Pacific Black Duck CoV-G0001-2016/12/21-LC/VIC) was found to contain both a gamma-CoV and a delta-CoV. The gamma-CoV sequence used in this analysis was obtained as described above, however the delta-CoV sequence was obtained from the analysis performed by Vibin,
       <italic>
        et al
       </italic>
       .
       <sup>
        <xref ref-type="bibr" rid="CR38">
         38
        </xref>
       </sup>
       (submitted). All sequences generated in this study have been deposited in Genbank under accession numbers MG764091 to MG764157 and MH090080 and MH090081.
      </p>
      <p id="Par32">
       DNA sequences were aligned in MEGA 7
       <sup>
        <xref ref-type="bibr" rid="CR39">
         39
        </xref>
       </sup>
       . Each sequence was then trimmed to where both forward and reverse reads 100% agreed on the consensus sequence. Consensus sequences between 315 and 515 nt were generated and queried against the Genbank database using a BLASTn query to identify the genus of coronavirus. Ten amplicons which were too short or did not have 100% agreement between the forward and reverse strands were excluded from subsequent multiple sequence alignments and phylogenetic analysis.
      </p>
      <p id="Par33">
       A final dataset (57) of 44 gamma-CoV and 13 delta-CoV sequences were aligned with gamma- and delta-CoV sequences available on Genbank using the ClustalW algorithm in MEGA 7. The aligned region belonged to the Orf1/Polymerase gene between nucleotides 14203 to 14761 of the reference avian infectious bronchitis virus sequence (Genbank accession: NC_001451.1). Absence of evidence of recombination was confirmed using the Genetic Algorithm Recombination Detection (GARD) method
       <sup>
        <xref ref-type="bibr" rid="CR40">
         40
        </xref>
       </sup>
       of the HyPhy package hosted on the DataMonkey webserver
       <sup>
        <xref ref-type="bibr" rid="CR41">
         41
        </xref>
       </sup>
       . Codon specific selection pressure was analysed using the single likelihood ancestor counting (SLAC), fixed effects likelihood (FEL), internal fixed effects likelihood (IFEL) and random effects likelihood (REL) methods available on the DataMonkey server as previously described
       <sup>
        <xref ref-type="bibr" rid="CR42">
         42
        </xref>
       </sup>
       . All analyses were performed on the optimum model as determined by the model selection algorithm of the server, and using Neighbour-Joining phylogenetic trees. A p-value of 0.05 or Bayes factor of 100 were selected for the selection pressure analyses, which indicated evidence for negative selection and no evidence of positive selection (data not shown).
      </p>
      <p id="Par34">
       To understand the relationship between the coronavirus sequences identified in this study and those of other studies, a maximum likelihood (ML) phylogenetic analysis of the nucleotide sequences with 1000 bootstrap replicates was performed in MEGA 7. The gammacoronavirus phylogenetic tree was created from 277 nt of sequence using the Tamura-Nei model with 5 discrete gamma distribution categories
       <sup>
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
       </sup>
       . The deltacoronavirus phylogenetic tree was created from 311 nt of sequence using the Tamura 3 parameter model
       <sup>
        <xref ref-type="bibr" rid="CR44">
         44
        </xref>
       </sup>
       with 5 discrete gamma distribution categories with invariant sites. An amino acid maximum likelihood phylogenetic analysis was performed on the gammacoronavirus sequence (92 amino acids) using the Jones-Taylor-Thornton model with 5 discrete gamma distribution categories and 500 bootstrap replicates. All models were determined to be the best fitting models to the sequence data by MEGA 7.
      </p>
     </sec>
     <sec id="Sec15">
      <title>
       Statistical and data analysis
      </title>
      <p id="Par35">
       A sample was considered positive for coronavirus if it was positive in at least one of the PCR assays. The agreement between the pancoronavirus PCRs was evaluated using the McNemar’s test with Bonferroni’s correction and a significance value (α) of 0.05
       <sup>
        <xref ref-type="bibr" rid="CR45">
         45
        </xref>
       </sup>
       .
      </p>
     </sec>
     <sec id="Sec16" sec-type="data-availability">
      <title>
       Data availability
      </title>
      <p id="Par36">
       All sequences generated have been deposited in GenBank under accession numbers MG764091 - MG764157 and MH090080 and MH090081. Other datasets generated or analysed during the current study are available from the corresponding author on reasonable request.
      </p>
     </sec>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Electronic supplementary material
     </title>
     <sec id="Sec17">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="41598_2018_24407_MOESM1_ESM.pdf">
         <caption>
          <p>
           Supplementary Information
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher's note:
        </bold>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
     </fn-group>
     <sec>
      <title>
       Electronic supplementary material
      </title>
      <p>
       <bold>
        Supplementary information
       </bold>
       accompanies this paper at 10.1038/s41598-018-24407-x.
      </p>
     </sec>
     <ack>
      <title>
       Acknowledgements
      </title>
      <p>
       The work was supported by funding from Deakin University, Barwon Health and CSIRO and from NHMRC Equipment Grant GNT9000413 to S.A. The Melbourne WHO Collaborating Centre for Reference and Research on Influenza is funded by the Australian Department of Health. The sampling by Deakin University importantly relied on the assistance of a large number of volunteers within the Victorian Wader Study Group (sampling shorebirds) and Field &amp; Game Australia (ducks). Humpty Doo Barramundi (NT), Phillip Island Nature Parks (VIC) and Trent Leen (VIC) are thanked for providing access to their land and facilities and providing logistic support during field sampling. The sampling was financially supported by ARC discovery grants DP 130101935 and DP160102146 to M.K. Samples from dead birds were kindly provided by W. Steele from Ecology Balance, Victoria, Australia  and P. Whiteley from the Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Victoria, Australia. Infectious Bronchitis Virus (IBV) N1/62 for the PCR positive control was kindly provided by D. Williams, S. Sapats and B. Vanderheide at the Australian Animal Health Laboratory, CSIRO, Geelong, Victoria, Australia.
      </p>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Author Contributions
      </title>
      <p>
       A.C. designed the modified PCR and performed the PCRs and DNA sequencing. M.W. collected samples and extracted viral RNA. J.V. performed next generation sequencing on the pooled sample and provided the duck deltacoronavirus sequence. T.N. performed initial testing of pancoronavirus PCRs. M.K. collected samples and coordinated the bird sampling. S.A. coordinated all work done at GCEID. A.C. wrote initial manuscript with input from S.A. and later versions were based on input and suggestions from all.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing Interests
      </title>
      <p id="Par37">
       The authors declare no competing interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="other">
        World Bank
        <italic>
         . People, pathogens and our planet: the economics of one health
        </italic>
        . (
        <italic>
         World Bank
        </italic>
        ., Washington, DC
        <italic>
         2012
        </italic>
        ).
       </mixed-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Costly Lessons From the Middle East Respiratory Syndrome Coronavirus Outbreak in Korea
        </article-title>
        <source>
         Journal of Preventive Medicine and Public Health
        </source>
        <year>
         2015
        </year>
        <volume>
         48
        </volume>
        <fpage>
         274
        </fpage>
        <lpage>
         276
        </lpage>
        <pub-id pub-id-type="doi">
         10.3961/jpmph.15.064
        </pub-id>
        <pub-id pub-id-type="pmid">
         26639740
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="other">
        Lee, J.-W. &amp; McKibbin, W. J. In L
        <italic>
         ear
        </italic>
        ning fro
        <italic>
         m
        </italic>
        SARS:
        <italic>
         Preparing for the Next Disease Outbreak: Workshop Summary The National Academies Collection: Reports funded by National Institutes of Health
        </italic>
        (eds Knobler, S.
        <italic>
         et al
        </italic>
        .) (2004).
       </mixed-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cavanagh
          </surname>
          <given-names>
           D
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses in poultry and other birds
        </article-title>
        <source>
         Avian Pathol.
        </source>
        <year>
         2005
        </year>
        <volume>
         34
        </volume>
        <fpage>
         439
        </fpage>
        <lpage>
         448
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/03079450500367682
        </pub-id>
        <pub-id pub-id-type="pmid">
         16537157
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ignjatovic
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Ashton
          </surname>
          <given-names>
           DF
          </given-names>
         </name>
         <name>
          <surname>
           Reece
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity of Australian Strains of Avian Infectious Bronchitis Virus
        </article-title>
        <source>
         J. Comp. Pathol.
        </source>
        <year>
         2002
        </year>
        <volume>
         126
        </volume>
        <fpage>
         115
        </fpage>
        <lpage>
         123
        </lpage>
        <pub-id pub-id-type="doi">
         10.1053/jcpa.2001.0528
        </pub-id>
        <pub-id pub-id-type="pmid">
         11945000
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Origin, evolution, and virulence of porcine deltacoronaviruses in the United States
        </article-title>
        <source>
         American Society for Microbiology
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         e00064
        </fpage>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine epidemic diarrhea virus: An emerging and re-emerging epizootic swine virus
        </article-title>
        <source>
         Virol J.
        </source>
        <year>
         2015
        </year>
        <volume>
         12
        </volume>
        <fpage>
         193
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s12985-015-0421-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         26689811
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China
        </article-title>
        <source>
         Science
        </source>
        <year>
         2003
        </year>
        <volume>
         302
        </volume>
        <fpage>
         276
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1087139
        </pub-id>
        <pub-id pub-id-type="pmid">
         12958366
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats
        </article-title>
        <source>
         Proceedings of the National Academy of Science
        </source>
        <year>
         2005
        </year>
        <volume>
         102
        </volume>
        <fpage>
         14040
        </fpage>
        <lpage>
         14045
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0506735102
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ferguson
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Van Kerkhove
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Identification of MERS-CoV in dromedary camels
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         14
        </volume>
        <fpage>
         93
        </fpage>
        <lpage>
         94
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70691-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355867
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kin
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative molecular epidemiology of two closely related coronaviruses, bovine coronavirus (BCoV) and human coronavirus OC43 (HCoV-OC43), reveals a different evolutionary pattern
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <year>
         2016
        </year>
        <volume>
         40
        </volume>
        <fpage>
         186
        </fpage>
        <lpage>
         191
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.meegid.2016.03.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         26969241
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vijgen
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Complete Genomic Sequence of Human Coronavirus OC43: Molecular Clock Analysis Suggests a Relatively Recent Zoonotic Coronavirus Transmission Event
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         1595
        </fpage>
        <lpage>
         1604
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.3.1595-1604.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15650185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Discovery of a novel canine respiratory coronavirus support genetic recombination among betacoronavirus1
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2017
        </year>
        <volume>
         237
        </volume>
        <fpage>
         7
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2017.05.006
        </pub-id>
        <pub-id pub-id-type="pmid">
         28506792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Verhagen
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Herfst
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious disease. How a virus travels the world
        </article-title>
        <source>
         Science
        </source>
        <year>
         2015
        </year>
        <volume>
         347
        </volume>
        <fpage>
         616
        </fpage>
        <lpage>
         617
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.aaa6724
        </pub-id>
        <pub-id pub-id-type="pmid">
         25657235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Olsen
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Global patterns of influenza a virus in wild birds
        </article-title>
        <source>
         Science
        </source>
        <year>
         2006
        </year>
        <volume>
         312
        </volume>
        <fpage>
         384
        </fpage>
        <lpage>
         388
        </lpage>
        <pub-id pub-id-type="doi">
         10.1126/science.1122438
        </pub-id>
        <pub-id pub-id-type="pmid">
         16627734
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           DK
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Avian coronavirus in wild aquatic birds
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2011
        </year>
        <volume>
         85
        </volume>
        <fpage>
         12815
        </fpage>
        <lpage>
         12820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.05838-11
        </pub-id>
        <pub-id pub-id-type="pmid">
         21957308
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Duraes Carvalho
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Phylogenetic and phylogeographic mapping of the avian coronavirus spike protein-encoding gene in wild and synanthropic birds
        </article-title>
        <source>
         Virus Res.
        </source>
        <year>
         2015
        </year>
        <volume>
         201
        </volume>
        <fpage>
         101
        </fpage>
        <lpage>
         112
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virusres.2015.03.002
        </pub-id>
        <pub-id pub-id-type="pmid">
         25771408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lima
          </surname>
          <given-names>
           FED
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Diverse gammacoronaviruses detected in wild birds from Madagascar
        </article-title>
        <source>
         European Journal of Wildlife Research
        </source>
        <year>
         2015
        </year>
        <volume>
         61
        </volume>
        <fpage>
         635
        </fpage>
        <lpage>
         639
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s10344-015-0931-7
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wille
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Muradrasoli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nilsson
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Jarhult
          </surname>
          <given-names>
           JD
          </given-names>
         </name>
        </person-group>
        <article-title>
         High Prevalence and Putative Lineage Maintenance of Avian Coronaviruses in Scandinavian Waterfowl
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2016
        </year>
        <volume>
         11
        </volume>
        <fpage>
         e0150198
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0150198
        </pub-id>
        <pub-id pub-id-type="pmid">
         26938459
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muradrasoli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Prevalence and Phylogeny of Coronaviruses in Wild Birds from the Bering Strait Area (Beringia)
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2010
        </year>
        <volume>
         5
        </volume>
        <fpage>
         e13640
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0013640
        </pub-id>
        <pub-id pub-id-type="pmid">
         21060827
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Honkavuori
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Novel Coronavirus and Astrovirus in Delaware Bay Shorebirds
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2014
        </year>
        <volume>
         9
        </volume>
        <fpage>
         e93395
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0093395
        </pub-id>
        <pub-id pub-id-type="pmid">
         24699424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="other">
        Amery-Gale, J.
        <italic>
         Investigations into pathogens of potential public health and biosecurity significance in Australian native birds
        </italic>
        Masters of Veterinary Science thesis, The Univeristy of Melbourne, (2016).
       </mixed-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hughes
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genetically Diverse Coronaviruses in Wild Bird Populations of Northern England
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <year>
         2009
        </year>
        <volume>
         15
        </volume>
        <fpage>
         1091
        </fpage>
        <lpage>
         1094
        </lpage>
        <pub-id pub-id-type="doi">
         10.3201/eid1507.090067
        </pub-id>
        <pub-id pub-id-type="pmid">
         19624927
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Muradrasoli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Broadly targeted multiprobe QPCR for detection of coronaviruses: Coronavirus is common among mallard ducks (Anas platyrhynchos)
        </article-title>
        <source>
         J. Virol. Methods
        </source>
        <year>
         2009
        </year>
        <volume>
         159
        </volume>
        <fpage>
         277
        </fpage>
        <lpage>
         287
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jviromet.2009.04.022
        </pub-id>
        <pub-id pub-id-type="pmid">
         19406168
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wille
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Temporal dynamics, diversity, and interplay in three components of the virodiversity of a Mallard population: Influenza A virus, avian paramyxovirus and avian coronavirus
        </article-title>
        <source>
         Infect. Genet. Evol.
        </source>
        <year>
         2015
        </year>
        <volume>
         29
        </volume>
        <fpage>
         129
        </fpage>
        <lpage>
         137
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.meegid.2014.11.014
        </pub-id>
        <pub-id pub-id-type="pmid">
         25461850
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="other">
        Duraes-Carvalho, R.
        <italic>
         et al
        </italic>
        . Coronaviruses Detected in Brazilian Wild Birds Reveal Close Evolutionary Relationships with Beta- and Deltacoronaviruses Isolated From Mammals.
        <italic>
         J. Mol. Evol
        </italic>
        ., 21, 10.1007/s00239-015-9693-9 (2015).
       </mixed-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhuang
          </surname>
          <given-names>
           QY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Genomic Analysis and Surveillance of the Coronavirus Dominant in Ducks in China
        </article-title>
        <source>
         PLoS One
        </source>
        <year>
         2015
        </year>
        <volume>
         10
        </volume>
        <fpage>
         e0129256
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0129256
        </pub-id>
        <pub-id pub-id-type="pmid">
         26053682
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roshier
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Heinsohn
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Adcock
          </surname>
          <given-names>
           GJ
          </given-names>
         </name>
         <name>
          <surname>
           Beerli
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Joseph
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biogeographic models of gene flow in two waterfowl of the Australo-Papuan tropics
        </article-title>
        <source>
         Ecol. Evol.
        </source>
        <year>
         2012
        </year>
        <volume>
         2
        </volume>
        <fpage>
         2803
        </fpage>
        <lpage>
         2814
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/ece3.393
        </pub-id>
        <pub-id pub-id-type="pmid">
         23170215
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ignjatovic
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gould
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Sapats
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a variant infectious bronchitis virus in Australia that further illustrates diversity among emerging strains
        </article-title>
        <source>
         Arch. Virol.
        </source>
        <year>
         2006
        </year>
        <volume>
         151
        </volume>
        <fpage>
         1567
        </fpage>
        <lpage>
         1585
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-006-0726-y
        </pub-id>
        <pub-id pub-id-type="pmid">
         16501892
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Quinteros
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Full genome analysis of Australian infectious bronchitis viruses suggests frequent recombination events between vaccine strains and multiple phylogenetically distant avian coronaviruses of unknown origin
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <year>
         2016
        </year>
        <volume>
         197
        </volume>
        <fpage>
         27
        </fpage>
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.vetmic.2016.11.003
        </pub-id>
        <pub-id pub-id-type="pmid">
         27938680
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="other">
        Bamford, M., Watkins, D., Bancroft, W., Tischler, G. &amp; Wahl, J. Migratory shorebirds of the East Asian-Australasian Flyway; Population estimates and important sites. (Camberra, Australia, 2008).
       </mixed-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           HR
          </given-names>
         </name>
         <name>
          <surname>
           Oem
          </surname>
          <given-names>
           JK
          </given-names>
         </name>
        </person-group>
        <article-title>
         Surveillance of avian coronaviruses in wild bird populations of Korea
        </article-title>
        <source>
         J. Wildl. Dis.
        </source>
        <year>
         2014
        </year>
        <volume>
         50
        </volume>
        <fpage>
         964
        </fpage>
        <lpage>
         968
        </lpage>
        <pub-id pub-id-type="doi">
         10.7589/2013-11-298
        </pub-id>
        <pub-id pub-id-type="pmid">
         24949927
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="other">
        Pizzey, G. &amp; Knight, F.
        <italic>
         A Field guid to the Birds of Australia
        </italic>
        . 8th Edition edn, (Harper Collins Publishers, 2007).
       </mixed-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haynes
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Australian surveillance for avian influenza viruses in wild birds between July 2005 and June 2007
        </article-title>
        <source>
         Aust. Vet. J.
        </source>
        <year>
         2009
        </year>
        <volume>
         87
        </volume>
        <fpage>
         266
        </fpage>
        <lpage>
         272
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1751-0813.2009.00446.x
        </pub-id>
        <pub-id pub-id-type="pmid">
         19573149
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Callison
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Development and evaluation of a real-time Taqman RT-PCR assay for the detection of infectious bronchitis virus from infected chickens
        </article-title>
        <source>
         J. Virol. Methods
        </source>
        <year>
         2006
        </year>
        <volume>
         138
        </volume>
        <fpage>
         60
        </fpage>
        <lpage>
         65
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jviromet.2006.07.018
        </pub-id>
        <pub-id pub-id-type="pmid">
         16934878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           LLM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a Novel Coronavirus in Bats
        </article-title>
        <source>
         J. Virol.
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         2001
        </fpage>
        <lpage>
         2009
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.4.2001-2009.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15681402
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marshall
          </surname>
          <given-names>
           OJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2004
        </year>
        <volume>
         20
        </volume>
        <fpage>
         2471
        </fpage>
        <lpage>
         2472
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/bth254
        </pub-id>
        <pub-id pub-id-type="pmid">
         15073005
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="other">
        Vibin, J.
        <italic>
         et al
        </italic>
        . Detection and characterisation of viruses in Australian wild bird’s faeces: Metagenomics method optimisation and initial results.
        <italic>
         (Submitted)
        </italic>
        (2018).
       </mixed-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Stecher
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets
        </article-title>
        <source>
         Mol. Biol. Evol.
        </source>
        <year>
         2016
        </year>
        <volume>
         33
        </volume>
        <fpage>
         1870
        </fpage>
        <lpage>
         1874
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/molbev/msw054
        </pub-id>
        <pub-id pub-id-type="pmid">
         27004904
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kosakovsky Pond
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
         <name>
          <surname>
           Posada
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gravenor
          </surname>
          <given-names>
           MB
          </given-names>
         </name>
         <name>
          <surname>
           Woelk
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Frost
          </surname>
          <given-names>
           SDW
          </given-names>
         </name>
        </person-group>
        <article-title>
         GARD: a genetic algorithm for recombination detection
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2006
        </year>
        <volume>
         22
        </volume>
        <fpage>
         3096
        </fpage>
        <lpage>
         3098
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/btl474
        </pub-id>
        <pub-id pub-id-type="pmid">
         17110367
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delport
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           AF
          </given-names>
         </name>
         <name>
          <surname>
           Frost
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name>
          <surname>
           Kosakovsky Pond
          </surname>
          <given-names>
           SL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology
        </article-title>
        <source>
         Bioinformatics
        </source>
        <year>
         2010
        </year>
        <volume>
         26
        </volume>
        <fpage>
         2455
        </fpage>
        <lpage>
         2457
        </lpage>
        <pub-id pub-id-type="doi">
         10.1093/bioinformatics/btq429
        </pub-id>
        <pub-id pub-id-type="pmid">
         20671151
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alexandersen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Hodge
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Druce
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolutionary and network analysis of virus sequences from infants infected with an Australian recombinant strain of human parechovirus type 3
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <year>
         2017
        </year>
        <volume>
         7
        </volume>
        <fpage>
         3861
        </fpage>
        <pub-id pub-id-type="doi">
         10.1038/s41598-017-04145-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         28634337
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Nei
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees
        </article-title>
        <source>
         Mol. Biol. Evol.
        </source>
        <year>
         1993
        </year>
        <volume>
         10
        </volume>
        <fpage>
         512
        </fpage>
        <lpage>
         526
        </lpage>
        <pub-id pub-id-type="pmid">
         8336541
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tamura
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of the Number of Nucleotide Substitutions When There Are Strong Transition-Transversion and G + C-Content Biases
        </article-title>
        <source>
         Mol. Biol. Evol.
        </source>
        <year>
         1992
        </year>
        <volume>
         9
        </volume>
        <fpage>
         678
        </fpage>
        <lpage>
         687
        </lpage>
        <pub-id pub-id-type="pmid">
         1630306
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="other">
        Petrie, A. &amp; Watson, P.
        <italic>
         Statistics for Veterinary and Animal Science
        </italic>
        . 3rd Edition edn, (John Wiley &amp; Sons, 2013).
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Gen Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Gen. Virol
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JGV
      </journal-id>
      <journal-id journal-id-type="hwp">
       vir
      </journal-id>
      <journal-title-group>
       <journal-title>
        The Journal of General Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-1317
      </issn>
      <issn pub-type="epub">
       1465-2099
      </issn>
      <publisher>
       <publisher-name>
        Society for General Microbiology
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       25252685
      </article-id>
      <article-id pub-id-type="pmc">
       4811657
      </article-id>
      <article-id pub-id-type="publisher-id">
       069732
      </article-id>
      <article-id pub-id-type="doi">
       10.1099/vir.0.069732-0
      </article-id>
      <article-categories>
       <subj-group subj-group-type="article-type">
        <subject>
         Review
        </subject>
       </subj-group>
       <subj-group subj-group-type="heading">
        <subject>
         Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A review of genetic methods and models for analysis of coronavirus-induced severe pneumonitis
       </article-title>
       <alt-title alt-title-type="recto-page-foot">
        <ext-link ext-link-type="uri" xlink:href="http://vir.sgmjournals.org">
         http://vir.sgmjournals.org
        </ext-link>
       </alt-title>
       <alt-title alt-title-type="verso-running-head">
        B. McGruder and J. L. Leibowitz
       </alt-title>
       <alt-title alt-title-type="recto-running-head">
        Analysis of CoV-induced severe pneumonitis
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          McGruder
         </surname>
         <given-names>
          Brenna
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Leibowitz
         </surname>
         <given-names>
          Julian L.
         </given-names>
        </name>
       </contrib>
       <aff id="aff1">
        Department of Microbial Pathogenesis and Immunology, Texas A &amp; M University Health Science Center, Bryan, TX 77807, USA
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <bold>
         Correspondence
        </bold>
        Julian Leibowitz
        <email xlink:href="jleibowitz@tamu.edu">
         jleibowitz@tamu.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <day>
        1
       </day>
       <month>
        3
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       96
      </volume>
      <issue>
       Pt 3
      </issue>
      <fpage>
       494
      </fpage>
      <lpage>
       506
      </lpage>
      <history>
       <date date-type="received">
        <day>
         03
        </day>
        <month>
         7
        </month>
        <year>
         2014
        </year>
       </date>
       <date date-type="accepted">
        <day>
         23
        </day>
        <month>
         9
        </month>
        <year>
         2014
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2015 The Authors
       </copyright-statement>
      </permissions>
      <self-uri xlink:href="494_vir069732.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        Coronaviruses (CoVs) have been studied for over 60 years, but have only recently gained notoriety as deadly human pathogens with the emergence of severe respiratory syndrome CoV and Middle East respiratory syndrome virus. The rapid emergence of these viruses has demonstrated the need for good models to study severe CoV respiratory infection and pathogenesis. There are, currently, different methods and models for the study of CoV disease. The available genetic methods for the study and evaluation of CoV genetics are reviewed here. There are several animal models, both mouse and alternative animals, for the study of severe CoV respiratory disease that have been examined, each with different pros and cons relative to the actual pathogenesis of the disease in humans. A current limitation of these models is that no animal model perfectly recapitulates the disease seen in humans. Through the review and analysis of the available disease models, investigators can employ the most appropriate available model to study various aspects of CoV pathogenesis and evaluate possible antiviral treatments that may potentially be successful in future treatment and prevention of severe CoV respiratory infections.
       </p>
      </abstract>
      <funding-group>
       <award-group>
        <funding-source id="sp1">
         US National Institutes of Health
        </funding-source>
        <award-id rid="sp1">
         AI078148
        </award-id>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         access-type
        </meta-name>
        <meta-value>
         free
        </meta-value>
       </custom-meta>
       <custom-meta>
        <meta-name>
         OpenAccessEmbargo
        </meta-name>
        <meta-value>
         11
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Int J Antimicrob Agents
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Int. J. Antimicrob. Agents
      </journal-id>
      <journal-title-group>
       <journal-title>
        International Journal of Antimicrobial Agents
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0924-8579
      </issn>
      <issn pub-type="epub">
       1872-7913
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V. and International Society of Chemotherapy.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32201353
      </article-id>
      <article-id pub-id-type="pmc">
       7156162
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0924-8579(20)30098-4
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.ijantimicag.2020.105948
      </article-id>
      <article-id pub-id-type="publisher-id">
       105948
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0001">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Li-sheng
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0002">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Yi-ru
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="fn" rid="fn1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0003">
        <name>
         <surname>
          Ye
         </surname>
         <given-names>
          Da-wei
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0003">
         c
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0004">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Qing-quan
         </given-names>
        </name>
        <email>
         qqliutj@163.com
        </email>
        <xref ref-type="aff" rid="aff0001">
         a
        </xref>
        <xref ref-type="aff" rid="aff0002">
         b
        </xref>
        <xref ref-type="corresp" rid="cor0001">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0001">
       <label>
        a
       </label>
       Department of Nephrology, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China
      </aff>
      <aff id="aff0002">
       <label>
        b
       </label>
       Center of Blood Purification, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China
      </aff>
      <aff id="aff0003">
       <label>
        c
       </label>
       Cancer Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
      </aff>
      <author-notes>
       <corresp id="cor0001">
        <label>
         ⁎
        </label>
        Corresponding author.
        <email>
         qqliutj@163.com
        </email>
       </corresp>
       <fn id="fn1">
        <label>
         1
        </label>
        <p id="notep0001">
         These authors have contributed equally to this work and should be considered co-first authors
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        19
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="epub">
       <day>
        19
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <elocation-id>
       105948
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         7
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         14
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0001">
       <title>
        Highlights
       </title>
       <p>
        <list id="celist0001" list-type="simple">
         <list-item id="celistitem0001">
          <label>
           •
          </label>
          <p id="para0002">
           The SARS-CoV-2 infection is spreading fast with an increasing number of infected patients nationwide.
          </p>
         </list-item>
         <list-item id="celistitem0002">
          <label>
           •
          </label>
          <p id="para0003">
           Systematically summarizes the epidemiology, clinical characteristics, diagnosis, treatment and prevention of knowledge surrounding COVID-19.
          </p>
         </list-item>
         <list-item id="celistitem0003">
          <label>
           •
          </label>
          <p id="para0004">
           The specific mechanism of the virus remains unknown, and specific drugs for the virus have not been developed.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0002">
       <p>
        The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared the ongoing outbreak as a global public health emergency. Currently, the research on novel coronavirus is still in the primary stage. Based on the current published evidence, we systematically summarizes the epidemiology, clinical characteristics, diagnosis, treatment and prevention of knowledge surrounding COVID-19. This review in the hope of helping the public effectively recognize and deal with the 2019 novel coronavirus (SARS-CoV-2), and providing a reference for future studies.
       </p>
      </abstract>
      <kwd-group id="keys0001">
       <title>
        Keywords
       </title>
       <kwd>
        SARS-CoV-2
       </kwd>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        pneumonia
       </kwd>
       <kwd>
        Respiratory infection
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0001">
     <label>
      1
     </label>
     <title>
      Background
     </title>
     <p id="para0005">
      In late December 2019, a case of unidentified pneumonia was reported in Wuhan, Hubei Province, People's Republic of China (PRC). Its clinical characteristics are very similar to those of viral pneumonia. After analysis on respiratory samples, PRC Centers for Disease Control (CDC) experts declared that the pneumonia, later known as novel coronavirus pneumonia (NCP), was caused by novel coronavirus
      <xref ref-type="bibr" rid="bib0001">
       [1]
      </xref>
      . WHO officially named the disease COVID-19. International Committee on Taxonomy of Viruses (ICTV) named the virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Designation of a formal name for the novel coronavirus and the disease it caused is conducive to communications in clinical and scientific research. This virus belongs to β – coronavirus, a large class of viruses prevalent in nature. Similar to other viruses, SARS-CoV-2 has many potential natural hosts, intermediate hosts and final hosts. This poses great challenges to prevention and treatment of virus infection. Compared with SARS and MERS, this virus has high transmissibility and infectivity, despite of low mortality rate
      <xref ref-type="bibr" rid="bib0002">
       [2]
      </xref>
      . Genome analysis of novel coronavirus sequences revealed that the complete genome sequence recognition rates of SARS-CoV and bat SARS coronavirus (SARSr-CoV-RaTG13) were 79.5% and 96% respectively
      <xref ref-type="bibr" rid="bib0003">
       [3]
      </xref>
      . It implies that the coronavirus might originate from bat. On 29 February 2020, data published by World Health Organization showed that, since 12 December 2019 when the first case was reported, 79,394 cases were confirmed to be infected by novel coronavirus and 2,838 individuals were died in total
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      . In the meantime, 6009 cases were confirmed and 86 were died in 53 countries and regions outside of China (
      <xref ref-type="fig" rid="fig0001">
       Figure 1
      </xref>
      )
      <xref ref-type="bibr" rid="bib0004">
       [4]
      </xref>
      . It posed a great threat to global public health. This report reviews the genetic structure, infection source, transmission route, pathogenesis, clinical characteristics, and treatment and prevention of the SARS-CoV-2, so that it can provide references for follow-up research, prevention and treatment, and may help readers to have the latest understanding of this new infectious disease.
      <fig id="fig0001">
       <label>
        Figure 1
       </label>
       <caption>
        <p>
         Geographical distribution of 85403 confirmed cases of COVID-19 novel coronavirus pneumonia. The color depth represents the number of confirmed COVID-19 infection. The data vailable from:
         <ext-link ext-link-type="uri" id="interref0001" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200229-sitrep-40-covid-19">
          https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200229-sitrep-40-covid-19
         </ext-link>
         . Data as reported by 10AM CET 29 February 2020.
        </p>
       </caption>
       <alt-text id="alt0001">
        Figure 1
       </alt-text>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
     </p>
    </sec>
    <sec id="sec0002">
     <label>
      2
     </label>
     <title>
      Genetic structure and pathogenic mechanism of SARS-CoV-2
     </title>
     <p id="para0006">
      Coronavirus (COV) is a single strand RNA virus with a diameter of 80-120nm. It is divided into four types: α-coronavirus (α-COV), β-coronavirus (β-COV), δ-coronavirus (δ-COV) and γ - coronavirus (γ-COV)
      <xref ref-type="bibr" rid="bib0005">
       [5]
      </xref>
      . Six coronaviruses were previously known to cause disease in humans, SARS-CoV-2 is the seventh member of the coronavirus family that infects human beings after SARS-CoV and MERS-CoV
      <xref ref-type="bibr" rid="bib0006">
       [6]
      </xref>
      . SARS-CoV-2, like SARS-CoV and MERS-CoV, belongs to β-coronavirus. The genome sequence homology of SARS-CoV-2 and SARS is about 79%, the 2019-nCoV is closer to the SARS-like bat CoVs (MG772933) than the SARS-CoV
      <xref ref-type="bibr" rid="bib0007">
       [7]
      </xref>
      , which is descended from SARS-like bat CoVs. Interestingly, for high similarity of receptor-binding domain (RBD) in Spike-protein, several analyses reveal that SARS-CoV-2 uses angiotension-converting enzyme 2 (ACE2) as receptor, just like as SARS-CoV
      <xref ref-type="bibr" rid="bib0008">
       [8]
      </xref>
      . Coronavirus mainly recognizes the corresponding receptor on the target cell through the S protein on its surface and enters into the cell, then causing the occurrence of infection. A structure model analysis shows that SARS-CoV-2 binds ACE2 with above 10 folds higher affinity than SARS-CoV, but higher than the threshold required for virus infection
      <xref ref-type="bibr" rid="bib0009">
       [9]
      </xref>
      . The detailed mechanism about whether the SARS-CoV-2 would infect humans via binding of S-protein to ACE2, how strong the interaction is for risk of human transmission, and how SARS-CoV-2 causes pathological mechanisms of organs damage remains unknown, which need more studies to elaborate. These results further explains the more rapid transmission capability of the SARS-CoV-2 in humans than SARS-CoV, and the number of confirmed COVID-19 much higher than people with SARS-CoV infection. Considering the higher affinity of SARS-CoV-2 binds ACE2, soluble ACE2 might be a potential candidate for COVID-19 treatment.
     </p>
    </sec>
    <sec id="sec0003">
     <label>
      3
     </label>
     <title>
      Prevalence of SARS-CoV-2
     </title>
     <p id="para0007">
      Basic Reproduction Number (R
      <sub>
       0
      </sub>
      ) refers to the average amount of secondary infection that patients may produce in completely susceptible population without intervention
      <xref ref-type="bibr" rid="bib0010">
       [10]
      </xref>
      . The estimation of R
      <sub>
       0
      </sub>
      varies among different research teams and is updated as more information is exposed. Wu, JT, Leung et al. of York University estimated the R
      <sub>
       0
      </sub>
      of novel coronavirus to be 2.47-2.86
      <xref ref-type="bibr" rid="bib0011">
       [11]
      </xref>
      using the SEIR model. Majumder of Boston Children's Hospital and his colleagues adjusted R
      <sub>
       0
      </sub>
      to be 2.0-3.3 using the IDEA model
      <xref ref-type="bibr" rid="bib0012">
       [12]
      </xref>
      . The R
      <sub>
       0
      </sub>
      value of other viruses of β - coronavirus, such as SARS-CoV, is estimated to be 2.2-3.6
      <xref ref-type="bibr" rid="bib0013">
       [13]
      </xref>
      . The R
      <sub>
       0
      </sub>
      value of MERS-CoV is estimated to be 2.0-6.7
      <xref ref-type="bibr" rid="bib0014">
       [14]
      </xref>
      . These indicate that SARS-CoV-2 has relatively high transmissibility. Population is generally susceptible to SARS-CoV-2, the median age was 47.0 years (IQR, 35.0 to 58.0), 87% case patients were 30 to 79 years of age, and 3% were age 80 years or older, and the number of female patients was 41.9%. [
      <xref ref-type="bibr" rid="bib0015">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0016">
       16
      </xref>
      ]. Most cases were diagnosed in Hubei Province, China (75%). 81% cases were classified as mild, 14% cases were severe, and 5% were critical. The overall case-fatality rate (CFR) was 2.3%, but cases in those aged 70 to 79 years had an 8.0% CFR and cases in those aged 80 years and older had a 14.8% CFR
      <xref ref-type="bibr" rid="bib0016">
       [16]
      </xref>
      . This implies that elderly male citizens are more susceptible to this coronavirus as compared with other groups, and this virus is more likely to affect elderly male citizens with chronic underlying diseases (diabetes, hypertension, heart disease, etc.)
      <xref ref-type="bibr" rid="bib0017">
       [17]
      </xref>
      . In summary, COVID-19 is high in prevalence and population is generally susceptible to such virus, and COVID-19 rapidly spread from a single Wuhan city to the entire country in just 30 days. So that prompt measures should be taken to control the spread of the disease.
     </p>
    </sec>
    <sec id="sec0004">
     <label>
      4
     </label>
     <title>
      Transmission of SARS-CoV-2
     </title>
     <p id="para0008">
      Previous epidemiological studies have proved that there are three conditions for wide spread of virus, i.e. the source of infection, route of transmission, and susceptibility
      <xref ref-type="bibr" rid="bib0018">
       [18]
      </xref>
      . There is no exception for SARS-CoV-2.
     </p>
     <sec id="sec0005">
      <label>
       4.1
      </label>
      <title>
       From the perspective of infectious sources
      </title>
      <p id="para0009">
       Bats are considered to be the natural hosts of SARS-CoV-2, while pangolins and snakes are thought to be the intermediate hosts. Studies of Institut Pasteur of Shanghai showed that bats might be the natural hosts of SARS-CoV-2. Furthermore, studies of Peking University
       <xref ref-type="bibr" rid="bib0019">
        [19]
       </xref>
       suggest that SARS-CoV-2 infection is probably caused by snakes. However, later studies
       <xref ref-type="bibr" rid="bib0020">
        [20]
       </xref>
       found that no evidence showed that snakes are the hosts of SARS-CoV-2. Study from wuhan institute of virology showed that the similarity of gene sequence between SARS-CoV-2 and bat coronavirus is as high as 96.2% by sequencing technology
       <xref ref-type="bibr" rid="bib0021">
        [21]
       </xref>
       This also implied that bats are the possible source of SARS-CoV-2. Apart from those, Xu. et al.
       <xref ref-type="bibr" rid="bib0022">
        [22]
       </xref>
       showed that the similarity of SARS-CoV-2 isolated from pangolin and the virus strains currently infecting humans is as high as 99% using macrogenomic sequencing, molecular biological detection and electron microscopic analysis. The team also observed the typical novel coronavirus granules and revealed that pangolin is the potential intermediate host of the SARS-CoV-2. Although the results of current research have not yet fully elucidated the potential natural host and the intermediate host of the SARS-CoV-2, adequate evidence has proved that this virus might be sourced from wild animals. At present, it is considered that the main infectious source of sars-cov-2 is COVID-19 patients in the population. However, there is still a debate about whether SARS-CoV-2 patients in the incubation period are infectious, which needs further study.
      </p>
     </sec>
     <sec id="sec0006">
      <label>
       4.2
      </label>
      <title>
       From the perspective of route of transmission
      </title>
      <p id="para0010">
       Transmission and close contact are the most common ways of transmission for SARS-CoV-2. Aerosol transmission might also be a way of transmission. In addition, researchers also detected SARS-CoV-2 in the samples of stool, gastrointestinal tract, saliva and urine. Based on bioinformatics evidence indicated that digestive tract might be a potential route of SARS-CoV-2 infection
       <xref ref-type="bibr" rid="bib0023">
        [23]
       </xref>
       . Consistently, SARS-CoV-2 RNA was also dectected in gastrointestinal tissues from COVID-19 patients
       <xref ref-type="bibr" rid="bib0024">
        [24]
       </xref>
       . Moreover, SARS-CoV-2 was detected in the tears and conjunctival secretions of covid-19 patients
       <xref ref-type="bibr" rid="bib0025">
        [25]
       </xref>
       . Meanwhile, a retrospective study based nine pregnant women with COVID-19 had for the first time indicated that the possibility of intrauterine vertical transmission between mothers and infants in the late pregnancy was temporarily excluded
       <xref ref-type="bibr" rid="bib0026">
        [26]
       </xref>
       . However, available data on pregnant women infected with SARS-CoV-2 were inadequate, and hence further studies are required to verify the potential vertical transmission of SARS-CoV-2 in pregnant women.
      </p>
     </sec>
     <sec id="sec0007">
      <label>
       4.3
      </label>
      <title>
       From the perspective of viral latency
      </title>
      <p id="para0011">
       From the epidemiological investigation report, elderly citizens are susceptible groups for SARS-CoV-2, the median age of death was 75 years, and most of them had comorbidities or a history of surgery before admission
       <xref ref-type="bibr" rid="bib0027">
        [27]
       </xref>
       . Zhong.
       <italic>
        et al.
       </italic>
       found that, based on clinical features of 1,099 COVID-19 patients, the median incubation period was 3.0 days (range, 0 to 24.0), the median time from the first symptom to death was 14 days [
       <xref ref-type="bibr" rid="bib0015">
        15
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0027">
        27
       </xref>
       ]. For SARS, the median latency of SARS is 4 days, the average duration of first symptoms to hospital admission was 3.8 days, and admission to death was 17.4 days for casualties
       <xref ref-type="bibr" rid="bib0028">
        [28]
       </xref>
       , and the median latency of MERS is 7 days
       <xref ref-type="bibr" rid="bib0029">
        [29]
       </xref>
       . From the median incubation period, COVID-19 is shorter than SARS and MERS. However, the maximum latency of SARS-CoV-2 currently observed is as high as 24 days, which may increase the risk of virus transmission. Moreover, it also found that people 70 years or older had shorter median days (11.5 days) from the first symptom to death than those with ages below 70 years (20 days), demonstrating that elderly people have faster disease progression than younger people
       <xref ref-type="bibr" rid="bib0027">
        [27]
       </xref>
       . From the above, the public should pay more attention to elderly people who might be more vulnerable to the SARS-CoV-2.
      </p>
     </sec>
    </sec>
    <sec id="sec0008">
     <label>
      5
     </label>
     <title>
      Clinical characteristics of SARS-CoV-2 infection
     </title>
     <p id="para0012">
      COVID-19 produces an acute viral infection in humans with median incubation period was 3.0 days
      <xref ref-type="bibr" rid="bib0015">
       [15]
      </xref>
      , which is similar to the SRAS with an incubation period ranging from 2–10 days
      <xref ref-type="bibr" rid="bib0030">
       [30]
      </xref>
      . The presenting features of COVID-19 infection in adults are pronounced. The presenting features in adults are pronounced. The most common clinical symptoms of SARS-CoV-2 infection were fever (87.9%), cough (67.7%), fatigue (38.1%), whereas diarrhea (3.7%) and vomiting (5.0%) were rare [
      <xref ref-type="bibr" rid="bib0015">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0031">
       31
      </xref>
      ], which were similar to others coronavirus. Most patients had some degree of dyspnoea at presentation, because the time from onset of symptoms to the development of acute respiratory distress syndrome (ARDS) was only 9 days among the initial patients with COVID-19 infection
      <xref ref-type="bibr" rid="bib0001">
       [1]
      </xref>
      . Moreover, severe patients are prone to a variety of complications, including acute respiratory distress syndrome, acute heart injury and secondary infection
      <xref ref-type="bibr" rid="bib0017">
       [17]
      </xref>
      . There are already some evidences that COVID-19 can cause damage to tissues and organs other than the lung. In a study of 214 COVID-19 patients, 78 (36.4%) patients had neurological manifestations
      <xref ref-type="bibr" rid="bib0032">
       [32]
      </xref>
      . In addition, there is already evidence of ocular surface infection in patients with COVID-19, and SARS-CoV-2 RNA was detected in eye secretions of patient
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      . Some COVID-19 patients have arrhythmia, acute heart injury, impaired renal function, and abnormal liver function (50.7%) at admission [
      <xref ref-type="bibr" rid="bib0001">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0034">
       34
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0035">
       35
      </xref>
      ]. A case report of the pathological manifestations of a patient with pneumonia showed moderate microvesicular steatosis in his liver tissue
      <xref ref-type="bibr" rid="bib0036">
       [36]
      </xref>
      . Besides, tissue samples of stomach, duodenum, and rectal mucosa were confirmed positive for SARS-CoV-2 RNA
      <xref ref-type="bibr" rid="bib0037">
       [37]
      </xref>
      (
      <xref ref-type="fig" rid="fig0002">
       Figure 2
      </xref>
      ).
      <fig id="fig0002">
       <label>
        Figure 2
       </label>
       <caption>
        <p>
         Organ involvements confirmed by clinical features or biopsy in COVID-19.
        </p>
       </caption>
       <alt-text id="alt0002">
        Figure 2
       </alt-text>
       <graphic xlink:href="gr2_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para0013">
      <xref ref-type="fig" rid="fig0003">
       Figure 3
      </xref>
      .
      <fig id="fig0003">
       <label>
        Figure 3
       </label>
       <caption>
        <p>
         Serial Chest computer tomography (CT) scan of a 64-year-old female infected with SARS-CoV-2 in 2020. Several areas of ground-glass opacities, consolidations, air bronchogram and intralobular interstitial thickening involving predominantly the lower lobes of both lungs were observed.
        </p>
       </caption>
       <alt-text id="alt0003">
        Figure 3
       </alt-text>
       <graphic xlink:href="gr3_lrg">
       </graphic>
      </fig>
     </p>
     <p id="para0014">
      In general, the radiographical features of coronavirus are similar to those found in community-acquired pneumonia caused by other organisms
      <xref ref-type="bibr" rid="bib0038">
       [38]
      </xref>
      . Chest CT scan is important tool to diagnose this pneumonia. Nevertheless, several typical imaging features are frequently observed in COVID-19 pneumonia, including the predominant groundglass opacity (65%), consolidations (50%), smooth or irregular interlobular septal thickening (35%), air bronchogram (47%), and thickening of the adjacent pleura (32%), with predominantly peripheral and lower lobe involvement
      <xref ref-type="bibr" rid="bib0039">
       [39]
      </xref>
      . A recent study reported that most patients (90%) had bilateral chest CT findings and the sensitivity of chest CT to suggest COVID-19 was 97%
      <xref ref-type="bibr" rid="bib0033">
       [33]
      </xref>
      . Combining chest CT imaging features with clinical symptom and laboratory test could facilitate early diagnosis of COVID-19 pneumonia.
     </p>
     <p id="para0015">
      Laboratory examination revealed that 82.1% of patients was lymphopenia and 36.2% of patients was hrombocytopenia. Most patients had normal leukocytes, but leukopenia was observed in 33.7% of patients. In addition, most patients demonstrated elevated levels of C-reactive protein (CRP) , lactate dehydrogenase (LDH) and creatinine kinase (CK) , but minority of patients had elevated transaminase, abnormal myocardial enzyme spectrum, or elevated serum creatinine [
      <xref ref-type="bibr" rid="bib0001">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0015">
       15
      </xref>
      ]. As compared with bacterial pneumonia, patients with SARS-CoV-2 showed lower oxygenation index. Cytokine release syndrome is a vital factor that aggravates disease progression. A higher levels of IL-6 and IL-10, and lower levels of CD4+T and CD8+T are observed in COVID-19 patients parallel with the severity of the disease
      <xref ref-type="bibr" rid="bib0040">
       [40]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0009">
     <label>
      6
     </label>
     <title>
      Diagnosis of SARS-CoV-2
     </title>
     <p id="para0016">
      The detection of viral nucleic acid is the standard for noninvasive diagnosis of COVID-19. However, the present detection of SARS-CoV-2 nucleic acid was high in specificity and low in sensitivity, so that there might be false negatives and the testing time could be relatively long. The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (5
      <sup>
       th
      </sup>
      trial version) took “suspected cases with pneumonia imaging features” as the clinical diagnostic criteria in Hubei Province
      <xref ref-type="bibr" rid="bib0041">
       [41]
      </xref>
      . But the sixth edition of diagnostic criteria eliminates the distinction between Hubei and other provinces outside Hubei
      <xref ref-type="bibr" rid="bib0042">
       [42]
      </xref>
      . One reason might be to distinguish the flu from the COVID-19. Furthermore, Zhang F of MIT developed a test paper for rapid detection of SARS-CoV-2 in one hour by SHERLOCK technology. Although the clinical verification has not been carried out yet, this technology, once proved, might be conducive to rapid diagnosis of the disease
      <xref ref-type="bibr" rid="bib0043">
       [43]
      </xref>
      . A research group of Peking University claimed to have developed a new method for rapid construction of transcriptome sequencing library of SHERRY, which is helpful for rapid sequencing of SARS-CoV-2
      <xref ref-type="bibr" rid="bib0044">
       [44]
      </xref>
      .
     </p>
    </sec>
    <sec id="sec0010">
     <label>
      7
     </label>
     <title>
      Treatment of SARS-CoV-2
     </title>
     <sec id="sec0011">
      <label>
       7.1
      </label>
      <title>
       Antiviral western medicine treatment
      </title>
      <p id="para0017">
       At present, the treatments of patients with SARS-CoV-2 infection are mainly symptomatic treatments. Remdesivir was recently reported as a promising antiviral drug against a wide array of RNA viruses. Holshue et al. for the first time reported that treatment of a patient with COVID-19 used remdesivir and achieved good results
       <xref ref-type="bibr" rid="bib0045">
        [45]
       </xref>
       . Then, Xiao
       <italic>
        et al.
       </italic>
       findings reveal that remdesivir effectively in the control of 2019-nCoV infection in vitro. Meanwhile, also found that chloroquine has an immune-modulating activity and could effectively inhibit in this virus in vitro
       <xref ref-type="bibr" rid="bib0046">
        [46]
       </xref>
       . Clinical controlled trials have shown that Chloroquine was proved to be effective in the treatment of patients with COVID-19
       <xref ref-type="bibr" rid="bib0047">
        [47]
       </xref>
       . Remdesivir is undergoing a large number of clinical trials in several hospitals, and the final efficacy of the drug is uncertain. Arbidol, a small indole derivative molecule, was found to block viral fusion against influenza A and B viruses and hepatitis C viruses
       <xref ref-type="bibr" rid="bib0048">
        [48]
       </xref>
       and confirmed to have antiviral effect on SARS-CoV in cell experiment
       <xref ref-type="bibr" rid="bib0049">
        [49]
       </xref>
       , so that it might be a choice for COVID-19 treatment. The randomized controlled study on treatment of novel coronavirus by Arbidol and Kaletra undertaken at present showed that Arbidol had better therapeutic effect than Kaletra did and could significantly reduce the incidence of severe cases. Apart from the above, lopinavir/ritonavir, nucleoside analogues, neuraminidase inhibitors, remdesivir, and peptide EK1 could also be the choices of antiviral drugs for COVID-19 treatment
       <xref ref-type="bibr" rid="bib0050">
        [50]
       </xref>
       .
      </p>
     </sec>
     <sec id="sec0012">
      <label>
       7.2
      </label>
      <title>
       Chinese medicine treatment
      </title>
      <p id="para0018">
       Chinese medicine also played an important role in the treatment of SARS-CoV-2 infection. Local governments and medical institutions published a number of traditional Chinese medicine prescriptions. The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (6
       <sup>
        th
       </sup>
       trial version) suggested to use clearing lung and detoxification decoction in the clinical treatment
       <xref ref-type="bibr" rid="bib0042">
        [42]
       </xref>
       . A joint study made by Shanghai Institute of Materia Medica and Wuhan Institute of Virology. CAS found that Shuanghuanglian oral liquid could inhibit SARS-CoV-2. Previous studies have proved that baicalin, chlorogenic acid and forsythin in Shuanghuanglian oral liquid have certain inhibitory effects on a variety of viruses and bacteria [
       <xref ref-type="bibr" rid="bib0051">
        51
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0052">
        52
       </xref>
       ]. The mechanism might be that these components played a therapeutic role by effectively reducing the inflammatory response of the body caused by viruses and bacteria
       <xref ref-type="bibr" rid="bib0053">
        [53]
       </xref>
       . Lianhuaqingwen capsule has been proven to have a wide-spectrum effect on a series of influenza viruses, including H7N9, and could regulate the immune response of the virus, reducing the level of inflammatory factors in the early stage of infection
       <xref ref-type="bibr" rid="bib0054">
        [54]
       </xref>
       .
      </p>
     </sec>
     <sec id="sec0013">
      <label>
       7.3
      </label>
      <title>
       Immunoenhancement therapy
      </title>
      <p id="para0019">
       Synthetic recombinant interferon α has proven to be effective in treatment of SARS patients in clinic trials
       <xref ref-type="bibr" rid="bib0055">
        [55]
       </xref>
       . Pulmonary X-ray abnormal remission time was reduced by 50% in the interferon-treated group compared with the glucocorticoid-treated group alone. Interferon was also found to be an effective inhibitor of MERS-CoV replication
       <xref ref-type="bibr" rid="bib0056">
        [56]
       </xref>
       . Those findings suggested that interferon could be used in the treatment of COVID-19. Intravenous immunoglobulin might be the safest immunomodulator for long-term use in all ages, and could help to inhibit the production of proinflammatory cytokines and increase the production of anti-inflammatory mediators
       <xref ref-type="bibr" rid="bib0057">
        [57]
       </xref>
       . Moreover, Thymosin alpha-1 (Ta1) can be an immune booster for SARS patients, effectively controlling the spread of disease
       <xref ref-type="bibr" rid="bib0058">
        [58]
       </xref>
       . Intravenous immunoglobulin and Ta1 may also be considered as therapeutics for COVID-19.
      </p>
     </sec>
     <sec id="sec0014">
      <label>
       7.4
      </label>
      <title>
       Convalescent plasma therapy
      </title>
      <p id="para0020">
       When there are no sufficient vaccines and specific drugs, convalescent plasma therapy could be an effective way to alleviate the course of disease for severely infected patients
       <xref ref-type="bibr" rid="bib0059">
        [59]
       </xref>
       . In a retrospective analysis, convalescent plasma therapy is more effective than severe doses of hormonal shock in patients with severe SARS, reducing mortality and shortening hospital stays
       <xref ref-type="bibr" rid="bib0060">
        [60]
       </xref>
       . A prospective cohort study by Hung and colleagues showed that for patients with pandemic H1N1 influenza virus infection in 2009, the relative risk of death was significantly lower in patients treated with convalescent plasma
       <xref ref-type="bibr" rid="bib0061">
        [61]
       </xref>
       . Moreover, from the perspective of immunology, most of the patients recovered from COVID-19 would produce specific antibodies against the SARS-CoV-2, and their serum could be used to prevent reinfection. At the same time, antibodies can limit the virus reproduction in the acute phase of infection and help clear the virus, which is conducive to the rapid recovery of the disease
       <xref ref-type="bibr" rid="bib0062">
        [62]
       </xref>
       . Theoretically, viremia peaks during the first week of most viral infections, and it should be more effective to give recovery plasma early in the disease
       <xref ref-type="bibr" rid="bib0063">
        [63]
       </xref>
       . Therefore, the plasma of some patients recovered from COVID-19 could be collected to prepare plasma globulin specific to SARS-CoV-2. However, the safety of plasma globulin products specific to SARS-CoV-2 deserves further consideration.
      </p>
     </sec>
     <sec id="sec0015">
      <label>
       7.5
      </label>
      <title>
       Auxiliary blood purification treatment
      </title>
      <p id="para0021">
       At present, extracorporeal blood purification technology in the treatment of severe NCP patients
       <xref ref-type="bibr" rid="bib0042">
        [42]
       </xref>
       . According to the latest studies
       <xref ref-type="bibr" rid="bib0034">
        [34]
       </xref>
       , ACE2, the key receptor of SARS-CoV-2, is highly expressed in human kidney (nearly 100 times higher than that in lung). Kidney might be main target of attack for novel coronavirus. Early continuous blood purification treatment could reduce renal workload and help to promote the recovery of renal function
       <xref ref-type="bibr" rid="bib0064">
        [64]
       </xref>
       . Most of the severe patients with novel coronavirus might suffer from cytokine storm. The imbalance of pro-inflammatory factors and anti-inflammatory factors might cause immune damage. Therefore, blood purification technology could be used to remove inflammatory factors, eliminate cytokine storm, correct electrolyte imbalance, and maintain acid-base balance, to control patient's capacity load in an effective manner
       <xref ref-type="bibr" rid="bib0065">
        [65]
       </xref>
       . In this logic, the patient's symptoms could be improved and the blood oxygen saturation could be increased.
      </p>
      <p id="para0022">
       In summary, the drug treatment for COVID-19 mainly comprised four ways, i.e., antiviral Western medicine, Chinese medicine, immunoenhancement therapy, and viral specific plasma globulin. Machines could be used as auxiliary therapy. However, randomized double-blind large sample clinical trial should be served as the standard to determine whether the antiviral drugs could be used in clinical practice.
      </p>
     </sec>
    </sec>
    <sec id="sec0016">
     <label>
      8
     </label>
     <title>
      Prevention of SARS-CoV-2
     </title>
     <p id="para0023">
      So far, there are no specific antiviral treatments or vaccines for SARS-CoV-2. And the clinical treatment of COVID-19 has been limited to support and palliative care until now. Therefore, it is urgent to develop a safe and stable COVID-19 vaccine. Dr. Tedros, director-general of WHO, said that novel coronavirus vaccine was expected to be ready in 18 months. In addition, SARS-CoV-2 is an RNA virus. RNA virus related vaccines, including measles, polio, encephalitis B virus and influenza virus, could be the most promising alternatives. And interpersonal transmission of the virus could be prevented by immunizing health care workers and non-infected population
      <xref ref-type="bibr" rid="bib0066">
       [66]
      </xref>
      .
     </p>
     <p id="para0024">
      Prevention of infectious diseases by traditional Chinese medicine has been recorded for a long time in Chinese history, and there have been previous studies on the prevention of SARS by traditional Chinese medicine
      <xref ref-type="bibr" rid="bib0067">
       [67]
      </xref>
      . The present principles on prevention of COVID-19 are to tonify body energy to protect outside body, dispel wind, dissipate heat, and dissipate dampness with aromatic agent. The six most commonly used Chinese herbal medicines are astragalus, liquorice, fangfeng, baizhu and honeysuckle. However, the decoction is not suitable for long-term use, and the best period is one week only
      <xref ref-type="bibr" rid="bib0068">
       [68]
      </xref>
      . Studies have shown that vitamin C may prevent the susceptibility of lower respiratory tract infection under certain conditions
      <xref ref-type="bibr" rid="bib0069">
       [69]
      </xref>
      , while COVID-19 may cause lower respiratory tract infection. Therefore, a moderate amount of vitamin C supplementation may be a way to prevent COVID-19. In addition, the decrease in vitamin D and vitamin E levels in cattle could lead to the infection of bovine coronavirus
      <xref ref-type="bibr" rid="bib0070">
       [70]
      </xref>
      . This suggests that proper supplementation of vitamin D and vitamin E may enhance our resistance to SARS-CoV-2. Patients with primary basic diseases, especially those with chronic diseases such as hypertension, diabetes, coronary heart disease and tumor, are more susceptible to SARS-CoV-2 and their risk of poor prognosis will increase significantly after infection, because they have low systemic immunity as a result of the disease itself and treatments
      <xref ref-type="bibr" rid="bib0071">
       [71]
      </xref>
      . Therefore, it is particularly important to enhance self-resistance. The main way to boost personal immunity is to maintain personal hygiene, a healthy lifestyle and adequate nutritional intake [
      <xref ref-type="bibr" rid="bib0072">
       72
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0073">
       73
      </xref>
      ]. For individuals, taking protective measures can effectively prevent SARS-CoV-2 infection, including improving personal hygiene, wearing medical masks, adequate rest and good ventilation
      <xref ref-type="bibr" rid="bib0015">
       [15]
      </xref>
      .
     </p>
     <p id="para0025">
      In conclusion, COVID-19 is a serious infectious disease caused by the novel coronavirus, SARS-CoV-2. Its main initial symptoms, fever, cough and fatigue, are similar to that of SARS. The most likely source of SARS-CoV-2 is bats. This virus is highly infectious and can be transmitted through droplets and close contact. Some patients are life-threatening and such disease has posed a great threat to global health and safety, so to control the spread of the epidemic and reduce the mortality as soon as possible is our burning issue. But by far, the specific mechanism of the virus remains unknown, and no specific drugs for the virus have been developed. At present, it is important to control the source of infection, cut off the transmission route, and use the existing drugs and means to control the progress of the disease proactively. We should also strive to develop specific drugs, promote the research and development of vaccines, and reduce morbidity and mortality of the disease, so as to better protect the safety of people's lives.
     </p>
    </sec>
    <sec sec-type="COI-statement">
     <title>
      Declaration of Competing Interest
     </title>
     <p id="para0026">
      The authors report no conflicts of interest in this work.
     </p>
    </sec>
    <back>
     <ref-list id="cebibl1">
      <title>
       References
      </title>
      <ref id="bib0001">
       <label>
        1
       </label>
       <element-citation id="sbref0001" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan
        </article-title>
        <source>
         China. Lancet (London, England)
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0002">
       <label>
        2
       </label>
       <element-citation id="sbref0002" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Gayle
          </surname>
          <given-names>
           A.A.
          </given-names>
         </name>
         <name>
          <surname>
           Wilder-Smith
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Rocklov
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The reproductive number of COVID-19 is higher compared to SARS coronavirus
        </article-title>
        <source>
         J Travel Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0003">
       <label>
        3
       </label>
       <element-citation id="sbref0003" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan
        </article-title>
        <source>
         China: a descriptive study. Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0004">
       <label>
        4
       </label>
       <mixed-citation id="othref0001" publication-type="other">
        Organization W.H.Coronavirus disease 2019(COVID-19) SituationReport-40. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0005">
       <label>
        5
       </label>
       <element-citation id="sbref0004" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tse
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           D.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interspecies transmission and emergence of novel viruses: lessons from bats and birds
        </article-title>
        <source>
         Trends Microbiol
        </source>
        <volume>
         21
        </volume>
        <year>
         2013
        </year>
        <fpage>
         544
        </fpage>
        <lpage>
         555
        </lpage>
        <pub-id pub-id-type="pmid">
         23770275
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0006">
       <label>
        6
       </label>
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A Novel Coronavirus from Patients with Pneumonia in China, 2019
        </article-title>
        <source>
         The New England journal of medicine
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0007">
       <label>
        7
       </label>
       <element-citation id="sbref0006" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Niu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China
        </article-title>
        <source>
         Cell host &amp; microbe
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0008">
       <label>
        8
       </label>
       <element-citation id="sbref0007" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hoffmann
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Kleine-Weber
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Krüger
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pöhlmann
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
        </article-title>
        <source>
         bioRxiv.
        </source>
        <year>
         2020
        </year>
        <comment>
         2020.01.31.929042
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0009">
       <label>
        9
       </label>
       <element-citation id="sbref0008" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wrapp
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Corbett
          </surname>
          <given-names>
           K.S.
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           C.L.
          </given-names>
         </name>
         <name>
          <surname>
           Abiona
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
        </article-title>
        <source>
         Science (New York, NY)
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <label>
        10
       </label>
       <element-citation id="sbref0009" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Remais
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Modelling environmentally-mediated infectious diseases of humans: transmission dynamics of schistosomiasis in China
        </article-title>
        <source>
         Adv Exp Med Biol
        </source>
        <volume>
         673
        </volume>
        <year>
         2010
        </year>
        <fpage>
         79
        </fpage>
        <lpage>
         98
        </lpage>
        <pub-id pub-id-type="pmid">
         20632531
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0011">
       <label>
        11
       </label>
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan
        </article-title>
        <source>
         China: a modelling study. The Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0012">
       <label>
        12
       </label>
       <element-citation id="sbref0011" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           MaM
          </given-names>
         </name>
         <name>
          <surname>
           Kenneth
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China
        </article-title>
        <source>
         Available at SSRN
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0013">
       <label>
        13
       </label>
       <element-citation id="sbref0012" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lipsitch
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cohen
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Robins
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           James
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission dynamics and control of severe acute respiratory syndrome
        </article-title>
        <source>
         Science (New York, NY)
        </source>
        <volume>
         300
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1966
        </fpage>
        <lpage>
         1970
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0014">
       <label>
        14
       </label>
       <element-citation id="sbref0013" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Majumder
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
         <name>
          <surname>
           Rivers
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lofgren
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Fisman
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Estimation of MERS-Coronavirus Reproductive Number and Case Fatality Rate for the Spring 2014 Saudi Arabia Outbreak: Insights from Publicly Available Data
        </article-title>
        <source>
         PLoS Curr.
        </source>
        <volume>
         6
        </volume>
        <year>
         2014
        </year>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <label>
        15
       </label>
       <mixed-citation id="othref0002" publication-type="other">
        Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of 2019 novel coronavirus infection in China. 2020:2020.02.06.20020974.
       </mixed-citation>
      </ref>
      <ref id="bib0016">
       <label>
        16
       </label>
       <element-citation id="sbref0014" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           McGoogan
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention
        </article-title>
        <source>
         Jama
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0017">
       <label>
        17
       </label>
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan
        </article-title>
        <source>
         China: a descriptive study. Lancet (London, England)
        </source>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0018">
       <label>
        18
       </label>
       <element-citation id="sbref0016" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Barreto
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Teixeira
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
         <name>
          <surname>
           Carmo
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infectious diseases epidemiology
        </article-title>
        <source>
         J Epidemiol Community Health
        </source>
        <volume>
         60
        </volume>
        <year>
         2006
        </year>
        <fpage>
         192
        </fpage>
        <lpage>
         195
        </lpage>
        <pub-id pub-id-type="pmid">
         16476746
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0019">
       <label>
        19
       </label>
       <element-citation id="sbref0017" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ji
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zai
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human
        </article-title>
        <source>
         Journal of medical virology
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <label>
        20
       </label>
       <mixed-citation id="othref0003" publication-type="other">
        Zhang C., Zheng W., Huang X., Bell E.W., Zhou X., Zhang Y.Protein structure and sequence re-analysis of 2019-nCoV genome does not indicate snakes as its intermediate host or the unique similarity between its spike protein insertions and HIV-1. 2020:2020.02.04.933135.
       </mixed-citation>
      </ref>
      <ref id="bib0021">
       <label>
        21
       </label>
       <element-citation id="sbref0018" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X.G.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0022">
       <label>
        22
       </label>
       <element-citation id="sbref0019" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
        </article-title>
        <source>
         Sci China Life Sci
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0023">
       <label>
        23
       </label>
       <mixed-citation id="othref0004" publication-type="other">
        Wang J., Zhao S., Liu M., Zhao Z., Xu Y., Wang P., et al. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. 2020:2020.02.05.20020545.
       </mixed-citation>
      </ref>
      <ref id="bib0024">
       <label>
        24
       </label>
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence for gastrointestinal infection of SARS-CoV-2
        </article-title>
        <source>
         medRxiv.
        </source>
        <year>
         2020
        </year>
        <comment>
         2020.02.17.20023721
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <label>
        25
       </label>
       <element-citation id="sbref0021" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xia
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection
        </article-title>
        <source>
         Journal of medical virology
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0026">
       <label>
        26
       </label>
       <element-citation id="sbref0022" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </article-title>
        <source>
         The Lancet
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0027">
       <label>
        27
       </label>
       <element-citation id="sbref0023" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China.
        </article-title>
        <source>
         Journal of medical virology
        </source>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <fpage>
         441
        </fpage>
        <lpage>
         447
        </lpage>
        <pub-id pub-id-type="pmid">
         31994742
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0028">
       <label>
        28
       </label>
       <element-citation id="sbref0024" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lessler
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Reich
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Brookmeyer
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Perl
          </surname>
          <given-names>
           T.M.
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Cummings
          </surname>
          <given-names>
           D.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Incubation periods of acute respiratory viral infections: a systematic review
        </article-title>
        <source>
         The Lancet Infectious diseases
        </source>
        <volume>
         9
        </volume>
        <year>
         2009
        </year>
        <fpage>
         291
        </fpage>
        <lpage>
         300
        </lpage>
        <pub-id pub-id-type="pmid">
         19393959
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0029">
       <label>
        29
       </label>
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           Y.E.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study
        </article-title>
        <source>
         Lancet (London, England)
        </source>
        <volume>
         388
        </volume>
        <year>
         2016
        </year>
        <fpage>
         994
        </fpage>
        <lpage>
         1001
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <label>
        30
       </label>
       <element-citation id="sbref0026" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           P.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS: clinical presentation, transmission, pathogenesis and treatment options
        </article-title>
        <source>
         Clinical science (London, England: 1979)
        </source>
        <volume>
         110
        </volume>
        <year>
         2006
        </year>
        <fpage>
         193
        </fpage>
        <lpage>
         204
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0031">
       <label>
        31
       </label>
       <mixed-citation id="othref0005" publication-type="other">
        Yang Y., Lu Q., Liu M., Wang Y., Zhang A., Jalali N., et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. 2020:2020.02.10.20021675.
       </mixed-citation>
      </ref>
      <ref id="bib0032">
       <label>
        32
       </label>
       <element-citation id="sbref0027" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan
        </article-title>
        <source>
         China: a retrospective case series study
        </source>
        <year>
         2020
        </year>
        <comment>
         2020.02.22.20026500
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0033">
       <label>
        33
       </label>
       <element-citation id="sbref0028" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Zhan
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2020
        </year>
        <comment>
         200642
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0034">
       <label>
        34
       </label>
       <mixed-citation id="othref0006" publication-type="other">
        Li Z., Wu M., Guo J., Yao J., Liao X., Song S., et al. Caution on Kidney Dysfunctions of 2019-nCoV Patients. 2020:2020.02.08.20021212.
       </mixed-citation>
      </ref>
      <ref id="bib0035">
       <label>
        35
       </label>
       <element-citation id="sbref0029" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0036">
       <label>
        36
       </label>
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathological findings of COVID-19 associated with acute respiratory distress syndrome
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0037">
       <label>
        37
       </label>
       <mixed-citation id="othref0007" publication-type="other">
        Xiao F., Tang M., Zheng X., Li C., He J., Hong Z., et al. Evidence for gastrointestinal infection of SARS-CoV-2. 2020:2020.02.17.20023721.
       </mixed-citation>
      </ref>
      <ref id="bib0038">
       <label>
        38
       </label>
       <element-citation id="sbref0031" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           K.T.
          </given-names>
         </name>
         <name>
          <surname>
           Antonio
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           E.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients
        </article-title>
        <source>
         Radiology
        </source>
        <volume>
         228
        </volume>
        <year>
         2003
        </year>
        <fpage>
         401
        </fpage>
        <lpage>
         406
        </lpage>
        <pub-id pub-id-type="pmid">
         12759474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0039">
       <label>
        39
       </label>
       <element-citation id="sbref0032" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Alwalid
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Gu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         The Lancet Infectious diseases
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <label>
        40
       </label>
       <element-citation id="sbref0033" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)
        </article-title>
        <source>
         medRxiv.
        </source>
        <year>
         2020
        </year>
        <comment>
         2020.02.10.20021832
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0041">
       <label>
        41
       </label>
       <mixed-citation id="othref0008" publication-type="other">
        PRC NHCot. The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (5th trial version). 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0042">
       <label>
        42
       </label>
       <mixed-citation id="othref0009" publication-type="other">
        PRC NHCot. The Novel Coronavirus Pneumonia Diagnosis and Treatment Plan (6th trial version). 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0043">
       <label>
        43
       </label>
       <mixed-citation id="othref0010" publication-type="other">
        Feng Zhang O.O.A., Jonathan S. Gootenberg. A protocol for detection of COVID-19 using CRISPR diagnostics. 2020.
       </mixed-citation>
      </ref>
      <ref id="bib0044">
       <label>
        44
       </label>
       <mixed-citation id="othref0011" publication-type="other">
        Di L., Fu Y., Sun Y., Li J., Liu L., Yao J., et al. RNA sequencing by direct tagmentation of RNA/DNA hybrids. 2020;117:2886-93.
       </mixed-citation>
      </ref>
      <ref id="bib0045">
       <label>
        45
       </label>
       <element-citation id="sbref0034" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Holshue
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           DeBolt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Lindquist
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lofy
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wiesman
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Bruce
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         First Case of 2019 Novel Coronavirus in the United States
        </article-title>
        <source>
         The New England journal of medicine
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0046">
       <label>
        46
       </label>
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0047">
       <label>
        47
       </label>
       <element-citation id="sbref0036" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Tian
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0048">
       <label>
        48
       </label>
       <element-citation id="sbref0037" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Boriskin
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Leneva
          </surname>
          <given-names>
           I.A.
          </given-names>
         </name>
         <name>
          <surname>
           Pecheur
          </surname>
          <given-names>
           E.I.
          </given-names>
         </name>
         <name>
          <surname>
           Polyak
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Arbidol: a broad-spectrum antiviral compound that blocks viral fusion
        </article-title>
        <source>
         Curr Med Chem
        </source>
        <volume>
         15
        </volume>
        <year>
         2008
        </year>
        <fpage>
         997
        </fpage>
        <lpage>
         1005
        </lpage>
        <pub-id pub-id-type="pmid">
         18393857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0049">
       <label>
        49
       </label>
       <element-citation id="sbref0038" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Khamitov
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
         <name>
          <surname>
           Loginova
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Shchukina
          </surname>
          <given-names>
           V.N.
          </given-names>
         </name>
         <name>
          <surname>
           Borisevich
          </surname>
          <given-names>
           S.V.
          </given-names>
         </name>
         <name>
          <surname>
           Maksimov
          </surname>
          <given-names>
           V.A.
          </given-names>
         </name>
         <name>
          <surname>
           Shuster
          </surname>
          <given-names>
           A.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]
        </article-title>
        <source>
         Vopr Virusol
        </source>
        <volume>
         53
        </volume>
        <year>
         2008
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         13
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <label>
        50
       </label>
       <element-citation id="sbref0039" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Drug treatment options for the 2019-new coronavirus (2019-nCoV)
        </article-title>
        <source>
         Biosci Trends
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0051">
       <label>
        51
       </label>
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [The curative effect observation of shuanghuanglian and penicillin on acute tonsillitis]
        </article-title>
        <source>
         Lin Chuang Er Bi Yan Hou Ke Za Zhi
        </source>
        <volume>
         16
        </volume>
        <year>
         2002
        </year>
        <fpage>
         475
        </fpage>
        <lpage>
         476
        </lpage>
        <pub-id pub-id-type="pmid">
         15515537
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0052">
       <label>
        52
       </label>
       <element-citation id="sbref0041" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H.T.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.C.
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Z.C.
          </given-names>
         </name>
         <name>
          <surname>
           Sheng
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         [Effect of combined treatment of Shuanghuanglian and recombinant interferon alpha 2a on coxsackievirus B3 replication in vitro]
        </article-title>
        <source>
         Zhongguo Zhong Yao Za Zhi
        </source>
        <volume>
         25
        </volume>
        <year>
         2000
        </year>
        <fpage>
         682
        </fpage>
        <lpage>
         684
        </lpage>
        <pub-id pub-id-type="pmid">
         12525074
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0053">
       <label>
        53
       </label>
       <element-citation id="sbref0042" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Howard
          </surname>
          <given-names>
           O.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Oppenheim
          </surname>
          <given-names>
           J.J.
          </given-names>
         </name>
         <name>
          <surname>
           Krakauer
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effects of Shuanghuanglian and Qingkailing, two multi-components of traditional Chinese medicinal preparations, on human leukocyte function
        </article-title>
        <source>
         Life Sci
        </source>
        <volume>
         70
        </volume>
        <year>
         2002
        </year>
        <fpage>
         2897
        </fpage>
        <lpage>
         2913
        </lpage>
        <pub-id pub-id-type="pmid">
         12269401
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0054">
       <label>
        54
       </label>
       <element-citation id="sbref0043" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ding
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function
        </article-title>
        <source>
         BMC Complement Altern Med
        </source>
        <volume>
         17
        </volume>
        <year>
         2017
        </year>
        <fpage>
         130
        </fpage>
        <pub-id pub-id-type="pmid">
         28235408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <label>
        55
       </label>
       <element-citation id="sbref0044" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Loutfy
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Blatt
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
         <name>
          <surname>
           Siminovitch
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Ward
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wolff
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lho
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study
        </article-title>
        <source>
         Jama
        </source>
        <volume>
         290
        </volume>
        <year>
         2003
        </year>
        <fpage>
         3222
        </fpage>
        <lpage>
         3228
        </lpage>
        <pub-id pub-id-type="pmid">
         14693875
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0056">
       <label>
        56
       </label>
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mustafa
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Balkhy
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Gabere
          </surname>
          <given-names>
           M.N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): A review
        </article-title>
        <source>
         J Infect Public Health
        </source>
        <volume>
         11
        </volume>
        <year>
         2018
        </year>
        <fpage>
         9
        </fpage>
        <lpage>
         17
        </lpage>
        <pub-id pub-id-type="pmid">
         28864360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0057">
       <label>
        57
       </label>
       <element-citation id="sbref0046" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gilardin
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bayry
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Kaveri
          </surname>
          <given-names>
           S.V.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intravenous immunoglobulin as clinical immune-modulating therapy
        </article-title>
        <source>
         Cmaj
        </source>
        <volume>
         187
        </volume>
        <year>
         2015
        </year>
        <fpage>
         257
        </fpage>
        <lpage>
         264
        </lpage>
        <pub-id pub-id-type="pmid">
         25667260
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0058">
       <label>
        58
       </label>
       <element-citation id="sbref0047" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           Y.S.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Anti-SARS coronavirus agents: a patent review (2008 - present)
        </article-title>
        <source>
         Expert Opin Ther Pat
        </source>
        <volume>
         23
        </volume>
        <year>
         2013
        </year>
        <fpage>
         1337
        </fpage>
        <lpage>
         1348
        </lpage>
        <pub-id pub-id-type="pmid">
         23905913
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0059">
       <label>
        59
       </label>
       <element-citation id="sbref0048" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mair-Jenkins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Saavedra-Campos
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Baillie
          </surname>
          <given-names>
           J.K.
          </given-names>
         </name>
         <name>
          <surname>
           Cleary
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Khaw
          </surname>
          <given-names>
           F.M.
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis
        </article-title>
        <source>
         J Infect Dis
        </source>
        <volume>
         211
        </volume>
        <year>
         2015
        </year>
        <fpage>
         80
        </fpage>
        <lpage>
         90
        </lpage>
        <pub-id pub-id-type="pmid">
         25030060
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <label>
        60
       </label>
       <element-citation id="sbref0049" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           Y.O.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients
        </article-title>
        <source>
         Clin Microbiol Infect
        </source>
        <volume>
         10
        </volume>
        <year>
         2004
        </year>
        <fpage>
         676
        </fpage>
        <lpage>
         678
        </lpage>
        <pub-id pub-id-type="pmid">
         15214887
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0061">
       <label>
        61
       </label>
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           I.F.
          </given-names>
         </name>
         <name>
          <surname>
           To
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yan
          </surname>
          <given-names>
           W.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection
        </article-title>
        <source>
         Clin Infect Dis.
        </source>
        <volume>
         52
        </volume>
        <year>
         2011
        </year>
        <fpage>
         447
        </fpage>
        <lpage>
         456
        </lpage>
        <pub-id pub-id-type="pmid">
         21248066
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0062">
       <label>
        62
       </label>
       <element-citation id="sbref0051" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           GR
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <collab>
          Immune Defenses
         </collab>
        </person-group>
        <comment>
         editor
        </comment>
        <person-group person-group-type="editor">
         <name>
          <surname>
           B
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <edition>
         4th edition
        </edition>
        <year>
         1996
        </year>
        <publisher-name>
         University of Texas Medical Branch at Galveston
        </publisher-name>
        <publisher-loc>
         Galveston (TX)
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bib0063">
       <label>
        63
       </label>
       <element-citation id="sbref0052" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Soo
          </surname>
          <given-names>
           Y.O.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           W.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.K.
          </given-names>
         </name>
         <name>
          <surname>
           Ng
          </surname>
          <given-names>
           M.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Use of convalescent plasma therapy in SARS patients in Hong Kong
        </article-title>
        <source>
         Eur J Clin Microbiol Infect Dis
        </source>
        <volume>
         24
        </volume>
        <year>
         2005
        </year>
        <fpage>
         44
        </fpage>
        <lpage>
         46
        </lpage>
        <pub-id pub-id-type="pmid">
         15616839
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0064">
       <label>
        64
       </label>
       <element-citation id="sbref0053" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zarbock
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Kellum
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Schmidt
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Van Aken
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Wempe
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pavenstadt
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial
        </article-title>
        <source>
         Jama
        </source>
        <volume>
         315
        </volume>
        <year>
         2016
        </year>
        <fpage>
         2190
        </fpage>
        <lpage>
         2199
        </lpage>
        <pub-id pub-id-type="pmid">
         27209269
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <label>
        65
       </label>
       <element-citation id="sbref0054" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Kaushik
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initiating acute dialysis at earlier Acute Kidney Injury Network stage in critically ill patients without traditional indications does not improve outcome: a prospective cohort study
        </article-title>
        <source>
         Nephrology (Carlton)
        </source>
        <volume>
         20
        </volume>
        <year>
         2015
        </year>
        <fpage>
         148
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="pmid">
         25395245
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0066">
       <label>
        66
       </label>
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potential Interventions for Novel Coronavirus in China: A Systematic Review
        </article-title>
        <source>
         Journal of medical virology
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0067">
       <label>
        67
       </label>
       <element-citation id="sbref0056" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           E.L.
          </given-names>
         </name>
         <name>
          <surname>
           Fong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           K.F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The use of an herbal formula by hospital care workers during the severe acute respiratory syndrome epidemic in Hong Kong to prevent severe acute respiratory syndrome transmission, relieve influenza-related symptoms, and improve quality of life: a prospective cohort study
        </article-title>
        <source>
         J Altern Complement Med
        </source>
        <volume>
         11
        </volume>
        <year>
         2005
        </year>
        <fpage>
         49
        </fpage>
        <lpage>
         55
        </lpage>
        <pub-id pub-id-type="pmid">
         15750363
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0068">
       <label>
        68
       </label>
       <element-citation id="sbref0057" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Luo
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Q.L.
          </given-names>
         </name>
         <name>
          <surname>
           Shang
          </surname>
          <given-names>
           Y.X.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           S.B.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Robinson
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs
        </article-title>
        <source>
         Chin J Integr Med.
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0069">
       <label>
        69
       </label>
       <element-citation id="sbref0058" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hemila
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vitamin C intake and susceptibility to pneumonia
        </article-title>
        <source>
         Pediatr Infect Dis J
        </source>
        <volume>
         16
        </volume>
        <year>
         1997
        </year>
        <fpage>
         836
        </fpage>
        <lpage>
         837
        </lpage>
        <pub-id pub-id-type="pmid">
         9306475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <label>
        70
       </label>
       <element-citation id="sbref0059" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nonnecke
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           McGill
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Ridpath
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Sacco
          </surname>
          <given-names>
           R.E.
          </given-names>
         </name>
         <name>
          <surname>
           Lippolis
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Reinhardt
          </surname>
          <given-names>
           T.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves
        </article-title>
        <source>
         J Dairy Sci
        </source>
        <volume>
         97
        </volume>
        <year>
         2014
        </year>
        <fpage>
         5566
        </fpage>
        <lpage>
         5579
        </lpage>
        <pub-id pub-id-type="pmid">
         25022687
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0071">
       <label>
        71
       </label>
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
        </article-title>
        <source>
         Lancet Oncol
        </source>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="bib0072">
       <label>
        72
       </label>
       <element-citation id="sbref0061" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           High
          </surname>
          <given-names>
           K.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nutritional strategies to boost immunity and prevent infection in elderly individuals
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <volume>
         33
        </volume>
        <year>
         2001
        </year>
        <fpage>
         1892
        </fpage>
        <lpage>
         1900
        </lpage>
        <pub-id pub-id-type="pmid">
         11692301
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0073">
       <label>
        73
       </label>
       <element-citation id="sbref0062" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simpson
          </surname>
          <given-names>
           R.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kunz
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Agha
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Graff
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exercise and the Regulation of Immune Functions
        </article-title>
        <source>
         Prog Mol Biol Transl Sci
        </source>
        <volume>
         135
        </volume>
        <year>
         2015
        </year>
        <fpage>
         355
        </fpage>
        <lpage>
         380
        </lpage>
        <pub-id pub-id-type="pmid">
         26477922
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0001">
      <sec id="sec0017">
       <title>
        Declarations
       </title>
       <p id="para0027">
        <bold>
         Funding:
        </bold>
        This study was supported by the grant from National Natural Science Foundation of P.R. China (No. 81800609).
       </p>
       <p id="para0028">
        <bold>
         Ethical Approval:
        </bold>
        Not required
       </p>
      </sec>
      <sec id="sec0018">
       <title>
        Author contributions
       </title>
       <p id="para0029">
        All authors contributed to data collection, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.
       </p>
      </sec>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Eur Radiol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Eur Radiol
      </journal-id>
      <journal-title-group>
       <journal-title>
        European Radiology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0938-7994
      </issn>
      <issn pub-type="epub">
       1432-1084
      </issn>
      <publisher>
       <publisher-name>
        Springer Berlin Heidelberg
       </publisher-name>
       <publisher-loc>
        Berlin/Heidelberg
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmc">
       7156903
      </article-id>
      <article-id pub-id-type="publisher-id">
       6827
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s00330-020-06827-4
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Chest
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        The role of imaging in 2019 novel coronavirus pneumonia (COVID-19)
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          Wenjing
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sirajuddin
         </surname>
         <given-names>
          Arlene
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zhang
         </surname>
         <given-names>
          Xiaochun
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Liu
         </surname>
         <given-names>
          Guanshu
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Teng
         </surname>
         <given-names>
          Zhongzhao
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff6">
         6
        </xref>
        <xref ref-type="aff" rid="Aff7">
         7
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          Shihua
         </given-names>
        </name>
        <address>
         <email>
          cjr_zhaoshihua@163.com
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          Minjie
         </given-names>
        </name>
        <address>
         <email>
          coolkan@163.com
         </email>
         <email>
          minjie.lu@nih.gov
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
        <xref ref-type="aff" rid="Aff8">
         8
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.413106.1
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0000 9889 6335
         </institution-id>
         <institution>
          Department of Magnetic Resonance Imaging, Fuwai Hospital, National Center for Cardiovascular Diseases,
         </institution>
         <institution>
          Chinese Academy of Medical Sciences and Peking Union Medical College,
         </institution>
        </institution-wrap>
        #167 Beilishi Road, Xicheng District, Beijing, 100037 China
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.49470.3e
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2331 6153
         </institution-id>
         <institution>
          Department of Clinical Medicine,
         </institution>
         <institution>
          Wuhan University,
         </institution>
        </institution-wrap>
        Wuhan, Hubei 430071 China
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.413247.7
         </institution-id>
         <institution>
          Department of Radiology,
         </institution>
         <institution>
          Zhongnan Hospital of Wuhan University,
         </institution>
        </institution-wrap>
        Wuhan, Hubei 430071 China
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.94365.3d
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2297 5165
         </institution-id>
         <institution>
          Department of Health and Human Services, National Heart, Lung and Blood Institute (NHLBI),
         </institution>
         <institution>
          National Institutes of Health (NIH),
         </institution>
        </institution-wrap>
        Bethesda, MD 20892 USA
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.21107.35
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 2171 9311
         </institution-id>
         <institution>
          Department of Radiology,
         </institution>
         <institution>
          Johns Hopkins University School of Medicine,
         </institution>
        </institution-wrap>
        Baltimore, MD 21205 USA
       </aff>
       <aff id="Aff6">
        <label>
         6
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.5335.0
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121885934
         </institution-id>
         <institution>
          Department of Radiology,
         </institution>
         <institution>
          University of Cambridge,
         </institution>
        </institution-wrap>
        Cambridge, UK
       </aff>
       <aff id="Aff7">
        <label>
         7
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.5335.0
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000121885934
         </institution-id>
         <institution>
          Department of Engineering,
         </institution>
         <institution>
          University of Cambridge,
         </institution>
        </institution-wrap>
        Cambridge, CB2 1TN UK
       </aff>
       <aff id="Aff8">
        <label>
         8
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.12527.33
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 0662 3178
         </institution-id>
         <institution>
          Key Laboratory of Cardiovascular Imaging (Cultivation),
         </institution>
         <institution>
          Chinese Academy of Medical Sciences,
         </institution>
        </institution-wrap>
        Beijing, 100037 China
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        15
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <fpage>
       1
      </fpage>
      <lpage>
       9
      </lpage>
      <history>
       <date date-type="received">
        <day>
         10
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         14
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         20
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © European Society of Radiology 2020
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p id="Par1">
        Almost the entire world, not only China, is currently experiencing the outbreak of a novel coronavirus that causes respiratory disease, severe pneumonia, and even death. The outbreak began in Wuhan, China, in December of 2019 and is currently still ongoing. This novel coronavirus is highly contagious and has resulted in a continuously increasing number of infections and deaths that have already surpassed the SARS-CoV outbreak that occurred in China between 2002 and 2003. It is now officially a pandemic, announced by WHO on the 11th of March. Currently, the 2019 novel coronavirus (SARS-CoV-2) can be identified by virus isolation or viral nucleic acid detection; however, false negatives associated with the nucleic acid detection provide a clinical challenge and thus make the imaging examination crucial. Imaging exams have been a main clinical diagnostic criteria for the 2019 novel coronavirus disease (COVID-19) in China. Imaging features of multiple patchy areas of ground glass opacity and consolidation predominately in the periphery of the lungs are characteristic manifestations on chest CT and extremely helpful in the early detection and diagnosis of this disease, which aids prompt diagnosis and the eventual control of this emerging global health emergency.
       </p>
       <p>
        Key Points
       </p>
       <p id="Par2">
        <italic>
         • In December 2019, China, an outbreak of pneumonia caused by a novel, highly contagious coronavirus raised grave concerns and posed a huge threat to global public health.
        </italic>
       </p>
       <p id="Par3">
        <italic>
         • Among the infected patients, characteristic findings on CT imaging include multiple, patchy, ground-glass opacity, crazy-paving pattern, and consolidation shadows, mainly distributed in the peripheral and subpleural areas of both lungs, which are very helpful for the frontline clinicians.
        </italic>
       </p>
       <p id="Par4">
        <italic>
         • Imaging examination has become the indispensable means not only in the early detection and diagnosis but also in monitoring the clinical course, evaluating the disease severity, and may be presented as an important warning signal preceding the negative RT-PCR test results.
        </italic>
       </p>
       <sec>
        <title>
         Electronic supplementary material
        </title>
        <p>
         The online version of this article (10.1007/s00330-020-06827-4) contains supplementary material, which is available to authorized users.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Coronavirus
       </kwd>
       <kwd>
        Pneumonia
       </kwd>
       <kwd>
        Diagnostic imaging
       </kwd>
       <kwd>
        Multidetector computed tomography
       </kwd>
       <kwd>
        Mass chest X-ray
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Construction of Key Laboratory (Cultivation) of Chinese Academy of Medical Sciences
         </institution>
        </funding-source>
        <award-id>
         2019PT310025
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Minjie
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution-wrap>
          <institution-id institution-id-type="FundRef">
           http://dx.doi.org/10.13039/501100001809
          </institution-id>
          <institution>
           National Natural Science Foundation of China
          </institution>
         </institution-wrap>
        </funding-source>
        <award-id>
         81971588 and 81771811
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Minjie
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Capital Clinically Characteristic Applied Research Fund
         </institution>
        </funding-source>
        <award-id>
         Z191100006619021
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Minjie
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          National Foreign Expert Talent Project
         </institution>
        </funding-source>
        <award-id>
         G20190001630
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Minjie
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Education Reform Project of Peking Union Medical College
         </institution>
        </funding-source>
        <award-id>
         10023201900204
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Minjie
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution>
          Clinical and Translational Fund of Chinese Academy of Medical Sciences
         </institution>
        </funding-source>
        <award-id>
         2019XK320063
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Minjie
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Introduction
     </title>
     <p id="Par7">
      In December of 2019, the city of Wuhan, located in the Hubei province of China, became the epicenter of an outbreak of a pneumonia of unknown cause. This pneumonia was later confirmed to be secondary to infection by a novel coronavirus. This virus was originally called the 2019 novel coronavirus (2019-nCoV), but on February 11, 2020, the disease was named COVID-19 by the World Health Organization (WHO), and the virus was named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV). It is believed that the COVID-19 outbreak has a zoonotic origin and began in the Huanan wet seafood wholesale market in Wuhan. SARS-CoV-2 has proven to be extremely contagious and spreads easily from person to person. Cases of COVID-19 have now spread beyond Wuhan to many other provinces in China as well as other countries, which has raised international attention and concern. As of March 12, 2020, more than 81,000 human infections with SARS-CoV-2 and at least 3100 deaths related to COVID-19 have been confirmed in China alone. Although the epidemic situation in China has been relatively under control, the situation outside China is getting worse. So far, the COVID-19 viral disease that has swept into at least 114 countries with more than 60,000 cases diagnosed and more than 4000 people killed is now officially a pandemic, as WHO Director-General Tedros Adhanom Ghebreyesus announced in Geneva on March 11.
     </p>
     <p id="Par8">
      At first, COVID-19 appeared in a few clusters and was more likely to affect persons with advanced age or other comorbidities, but it is now more widespread. Infection can result in severe pneumonia and even fatal respiratory diseases such as acute respiratory distress syndrome (ARDS) [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. The main clinical presentation includes fever, dry cough, fatigue, and malaise and/or non-specific upper respiratory tract infection symptoms that may not be particularly noticeable. As previously reported [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ], patients with severe illness can develop dyspnea and some even developed ARDS and required ICU admission and oxygen therapy. Laboratory findings of patients infected with SARS-CoV-2 include lymphopenia, elevated CRP, and erythrocyte sedimentation rate. Genetic sequencing of SARS-CoV-2 has enabled the rapid development of point-of-care real-time RT-PCR diagnostic tests specific for COVID-19 [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. Novel coronavirus nucleic acids are detected in throat swabs, sputum, lower respiratory tract secretions, and blood. At present, the diagnosis of COVID-19 is primarily based on the patient’s epidemiological history, clinical symptoms, chest imaging findings, and etiological evidence. Viral nucleic acid testing is an important diagnostic criterion; however, it has some limitations. False negatives from viral nucleic acid testing arise from the uneven quantity of detection technology, disease characteristics (asymptomatic patients), and status of epidemic prevention and control, as well as errors in clinical sampling [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ]. COVID-19 is highly contagious; thus, early detection and diagnosis are of paramount importance to isolate suspected cases and contacts to control the outbreak. The challenges in identification of pathogens by viral nucleic acid testing have made some frontline clinicians propose CT as a diagnostic method for identifying COVID-19 patients. This review aims to briefly introduce the novel coronavirus pneumonia and highlight the value of imaging in its diagnosis.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Etiology and epidemiology
     </title>
     <p id="Par9">
      Coronaviruses typically result in respiratory and enteric infections and affect both animals and humans. Six coronavirus species are known to cause human infection, two of which typically can cause severe respiratory illness and fatalities: SARS-CoV (severe acute respiratory syndrome coronavirus) which had an outbreak in Guangdong, China, between 2002 and 2003 and MERS-CoV (Middle East respiratory syndrome coronavirus) which had an outbreak in 2012 outbreaks in the Middle East [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ,
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. By January 7, 2020, Chinese scientists had isolated the novel coronavirus from patients in Wuhan [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. It has been reported [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ] that SARS-CoV-2 was more similar to two bat-derived coronavirus strains (bat-SL-CoVZC45 and bat-SL-CoVZXC21) than to known human-infecting coronaviruses, including the virus that caused the SARS outbreak of 2003. Molecular modeling has shown structural similarity between the receptor-binding domains of SARS-CoV and SARS-CoV-2, which suggests that SARS-CoV-2 may use angiotensin-converting enzyme 2 (ACE 2) as a receptor. The differences of the etiological characteristics among SARS-COV, MERS-COV, and SARS-CoV-2 are shown in Table
      <xref ref-type="table" rid="Tab1">
       1
      </xref>
      .
      <table-wrap id="Tab1">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Etiological characteristics of SARS-COV, MERS-COV, and SARS-CoV-2
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Virus
          </th>
          <th>
           Genus
          </th>
          <th>
           Intermediate host
          </th>
          <th>
           Reservoir host
          </th>
          <th>
           Receptor
          </th>
          <th>
           Origin
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           SARS-COV-2
          </td>
          <td>
           β-coronavirus
          </td>
          <td>
           ?
          </td>
          <td>
           Bat
          </td>
          <td>
           ACE2
          </td>
          <td>
           Wuhan, China
          </td>
         </tr>
         <tr>
          <td>
           SARS-COV
          </td>
          <td>
           β-coronavirus
          </td>
          <td>
           Civet
          </td>
          <td>
           Bat
          </td>
          <td>
           ACE2
          </td>
          <td>
           Guangzhou, China
          </td>
         </tr>
         <tr>
          <td>
           MERS-COV
          </td>
          <td>
           β-coronavirus
          </td>
          <td>
           Dromedary
          </td>
          <td>
           Bat
          </td>
          <td>
           CD26/DPP4
          </td>
          <td>
           Saudi Arabia
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="Par10">
      On December 31, 2019, the Health Commission of Hubei province in China announced that 27 patients were afflicted with this mysterious disease, which was subsequently discovered to be COVID-19. The outbreak is believed to zoonotic in origin and likely started at the Huanan wet seafood wholesale market in Wuhan. SARS-CoV-2 is highly contagious and the basic reproductive number of the virus was estimated to be 2·2 [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ,
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. COVID-19 has spread beyond Wuhan to other cities in China and other countries. In recent days, there is a significant growth trend in other countries, especially in South Korea, Japan, Italy, and Iran. The current global situation as of March 13 2020, of COVID-19 is shown in Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      .
      <fig id="Fig1">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Countries, territories, and areas with reported confirmed cases of COVID-19, as of March 13, 2020.
         <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">
          https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
         </ext-link>
        </p>
       </caption>
       <graphic id="MO1" xlink:href="330_2020_6827_Fig1_HTML">
       </graphic>
      </fig>
     </p>
     <p id="Par11">
      In the available reports, the bat is the most possible host of the SARS-CoV-2 and another animal may act as an intermediate host between bats and humans [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="CR11">
       11
      </xref>
      ]. To this point, the main infection sources were the patients infected with SARS-CoV-2. COVID-19 mainly spread via human-to-human transmission through respiratory droplets and contact. The human population in general is susceptible, while the elderly as well as people with underlying diseases show more serious conditions after infection [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. Although most people were reported to have a good prognosis of COVID-19, it is unknown whether there are potential impacts on the patients in the future and the sequelae are not available. In the case of the SARS outbreak, significant impact on pulmonary function, functional capacity, and quality of life was found during patient follow-up [
      <xref ref-type="bibr" rid="CR13">
       13
      </xref>
      ,
      <xref ref-type="bibr" rid="CR14">
       14
      </xref>
      ]. The additional and detailed information about “Etiology and Epidemiology” is provided in
      <xref ref-type="media" rid="MOESM1">
       Electronic Supplementary Material (ESM)
      </xref>
      .
     </p>
    </sec>
    <sec id="Sec3">
     <title>
      Imaging features
     </title>
     <p id="Par12">
      According to current diagnostic criteria, identification of the viral pathogen via nucleic acid detection (usually from swab test) is considered as the gold standard and formative assessment for the diagnosis of COVID-19 [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. However, due to various problems of virus detection in the clinical setting such as a shortage of supply test kits, irregular sampling of samples, laboratory error, insufficient viral material in the specimen, improper extraction of nucleic acid from clinical materials, and contaminatory and technical problems, there have been false negatives. Health care workers on the front line have found the diagnostic value of imaging to be increasingly valuable, which has translated over into clinical diagnosis of COVID-19 patients [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      ]. In the clinical work of this epidemic, the radiologists play a crucial role in the rapid identification and early diagnosis of a suspected patient—this can be of great benefit not only to the patient but also to the larger public health surveillance and response systems.
     </p>
     <sec id="Sec4">
      <title>
       Chest radiograph
      </title>
      <p id="Par13">
       Chest radiograph of COVID-19 is not routinely recommended in clinical practice currently because they are insensitive to detecting COVID-19 in the early stage. However, chest radiography may have some utility, with the potential to serve as a screening tool on the frontlines in medical settings with limited resources or in cases where the patient’s physical condition does not allow for transport to the radiology department CT scanner. As the disease progresses beyond the early stage, chest radiography can detect multiple patchy opacities throughout the lungs. These opacities eventually become confluent and severe cases may appear as a “whited out lung” [
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ]. In more advanced cases, in addition to the ground glass opacity and consolidation, even pleural fluid (in a severe case) has been reported on the chest radiographs [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ,
       <xref ref-type="bibr" rid="CR16">
        16
       </xref>
       ]. Progressive opacities and consolidation have been observed on chest radiographs over the time course of the illness [
       <xref ref-type="bibr" rid="CR17">
        17
       </xref>
       ]. In the first case of COVID-19 reported in the USA, there were no obvious abnormalities on the chest radiograph during the early stages after the onset of symptoms. However, on day 9 of the illness, an increased area left basilar opacity was visible on chest radiography. Then, stable streaky opacities in the lung bases were visible, and the opacities have steadily increased over time [
       <xref ref-type="bibr" rid="CR18">
        18
       </xref>
       ].
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Chest computed tomography
      </title>
      <p id="Par14">
       Computed tomography (CT) imaging is strongly recommended because it is very sensitive to detecting early disease, assessing the nature and extent of lesions, and discovering subtle changes that are often not visible on chest radiography. The imaging features of lesions are always described with the following factors: distribution, quantity, shape, pattern, density, and concomitant signs [
       <xref ref-type="bibr" rid="CR19">
        19
       </xref>
       ].
      </p>
      <p id="Par15">
       The typical chest CT imaging characteristics of COVID-19 include multiple, peripheral, bilateral, patchy, sub-segmental, or segmental ground glass opacities and areas of consolidation, which are mostly distributed along the bronchovascular bundles and subpleural space. The presence of associated interlobular septal thickening in the areas of ground glass opacity can give a crazy paving appearance. Air bronchograms with the areas of consolidation and bronchial wall thickening are often present. More rarely, there is a thickening of the adjacent pleura or interlobar pleura, and a small amount of pleural effusion. There is no obvious lymphadenopathy [
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ] (Tables
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ,
       <xref ref-type="table" rid="Tab3">
        3
       </xref>
       ). The imaging features mentioned above are consistent with the findings from 81 patients in a recently reported article, in which the predominant pattern of abnormality observed was bilateral, peripheral, ill-defined, and ground glass opacification, mainly involving the right lower lobes [
       <xref ref-type="bibr" rid="CR20">
        20
       </xref>
       ]. Furthermore, in the currently available reports, the most common chest CT findings in COVID-19 patients are the peripheral areas of ground glass opacity/consolidation (without subpleural sparing) which are bilateral in distribution [
       <xref ref-type="bibr" rid="CR21">
        21
       </xref>
       –
       <xref ref-type="bibr" rid="CR23">
        23
       </xref>
       ]. In one study, of 21 patients, most had more than two lobes affected (15 of 21, 71%) with bilateral involvement (16 of 21, 76%) [
       <xref ref-type="bibr" rid="CR24">
        24
       </xref>
       ]. Another study showed that the most common patterns of COVID-19 on thin-section CT images are pure ground glass opacity, ground glass opacity with intra- and/or interlobular septal thickening, and ground glass opacity with consolidation and consolidation, with prominent distribution in the posterior and peripheral part of the lungs [
       <xref ref-type="bibr" rid="CR25">
        25
       </xref>
       ]. In a large research cohort study, chest CT findings showed a bilateral distribution of patchy ground glass opacity and consolidation in 138 patients [
       <xref ref-type="bibr" rid="CR26">
        26
       </xref>
       ]. Typical chest radiograph and chest CT of COVID-19 are shown in Figs.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       and
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       .
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          The typical features on CT imaging of COVID-19
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Parameter
           </th>
           <th>
            Characteristic manifestations on CT imaging
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Density
           </td>
           <td>
            Ground glass opacity and consolidation, possible interlobular septal thickening
           </td>
          </tr>
          <tr>
           <td>
            Shape
           </td>
           <td>
            Patchy, sub-segmental, or segmental
           </td>
          </tr>
          <tr>
           <td>
            Distribution
           </td>
           <td>
            Mid and lower lungs along the bronchovascular bundles with bilateral involvement
           </td>
          </tr>
          <tr>
           <td>
            Location
           </td>
           <td>
            Peripheral and subpleural areas of the lung parenchyma
           </td>
          </tr>
          <tr>
           <td>
            Concomitant signs (variable)
           </td>
           <td>
            Air bronchogram, a small amount of pleural effusion, no obvious lymphadenopathy
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
       <table-wrap id="Tab3">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Frequency of chest CT findings in COVID-19
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            CT signs
           </th>
           <th>
            Frequency
           </th>
           <th>
            Stage
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Ground glass opacity
           </td>
           <td>
            ++++
           </td>
           <td>
            E/A/S
           </td>
          </tr>
          <tr>
           <td>
            Consolidation without ground glass opacity
           </td>
           <td>
            ++
           </td>
           <td>
            S
           </td>
          </tr>
          <tr>
           <td>
            Ground glass opacity and crazy paving
           </td>
           <td>
            ++
           </td>
           <td>
            E/A/S
           </td>
          </tr>
          <tr>
           <td>
            Ground glass opacity with consolidation
           </td>
           <td>
            +++
           </td>
           <td>
            E/A/S
           </td>
          </tr>
          <tr>
           <td>
            Patchy ground glass opacity
           </td>
           <td>
            +++
           </td>
           <td>
            E
           </td>
          </tr>
          <tr>
           <td>
            Bilateral distribution
           </td>
           <td>
            ++++
           </td>
           <td>
            E/A/S/D
           </td>
          </tr>
          <tr>
           <td>
            Peripheral distribution
           </td>
           <td>
            +++
           </td>
           <td>
            E
           </td>
          </tr>
          <tr>
           <td>
            Air bronchogram
           </td>
           <td>
            ++
           </td>
           <td>
            E/A/S
           </td>
          </tr>
          <tr>
           <td>
            Pleural effusion
           </td>
           <td>
            +
           </td>
           <td>
            S
           </td>
          </tr>
          <tr>
           <td>
            Strip-like opacity
           </td>
           <td>
            +
           </td>
           <td>
            D
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          The appearance frequency of each CT characteristic is described in order from low to high as (+~++++);
          <italic>
           E
          </italic>
          ,
          <italic>
           A
          </italic>
          ,
          <italic>
           S
          </italic>
          , and
          <italic>
           D
          </italic>
          stand for stage early, advanced, severe, and dissipation
         </p>
        </table-wrap-foot>
       </table-wrap>
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Chest radiograph (
          <bold>
           a
          </bold>
          ) in a 61-year-old man shows bilateral patchy, somewhat nodular opacities in the mid to lower lungs [
          <xref ref-type="bibr" rid="CR16">
           16
          </xref>
          ]. Unenhanced computed tomography (CT) images (
          <bold>
           b
          </bold>
          ) in a 33-year-old woman.
          <italic>
           ,
          </italic>
          Images show multiple ground glass opacities in the periphery of the bilateral lungs. The bilateral, peripheral patterns of opacities without subpleural sparing are common and characteristic CT findings of the 2019 novel coronavirus pneumonia [
          <xref ref-type="bibr" rid="CR22">
           22
          </xref>
          ]. Chest CT image of a 71-year-old male (
          <bold>
           c
          </bold>
          ) shows consolidation in the peripheral right upper lobe and a patchy area of ground glass opacity with some associated consolidation intra- and interlobular septal thickening within the left upper lobe [
          <xref ref-type="bibr" rid="CR25">
           25
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO2" xlink:href="330_2020_6827_Fig2_HTML">
        </graphic>
       </fig>
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Typical CT findings of COVID-19. Chest CT (
          <bold>
           a
          </bold>
          ) in a 75-year-old male show multiple patchy areas of pure ground glass opacity (GGO) and GGO with reticular and/or interlobular septal thickening [
          <xref ref-type="bibr" rid="CR25">
           25
          </xref>
          ]. Chest CT image of a 38-year-old male (
          <bold>
           b
          </bold>
          ) shows multiple patches, grid-like lobule, and thickening of interlobular septa, typical “paving stone-like” signs [
          <xref ref-type="bibr" rid="CR19">
           19
          </xref>
          ]. An axial CT image obtained in 65-year-old female (
          <bold>
           c
          </bold>
          ) shows bilateral ground glass and consolidative opacities with a striking peripheral distribution [
          <xref ref-type="bibr" rid="CR23">
           23
          </xref>
          ]. CT image of a 65-year-old male (
          <bold>
           d
          </bold>
          ) shows large consolidation in the right middle lobe, patchy consolidation in the posterior and basal segment of right lower lobe, with air bronchogram inside [
          <xref ref-type="bibr" rid="CR19">
           19
          </xref>
          ]
         </p>
        </caption>
        <graphic id="MO3" xlink:href="330_2020_6827_Fig3_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par16">
       In “Expert Recommendations from the Chinese Medical Association Radiology Branch,” chest CT manifestations of COVID-19 are divided into three stages: early, advanced, and severe, based on the extent of lesion involvement [
       <xref ref-type="bibr" rid="CR15">
        15
       </xref>
       ]. This current clinical guideline recommends dividing COVID-19 into four stages according to the time of onset and the response of body to the virus with additional dissipation stage (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       ).
       <list list-type="order">
        <list-item>
         <p id="Par17">
          Early stage: Chest CT shows single or multiple scattered patchy or conglomerate ground glass opacities, predominantly in the middle and lower lungs and along the bronchovascular bundles. These ground glass lesions are often located in peripheral and subpleural areas of the lung. Intra- and interlobular septal thickening sometimes present in the areas of ground glass opacity can give a crazy paving pattern. The pathological process during this stage is dilatation and congestion of the alveolar septal capillary, exudation of fluid in alveolar cavity, and interlobular interstitial edema [
          <xref ref-type="bibr" rid="CR19">
           19
          </xref>
          ]. One patient had normal chest CT at initial presentation; however, 3 days later the disease progressed and developed a solitary rounded ground glass lesion in the right lower lobe, indicating this pattern may represent the very first radiologically visible manifestation in patients infected with SARS-CoV-2 [
          <xref ref-type="bibr" rid="CR24">
           24
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p id="Par18">
          Advanced stage: At this stage, chest CTs will show new lesions that are similar to the earlier lesions described above. In addition, findings from the early stage of disease increase in density and extent, coexisting with the new areas of disease. As areas of consolidation grow, air bronchograms are often present in the areas of consolidation. A previous case report described a patient who had evolved into a mixed pattern of ground glass opacities and consolidation by 15 after onset of symptoms [
          <xref ref-type="bibr" rid="CR27">
           27
          </xref>
          ]. The pathological features in this stage are the accumulation of a cell-rich exudate in the alveolar cavity, vascular expansion, and exudation in the interstitium. The fibrous exudation connects each alveolus through the interalveolar space to form a fusion state [
          <xref ref-type="bibr" rid="CR19">
           19
          </xref>
          ].
         </p>
        </list-item>
        <list-item>
         <p id="Par19">
          Severe stage: As the disease further progresses, chest CT shows diffuse consolidation of the lungs of varying density secondary to the fibrous exudate into the alveolar cavity, air bronchograms, and bronchial dilation. Non-consolidated areas of the lung appear as patchy ground glass opacity. When most of the lungs are involved, the lungs appear as a “whited out lung.” The pleura is thickened and there can be a small amount of pleural effusion.
         </p>
        </list-item>
        <list-item>
         <p id="Par20">
          Dissipation stage: Images show gradual resolution of the ground glass opacity and consolidation in the lungs with some residual curvilinear opacities compatible with fibrosis.
         </p>
        </list-item>
       </list>
       <fig id="Fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          CT manifestations of different stages of COVID-19
         </p>
        </caption>
        <graphic id="MO4" xlink:href="330_2020_6827_Fig4_HTML">
        </graphic>
       </fig>
      </p>
      <p id="Par21">
       After isolation and treatment, a majority of patients infected by COVID-19 stabilize and gradually recover and on imaging the areas of disease decrease correspondingly. However, in a small number of patients with underlying disease or advanced age, the disease progresses during the treatment with the scope of the lesions in the lungs expanding and increasing density, eventually appearing as “whited out lungs.”
      </p>
     </sec>
    </sec>
    <sec id="Sec6">
     <title>
      Role of imaging in COVID-19
     </title>
     <p id="Par22">
      On the frontlines of fighting the COVID-19 epidemic, chest imaging (particularly chest CT) now has an irreplaceable role in the early diagnosis of COVID-19 as well as monitoring the disease’s clinical course. COVID-19 has characteristic manifestations in the lung that are readily detected on chest CT as described in some recent publications [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ,
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. In several prior reports, chest CT showed progression of disease that corresponded with worsening clinical symptoms and also disease resolution as the patients clinically recovered [
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="CR27">
       27
      </xref>
      ]. In a recent report [
      <xref ref-type="bibr" rid="CR20">
       20
      </xref>
      ], the predominant pattern of abnormality in COVID-19 observed on the basis of the interval between symptom onset and the first CT scan has some differences. Lesions quickly evolved from focal unilateral to diffuse bilateral ground glass opacities that progressed to or co-existed with consolidations within 1–3 weeks, indicating the change through clinical course which was also reflected on the number of involved lung segments. In a prior study of 51 patients, the absolute number of lung findings increased with the time from symptom onset and lesions with consolidations including ground glass opacities with consolidation and pure consolidation showed mildly positive correlation with the time between symptom onset and the CT [
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. Another report demonstrated mild or moderate progression of disease as manifested by increasing extent and density of lung opacities during follow-up [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ]. In the context of typical clinical presentation and exposure history, some patients may present with negative results of RT-PCR for COVID-19 but have characteristic imaging features of COVID-19 on chest CT. Subsequently, these patients whose labs were initially negative for COVID-19 did test positive later with repeat swab tests. Thus, in patients at high risk for COVID-19, chest CT evidence of viral pneumonia may precede negative RT-PCR test results and present as an important warning signal. A combination of repeated swab tests and CT scanning may be helpful for individuals with high clinical suspicion of COVID-19 but negative RT-PCR screening [
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]. Chest CT has a high sensitivity for diagnosis of COVID-19. In a report of 51 patients with chest CT and RT-PCR assay performed within 3 days, the sensitivity of chest CT was greater than that of RT-PCR for COVID-19 at initial patient presentation (98% vs 71%, respectively,
      <italic>
       p
      </italic>
      &lt; 0.001) [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ]. In another study of 1014 patients, 59% had positive RT-PCR results, and 88% had positive chest CT scans. The sensitivity of chest CT in suggesting COVID-19 was 97% based on positive RT-PCR results. Between 60% and 93% of cases had initial positive CT consistent with COVID-19 prior (or parallel) to the initial positive RT-PCR results [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ]. In addition, chest CT can evaluate disease severity. In terms of the percentage of pneumonia lesions in the entire lung volume, the difference between the earlier stage patients and the severe stage patients is statistically significant [
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ]. In an initial prospective analysis of the clinical features of 41 patients, chest CT images of ICU patients on admission showed bilateral multiple lobular and subsegmental areas of consolidation, and overall had more imaging abnormalities than non-ICU patients [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. Older patients may have more systemic symptoms, more extensive lung involvement, and worse prognosis than younger patients [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ]. Thus, the typical CT findings of COVID-19 can not only help early screening suspected cases, but can also monitor the clinical progression and may predict severe complications such as acute respiratory diseases. With high sensitivity for COVID-19, chest CT would play a very important role in the diagnosis and treatment of COVID-19 in the high-risk regions and countries. In some extreme situations in very high-risk areas (Wuhan, China), CT was the one of main diagnostic criteria for this disease due to the relatively high false negative of RT-PCR. For some low-risk regions and countries, positive predictive value of CT alone or adding CT to RT-PCR should be adjusted. The proposition of CT could be tempered to some degree. Therefore, to be more accurate, the role of chest CT in COVID-19 should be assessed based on the prevalence of the disease in each area.
     </p>
    </sec>
    <sec id="Sec7">
     <title>
      Differential diagnosis
     </title>
     <p id="Par23">
      The CT appearance of COVID-19 shares some similarities with other diseases that cause viral pneumonia, including influenza viruses, parainfluenza virus, adenovirus, respiratory syncytial virus, rhinovirus, human metapneumovirus, etc. (Table
      <xref ref-type="table" rid="Tab4">
       4
      </xref>
      ). In particular, those within the same viridae (SARS and MERS) have great similarities in imaging findings because they belong to the same coronaviridae family, and thus need to be excluded through clinical manifestations and laboratory pathogen detection. Imaging in MERS pneumonia can also show ground glass lesions in the subpleural and basal parts with consolidation, and fibrosis changes can be left after healing [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. In the pneumonia patients infected by respiratory syncytial virus, chest CT mainly manifested as small centrilobular nodules and areas of consolidation which are often asymmetrically distributed in the lungs. Adenovirus pneumonia shows bilateral multifocal ground glass opacities with patchy consolidations on CT images and may show lobar or segmental distribution. Human parainfluenza virus pneumonia may show centrilobular nodules with bronchial wall thickening that differentiates it from the imaging appearances of the other viruses. Radiographs in patients with influenza pneumonia show bilateral patchy areas of ground glass opacity with or without focal areas of consolidation, usually in the lower lobes [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. In a report on H1N1 influenza infection, in addition to the most common findings of ground glass opacity, interlobular septal thickening, and centrilobular nodules were the second most frequent findings [
      <xref ref-type="bibr" rid="CR35">
       35
      </xref>
      ]. Rapidly progressive ground glass opacities and consolidations with air bronchograms and interlobular septal thickening, with right lower lobe predominance, are the main imaging findings in H7N9 pneumonia [
      <xref ref-type="bibr" rid="CR36">
       36
      </xref>
      ]. Viruses are a common cause of respiratory infection and recognition of viral pneumonia patterns may help in the differentiation among viral pathogens, while the definite diagnosis is achieved by laboratory detection of virus.
      <table-wrap id="Tab4">
       <label>
        Table 4
       </label>
       <caption>
        <p>
         Differential diagnosis of different viral pneumonia
        </p>
       </caption>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
           Virus
          </th>
          <th>
           Imaging characteristics
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td>
           MERS-COV
          </td>
          <td>
           Ground glass lesions in the subpleural and basal portions of the lung parenchyma with areas of consolidation; fibrotic changes can be present after healing
          </td>
         </tr>
         <tr>
          <td>
           H1N1
          </td>
          <td>
           Ground glass opacity, interlobular septal thickening, and centrilobular nodules
          </td>
         </tr>
         <tr>
          <td>
           H7N9
          </td>
          <td>
           Ground glass opacity and consolidation with air bronchograms and interlobular septal thickening
          </td>
         </tr>
         <tr>
          <td>
           Human parainfluenza virus
          </td>
          <td>
           Centrilobular nodules with bronchial wall thickening, findings which differentiate it from other viral infections
          </td>
         </tr>
         <tr>
          <td>
           Respiratory syncytial virus
          </td>
          <td>
           Small centrilobular nodules and areas of parenchymal consolidation; asymmetrically distributed in the lungs
          </td>
         </tr>
         <tr>
          <td>
           Adenovirus pneumonia
          </td>
          <td>
           Bilateral multifocal ground glass opacities, patchy consolidation in a lobar and/or segmental distribution
          </td>
         </tr>
        </tbody>
       </table>
      </table-wrap>
     </p>
     <p id="Par24">
      In addition, COVID-19 also needs to be distinguished from mycoplasma pneumonia, chlamydia pneumonia, and bacterial pneumonia. Other diseases that need to be identified are vasculitis, acute interstitial pneumonia, connective tissue-related lung disease, and cryptogenic organizing pneumonia [
      <xref ref-type="bibr" rid="CR15">
       15
      </xref>
      ].
     </p>
    </sec>
    <sec id="Sec8">
     <title>
      Conclusions
     </title>
     <p id="Par25">
      The COVID-19 initially began in China; however, it is extremely contagious and has spread beyond China to many other countries, raising concerns and posing not only a huge threat to global public health but also a huge economic burden and panic to society. Early disease recognition can prompt early patient isolation and early diagnosis and treatment. In the current situation, imaging of COVID-19, particularly with chest CT, has a very high value because it shows characteristic manifestations and has enabled frontline clinicians to have primary diagnosis in their first contact with suspected patients, even in the presence of initially false negative lab results. Earlier diagnosis with the aid of imaging allows for early containment and response to this communicable disease as well as overcoming the outbreak as soon as possible through a joint effort.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Electronic supplementary material
     </title>
     <sec id="Sec9">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="330_2020_6827_MOESM1_ESM.docx">
         <label>
          ESM 1
         </label>
         <caption>
          <p>
           (DOCX 39 kb)
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        <bold>
         Publisher’s note
        </bold>
       </p>
       <p>
        Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
       </p>
      </fn>
     </fn-group>
     <ack>
      <p>
       We are very grateful to the worldwide front-line medical staff for their dedication in the fighting against the outbreak of COVID-19, despite the potential threat to their own lives and the lives of their families. And we also believe this pandemic will be controlled by the efforts of all mankind.
      </p>
     </ack>
     <notes notes-type="funding-information">
      <title>
       Funding information
      </title>
      <p>
       This study was funded by Construction of Key Laboratory (Cultivation) of Chinese Academy of Medical Sciences(2019PT310025), National Foreign Expert Talent Project (G20190001630), Education Reform Project of Peking Union Medical College (10023201900204), and Clinical and Translational Fund of Chinese Academy of Medical Sciences (2019XK320063).
      </p>
     </notes>
     <notes notes-type="ethics">
      <title>
       Compliance with ethical standards
      </title>
      <notes>
       <title>
        Guarantor
       </title>
       <p id="Par26">
        The scientific guarantor of this publication is Minjie Lu.
       </p>
      </notes>
      <notes notes-type="COI-statement">
       <title>
        Conflict of interest
       </title>
       <p id="Par27">
        The authors have no conflict of interest to disclose.
       </p>
      </notes>
      <notes>
       <title>
        Statistics and biometry
       </title>
       <p id="Par28">
        No complex statistical methods were necessary for this paper.
       </p>
      </notes>
      <notes>
       <title>
        Informed consent
       </title>
       <p id="Par29">
        Written informed consent was not required for this study because this is a review of literature.
       </p>
      </notes>
      <notes>
       <title>
        Ethical approval
       </title>
       <p id="Par30">
        Institutional Review Board approval was not required because this is a review of literature.
       </p>
      </notes>
      <notes>
       <title>
        Methodology
       </title>
       <p id="Par31">
        • N/A
       </p>
      </notes>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30183-5
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Horby
          </surname>
          <given-names>
           PW
          </given-names>
         </name>
         <name>
          <surname>
           Hayden
          </surname>
          <given-names>
           FG
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           GF
          </given-names>
         </name>
        </person-group>
        <article-title>
         A novel coronavirus outbreak of global health concern
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         470
        </fpage>
        <lpage>
         473
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30185-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="other">
        Yu F, Du L, Ojcius DM, Pan C, Jiang S (2020) Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 10.1016/j.micinf.2020.01.003
       </mixed-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mo
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Fei
          </surname>
          <given-names>
           QH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Correctly understand the influencing factors of nucleic acid detection of novel coronavirus
        </article-title>
        <source>
         Chin J Lab Med
        </source>
        <year>
         2020
        </year>
        <volume>
         43
        </volume>
        <issue>
         00
        </issue>
        <fpage>
         E002
        </fpage>
        <lpage>
         E002
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <issue>
         20
        </issue>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030781
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <issue>
         19
        </issue>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="other">
        Lu R, Zhao X, Li J et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 10.1016/s0140-6736(20)30251-8
       </mixed-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="other">
        Li Q, Guan X, Wu P et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 10.1056/NEJMoa2001316
       </mixed-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="other">
        Riou J, Althaus CL (2020) Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill 25(4)
       </mixed-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        Zhou P, Yang XL, Wang XG et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 10.1038/s41586-020-2012-7
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="other">
        General Office of National Health Committee (2020) Office of State Administration of Traditional Chinese Medicine. Notice on the issuance of a programme for the diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia (Trial Version 5)
       </mixed-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hui
          </surname>
          <given-names>
           DS
          </given-names>
         </name>
         <name>
          <surname>
           Joynt
          </surname>
          <given-names>
           GM
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           KT
          </given-names>
         </name>
         <name>
          <surname>
           Gomersall
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors
        </article-title>
        <source>
         Thorax
        </source>
        <year>
         2005
        </year>
        <volume>
         60
        </volume>
        <issue>
         5
        </issue>
        <fpage>
         401
        </fpage>
        <lpage>
         409
        </lpage>
        <pub-id pub-id-type="doi">
         10.1136/thx.2004.030205
        </pub-id>
        <pub-id pub-id-type="pmid">
         15860716
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Hui DS, Wong KT, Antonio GE, Tong M, Chan DP, Sung J (2009) Long-term sequelae of SARS: physical, neuropsychiatric, and quality-of-life assessment. Hong Kong Med J 15(Suppl 8)
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Chinese Medical Association Radiology Branch
         </collab>
        </person-group>
        <article-title>
         Radiological diagnosis of new coronavirus pneumonia: expert recommendations from the Chinese Medical Association Radiology Branch (first edition)
        </article-title>
        <source>
         Chin J Radiol
        </source>
        <year>
         2020
        </year>
        <volume>
         54
        </volume>
        <issue>
         00
        </issue>
        <fpage>
         E001
        </fpage>
        <lpage>
         E001
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        Zhu N, Zhang DY, Wang WL et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 10.1056/NEJMoa2001017
       </mixed-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="other">
        Phan LT, Nguyen TV, Luong QC et al (2020) Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 10.1056/NEJMc2001272
       </mixed-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="other">
        Holshue ML, DeBolt C, Lindquist S et al (2020) First case of 2019 novel coronavirus in the United States. N Engl J Med. 10.1056/NEJMoa2001191
       </mixed-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           YH
          </given-names>
         </name>
         <name>
          <surname>
           Cai
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           ZS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)
        </article-title>
        <source>
         Mil Med Res
        </source>
        <year>
         2020
        </year>
        <volume>
         7
        </volume>
        <issue>
         1
        </issue>
        <fpage>
         4
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/s40779-020-0233-6
        </pub-id>
        <pub-id pub-id-type="pmid">
         32029004
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="other">
        Shi H, Han X, Jiang N et al (2020) Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 10.1016/s1473-3099(20)30086-4
       </mixed-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="other">
        Duan YN, Qin J (2020) Pre- and posttreatment chest CT findings: 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 10.1148/radiol.2020200323
       </mixed-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="other">
        Lei J, Li J, Qi X (2020) CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 10.1148/radiol.2020200236
       </mixed-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="other">
        Bernheim A, Mei X, Huang MQ et al (2020) Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 10.1148/radiol.2020200463
       </mixed-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="other">
        Chung M, Bernheim A, Mei X et al (2020) CT imaging features of 2019 novel coronavirus (2019-nCoV). Radiology. 10.1148/radiol.2020200230
       </mixed-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="other">
        Song FX, Shi NN, Shan F, Zhang ZY, Shen J et al (2020) Emerging coronavirus 2019-nCoV pneumonia. Radiology. 10.1148/radiol.2020200274
       </mixed-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="other">
        Wang D, Hu B, Hu C et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 10.1001/jama.2020.1585
       </mixed-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        Shi H, Han X, Zheng C (2020) Evolution of CT manifestations in a patient recovered from 2019 novel coronavirus (2019-nCoV) pneumonia in Wuhan, China. Radiology. 10.1148/radiol.2020200269
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="other">
        Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J (2020) Chest CT for typical 2019-nCoV pneumonia: relationship to negative RT-PCR testing. Radiology. 10.1148/radiol.2020200343
       </mixed-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        Huang P, Liu T, Huang L et al (2020) Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 10.1148/radiol.2020200330
       </mixed-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        Fang Y, Zhang HQ, Xie J et al (2020) Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 10.1148/radiol.2020200432
       </mixed-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="other">
        Ai T, Yang Z, Hou HY et al (2020) Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 10.1148/radiol.2020200642
       </mixed-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           PX
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Correlation between CT and clinical manifestations of different clinical types of new coronavirus pneumonia
        </article-title>
        <source>
         Chin J Radiol
        </source>
        <year>
         2020
        </year>
        <volume>
         54
        </volume>
        <issue>
         00
        </issue>
        <fpage>
         E003
        </fpage>
        <lpage>
         E003
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           JF-W
          </given-names>
         </name>
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Kok
          </surname>
          <given-names>
           K-H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <issue>
         10223
        </issue>
        <fpage>
         514
        </fpage>
        <lpage>
         523
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30154-9
        </pub-id>
        <pub-id pub-id-type="pmid">
         31986261
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Koo
          </surname>
          <given-names>
           HJ
          </given-names>
         </name>
         <name>
          <surname>
           Lim
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Choe
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <name>
          <surname>
           Sung
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Do
          </surname>
          <given-names>
           KH
          </given-names>
         </name>
        </person-group>
        <article-title>
         Radiographic and CT features of viral pneumonia
        </article-title>
        <source>
         Radiographics
        </source>
        <year>
         2018
        </year>
        <volume>
         38
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         719
        </fpage>
        <lpage>
         739
        </lpage>
        <pub-id pub-id-type="doi">
         10.1148/rg.2018170048
        </pub-id>
        <pub-id pub-id-type="pmid">
         29757717
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yuan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           XF
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           YX
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           JQ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Initial HRCT findings of novel influenza A (H1N1) infection
        </article-title>
        <source>
         Influenza Other Respi Viruses
        </source>
        <year>
         2012
        </year>
        <volume>
         6
        </volume>
        <issue>
         6
        </issue>
        <fpage>
         e114
        </fpage>
        <lpage>
         e119
        </lpage>
        <pub-id pub-id-type="doi">
         10.1111/j.1750-2659.2012.00368.x
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           QL
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           ZY
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           YX
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           YB
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings
        </article-title>
        <source>
         Radiology
        </source>
        <year>
         2013
        </year>
        <volume>
         268
        </volume>
        <issue>
         3
        </issue>
        <fpage>
         882
        </fpage>
        <lpage>
         889
        </lpage>
        <pub-id pub-id-type="doi">
         10.1148/radiol.13130988
        </pub-id>
        <pub-id pub-id-type="pmid">
         23821754
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Virus Res
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Virus Res
      </journal-id>
      <journal-title-group>
       <journal-title>
        Virus Research
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0168-1702
      </issn>
      <issn pub-type="epub">
       1872-7492
      </issn>
      <publisher>
       <publisher-name>
        Elsevier B.V.
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       27086031
      </article-id>
      <article-id pub-id-type="pmc">
       7114557
      </article-id>
      <article-id pub-id-type="publisher-id">
       S0168-1702(16)30156-3
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.virusres.2016.04.009
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Porcine deltacoronavirus infection: Etiology, cell culture for virus isolation and propagation, molecular epidemiology and pathogenesis
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="aut0005">
        <name>
         <surname>
          Jung
         </surname>
         <given-names>
          Kwonil
         </given-names>
        </name>
        <email>
         jung.221@osu.edu
        </email>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0010">
        <name>
         <surname>
          Hu
         </surname>
         <given-names>
          Hui
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="aff" rid="aff0010">
         b
        </xref>
       </contrib>
       <contrib contrib-type="author" id="aut0015">
        <name>
         <surname>
          Saif
         </surname>
         <given-names>
          Linda J.
         </given-names>
        </name>
        <email>
         saif.2@osu.edu
        </email>
        <xref ref-type="aff" rid="aff0005">
         a
        </xref>
        <xref ref-type="corresp" rid="cor0005">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff0005">
       <label>
        a
       </label>
       Food Animal Health Research Program, Ohio Agricultural Research and Development Center, Department of Veterinary Preventive Medicine, The Ohio State University, Wooster, OH, USA
      </aff>
      <aff id="aff0010">
       <label>
        b
       </label>
       College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou, China
      </aff>
      <author-notes>
       <corresp id="cor0005">
        <label>
         ⁎
        </label>
        Corresponding authors.
        <email>
         jung.221@osu.edu
        </email>
        <email>
         saif.2@osu.edu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        13
       </day>
       <month>
        4
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <day>
        2
       </day>
       <month>
        12
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        13
       </day>
       <month>
        4
       </month>
       <year>
        2016
       </year>
      </pub-date>
      <volume>
       226
      </volume>
      <fpage>
       50
      </fpage>
      <lpage>
       59
      </lpage>
      <history>
       <date date-type="received">
        <day>
         7
        </day>
        <month>
         3
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         7
        </day>
        <month>
         4
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="accepted">
        <day>
         8
        </day>
        <month>
         4
        </month>
        <year>
         2016
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2016 Elsevier B.V. All rights reserved.
       </copyright-statement>
       <copyright-year>
        2016
       </copyright-year>
       <copyright-holder>
        Elsevier B.V.
       </copyright-holder>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract abstract-type="author-highlights" id="abs0005">
       <title>
        Highlights
       </title>
       <p>
        <list id="lis0005" list-type="simple">
         <list-item id="lsti0005">
          <label>
           •
          </label>
          <p id="par0005">
           Porcine deltacoronavirus (PDCoV) is a novel swine enteropathogenic coronavirus.
          </p>
         </list-item>
         <list-item id="lsti0010">
          <label>
           •
          </label>
          <p id="par0010">
           The etiology and molecular epidemiology of PDCoV are described.
          </p>
         </list-item>
         <list-item id="lsti0015">
          <label>
           •
          </label>
          <p id="par0015">
           The cell culture for PDCoV isolation and propagation are demonstrated.
          </p>
         </list-item>
         <list-item id="lsti0020">
          <label>
           •
          </label>
          <p id="par0020">
           The disease mechanisms and pathogenesis of PDCoV are reviewed.
          </p>
         </list-item>
        </list>
       </p>
      </abstract>
      <abstract id="abs0010">
       <p>
        Porcine deltacoronavirus (PDCoV) (family
        <italic>
         Coronaviridae
        </italic>
        , genus
        <italic>
         Deltacoronavirus
        </italic>
        ) is a novel swine enteropathogenic coronavirus that causes acute diarrhea/vomiting, dehydration and mortality in seronegative neonatal piglets. PDCoV diarrhea was first reported in the US in early 2014, concurrently with co-circulation of porcine epidemic diarrhea virus (PEDV) (family
        <italic>
         Coronaviridae,
        </italic>
        genus
        <italic>
         Alphacoronavirus
        </italic>
        ). The origin of PDCoV in pigs and also its sudden emergence or route of introduction into the US still remains unclear. In the US, since 2013–2014, the newly emerged PDCoV and PEDV have spread nationwide, causing a high number of pig deaths and significant economic impacts. The current US PDCoV strains are enteropathogenic and infect villous epithelial cells of the entire small and large intestines although the jejunum and ileum are the primary sites of infection. Similar to PEDV infections, PDCoV infections also cause acute, severe atrophic enteritis accompanied by transient viremia (viral RNA) that leads to severe diarrhea and/or vomiting, followed by dehydration as the potential cause of death in nursing piglets. At present, differential diagnosis of PDCoV, PEDV, and transmissible gastroenteritis virus (TGEV) is essential to control viral diarrheas in US swine. Cell culture-adapted US PDCoV (TC-PDCoV) strains have been isolated and propagated by us and in several other laboratories. TC-PDCoV strains will be useful to develop serologic assays and to evaluate if serial cell-culture passage attenuates TC-PDCoV as a potential vaccine candidate strain. A comprehensive understanding of the pathogenesis and epidemiology of epidemic PDCoV strains is currently needed to prevent and control the disease in affected regions and to develop an effective vaccine. This review focuses on the etiology, cell culture isolation and propagation, molecular epidemiology, disease mechanisms and pathogenesis of PDCoV infection.
       </p>
      </abstract>
      <kwd-group id="kwd0005">
       <title>
        Keywords
       </title>
       <kwd>
        Porcine deltacoronavirus
       </kwd>
       <kwd>
        Pathogenesis
       </kwd>
       <kwd>
        Review
       </kwd>
       <kwd>
        Disease
       </kwd>
       <kwd>
        Virus
       </kwd>
       <kwd>
        Pigs
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="sec0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="par0025">
      Porcine deltacoronavirus (PDCoV), a member of the genus
      <italic>
       Deltacoronavirus
      </italic>
      in the family
      <italic>
       Coronaviridae
      </italic>
      of the order
      <italic>
       Nidovirales
      </italic>
      , causes acute diarrhea, vomiting, dehydration and mortality in neonatal piglets (
      <xref ref-type="bibr" rid="bib0025">
       Chen et al., 2015b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0080">
       Hu et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0115">
       Jung et al., 2015c
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0170">
       Ma et al., 2015
      </xref>
      ). PDCoV was first reported in pigs in Hong Kong in 2012 (
      <xref ref-type="bibr" rid="bib0265">
       Woo et al., 2012
      </xref>
      ). Among a total of 7140 rectal, tracheal, or cloacal swab samples from wild Asian leopard cats, bats, wild birds, domestic cats, cattle, chickens, dogs, pigs, rodents, monkeys, and humans in China and Hong Kong in 2007–2011, DCoVs were detected only in pigs and wild birds, with a 10.1% positive rate for PDCoV in the 169 swine rectal swab samples tested (
      <xref ref-type="bibr" rid="bib0265">
       Woo et al., 2012
      </xref>
      ). However, it appears that DCoVs were present in rectal swabs of small mammals, such as Asian leopard cats and Chinese ferret badgers, at live-animal markets in China since 2005–2006 (
      <xref ref-type="bibr" rid="bib0060">
       Dong et al., 2007
      </xref>
      ). PDCoV diarrhea was first reported in the US in early 2014 (
      <xref ref-type="bibr" rid="bib0160">
       Li et al., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0190">
       Marthaler et al., 2014b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0235">
       Wang et al., 2014a
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0240">
       Wang et al., 2014b
      </xref>
      ), concurrently with porcine epidemic diarrhea virus (PEDV) (family
      <italic>
       Coronaviridae,
      </italic>
      genus
      <italic>
       Alphacoronavirus
      </italic>
      ), which causes similar, but more severe clinical disease in neonatal piglets (
      <xref ref-type="bibr" rid="bib0030">
       Cima, 2013
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0225">
       Stevenson et al., 2013
      </xref>
      ). Recent studies reported that PDCoV CHN-AH-2004 and CH/Sichuan/S27/2012 strains, genetically related to the current US PDCoV strains, were previously present in diarrheic piglets in China in 2004 and 2012, respectively, prior to the first outbreak of PDCoV infection in the US in early 2014 (
      <xref ref-type="bibr" rid="bib0065">
       Dong et al., 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0250">
       Wang et al., 2015b
      </xref>
      ).
     </p>
     <p id="par0030">
      The family
      <italic>
       Coronaviridae
      </italic>
      can be genetically divided into the four genera:
      <italic>
       Alphacoronavirus, Betacoronavirus, Gammacoronavirus,
      </italic>
      and
      <italic>
       Deltacoronavirus
      </italic>
      (
      <xref ref-type="bibr" rid="bib0265">
       Woo et al., 2012
      </xref>
      ). Bats are the projected host for the gene source of
      <italic>
       Alphacoronaviruses
      </italic>
      and
      <italic>
       Betacoronaviruses
      </italic>
      , while birds are the suspect host for
      <italic>
       Gammacoronaviruses
      </italic>
      and
      <italic>
       Deltacoronaviruses
      </italic>
      (
      <xref ref-type="bibr" rid="bib0265">
       Woo et al., 2012
      </xref>
      ). The other swine enteropathogenic coronavirus, transmissible gastroenteritis virus (TGEV), also belongs to
      <italic>
       Alphacoronavirus
      </italic>
      . Similar epidemiological, clinical, and pathological features among PDCoV, PEDV and TGEV have complicated their diagnosis, requiring differential laboratory tests (
      <xref ref-type="bibr" rid="bib0090">
       Jung and Saif, 2015
      </xref>
      ). In the US, since 2013–2014, the newly emerged PEDV and PDCoV have spread nationwide and affected pigs alone or jointly, causing a high number of pig deaths and significant economic impacts and hindering the control of both viral infections in farms dually affected by these two viruses (
      <xref ref-type="bibr" rid="bib0015">
       Anon., 2014
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0090">
       Jung and Saif, 2015
      </xref>
      ). At present, differential diagnosis of PEDV, PDCoV, and TGEV is critical to control the coronaviral epidemic diarrheas in US pig farms.
     </p>
     <p id="par0035">
      Cultivable, cell culture-adapted PDCoV (TC-PDCoV) strains include the two isolates, USA/IL/2014 and Michigan/8977/2014, isolated at the USDA National Veterinary Services Laboratories (
      <xref ref-type="bibr" rid="bib0025">
       Chen et al., 2015b
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0170">
       Ma et al., 2015
      </xref>
      ) and TC-PDCoV strain OH-FD22 isolated in our lab (
      <xref ref-type="bibr" rid="bib0075">
       Hu et al., 2015
      </xref>
      ). The TC-PDCoV OH-FD22 has been serially passaged &gt;90 times on LLC-PK cells, with high sustained infectious titers (
      <xref ref-type="bibr" rid="bib0075">
       Hu et al., 2015
      </xref>
      ). The TC-PDCoV strains are useful for PDCoV pathogenesis studies, virological and serological assays, and vaccine development. This review focuses on the current understanding of the etiology, molecular epidemiology, disease mechanisms and pathogenesis of PDCoV, and cell culture isolation and propagation of the virus.
     </p>
    </sec>
    <sec id="sec0010">
     <label>
      2
     </label>
     <title>
      Etiology
     </title>
     <sec id="sec0015">
      <label>
       2.1
      </label>
      <title>
       PDCoV structure and genome
      </title>
      <p id="par0040">
       PDCoV is enveloped and pleomorphic with diameter of 60–180 nm, excluding the projections (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). PDCoV has a single-stranded positive-sense RNA genome of approximately 25.4 kb in size (excluding the poly A-tail) that encodes four structural proteins, namely, spike (S), envelope (E), membrane (M), and nucleocapsid (N), and four nonstructural proteins (
       <xref ref-type="bibr" rid="bib0140">
        Lee and Lee, 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0160">
        Li et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0185">
        Marthaler et al., 2014a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0250">
        Wang et al., 2015b
       </xref>
       ). The PDCoV genome organization and arrangement consist of: 5′ untranslated region, open reading frame 1a/1b (ORF1a/1b), S, E, M, nonstructural protein 6 (NS6), N, nonstructural protein 7 (NS7), and 3′ UTR. Although general characteristics of the structural and nonstructural proteins of coronaviruses and their roles in viral replication have been identified (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), the detailed functions and roles of structural and nonstructural proteins of PDCoV in host cells are unknown. A recent study reported multifunctional roles of PDCoV N protein similar to those of other coronaviruses. The N protein was identified in both the nucleus and cytoplasm of stably N-expressing porcine kidney cells, suggesting RNA synthesis or ribosome biogenesis through its interactions with ribosomal subunits or nucleolar proteins (
       <xref ref-type="bibr" rid="bib0145">
        Lee and Lee, 2015
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0020">
      <label>
       2.2
      </label>
      <title>
       Antigenic cross-reactivity between PDCoV and PEDV/TGEV
      </title>
      <p id="par0045">
       There was no cross-reactivity of PDCoV USA/IL/2014 strain with antibodies to either PEDV or TGEV, as determined by indirect immunofluorescence assays of virus-infected cells using a rabbit antiserum against synthetic M protein of PDCoV, a PEDV monoclonal antibody (SD6-29) targeting the N protein, and a TGEV polyclonal antiserum (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ). This finding was also supported by other reports (
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ), showing no cross-reactivity of pig hyperimmune or convalescent antiserum to PDCoV OH-FD22 or CVM1 strains with PEDV, as determined by immunohistochemical staining of frozen or formalin-fixed intestinal tissues of PEDV-infected pigs. However, a recent study reported evidence of antigenic cross-reactivity between PDCoV Michigan/8977/2014 strain and PEDV, possibly sharing at least one conserved or similar epitope on their N proteins, as determined by enzyme-linked immunosorbent assay (ELISA) and western blot using monoclonal PEDV and PDCoV N-specific antibodies, whereas no cross-reactivity was detected when virus neutralization, indirect immunofluorescence, and immunostaining assays were conducted on either virus-infected cells or intestinal tissues using pig hyperimmune antisera to PEDV or PDCoV (
       <xref ref-type="bibr" rid="bib0175">
        Ma et al., 2016
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec0025">
     <label>
      3
     </label>
     <title>
      Cell culture for isolation and propagation of PDCoV
     </title>
     <p id="par0050">
      LLC porcine kidney (LLC-PK) and swine testicular (ST) cells support the isolation and serial propagation of PDCoV in cell cultures supplemented with exogenous protease trypsin or pancreatin (
      <xref ref-type="bibr" rid="bib0075">
       Hu et al., 2015
      </xref>
      ). Trypsin contributed to a significant increase in PDCoV growth after several passages in LLC-PK cells. However, even without supplemental trypsin, PDCoV replicated in LLC-PK cells, but without cytopathic effects (CPE) and at relatively lower virus titers compared to the trypsin supplemented cell cultures (
      <xref ref-type="bibr" rid="bib0075">
       Hu et al., 2015
      </xref>
      ). Thus, trypsin is not essential, but is beneficial for the propagation of PDCoV in LLC-PK cells. The cell-culture conditions required for the propagation of PDCoV in ST cells differ from those in LLC-PK cells. Trypsin did not support PDCoV propagation in ST cells. In contrast, PDCoV could be serially propagated in ST cells supplemented with pancreatin or small intestinal contents from gnotobiotic (Gn) piglets (
      <xref ref-type="bibr" rid="bib0075">
       Hu et al., 2015
      </xref>
      ). The addition of trypsin and pancreatin in PDCoV-inoculated LLC-PK and ST cells, respectively, resulted in similar CPE that consisted of enlarged, rounded, and densely granular cells that occurred singly or in clusters and then, cell shrinkage and detachment as a result of apoptotic cell death (
      <xref ref-type="bibr" rid="bib0120">
       Jung et al., 2016
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0075">
       Hu et al., 2015
      </xref>
      ). The roles of trypsin or pancreatin in cell entry and release of PDCoV virions in LLC-PK or ST cells remain unknown.
     </p>
    </sec>
    <sec id="sec0030">
     <label>
      4
     </label>
     <title>
      Molecular epidemiology
     </title>
     <sec id="sec0035">
      <label>
       4.1
      </label>
      <title>
       Discovery of deltacoronaviruses
      </title>
      <p id="par0055">
       Coronaviruses in the genus
       <italic>
        Deltacoronavirus
       </italic>
       have been identified recently in a variety of wild small mammals and avian species (
       <xref ref-type="bibr" rid="bib0060">
        Dong et al., 2007
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0255">
        Woo et al., 2009a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0260">
        Woo et al., 2009b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ). In 2006, novel coronaviruses were detected in feces of wild Asian leopard cats (
       <italic>
        Prionailurus bengalensis
       </italic>
       ) and Chinese ferret badgers (
       <italic>
        Melogale moschata
       </italic>
       ) during a virological surveillance for severe acute respiratory syndrome (SARS) coronavirus in southern China. The isolates were genetically similar to each other and commonly had low amino acid similarity and unique phylogeny distinct from other coronavirus groups (
       <xref ref-type="bibr" rid="bib0060">
        Dong et al., 2007
       </xref>
       ). The two isolates were subsequently shown genetically to belong to
       <italic>
        Deltacoronavirus
       </italic>
       (
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ). Another molecular epidemiology study was conducted in dead wild birds for a 7-month period (December 2006 to June 2007) in Hong Kong (
       <xref ref-type="bibr" rid="bib0260">
        Woo et al., 2009b
       </xref>
       ). Three novel avian coronaviruses (BuCoV HKU11, ThCoV HKU12, and MuCoV HKU13) were identified and proposed as a novel coronavirus subgroup 3C under the group 3 coronaviruses (
       <xref ref-type="bibr" rid="bib0260">
        Woo et al., 2009b
       </xref>
       ). Recently, the three isolates were further identified genetically to belong to
       <italic>
        Deltacoronavirus
       </italic>
       (
       <xref ref-type="bibr" rid="bib0130">
        King et al., 2012
       </xref>
       ).
      </p>
      <p id="par0060">
       A coronavirus surveillance study was conducted in a variety of domestic and wild animal species from 2007 to 2011, and the presence of DCoVs in the feces of domestic pigs was first reported in 2012 (
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ). Seven DCoVs in pigs and wild birds were identified, which were designated porcine coronavirus HKU15 and the avian coronavirueses, white-eye coronavirus HKU16, sparrow coronavirus HKU17, magpie robin coronavirus HKU18, night heron coronavirus HKU19, wigeon coronavirus HKU20, and common moorhen coronavirus HKU21 (
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ). This study first verified that PDCoV was present in the feces of pigs in Mainland China and Hong Kong in 2007–2011, with a positive rate of 10.1%. Two Chinese PDCoV complete genome sequences were generated from two different isolates, HKU15-44 and HKU15-155 (GenBank accession no.
       <ext-link ext-link-type="uri" id="intr0010" xlink:href="ncbi-n:JQ065042">
        JQ065042
       </ext-link>
       and
       <ext-link ext-link-type="uri" id="intr0015" xlink:href="ncbi-n:JQ065043">
        JQ065043
       </ext-link>
       , respectively) (
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ). The helicase, S and N genes of PDCoV HKU15-44 and HKU15-155 were closely related to those of the coronaviruses isolated from the Asian leopard cats and Chinese ferret badgers [nucleotide (nt) similarity ≥99.8%] (
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ) (
       <xref ref-type="fig" rid="fig0005">
        Fig. 1
       </xref>
       A), implying the potential interspecies transmission of a DCoV between these wild small mammals and pigs. Further molecular surveillance studies are needed to define the potential role of the small mammals as an intermediate host of PDCoV and the mechanisms of interspecies transmission of DCoVs between the small mammals and domestic pigs or wild birds, and also between domestic pigs and wild birds.
       <fig id="fig0005">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          Phylogenetic analyses of the S gene nucleotide sequences (A) and complete genomes (B) of some representative porcine and avian deltacoronaviruses. Reference sequences obtained from GenBank are indicated by strain names and accession numbers. The trees were constructed using the distance-based neighbor-joining method of the software MEGA6.06 (
          <ext-link ext-link-type="uri" id="intr0005" xlink:href="http://www.megasoftware.net">
           http://www.megasoftware.net
          </ext-link>
          ). Bootstrap analysis was carried out on 1000 replicate data sets, and values are indicated adjacent to the branching points. Scale bars represent 0.1 nucleotide substitutions per site.
         </p>
        </caption>
        <alt-text id="at0015">
         Fig. 1
        </alt-text>
        <graphic xlink:href="gr1a_lrg">
        </graphic>
        <graphic xlink:href="gr1b_lrg">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="sec0040">
      <label>
       4.2
      </label>
      <title>
       Emergence of PDCoV infection in US swine in february 2014
      </title>
      <p id="par0065">
       On February 11, 2014, the Ohio Department of Agriculture first announced the presence of PDCoV in US swine. In early February 2014, the Animal Disease Diagnostic Laboratory at the Ohio Department of Agriculture received 42 fecal or intestinal samples from diarrheic sows and piglets on 5 Ohio farms, and 39 (92.9%) were positive for PDCoV by RT-PCR (
       <xref ref-type="bibr" rid="bib0235">
        Wang et al., 2014a
       </xref>
       ). The PDCoV HKU15-OH1987 strain identified (GenBank accession no.
       <ext-link ext-link-type="uri" id="intr0020" xlink:href="ncbi-n:KJ462462">
        KJ462462
       </ext-link>
       ) had a 99% nt identity to PDCoV HKU15-44 and HKU15-155 (
       <xref ref-type="bibr" rid="bib0235">
        Wang et al., 2014a
       </xref>
       ) (
       <xref ref-type="fig" rid="fig0005">
        Fig. 1
       </xref>
       B), implying a possible importation of a Chinese PDCoV into US swine. During a similar period, the University of Minnesota Veterinary Diagnostic Laboratory also received fecal swabs from diarrheic pigs. The causative agent of the diarrhea was identified as the PDCoV SDCV/USA/Illinois121/2014 strain (GenBank accession no:
       <ext-link ext-link-type="uri" id="intr0025" xlink:href="ncbi-n:KJ481931.1">
        KJ481931.1
       </ext-link>
       ) that also had approximately 99% nt identity to the two Hong Kong PDCoV strains (
       <xref ref-type="bibr" rid="bib0185">
        Marthaler et al., 2014a
       </xref>
       ). The Iowa State University Veterinary Diagnostic Laboratory also identified another US PDCoV strain USA/IA/2014/8734 (GenBank accession no:
       <ext-link ext-link-type="uri" id="intr0030" xlink:href="ncbi-n:KJ567050">
        KJ567050
       </ext-link>
       ) that had 98.9% nt identity to the HKU15-44 strain and 99.2% nt identity to the HKU15-155 strain (
       <xref ref-type="bibr" rid="bib0160">
        Li et al., 2014
       </xref>
       ). PDCoVs were further detected in other US states (Minnesota, South Dakota, Nebraska, Illinois, Indiana, Michigan, Kentucky, Pennsylvania, and Ohio) (
       <xref ref-type="bibr" rid="bib0240">
        Wang et al., 2014b
       </xref>
       ). Of the 435 samples tested, 109 (25%) were positive for PDCoV by RT-PCR, and they shared high nt similarity (≥99.8%) with each other and also 98.9–99.2% nt similarity with PDCoV HKU15-44 and HKU15-155 (
       <xref ref-type="bibr" rid="bib0240">
        Wang et al., 2014b
       </xref>
       ). As of March 2016, PDCoV has been detected in 18 US states according to a report of the USDA Animal and Plant Health Inspection Service (
       <ext-link ext-link-type="uri" id="intr0035" xlink:href="http://www.aphis.usda.gov/animal-health/secd">
        www.aphis.usda.gov/animal-health/secd
       </ext-link>
       ).
      </p>
     </sec>
     <sec id="sec0045">
      <label>
       4.3
      </label>
      <title>
       Evidence of presence of PDCoV in US swine prior to the first detection in february 2014
      </title>
      <p id="par0070">
       Several retrospective studies were conducted to determine the earliest date when PDCoV existed in US swine. A retrospective study using real-time RT-PCR was performed on swine samples that were submitted to the Iowa State University Veterinary Diagnostic Laboratory for investigation of enteric diseases between October 2012 and December 2013 (
       <xref ref-type="bibr" rid="bib0210">
        Sinha et al., 2015
       </xref>
       ). A total of 5 samples were positive for PDCoV RNA among the 1734 clinical samples from 18 states tested. PDCoV RNA was detected in fecal samples collected on August 19th 2013 from Minnesota, August 20th and August 27th from Iowa, and August 29th 2013 from Illinois (
       <xref ref-type="bibr" rid="bib0210">
        Sinha et al., 2015
       </xref>
       ). Based on these data, PDCoV has been present in US swine since at least August 2013. Another retrospective study using an indirect ELISA for the detection of PDCoV IgG antibodies demonstrated their prevalence in US pigs (
       <xref ref-type="bibr" rid="bib0230">
        Thachil et al., 2015
       </xref>
       ). A total of 968 serum samples collected between 2006 and 2014 were tested. The PDCoV IgG antibodies were first detected in the archival serum samples collected in 2010 (
       <xref ref-type="bibr" rid="bib0230">
        Thachil et al., 2015
       </xref>
       ). However, the origin of US PDCoV in US swine remains unclear.
      </p>
     </sec>
     <sec id="sec0050">
      <label>
       4.4
      </label>
      <title>
       Epidemiology of PDCoV in other countries
      </title>
      <p id="par0075">
       To date, PDCoV also has been reported in Canada, Korea, China, and Thailand. Epidemic diarrhea related to PDCoV was first detected in 6 Ontario farms in Canada in March 2014 (
       <xref ref-type="bibr" rid="bib0190">
        Marthaler et al., 2014b
       </xref>
       ). In April 2014, PDCoV (KUN14-04 strain, Genbank accession no.
       <ext-link ext-link-type="uri" id="intr0040" xlink:href="ncbi-n:KM820765">
        KM820765
       </ext-link>
       ) was first identified in feces of diarrheic piglets in South Korea. The Korean strain had nt identities of 98.8–99.0% to HKU15-44 and HKU15-155 and 99.6–99.8% to US PDCoV strains (
       <xref ref-type="bibr" rid="bib0140">
        Lee and Lee, 2014
       </xref>
       ). A recent survey conducted in South Korea reported that of 691 diarrheic fecal samples collected on 59 pig farms in January 2014 to March 2015, only 2 samples from 1 pig farm (March 2015) were PDCoV-positive by RT-PCR (
       <xref ref-type="bibr" rid="bib0150">
        Lee et al., 2016
       </xref>
       ). Two Korean PDCoV strains SL2 and SL5 isolated in the study were also closely related to US PDCoV strains, but they appeared to genetically differ from the previous Korean strain KNU14-04 isolated in 2014 (
       <xref ref-type="bibr" rid="bib0150">
        Lee et al., 2016
       </xref>
       ). The first identification of PDCoV HKU15-44 and HKU15-155 strains in swine in Hong Kong, China for the period 2007–2011 were documented in 2012 (
       <xref ref-type="bibr" rid="bib0265">
        Woo et al., 2012
       </xref>
       ). Since then, PDCoV has been identified in diarrheic pigs in mainland China (
       <xref ref-type="bibr" rid="bib0065">
        Dong et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0220">
        Song et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0250">
        Wang et al., 2015b
       </xref>
       ). A study also found PDCoV RNA in diarrheic pig samples collected in 2004 in China (
       <xref ref-type="bibr" rid="bib0065">
        Dong et al., 2015
       </xref>
       ). The prevalence of PDCoV in mainland China was high (&gt;30%), and co-infections with PDCoV and PEDV (51%) were also common (
       <xref ref-type="bibr" rid="bib0065">
        Dong et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0220">
        Song et al., 2015
       </xref>
       ). All PDCoV strains reported from China shared high nt identities (≥98.9%) with each other and with the other PDCoV strains found globally (
       <xref ref-type="bibr" rid="bib0065">
        Dong et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0220">
        Song et al., 2015
       </xref>
       ) (
       <xref ref-type="fig" rid="fig0005">
        Fig. 1
       </xref>
       B), implying a possible global circulation of a single genotype. PDCoV strains with multiple mutation or deletion sites in their S, nonstructural, or 3′ UTR genes have been also found in China, whereas the mutations were not found in the genomes of US PDCoV strains (
       <xref ref-type="bibr" rid="bib0245">
        Wang et al., 2015a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0250">
        Wang et al., 2015b
       </xref>
       ). In June 2015, a PDCoV-related diarrhea outbreak was identified on a pig farm in Thailand (
       <xref ref-type="bibr" rid="bib0085">
        Janetanakit et al., 2016
       </xref>
       ). PDCoV strains detected in Thailand shared the highest nt identities (≥98.4%) with the Chinese PDCoV strain CHN-AH-2004 (
       <xref ref-type="bibr" rid="bib0085">
        Janetanakit et al., 2016
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec0055">
     <label>
      5
     </label>
     <title>
      Transmission
     </title>
     <p id="par0080">
      Like PEDV and TGEV (
      <xref ref-type="bibr" rid="bib0090">
       Jung and Saif, 2015
      </xref>
      ,
      <xref ref-type="bibr" rid="bib0200">
       Saif et al., 2012
      </xref>
      ), the fecal–oral route may be the main means of PDCoV transmission. Since aerosolized PEDV remains infectious (
      <xref ref-type="bibr" rid="bib0005">
       Alonso et al., 2014
      </xref>
      ), whether aerosolized PDCoV is also infectious should be investigated. Like PEDV transmission, diarrheal feces and/or vomitus and other contaminated fomites, such as transport trailers (
      <xref ref-type="bibr" rid="bib0165">
       Lowe et al., 2014
      </xref>
      ) and feed (
      <xref ref-type="bibr" rid="bib0050">
       Dee et al., 2014
      </xref>
      ), may be major transmission sources of the virus. Another possible reservoir for PDCoV includes carriers, such as older pigs with subclinical infection, similar to PEDV infection in weaned pigs (
      <xref ref-type="bibr" rid="bib0105">
       Jung et al., 2015a
      </xref>
      ).
     </p>
    </sec>
    <sec id="sec0060">
     <label>
      6
     </label>
     <title>
      Disease mechanisms and pathogenesis of PDCoV
     </title>
     <sec id="sec0065">
      <label>
       6.1
      </label>
      <title>
       Tissue tropism of PDCoV
      </title>
      <p id="par0085">
       Like PEDV and TGEV (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), PDCoV is cytolytic, and infected enterocytes rapidly undergo acute necrosis, leading to marked villous atrophy in the small but not in the large intestine (
       <xref ref-type="fig" rid="fig0010">
        Fig. 2
       </xref>
       A) (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Like PEDV (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ) and TGEV (
       <xref ref-type="bibr" rid="bib0125">
        Kim et al., 2000
       </xref>
       ), PDCoV may not induce apoptotic death of enterocytes in the small intestine of infected pigs (
       <xref ref-type="bibr" rid="bib0120">
        Jung et al., 2016
       </xref>
       ). PDCoV antigens (Fig. 2B and C) and nucleic acids (
       <xref ref-type="fig" rid="fig0010">
        Fig. 2
       </xref>
       D) are observed mainly in villous enterocytes of the small (duodenum to ileum) and large intestines (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). As tested at post-inoculation days (PID) 3–7, PDCoV antigens were detected mainly in the villous epithelium of the atrophied mid-jejunum to ileum of experimentally infected pigs and to a lesser extent, in duodenum, proximal jejunum and cecum/colon (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Occasionally, a few PDCoV antigen-positive cells are detected in the intestinal crypts (
       <xref ref-type="bibr" rid="bib0120">
        Jung et al., 2016
       </xref>
       ). Porcine small intestinal villous enterocytes express large amounts of aminopeptidase N (APN), a 150-kDa glycosylated transmembrane protein, identified as the cellular receptor for PEDV and TGEV (
       <xref ref-type="bibr" rid="bib0055">
        Delmas et al., 1992
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0155">
        Li et al., 2007
       </xref>
       ). Whether APN also functions as the cellular receptor for PDCoV or if other cellular receptors are involved in cell entry of this virus is unknown. In addition, a few PDCoV antigen-positive cells were also detected in the intestinal lamina propria, Peyer’s patches, and mesenteric lymph nodes (MLN) during the early stages of infection (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0120">
        Jung et al., 2016
       </xref>
       ). As tested at PID 23–24 after experimentally infected pigs had recovered from clinical disease and ceased fecal virus shedding, larger numbers of PDCoV antigen-positive cells were detected in these tissues (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). The PDCoV antigen-positive cells might include antigen-presenting cells, such as macrophages.
       <fig id="fig0010">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Histopathology and localization of porcine deltacoronavirus (PDCoV) antigens by immunofluorescence (IF) staining and PDCoV nucleic acids by in situ hybridization in the small intestine of gnotobiotic pigs inoculated with US PDCoV strain OH-FD22. (A) Hematoxylin and eosin–stained jejunum of an inoculated pig at post-inoculation day (PID) 3 (48–51 h after onset of clinical signs), showing acute diffuse, severe atrophic enteritis, with diffuse, moderate vacuolation of enterocytes lining the epithelium of atrophied villi. Original magnification, ×200. (B) IF staining of a serial section of the jejunum (Panel A) of inoculated pig at PID 3, showing that the epithelial cells lining atrophied villi are positive for PDCoV antigen (green staining). Original magnification, ×200. (C) IF staining (higher magnification) of formalin-fixed, paraffin-embedded jejunum of the inoculated pig at PID 3, showing localization of PDCoV antigens (green staining) in the cytoplasm of villous epithelial cells. Nuclei were stained with blue-fluorescent 4′, 6-diamidino-2-phenylindole dihydrochloride. Hyperimmune pig antiserum to PDCoV strain OH-FD22 was used for IF staining. Original magnification, ×600. (D) In situ hybridization of formalin-fixed, paraffin-embedded jejunum of the inoculated pig at PID 3, indicating that the epithelial cells lining the atrophied villi are PDCoV RNA-positive (black staining). Nitroblue tetrazolium/5-bromocresyl-3-indolylphosphate, methyl green counterstain. Original magnification ×80.
         </p>
        </caption>
        <alt-text id="at0020">
         Fig. 2
        </alt-text>
        <graphic xlink:href="gr2_lrg">
        </graphic>
       </fig>
      </p>
      <p id="par0090">
       PDCoV antigens were not detected in other organs, such as stomach, lung, heart, tonsil, spleen, liver and kidney (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). However, by qRT-PCR, PDCoV RNA could be detected in low to moderate quantities in multiple organs, possibly due to the effect of viremia (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Lung tissues of orally infected pigs were negative for PDCoV antigen (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ). In our preliminary study, four 10- to 14-day-old Gn pigs orally and nasally inoculated with TC-PDCoV OH-FD22 at LLC-PK cell-culture passages 5 (P5) or 80 (P80) were negative for PDCoV RNA in nasal swabs and bronchoalveolar lavage fluids at PID 3–10, although the inoculated pigs were positive for both clinical disease and fecal virus shedding for the period, suggesting lack of PDCoV replication in the respiratory tract. However, further studies are still needed to investigate whether extra-intestinal replication of PDCoV occurs.
      </p>
     </sec>
     <sec id="sec0070">
      <label>
       6.2
      </label>
      <title>
       Pathophysiology
      </title>
      <p id="par0095">
       Based on clinical observations in experimentally infected Gn or conventional nursing pigs, like PEDV and TGEV (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), PDCoV also induces acute, watery diarrhea, frequently accompanied by acute, mild to moderate vomiting, ultimately leading to dehydration, loss of body weight, lethargy, and death (
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Similar to PEDV infection (
       <xref ref-type="bibr" rid="bib0100">
        Jung et al., 2014
       </xref>
       ), in a controlled experimental setting, clinical pigs exhibited dehydration, loss of bodyweight, and lethargy, but frequently maintained their appetite until sudden death (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Among the different clinical signs identified in Gn or conventional pigs, only diarrhea could be observed in experimentally infected conventional nursing pigs (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ), indicating that a variety of disease outcomes are expected based on different experimental conditions. However, conventional pigs appeared to be more susceptible to PDCoV infection, compared to Gn pigs, under similar experimental conditions, such as when the same virus and inoculation dose and age of pigs were used (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Based on field observations in US swine (
       <xref ref-type="bibr" rid="bib0015">
        Anon., 2014
       </xref>
       ), PDCoV caused a number of deaths (up to a 40% mortality rate) among suckling pigs, a lower rate than that found in PEDV infections. The clinical impact and disease severity of PDCoV in the field may be less than that of PEDV (
       <xref ref-type="bibr" rid="bib0015">
        Anon., 2014
       </xref>
       ). On the other hand, a PDCoV-related diarrhea outbreak in a breeding farm in China resulted in a higher mortality rate (more than 80%) among suckling piglets (
       <xref ref-type="bibr" rid="bib0220">
        Song et al., 2015
       </xref>
       ).
      </p>
      <p id="par0100">
       Like PEDV and TGEV (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), diarrhea induced by PDCoV may be a consequence of malabsorption due to massive loss of absorptive enterocytes. Functional disorders of infected enterocytes may also contribute to the malabsorptive diarrhea. Like PEDV (
       <xref ref-type="bibr" rid="bib0070">
        Ducatelle et al., 1982
       </xref>
       ), mild vacuolation observed in the infected colonic epithelial cells may interfere with the vital reabsorption of water and electrolytes (
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ). As a consequence of extensive loss of enterocytes, brush border membrane-bound digestive enzymes such as disaccharidases (lactase, sucrase, and maltase), leucine APN, and alkaline phosphatase were significantly decreased in the small intestine of diarrheic piglets after PEDV infection (
       <xref ref-type="bibr" rid="bib0035">
        Coussement et al., 1982
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0095">
        Jung et al., 2006
       </xref>
       ), resulting in maldigestive diarrhea. Because of the similar pathological features between PDCoV and PEDV, PDCoV infection may also result in maldigestive diarrhea. Dehydration is exacerbated by vomiting, but the mechanisms by which vomiting is induced in PDCoV infection are poorly understood. Whether PDCoV infection induces metabolic acidosis, similar to hyperkalemia and acidosis in acute TGEV and PEDV infections (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), needs to be studied.
      </p>
     </sec>
     <sec id="sec0075">
      <label>
       6.3
      </label>
      <title>
       Onset of diarrhea and fecal virus shedding and peak viral titers
      </title>
      <p id="par0105">
       Based on experimental findings (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ), the onset of diarrhea after PDCoV infection appears to be acute, which coincided mostly with or was detected 1–2 days later than the detection of viral RNA in feces. Fecal viral RNA titers peaked 1–3 days later. The findings of these studies are summarized in
       <xref ref-type="table" rid="tbl0005">
        Table 1
       </xref>
       . Five 14-day-old Gn pigs inoculated with 8.8 or 11.0 log
       <sub>
        10
       </sub>
       GE of two field PDCoV strains OH-FD22 and OH-FD100 all showed severe diarrhea and/or vomiting at post-inoculation hours (PIH) 21–24, which coincided with the detection of viral RNA in feces (
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ). Six 14-day-old Gn pigs inoculated with 10.1-10.8 log
       <sub>
        10
       </sub>
       GE [≈11 log
       <sub>
        10
       </sub>
       50% tissue culture infectious dose (TCID
       <sub>
        50
       </sub>
       ) or 9 log
       <sub>
        10
       </sub>
       plaque forming units (PFU) per pig (
       <xref ref-type="bibr" rid="bib0075">
        Hu et al., 2015
       </xref>
       )] of the TC-PDCoV OH-FD22 P5, P20, and P40 all showed severe diarrhea and/or vomiting at PID 2, which also coincided with the detection of viral RNA in feces (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). In this study, fecal viral RNA titers peaked, ranging from 7.8 to 8.9 log
       <sub>
        10
       </sub>
       GE/ml, at PID 2–5 and then decreased gradually thereafter (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ).
       <table-wrap id="tbl0005" position="float">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Summary of clinical signs and fecal virus RNA shedding in gnotobiotic (Gn) or conventional pigs experimentally inoculated with US porcine deltacoronavirus (PDCoV).
         </p>
        </caption>
        <alt-text id="at0025">
         Table 1
        </alt-text>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th align="left">
            Pig, age (days) at inoculation
           </th>
           <th align="left">
            PDCoV strain, oral inoculation dose
           </th>
           <th align="left">
            Onset of diarrhea (PIH or PID)
            <xref ref-type="table-fn" rid="tblfn0010">
             b
            </xref>
           </th>
           <th align="left">
            Onset of fecal virus shedding (PIH or PID)
            <xref ref-type="table-fn" rid="tblfn0010">
             b
            </xref>
           </th>
           <th align="left">
            Peak viral RNA titer in feces (gram) or rectal swab fluids (ml)
           </th>
           <th align="left">
            Duration of diarrhea (days)
           </th>
           <th align="left">
            Duration of fecal virus shedding
           </th>
           <th align="left">
            Reference
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left">
            Gn, 14
           </td>
           <td align="left">
            Wild-type OH-FD22 or OH–FD100, 8.8–11.0 log
            <sub>
             10
            </sub>
            GE/pig
            <xref ref-type="table-fn" rid="tblfn0005">
             a
            </xref>
           </td>
           <td align="left">
            PIH 21-24
           </td>
           <td align="left">
            PIH 21-24
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left">
            6
           </td>
           <td align="left">
            PID 1 to 20
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bib0115">
             Jung et al., 2015c
            </xref>
            ,
            <xref ref-type="bibr" rid="bib0080">
             Hu et al., 2016
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Conventional, 5
           </td>
           <td align="left">
            Cell culture-adapted USA/IL/2014 (P11), 3 × 10
            <sup>
             4
            </sup>
            TCID
            <sub>
             50
            </sub>
            /pig
            <xref ref-type="table-fn" rid="tblfn0005">
             a
            </xref>
           </td>
           <td align="left">
            PID 5
           </td>
           <td align="left">
            PID 4 or 5
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bib0025">
             Chen et al., 2015b
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Gn, 10
           </td>
           <td align="left" rowspan="2">
            Cell culture-adapted Michigan/8977/2014 (P15), 10
            <sup>
             6
            </sup>
            PFU/pig
            <xref ref-type="table-fn" rid="tblfn0005">
             a
            </xref>
           </td>
           <td align="left">
            PID 3
           </td>
           <td align="left">
            PID 1 or 2
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left">
            ND
            <xref ref-type="table-fn" rid="tblfn0015">
             c
            </xref>
           </td>
           <td align="left" rowspan="2">
            <xref ref-type="bibr" rid="bib0170">
             Ma et al., 2015
            </xref>
           </td>
          </tr>
          <tr>
           <td align="left">
            Conventional, 10
           </td>
           <td align="left">
            PID 1
           </td>
           <td align="left">
            PID 1 or 2
           </td>
           <td align="left">
            6-7 log
            <sub>
             10
            </sub>
            RNA copies/gram at PID 7
           </td>
           <td align="left">
            7–10
           </td>
           <td align="left">
            PID 1 to 21
           </td>
          </tr>
          <tr>
           <td align="left">
            Gn, 14
           </td>
           <td align="left">
            Cell culture-adapted OH-FD22 at cell-culture passages 5 (P5), 20 (P20), and 40 (P40), 10.1–10.8 log
            <sub>
             10
            </sub>
            GE/pig
            <xref ref-type="table-fn" rid="tblfn0005">
             a
            </xref>
           </td>
           <td align="left">
            PID 2
           </td>
           <td align="left">
            PID 2
           </td>
           <td align="left">
            7.8–8.9 log
            <sub>
             10
            </sub>
            GE/ml at PID 2 to 5
           </td>
           <td align="left">
            5–7
           </td>
           <td align="left">
            PID 2 to 20 (for the strain OH-FD22 P20)
           </td>
           <td align="left">
            <xref ref-type="bibr" rid="bib0080">
             Hu et al., 2016
            </xref>
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <fn id="tblfn0005">
          <label>
           a
          </label>
          <p id="npar0005">
           GE, genome equivalents; TCID
           <sub>
            50
           </sub>
           , 50% tissue culture infectious dose; PFU, plaque forming unit; P11 or P15, PDCoV cell-culture passages 11 or 15.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tblfn0010">
          <label>
           b
          </label>
          <p id="npar0010">
           PIH, postinoculation hour; PID, postinoculation day.
          </p>
         </fn>
        </table-wrap-foot>
        <table-wrap-foot>
         <fn id="tblfn0015">
          <label>
           c
          </label>
          <p id="npar0015">
           ND, not determined.
          </p>
         </fn>
        </table-wrap-foot>
       </table-wrap>
      </p>
      <p id="par0110">
       Another study using conventional 5-day-old pigs and a cell culture-adapted PDCoV USA/IL/2014 strain (P11) reported the onset of diarrhea at PID 5 in 5 of 5 pigs orally inoculated with 3 × 10
       <sup>
        4
       </sup>
       TCID
       <sub>
        50
       </sub>
       /pig of the virus, which was 1 day later or coincided with the detection of viral RNA in feces at PID 4 (3/5 pigs tested) or 5 (2/5 pigs tested) (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ). Fecal viral RNA peaked at approximately PID 5–7 (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ). In another study using another strain genetically similar to the USA/IL/2014 strain, four 10-day-old conventional and three 10-day-old Gn pigs orally inoculated with 10
       <sup>
        6
       </sup>
       PFU (≈10
       <sup>
        9
       </sup>
       genomic RNA copies) of a cell culture-adapted PDCoV Michigan/8977/2014 strain (P15) all exhibited moderate to severe diarrhea at PID 1 (conventional pig) and PID 3 (Gn pig), respectively (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Fecal shedding occurred at PID 1 (1/4 pigs tested) or PID 2 (3/4 pigs tested) in conventional pigs, whereas fecal shedding was detected at PID 1 (1/3 pigs tested) or PID 2 (2/3 pigs tested) in Gn pigs prior to the onset of diarrhea (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). In the infected conventional pigs, fecal viral RNA titers peaked, ranging from 6 to 7 log
       <sub>
        10
       </sub>
       RNA copies/gram, on PID 7 and then decreased gradually thereafter (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0080">
      <label>
       6.4
      </label>
      <title>
       Duration of diarrhea and fecal virus shedding
      </title>
      <p id="par0115">
       Based on experimental findings (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ), persisting diarrhea in infected nursing pigs is observed for approximately 5–10 days. Prolonged fecal virus RNA shedding was also evident in PDCoV-infected nursing pigs. After recovery from disease, pigs continued to shed PDCoV RNA in the feces. The findings of these studies are summarized in
       <xref ref-type="table" rid="tbl0005">
        Table 1
       </xref>
       . The Gn pig inoculated with 8.8 log
       <sub>
        10
       </sub>
       GE of the field PDCoV strain OH-FD22 developed diarrhea at PIH 21–24, which was consistently observed until PID 7 (
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ). Four 10-day-old conventional pigs orally inoculated with 10
       <sup>
        6
       </sup>
       PFU of the Michigan/8977/2014 strain all exhibited diarrhea at PID 1, which then persisted for another 6–9 days (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). The Gn pigs inoculated with 10.1–10.8 log
       <sub>
        10
       </sub>
       GE of the TC-PDCoV OH-FD22 P5, P20, and P40 all showed diarrhea at PID 2, which then persisted for another 4–6 days (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ).
       <xref ref-type="bibr" rid="bib0080">
        Hu et al. (2016)
       </xref>
       reported that similar to prolonged fecal virus RNA shedding (until PID 20) observed in the wild-type PDCoV OH-FD22-inoculated pigs, fecal virus shedding in the TC-PDCoV OH-FD22 P5 or P20-inoculated pigs was detectable until PID 18 or 20, respectively (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). The TC-PDCoV OH-FD22 P40-inoculated pig also had PDCoV RNA-positive feces until PID 15 (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). One of the four 10-day-old conventional pigs (25%) inoculated with the Michigan/8977/2014 strain had detectable PDCoV RNA in the feces until PID 21 (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0085">
      <label>
       6.5
      </label>
      <title>
       Intestinal replication of PDCoV during disease progression
      </title>
      <p id="par0120">
       There is little information on intestinal replication of PDCoV during disease progression in pigs of varying ages. In previous experimental infection studies, most of the infected Gn or conventional suckling pigs were euthanized at PID 3–7 (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). Thus, the earlier, pathological characteristics related to PDCoV infection at PID 1–3 are unknown. In experimental PEDV infections in seronegative suckling pigs, during the incubation period, i.e. at approximately PIH 12–24, PEDV antigen-positive cells were seen throughout the small intestine and as many as 30–100% of the absorptive epithelial cells were positive (
       <xref ref-type="bibr" rid="bib0045">
        Debouck et al., 1981
       </xref>
       ;
       <xref ref-type="bibr" rid="bib0180">
        Madson et al., 2015
       </xref>
       ), consistent with fecal virus shedding in subclinical pigs. After that, during the clinical period, moderate to large numbers of PEDV antigen-positive cells were observed throughout the small intestine (
       <xref ref-type="bibr" rid="bib0045">
        Debouck et al., 1981
       </xref>
       ;
       <xref ref-type="bibr" rid="bib0105">
        Jung et al., 2015a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0180">
        Madson et al., 2015
       </xref>
       ). Whether PDCoV also replicates similarly in the small intestine of nursing pigs, needs to be studied in well-controlled experimental settings with large numbers of pigs and multiple time-points. More information on the pathogenesis of PDCoV in pigs at earlier time-points (PIDs 1–2) is needed to fully understand disease progression. Relative to experimental PEDV infections (
       <xref ref-type="bibr" rid="bib0105">
        Jung et al., 2015a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0100">
        Jung et al., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0180">
        Madson et al., 2015
       </xref>
       ), PDCoV-infected pigs also appeared to shed less PDCoV RNA and had lower peak shedding titers in the feces (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ), implying a potentially lower replication rate of PDCoV in the gastrointestinal tract of pigs. Studies are also needed to investigate if this might contribute to the lower mortality of PDCoV-infected nursing pigs, as compared to PEDV infections.
      </p>
     </sec>
     <sec id="sec0090">
      <label>
       6.6
      </label>
      <title>
       Age-dependent variation to PDCoV infection
      </title>
      <p id="par0125">
       Based on field observations (
       <xref ref-type="bibr" rid="bib0015">
        Anon., 2014
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0220">
        Song et al., 2015
       </xref>
       ), PDCoV caused a number of deaths (up to a 40% mortality rate in US and &gt;80% in China) among suckling pigs. Similarly, PED is the most devastating in nursing piglets causing 100% morbidity and 50–100% mortality (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ). Several mechanisms by which PEDV infection induces greater disease severity in nursing versus weaned pigs, have been defined (
       <xref ref-type="bibr" rid="bib0010">
        Annamalai et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0105">
        Jung et al., 2015a
       </xref>
       ). Compared to 9-day-old nursing pigs that began to show severe clinical disease, villous atrophy and fecal virus shedding at PID 1, a longer incubation period of PEDV was evident before 26-day-old weaned pigs shed fecal virus RNA (by 1 more day) or developed lesions and clinical disease (by 2 more days) (
       <xref ref-type="bibr" rid="bib0010">
        Annamalai et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0105">
        Jung et al., 2015a
       </xref>
       ). There were significantly decreased functional natural killer cells in the ileum and blood of nursing piglets, compared to weaned pigs, which may have contributed to the greater susceptibility of nursing pigs to PEDV infection (
       <xref ref-type="bibr" rid="bib0010">
        Annamalai et al., 2015
       </xref>
       ). Studies are needed to confirm if nursing pigs also have higher susceptibility to PDCoV infection. Anatomical and physiological factors that may contribute to the longer recovery of nursing pigs from PED include: 1) the slower turnover of enterocytes (5–7 days) in neonatal piglets compared to 2–3 days in 3-week-old weaned pigs (
       <xref ref-type="bibr" rid="bib0195">
        Moon et al., 1973
       </xref>
       ); and 2) the anatomically underdeveloped large intestine of nursing piglets that may increase their vulnerability to dehydration, compared to weaned pigs (
       <xref ref-type="bibr" rid="bib0105">
        Jung et al., 2015a
       </xref>
       ). There was also a lack of crypt stem cells and lower numbers of proliferating crypt cells in the small intestine of nursing pigs, compared to weaned pigs (
       <xref ref-type="bibr" rid="bib0105">
        Jung et al., 2015a
       </xref>
       ). This could lead to the slower turnover of enterocytes in nursing vs weaned pigs, contributing to a slower recovery from PED in nursing piglets and the greater susceptibility of nursing pigs to PED (diarrhea and dehydration). Because of the similar pathological features between PDCoV and PEDV, studies are needed to confirm if PDCoV infection may also induce greater disease severity and deaths of nursing piglets vs. weaned pigs by mechanisms similar to those contributing factors to PEDV infection.
      </p>
     </sec>
     <sec id="sec0095">
      <label>
       6.7
      </label>
      <title>
       Acute viremia
      </title>
      <p id="par0130">
       Viremia where viral RNA in serum ranged from 10
       <sup>
        0.5
       </sup>
       –10
       <sup>
        3
       </sup>
       TCID
       <sub>
        50
       </sub>
       /mL was detected in conventional 5-day-old pigs (15/15; 100%) inoculated with the USA/IL/2014 strain at PID 4 (incubation period) and PID 5–7 (clinical period) (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ). Similarly, viral RNA in serum ranged from 3.4–4.1 log
       <sub>
        10
       </sub>
       copies of PDCoV RNA/mL in 19-day-old Gn pigs inoculated with the Ohio wild-type field CVM1 strain at PID 1–3 (clinical period) (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). In another study, viral RNA in serum ranged from 4.8–5.2 log
       <sub>
        10
       </sub>
       GE/mL in Gn piglets (6/6; 100%) inoculated with the US TC-PDCoV OH-FD22 during the clinical period at PID 3 (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). The early, severe diarrhea/vomiting might be accompanied by acute, transient viremia, but no one has yet confirmed the presence of infectious virus in the serum. Similar to PEDV infection of nursing pigs that was accompanied by early viremia (viral RNA, up to 100%), viremia in PDCoV-infected pigs might also be related to the severity of atrophic enteritis and structural alteration of tight and adherens junctions in the jejunal and ileal villous epithelium in the small intestine (
       <xref ref-type="bibr" rid="bib0110">
        Jung et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0100">
        Jung et al., 2014
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0100">
      <label>
       6.8
      </label>
      <title>
       Immune responses to PDCoV
      </title>
      <p id="par0135">
       There is a dearth of information on the innate and adaptive immune responses to PDCoV. After PDCoV infection, infiltration of macrophages, lymphocytes, eosinophils, and neutrophils were observed in the lamina propria of the small intestine (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0245">
        Wang et al., 2015a
       </xref>
       ). Our study reported the development of PDCoV-specific antibodies in serum of PDCoV-infected pigs (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). The 14-day-old Gn pigs orally inoculated with the original OH-FD22 and TC-PDCoV OH-FD22 (P5, P20, and P40) had detectable serum IgG, IgA and virus neutralization (VN) antibodies at PID 14. Thereafter, PDCoV-specific IgG, IgA and VN antibody titers increased and remained high at the end of experiment, PID 23/24, when the pigs were fully recovered from clinical disease and fecal virus RNA shedding. Similarly, in PEDV CV777-infected pigs, serum PEDV-specific IgG antibody was first detected at approximately PID 7–12 (
       <xref ref-type="bibr" rid="bib0040">
        de Arriba et al., 2002
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0105">
      <label>
       6.9
      </label>
      <title>
       Virulence of high cell culture-passaged PDCoV (P80)
      </title>
      <p id="par0140">
       The TC-PDCoV OH-FD22 has been serially passaged &gt;P90 on LLC-PK cells. Our study confirmed the enteropathogenicity of TC-PDCoV OH-FD22 P5, P20, and P40 in Gn pigs (
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ). The virulence appeared to be similar to that of the parent wild-type virus, as evident by severe diarrhea/vomiting, atrophic enteritis, and high levels of serum IgG, IgA and VN antibodies in inoculated Gn pigs. Our pilot study also revealed that two 10-day-old Gn pigs inoculated orally with 10.2 log
       <sub>
        10
       </sub>
       GE of the TC-PDCoV OH-FD22 P80 (passage 80) developed delayed (by 1–3 days), but severe clinical signs with high viral RNA shedding titers in the feces, ranging from 7.7 to 8.8 log
       <sub>
        10
       </sub>
       GE/ml at PIDs 5 and 6, which is similar to those in Gn pigs inoculated with the original field strain OH-FD22 or TC-PDCoV OH-FD22 (cell passages 5–40). Therefore, the TC-PDCoV OH-FD22 needs to be further passaged to evaluate if higher cell-culture passaged virus becomes attenuated, because attenuation of the virulence of PEDV strains has been induced through high cell-culture passages (93rd–144th) (
       <xref ref-type="bibr" rid="bib0020">
        Chen et al., 2015a
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0135">
        Kweon et al., 1999
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0205">
        Sato et al., 2011
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0215">
        Song et al., 2003
       </xref>
       ).
      </p>
     </sec>
     <sec id="sec0110">
      <label>
       6.10
      </label>
      <title>
       Co-infections with PDCoV and other enteric viruses
      </title>
      <p id="par0145">
       The severity of clinical disease caused by PDCoV in nursing piglets may be affected by co-infections with other viruses including rotavirus (RV) and PEDV. However, the impact of dual PDCoV and PEDV or rotavirus infection on the disease outcome in pigs needs to be delineated. A survey conducted in the US reported that of 293 samples collected from diarrheic pigs in the US and Canada in early 2014, 89 (30%) were PDCoV-positive by RT-PCR (
       <xref ref-type="bibr" rid="bib0190">
        Marthaler et al., 2014b
       </xref>
       ). Of the 89 PDCoV-positive samples, 69 (78%) were positive for PEDV, group A RV (RVA), RVB, or RVC. Co-infections with PDCoV and RVC were the most common [52 (58%) samples], and 29 (29/89; 33%) were also positive for PEDV. Our lab also identified that seven (41.2%) of 42 PDCoV-positive samples, collected on different farms with diarrhea outbreaks in Ohio and Indiana, were also positive for PEDV (3 samples) or RVC (4 samples) by RT-PCR (
       <xref ref-type="bibr" rid="bib0075">
        Hu et al., 2015
       </xref>
       ). In mainland China, a surveillance study based on nested RT-PCR results reported that of 356 porcine diarrheic samples collected in Jiangxi during 2012–2015, 120 (33.7%) were PDCoV-positive; 231 (64.9%) were PEDV-positive; and 281(78.9%) were positive for either PEDV or PDCoV (
       <xref ref-type="bibr" rid="bib0220">
        Song et al., 2015
       </xref>
       ). Co-infections with PDCoV and PEDV (19.7%) were common in diarrheic pigs in Jiangxi, China. Another study tested by RT-PCR reported that of 215 diarrheic samples collected in Anhui, Guangxi, Hubei, and Jiangsu during 2004–2014, 14 (6.51%) were positive for PDCoV, 110 (51.2%) were positive for PEDV, and 5 (2.3%) were positive for TGEV. Of the 14 PDCoV-positive samples, 7 (50%) were also positive for PEDV; and 2 were co-infected with PEDV, TGEV, and PDCoV.
      </p>
     </sec>
    </sec>
    <sec id="sec0115">
     <label>
      7
     </label>
     <title>
      Lesions
     </title>
     <sec id="sec0120">
      <label>
       7.1
      </label>
      <title>
       Gross lesions
      </title>
      <p id="par0150">
       In infected nursing pigs, similar to PEDV and TGEV infections (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), gross lesions are limited to the gastrointestinal tract and are characterized by thin and transparent intestinal walls (proximal jejunum to colon) with accumulation of large amounts of yellow fluid in the intestinal lumen (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). The stomach is filled with curdled milk. The transparency and fragility of affected intestines appeared milder, as compared to PEDV infections.
      </p>
     </sec>
     <sec id="sec0125">
      <label>
       7.2
      </label>
      <title>
       Histological lesions
      </title>
      <p id="par0155">
       In infected nursing pigs, similar to PEDV and TGEV infections (
       <xref ref-type="bibr" rid="bib0090">
        Jung and Saif, 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0200">
        Saif et al., 2012
       </xref>
       ), histological lesions are characterized by acute, multifocal to diffuse, mild to severe atrophic enteritis in the proximal jejunum to ileum (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0245">
        Wang et al., 2015a
       </xref>
       ), occasionally accompanied by mild vacuolation of superficial epithelial cells in the cecum and colon that coincided with a few PDCoV antigen-positive cecal and colonic epithelial cells (
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ). No villous atrophy or histologic lesions were evident in the remainder of the small intestine, duodenum (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ), which coincided with few PDCoV antigen-positive duodenal epithelial cells. During acute infection, vacuolated enterocytes or massive cell exfoliation were seen on the tips or the entire villi in the jejunum and ileum. Atrophied villi are frequently fused and covered with a degenerated or regenerated flattened epithelium. Infiltration of inflammatory cells, such as macrophages, lymphocytes, neutrophils, and eosinophils, was evident in the lamina propria (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0245">
        Wang et al., 2015a
       </xref>
       ). No lesions were seen in other organs, such as stomach, lung, spleen, liver, kidney, and MLN of infected pigs, all of which were also negative for PDCoV antigen (
       <xref ref-type="bibr" rid="bib0025">
        Chen et al., 2015b
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0080">
        Hu et al., 2016
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0115">
        Jung et al., 2015c
       </xref>
       ,
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ). However, one study found an acute, focal, mild degeneration or necrosis of gastric epithelial cells in the gastric pits of stomach (
       <xref ref-type="bibr" rid="bib0170">
        Ma et al., 2015
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec id="sec0130">
     <label>
      8
     </label>
     <title>
      Conclusions
     </title>
     <p id="par0160">
      PDCoV is a novel enteropathogenic coronavirus in pigs. The disease related to PDCoV was first reported in the US in early 2014, when PEDV infections were also epidemic. However, since 2005–2006, DCoVs already had been identified in rectal swabs of wild small mammals (Asian leopard cats and Chinese ferret badgers), domestic pigs, and wild birds. Moreover, PDCoV (CHN-AH-2004 and CH/Sichuan/S27/2012 strains), genetically related to the current US PDCoV strains, has been present in Chinese diarrheic pigs since 2004, prior to the first outbreak of PDCoV infection in US swine. Although birds are thought to be the suspect host for
      <italic>
       Deltacoronaviruses,
      </italic>
      the detailed genetic relatedness of PDCoV with other DCoV isolates from wild birds and other mammal species should be studied further to clarify the origin of PDCoV in pigs and also the source of the sudden emergence of US PDCoV in US swine.
     </p>
     <p id="par0165">
      US PDCoV strains are enteropathogenic and infect villous epithelial cells of the entire small and large intestines, although the jejunum and ileum are the primary sites of infection. Similar to PEDV (alphacoronavirus) infections, PDCoV (deltacoronavirus) infections also cause acute, severe atrophic enteritis accompanied by viremia (viral RNA) that leads to severe diarrhea and/or vomiting, followed by dehydration as the potential cause of death in nursing piglets. Differential diagnosis of PEDV, PDCoV and TGEV is essential to control viral diarrheas in US pig farms. Currently, cultivable, US TC-PDCoV strains have been isolated and propagated in several laboratories. TC-PDCoV strains will be useful to evaluate if high level cell-culture passaged viruses become attenuated and can be potential vaccine candidate strains. Relative to PEDV infections, causing similar, but more severe clinical disease and lesions, the lack of comprehensive understanding of the pathogenic characteristics of PDCoV and effective preventive (PDCoV vaccine) and therapeutic interventions has impeded biosecurity and development of methods for prevention and control of PDCoV in US swine. It is also critical to understand the pathogenic aspects of PDCoV infection distinct from those of PEDV, possibly clarifying why PDCoV infection results in distinctively lower mortality rates in nursing pigs, as compared to the high mortality usually observed among PEDV-infected seronegative nursing pigs.
     </p>
    </sec>
    <sec id="sec0135">
     <title>
      Conflict of interest
     </title>
     <p id="par0170">
      None of the authors of this paper has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper. The authors have no conflict of interest to declare.
     </p>
    </sec>
    <back>
     <ref-list id="bibl0005">
      <title>
       References
      </title>
      <ref id="bib0005">
       <element-citation id="sbref0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alonso
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Goede
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Morrison
          </surname>
          <given-names>
           R.B.
          </given-names>
         </name>
         <name>
          <surname>
           Davies
          </surname>
          <given-names>
           P.R.
          </given-names>
         </name>
         <name>
          <surname>
           Rovira
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Marthaler
          </surname>
          <given-names>
           D.G.
          </given-names>
         </name>
         <name>
          <surname>
           Torremorell
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Evidence of infectivity of airborne porcine epidemic diarrhea virus and detection of airborne viral RNA at long distances from infected herds
        </article-title>
        <source>
         Vet. Res.
        </source>
        <volume>
         45
        </volume>
        <year>
         2014
        </year>
        <fpage>
         73
        </fpage>
        <pub-id pub-id-type="pmid">
         25017790
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0010">
       <element-citation id="sbref0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Annamalai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Age-dependent variation in innate immune responses to porcine epidemic diarrhea virus infection in suckling versus weaned pigs
        </article-title>
        <source>
         Vet. Immunol. Immunopathol.
        </source>
        <volume>
         168
        </volume>
        <year>
         2015
        </year>
        <fpage>
         193
        </fpage>
        <lpage>
         202
        </lpage>
        <pub-id pub-id-type="pmid">
         26433606
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0015">
       <element-citation id="sbref0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anon
          </surname>
         </name>
        </person-group>
        <article-title>
         USDA to require reports of PED
        </article-title>
        <source>
         J. Am. Vet. Med. Assoc.
        </source>
        <volume>
         244
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1234
        </fpage>
        <pub-id pub-id-type="pmid">
         24968453
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0020">
       <element-citation id="sbref0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Ku
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative genomic analysis of classical and variant virulent parental/attenuated strains of porcine epidemic diarrhea virus
        </article-title>
        <source>
         Viruses
        </source>
        <volume>
         7
        </volume>
        <year>
         2015
        </year>
        <fpage>
         5525
        </fpage>
        <lpage>
         5538
        </lpage>
        <pub-id pub-id-type="pmid">
         26512689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0025">
       <element-citation id="sbref0025" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Stafne
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Arruda
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Burrough
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Madson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Brodie
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Magstadt
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Derscheid
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Welch
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity and pathogenesis of a United States porcine deltacoronavirus cell culture isolate in 5-day-old neonatal piglets
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         482
        </volume>
        <year>
         2015
        </year>
        <fpage>
         51
        </fpage>
        <lpage>
         59
        </lpage>
        <pub-id pub-id-type="pmid">
         25817405
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0030">
       <element-citation id="sbref0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cima
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viral disease affects U.S. pigs: porcine epidemic diarrhea found in at least 11 states
        </article-title>
        <source>
         J. Am. Vet. Med. Assoc.
        </source>
        <volume>
         243
        </volume>
        <year>
         2013
        </year>
        <fpage>
         30
        </fpage>
        <lpage>
         31
        </lpage>
        <pub-id pub-id-type="pmid">
         23943942
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0035">
       <element-citation id="sbref0035" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coussement
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Ducatelle
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Debouck
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hoorens
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of experimental CV777 coronavirus enteritis in piglets. I. Histological and histochemical studyI
        </article-title>
        <source>
         Vet. Pathol.
        </source>
        <volume>
         19
        </volume>
        <year>
         1982
        </year>
        <fpage>
         46
        </fpage>
        <lpage>
         56
        </lpage>
        <pub-id pub-id-type="pmid">
         6280359
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0040">
       <element-citation id="sbref0040" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Arriba
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Carvajal
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Pozo
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rubio
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isotype-specific antibody-secreting cells in systemic and mucosal associated lymphoid tissues and antibody responses in serum of conventional pigs inoculated with PEDV
        </article-title>
        <source>
         Vet. Immunol. Immunopathol.
        </source>
        <volume>
         84
        </volume>
        <year>
         2002
        </year>
        <fpage>
         1
        </fpage>
        <lpage>
         16
        </lpage>
        <pub-id pub-id-type="pmid">
         11825594
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0045">
       <element-citation id="sbref0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Debouck
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Coussement
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The pathogenesis of an enteric infection in pigs, experimentally induced by the coronavirus-like agent, CV 777
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         6
        </volume>
        <year>
         1981
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         165
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0050">
       <element-citation id="sbref0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Clement
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Schelkopf
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Nerem
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Knudsen
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Christopher-Hennings
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Nelson
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An evaluation of contaminated complete feed as a vehicle for porcine epidemic diarrhea virus infection of naive pigs following consumption via natural feeding behavior: proof of concept
        </article-title>
        <source>
         BMC Vet. Res.
        </source>
        <volume>
         10
        </volume>
        <year>
         2014
        </year>
        <fpage>
         176
        </fpage>
        <pub-id pub-id-type="pmid">
         25091641
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0055">
       <element-citation id="sbref0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Delmas
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Gelfi
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           L’Haridon
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Vogel
          </surname>
          <given-names>
           L.K.
          </given-names>
         </name>
         <name>
          <surname>
           Sjostrom
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Noren
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Laude
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         357
        </volume>
        <year>
         1992
        </year>
        <fpage>
         417
        </fpage>
        <lpage>
         420
        </lpage>
        <pub-id pub-id-type="pmid">
         1350661
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0060">
       <element-citation id="sbref0060" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           B.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Fan
          </surname>
          <given-names>
           X.H.
          </given-names>
         </name>
         <name>
          <surname>
           Vijaykrishna
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X.C.
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.F.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.X.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           L.Q.
          </given-names>
         </name>
         <name>
          <surname>
           Poon
          </surname>
          <given-names>
           L.L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Smith
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection of a novel and highly divergent coronavirus from asian leopard cats and Chinese ferret badgers in Southern China
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         81
        </volume>
        <year>
         2007
        </year>
        <fpage>
         6920
        </fpage>
        <lpage>
         6926
        </lpage>
        <pub-id pub-id-type="pmid">
         17459938
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0065">
       <element-citation id="sbref0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zeng
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine deltacoronavirus in mainland China
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         2254
        </fpage>
        <lpage>
         2255
        </lpage>
        <pub-id pub-id-type="pmid">
         26584185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0070">
       <element-citation id="sbref0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ducatelle
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Coussement
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Debouck
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Hoorens
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of experimental CV777 coronavirus enteritis in piglets. II. Electron microscopic study
        </article-title>
        <source>
         Vet. Pathol.
        </source>
        <volume>
         19
        </volume>
        <year>
         1982
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         6280360
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0075">
       <element-citation id="sbref0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vlasova
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Chepngeno
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation and characterization of porcine deltacoronavirus from pigs with diarrhea in the United States
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         1537
        </fpage>
        <lpage>
         1548
        </lpage>
        <pub-id pub-id-type="pmid">
         25740769
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0080">
       <element-citation id="sbref0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Vlasova
          </surname>
          <given-names>
           A.N.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experimental infection of gnotobiotic pigs with the cell culture-adapted porcine deltacoronavirus strain OH-FD22
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <year>
         2016
        </year>
        <comment>
         (submitted)
        </comment>
       </element-citation>
      </ref>
      <ref id="bib0085">
       <element-citation id="sbref0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Janetanakit
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lumyai
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Bunpapong
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Boonyapisitsopa
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Chaiyawong
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Nonthabenjawan
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Kesdaengsakonwut
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Amonsin
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine deltacoronavirus, Thailand, 2015
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         22
        </volume>
        <year>
         2016
        </year>
        <fpage>
         757
        </fpage>
        <lpage>
         759
        </lpage>
        <pub-id pub-id-type="pmid">
         26982324
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0090">
       <element-citation id="sbref0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine epidemic diarrhea virus infection: etiology, epidemiology, pathogenesis and immunoprophylaxis
        </article-title>
        <source>
         Vet. J.
        </source>
        <volume>
         204
        </volume>
        <year>
         2015
        </year>
        <fpage>
         134
        </fpage>
        <lpage>
         143
        </lpage>
        <pub-id pub-id-type="pmid">
         25841898
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0095">
       <element-citation id="sbref0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Ahn
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Chae
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Decreased activity of brush border membrane-bound digestive enzymes in small intestines from pigs experimentally infected with porcine epidemic diarrhea virus
        </article-title>
        <source>
         Res. Vet. Sci.
        </source>
        <volume>
         81
        </volume>
        <year>
         2006
        </year>
        <fpage>
         310
        </fpage>
        <lpage>
         315
        </lpage>
        <pub-id pub-id-type="pmid">
         16759679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0100">
       <element-citation id="sbref0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Scheuer
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathology of US porcine epidemic diarrhea virus strain PC21A in gnotobiotic pigs
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         662
        </fpage>
        <lpage>
         665
        </lpage>
        <pub-id pub-id-type="pmid">
         24795932
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0105">
       <element-citation id="sbref0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Annamalai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative pathogenesis of US porcine epidemic diarrhea virus (PEDV) strain PC21A in conventional 9-day-old nursing piglets vs. 26-day-old weaned pigs
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         178
        </volume>
        <year>
         2015
        </year>
        <fpage>
         31
        </fpage>
        <lpage>
         40
        </lpage>
        <pub-id pub-id-type="pmid">
         25939885
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0110">
       <element-citation id="sbref0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Eyerly
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Annamalai
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structural alteration of tight and adherens junctions in villous and crypt epithelium of the small and large intestine of conventional nursing piglets infected with porcine epidemic diarrhea virus
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         177
        </volume>
        <year>
         2015
        </year>
        <fpage>
         373
        </fpage>
        <lpage>
         378
        </lpage>
        <pub-id pub-id-type="pmid">
         25843943
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0115">
       <element-citation id="sbref0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Eyerly
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           Z.
          </given-names>
         </name>
         <name>
          <surname>
           Chepngeno
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pathogenicity of 2 porcine deltacoronavirus strains in gnotobiotic pigs
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         21
        </volume>
        <year>
         2015
        </year>
        <fpage>
         650
        </fpage>
        <lpage>
         654
        </lpage>
        <pub-id pub-id-type="pmid">
         25811229
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0120">
       <element-citation id="sbref0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine deltacoronavirus induces apoptosis in swine testicular and LLC porcine kidney cell lines in vitro but not in infected intestinal enterocytes in vivo
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         182
        </volume>
        <year>
         2016
        </year>
        <fpage>
         57
        </fpage>
        <lpage>
         63
        </lpage>
        <pub-id pub-id-type="pmid">
         26711029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0125">
       <element-citation id="sbref0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chae
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmissible gastroenteritis virus induces apoptosis in swine testicular cell lines but not in intestinal enterocytes
        </article-title>
        <source>
         J. Comp. Pathol.
        </source>
        <volume>
         123
        </volume>
        <year>
         2000
        </year>
        <fpage>
         64
        </fpage>
        <lpage>
         66
        </lpage>
        <pub-id pub-id-type="pmid">
         10906258
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0130">
       <element-citation id="sbref0130" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           King
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Carstens
          </surname>
          <given-names>
           E.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lefkowitz
          </surname>
          <given-names>
           E.J.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses
        </chapter-title>
        <year>
         2012
        </year>
        <publisher-name>
         Elsevier Academic Press
        </publisher-name>
        <publisher-loc>
         San Diego, CA, USA
        </publisher-loc>
        <fpage>
         785
        </fpage>
        <lpage>
         795
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0135">
       <element-citation id="sbref0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Kweon
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Kwon
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Kwon
          </surname>
          <given-names>
           G.O.
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           Y.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Derivation of attenuated porcine epidemic diarrhea virus (PEDV) as vaccine candidate
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         17
        </volume>
        <year>
         1999
        </year>
        <fpage>
         2546
        </fpage>
        <lpage>
         2553
        </lpage>
        <pub-id pub-id-type="pmid">
         10418901
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0140">
       <element-citation id="sbref0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complete genome characterization of Korean Porcine deltacoronavirus strain KOR/KNU14-04/2014
        </article-title>
        <source>
         Genome Announc.
        </source>
        <volume>
         2
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e01191
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         25428966
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0145">
       <element-citation id="sbref0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Functional characterization and proteomic analysis of the nucleocapsid protein of porcine deltacoronavirus
        </article-title>
        <source>
         Virus Res.
        </source>
        <volume>
         208
        </volume>
        <year>
         2015
        </year>
        <fpage>
         136
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         26103099
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0150">
       <element-citation id="sbref0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           H.C.
          </given-names>
         </name>
         <name>
          <surname>
           Nguyen
          </surname>
          <given-names>
           V.G.
          </given-names>
         </name>
         <name>
          <surname>
           Moon
          </surname>
          <given-names>
           H.J.
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           H.K.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           S.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           G.E.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection and phylogenetic analysis of porcine deltacoronavirus in Korean swine farms, 2015
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <year>
         2016
        </year>
       </element-citation>
      </ref>
      <ref id="bib0155">
       <element-citation id="sbref0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           B.X.
          </given-names>
         </name>
         <name>
          <surname>
           Ge
          </surname>
          <given-names>
           J.W.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine aminopeptidase N is a functional receptor for the PEDV coronavirus
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         365
        </volume>
        <year>
         2007
        </year>
        <fpage>
         166
        </fpage>
        <lpage>
         172
        </lpage>
        <pub-id pub-id-type="pmid">
         17467767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0160">
       <element-citation id="sbref0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Harmon
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Hoogland
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Main
          </surname>
          <given-names>
           R.G.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Full-length genome sequence of porcine deltacoronavirus strain USA/IA/2014/8734
        </article-title>
        <source>
         Genome Announc.
        </source>
        <volume>
         2
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e00278
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         24723718
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0165">
       <element-citation id="sbref0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lowe
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Harmon
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Connor
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yeske
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Loula
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Levis
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
         <name>
          <surname>
           Dufresne
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Main
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Role of transportation in spread of porcine epidemic diarrhea virus infection, United States
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         872
        </fpage>
        <lpage>
         874
        </lpage>
        <pub-id pub-id-type="pmid">
         24750785
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0170">
       <element-citation id="sbref0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Lou
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Oglesbee
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krakowka
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Origin, evolution, and virulence of porcine deltacoronaviruses in the United States
        </article-title>
        <source>
         mBio
        </source>
        <volume>
         6
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e00064
        </fpage>
        <pub-id pub-id-type="pmid">
         25759498
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0175">
       <element-citation id="sbref0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ma
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Oglesbee
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Krakowka
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Neihaus
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Two-way antigenic cross-activity between porcine epidemic diarrhea virus and porcine deltacoronavirus
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         186
        </volume>
        <year>
         2016
        </year>
        <fpage>
         90
        </fpage>
        <lpage>
         96
        </lpage>
        <pub-id pub-id-type="pmid">
         27016762
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0180">
       <element-citation id="sbref0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Madson
          </surname>
          <given-names>
           D.M.
          </given-names>
         </name>
         <name>
          <surname>
           Arruda
          </surname>
          <given-names>
           P.H.
          </given-names>
         </name>
         <name>
          <surname>
           Magstadt
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Burrough
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hoang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bower
          </surname>
          <given-names>
           L.P.
          </given-names>
         </name>
         <name>
          <surname>
           Bhandari
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Stevenson
          </surname>
          <given-names>
           G.W.
          </given-names>
         </name>
         <name>
          <surname>
           Wilberts
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Characterization of porcine epidemic diarrhea virus isolate US/Iowa/18984/2013 infection in 1-day-old cesarean-derived colostrum-deprived piglets
        </article-title>
        <source>
         Vet. Pathol.
        </source>
        <volume>
         53
        </volume>
        <year>
         2015
        </year>
        <fpage>
         44
        </fpage>
        <lpage>
         52
        </lpage>
        <pub-id pub-id-type="pmid">
         26113613
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0185">
       <element-citation id="sbref0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marthaler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rossow
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complete genome sequence of strain SDCV/USA/Illinois121/2014, a porcine deltacoronavirus from the United States
        </article-title>
        <source>
         Genome Announc.
        </source>
        <volume>
         2
        </volume>
        <year>
         2014
        </year>
        <fpage>
         e00218
        </fpage>
        <lpage>
         14
        </lpage>
        <pub-id pub-id-type="pmid">
         24723704
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0190">
       <element-citation id="sbref0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Marthaler
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Raymond
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Collins
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Rossow
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Rovira
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid detection, complete genome sequencing, and phylogenetic analysis of porcine deltacoronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1347
        </fpage>
        <lpage>
         1350
        </lpage>
        <pub-id pub-id-type="pmid">
         25075556
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0195">
       <element-citation id="sbref0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Moon
          </surname>
          <given-names>
           H.W.
          </given-names>
         </name>
         <name>
          <surname>
           Norman
          </surname>
          <given-names>
           J.O.
          </given-names>
         </name>
         <name>
          <surname>
           Lambert
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Age dependent resistance to transmissible gastroenteritis of swine (TGE). I. Clinical signs and some mucosal dimensions in small intestine
        </article-title>
        <source>
         Can. J. Comp. Med.
        </source>
        <volume>
         37
        </volume>
        <year>
         1973
        </year>
        <fpage>
         157
        </fpage>
        <lpage>
         166
        </lpage>
        <pub-id pub-id-type="pmid">
         4266695
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0200">
       <element-citation id="sbref0200" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Saif
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Pensaert
          </surname>
          <given-names>
           M.P.
          </given-names>
         </name>
         <name>
          <surname>
           Sestak
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Yeo
          </surname>
          <given-names>
           S.G.
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <chapter-title>
         Coronaviruses
        </chapter-title>
        <source>
         Diseases of Swine
        </source>
        <edition>
         10th ed.
        </edition>
        <year>
         2012
        </year>
        <publisher-name>
         Wiley-Blackwell Iowa State University
        </publisher-name>
        <fpage>
         501
        </fpage>
        <lpage>
         524
        </lpage>
       </element-citation>
      </ref>
      <ref id="bib0205">
       <element-citation id="sbref0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sato
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Takeyama
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Katsumata
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Tuchiya
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Kodama
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Kusanagi
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Mutations in the spike gene of porcine epidemic diarrhea virus associated with growth adaptation in vitro and attenuation of virulence in vivo
        </article-title>
        <source>
         Virus Genes
        </source>
        <volume>
         43
        </volume>
        <year>
         2011
        </year>
        <fpage>
         72
        </fpage>
        <lpage>
         78
        </lpage>
        <pub-id pub-id-type="pmid">
         21559974
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0210">
       <element-citation id="sbref0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sinha
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Harmon
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         PCR-based retrospective evaluation of diagnostic samples for emergence of porcine deltacoronavirus in US swine
        </article-title>
        <source>
         Vet. Microbiol.
        </source>
        <volume>
         179
        </volume>
        <year>
         2015
        </year>
        <fpage>
         296
        </fpage>
        <lpage>
         298
        </lpage>
        <pub-id pub-id-type="pmid">
         26119039
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0215">
       <element-citation id="sbref0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           D.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           B.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Differentiation of a Vero cell adapted porcine epidemic diarrhea virus from Korean field strains by restriction fragment length polymorphism analysis of ORF 3
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         21
        </volume>
        <year>
         2003
        </year>
        <fpage>
         1833
        </fpage>
        <lpage>
         1842
        </lpage>
        <pub-id pub-id-type="pmid">
         12706667
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0220">
       <element-citation id="sbref0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
         <name>
          <surname>
           He
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Newly emerged porcine deltacoronavirus associated with diarrhoea in swine in China: identification, prevalence and full-length genome sequence analysis
        </article-title>
        <source>
         Transbound. Emerg. Dis.
        </source>
        <volume>
         62
        </volume>
        <year>
         2015
        </year>
        <fpage>
         575
        </fpage>
        <lpage>
         580
        </lpage>
        <pub-id pub-id-type="pmid">
         26250097
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0225">
       <element-citation id="sbref0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stevenson
          </surname>
          <given-names>
           G.W.
          </given-names>
         </name>
         <name>
          <surname>
           Hoang
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Schwartz
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Burrough
          </surname>
          <given-names>
           E.R.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Madson
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Cooper
          </surname>
          <given-names>
           V.L.
          </given-names>
         </name>
         <name>
          <surname>
           Pillatzki
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gauger
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Schmitt
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Koster
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
         <name>
          <surname>
           Killian
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Yoon
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Emergence of Porcine epidemic diarrhea virus in the United States: clinical signs, lesions, and viral genomic sequences
        </article-title>
        <source>
         J. Vet. Diagn. Invest.
        </source>
        <volume>
         25
        </volume>
        <year>
         2013
        </year>
        <fpage>
         649
        </fpage>
        <lpage>
         654
        </lpage>
        <pub-id pub-id-type="pmid">
         23963154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0230">
       <element-citation id="sbref0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Thachil
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           P.F.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Opriessnig
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development and application of an ELISA for the detection of porcine deltacoronavirus IgG antibodies
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         10
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e0124363
        </fpage>
        <pub-id pub-id-type="pmid">
         25881086
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0235">
       <element-citation id="sbref0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Detection and genetic characterization of deltacoronavirus in pigs, Ohio, USA, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1227
        </fpage>
        <lpage>
         1230
        </lpage>
        <pub-id pub-id-type="pmid">
         24964136
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0240">
       <element-citation id="sbref0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine coronavirus HKU15 detected in 9 US states, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <year>
         2014
        </year>
        <fpage>
         1594
        </fpage>
        <lpage>
         1595
        </lpage>
        <pub-id pub-id-type="pmid">
         25153521
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0245">
       <element-citation id="sbref0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Hayes
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Sarver
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Byrum
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Porcine deltacoronavirus: histological lesions and genetic characterization
        </article-title>
        <source>
         Arch. Virol.
        </source>
        <volume>
         161
        </volume>
        <year>
         2015
        </year>
        <fpage>
         171
        </fpage>
        <lpage>
         175
        </lpage>
        <pub-id pub-id-type="pmid">
         26475155
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0250">
       <element-citation id="sbref0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
         <name>
          <surname>
           Yue
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Complete genome sequence of porcine deltacoronavirus strain CH/Sichuan/S27/2012 from mainland China
        </article-title>
        <source>
         Genome Announc.
        </source>
        <volume>
         3
        </volume>
        <year>
         2015
        </year>
        <fpage>
         e00945
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="pmid">
         26337879
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0255">
       <element-citation id="sbref0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus diversity: phylogeny and interspecies jumping
        </article-title>
        <source>
         Exp. Biol. Med. (Maywood)
        </source>
        <volume>
         234
        </volume>
        <year>
         2009
        </year>
        <fpage>
         1117
        </fpage>
        <lpage>
         1127
        </lpage>
        <pub-id pub-id-type="pmid">
         19546349
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0260">
       <element-citation id="sbref0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           K.K.
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Luk
          </surname>
          <given-names>
           G.S.
          </given-names>
         </name>
         <name>
          <surname>
           Dyrting
          </surname>
          <given-names>
           K.C.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         83
        </volume>
        <year>
         2009
        </year>
        <fpage>
         908
        </fpage>
        <lpage>
         917
        </lpage>
        <pub-id pub-id-type="pmid">
         18971277
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bib0265">
       <element-citation id="sbref0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Woo
          </surname>
          <given-names>
           P.C.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           S.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Lau
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Bai
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Teng
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
         <name>
          <surname>
           Tsang
          </surname>
          <given-names>
           C.C.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           K.H.
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         86
        </volume>
        <year>
         2012
        </year>
        <fpage>
         3995
        </fpage>
        <lpage>
         4008
        </lpage>
        <pub-id pub-id-type="pmid">
         22278237
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ack0005">
      <title>
       Acknowledgements
      </title>
      <p>
       Salaries and research support were provided by state and federal funds appropriated to the
       <funding-source id="gs0005">
        Ohio Agricultural Research and Development Center, The Ohio State University
       </funding-source>
       . This paper was in part supported by a grant from the
       <funding-source id="gs0010">
        OARDC SEEDS
       </funding-source>
       Grants Program, Grant OHOA1536 (Jung K, PI).
      </p>
     </ack>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Emerg Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Emerging Infect. Dis
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       EID
      </journal-id>
      <journal-title-group>
       <journal-title>
        Emerging Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1080-6040
      </issn>
      <issn pub-type="epub">
       1080-6059
      </issn>
      <publisher>
       <publisher-name>
        Centers for Disease Control and Prevention
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       31961300
      </article-id>
      <article-id pub-id-type="pmc">
       6986839
      </article-id>
      <article-id pub-id-type="publisher-id">
       19-0697
      </article-id>
      <article-id pub-id-type="doi">
       10.3201/eid2602.190697
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Perspective
        </subject>
       </subj-group>
       <subj-group subj-group-type="article-type">
        <subject>
         Perspective
        </subject>
       </subj-group>
       <subj-group subj-group-type="TOC-title">
        <subject>
         Middle East Respiratory Syndrome Coronavirus Transmission
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Middle East Respiratory Syndrome Coronavirus Transmission
       </article-title>
       <alt-title alt-title-type="running-head">
        MERS-CoV Transmission
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Killerby
         </surname>
         <given-names>
          Marie E.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Biggs
         </surname>
         <given-names>
          Holly M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Midgley
         </surname>
         <given-names>
          Claire M.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gerber
         </surname>
         <given-names>
          Susan I.
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Watson
         </surname>
         <given-names>
          John T.
         </given-names>
        </name>
       </contrib>
       <aff id="aff1">
        Centers for Disease Control and Prevention, Atlanta, Georgia, USA
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address for correspondence: Marie E. Killerby, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop H24-5, Atlanta, GA 30329-4027, USA; email:
        <email xlink:href="lxo9@cdc.gov">
         lxo9@cdc.gov
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        2
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       26
      </volume>
      <issue>
       2
      </issue>
      <fpage>
       191
      </fpage>
      <lpage>
       198
      </lpage>
      <abstract>
       <p>
        Middle East respiratory syndrome coronavirus (MERS-CoV) infection causes a spectrum of respiratory illness, from asymptomatic to mild to fatal. MERS-CoV is transmitted sporadically from dromedary camels to humans and occasionally through human-to-human contact. Current epidemiologic evidence supports a major role in transmission for direct contact with live camels or humans with symptomatic MERS, but little evidence suggests the possibility of transmission from camel products or asymptomatic MERS cases. Because a proportion of case-patients do not report direct contact with camels or with persons who have symptomatic MERS, further research is needed to conclusively determine additional mechanisms of transmission, to inform public health practice, and to refine current precautionary recommendations.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <title>
        Keywords:
       </title>
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        Middle East respiratory syndrome
       </kwd>
       <kwd>
        coronavirus
       </kwd>
       <kwd>
        emerging infectious disease
       </kwd>
       <kwd>
        healthcare-associated transmission
       </kwd>
       <kwd>
        dromedary
       </kwd>
       <kwd>
        camel
       </kwd>
       <kwd>
        epidemiology
       </kwd>
       <kwd>
        viruses
       </kwd>
       <kwd>
        zoonoses
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <p>
     Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) was first detected in Saudi Arabia in 2012 (
     <xref ref-type="bibr" rid="R1">
      <italic>
       1
      </italic>
     </xref>
     ). To date, &gt;2,400 cases globally have been reported to the World Health Organization (WHO), including &gt;850 deaths (case fatality rate ≈35%) (
     <xref ref-type="bibr" rid="R2">
      <italic>
       2
      </italic>
     </xref>
     ). Illness associated with MERS-CoV infection ranges from asymptomatic or mild upper respiratory illness to severe respiratory distress and death.
    </p>
    <p>
     MERS-CoV is a zoonotic virus, and dromedary camels are a reservoir host (
     <xref ref-type="bibr" rid="R3">
      <italic>
       3
      </italic>
     </xref>
     –
     <xref ref-type="bibr" rid="R5">
      <italic>
       5
      </italic>
     </xref>
     ). Bats are a likely original reservoir; coronaviruses similar to MERS-CoV have been identified in bats (
     <xref ref-type="bibr" rid="R6">
      <italic>
       6
      </italic>
     </xref>
     ), but epidemiologic evidence of their role in transmission is lacking. Infection of other livestock species with MERS-CoV is possible (
     <xref ref-type="bibr" rid="R7">
      <italic>
       7
      </italic>
     </xref>
     ); however, attempts to inoculate goats, sheep, and horses with live MERS-CoV did not produce viral shedding (
     <xref ref-type="bibr" rid="R8">
      <italic>
       8
      </italic>
     </xref>
     ), and no epidemiologic evidence has implicated any species other than dromedaries in transmission.
    </p>
    <p>
     Sporadic zoonotic transmission from dromedaries has resulted in limited human-to-human transmission chains, usually in healthcare or household settings (
     <xref ref-type="bibr" rid="R9">
      <italic>
       9
      </italic>
     </xref>
     –
     <xref ref-type="bibr" rid="R14">
      <italic>
       14
      </italic>
     </xref>
     ) (
     <xref ref-type="fig" rid="F1">
      Figure
     </xref>
     ). MERS-CoV human cases result from primary or secondary transmission. Primary transmission is classified as transmission not resulting from contact with a confirmed human MERS case-patient (
     <xref ref-type="bibr" rid="R15">
      <italic>
       15
      </italic>
     </xref>
     ) and can result from zoonotic transmission from camels or from an unidentified source. Conzade et al. reported that, among cases classified as primary by the WHO, only 191 (54.9%) persons reported contact with dromedaries (
     <xref ref-type="bibr" rid="R15">
      <italic>
       15
      </italic>
     </xref>
     ). Secondary transmission is classified as transmission resulting from contact with a human MERS case-patient, typically characterized as healthcare-associated or household-associated, as appropriate. However, many MERS case-patients have no reported exposure to a prior MERS patient or healthcare setting or to camels, meaning the source of infection is unknown. Among 1,125 laboratory-confirmed MERS-CoV cases reported to WHO during January 1, 2015–April 13, 2018, a total of 157 (14%) had unknown exposure (
     <xref ref-type="bibr" rid="R15">
      <italic>
       15
      </italic>
     </xref>
     ).
    </p>
    <fig fig-type="figure" id="F1" position="float">
     <label>
      Figure
     </label>
     <caption>
      <p>
       Summary of Middle East respiratory syndrome coronavirus transmission pathways. Solid lines indicate known transmission pathways; dashed lines indicate possible transmission pathways for which supporting evidence is limited or unknown.
      </p>
     </caption>
     <graphic xlink:href="19-0697-F">
     </graphic>
    </fig>
    <p>
     Although broad categories of exposure are associated with transmission (e.g., exposure to camels or to healthcare facilities with ill patients), exact mechanisms of MERS-CoV transmission are not fully understood. Little direct epidemiologic evidence exists regarding transmission routes or the efficacy of interventions in reducing transmission. However, other potentially important factors, including detection of virus in different secretions, detection and survival of virus in the environment, and detection of virus in aerosols, lend support for the biological plausibility of certain transmission pathways. We summarize the available evidence regarding camel-to-camel, camel-to-human, and human-to-human transmission of MERS-CoV, including direct epidemiologic evidence and evidence supporting biologically plausible transmission routes.
    </p>
    <sec sec-type="other1">
     <title>
      MERS-CoV in Camels
     </title>
     <sec>
      <title>
       Evidence for Infection of Camels
      </title>
      <p>
       MERS-CoV infection in camels has been demonstrated through serologic investigations, molecular evidence using real-time reverse transcription PCR (rRT-PCR), and by virus isolation, as described in recent reviews (
       <xref ref-type="bibr" rid="R16">
        <italic>
         16
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R17">
        <italic>
         17
        </italic>
       </xref>
       ). Geographically wide-ranging seroprevalence studies have identified MERS-CoV–specific antibodies in camels in countries across the Middle East and North, West, and East Africa, often with &gt;90% seroprevalence in adult camels (
       <xref ref-type="bibr" rid="R18">
        <italic>
         18
        </italic>
       </xref>
       ). Studies in many of these countries have shown molecular evidence of MERS-CoV RNA and isolation of infectious MERS-CoV in camels (
       <xref ref-type="bibr" rid="R16">
        <italic>
         16
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R17">
        <italic>
         17
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R19">
        <italic>
         19
        </italic>
       </xref>
       –
       <xref ref-type="bibr" rid="R21">
        <italic>
         21
        </italic>
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Viral Shedding in Camels
      </title>
      <p>
       In naturally or experimentally infected camels, MERS-CoV appears to cause an upper respiratory tract infection with or without symptoms, including nasal and lachrymal discharge, coughing, sneezing, elevated body temperature, and loss of appetite (
       <xref ref-type="bibr" rid="R20">
        <italic>
         20
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R23">
        <italic>
         23
        </italic>
       </xref>
       ). In naturally infected camels, MERS-CoV RNA has been recovered most commonly from nasal swabs but also from fecal swabs, rectal swabs, and lung tissue (
       <xref ref-type="bibr" rid="R20">
        <italic>
         20
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R24">
        <italic>
         24
        </italic>
       </xref>
       ). No evidence of viral RNA has been demonstrated in camel serum, blood, or urine using rRT-PCR (
       <xref ref-type="bibr" rid="R25">
        <italic>
         25
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R26">
        <italic>
         26
        </italic>
       </xref>
       ). In experimentally infected camels, infectious virus and RNA was detected in nasal swab and oral samples but not in blood, serum, feces, or urine (
       <xref ref-type="bibr" rid="R23">
        <italic>
         23
        </italic>
       </xref>
       ). MERS-CoV RNA has been detected in raw camel milk collected using traditional milking methods, including using a suckling calf as stimulus for milk letdown; presence of live virus was not evaluated (
       <xref ref-type="bibr" rid="R27">
        <italic>
         27
        </italic>
       </xref>
       ). Virus RNA may therefore have been introduced via calf saliva or nasal secretions or fecal contamination. Experimentally introduced virus can survive in milk but did not survive when heat treated (
       <xref ref-type="bibr" rid="R28">
        <italic>
         28
        </italic>
       </xref>
       ). It is also not known if the virus would remain viable in milk from seropositive dams when antibodies could be found in the milk.
      </p>
      <p>
       These shedding data indicate that contact with camel nasal secretions, saliva, and respiratory droplets carry potential risk for camel-to-human or camel-to-camel transmission. Contact with nasal secretions can occur when directly handling live camels, and virus from camel nasal secretions can contaminate fomites in the environment (
       <xref ref-type="bibr" rid="R29">
        <italic>
         29
        </italic>
       </xref>
       ). Although rRT-PCR evidence of MERS-CoV and genome fragments have been detected in air samples from a camel barn (
       <xref ref-type="bibr" rid="R30">
        <italic>
         30
        </italic>
       </xref>
       ), no live virus was detected, and no epidemiologic study has implicated airborne transmission. Transmission following exposure to camel feces may be biologically plausible, although no epidemiologic evidence indicates the likelihood of such transmission. Similarly, although transmission following consumption of raw camel milk may be biologically plausible, epidemiologic studies have not consistently identified milk consumption as a unique risk factor for MERS-CoV infection or illness, independent of other direct or indirect camel exposures (
       <xref ref-type="bibr" rid="R31">
        <italic>
         31
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R32">
        <italic>
         32
        </italic>
       </xref>
       ). No epidemiologic evidence supports transmission associated with camel urine or meat.
      </p>
     </sec>
     <sec>
      <title>
       Camel-to-Camel Transmission Dynamics
      </title>
      <p>
       MERS-CoV RNA is detected most frequently in younger camels (
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R25">
        <italic>
         25
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R33">
        <italic>
         33
        </italic>
       </xref>
       ) but has been detected in camels &gt;4 years of age (
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       ). In a longitudinal study of a camel dairy herd, most calves became infected with MERS-CoV at 5–6 months of age, around the time maternal MERS-CoV antibodies wane. The calves then produced MERS-CoV antibodies by 11–12 months of age (
       <xref ref-type="bibr" rid="R34">
        <italic>
         34
        </italic>
       </xref>
       ). In seroprevalence studies, camels &lt;2 years of age demonstrated lower seroprevalence than camels &gt;2 years of age (
       <xref ref-type="bibr" rid="R25">
        <italic>
         25
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R35">
        <italic>
         35
        </italic>
       </xref>
       ). Across many countries, the seroprevalence of adult camels is &gt;90% (
       <xref ref-type="bibr" rid="R16">
        <italic>
         16
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R17">
        <italic>
         17
        </italic>
       </xref>
       ). Overall, these data suggest most camels are initially infected with MERS-CoV at &lt;2 years of age. However, camels can shed virus despite preexisting MERS-CoV antibodies, suggesting that repeat infections are possible (
       <xref ref-type="bibr" rid="R36">
        <italic>
         36
        </italic>
       </xref>
       ,
       <xref ref-type="bibr" rid="R37">
        <italic>
         37
        </italic>
       </xref>
       ). Varying prevalence of MERS-CoV RNA in camels has been reported in different countries and settings, such as farms (
       <xref ref-type="bibr" rid="R33">
        <italic>
         33
        </italic>
       </xref>
       ) and live animal markets (
       <xref ref-type="bibr" rid="R38">
        <italic>
         38
        </italic>
       </xref>
       ). Risk for camel-to-camel or camel-to-human transmission may be influenced by crowding, mixing of camels from multiple sources, transportation, and characteristics of live animal markets (
       <xref ref-type="bibr" rid="R39">
        <italic>
         39
        </italic>
       </xref>
       ). Phylogenetic modeling has provided supportive evidence that long-term MERS-CoV evolution has occurred exclusively in camels, with humans acting as a transient and usually terminal host (
       <xref ref-type="bibr" rid="R40">
        <italic>
         40
        </italic>
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec sec-type="other2">
     <title>
      Zoonotic Transmission
     </title>
     <sec>
      <title>
       Evidence and Risk Factors for Zoonotic Transmission
      </title>
      <p>
       Persons in Saudi Arabia with occupational exposure to camels demonstrated higher seroprevalence of MERS-CoV–specific antibodies (camel shepherds, 2.3%; slaughterhouse workers, 3.6%) compared with the general population (0.2%) (
       <xref ref-type="bibr" rid="R41">
        <italic>
         41
        </italic>
       </xref>
       ). A case–control study of primary human cases and matched controls also showed that camel exposure was more likely among case-patients than matched controls (
       <xref ref-type="bibr" rid="R31">
        <italic>
         31
        </italic>
       </xref>
       ). Further evidence supporting camel-to-human transmission includes identical or nearly identical MERS-CoV sequences found in camels and humans (
       <xref ref-type="bibr" rid="R41">
        <italic>
         41
        </italic>
       </xref>
       –
       <xref ref-type="bibr" rid="R45">
        <italic>
         45
        </italic>
       </xref>
       ).
      </p>
      <p>
       Occupational groups with frequent exposure to camels have been assessed through seroepidemiologic studies. In Qatar, a study of 9 seropositive and 43 matched seronegative camel workers showed that regular involvement in training and herding of camels, cleaning farm equipment, not handwashing before and after camel handling, and milking camels were associated with seropositivity (
       <xref ref-type="bibr" rid="R46">
        <italic>
         46
        </italic>
       </xref>
       ). In a Saudi Arabia study of 30 camel workers in which 50% were seropositive for MERS-CoV, no association was identified between seropositivity and factors including age, smoking, handwashing after camel contact, consuming camel meat or milk, or specific occupation (camel truck driver, handler, or herder) (
       <xref ref-type="bibr" rid="R47">
        <italic>
         47
        </italic>
       </xref>
       ). Neither investigation controlled for possible confounding risk factors (e.g., age or duration of exposure to camels). In Abu Dhabi, an investigation of 235 market and slaughterhouse workers showed that 17% were seropositive for MERS-CoV and that daily contact with camels or their waste, working as a camel salesman, and self-reported diabetes were risk factors for seropositivity (
       <xref ref-type="bibr" rid="R32">
        <italic>
         32
        </italic>
       </xref>
       ). Among market workers in the same study, handling live camels and either cleaning equipment (e.g., halters, water troughs, etc.) or administering medications to camels were risk factors on multivariable analysis (
       <xref ref-type="bibr" rid="R32">
        <italic>
         32
        </italic>
       </xref>
       ). These studies generally support the hypothesis that direct physical contact with camels is a risk factor for transmission, although cleaning equipment could also result in indirect transmission.
      </p>
     </sec>
     <sec>
      <title>
       Potential Seasonality of Human Cases
      </title>
      <p>
       Previous findings suggest that MERS-CoV circulation among camels peaks in late winter through early summer (
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       <italic>
        ,
       </italic>
       <xref ref-type="bibr" rid="R26">
        <italic>
         26
        </italic>
       </xref>
       <italic>
        ,
       </italic>
       <xref ref-type="bibr" rid="R48">
        <italic>
         48
        </italic>
       </xref>
       ). Initial MERS-CoV infection in camels is thought to occur at ≈6 months of age, after the typical winter calving season. Investigations have demonstrated different seasonal peaks for MERS-CoV infection in camels: November–January (
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       ) and December–April (
       <xref ref-type="bibr" rid="R48">
        <italic>
         48
        </italic>
       </xref>
       ) in Saudi Arabia, January–June in Egypt (
       <xref ref-type="bibr" rid="R26">
        <italic>
         26
        </italic>
       </xref>
       ). A seasonal peak has been suggested to result in a corresponding peak in zoonotic transmission, and an April–July peak has been supported by phylogenetic modeling (
       <xref ref-type="bibr" rid="R40">
        <italic>
         40
        </italic>
       </xref>
       ). However, camels have been found to be rRT-PCR positive for MERS-CoV throughout the year (
       <xref ref-type="bibr" rid="R22">
        <italic>
         22
        </italic>
       </xref>
       ). Further investigations are needed to demonstrate seasonality of MERS-CoV infection in camels and link these patterns to seasonal peaks of zoonotic transmission.
      </p>
     </sec>
     <sec>
      <title>
       Zoonotic MERS-CoV Transmission outside the Arabian Peninsula
      </title>
      <p>
       Despite evidence of circulating MERS-CoV in camels in North, East, and West Africa (
       <xref ref-type="bibr" rid="R49">
        <italic>
         49
        </italic>
       </xref>
       ), limited evidence of human infection exists from Africa. In Kenya, no MERS-CoV antibodies were detected among 760 persons with occupational exposure to camels (
       <xref ref-type="bibr" rid="R50">
        <italic>
         50
        </italic>
       </xref>
       ). In a separate study in Kenya, 2 seropositive adults who kept other livestock but not camels were identified among 1,122 persons who were predominantly without occupational exposure to camels (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        51
       </italic>
       ). In Nigeria, no MERS-CoV antibodies were found in 261 slaughterhouse workers with exposure to camels (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        52
       </italic>
       ). MERS-CoV sequences from camels in Africa phylogenetically cluster separately relative to camel and human MERS-CoV from the Arabian Peninsula, suggesting single or few introductions into Saudi Arabia and limited contact (
       <xref ref-type="bibr" rid="R19">
        <italic>
         19
        </italic>
       </xref>
       ). Differences in virus growth have been shown between MERS-CoV strains isolated from West Africa and those isolated from the Middle East (
       <xref ref-type="bibr" rid="R19">
        <italic>
         19
        </italic>
       </xref>
       ); relative to human and camel MERS-CoV from Saudi Arabia, virus isolates from Burkina Faso and Nigeria had lower virus replication competence in ex vivo cultures of human bronchus and lung. These findings may suggest regional variation in the potential for MERS-CoV replication in humans. Other factors contributing to the limited evidence of zoonotic MERS transmission in Africa may include differences between virus surveillance, human populations, camel populations, camel husbandry, and the type of human–camel interactions in these regions.
      </p>
     </sec>
     <sec>
      <title>
       Prevention of Zoonotic Transmission
      </title>
      <p>
       WHO recommends that anyone presumed at higher risk for severe illness (e.g., persons who are older, have diabetes, or are immunocompromised) should avoid contact with camels and raw camel products (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        53
       </italic>
       ). Although no evidence definitively links raw camel products with MERS-CoV infection, WHO presents these precautions in the context of considerable knowledge gaps surrounding MERS-CoV transmission. In addition, WHO recommends basic hygiene precautions for persons with occupational exposure to camels (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        53
       </italic>
       ).
      </p>
     </sec>
    </sec>
    <sec sec-type="other3">
     <title>
      Human-to-Human Transmission
     </title>
     <p>
      After zoonotic introduction, human-to-human transmission of MERS-CoV can occur, but humans are considered transient or terminal hosts (
      <xref ref-type="bibr" rid="R40">
       <italic>
        40
       </italic>
      </xref>
      ), with no evidence for sustained human-to-human community transmission. In addition to limited household transmission, large, explosive outbreaks in healthcare settings have been periodically documented. In South Korea in 2015, a single infected traveler returning from the Arabian Peninsula was linked to an outbreak of 186 cases, including 38 deaths (case-fatality rate 20%) (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       54
      </italic>
      ). Multiple other healthcare-associated outbreaks have been described in Saudi Arabia (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      references
      <italic>
       55
      </italic>
      ,
      <italic>
       56
      </italic>
      ), Jordan (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       57
      </italic>
      ), and United Arab Emirates (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       58
      </italic>
      ). Healthcare transmission has also occurred outside the Arabian Peninsula from exported cases, including in the United Kingdom (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       59
      </italic>
      ) and France (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       60
      </italic>
      ). Given their size and scope, healthcare-associated outbreaks have provided most of the context for investigation of risk factors for human-to-human transmission.
     </p>
     <sec>
      <title>
       Viral Shedding in Humans
      </title>
      <p>
       MERS-CoV shedding in humans appears to differ from the pattern of viral shedding in camels. In humans, MERS-CoV RNA and live virus have been detected in both upper (nasopharyngeal and oropharyngeal swab) and lower (sputum, tracheal aspirate, and bronchoalveolar lavage fluid) respiratory tract samples, although RNA levels are often higher in the lower respiratory tract (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        61
       </italic>
       ). In humans, MERS-CoV is predominantly thought to infect the lower respiratory tract (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        62
       </italic>
       ), where the MERS-CoV dipeptidyl peptidase-4 (DPP4) receptor predominates, in contrast to camels, where DPP4 is found predominantly in the upper respiratory tract (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        63
       </italic>
       ). More severely ill patients typically have higher MERS-CoV RNA levels, as indicated by rRT-PCR cycle threshold (C
       <sub>
        t
       </sub>
       ) values and more prolonged viral shedding (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        64
       </italic>
       ). MERS-CoV RNA has been detected from the lower respiratory tract &gt;1 month after illness onset (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        65
       </italic>
       ,
       <italic>
        66
       </italic>
       ), and live virus has been isolated up to 25 days after symptom onset (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        67
       </italic>
       ). RNA detection is prolonged in the respiratory tract of patients with diabetes mellitus, even when adjusting for illness severity (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        66
       </italic>
       ). Among mildly ill patients, who might typically be isolated at home, viral RNA levels in the upper respiratory tract have been detected for several weeks (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        68
       </italic>
       ,
       <italic>
        69
       </italic>
       ). Infectious virus has been isolated from the upper respiratory tract of a patient with mild symptoms (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        68
       </italic>
       ), suggesting a potential for transmission among less severely ill patients. However, there is no definitive evidence of transmission from asymptomatic cases, and epidemiologic evidence suggests that transmission from mildly symptomatic or asymptomatic cases does not readily occur (Appendix reference
       <italic>
        70
       </italic>
       ).
      </p>
      <p>
       In humans, MERS-CoV RNA has been detected outside of the respiratory tract (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        66
       </italic>
       ,
       <italic>
        71
       </italic>
       ,
       <italic>
        72
       </italic>
       ). Viral RNA has been detected in the whole blood or serum of mildly or severely ill patients (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        66
       </italic>
       ,
       <italic>
        72
       </italic>
       ) and in the urine of patients who subsequently died (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        66
       </italic>
       ), although virus isolation attempts on urine samples (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        66
       </italic>
       ) and serum (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        71
       </italic>
       ) have been unsuccessful. MERS-CoV RNA has also been detected from the stool of mildly and severely ill patients (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        66
       </italic>
       ). Subgenomic MERS-CoV RNA, an intermediate in the virus replication cycle, has been detected in stool, suggesting that MERS-CoV might replicate in the gastrointestinal tract (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        73
       </italic>
       ); however, it is not clear if this contributes to pathogenesis or transmission.
      </p>
     </sec>
     <sec>
      <title>
       Reproduction Number and Attack Rates
      </title>
      <p>
       The number of secondary cases resulting from a single initial case (reproduction number, R0) (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        74
       </italic>
       ) ranges widely for MERS-CoV, e.g., from 8.1 in the South Korea outbreak, compared with an overall R0 of 0.45 in Saudi Arabia (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        74
       </italic>
       ). Superspreading events, which generally describe a single MERS-CoV case epidemiologically linked to
       <underline>
        &gt;
       </underline>
       5 subsequent cases, have been frequently described, particularly in healthcare-associated outbreaks (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        55
       </italic>
       ,
       <italic>
        56
       </italic>
       ). R0 estimates, however, can vary depending on numerous biologic, sociobehavioral, and environmental factors, and must be interpreted with caution (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        75
       </italic>
       ). Most studies estimating R0 across multiple areas, or at the end stage of an outbreak, result in estimates of R0&lt;1, consistent with the knowledge that the virus does not continue to circulate in humans and that outbreaks are eventually contained. A wide range in published attack rates (the proportion of exposed persons who are infected) has also been reported (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        74
       </italic>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Transmission in Healthcare Facilities
      </title>
      <p>
       Multiple studies have examined risk factors for MERS-CoV transmission in healthcare facilities. Higher viral loads (rRT-PCR C
       <sub>
        t
       </sub>
       values) in respiratory tract samples have been linked to transmission risk (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        76
       </italic>
       ). Kim et al. described heterogeneity of transmission in South Korea in 2015, where 22 of 186 cases were associated with further transmission of MERS-CoV and 5 superspreading events accounted for 150 of 186 cases (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        54
       </italic>
       ). On multivariable analysis, transmission was associated with lower C
       <sub>
        t
       </sub>
       values (indicating higher viral RNA load) and preisolation hospitalization or emergency department visits. Superspreading events were associated with a higher number of preisolation contacts, increased preisolation emergency room visits, and visiting multiple healthcare providers.
      </p>
      <p>
       Alraddadi et al. studied risk factors for MERS-CoV infection in 20 healthcare workers in Saudi Arabia using serologic testing (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        77
       </italic>
       ) and found that N95 respirator use among healthcare workers decreased the risk for seropositivity. Conversely, wearing a medical mask (as opposed to not wearing a medical mask) increased the risk for seropositivity, but this finding was observed in a small number of persons and was strongly correlated with not wearing an N95 respirator. All 20 healthcare workers had been in the same room or automobile or within 2 m of a MERS patient. This study provided evidence to suggest that aerosol transmission of MERS-CoV may be possible at close range, as seen with other respiratory viruses (e.g., influenza) spread primarily by droplet or contact transmission, particularly during aerosol-generating procedures. Having participated in infection control training specific to MERS-CoV was associated with a decreased risk for seropositivity; in healthcare workers in South Korea, a lack of personal protective equipment (PPE) use was more likely in MERS-CoV–infected healthcare workers than among exposed uninfected healthcare workers (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        78
       </italic>
       ).
      </p>
      <p>
       Studies have shown infection among persons without close and prolonged exposure to MERS case-patients during healthcare-associated outbreaks. In Jeddah during 2014, a total of 53 healthcare-associated cases were reported among hospitalized patients, of whom only 5 had documented presence in the same room as a MERS case-patient (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        79
       </italic>
       ). Among the remaining healthcare-associated cases, many shared common treatment locations (e.g., dialysis unit) but denied being in the same room as a MERS case-patient. Similar observations were documented during a multihospital outbreak in Jordan in 2015, and anecdotal evidence suggested a potential role for fomite transmission associated with a common imaging table and portable echocardiogram machine (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        80
       </italic>
       ).
      </p>
      <p>
       MERS-CoV has been cultured from environmental objects, such as bed sheets, bedrails, intravenous fluid hangers, and radiograph devices, suggesting the potential for environmental transmission (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        67
       </italic>
       ). Viral RNA has also been identified in air samples from the hospital rooms of MERS patients (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        81
       </italic>
       ). MERS-CoV has also been shown to be relatively stable in the environment under various conditions (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        82
       </italic>
       ), supporting the possibility of fomite transmission, although definitive epidemiologic evidence implicating fomite or aerosol transmission is lacking.
      </p>
     </sec>
     <sec>
      <title>
       Prevention of Healthcare-Associated Transmission
      </title>
      <p>
       Studies have described delays in case recognition and establishment of infection control precautions as factors in healthcare-associated transmission (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        54
       </italic>
       ,
       <italic>
        56
       </italic>
       ,
       <italic>
        79
       </italic>
       ). Triage practices that result in rapid isolation of suspected MERS case-patients and application of transmission-based precautions can decrease opportunities for early transmission. However, implementing triage procedures to quickly identify potential MERS cases in areas with local MERS-CoV transmission (e.g., Arabian Peninsula) is challenging because signs and symptoms are often nonspecific (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        83
       </italic>
       ). In addition, complications or exacerbations of concurrent conditions, including chronic kidney or heart disease, can manifest with acute or worsening respiratory symptoms that delay suspicion for MERS. Patient crowding has been associated with transmission in healthcare facilities, particularly in emergency departments (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        54
       </italic>
       ,
       <italic>
        79
       </italic>
       ). In multiple outbreaks, inconsistent PPE use has been reported as contributing to transmission (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        56,58
       </italic>
       ), and transmission to healthcare personnel despite reported use of appropriate PPE (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        56
       </italic>
       ,
       <italic>
        78
       </italic>
       ) suggests that improper PPE use may contribute to transmission. Transmission risk may be particularly high during aerosol-generating procedures, in which large quantities of virus might be aerosolized.
      </p>
     </sec>
     <sec>
      <title>
       Household Transmission
      </title>
      <p>
       Human-to-human transmission of MERS-CoV has been reported among household contacts. Drosten et al. described 12 probable cases among 280 household contacts of 26 index case-patients (
       <xref ref-type="bibr" rid="R13">
        <italic>
         13
        </italic>
       </xref>
       ). Arwady et al. investigated MERS-CoV infections in an extended family of 79 relatives, of whom 19 (24%) tested positive for MERS-CoV by rRT-PCR or serology (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        84
       </italic>
       ). Risk factors for acquisition included sleeping in an index case-patient’s room and touching their secretions. A study of MERS-CoV infection in a group of expatriate women housed in a dormitory in Riyadh, Saudi Arabia, showed an overall infection attack rate of 2.7% (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        85
       </italic>
       ). Risk factors for infection include direct contact with a confirmed case-patient and sharing a room with a confirmed case-patient; a protective factor was having an air conditioner in the bedroom. However, transmission among household contacts is variable; Hosani et al. found that none of 105 household contacts of 34 MERS-CoV case-patients showed antibodies to MERS-CoV (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        70
       </italic>
       ). Among those 34 patients, 31 were asymptomatic or mildly symptomatic, suggesting a lower risk for transmission among this group.
      </p>
     </sec>
     <sec>
      <title>
       Viral Factors Affecting Human-to-Human Transmission
      </title>
      <p>
       No evidence has been reported that mutations or recombinations in MERS-CoV have led to changes in human-to-human transmission. Recombination has been documented among coronaviruses (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        86
       </italic>
       ) and has been linked to increasing pathogenicity in strains of other animal RNA viruses (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        87
       </italic>
       ). Circulation of recombinant MERS-CoV has beenoc described in Saudi Arabia in camels (
       <xref ref-type="bibr" rid="R48">
        <italic>
         48
        </italic>
       </xref>
       ) and humans (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       references
       <italic>
        88,89
       </italic>
       ) but no substantial change in human epidemiology was seen with this circulating variant (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        89
       </italic>
       ). Deletion variants of MERS-CoV were identified in humans in Jordan (
       <xref ref-type="local-data" rid="SD1">
        Appendix
       </xref>
       reference
       <italic>
        57
       </italic>
       ), also without notable changes in epidemiology (Appendix reference
       <italic>
        80
       </italic>
       ).
      </p>
     </sec>
    </sec>
    <sec sec-type="conclusions">
     <title>
      Conclusions
     </title>
     <p>
      In areas in which MERS-CoV actively circulates among camels, human cases can result from zoonotic transmission. In these areas, close contact with camels (e.g., handling or training) is an identified risk factor for infection. Direct or indirect contact with nasal secretions probably plays a role. Given limited knowl­edge of mechanisms of MERS-CoV transmission, current precautions to prevent zoonotic transmission, such as recommendations to avoid consumption of raw cam­el milk and meat, are prudent despite the lack of epidemiologic evidence linking these exposures to MERS-CoV infec­tion. Such precautionary recommendations, while appropriate in the context of limited knowledge, should not be interpreted as evidence of an epidemiologic association with MERS-CoV transmission.
     </p>
     <p>
      Human-to-human transmission of MERS-CoV most frequently occurs following close contact with MERS patients, predominantly in healthcare settings and less frequently in household settings. Specifically, contact with respiratory secretions, whether through direct contact or through aerosolization of secretions during aerosol-generating procedures, plays a role in transmission. Virus isolation from fomites suggests the potential for alternative mechanisms of transmission, but direct epidemiologic evidence is lacking. Although MERS-CoV has been isolated from a mildly ill case-patient, available evidence is not sufficient to conclusively state that asymptomatic patients play an appreciable role in MERS-CoV transmission. Given the knowledge gaps surrounding transmission from asymptomatic patients, WHO recommendations state “until more is known, asymptomatic RT-PCR positive persons should be isolated, followed up daily for development of any symptoms, and tested at least weekly—or earlier, if symptoms develop—for MERS-CoV” (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       90
      </italic>
      ). Available evidence supports published Centers for Disease Control and Prevention guidance for infection prevention and control for hospitalized MERS patients (
      <xref ref-type="local-data" rid="SD1">
       Appendix
      </xref>
      reference
      <italic>
       91
      </italic>
      ).
     </p>
     <p>
      Large, explosive MERS-CoV outbreaks have repeatedly resulted in devastating impacts on health systems and in settings where transmission most frequently occurs. Sporadic community cases continue to be reported, and a small but consistent proportion of MERS cases have no camel, healthcare, or MERS-CoV exposure. Continuous epidemiologic and virologic monitoring is required to determine other exposures resulting in transmission and to assess for the possibility of improved virus fitness and adaptation. Until additional evidence is available to further refine recommendations to prevent MERS-CoV transmission, continued use of existing precautionary recommendations is necessary.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
     </title>
     <supplementary-material content-type="local-data" id="SD1">
      <caption>
       <title>
        Appendix
       </title>
       <p>
        Additional information about Middle East respiratory syndrome coronavirus transmission.
       </p>
      </caption>
      <media id="d35e929" mime-subtype="pdf" mimetype="application" position="anchor" xlink:href="19-0697-Techapp-s1.pdf" xlink:type="simple">
      </media>
     </supplementary-material>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="citation">
       <p>
        <italic>
         Suggested citation for this article:
        </italic>
        Killerby ME, Biggs HM, Midgley CM, Gerber SI, Watson JT. Middle East respiratory syndrome coronavirus transmission. Emerg Infect Dis. 2020 Feb [
        <italic>
         date cited
        </italic>
        ].
        <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3201/eid2602.190697">
         https://doi.org/10.3201/eid2602.190697
        </ext-link>
       </p>
      </fn>
     </fn-group>
     <bio id="d35e942">
      <p>
       Dr. Killerby is an epidemiologist in the Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention. Her research interests include respiratory viruses, such as MERS-CoV, human coronaviruses, and adenoviruses.
      </p>
     </bio>
     <ref-list>
      <title>
       References
      </title>
      <ref id="R1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Zaki
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van Boheemen
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bestebroer
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osterhaus
         </surname>
         <given-names>
          ADME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Fouchier
         </surname>
         <given-names>
          RAM
         </given-names>
        </string-name>
        .
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2012
        </year>
        ;
        <volume>
         367
        </volume>
        :
        <fpage>
         1814
        </fpage>
        –
        <lpage>
         20
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        . Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2019 Nov 1].
        <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov">
         http://www.who.int/emergencies/mers-cov
        </ext-link>
       </mixed-citation>
      </ref>
      <ref id="R3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Paden
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Yusof
         </surname>
         <given-names>
          MFBM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Hammadi
         </surname>
         <given-names>
          ZM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Queen
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tao
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eltahir
         </surname>
         <given-names>
          YM
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Zoonotic origin and transmission of Middle East respiratory syndrome coronavirus in the UAE.
        </article-title>
        <source>
         Zoonoses Public Health
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         65
        </volume>
        :
        <fpage>
         322
        </fpage>
        –
        <lpage>
         33
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1111/zph.12435
        </pub-id>
        <pub-id pub-id-type="pmid">
         29239118
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Wernery
         </surname>
         <given-names>
          U
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Woo
         </surname>
         <given-names>
          PC
         </given-names>
        </string-name>
        .
        <article-title>
         Middle East respiratory syndrome (MERS) coronavirus and dromedaries.
        </article-title>
        <source>
         Vet J
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         220
        </volume>
        :
        <fpage>
         75
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.tvjl.2016.12.020
        </pub-id>
        <pub-id pub-id-type="pmid">
         28190501
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Koopmans
         </surname>
         <given-names>
          MP
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          BL
         </given-names>
        </string-name>
        .
        <article-title>
         Cross host transmission in the emergence of MERS coronavirus.
        </article-title>
        <source>
         Curr Opin Virol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         16
        </volume>
        :
        <fpage>
         55
        </fpage>
        –
        <lpage>
         62
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.coviro.2016.01.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         26826951
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ithete
         </surname>
         <given-names>
          NL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Richards
         </surname>
         <given-names>
          LR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Schoeman
         </surname>
         <given-names>
          MC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Preiser
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat.
        </article-title>
        <source>
         J Virol
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         88
        </volume>
        :
        <fpage>
         11297
        </fpage>
        –
        <lpage>
         303
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01498-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25031349
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Kandeil
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gomaa
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shehata
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Taweel
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kayed
         </surname>
         <given-names>
          AE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abiadh
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in non-camelid domestic mammals.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         103
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1080/22221751.2018.1560235
        </pub-id>
        <pub-id pub-id-type="pmid">
         30866764
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R8">
       <label>
        8.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Adney
         </surname>
         <given-names>
          DR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Brown
         </surname>
         <given-names>
          VR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Porter
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bielefeldt-Ohmann
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hartwig
         </surname>
         <given-names>
          AE
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bowen
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        .
        <article-title>
         Inoculation of goats, sheep, and horses with MERS-CoV does not result in productive viral shedding.
        </article-title>
        <source>
         Viruses
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         8
        </volume>
        :
        <fpage>
         230
        </fpage>
        .
        <pub-id pub-id-type="doi">
         10.3390/v8080230
        </pub-id>
        <pub-id pub-id-type="pmid">
         27548203
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Assiri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abedi
         </surname>
         <given-names>
          GR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bin Saeed
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abdalla
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          al-Masry
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Choudhry
         </surname>
         <given-names>
          AJ
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         32
        </fpage>
        –
        <lpage>
         40
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2201.151370
        </pub-id>
        <pub-id pub-id-type="pmid">
         26692003
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R10">
       <label>
        10.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Balkhy
         </surname>
         <given-names>
          HH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alenazi
         </surname>
         <given-names>
          TH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alshamrani
         </surname>
         <given-names>
          MM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Baffoe-Bonnie
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Arabi
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hijazi
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Description of a hospital outbreak of Middle East Respiratory syndrome in a large tertiary care hospital in Saudi Arabia.
        </article-title>
        <source>
         Infect Control Hosp Epidemiol
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         37
        </volume>
        :
        <fpage>
         1147
        </fpage>
        –
        <lpage>
         55
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1017/ice.2016.132
        </pub-id>
        <pub-id pub-id-type="pmid">
         27426423
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Assiri
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          McGeer
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perl
         </surname>
         <given-names>
          TM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Price
         </surname>
         <given-names>
          CS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cummings
         </surname>
         <given-names>
          DA
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        ;
        <collab>
         KSA MERS-CoV Investigation Team
        </collab>
        .
        <article-title>
         Hospital outbreak of Middle East respiratory syndrome coronavirus.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         369
        </volume>
        :
        <fpage>
         407
        </fpage>
        –
        <lpage>
         16
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1306742
        </pub-id>
        <pub-id pub-id-type="pmid">
         23782161
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Oboho
         </surname>
         <given-names>
          IK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tomczyk
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Asmari
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Banjar
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Mugti
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Aloraini
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah—a link to health care facilities.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         372
        </volume>
        :
        <fpage>
         846
        </fpage>
        –
        <lpage>
         54
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1408636
        </pub-id>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Drosten
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Masri
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hossain
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Transmission of MERS-coronavirus in household contacts.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         371
        </volume>
        :
        <fpage>
         828
        </fpage>
        –
        <lpage>
         35
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1405858
        </pub-id>
        <pub-id pub-id-type="pmid">
         25162889
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zumla
         </surname>
         <given-names>
          AI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Hakeem
         </surname>
         <given-names>
          RF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stephens
         </surname>
         <given-names>
          GM
         </given-names>
        </string-name>
        .
        <article-title>
         Family cluster of Middle East respiratory syndrome coronavirus infections.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2013
        </year>
        ;
        <volume>
         368
        </volume>
        :
        <fpage>
         2487
        </fpage>
        –
        <lpage>
         94
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1303729
        </pub-id>
        <pub-id pub-id-type="pmid">
         23718156
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Conzade
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Grant
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Malik
         </surname>
         <given-names>
          MR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Elkholy
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Elhakim
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Samhouri
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Reported direct and indirect contact with dromedary camels among laboratory-confirmed MERS-CoV cases.
        </article-title>
        <source>
         Viruses
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         10
        </volume>
        :
        <fpage>
         425
        </fpage>
        .
        <pub-id pub-id-type="doi">
         10.3390/v10080425
        </pub-id>
        <pub-id pub-id-type="pmid">
         30104551
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Sikkema
         </surname>
         <given-names>
          RS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farag
         </surname>
         <given-names>
          EABA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Islam
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Atta
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CBEM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Hajri
         </surname>
         <given-names>
          MM
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Global status of Middle East respiratory syndrome coronavirus in dromedary camels: a systematic review.
        </article-title>
        <source>
         Epidemiol Infect
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         147
        </volume>
        :
        <elocation-id>
         e84
        </elocation-id>
        .
        <pub-id pub-id-type="doi">
         10.1017/S095026881800345X
        </pub-id>
        <pub-id pub-id-type="pmid">
         30869000
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R17">
       <label>
        17.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Dighe
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jombart
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Van Kerkhove
         </surname>
         <given-names>
          MD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ferguson
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        .
        <article-title>
         A systematic review of MERS-CoV seroprevalence and RNA prevalence in dromedary camels: Implications for animal vaccination.
        </article-title>
        <source>
         Epidemics
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         29
        </volume>
        :
        <elocation-id>
         100350
        </elocation-id>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.epidem.2019.100350
        </pub-id>
        <pub-id pub-id-type="pmid">
         31201040
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R18">
       <label>
        18.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Hemida
         </surname>
         <given-names>
          MG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Elmoslemany
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Hizab
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alnaeem
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Almathen
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Faye
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Dromedary camels and the transmission of Middle East respiratory syndrome coronavirus (MERS-CoV).
        </article-title>
        <source>
         Transbound Emerg Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         64
        </volume>
        :
        <fpage>
         344
        </fpage>
        –
        <lpage>
         53
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1111/tbed.12401
        </pub-id>
        <pub-id pub-id-type="pmid">
         26256102
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R19">
       <label>
        19.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          DKW
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hui
         </surname>
         <given-names>
          KPY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perera
         </surname>
         <given-names>
          RAPM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Miguel
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Niemeyer
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhao
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         MERS coronaviruses from camels in Africa exhibit region-dependent genetic diversity.
        </article-title>
        <source>
         Proc Natl Acad Sci U S A
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         115
        </volume>
        :
        <fpage>
         3144
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1073/pnas.1718769115
        </pub-id>
        <pub-id pub-id-type="pmid">
         29507189
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Hemida
         </surname>
         <given-names>
          MG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          DK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Poon
         </surname>
         <given-names>
          LL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perera
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alhammadi
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ng
         </surname>
         <given-names>
          HY
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         MERS coronavirus in dromedary camel herd, Saudi Arabia.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1231
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2007.140571
        </pub-id>
        <pub-id pub-id-type="pmid">
         24964193
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R21">
       <label>
        21.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farag
         </surname>
         <given-names>
          EA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lamers
         </surname>
         <given-names>
          MM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pas
         </surname>
         <given-names>
          SD
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Voermans
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1339
        </fpage>
        –
        <lpage>
         42
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2008.140663
        </pub-id>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Khalafalla
         </surname>
         <given-names>
          AI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lu
         </surname>
         <given-names>
          X
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Mubarak
         </surname>
         <given-names>
          AI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Dalab
         </surname>
         <given-names>
          AH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Busadah
         </surname>
         <given-names>
          KA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Erdman
         </surname>
         <given-names>
          DD
         </given-names>
        </string-name>
        .
        <article-title>
         MERS-CoV in upper respiratory tract and lungs of dromedary camels, Saudi Arabia, 2013–2014.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         1153
        </fpage>
        –
        <lpage>
         8
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2107.150070
        </pub-id>
        <pub-id pub-id-type="pmid">
         26079346
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Adney
         </surname>
         <given-names>
          DR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van Doremalen
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Brown
         </surname>
         <given-names>
          VR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bushmaker
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Scott
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          de Wit
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1999
        </fpage>
        –
        <lpage>
         2005
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2012.141280
        </pub-id>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Farag
         </surname>
         <given-names>
          EA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          BL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mohran
         </surname>
         <given-names>
          KA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Stalin Raj
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pas
         </surname>
         <given-names>
          SD
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014.
        </article-title>
        <source>
         Infect Ecol Epidemiol
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         28305
        </fpage>
        .
        <pub-id pub-id-type="doi">
         10.3402/iee.v5.28305
        </pub-id>
        <pub-id pub-id-type="pmid">
         26183160
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Alagaili
         </surname>
         <given-names>
          AN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Briese
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Mishra
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kapoor
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sameroff
         </surname>
         <given-names>
          SC
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Burbelo
         </surname>
         <given-names>
          PD
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia.
        </article-title>
        <source>
         MBio
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e00884
        </fpage>
        –
        <lpage>
         14
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.01002-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         24570370
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Ali
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shehata
         </surname>
         <given-names>
          MM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Gomaa
         </surname>
         <given-names>
          MR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kandeil
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Shesheny
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Kayed
         </surname>
         <given-names>
          AS
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Systematic, active surveillance for Middle East respiratory syndrome coronavirus in camels in Egypt.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <elocation-id>
         e1
        </elocation-id>
        .
        <pub-id pub-id-type="doi">
         10.1038/emi.2016.130
        </pub-id>
        <pub-id pub-id-type="pmid">
         28050021
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farag
         </surname>
         <given-names>
          EA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Jonges
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Godeke
         </surname>
         <given-names>
          GJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Sayed
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Pas
         </surname>
         <given-names>
          SD
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         19
        </volume>
        :
        <fpage>
         20829
        </fpage>
        .
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES2014.19.23.20829
        </pub-id>
        <pub-id pub-id-type="pmid">
         24957745
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          van Doremalen
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bushmaker
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Karesh
         </surname>
         <given-names>
          WB
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Munster
         </surname>
         <given-names>
          VJ
         </given-names>
        </string-name>
        .
        <article-title>
         Stability of Middle East respiratory syndrome coronavirus in milk.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1263
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2007.140500
        </pub-id>
        <pub-id pub-id-type="pmid">
         24960335
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Omrani
         </surname>
         <given-names>
          AS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Tawfiq
         </surname>
         <given-names>
          JA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        .
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction.
        </article-title>
        <source>
         Pathog Glob Health
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         109
        </volume>
        :
        <fpage>
         354
        </fpage>
        –
        <lpage>
         62
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1080/20477724.2015.1122852
        </pub-id>
        <pub-id pub-id-type="pmid">
         26924345
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Azhar
         </surname>
         <given-names>
          EI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hashem
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Kafrawy
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sohrab
         </surname>
         <given-names>
          SS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Aburizaiza
         </surname>
         <given-names>
          AS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farraj
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Detection of the Middle East respiratory syndrome coronavirus genome in an air sample originating from a camel barn owned by an infected patient.
        </article-title>
        <source>
         MBio
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         5
        </volume>
        :
        <fpage>
         e01450
        </fpage>
        –
        <lpage>
         14
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.01450-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25053787
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R31">
       <label>
        31.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Alraddadi
         </surname>
         <given-names>
          BM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Watson
         </surname>
         <given-names>
          JT
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Almarashi
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abedi
         </surname>
         <given-names>
          GR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Turkistani
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Sadran
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         49
        </fpage>
        –
        <lpage>
         55
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2201.151340
        </pub-id>
        <pub-id pub-id-type="pmid">
         26692185
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Khudhair
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Killerby
         </surname>
         <given-names>
          ME
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Mulla
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abou Elkheir
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ternanni
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bandar
         </surname>
         <given-names>
          Z
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Risk factors for MERS-CoV seropositivity among animal market and slaughterhouse workers, Abu Dhabi, United Arab Emirates, 2014–2017.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2019
        </year>
        ;
        <volume>
         25
        </volume>
        :
        <fpage>
         927
        </fpage>
        –
        <lpage>
         35
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2505.181728
        </pub-id>
        <pub-id pub-id-type="pmid">
         31002068
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Wernery
         </surname>
         <given-names>
          U
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wong
         </surname>
         <given-names>
          EY
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tsang
         </surname>
         <given-names>
          AK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Muth
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lau
         </surname>
         <given-names>
          SK
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Acute middle East respiratory syndrome coronavirus infection in livestock Dromedaries, Dubai, 2014.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         1019
        </fpage>
        –
        <lpage>
         22
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2106.150038
        </pub-id>
        <pub-id pub-id-type="pmid">
         25989145
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Juhasz
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Barua
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Das Gupta
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hakimuddin
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Time course of MERS-CoV infection and immunity in dromedary camels.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         2171
        </fpage>
        –
        <lpage>
         3
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2212.160382
        </pub-id>
        <pub-id pub-id-type="pmid">
         27224315
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R35">
       <label>
        35.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          van Doremalen
         </surname>
         <given-names>
          N
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hijazeen
         </surname>
         <given-names>
          ZS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Holloway
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Omari
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          McDowell
         </surname>
         <given-names>
          C
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Adney
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         High prevalence of Middle East Respiratory coronavirus in young dromedary camels in Jordan.
        </article-title>
        <source>
         Vector Borne Zoonotic Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         17
        </volume>
        :
        <fpage>
         155
        </fpage>
        –
        <lpage>
         9
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1089/vbz.2016.2062
        </pub-id>
        <pub-id pub-id-type="pmid">
         28009529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Hemida
         </surname>
         <given-names>
          MG
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alnaeem
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          DK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Perera
         </surname>
         <given-names>
          RA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chan
         </surname>
         <given-names>
          SM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Almathen
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Longitudinal study of Middle East Respiratory Syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014-2015.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <elocation-id>
         e56
        </elocation-id>
        .
        <pub-id pub-id-type="doi">
         10.1038/emi.2017.44
        </pub-id>
        <pub-id pub-id-type="pmid">
         28634355
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R37">
       <label>
        37.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          BL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          van den Brand
         </surname>
         <given-names>
          JM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Volz
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Wohlsein
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Smits
         </surname>
         <given-names>
          SL
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels.
        </article-title>
        <source>
         Science
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         77
        </fpage>
        –
        <lpage>
         81
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.aad1283
        </pub-id>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R38">
       <label>
        38.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Yusof
         </surname>
         <given-names>
          MF
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Queen
         </surname>
         <given-names>
          K
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eltahir
         </surname>
         <given-names>
          YM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Paden
         </surname>
         <given-names>
          CR
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Hammadi
         </surname>
         <given-names>
          ZMAH
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tao
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Diversity of Middle East respiratory syndrome coronaviruses in 109 dromedary camels based on full-genome sequencing, Abu Dhabi, United Arab Emirates.
        </article-title>
        <source>
         Emerg Microbes Infect
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         6
        </volume>
        :
        <elocation-id>
         e101
        </elocation-id>
        .
        <pub-id pub-id-type="doi">
         10.1038/emi.2017.89
        </pub-id>
        <pub-id pub-id-type="pmid">
         29116217
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Fèvre
         </surname>
         <given-names>
          EM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bronsvoort
         </surname>
         <given-names>
          BM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hamilton
         </surname>
         <given-names>
          KA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cleaveland
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        .
        <article-title>
         Animal movements and the spread of infectious diseases.
        </article-title>
        <source>
         Trends Microbiol
        </source>
        .
        <year>
         2006
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         125
        </fpage>
        –
        <lpage>
         31
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2006.01.004
        </pub-id>
        <pub-id pub-id-type="pmid">
         16460942
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Dudas
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Carvalho
         </surname>
         <given-names>
          LM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Rambaut
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bedford
         </surname>
         <given-names>
          T
         </given-names>
        </string-name>
        .
        <article-title>
         MERS-CoV spillover at the camel-human interface.
        </article-title>
        <source>
         eLife
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         7
        </volume>
        :
        <elocation-id>
         e31257
        </elocation-id>
        .
        <pub-id pub-id-type="doi">
         10.7554/eLife.31257
        </pub-id>
        <pub-id pub-id-type="pmid">
         29336306
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Masri
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Turkestani
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ritz
         </surname>
         <given-names>
          D
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         15
        </volume>
        :
        <fpage>
         559
        </fpage>
        –
        <lpage>
         64
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(15)70090-3
        </pub-id>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Haagmans
         </surname>
         <given-names>
          BL
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Dhahiry
         </surname>
         <given-names>
          SHS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Reusken
         </surname>
         <given-names>
          CBEM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Raj
         </surname>
         <given-names>
          VS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Galiano
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Myers
         </surname>
         <given-names>
          R
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         14
        </volume>
        :
        <fpage>
         140
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/S1473-3099(13)70690-X
        </pub-id>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Al Hammadi
         </surname>
         <given-names>
          ZM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          DK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Eltahir
         </surname>
         <given-names>
          YM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Hosani
         </surname>
         <given-names>
          F
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Mulla
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Tarnini
         </surname>
         <given-names>
          W
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Asymptomatic MERS-CoV infection in humans possibly linked to infected dromedaries imported from Oman to United Arab Emirates, May 2015.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2015
        </year>
        ;
        <volume>
         21
        </volume>
        :
        <fpage>
         2197
        </fpage>
        –
        <lpage>
         200
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2112.151132
        </pub-id>
        <pub-id pub-id-type="pmid">
         26584223
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Memish
         </surname>
         <given-names>
          ZA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Cotten
         </surname>
         <given-names>
          M
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Watson
         </surname>
         <given-names>
          SJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Alsahafi
         </surname>
         <given-names>
          AJ
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al Rabeeah
         </surname>
         <given-names>
          AA
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013.
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         20
        </volume>
        :
        <fpage>
         1012
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3201/eid2006.140402
        </pub-id>
        <pub-id pub-id-type="pmid">
         24857749
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Azhar
         </surname>
         <given-names>
          EI
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          El-Kafrawy
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farraj
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hassan
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Saeed
         </surname>
         <given-names>
          MS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Hashem
         </surname>
         <given-names>
          AM
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Evidence for camel-to-human transmission of MERS coronavirus.
        </article-title>
        <source>
         N Engl J Med
        </source>
        .
        <year>
         2014
        </year>
        ;
        <volume>
         370
        </volume>
        :
        <fpage>
         2499
        </fpage>
        –
        <lpage>
         505
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1401505
        </pub-id>
        <pub-id pub-id-type="pmid">
         24896817
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Sikkema
         </surname>
         <given-names>
          RS
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Farag
         </surname>
         <given-names>
          EABA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Himatt
         </surname>
         <given-names>
          S
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ibrahim
         </surname>
         <given-names>
          AK
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Romaihi
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Al-Marri
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Risk factors for primary Middle East respiratory syndrome coronavirus infection in camel workers in Qatar during 2013–2014: a case–control study.
        </article-title>
        <source>
         J Infect Dis
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         215
        </volume>
        :
        <fpage>
         1702
        </fpage>
        –
        <lpage>
         5
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1093/infdis/jix174
        </pub-id>
        <pub-id pub-id-type="pmid">
         28387845
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Alshukairi
         </surname>
         <given-names>
          AN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zheng
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Zhao
         </surname>
         <given-names>
          J
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Nehdi
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Baharoon
         </surname>
         <given-names>
          SA
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Layqah
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         High prevalence of MERS-CoV infection in camel workers in Saudi Arabia.
        </article-title>
        <source>
         MBio
        </source>
        .
        <year>
         2018
        </year>
        ;
        <volume>
         9
        </volume>
        :
        <fpage>
         e01985
        </fpage>
        –
        <lpage>
         18
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/mBio.01985-18
        </pub-id>
        <pub-id pub-id-type="pmid">
         30377284
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Sabir
         </surname>
         <given-names>
          JSM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Lam
         </surname>
         <given-names>
          TT-Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ahmed
         </surname>
         <given-names>
          MMM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Li
         </surname>
         <given-names>
          L
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Shen
         </surname>
         <given-names>
          Y
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Abo-Aba
         </surname>
         <given-names>
          SEM
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia.
        </article-title>
        <source>
         Science
        </source>
        .
        <year>
         2016
        </year>
        ;
        <volume>
         351
        </volume>
        :
        <fpage>
         81
        </fpage>
        –
        <lpage>
         4
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1126/science.aac8608
        </pub-id>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Miguel
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chevalier
         </surname>
         <given-names>
          V
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ayelet
         </surname>
         <given-names>
          G
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Ben Bencheikh
         </surname>
         <given-names>
          MN
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Boussini
         </surname>
         <given-names>
          H
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Chu
         </surname>
         <given-names>
          DK
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         Risk factors for MERS coronavirus infection in dromedary camels in Burkina Faso, Ethiopia, and Morocco, 2015.
        </article-title>
        <source>
         Euro Surveill
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         22
        </volume>
        :
        <fpage>
         30498
        </fpage>
        .
        <pub-id pub-id-type="doi">
         10.2807/1560-7917.ES.2017.22.13.30498
        </pub-id>
        <pub-id pub-id-type="pmid">
         28382915
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="R50">
       <label>
        50.
       </label>
       <mixed-citation publication-type="journal">
        <string-name>
         <surname>
          Munyua
         </surname>
         <given-names>
          P
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Corman
         </surname>
         <given-names>
          VM
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Bitek
         </surname>
         <given-names>
          A
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Osoro
         </surname>
         <given-names>
          E
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Meyer
         </surname>
         <given-names>
          B
         </given-names>
        </string-name>
        ,
        <string-name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </string-name>
        ,
        <etal>
         et al.
        </etal>
        <article-title>
         No serologic evidence of Middle East respiratory syndrome coronavirus infection among camel farmers exposed to highly seropositive camel herds: a household linked study, Kenya, 2013.
        </article-title>
        <source>
         Am J Trop Med Hyg
        </source>
        .
        <year>
         2017
        </year>
        ;
        <volume>
         96
        </volume>
        :
        <fpage>
         1318
        </fpage>
        –
        <lpage>
         24
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.4269/ajtmh.16-0880
        </pub-id>
        <pub-id pub-id-type="pmid">
         28719257
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="brief-report" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Virol
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Virol
      </journal-id>
      <journal-id journal-id-type="hwp">
       jvi
      </journal-id>
      <journal-id journal-id-type="pmc">
       jvi
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JVI
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-538X
      </issn>
      <issn pub-type="epub">
       1098-5514
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       24131722
      </article-id>
      <article-id pub-id-type="pmc">
       3911734
      </article-id>
      <article-id pub-id-type="publisher-id">
       01600-13
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/JVI.01600-13
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Genetic Diversity and Evolution
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Characterization of a Novel Betacoronavirus Related to Middle East Respiratory Syndrome Coronavirus in European Hedgehogs
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Corman
         </surname>
         <given-names>
          Victor Max
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kallies
         </surname>
         <given-names>
          René
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Philipps
         </surname>
         <given-names>
          Heike
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Göpner
         </surname>
         <given-names>
          Gertraude
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          b
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          Marcel Alexander
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Eckerle
         </surname>
         <given-names>
          Isabella
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Brünink
         </surname>
         <given-names>
          Sebastian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          Christian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Drexler
         </surname>
         <given-names>
          Jan Felix
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          a
         </sup>
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         a
        </label>
        Institute of Virology, University of Bonn Medical Centre, Bonn, Germany
       </aff>
       <aff id="aff2">
        <label>
         b
        </label>
        Igel-Schutz-Initiative e.V., Laatzen, Germany
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        Address correspondence to Christian Drosten,
        <email>
         drosten@virology-bonn.de
        </email>
        , or Jan Felix Drexler,
        <email>
         drexler@virology-bonn.de
        </email>
        .
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        1
       </month>
       <year>
        2014
       </year>
      </pub-date>
      <volume>
       88
      </volume>
      <issue>
       1
      </issue>
      <fpage>
       717
      </fpage>
      <lpage>
       724
      </lpage>
      <history>
       <date date-type="received">
        <day>
         13
        </day>
        <month>
         6
        </month>
        <year>
         2013
        </year>
       </date>
       <date date-type="accepted">
        <day>
         3
        </day>
        <month>
         10
        </month>
        <year>
         2013
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2014, American Society for Microbiology. All Rights Reserved.
       </copyright-statement>
       <copyright-year>
        2014
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri xlink:href="zjv00114000717.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        Bats are known to host viruses closely related to important human coronaviruses (HCoVs), such as HCoV-229E, severe-acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome CoV (MERS-CoV). As RNA viruses may coevolve with their hosts, we sought to investigate the closest sister taxon to bats, the
        <named-content content-type="genus-species">
         Eulipotyphla
        </named-content>
        , and screened European hedgehogs (
        <named-content content-type="genus-species">
         Erinaceus europaeus
        </named-content>
        ) from Germany for CoV by nested reverse transcriptase PCR. A novel betacoronavirus species in a phylogenetic sister relationship to MERS-CoV and clade c bat CoVs was detected and characterized on the whole-genome level. A total of 58.9% of hedgehog fecal specimens were positive for the novel CoV (EriCoV) at 7.9 log
        <sub>
         10
        </sub>
        mean RNA copies per ml. EriCoV RNA concentrations were higher in the intestine than in other solid organs, blood, or urine. Detailed analyses of the full hedgehog intestine showed the highest EriCoV concentrations in lower gastrointestinal tract specimens, compatible with viral replication in the lower intestine and fecal-oral transmission. Thirteen of 27 (48.2%) hedgehog sera contained non-neutralizing antibodies against MERS-CoV. The animal origins of this betacoronavirus clade that includes MERS-CoV may thus include both bat and nonbat hosts.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Korean Med Sci
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       J. Korean Med. Sci
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JKMS
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Korean Medical Science
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       1011-8934
      </issn>
      <issn pub-type="epub">
       1598-6357
      </issn>
      <publisher>
       <publisher-name>
        The Korean Academy of Medical Sciences
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28378546
      </article-id>
      <article-id pub-id-type="pmc">
       5383605
      </article-id>
      <article-id pub-id-type="doi">
       10.3346/jkms.2017.32.5.744
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Original Article
        </subject>
        <subj-group subj-group-type="subheading">
         <subject>
          Infectious Diseases, Microbiology &amp; Parasitology
         </subject>
        </subj-group>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Clinical and Epidemiologic Characteristics of Spreaders of Middle East Respiratory Syndrome Coronavirus during the 2015 Outbreak in Korea
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0003-1952-072X
        </contrib-id>
        <name>
         <surname>
          Kang
         </surname>
         <given-names>
          Chang Kyung
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0002-4517-3840
        </contrib-id>
        <name>
         <surname>
          Song
         </surname>
         <given-names>
          Kyoung-Ho
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0001-6794-7918
        </contrib-id>
        <name>
         <surname>
          Choe
         </surname>
         <given-names>
          Pyoeng Gyun
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0003-0022-9625
        </contrib-id>
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          Wan Beom
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0002-7628-1182
        </contrib-id>
        <name>
         <surname>
          Bang
         </surname>
         <given-names>
          Ji Hwan
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0001-7132-0157
        </contrib-id>
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          Eu Suk
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0002-0550-1897
        </contrib-id>
        <name>
         <surname>
          Park
         </surname>
         <given-names>
          Sang Won
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0001-6262-372X
        </contrib-id>
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          Hong Bin
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0001-6793-9467
        </contrib-id>
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          Nam Joong
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0003-4085-1494
        </contrib-id>
        <name>
         <surname>
          Cho
         </surname>
         <given-names>
          Sung-il
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0003-4833-1178
        </contrib-id>
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          Jong-koo
         </given-names>
        </name>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
        <xref ref-type="aff" rid="A3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <contrib-id authenticated="true" contrib-id-type="orcid">
         http://orcid.org/0000-0002-2344-7695
        </contrib-id>
        <name>
         <surname>
          Oh
         </surname>
         <given-names>
          Myoung-don
         </given-names>
        </name>
        <xref ref-type="aff" rid="A1">
         1
        </xref>
        <xref ref-type="aff" rid="A2">
         2
        </xref>
       </contrib>
      </contrib-group>
      <aff id="A1">
       <label>
        1
       </label>
       Department of Internal Medicine, Seoul National University College of Medicine, Seoul,
       <country>
        Korea
       </country>
       .
      </aff>
      <aff id="A2">
       <label>
        2
       </label>
       JW Lee Center for Global Medicine, Seoul National University College of Medicine, Seoul,
       <country>
        Korea
       </country>
       .
      </aff>
      <aff id="A3">
       <label>
        3
       </label>
       Graduate School of Public Health and Institute of Health and Environment, Seoul National University, Seoul,
       <country>
        Korea
       </country>
       .
      </aff>
      <author-notes>
       <corresp>
        Address for Correspondence: Myoung-don Oh, MD, PhD. Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea.
        <email>
         mdohmd@snu.ac.kr
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        3
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       32
      </volume>
      <issue>
       5
      </issue>
      <fpage>
       744
      </fpage>
      <lpage>
       749
      </lpage>
      <history>
       <date date-type="received">
        <day>
         27
        </day>
        <month>
         12
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="accepted">
        <day>
         30
        </day>
        <month>
         1
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2017 The Korean Academy of Medical Sciences.
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
        <license-p>
         This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (
         <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">
          https://creativecommons.org/licenses/by-nc/4.0/
         </ext-link>
         ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
        </license-p>
       </license>
      </permissions>
      <abstract>
       <p>
        Nosocomial transmission is an important characteristic of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. Risk factors for transmission of MERS-CoV in healthcare settings are not well defined. During the Korean outbreak in 2015, 186 patients had laboratory-confirmed MERS-CoV infection. Those suspected as a source of viral transmission were categorized into the spreader groups (super-spreader [n = 5] and usual-spreader [n = 10]) and compared to the non-spreader group (n = 171). Body temperature of ≥ 38.5°C (adjusted odds ratio [aOR], 5.54; 95% confidence interval [CI], 1.38–22.30;
        <italic>
         P
        </italic>
        = 0.016), pulmonary infiltration of ≥ 3 lung zones (aOR, 7.33; 95% CI, 1.93–27.79;
        <italic>
         P
        </italic>
        = 0.003), and a more nonisolated in-hospital days (aOR, 1.32 per 1 day; 95% CI, 1.09–1.60;
        <italic>
         P
        </italic>
        = 0.004) were significant risk factors in the spreader group. There was no different clinical factor between super-spreaders and usual-spreaders. Nonisolated in-hospital days was the only factor which tended to be higher in super-spreaders than usual-spreaders (Mean, 6.6 vs. 2.9 days;
        <italic>
         P
        </italic>
        = 0.061). Early active quarantine might help reducing the size of an outbreak.
       </p>
      </abstract>
      <abstract abstract-type="graphical">
       <title>
        Graphical Abstract
       </title>
       <p>
        <graphic orientation="portrait" position="float" xlink:href="jkms-32-744-abf001.jpg">
        </graphic>
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <kwd>
        MERS-CoV
       </kwd>
       <kwd>
        Outbreak
       </kwd>
       <kwd>
        Hospital Infection
       </kwd>
       <kwd>
        Infection Transmission
       </kwd>
       <kwd>
        Korea
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source country="KR">
         <institution-wrap>
          <institution>
           Korea Health Industry Development Institute
          </institution>
          <institution-id institution-id-type="CrossRef">
           http://dx.doi.org/10.13039/501100003710
          </institution-id>
         </institution-wrap>
        </funding-source>
        <award-id>
         HI15C3227
        </award-id>
       </award-group>
      </funding-group>
     </article-meta>
    </front>
    <sec sec-type="intro">
     <title>
      INTRODUCTION
     </title>
     <p>
      Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel beta-coronavirus first identified in Saudi Arabia in 2012 (
      <xref ref-type="bibr" rid="B1">
       1
      </xref>
      ). It causes severe acute respiratory infection, with a mortality rate of 36% (
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      ). Most MERS-CoV infections occur in the Middle East, although travel-associated MERS cases have been reported in 17 countries outside the Middle East. As of November 3, 2016, 27 countries reported 1,813 laboratory-confirmed cases of infection with MERS-CoV, including 645 deaths, to the World Health Organization (WHO) (
      <xref ref-type="bibr" rid="B2">
       2
      </xref>
      ).
     </p>
     <p>
      In the Korean outbreak of MERS-CoV in 2015, the first known patient was a businessman returning from the Middle East. The outbreak was amplified by super-spreading events at hospitals and movement of patients between hospitals. Spreading events occurred until late June 2015, more than a month after the index patient was identified, resulting in a total of 186 patients with MERS-CoV infection and 38 fatalities, which is the largest outbreak outside the Arabian Peninsula (
      <xref ref-type="bibr" rid="B3">
       3
      </xref>
      <xref ref-type="bibr" rid="B4">
       4
      </xref>
      ). During the outbreak, almost 17,000 individuals at epidemiologic risk were quarantined, and all laboratory-confirmed cases were admitted to hospitals for isolation.
     </p>
     <p>
      Of MERS-CoV cases, 44%–100% of individual outbreaks were linked to hospitals (
      <xref ref-type="bibr" rid="B5">
       5
      </xref>
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      ) and a nosocomial outbreak of MERS-CoV may result in a large cluster of cases, the so called “super-spreading events (
      <xref ref-type="bibr" rid="B6">
       6
      </xref>
      <xref ref-type="bibr" rid="B7">
       7
      </xref>
      ).” However, it is not known whether the spreading events are attributable to host factors such as clinical manifestations or epidemiologic factors such as duration of the nonisolated period (
      <xref ref-type="bibr" rid="B8">
       8
      </xref>
      ). To understand the transmission risk of MERS-CoV in healthcare settings, we assessed the clinical and epidemiologic characteristics of non-spreaders, spreaders, and super-spreaders during the Korean outbreak.
     </p>
    </sec>
    <sec sec-type="materials|methods">
     <title>
      MATERIALS AND METHODS
     </title>
     <sec>
      <title>
       Patients and data collection
      </title>
      <p>
       All laboratory-confirmed cases were admitted to government-designated hospitals, regardless of the severity of their illness. They were discharged after the resolution of all clinical symptoms and when 2 consecutive daily sputum samples were negative for MERS-CoV by real-time reverse transcription polymerase chain reaction (rRT-PCR). Laboratory diagnoses were made according to the WHO guideline (
       <xref ref-type="bibr" rid="B9">
        9
       </xref>
       ).
      </p>
      <p>
       We reviewed the publically available epidemiologic database compiled by the Korea Centers for Disease Control and Prevention (
       <xref ref-type="bibr" rid="B3">
        3
       </xref>
       ) and clinical database compiled by the Korean Society of Infectious Diseases (KSID) (
       <xref ref-type="bibr" rid="B10">
        10
       </xref>
       ). Infectious disease specialists who had cared for MERS patients completed case record form which KSID developed. The clinical data included demographics, clinical features, and the results of the laboratory tests. Government daily reports and local Korean news reports on the MERS outbreak were also reviewed (
       <xref ref-type="bibr" rid="B11">
        11
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Definitions and subgroup analyses
      </title>
      <p>
       A spreader was defined as an index patient who was suspected of causing a secondary infection of MERS-CoV. Super-spreaders and usual-spreaders were defined as those who transmitted MERS-CoV to 6 or more and those who transmitted to fewer than 6 individuals, respectively. Nonisolated in-hospital days were defined as the sum of calendar days of the patient's hospital stay before being effectively isolated. Chest radiographs at presentation were analyzed and the number of abnormal lung zones, which were arbitrarily divided into 6 areas, was counted.
      </p>
      <p>
       For subgroup analyses, we censored cases with symptom onset after June 7 after which stricter infection control measures were implemented by the government, such as public disclosure of the names of affected hospitals, organizing rapid response teams, and applying stronger surveillance and isolation policies (
       <xref ref-type="bibr" rid="B12">
        12
       </xref>
       ). Healthcare workers were also censored in another subgroup analyses because many wore personal protective equipment, which could also confound the transmission risk.
      </p>
     </sec>
     <sec>
      <title>
       Statistical analysis
      </title>
      <p>
       Multivariate analyses in a forward stepwise manner were performed with
       <italic>
        P
       </italic>
       = 0.050 as the threshold for entering and removing variables. For all analyses, a 2-tailed
       <italic>
        P
       </italic>
       value of 0.05 was considered significant. Statistical analyses were performed with PASW for Windows (version 18 software package; SPSS, Inc., Chicago, IL, USA).
      </p>
     </sec>
     <sec>
      <title>
       Ethics statement
      </title>
      <p>
       The Institutional Review Board at the Seoul National University Hospital approved the study. The board waived the requirement for written consent (IRB registration number 1607-062-775).
      </p>
     </sec>
    </sec>
    <sec sec-type="results">
     <title>
      RESULTS
     </title>
     <sec>
      <title>
       Baseline characteristics
      </title>
      <p>
       Characteristics of 186 patients with laboratory-confirmed MERS-CoV infection are shown in
       <xref ref-type="table" rid="T1">
        Table 1
       </xref>
       . Of them, 15 patients (8.1%) transmitted MERS-CoV (the spreader group) to others, and 171 patients (91.9%) did not (the non-spreader group). Age, sex, and underlying diseases were not different between the 2 groups. Among the spreaders, 5 patients (33.3%) were super-spreaders, while 10 (66.7%) were usual-spreaders. Baseline characteristics of these 2 groups were not significantly different.
      </p>
      <table-wrap id="T1" orientation="portrait" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <title>
         Comparison of patient demographics and clinical parameters between non-spreaders and spreaders, or usual-spreaders and super-spreaders during the 2015 Korean outbreak of MERS-CoV
        </title>
       </caption>
       <alternatives>
        <graphic xlink:href="jkms-32-744-i001">
        </graphic>
        <table frame="hsides" rules="rows">
         <col span="1" width="36.6%"/>
         <col span="1" width="12.68%"/>
         <col span="1" width="12.68%"/>
         <col span="1" width="12.68%"/>
         <col span="1" width="12.68%"/>
         <col span="1" width="12.68%"/>
         <thead>
          <tr>
           <th align="left" colspan="1" rowspan="2" style="background-color:rgb(200,199,223)" valign="top">
            Characteristics
           </th>
           <th align="center" colspan="1" rowspan="2" style="background-color:rgb(200,199,223)" valign="top">
            Non-spreader (n = 171)
           </th>
           <th align="center" colspan="2" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Spreader (n = 15)
           </th>
           <th align="center" colspan="2" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            <italic>
             P
            </italic>
            value
           </th>
          </tr>
          <tr>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Usual-spreader (n = 10)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Super-spreader (n = 5)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Non-spreader vs. spreader
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Usual-spreader vs. super-spreader
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Patient characteristics
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Age, mean (± SD)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            54.4 (± 16.2)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            54.4 (± 18.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            50.6 (± 19.3)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.780
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.689
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Male
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            99 (57.9)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            8 (80.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            4 (80.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.108
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            1.000
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Underlying diseases
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            DM
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            33 (19.3)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (20.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.251
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            1.000
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Hypertension
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            51 (29.8)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            3 (30.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (20.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.797
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.682
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Chronic kidney diseases
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            8 (4.7)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (10.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.732
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            1.000
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Chronic heart diseases
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            15 (8.8)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.999
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            NA
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Chronic lung diseases
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            17 (9.9)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            2 (20.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.679
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.999
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Chronic liver diseases
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            9 (5.3)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (10.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.818
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            1.000
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Clinical characteristics at presentation
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Signs and symptoms
            <sup>
             *
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Fever (≥ 38.5℃)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            22 (13.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5 (50.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1 (20.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.009
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.280
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Systolic BP ≤ 90 mmHg
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            9 (5.3)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (20.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.227
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.999
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Diastolic BP ≤ 60 mmHg
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            28 (16.6)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            3 (30.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1 (20.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.329
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.682
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Respiratory rate &gt; 24/min
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            21 (12.4)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5 (50.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.034
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.999
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Cough
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            93 (55.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            9 (90.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            4 (80.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.031
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.598
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Sputum
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            63 (37.3)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            9 (90.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (40.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.011
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.062
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Dyspnea
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            32 (18.9)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            6 (60.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            3 (60.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.001
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1.000
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Myalgia
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            71 (42.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5 (50.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            3 (60.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.399
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.715
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Headache
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            34 (20.1)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1 (10.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (40.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.991
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.199
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Diarrhea
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            32 (18.9)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1 (10.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (40.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.920
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.199
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Laboratory tests
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            WBC &gt; 10,000 /μL or &lt; 4,000 /μL
            <sup>
             †
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            75 (46.6)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            4 (40.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            4 (80.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.617
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.165
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Platelet &lt; 100,000 /μL
            <sup>
             †
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            28 (17.4)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            3 (30.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (40.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.140
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.699
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            CRP ≥ 3.0 mg/dL
            <sup>
             ‡
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            66 (43.4)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            8 (88.9)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            4 (80.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.008
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.653
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            BUN &gt; 20 mg/dL
            <sup>
             §
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            24 (15.4)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            4 (40.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.267
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.999
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Creatinine &gt; 1.5 mg/dL
            <sup>
             §
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            8 (5.1)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1 (10.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.799
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1.000
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            CXR abnormality in more than 3 lung zones
            <sup>
             ∥
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            17 (10.3)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5 (50.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (40.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            &lt; 0.001
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.715
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Symptom onset to negative conversion, day, median (IQR)
            <sup>
             ¶
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            17.0 (13.0–21.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            23.5 (17.8–28.3)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            32.0 (28.3–43.3)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            &lt; 0.001
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.129
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Clinical outcomes
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Mechanical ventilation
            <sup>
             *
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            36 (21.3)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            7 (70.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2 (40.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.002
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.274
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Days from symptom onset to mechanical ventilation, (IQR)
            <sup>
             *
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            10.0 (7.0–12.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            6.5 (5.5–8.8)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            10.5 (9.0–12.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.221
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.159
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Mortality
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            31 (18.1)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            4 (40.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            1 (20.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.162
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.447
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Days from symptom onset to death, median (IQR)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            15.0 (12.0–21.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            9.0 (3.8–9.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5.0 (5.0–5.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.032
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.504
           </td>
          </tr>
         </tbody>
        </table>
       </alternatives>
       <table-wrap-foot>
        <p>
         Data shown are number (%) not otherwise specified.
        </p>
        <p>
         MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, DM = diabetes mellitus, NA = not available, BP = blood pressure, WBC = white blood cell, CRP = C-reactive protein, BUN = blood urea nitrogen, CXR = chest X-ray, IQR = interquartile range.
        </p>
        <p>
         <sup>
          *
         </sup>
         Data were unavailable in 2 cases (1.1%);
         <sup>
          †
         </sup>
         Data were unavailable in 10 cases (5.4%);
         <sup>
          ‡
         </sup>
         Data were unavailable in 20 cases (10.8%);
         <sup>
          §
         </sup>
         Data were unavailable in 15 cases (8.1%);
         <sup>
          ∥
         </sup>
         Data were unavailable in 6 cases (3.2%);
         <sup>
          ¶
         </sup>
         Data were unavailable in 43 cases (23.1%).
        </p>
       </table-wrap-foot>
      </table-wrap>
     </sec>
     <sec>
      <title>
       Clinical characteristics
      </title>
      <p>
       At presentation, patients in the spreader group were more likely than those in the non-spreader group to have a fever of ≥ 38.5°C (40.0% vs. 13.0%,
       <italic>
        P
       </italic>
       = 0.009) and a tachypnea of &gt; 24 breaths per minute (33.3% vs. 12.4%,
       <italic>
        P
       </italic>
       = 0.034). They were also more likely to have lower respiratory manifestations such as cough, sputum, and dyspnea (86.7% vs. 55.0%,
       <italic>
        P
       </italic>
       = 0.031; 73.3% vs. 37.3%,
       <italic>
        P
       </italic>
       = 0.011; and 60.0% vs. 18.9%,
       <italic>
        P
       </italic>
       = 0.001, respectively).
      </p>
      <p>
       On admission, elevated C-reactive protein (≥ 3.0 mg/dL) was the only laboratory parameter that was more common in the spreader than the non-spreader group (85.7% vs. 43.4%,
       <italic>
        P
       </italic>
       = 0.008). Infiltrates involving 3 or more lung zones on chest radiographs taken at presentation were more common in the spreader group than in the non-spreader group (46.7% vs. 10.3%,
       <italic>
        P
       </italic>
       &lt; 0.001). The median days from the onset of illness to the negative conversion of sputum MERS-CoV by rRT-PCR were significantly different (27.0 vs. 17.0 days,
       <italic>
        P
       </italic>
       &lt; 0.001).
      </p>
      <p>
       Treatment with mechanical ventilation was required in 21.3% (36/169) of the non-spreader group and 60.0% (9/15) of the spreader group (
       <italic>
        P
       </italic>
       = 0.002). Deaths occurred in 18.1% (31/171) of the non-spreader group and 33.3% (5/15) of the spreader group (
       <italic>
        P
       </italic>
       = 0.162). Median days from symptom onset to death was significantly different (15.0 vs. 9.0 days,
       <italic>
        P
       </italic>
       = 0.032). Clinical parameters were not different between super-spreaders and usual-spreaders.
      </p>
     </sec>
     <sec>
      <title>
       Epidemiologic characteristics
      </title>
      <p>
       The course of disease spread could not be determined in 10 patients, including 5 with an unidentified source of infection and 5 with more than one possible scenario. Excluding the first imported case, the courses of disease spread could be determined in 175 patients. Of them, 173 were infected at healthcare facilities (12 hospitals, 3 clinics, and 2 ambulances). The disease was transmitted to 2 remaining patients in household settings. The date of symptom onset could not be determined in 5 patients, including 2 patients who were asymptomatic and 3 with an ambiguous onset of MERS-CoV symptoms during another illness.
      </p>
      <p>
       Of the 15 spreaders, 5 and 8 cases were in the second- and third-chain of transmission, respectively (
       <xref ref-type="table" rid="T2">
        Table 2
       </xref>
       ). Spreaders transmitted MERS-CoV from days 1 to 11 of their illness (median, 7 days; interquartile range [IQR], 5 to 8 days) (
       <xref ref-type="fig" rid="F1">
        Fig. 1A
       </xref>
       ). The number of patients infected by each spreader ranged from 1 to 84 (IQR, 1 to 12).
      </p>
      <table-wrap id="T2" orientation="portrait" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <title>
         Comparison of epidemiologic characteristics between non-spreaders and spreaders, or usual-spreaders and super-spreaders during the 2015 Korean outbreak of MERS-CoV
        </title>
       </caption>
       <alternatives>
        <graphic xlink:href="jkms-32-744-i002">
        </graphic>
        <table frame="hsides" rules="rows">
         <col span="1" width="35.76%"/>
         <col span="1" width="11.39%"/>
         <col span="1" width="12.76%"/>
         <col span="1" width="12.76%"/>
         <col span="1" width="13.67%"/>
         <col span="1" width="13.67%"/>
         <thead>
          <tr>
           <th align="left" colspan="1" rowspan="2" style="background-color:rgb(200,199,223)" valign="top">
            Epidemiologic characteristics
           </th>
           <th align="center" colspan="1" rowspan="2" style="background-color:rgb(200,199,223)" valign="top">
            Non-spreader (n = 171)
           </th>
           <th align="center" colspan="2" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Spreader (n = 15)
           </th>
           <th align="center" colspan="2" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            <italic>
             P
            </italic>
            value
           </th>
          </tr>
          <tr>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Usual-spreader (n = 10)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Super-spreader (n = 5)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Non-spreader vs. spreader
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Usual-spreader vs. super-spreader
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Phase in chain of transmission
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
           </td>
           <td align="right" colspan="1" rowspan="6" valign="top">
            0.003
           </td>
           <td align="right" colspan="1" rowspan="6" valign="top">
            0.058
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Primary
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (20.0)
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Secondary
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            25 (14.6)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            2 (22.2)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            3 (60.0)
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Tertiary
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            116 (67.8)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7 (77.8)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (20.0)
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Quaternary
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            23 (13.5)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Undetermined
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7 (4.1)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1 (10.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0 (0.0)
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Symptom onset after June 7
            <sup>
             *
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            48 (28.9)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            3 (30.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0 (0.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.466
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.999
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Median incubation period, day, mean (± SD)
            <sup>
             †
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7.4 (± 4.5)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7.8 (± 2.6)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            8.0 (± 5.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.716
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.905
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Symptom onset to isolation, day, median (IQR)
            <sup>
             *
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            2.0 (1.0–6.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5.0 (3.8–5.8)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            8.0 (4.0–9.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.057
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.267
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Nonisolated in-hospital days, median (IQR)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0.0 (0.0–2.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            2.0 (0.8–4.5)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7.0 (4.0–9.0)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            &lt; 0.001
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.061
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            Nonisolated in-hospital days ≥ 2 day
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            54 (31.6)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            6 (60.0)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            5 (100.0)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.003
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.999
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Symptom onset to diagnosis, day, mean (± SD)
            <sup>
             *
            </sup>
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            6.5 (± 3.9)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            7.5 (± 2.6)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            8.8 (± 3.4)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.178
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.400
           </td>
          </tr>
         </tbody>
        </table>
       </alternatives>
       <table-wrap-foot>
        <p>
         Data shown are number (%) not otherwise specified.
        </p>
        <p>
         MERS-CoV = Middle East Respiratory Syndrome Coronavirus, SD = standard deviation, IQR = interquartile range.
        </p>
        <p>
         <sup>
          *
         </sup>
         Data were unavailable in 5 cases (2.7%);
         <sup>
          †
         </sup>
         Data were unavailable in 7 cases (3.8%).
        </p>
       </table-wrap-foot>
      </table-wrap>
      <fig fig-type="figure" id="F1" orientation="portrait" position="float">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Epidemiologic characteristics of 2015 Korean MERS-CoV outbreak. (
         <bold>
          A
         </bold>
         ) Cumulative number of infected patients according to day of illness of each spreader. When infected patients were exposed to a spreader for more than one day, the number of infected patients was equally divided by the duration (day) of exposure. Different colors denote infections transmitted by different spreaders. Note that the 5 super-spreaders transmitted the virus to 92% (161/175) of all cases. (
         <bold>
          B
         </bold>
         ) Nonisolated in-hospital days according to the date of symptom onset of each patient. Two spreaders transmitted MERS-CoV to healthcare workers despite the fact that they had been isolated before their symptom onset. (
         <bold>
          C
         </bold>
         ) Days from symptom onset to diagnosis according to the date of symptom onset of each patient.
        </p>
        <p>
         MERS-CoV = Middle East Respiratory Syndrome Coronavirus.
        </p>
       </caption>
       <graphic xlink:href="jkms-32-744-g001">
       </graphic>
      </fig>
      <p>
       The median duration of incubation was not different between the spreader and non-spreader groups. Median nonisolated in-hospital days were 4 and 0 days in the spreader and non-spreader groups, respectively (IQR, 1 to 7 vs. 0 to 2 days,
       <italic>
        P
       </italic>
       &lt; 0.001).
      </p>
      <p>
       Nonisolated in-hospital days were significantly different among the non-spreader, usual-spreader, and super-spreader groups (
       <xref ref-type="fig" rid="F2">
        Fig. 2A
       </xref>
       ). Nonisolated in-hospital days of spreaders were also positively associated with the total number of infected patients, and the number of infected patients per spreader (R
       <sup>
        2
       </sup>
       = 0.520 and 0.625;
       <italic>
        P
       </italic>
       = 0.068 and 0.034, respectively) (
       <xref ref-type="fig" rid="F2">
        Fig. 2B
       </xref>
       ).
      </p>
      <fig fig-type="figure" id="F2" orientation="portrait" position="float">
       <label>
        Fig. 2
       </label>
       <caption>
        <p>
         Contribution of nonisolated in-hospital days to spreading events. (
         <bold>
          A
         </bold>
         ) Nonisolated in-hospital days in non-spreader, usual-spreader, and super-spreader groups. Dashed lines denote median values at each group. Data points at 0 are shown at different level for clarity. (
         <bold>
          B
         </bold>
         ) Number of spreaders (S) and infected patients (I), and I/S ratio according to nonisolated in-hospital days of spreaders. There were positive correlation between nonisolated in-hospital days of spreaders and I (red broken line) or I/S ratio (green broken line).
        </p>
       </caption>
       <graphic xlink:href="jkms-32-744-g002">
       </graphic>
      </fig>
      <p>
       Epidemiologic characteristics of super-spreaders and usual-spreaders were not different. However, nonisolated in-hospital days tended to be higher in the super-spreader group (median, 2.0 vs. 7.0 days,
       <italic>
        P
       </italic>
       = 0.061). The median number of nonisolated in-hospital days was 1 day in patients who developed symptoms before June 7 and 0 days in patients who developed symptoms after that date (IQR, 0 to 3 vs. 0 to 1 day,
       <italic>
        P
       </italic>
       = 0.001) (
       <xref ref-type="fig" rid="F1">
        Fig. 1B
       </xref>
       ,
       <xref ref-type="supplementary-material" rid="S1">
        Supplementary Table 1
       </xref>
       ). Days from symptom onset to diagnosis were also significantly different between these groups (mean, 7.5 vs. 4.6,
       <italic>
        P
       </italic>
       &lt; 0.001) (
       <xref ref-type="fig" rid="F1">
        Fig. 1C
       </xref>
       ,
       <xref ref-type="supplementary-material" rid="S1">
        Supplementary Table 1
       </xref>
       ).
      </p>
     </sec>
     <sec>
      <title>
       Risk factors for transmission
      </title>
      <p>
       In multivariate analysis, fever (≥ 38.5°C) (adjusted odds ratio [aOR], 5.54; 95% confidence interval [CI], 1.38–22.30;
       <italic>
        P
       </italic>
       = 0.016), chest infiltrates in more than 3 lung zones (aOR, 7.33; 95% CI, 1.93–27.79;
       <italic>
        P
       </italic>
       = 0.003), and a longer nonisolated in-hospital day (aOR, 1.32 per 1 day; 95% CI, 1.09–1.60;
       <italic>
        P
       </italic>
       = 0.004) were independently associated with the spreader group vs. the non-spreader group (
       <xref ref-type="table" rid="T3">
        Table 3
       </xref>
       ). Further inclusion of other variables did not result in additional significance.
      </p>
      <table-wrap id="T3" orientation="portrait" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <title>
         Forward stepwise multivariate analysis for risk factors for transmission of MERS-CoV
        </title>
       </caption>
       <alternatives>
        <graphic xlink:href="jkms-32-744-i003">
        </graphic>
        <table frame="hsides" rules="rows">
         <col span="1" width="27.5%"/>
         <col span="1" width="18.13%"/>
         <col span="1" width="18.13%"/>
         <col span="1" width="18.13%"/>
         <col span="1" width="18.13%"/>
         <thead>
          <tr>
           <th align="left" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Variables
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Non-spreader (n = 171)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            Spreader (n = 15)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            aOR (95% CI)
           </th>
           <th align="center" colspan="1" rowspan="1" style="background-color:rgb(200,199,223)" valign="top">
            <italic>
             P
            </italic>
            value
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Fever (≥ 38.5℃)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            22 (13.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            6 (40.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            5.54 (1.38–22.30)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.016
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            CXR abnormality in more than 3 lung zones
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            17 (10.3)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            7 (46.7)
           </td>
           <td align="center" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            7.33 (1.93–27.79)
           </td>
           <td align="right" colspan="1" rowspan="1" style="background-color:rgb(225,224,237)" valign="top">
            0.003
           </td>
          </tr>
          <tr>
           <td align="left" colspan="1" rowspan="1" valign="top">
            Nonisolated in-hospital days, median (IQR)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            0.0 (0.0–2.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            4.0 (1.0–7.0)
           </td>
           <td align="center" colspan="1" rowspan="1" valign="top">
            1.32 (1.09–1.60)
           </td>
           <td align="right" colspan="1" rowspan="1" valign="top">
            0.004
           </td>
          </tr>
         </tbody>
        </table>
       </alternatives>
       <table-wrap-foot>
        <p>
         Data shown are number (%).
        </p>
        <p>
         MERS-CoV = Middle East Respiratory Syndrome Coronavirus, aOR = adjusted odds ratio, CI = confidence interval, CXR = chest X-ray, IQR = interquartile range.
        </p>
       </table-wrap-foot>
      </table-wrap>
      <p>
       When we censored the data on symptom onset after June 7 or unknown onset (n = 56), dyspnea (aOR, 4.38; 95% CI, 1.13–16.90;
       <italic>
        P
       </italic>
       = 0.032), and a more nonisolated in-hospital days (aOR, 1.31 per 1 day; 95% CI, 1.07–1.60;
       <italic>
        P
       </italic>
       = 0.009) were associated with the spreader group (
       <xref ref-type="supplementary-material" rid="S2">
        Supplementary Tables 2
       </xref>
       and
       <xref ref-type="supplementary-material" rid="S3">
        3
       </xref>
       ).
      </p>
      <p>
       When healthcare workers were censored (n = 39), chest X-ray abnormalities in more than 3 lung zones (aOR, 4.97; 95% CI, 1.28–19.35;
       <italic>
        P
       </italic>
       = 0.021), and a more nonisolated in-hospital days (aOR, 5.63 per 1 day; 95% CI, 1.10–28.75;
       <italic>
        P
       </italic>
       = 0.038) were associated with the spreader groups (
       <xref ref-type="supplementary-material" rid="S4">
        Supplementary Tables 4
       </xref>
       and
       <xref ref-type="supplementary-material" rid="S5">
        5
       </xref>
       ).
      </p>
     </sec>
    </sec>
    <sec sec-type="discussion">
     <title>
      DISCUSSION
     </title>
     <p>
      Hospital outbreaks were the defining characteristic of the Korean MERS-CoV outbreak in 2015. In this study, spreaders more frequently had high fever, more extensive infiltrates on chest radiographs, and a longer time to negative conversion of MERS-CoV rRT-PCR than non-spreaders, all suggesting more severe pneumonia. The spreader group had a significantly longer duration of nonisolated in-hospital days than the non-spreader groups.
     </p>
     <p>
      Clinical parameters did not differ between super-spreaders and usual-spreaders, whereas nonisolated in-hospital days were substantially different between these 2 groups. These data suggest that large hospital outbreaks or super-spreading events may not be attributable to clinical manifestations, but to delay in isolation.
     </p>
     <p>
      Spreaders transmitted MERS-CoV between days 1 and 11 of their illness. Of note, even a 1- or 2-day delay in isolating patients led secondary infections, with a peak of cumulative number on the seventh day of illness. These findings imply that MERS-CoV could be transmitted frequently during the early course of the disease. A recent virus shedding study showed that MERS-CoV titers in sputum samples were around 10
      <sup>
       8
      </sup>
      copies per milliliter as early as 3 days after symptom onset, while the viral shedding kinetics of the SARS-CoV infection was an inverted V shape, with its sharp peak around day 10 (
      <xref ref-type="bibr" rid="B13">
       13
      </xref>
      ). These findings suggest that control of a MERS-CoV outbreak would be more difficult than that of a SARS-CoV outbreak. Considering that the shortest incubation period of MERS-CoV infection is 2 days and that patients may transmit the disease with a high viral load even in the early course of their illness, early detection and isolation of patients is imperative to control an outbreak of MERS-CoV.
     </p>
     <p>
      A standard approach to control an outbreak begins with identifying all exposed individuals and assessing them for close contact, followed by quarantine. However, this approach is labor-intensive and time-consuming, especially when many individuals are exposed. Moreover, identification of all exposed individuals is difficult, because many, such as visitors and family members, may not be registered with hospitals. Indeed, 43.2% of the patients in Korea during the 2015 outbreak had not been identified as exposed individuals and were not monitored (
      <xref ref-type="bibr" rid="B14">
       14
      </xref>
      ). Our experience suggests that quarantining all exposed individuals first, followed by an assessment of and monitoring of their close contacts may shorten the delay in isolating MERS patients, especially in healthcare settings.
     </p>
     <p>
      Days of nonisolated in-hospital stay and symptom onset to diagnosis were significantly longer in patients who developed symptoms before June 7 than in patients who did after that date. The last super-spreader developed symptoms on June 5, and no additional super-spreading events occurred after June 7. All advocate the necessity of early adoption of an aggressive isolation policy.
     </p>
     <p>
      Since this was an analysis of a single outbreak, it should be interpreted with caution. Additionally, although we analyzed the severity of symptom or chest infiltrations and time to negative conversion of MERS-CoV rRT-PCR, lack of each patient's serial viral load titers limited a direct evaluation of the degree of viral shedding, which could be another limitation.
     </p>
     <p>
      In conclusion, high fever, more extensive chest infiltrates, and delay in isolation were associated with the transmission of MERS-CoV. Nonisolated in-hospital days were the only parameter that tended to be associated with super-spreaders compared with usual-spreaders. Early active quarantine might help control a future outbreak of MERS.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn fn-type="supported-by">
       <p>
        <bold>
         Funding:
        </bold>
        This work was supported by a grant from the Korean Healthcare Technology R &amp; D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Korea (Grant No. HI15C3227).
       </p>
      </fn>
      <fn fn-type="COI-statement">
       <p>
        <bold>
         DISCLOSURE:
        </bold>
        The authors have no potential conflicts of interest to disclose.
       </p>
      </fn>
      <fn fn-type="con">
       <p>
        <bold>
         AUTHOR CONTRIBUTION:
        </bold>
        Conceptualization: Oh MD. Data curation: Kang CK, Choe PG. Investigation: Kang CK, Song KH, Choe PG, Park WB, Bang JH, Kim ES, Park SW, Kim HB, Kim NJ, Cho SI, Lee JK, Oh MD. Writing - original draft: Kang CK, Oh MD. Writing - review &amp; editing: Kang CK, Oh MD.
       </p>
      </fn>
     </fn-group>
     <ref-list>
      <ref id="B1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           van Boheemen
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B2">
       <label>
        2
       </label>
       <element-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        <source>
         Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [Internet]
        </source>
        <date-in-citation content-type="access-date">
         accessed on 3 November 2016
        </date-in-citation>
        <comment>
         Available at
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
          http://www.who.int/emergencies/mers-cov/en/
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <collab>
         Korea Centers for Disease Control and Prevention
        </collab>
        <article-title>
         Middle East Respiratory Syndrome Coronavirus outbreak in the Republic of Korea, 2015
        </article-title>
        <source>
         Osong Public Health Res Perspect
        </source>
        <year>
         2015
        </year>
        <volume>
         6
        </volume>
        <fpage>
         269
        </fpage>
        <lpage>
         278
        </lpage>
        <pub-id pub-id-type="pmid">
         26473095
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oh
          </surname>
          <given-names>
           MD
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Korean Middle East Respiratory Syndrome Coronavirus outbreak and our responsibility to the global scientific community
        </article-title>
        <source>
         Infect Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         48
        </volume>
        <fpage>
         145
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="pmid">
         27433388
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chowell
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Abdirizak
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Viboud
          </surname>
          <given-names>
           C
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study
        </article-title>
        <source>
         BMC Med
        </source>
        <year>
         2015
        </year>
        <volume>
         13
        </volume>
        <fpage>
         210
        </fpage>
        <pub-id pub-id-type="pmid">
         26336062
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Oboho
          </surname>
          <given-names>
           IK
          </given-names>
         </name>
         <name>
          <surname>
           Tomczyk
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Al-Asmari
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Banjar
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Al-Mugti
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Aloraini
          </surname>
          <given-names>
           MS
          </given-names>
         </name>
         <name>
          <surname>
           Alkhaldi
          </surname>
          <given-names>
           KZ
          </given-names>
         </name>
         <name>
          <surname>
           Almohammadi
          </surname>
          <given-names>
           EL
          </given-names>
         </name>
         <name>
          <surname>
           Alraddadi
          </surname>
          <given-names>
           BM
          </given-names>
         </name>
         <name>
          <surname>
           Gerber
          </surname>
          <given-names>
           SI
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         2014 MERS-CoV outbreak in Jeddah--a link to health care facilities
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2015
        </year>
        <volume>
         372
        </volume>
        <fpage>
         846
        </fpage>
        <lpage>
         854
        </lpage>
        <pub-id pub-id-type="pmid">
         25714162
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cho
          </surname>
          <given-names>
           SY
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           YE
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           GE
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Ko
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <name>
          <surname>
           Lee
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           JM
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Jo
          </surname>
          <given-names>
           IJ
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study
        </article-title>
        <source>
         Lancet
        </source>
        <year>
         2016
        </year>
        <volume>
         388
        </volume>
        <fpage>
         994
        </fpage>
        <lpage>
         1001
        </lpage>
        <pub-id pub-id-type="pmid">
         27402381
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Stein
          </surname>
          <given-names>
           RA
          </given-names>
         </name>
        </person-group>
        <article-title>
         Super-spreaders in infectious diseases
        </article-title>
        <source>
         Int J Infect Dis
        </source>
        <year>
         2011
        </year>
        <volume>
         15
        </volume>
        <fpage>
         e510
        </fpage>
        <lpage>
         e513
        </lpage>
        <pub-id pub-id-type="pmid">
         21737332
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B9">
       <label>
        9
       </label>
       <element-citation publication-type="webpage">
        <collab>
         World Health Organization
        </collab>
        <source>
         Laboratory testing for Middle East Respiratory Syndrome Coronavirus: interim guidance [Internet]
        </source>
        <date-in-citation content-type="access-date">
         accessed on 3 November 2016
        </date-in-citation>
        <comment>
         Available at
         <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en/">
          http://www.who.int/csr/disease/coronavirus_infections/mers-laboratory-testing/en/
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           WS
          </given-names>
         </name>
         <name>
          <surname>
           Kang
          </surname>
          <given-names>
           CI
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JP
          </given-names>
         </name>
         <name>
          <surname>
           Joh
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           HS
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           KR
          </given-names>
         </name>
         <name>
          <surname>
           Chung
          </surname>
          <given-names>
           DR
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           HO
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Clinical presentation and outcomes of Middle East Respiratory Syndrome in the Republic of Korea
        </article-title>
        <source>
         Infect Chemother
        </source>
        <year>
         2016
        </year>
        <volume>
         48
        </volume>
        <fpage>
         118
        </fpage>
        <lpage>
         126
        </lpage>
        <pub-id pub-id-type="pmid">
         27433382
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B11">
       <label>
        11
       </label>
       <element-citation publication-type="webpage">
        <collab>
         Ministry of Welfare and Health (KR)
        </collab>
        <source>
         MERS statistics [Internet]
        </source>
        <date-in-citation content-type="access-date">
         accessed on 3 November 2016
        </date-in-citation>
        <comment>
         Available at
         <ext-link ext-link-type="uri" xlink:href="http://www.mers.go.kr/mers/html/jsp/main.jsp">
          http://www.mers.go.kr/mers/html/jsp/main.jsp
         </ext-link>
        </comment>
       </element-citation>
      </ref>
      <ref id="B12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <collab>
          Korean Society of Infectious Diseases
         </collab>
         <collab>
          Korean Society for Healthcare-associated Infection Control and Prevention
         </collab>
        </person-group>
        <article-title>
         The same Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) yet different outbreak patterns and public health impacts on the far east expert opinion from the rapid response team of the Republic of Korea
        </article-title>
        <source>
         Infect Chemother
        </source>
        <year>
         2015
        </year>
        <volume>
         47
        </volume>
        <fpage>
         247
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         26788408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Min
          </surname>
          <given-names>
           CK
          </given-names>
         </name>
         <name>
          <surname>
           Cheon
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Ha
          </surname>
          <given-names>
           NY
          </given-names>
         </name>
         <name>
          <surname>
           Sohn
          </surname>
          <given-names>
           KM
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Aigerim
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Shin
          </surname>
          <given-names>
           HM
          </given-names>
         </name>
         <name>
          <surname>
           Choi
          </surname>
          <given-names>
           JY
          </given-names>
         </name>
         <name>
          <surname>
           Inn
          </surname>
          <given-names>
           KS
          </given-names>
         </name>
         <name>
          <surname>
           Kim
          </surname>
          <given-names>
           JH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity
        </article-title>
        <source>
         Sci Rep
        </source>
        <year>
         2016
        </year>
        <volume>
         6
        </volume>
        <fpage>
         25359
        </fpage>
        <pub-id pub-id-type="pmid">
         27146253
        </pub-id>
       </element-citation>
      </ref>
      <ref id="B14">
       <label>
        14
       </label>
       <element-citation publication-type="webpage">
        <collab>
         Ministry of Health and Welfare (KR)
        </collab>
        <source>
         The 2015 MERS outbreak in the Republic of Korea: learning from MERS [Internet]
        </source>
        <date-in-citation content-type="access-date">
         accessed on 3 November 2016
        </date-in-citation>
        <comment>
         Available at
         <ext-link ext-link-type="uri" xlink:href="http://www.mers.go.kr/mers/html/jsp/Menu_I/mers00_01.jsp">
          http://www.mers.go.kr/mers/html/jsp/Menu_I/mers00_01.jsp
         </ext-link>
        </comment>
       </element-citation>
      </ref>
     </ref-list>
     <sec sec-type="supplementary-material">
      <title>
       SUPPLEMENTARY MATERIALS
      </title>
      <supplementary-material content-type="local-data" id="S1">
       <caption>
        <title>
         Supplementary Table 1
        </title>
        <p>
         Comparison of epidemiologic characteristics before and after June 7, 2015, when more strict infection control measures were implemented by the government
        </p>
       </caption>
       <media id="d35e1865" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="jkms-32-744-s001.pdf">
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S2">
       <caption>
        <title>
         Supplementary Table 2
        </title>
        <p>
         Comparison of clinical features and epidemiologic characteristics between the non-spreaders and the spreaders during the 2015 Korean outbreak of MERS-CoV, after censoring patients who had developed symptoms later than June 7 or unknown symptom onset (n = 56)
        </p>
       </caption>
       <media id="d35e1872" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="jkms-32-744-s002.pdf">
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S3">
       <caption>
        <title>
         Supplementary Table 3
        </title>
        <p>
         Forward stepwise multivariate analysis for risk factors for spreader of MERS-CoV, after censoring patients who had developed their symptom later than June 7
        </p>
       </caption>
       <media id="d35e1879" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="jkms-32-744-s003.pdf">
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S4">
       <caption>
        <title>
         Supplementary Table 4
        </title>
        <p>
         Clinical features and epidemiologic characteristics in non-spreaders, usual-spreaders, and super-spreaders during the 2015 Korean outbreak of MERS-CoV, after censoring healthcare workers (n = 39)
        </p>
       </caption>
       <media id="d35e1886" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="jkms-32-744-s004.pdf">
       </media>
      </supplementary-material>
      <supplementary-material content-type="local-data" id="S5">
       <caption>
        <title>
         Supplementary Table 5
        </title>
        <p>
         Forward stepwise multivariate analysis for risk factors for spreader of MERS-CoV, after censoring healthcare workers
        </p>
       </caption>
       <media id="d35e1893" mime-subtype="pdf" mimetype="application" orientation="portrait" position="anchor" xlink:href="jkms-32-744-s005.pdf">
       </media>
      </supplementary-material>
     </sec>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Infect Dis Poverty
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Infect Dis Poverty
      </journal-id>
      <journal-title-group>
       <journal-title>
        Infectious Diseases of Poverty
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       2095-5162
      </issn>
      <issn pub-type="epub">
       2049-9957
      </issn>
      <publisher>
       <publisher-name>
        BioMed Central
       </publisher-name>
       <publisher-loc>
        London
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32183901
      </article-id>
      <article-id pub-id-type="pmc">
       7079521
      </article-id>
      <article-id pub-id-type="publisher-id">
       646
      </article-id>
      <article-id pub-id-type="doi">
       10.1186/s40249-020-00646-x
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Scoping Review
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Adhikari
         </surname>
         <given-names>
          Sasmita Poudel
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Meng
         </surname>
         <given-names>
          Sha
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Yu-Ju
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Mao
         </surname>
         <given-names>
          Yu-Ping
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff2">
         2
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Ye
         </surname>
         <given-names>
          Rui-Xue
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          Qing-Zhi
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sun
         </surname>
         <given-names>
          Chang
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Sylvia
         </surname>
         <given-names>
          Sean
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff3">
         3
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Rozelle
         </surname>
         <given-names>
          Scott
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff4">
         4
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Raat
         </surname>
         <given-names>
          Hein
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff5">
         5
        </xref>
       </contrib>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          Huan
         </given-names>
        </name>
        <address>
         <email>
          zhouhuan@scu.edu.cn
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
         1
        </xref>
       </contrib>
       <aff id="Aff1">
        <label>
         1
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.13291.38
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0001 0807 1581
         </institution-id>
         <institution>
          West China School of Public Health and West China Fourth Hospital,
         </institution>
         <institution>
          Sichuan University,
         </institution>
        </institution-wrap>
        Chengdu, China
       </aff>
       <aff id="Aff2">
        <label>
         2
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.213902.b
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000 0000 9093 6830
         </institution-id>
         <institution>
          Department of Communication Studies,
         </institution>
         <institution>
          California State University,
         </institution>
        </institution-wrap>
        Long Beach, CA 90802 USA
       </aff>
       <aff id="Aff3">
        <label>
         3
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.10698.36
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000122483208
         </institution-id>
         <institution>
          Health Policy and Management,
         </institution>
         <institution>
          University of North Carolina at Chapel Hill,
         </institution>
        </institution-wrap>
        Chapel Hill, NC USA
       </aff>
       <aff id="Aff4">
        <label>
         4
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.168010.e
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000419368956
         </institution-id>
         <institution>
          Freeman Spogli Institute for International Studies,
         </institution>
         <institution>
          Stanford University,
         </institution>
        </institution-wrap>
        Stanford, CA USA
       </aff>
       <aff id="Aff5">
        <label>
         5
        </label>
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.5645.2
         </institution-id>
         <institution-id institution-id-type="ISNI">
          000000040459992X
         </institution-id>
         <institution>
          Department of Public Health,
         </institution>
         <institution>
          Erasmus MC—University Medical Center Rotterdam,
         </institution>
        </institution-wrap>
        3000 CA Rotterdam, The Netherlands
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="pmc-release">
       <day>
        17
       </day>
       <month>
        3
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       9
      </volume>
      <elocation-id>
       29
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         11
        </day>
        <month>
         2
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         5
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © The Author(s) 2020
       </copyright-statement>
       <license license-type="OpenAccess">
        <license-p>
         <bold>
          Open Access
         </bold>
         This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          http://creativecommons.org/licenses/by/4.0/
         </ext-link>
         . The Creative Commons Public Domain Dedication waiver (
         <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">
          http://creativecommons.org/publicdomain/zero/1.0/
         </ext-link>
         ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <sec>
        <title>
         Background
        </title>
        <p id="Par1">
         The coronavirus disease (COVID-19) has been identified as the cause of an outbreak of respiratory illness in Wuhan, Hubei Province, China beginning in December 2019. As of 31 January 2020, this epidemic had spread to 19 countries with 11 791 confirmed cases, including 213 deaths. The World Health Organization has declared it a Public Health Emergency of International Concern.
        </p>
       </sec>
       <sec>
        <title>
         Methods
        </title>
        <p id="Par2">
         A scoping review was conducted following the methodological framework suggested by Arksey and O’Malley. In this scoping review, 65 research articles published before 31 January 2020 were analyzed and discussed to better understand the epidemiology, causes, clinical diagnosis, prevention and control of this virus. The research domains, dates of publication, journal language, authors’ affiliations, and methodological characteristics were included in the analysis. All the findings and statements in this review regarding the outbreak are based on published information as listed in the references.
        </p>
       </sec>
       <sec>
        <title>
         Results
        </title>
        <p id="Par3">
         Most of the publications were written using the English language (89.2%). The largest proportion of published articles were related to causes (38.5%) and a majority (67.7%) were published by Chinese scholars. Research articles initially focused on causes, but over time there was an increase of the articles related to prevention and control. Studies thus far have shown that the virus’ origination is in connection to a seafood market in Wuhan, but specific animal associations have not been confirmed. Reported symptoms include fever, cough, fatigue, pneumonia, headache, diarrhea, hemoptysis, and dyspnea. Preventive measures such as masks, hand hygiene practices, avoidance of public contact, case detection, contact tracing, and quarantines have been discussed as ways to reduce transmission. To date, no specific antiviral treatment has proven effective; hence, infected people primarily rely on symptomatic treatment and supportive care.
        </p>
       </sec>
       <sec>
        <title>
         Conclusions
        </title>
        <p id="Par4">
         There has been a rapid surge in research in response to the outbreak of COVID-19. During this early period, published research primarily explored the epidemiology, causes, clinical manifestation and diagnosis, as well as prevention and control of the novel coronavirus. Although these studies are relevant to control the current public emergency, more high-quality research is needed to provide valid and reliable ways to manage this kind of public health emergency in both the short- and long-term.
        </p>
       </sec>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        COVID-19
       </kwd>
       <kwd>
        Epidemiology
       </kwd>
       <kwd>
        Causes
       </kwd>
       <kwd>
        Prevention and control
       </kwd>
       <kwd>
        Review
       </kwd>
      </kwd-group>
      <funding-group>
       <award-group>
        <funding-source>
         <institution-wrap>
          <institution-id institution-id-type="FundRef">
           http://dx.doi.org/10.13039/100001547
          </institution-id>
          <institution>
           China Medical Board
          </institution>
         </institution-wrap>
        </funding-source>
        <award-id>
         CMB-18-297
        </award-id>
        <principal-award-recipient>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           Huan
          </given-names>
         </name>
        </principal-award-recipient>
       </award-group>
      </funding-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © The Author(s) 2020
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1">
     <title>
      Background
     </title>
     <p id="Par12">
      The coronavirus belongs to a family of viruses that may cause various symptoms such as pneumonia, fever, breathing difficulty, and lung infection [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ]. These viruses are common in animals worldwide, but very few cases have been known to affect humans. The World Health Organization (WHO) used the term 2019 novel coronavirus to refer to a coronavirus that affected the lower respiratory tract of patients with pneumonia in Wuhan, China on 29 December 2019 [
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      –
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. The WHO announced that the official name of the 2019 novel coronavirus is coronavirus disease (COVID-19) [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. And the current reference name for the virus is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was reported that a cluster of patients with pneumonia of unknown cause was linked to a local Huanan South China Seafood Market in Wuhan, Hubei Province, China in December 2019 [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ].
     </p>
     <p id="Par13">
      In response to the outbreak, the Chinese Center for Disease Control and Prevention (China CDC) dispatched a rapid response team to accompany health authorities of Hubei province and Wuhan city to conduct epidemiological and etiological investigations. The WHO confirmed that the outbreak of the coronavirus epidemic was associated with the Huanan South China Seafood Marketplace, but no specific animal association was identified [
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ]. Scientists immediately started to research the source of the new coronavirus, and the first genome of COVID-19 was published by the research team led by Prof. Yong-Zhen Zhang, on 10 January 2020 [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ]. Within 1 month, this virus spread quickly throughout China during the Chinese New Year – a period when there is a high level of human mobility among Chinese people. Although it is still too early to predict susceptible populations, early patterns have shown a trend similar to Severe Acute Respiratory Syndrome (SARS) and Middle East respiratory syndrome (MERS) coronaviruses. Susceptibility seems to be associated with age, biological sex, and other health conditions [
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. COVID-19 has now been declared as a Public Health Emergency of International Concern by the WHO [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ].
     </p>
     <p id="Par14">
      Given the spread of the new coronavirus and its impacts on human health, the research community has responded rapidly to the new virus and many preliminary research articles have already been published about this epidemic (Additional file
      <xref ref-type="media" rid="MOESM1">
       1
      </xref>
      ). We conducted a scoping review to summarize and critically analyze all the published scientific articles regarding the new coronavirus in January 2020. This review aims to provide the evidence of early findings on the epidemiology, causes, clinical diagnosis, as well as prevention and control of COVID-19 in relation to time, location, and source of publication. This review can provide meaningful information for future research related to this topic and may support government decision-making on strategies to handle this public health emergency at the community, national, and international levels.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Methods
     </title>
     <sec id="Sec3">
      <title>
       Study design
      </title>
      <p id="Par15">
       A scoping review was conducted following the methodological framework suggested by Arksey and O’Malley [
       <xref ref-type="bibr" rid="CR10">
        10
       </xref>
       ]. The following five steps were followed to conduct this scoping review: a) identifying a clear research objective and search strategies, b) identifying relevant research articles, c) selection of research articles, d) extraction and charting of data, and e) summarizing, discussing, analyzing, and reporting the results.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Literature search strategies
      </title>
      <p id="Par16">
       Literature for this review was identified by searching the following online databases: bioRxiv, medRxiv, ChemRxiv, Google scholar, PubMed, as well as CNKI and WanFang Data (the two primary databases for biomedical research in mainland China). These online databases contain archives of most English and Chinese biomedical journals. In addition, some white papers published online by the National Health Commission of the People’s Republic of China, Chinese Center for Disease Prevention and Control, and the WHO were included in the analysis. We searched scientific publications from 1 January to 31 January 2020. The search terms were ‘nCoV’, ‘2019 novel coronavirus’, ‘2019-nCoV’, ‘novel coronavirus’, ‘Pneumonia’, ‘新型冠状病毒’ (Chinese), ‘新型肺炎’ (Chinese), and ‘新冠病毒’ (Chinese). We included all the relevant scientific publications written in English or Chinese in the review. Non-scientific commentary, reports, and news articles were excluded from the analysis.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       Identification and selection of relevant studies
      </title>
      <p id="Par17">
       Two researchers (YW and SPA) independently searched through the literature. The two sets of literature were then compared. Disagreements on the inclusion or exclusion of literature were resolved through discussion or, if necessary, by including a third researcher (HZ) to make the final decision. Duplicate articles were eliminated. Eventually, 65 unique academic publications were included in this analysis (Additional file
       <xref ref-type="media" rid="MOESM1">
        1
       </xref>
       ). Figure
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       presents a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing the process of searching and selecting the research articles [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ].
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          PRISMA flow diagram for the scoping review process
         </p>
        </caption>
        <graphic id="MO1" xlink:href="40249_2020_646_Fig1_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Data extraction from the included studies
      </title>
      <p id="Par18">
       After the articles were selected, data were extracted and recorded in an excel spreadsheet. The extracted data were date of publication, language of publication, title of article, name of journal, author’s country and affiliation, study design, targets of study, sample size, study setting, data collection instrument, research domain, and key findings.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Summarizing the findings
      </title>
      <p id="Par19">
       Based on the main research objectives, articles were classified into one of the following four research domains: epidemiology, causes, clinical manifestation and diagnosis, or prevention and control. ‘Epidemiology’ includes studies on the epidemic distribution (when, where, who); ‘causes’ includes studies on virology, pathogenesis, and transmission patterns; ‘clinical manifestation and diagnosis’ includes studies on the clinical features (signs and symptoms) and diagnosis; and ‘prevention and control’ includes studies on prevention, control, and treatment measures.
      </p>
      <p id="Par20">
       Authors’ affiliations were used to categorize the type of research collaboration. A publication was considered as deriving from ‘inside China’ when all affiliations of the authors were from China; a publication was considered as deriving from ‘outside China’ when all affiliations were outside China; a publication was considered as deriving from ‘international collaboration’ when at least one affiliation was from China and at least one was from outside China. The research domains, publishing dates, journal language, authors’ affiliations, as well as methodological characteristics were analyzed respectively. All findings and statements regarding the outbreak in this review are based on published information as listed in the references.
      </p>
     </sec>
    </sec>
    <sec id="Sec8">
     <title>
      Results and discussion
     </title>
     <sec id="Sec9">
      <title>
       Characteristics of published studies
      </title>
      <p id="Par21">
       Among the 65 research articles included in the analysis, more than 31 are on preprint servers, and 34 are published in peer-reviewed journals, including
       <italic>
        The Lancet
       </italic>
       and
       <italic>
        The New England Journal of Medicine
       </italic>
       . Most of the publications (
       <italic>
        n
       </italic>
       = 58, 89.2%) are in English and few (
       <italic>
        n
       </italic>
       = 7, 10.8%) are in Chinese. Around 75.9% of English language publications focus on epidemiology and causes, while 85.7% of Chinese papers focus on prevention and control (Table
       <xref ref-type="table" rid="Tab1">
        1
       </xref>
       ).
       <table-wrap id="Tab1">
        <label>
         Table 1
        </label>
        <caption>
         <p>
          Breakdown of research domains by language in January 2020
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Research domains
           </th>
           <th colspan="2">
            English literature
           </th>
           <th colspan="2">
            Chinese literature
           </th>
           <th colspan="2">
            Total
           </th>
          </tr>
          <tr>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Epidemiology
           </td>
           <td>
            19
           </td>
           <td>
            32.8
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            19
           </td>
           <td>
            29.2
           </td>
          </tr>
          <tr>
           <td>
            Causes
           </td>
           <td>
            25
           </td>
           <td>
            43.1
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            25
           </td>
           <td>
            38.5
           </td>
          </tr>
          <tr>
           <td>
            Clinical manifestation and diagnosis
           </td>
           <td>
            8
           </td>
           <td>
            13.8
           </td>
           <td>
            1
           </td>
           <td>
            14.3
           </td>
           <td>
            9
           </td>
           <td>
            13.8
           </td>
          </tr>
          <tr>
           <td>
            Prevention and control
           </td>
           <td>
            6
           </td>
           <td>
            10.3
           </td>
           <td>
            6
           </td>
           <td>
            85.7
           </td>
           <td>
            12
           </td>
           <td>
            18.5
           </td>
          </tr>
          <tr>
           <td>
            Total
           </td>
           <td>
            58
           </td>
           <td>
            89.2
           </td>
           <td>
            7
           </td>
           <td>
            10.8
           </td>
           <td>
            65
           </td>
           <td>
            100
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <p id="Par22">
       As shown in Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       , academic publications are distributed across the following research domains: epidemiology, causes, clinical manifestation and diagnosis, and prevention and control. The largest portion of the papers (
       <italic>
        n
       </italic>
       = 25, 38.5%) are related to causes, followed by papers on epidemiology (
       <italic>
        n
       </italic>
       = 19, 29.2%), while 18.5% examined prevention and control and 13.8% reported clinical manifestations and diagnosis. Initially, there were more research articles focused on causes of the outbreak, yet studies on prevention and control gradually increased over time (Fig.
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       ). The majority of the articles (
       <italic>
        n
       </italic>
       = 44, 67.7%) were published by Chinese scholars whereas 29.2% (
       <italic>
        n
       </italic>
       = 19) articles were from scholars outside of China. A small number (
       <italic>
        n
       </italic>
       = 2, 3.1%) were based on international collaborative research by scholars from different countries (Table
       <xref ref-type="table" rid="Tab2">
        2
       </xref>
       ).
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Research domains of published research articles
         </p>
        </caption>
        <graphic id="MO2" xlink:href="40249_2020_646_Fig2_HTML">
        </graphic>
       </fig>
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Publication dates of research articles
         </p>
        </caption>
        <graphic id="MO3" xlink:href="40249_2020_646_Fig3_HTML">
        </graphic>
       </fig>
       <table-wrap id="Tab2">
        <label>
         Table 2
        </label>
        <caption>
         <p>
          Breakdown of research domains by collaboration type in January 2020
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th rowspan="2">
            Research domains
           </th>
           <th colspan="2">
            Inside China
           </th>
           <th colspan="2">
            Outside China
           </th>
           <th colspan="2">
            International collaboration
           </th>
           <th colspan="2">
            Total
           </th>
          </tr>
          <tr>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td>
            Epidemiology
           </td>
           <td>
            8
           </td>
           <td>
            18.2
           </td>
           <td>
            9
           </td>
           <td>
            47.4
           </td>
           <td>
            2
           </td>
           <td>
            100
           </td>
           <td>
            19
           </td>
           <td>
            29.2
           </td>
          </tr>
          <tr>
           <td>
            Causes
           </td>
           <td>
            17
           </td>
           <td>
            38.6
           </td>
           <td>
            8
           </td>
           <td>
            42.1
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            25
           </td>
           <td>
            38.5
           </td>
          </tr>
          <tr>
           <td>
            Clinical manifestation and diagnosis
           </td>
           <td>
            8
           </td>
           <td>
            18.2
           </td>
           <td>
            1
           </td>
           <td>
            5.3
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            9
           </td>
           <td>
            13.8
           </td>
          </tr>
          <tr>
           <td>
            Prevention and control
           </td>
           <td>
            11
           </td>
           <td>
            25.0
           </td>
           <td>
            1
           </td>
           <td>
            5.3
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
           <td>
            12
           </td>
           <td>
            18.5
           </td>
          </tr>
          <tr>
           <td>
            Total
           </td>
           <td>
            44
           </td>
           <td>
            67.7
           </td>
           <td>
            19
           </td>
           <td>
            29.2
           </td>
           <td>
            2
           </td>
           <td>
            3.1
           </td>
           <td>
            65
           </td>
           <td>
            100
           </td>
          </tr>
         </tbody>
        </table>
       </table-wrap>
      </p>
      <p id="Par23">
       We also analyzed the methodological characteristics of the publications in the final sample. The majority of the articles are based on mathematical modeling (44.6%) and cross-sectional study designs (18.5%). Around half of the studies include targeted populations (patients, general populations, and healthcare workers) (49.2%) in their analysis, followed by studies that attempt to identify the species of the virus (virus structure, gene sequence) (36.9%). Among the 32 articles with population as the target of study, 34.4% had a sample size of less than 10, 31.3% were conducted in a hospital setting, and 50% used secondary data. Quality control activities for data collection were mentioned in 56.3% of the population studies (Table
       <xref ref-type="table" rid="Tab3">
        3
       </xref>
       ).
       <table-wrap id="Tab3">
        <label>
         Table 3
        </label>
        <caption>
         <p>
          Methodological characteristics of COVID-19 research articles in January 2020
         </p>
        </caption>
        <table frame="hsides" rules="groups">
         <thead>
          <tr>
           <th>
            Characteristics
           </th>
           <th>
            Categories
           </th>
           <th>
            <italic>
             n
            </italic>
           </th>
           <th>
            %
           </th>
          </tr>
         </thead>
         <tbody>
          <tr>
           <td rowspan="6">
            <p>
             Study design
            </p>
            <p>
             (
             <italic>
              n
             </italic>
             = 65)
            </p>
           </td>
           <td>
            Cross-sectional studies
           </td>
           <td>
            12
           </td>
           <td>
            18.5
           </td>
          </tr>
          <tr>
           <td>
            Mathematical modeling
           </td>
           <td>
            29
           </td>
           <td>
            44.6
           </td>
          </tr>
          <tr>
           <td>
            Molecular studies
           </td>
           <td>
            10
           </td>
           <td>
            15.4
           </td>
          </tr>
          <tr>
           <td>
            Diagnostic studies
           </td>
           <td>
            2
           </td>
           <td>
            3.1
           </td>
          </tr>
          <tr>
           <td>
            Review
           </td>
           <td>
            3
           </td>
           <td>
            4.6
           </td>
          </tr>
          <tr>
           <td>
            Theoretical study
           </td>
           <td>
            9
           </td>
           <td>
            13.9
           </td>
          </tr>
          <tr>
           <td rowspan="6">
            <p>
             Targets of study
            </p>
            <p>
             (
             <italic>
              n
             </italic>
             = 65)
            </p>
           </td>
           <td>
            Population
           </td>
           <td>
            32
           </td>
           <td>
            49.2
           </td>
          </tr>
          <tr>
           <td>
            Patients
           </td>
           <td>
            22
           </td>
           <td>
            33.9
           </td>
          </tr>
          <tr>
           <td>
            General population
           </td>
           <td>
            6
           </td>
           <td>
            9.2
           </td>
          </tr>
          <tr>
           <td>
            Healthcare workers
           </td>
           <td>
            4
           </td>
           <td>
            6.2
           </td>
          </tr>
          <tr>
           <td>
            Species (virus structure, gene sequence)
           </td>
           <td>
            24
           </td>
           <td>
            36.9
           </td>
          </tr>
          <tr>
           <td>
            Other
           </td>
           <td>
            9
           </td>
           <td>
            13.9
           </td>
          </tr>
          <tr>
           <td colspan="4">
            Study related to population (
            <italic>
             n
            </italic>
            = 32)
           </td>
          </tr>
          <tr>
           <td rowspan="5">
            Sample size
           </td>
           <td>
            1–10
           </td>
           <td>
            11
           </td>
           <td>
            34.4
           </td>
          </tr>
          <tr>
           <td>
            11–50
           </td>
           <td>
            5
           </td>
           <td>
            15.6
           </td>
          </tr>
          <tr>
           <td>
            51–100
           </td>
           <td>
            3
           </td>
           <td>
            9.4
           </td>
          </tr>
          <tr>
           <td>
            &gt; 100
           </td>
           <td>
            3
           </td>
           <td>
            9.4
           </td>
          </tr>
          <tr>
           <td>
            Not specified
           </td>
           <td>
            10
           </td>
           <td>
            31.3
           </td>
          </tr>
          <tr>
           <td rowspan="6">
            Study setting
           </td>
           <td>
            Laboratory
           </td>
           <td>
            2
           </td>
           <td>
            6.3
           </td>
          </tr>
          <tr>
           <td>
            Hospital
           </td>
           <td>
            10
           </td>
           <td>
            31.3
           </td>
          </tr>
          <tr>
           <td>
            Community
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Hospital and community
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Not specified
           </td>
           <td>
            20
           </td>
           <td>
            62.5
           </td>
          </tr>
          <tr>
           <td>
            Questionnaire
           </td>
           <td>
            7
           </td>
           <td>
            10.8
           </td>
          </tr>
          <tr>
           <td rowspan="5">
            Data-collection instrument
            <sup>
             a
            </sup>
           </td>
           <td>
            Biological specimen collection
           </td>
           <td>
            1
           </td>
           <td>
            3.1
           </td>
          </tr>
          <tr>
           <td>
            Physical examinations
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Environmental sample
           </td>
           <td>
            0
           </td>
           <td>
            0.0
           </td>
          </tr>
          <tr>
           <td>
            Hospital, medical, or exposure records
           </td>
           <td>
            14
           </td>
           <td>
            43.7
           </td>
          </tr>
          <tr>
           <td>
            Secondary data
           </td>
           <td>
            16
           </td>
           <td>
            50.0
           </td>
          </tr>
          <tr>
           <td rowspan="2">
            Quality-control activities for data collection
           </td>
           <td>
            Indicated in the article
           </td>
           <td>
            14
           </td>
           <td>
            56.3
           </td>
          </tr>
          <tr>
           <td>
            Not specified
           </td>
           <td>
            18
           </td>
           <td>
            43.8
           </td>
          </tr>
         </tbody>
        </table>
        <table-wrap-foot>
         <p>
          <sup>
           a
          </sup>
          Percentages in this section do not add up to 100% because multiple answers were possible
         </p>
        </table-wrap-foot>
       </table-wrap>
      </p>
     </sec>
     <sec id="Sec10">
      <title>
       Research domains
      </title>
      <sec id="Sec11">
       <title>
        Epidemiology
       </title>
       <p id="Par24">
        On 29 December 2019, the first four cases of an acute respiratory syndrome of unknown etiology were reported in Wuhan City, Hubei Province, China among people linked to a local seafood market (“wet market”) [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ]. Research is underway to understand more about transmissibility, severity, and other features associated with COVID-19 [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ]. It appears that most of the early cases had some sort of contact history with the original seafood market [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="CR12">
         12
        </xref>
        –
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ]. Soon, a secondary source of infection was found to be human-to-human transmission via close contact. There was an increase of infected people with no history of exposure to wildlife or visiting Wuhan, and multiple cases of infection were detected among medical professionals [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        –
        <xref ref-type="bibr" rid="CR17">
         17
        </xref>
        ]. It became clear that the COVID-19 infection occurs through exposure to the virus, and both the immunosuppressed and normal population appear susceptible. Some studies have reported an age distribution of adult patients between 25 and 89 years old. Most adult patients were between 35 and 55 years old [
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ], and there were fewer identified cases among children and infants [
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ]. A study on early transmission dynamics of the virus reported the median age of patients to be 59 years, ranging from 15 to 89 years, with the majority (59%) being male [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ]. It was suggested that the population most at risk may be people with poor immune function such as older people and those with renal and hepatic dysfunction [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ].
       </p>
       <p id="Par25">
        The COVID-19 has been found to have higher levels of transmissibility and pandemic risk than the SARS-CoV, as the effective reproductive number (R) of COVID-19 (2.9) is estimated to be higher than the reported effective reproduction number (R) of SARS (1.77) at this early stage [
        <xref ref-type="bibr" rid="CR15">
         15
        </xref>
        ]. Different studies of COVID-19 have estimated the basic reproduction (R
        <sub>
         0
        </sub>
        ) range to be from 2.6 to 4.71 (Table
        <xref ref-type="table" rid="Tab4">
         4
        </xref>
        ). The average incubation duration of COVID-19 was estimated to be 4.8 ± 2.6, ranging from 2 to 11 days [
        <xref ref-type="bibr" rid="CR15">
         15
        </xref>
        ] and 5.2 days (95% confidence interval, 4.1 to 7) [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ]. The latest guidelines from Chinese health authorities stated an average incubation duration of 7 days, ranging from 2 to 14 days [
        <xref ref-type="bibr" rid="CR23">
         23
        </xref>
        ]. Table
        <xref ref-type="table" rid="Tab4">
         4
        </xref>
        summarizes the findings on important indicators from these epidemiological studies.
        <table-wrap id="Tab4">
         <label>
          Table 4
         </label>
         <caption>
          <p>
           Main epidemiological indicators of COVID-19 research articles in January 2020
          </p>
         </caption>
         <table frame="hsides" rules="groups">
          <thead>
           <tr>
            <th>
             Indicators
            </th>
            <th>
             Description
            </th>
           </tr>
          </thead>
          <tbody>
           <tr>
            <td rowspan="4">
             Age of patients
            </td>
            <td>
             • Cases range between 25 and 89 years, with most patients aged between 35 and 55 years and fewer cases among children and infants [
             <xref ref-type="bibr" rid="CR14">
              14
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Median age of patients is 59 years, ranging from 51 to 89 [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average age of patients was 55.5 years; age distribution: ≤ 39: 10%; 40–49: 22%, 50–59: 30%; 60–69: 22%, ≥ 70: 15% [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Cases range from 2 to 72 years [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="3">
             Sex of patients
            </td>
            <td>
             • More cases were males [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 59% males [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 68% males [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             Age of the deaths
            </td>
            <td>
             • Median age of death was 75 (with a range between 48 and 89 years) [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="2">
             Exposure history
            </td>
            <td>
             • Huanan Seafood Market in Wuhan [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ,
             <xref ref-type="bibr" rid="CR22">
              22
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Wuhan residents or people who visited Wuhan [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="6">
             Incubation time
            </td>
            <td>
             • 4.8 ± 2.6 days (2–11 days) [
             <xref ref-type="bibr" rid="CR15">
              15
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 5.2 days (4.1–7 days) [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average of 7 days (2–14 days) [
             <xref ref-type="bibr" rid="CR23">
              23
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average of 10 days [
             <xref ref-type="bibr" rid="CR22">
              22
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 5–6 days [
             <xref ref-type="bibr" rid="CR24">
              24
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Average of 6.4 days (5.6–7.7 days) [
             <xref ref-type="bibr" rid="CR20">
              20
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="5">
             Basic Reproduction (R
             <sub>
              0
             </sub>
             )
            </td>
            <td>
             • 2.6 (uncertainty range: 1.5–3.5) [
             <xref ref-type="bibr" rid="CR25">
              25
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 3.8 (95%
             <italic>
              CI
             </italic>
             : 3.6–4.0) [
             <xref ref-type="bibr" rid="CR26">
              26
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.2 (1.4–3.8) [
             <xref ref-type="bibr" rid="CR27">
              27
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 4.71 (4.50–4.92) [
             <xref ref-type="bibr" rid="CR24">
              24
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.68 (95%
             <italic>
              CI
             </italic>
             : 2.47–2.86) [
             <xref ref-type="bibr" rid="CR28">
              28
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="5">
             Susceptible populations
            </td>
            <td>
             • Elderly people [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • People with poor immune function [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • People with chronic co-morbidities [
             <xref ref-type="bibr" rid="CR2">
              2
             </xref>
             ,
             <xref ref-type="bibr" rid="CR15">
              15
             </xref>
             ,
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ,
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • People with long-term use of immunosuppressive agents [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • Surgery history before admission [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td rowspan="6">
             Mortality rate
            </td>
            <td>
             • 3% (between 29 December 2019 to 23 January, 2020) [
             <xref ref-type="bibr" rid="CR15">
              15
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.3% (as of 28 January 2020) [
             <xref ref-type="bibr" rid="CR29">
              29
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.8% (as of 25 January, 2020) [
             <xref ref-type="bibr" rid="CR21">
              21
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 2.9% (as of 25 January, 2020) [
             <xref ref-type="bibr" rid="CR30">
              30
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 11% (as of 25 January, 2020) [
             <xref ref-type="bibr" rid="CR19">
              19
             </xref>
             ]
            </td>
           </tr>
           <tr>
            <td>
             • 3.1% (as of 24 January 2020) [
             <xref ref-type="bibr" rid="CR31">
              31
             </xref>
             ]
            </td>
           </tr>
          </tbody>
         </table>
        </table-wrap>
       </p>
       <p id="Par26">
        In China, 11 791 cases were confirmed and 17 988 cases were suspected in 34 provinces as of 24:00, 31 January 2020 (Fig.
        <xref ref-type="fig" rid="Fig4">
         4
        </xref>
        ) [
        <xref ref-type="bibr" rid="CR32">
         32
        </xref>
        ]. Studies indicated that the spread of COVID-19 was relatively quick and reported that it had spread to several other countries after its outbreak in China. On 31 January 2020, there were 213 deaths reported globally [
        <xref ref-type="bibr" rid="CR33">
         33
        </xref>
        ]. Confirmed cases were reported in the following 19 countries outside of China: Australia (9), Canada (3), Cambodia (1), France (6), Finland (1), Germany (5), India (1), Italy (2), Japan (14), Nepal (1), Malaysia (8), the Philippines (1), the Republic of Korea (11), Singapore (13), Sri Lanka (1), Thailand (14), the United States of America (6), United Arab Emirates (4) and Vietnam (5) (Fig.
        <xref ref-type="fig" rid="Fig5">
         5
        </xref>
        ) [
        <xref ref-type="bibr" rid="CR33">
         33
        </xref>
        ].
        <fig id="Fig4">
         <label>
          Fig. 4
         </label>
         <caption>
          <p>
           Distribution of COVID-19 cases in China
          </p>
         </caption>
         <graphic id="MO4" xlink:href="40249_2020_646_Fig4_HTML">
         </graphic>
        </fig>
        <fig id="Fig5">
         <label>
          Fig. 5
         </label>
         <caption>
          <p>
           Global distribution of COVID-19 cases
          </p>
         </caption>
         <graphic id="MO5" xlink:href="40249_2020_646_Fig5_HTML">
         </graphic>
        </fig>
       </p>
      </sec>
      <sec id="Sec12">
       <title>
        Causes
       </title>
       <sec id="FPar1">
        <title>
         Virology and pathogenesis
        </title>
        <p id="Par27">
         Coronaviruses are enveloped single-stranded RNA viruses that are zoonotic in nature and cause symptoms ranging from those similar to the common cold to more severe respiratory, enteric, hepatic, and neurological symptoms [
         <xref ref-type="bibr" rid="CR5">
          5
         </xref>
         ,
         <xref ref-type="bibr" rid="CR34">
          34
         </xref>
         ]. Other than SARS-CoV-2, there are six known coronaviruses in humans: HCoV-229E, HCoV-OC43, SARS-CoV, HCoV-NL63, HCoV-HKU1, and MERS-CoV [
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ,
         <xref ref-type="bibr" rid="CR35">
          35
         </xref>
         ,
         <xref ref-type="bibr" rid="CR36">
          36
         </xref>
         ]. Coronavirus has caused two large-scale pandemics in the last two decades: SARS [
         <xref ref-type="bibr" rid="CR37">
          37
         </xref>
         ] and MERS [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ,
         <xref ref-type="bibr" rid="CR38">
          38
         </xref>
         ].
        </p>
        <p id="Par28">
         To detect the infection source of COVID-19, China CDC researchers collected 585 environmental samples from the Huanan Seafood Market in Wuhan, Hubei Province, China on 1 January and 12 January 2020. They detected 33 samples containing SARS-CoV-2 and indicated that it originated from wild animals sold in the market [
         <xref ref-type="bibr" rid="CR39">
          39
         </xref>
         ]. Then, researchers used the lung fluid, blood, and throat swab samples of 15 patients to conduct laboratory tests. These laboratory tests found that the virus-specific nucleic acid sequences in the sample are different from those of known human coronavirus species. Laboratory results also indicated that SARS-CoV-2 is similar to some of the beta (β) coronaviruses genera identified in bats [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ,
         <xref ref-type="bibr" rid="CR18">
          18
         </xref>
         ,
         <xref ref-type="bibr" rid="CR40">
          40
         </xref>
         ], which is situated in a group of SARS/SARS-like CoV [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ].
        </p>
        <p id="Par29">
         To conduct next-generation sequencing from bronchoalveolar lavage fluid and cultured isolates, researchers enrolled nine inpatients in Wuhan with viral pneumonia and negative in common respiratory pathogens. The results of this next-generation sequencing indicated that SARS-CoV-2 was more distant from SARS-CoV (with about 79% sequence identity) and MERS-CoV (with about 50% sequence identity) than from two bat-derived SARS-like coronaviruses – bat-SL-CoVZC45 (with 87.9% sequence identity) and bat-SL-CoVZXC21 (with 87.2% sequence identity) [
         <xref ref-type="bibr" rid="CR41">
          41
         </xref>
         ]. Studies also reported that COVID-19 S-protein supported strong interaction with human ACE2 molecules despite the dissimilarity of its sequence with that of SARS-CoV [
         <xref ref-type="bibr" rid="CR12">
          12
         </xref>
         ,
         <xref ref-type="bibr" rid="CR42">
          42
         </xref>
         ].
        </p>
       </sec>
       <sec id="FPar2">
        <title>
         Transmission pattern
        </title>
        <p id="Par30">
         Many domestic and wild animals, including camels, cattle, cats, and bats, may serve as hosts for coronaviruses [
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ]. It is considered that, generally, animal coronaviruses do not spread among humans [
         <xref ref-type="bibr" rid="CR3">
          3
         </xref>
         ]. However, there are exceptions, such as SARS and MERS, which are mainly spread though close contact with infected people via respiratory droplets from cough or sneezing. With regard to COVID-19, early patients were reported to have some link to the Huanan Seafood Market in Wuhan, China, suggesting that these early infections were due to animal-to-person transmission. However, later cases were reported among medical staff and others with no history of exposure to that market or visiting Wuhan, which was taken as an indication of human-to-human transmission [
         <xref ref-type="bibr" rid="CR2">
          2
         </xref>
         ,
         <xref ref-type="bibr" rid="CR4">
          4
         </xref>
         ,
         <xref ref-type="bibr" rid="CR15">
          15
         </xref>
         –
         <xref ref-type="bibr" rid="CR17">
          17
         </xref>
         ].
        </p>
        <p id="Par31">
         The latest guidelines from Chinese health authorities [
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ,
         <xref ref-type="bibr" rid="CR43">
          43
         </xref>
         ] described three main transmission routes for the COVID-19: 1) droplets transmission, 2) contact transmission, and 3) aerosol transmission. Droplets transmission was reported to occur when respiratory droplets (as produced when an infected person coughs or sneezes) are ingested or inhaled by individuals nearby in close proximity; contact transmission may occur when a subject touches a surface or object contaminated with the virus and subsequently touch their mouth, nose, or eyes; and aerosol transmission may occur when respiratory droplets mix into the air, forming aerosols and may cause infection when inhaled high dose of aerosols into the lungs in a relatively closed environment [
         <xref ref-type="bibr" rid="CR23">
          23
         </xref>
         ,
         <xref ref-type="bibr" rid="CR43">
          43
         </xref>
         ]. In addition to these three routes, one study also indicated the digestive system as a potential transmission route for COVID-19 infection. Since patients had abdominal discomfort and diarrhea symptoms, researchers analyzed four datasets with single-cell transcriptomes of digestive systems and found that ACE2 was highly expressed in absorptive enterocytes from ileum and colon [
         <xref ref-type="bibr" rid="CR44">
          44
         </xref>
         ].
        </p>
       </sec>
      </sec>
      <sec id="Sec1111">
       <title>
        Clinical manifestation and diagnosis
       </title>
       <p id="Par32">
        The complete clinical manifestation is not clear yet, as the reported symptoms range from mild to severe, with some cases even resulting in death [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ]. The most commonly reported symptoms are fever, cough, myalgia or fatigue, pneumonia, and complicated dyspnea, whereas less common reported symptoms include headache, diarrhea, hemoptysis, runny nose, and phlegm-producing cough [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ,
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ]. Patients with mild symptoms were reported to recover after 1 week while severe cases were reported to experience progressive respiratory failure due to alveolar damage from the virus, which may lead to death [
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
        ]. Cases resulting in death were primarily middle-aged and elderly patients with pre-existing diseases (tumor surgery, cirrhosis, hypertension, coronary heart disease, diabetes, and Parkinson’s disease) [
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
        ]. Case definition guidelines mention the following symptoms: fever, decrease in lymphocytes and white blood cells, new pulmonary infiltrates on chest radiography, and no improvement in symptoms after 3 days of antibiotics treatment [
        <xref ref-type="bibr" rid="CR2">
         2
        </xref>
        ].
       </p>
       <p id="Par33">
        For patients with suspected infection, the following procedures have been suggested for diagnosis: performing real-time fluorescence (RT-PCR) to detect the positive nucleic acid of SARS-CoV-2 in sputum, throat swabs, and secretions of the lower respiratory tract samples [
        <xref ref-type="bibr" rid="CR13">
         13
        </xref>
        ,
        <xref ref-type="bibr" rid="CR14">
         14
        </xref>
        ,
        <xref ref-type="bibr" rid="CR43">
         43
        </xref>
        ].
       </p>
      </sec>
      <sec id="Sec121">
       <title>
        Prevention and control
       </title>
       <p id="Par34">
        Prevention and control strategies and methods are reported at three levels: national level, case-related population level, and general population level. At the national level, the National Health Commission of the People’s Republic of China issued the “No.1 announcement” on 20 January 2020, which officially included the COVID-19 into the management of class B legal infectious diseases, and allowed for class A infectious disease preventive and control measures to be implemented [
        <xref ref-type="bibr" rid="CR45">
         45
        </xref>
        ]. Under this policy, medical institutes can adopt isolation treatment and observation protocols to prevent and control the spread of the COVID-19. On 22 January 2020, the National Health Commission published national guidelines for the prevention and control of COVID-19 for medical institutes to prevent nosocomial infection [
        <xref ref-type="bibr" rid="CR46">
         46
        </xref>
        ]. On 28 January 2020, the National Health Commission issued protocols for rapid prevention and control measures in order to effectively contain the spread of the epidemic through a “big isolation and big disinfection” policy during the Chinese Spring Festival [
        <xref ref-type="bibr" rid="CR47">
         47
        </xref>
        ]. National-level strategies have also been issued with targeted measures for rural areas (issued on 28 January 2020) and the elderly population (issued on 31 January 2020) [
        <xref ref-type="bibr" rid="CR48">
         48
        </xref>
        ,
        <xref ref-type="bibr" rid="CR49">
         49
        </xref>
        ]. Several public health measures that may prevent or slow down the transmission of the COVID-19 were introduced; these include case isolation, identification and follow-up of contacts, environmental disinfection, and use of personal protective equipment [
        <xref ref-type="bibr" rid="CR50">
         50
        </xref>
        ].
       </p>
       <p id="Par35">
        To date, no specific antiviral treatment has been confirmed to be effective against COVID-19. Regarding patients infected with COVID-19, it has been recommended to apply appropriate symptomatic treatment and supportive care [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ,
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ]. There are six clinical trials registered in both the International Clinical Trials Registry platform and the Chinese Clinical Trial Registry to evaluate the efficacy or safety of targeted medicine in the treatment or prognosis of COVID-19 (Additional file
        <xref ref-type="media" rid="MOESM2">
         2
        </xref>
        ) [
        <xref ref-type="bibr" rid="CR51">
         51
        </xref>
        ,
        <xref ref-type="bibr" rid="CR52">
         52
        </xref>
        ]. Regarding infected patients with COVID-19, it has been recommended to apply appropriate symptomatic treatment and supportive care [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ,
        <xref ref-type="bibr" rid="CR16">
         16
        </xref>
        ]. Studies have also explored the prevention of nosocomial infection and psychological health issues associated with COVID-19. A series of measures have been suggested to reduce nosocomial infection, including knowledge training for prevention and control, isolation, disinfection, classified protections at different degrees in infection areas, and protection of confirmed cases [
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR50">
         50
        </xref>
        ,
        <xref ref-type="bibr" rid="CR53">
         53
        </xref>
        ]. Concerning psychological health, some suggested psychological intervention for confirmed cases, suspected cases, and medical staff [
        <xref ref-type="bibr" rid="CR18">
         18
        </xref>
        ,
        <xref ref-type="bibr" rid="CR54">
         54
        </xref>
        ].
       </p>
       <p id="Par36">
        For the general population, at this moment there is no vaccine preventing COVID-19. The best prevention is to avoid being exposed to the virus [
        <xref ref-type="bibr" rid="CR55">
         55
        </xref>
        ]. Airborne precautions and other protective measures have been discussed and proposed for prevention. Infection preventive and control (IPC) measures that may reduce the risk of exposure include the following: use of face masks; covering coughs and sneezes with tissues that are then safely disposed of (or, if no tissues are available, use a flexed elbow to cover the cough or sneeze); regular hand washing with soap or disinfection with hand sanitizer containing at least 60% alcohol (if soap and water are not available); avoidance of contact with infected people and maintaining an appropriate distance as much as possible; and refraining from touching eyes, nose, and mouth with unwashed hands [
        <xref ref-type="bibr" rid="CR3">
         3
        </xref>
        ].
       </p>
       <p id="Par37">
        The WHO also issued detailed guidelines on the use of face masks in the community, during care at home, and in the health care settings of COVID-19 [
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
        ]. In this document, health care workers are recommended to use particulate respirators such as those certified N95 or FFP2 when performing aerosol-generating procedures and to use medical masks while providing any care to suspected or confirmed cases. According to this guideline, individuals with respiratory symptoms are advised to use medical masks both in health care and home care settings properly following the infection prevention guidelines. According to this guideline, an individual without respiratory symptoms is not required to wear a medical mask when in public. Proper use and disposal of masks is important to avoid any increase in risk of transmission [
        <xref ref-type="bibr" rid="CR56">
         56
        </xref>
        ].
       </p>
       <p id="Par38">
        In addition to articles published in research journals, the China CDC published a guideline to raise awareness of the prevention and control of COVID-19 among the general population. The key messages of the guideline include causes, how to choose and wear face masks, proper hand washing habits, preventive measures at different locations (e.g., at home, on public transportation, and in public space), disinfection methods, and medical observation at home [
        <xref ref-type="bibr" rid="CR57">
         57
        </xref>
        ]. In addition to scientific knowledge on ways to handle the COVID-19 outbreak, the guideline also suggests ways to eliminate panic among the general population [
        <xref ref-type="bibr" rid="CR57">
         57
        </xref>
        ].
       </p>
      </sec>
     </sec>
     <sec id="Sec13">
      <title>
       Strengths and limitations of the study
      </title>
      <p id="Par39">
       The review applied a systematic and rigorous search strategy to retrieve relevant articles according to the research objectives. This research summarizes scientific foundations, identifies literature gaps, and suggests some evidence for future research directions on COVID-19 which will provide information for research community, policymakers, and health professionals to adjust and/or come up with new research, policies, and practices. Our study only focuses on the articles published either in English or in Chinese during the early outbreak period. Although, it cannot reflect the entire body of research on COVID-19 worldwide, it will provide some evidences for future study and control.
      </p>
     </sec>
    </sec>
    <sec id="Sec14">
     <title>
      Conclusions
     </title>
     <p id="Par40">
      This study shows a holistic picture of the current research in response to the outbreak of COVID-19. During this early period, many studies have been published exploring the epidemiology, causes, clinical manifestation and diagnosis, and prevention and control of the novel coronavirus. Thus far, most studies have focused on the epidemiology and potential causes. However, studies exploring prevention and control measures have begun to gradually increase. Studies in this domain are urgently needed to minimize the impact of the outbreak. Government agencies have quickly incorporated recent scientific findings into public policies at the community, regional, and national levels to slow down and/or prevent the further spread of the COVID-19. We recommend that the scholarly community conduct further research to provide valid and reliable ways to manage this kind of public health emergency in both the short-term and long-term.
     </p>
    </sec>
    <sec sec-type="supplementary-material">
     <title>
      Supplementary information
     </title>
     <sec id="Sec15">
      <p>
       <supplementary-material content-type="local-data" id="MOESM1">
        <media xlink:href="40249_2020_646_MOESM1_ESM.docx">
         <caption>
          <p>
           <bold>
            Additional file 1.
           </bold>
           Published research articles on COVID-19 in January 2020.
          </p>
         </caption>
        </media>
       </supplementary-material>
       <supplementary-material content-type="local-data" id="MOESM2">
        <media xlink:href="40249_2020_646_MOESM2_ESM.docx">
         <caption>
          <p>
           <bold>
            Additional file 2.
           </bold>
           Clinical trials registered as of 31 January 2020.
          </p>
         </caption>
        </media>
       </supplementary-material>
      </p>
     </sec>
    </sec>
    <back>
     <glossary>
      <title>
       Abbreviations
      </title>
      <def-list>
       <def-item>
        <term>
         ACE2
        </term>
        <def>
         <p id="Par5">
          Angiotensin converting enzyme 2
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         CDC
        </term>
        <def>
         <p id="Par6">
          Center for Disease Control
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         IPC
        </term>
        <def>
         <p id="Par7">
          Infection prevention and control
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         MERS
        </term>
        <def>
         <p id="Par8">
          Middle East Respiratory Syndrome
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         PRISMA
        </term>
        <def>
         <p id="Par9">
          Preferred Reporting Items for Systematic Reviews and Meta-Analyses
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         SARS
        </term>
        <def>
         <p id="Par10">
          Severe Acute Respiratory Syndrome
         </p>
        </def>
       </def-item>
       <def-item>
        <term>
         WHO
        </term>
        <def>
         <p id="Par11">
          World Health Organization
         </p>
        </def>
       </def-item>
      </def-list>
     </glossary>
     <sec>
      <title>
       Supplementary information
      </title>
      <p>
       <bold>
        Supplementary information
       </bold>
       accompanies this paper at 10.1186/s40249-020-00646-x.
      </p>
     </sec>
     <ack>
      <p>
       Our sincere thanks go to all the experts who have given insights for the writing of this paper.
      </p>
     </ack>
     <notes notes-type="author-contribution">
      <title>
       Authors’ contributions
      </title>
      <p>
       SPA and HZ designed the study, guided the methodology, and wrote the first draft; SM, WY, QW, SC, RY were responsible for searching the articles; WY, SPA, HZ were responsible for database selection, search strategy, article screening against inclusion criteria, and charting the data; QW, SM, SPA, and HZ were responsible for analysis; SPA, HZ, SS, YM, SR and HR critically reviewed, discussed, and modified the manuscript. All authors read and approved the final manuscript for publication.
      </p>
     </notes>
     <notes notes-type="funding-information">
      <title>
       Funding
      </title>
      <p>
       This study was funded by China Medical Board (CMB-18-297).
      </p>
     </notes>
     <notes notes-type="data-availability">
      <title>
       Availability of data and materials
      </title>
      <p>
       The dataset supporting the conclusions of this article is included as an Additional file table.
      </p>
     </notes>
     <notes>
      <title>
       Ethics approval and consent to participate
      </title>
      <p id="Par41">
       Not applicable.
      </p>
     </notes>
     <notes>
      <title>
       Consent for publication
      </title>
      <p id="Par42">
       Not applicable.
      </p>
     </notes>
     <notes notes-type="COI-statement">
      <title>
       Competing interests
      </title>
      <p id="Par43">
       The authors declare that they have no competing interests.
      </p>
     </notes>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <mixed-citation publication-type="other">
        WMHC. Wuhan Municipal Health and Health Commission’s Briefing on the Current Pneumonia Epidemic Situation in Our City. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989">
         http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <mixed-citation publication-type="other">
        Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. 10.1056/NEJMoa2001316.
       </mixed-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <mixed-citation publication-type="other">
        CDC. 2019 Novel coronavirus, Wuhan, China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-nCoV/summary.html">
         https://www.cdc.gov/coronavirus/2019-nCoV/summary.html
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <mixed-citation publication-type="other">
        WHO. Novel Coronavirus–China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/">
         https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <mixed-citation publication-type="other">
        Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. 10.1056/NEJMoa2001017.
       </mixed-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <mixed-citation publication-type="other">
        WHO. Novel Coronavirus-Japan (ex-China). 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/">
         https://www.who.int/csr/don/17-january-2020-novel-coronavirus-japan-ex-china/en/
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <mixed-citation publication-type="other">
        Virological.org. Novel 2019 Coronavirus Genome 2020.
        <ext-link ext-link-type="uri" xlink:href="http://virological.org/t/novel-2019-coronavirus-genome/319">
         http://virological.org/t/novel-2019-coronavirus-genome/319
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fehr
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Channappanavar
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Perlman
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome: emergence of a pathogenic human coronavirus
        </article-title>
        <source>
         Annu Rev Med
        </source>
        <year>
         2017
        </year>
        <volume>
         68
        </volume>
        <fpage>
         387
        </fpage>
        <lpage>
         399
        </lpage>
        <pub-id pub-id-type="doi">
         10.1146/annurev-med-051215-031152
        </pub-id>
        <pub-id pub-id-type="pmid">
         27576010
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <mixed-citation publication-type="other">
        WHO. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov)">
         https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov
        </ext-link>
        ). Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Arksey
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           O’Malley
          </surname>
          <given-names>
           L
          </given-names>
         </name>
        </person-group>
        <article-title>
         Scoping studies: towards a methodological framework
        </article-title>
        <source>
         Int J Soc Res Methodol
        </source>
        <year>
         2005
        </year>
        <volume>
         8
        </volume>
        <fpage>
         19
        </fpage>
        <lpage>
         32
        </lpage>
        <pub-id pub-id-type="doi">
         10.1080/1364557032000119616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <mixed-citation publication-type="other">
        Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6 (e100097). 10.1371/journal.pmed.1000097.
       </mixed-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <mixed-citation publication-type="other">
        Zhou P, Yang XL, Wang, XG, Hu B, Zhang L, Zhang W, et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020; doi: 10.1101/2020.01.22.914952.
       </mixed-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <mixed-citation publication-type="other">
        Li T, Wei C, Li W, Hongwei F, Shi J. Beijing Union Medical College Hospital on "pneumonia of novel coronavirus infection" diagnosis and treatment proposal (V2.0). Med J Peking Union Med Coll Hosp. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html">
         http://kns.cnki.net/kcms/detail/11.5882.r.20200130.1430.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <mixed-citation publication-type="other">
        Medical expert group of Tongji hospital. Quick guide to the diagnosis and treatment of pneumonia for novel coronavirus infections (third edition). Herald Med. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html">
         http://kns.cnki.net/kcms/detail/42.1293.r.20200130.1803.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <mixed-citation publication-type="other">
        Liu T, Hu J, Kang M, Lin L, Zhong H, Xiao J, et al. Transmission dynamics of 2019 novel coronavirus (2019-nCoV). 2020; doi: 10.1101/2020.01.25.919787.
       </mixed-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <mixed-citation publication-type="other">
        Huang C, Wang Y, Li X, Ren L, Zhao Jianping, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395:497–506. 10.1016/S0140-6736(20)30183-5.
       </mixed-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gralinski
          </surname>
          <given-names>
           LE
          </given-names>
         </name>
         <name>
          <surname>
           Menachery
          </surname>
          <given-names>
           VD
          </given-names>
         </name>
        </person-group>
        <article-title>
         Return of the coronavirus: 2019-nCoV
        </article-title>
        <source>
         Viruses.
        </source>
        <year>
         2020
        </year>
        <volume>
         12
        </volume>
        <fpage>
         135
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/v12020135
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prevalence, nosocomial infection and psychological prevention of novel coronavirus infection
        </article-title>
        <source>
         Chin General Pract Nurs
        </source>
        <year>
         2020
        </year>
        <volume>
         18
        </volume>
        <fpage>
         2
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Qu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Gong
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet.
        </source>
        <year>
         2020
        </year>
        <volume>
         395
        </volume>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0140-6736(20)30211-7
        </pub-id>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <mixed-citation publication-type="other">
        Backer JA, Klinkenberg D, Wallinga J. The incubation period of 2019-nCoV infections among travellers from Wuhan. China Euro Surveill. 2020; 10.2807/1560-7917.ES.2020.25.5.2000062.
       </mixed-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           F
          </given-names>
         </name>
        </person-group>
        <article-title>
         Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China
        </article-title>
        <source>
         J Med Virol
        </source>
        <year>
         2020
        </year>
        <volume>
         92
        </volume>
        <fpage>
         441
        </fpage>
        <lpage>
         447
        </lpage>
        <pub-id pub-id-type="doi">
         10.1002/jmv.25689
        </pub-id>
        <pub-id pub-id-type="pmid">
         31994742
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <mixed-citation publication-type="other">
        Imai N, Dorigatti I, Cori A, Riley S, Ferguson, NM. Estimating the potential total number of novel Coronavirus cases in Wuhan City, China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/2019-nCoV-outbreak-report-17-01-2020.pdf">
         https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/2019-nCoV-outbreak-report-17-01-2020.pdf
        </ext-link>
        . Accessed 31 Jan, 2020.
       </mixed-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Prevent guideline of 2019-nCoV. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqfkdt/202001/bc661e49b5bc487dba182f5c49ac445b.shtml">
         http://www.nhc.gov.cn/xcs/yqfkdt/202001/bc661e49b5bc487dba182f5c49ac445b.shtml
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <mixed-citation publication-type="other">
        Shen M, Peng Z, Xiao Y, Zhang L. Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. bioRxiv. 2020; 10.1101/2020.01.23.916726.
       </mixed-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <mixed-citation publication-type="other">
        Imai N, Cori A, Dorigatti I, Baguelin M, Donnelly CA, Riley S, et al. Report 3: Transmissibility of 2019-nCoV. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-2019-nCoV-transmissibility.pdf">
         https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-2019-nCoV-transmissibility.pdf
        </ext-link>
        . Accessed 31 Jan, 2020.
       </mixed-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <mixed-citation publication-type="other">
        Read JM, Bridgen JRE, Cummings DAT, Ho A, Jewell CP. Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. medRxiv
        <italic>
         .
        </italic>
        2020; doi: 10.1101/2020.01.23.20018549.
       </mixed-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <mixed-citation publication-type="other">
        Riou J, Althaus CL. Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. Euro Surveill. 2020;25(4). 10.2807/1560-7917.ES.2020.25.4.2000058.
       </mixed-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <mixed-citation publication-type="other">
        Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; 10.1016/S0140-6736(20)30260-9.
       </mixed-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <mixed-citation publication-type="other">
        Ming WK, Huang J, Zhang CJ. Breaking down of healthcare system: mathematical modelling for controlling the novel coronavirus (2019-nCoV) outbreak in Wuhan. China bioRxiv. 2020. 10.1101/2020.01.27.922443.
       </mixed-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <mixed-citation publication-type="other">
        Lai S, Bogoch II, Watts A, Khan K, Li Z, Tatem A. Preliminary risk analysis of 2019 novel coronavirus spread within and beyond China. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.worldpop.org/resources/docs/china/WorldPop-coronavirus-spread-risk-analysis-v1-25Jan.pdf">
         https://www.worldpop.org/resources/docs/china/WorldPop-coronavirus-spread-risk-analysis-v1-25Jan.pdf
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nishiura
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Jung
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Linton
          </surname>
          <given-names>
           NM
          </given-names>
         </name>
         <name>
          <surname>
           Kinoshita
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Hayashi
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         The extent of transmission of novel coronavirus in Wuhan, China, 2020
        </article-title>
        <source>
         J Clin Med
        </source>
        <year>
         2020
        </year>
        <volume>
         9
        </volume>
        <fpage>
         330
        </fpage>
        <pub-id pub-id-type="doi">
         10.3390/jcm9020330
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. An update on the incidence of pneumonia with novel coronavirus infection as at 24:00 on 31 January 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/yqfkdt/202002/84faf71e096446fdb1ae44939ba5c528.shtml">
         http://www.nhc.gov.cn/xcs/yqfkdt/202002/84faf71e096446fdb1ae44939ba5c528.shtml
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <mixed-citation publication-type="other">
        WHO. Novel Coronavirus (2019-nCoV) Situation Report–11. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4">
         https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200131-sitrep-11-ncov.pdf?sfvrsn=de7c0f7_4
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <mixed-citation publication-type="other">
        WHO. Coronavirus. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://www.who.int/health-topics/coronavirus">
         https://www.who.int/health-topics/coronavirus
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR35">
       <label>
        35.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Su
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Wong
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Lai
          </surname>
          <given-names>
           ACK
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Epidemiology, genetic recombination, and pathogenesis of coronaviruses
        </article-title>
        <source>
         Trend Microbiol
        </source>
        <year>
         2016
        </year>
        <volume>
         24
        </volume>
        <fpage>
         490
        </fpage>
        <lpage>
         502
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.tim.2016.03.003
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR36">
       <label>
        36.
       </label>
       <mixed-citation publication-type="other">
        Chen Y, Liu Q, Guo D. Coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020. 10.1002/jmv.25681.
       </mixed-citation>
      </ref>
      <ref id="CR37">
       <label>
        37.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peiris
          </surname>
          <given-names>
           JS
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yuen
          </surname>
          <given-names>
           K
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome
        </article-title>
        <source>
         Nature Med
        </source>
        <year>
         2004
        </year>
        <volume>
         10
        </volume>
        <fpage>
         S88
        </fpage>
        <lpage>
         S97
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nm1143
        </pub-id>
        <pub-id pub-id-type="pmid">
         15577937
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR38">
       <label>
        38.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zaki
          </surname>
          <given-names>
           AM
          </given-names>
         </name>
         <name>
          <surname>
           Boheemen
          </surname>
          <given-names>
           SV
          </given-names>
         </name>
         <name>
          <surname>
           Bestebroer
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           ADME
          </given-names>
         </name>
         <name>
          <surname>
           Fouchier
          </surname>
          <given-names>
           RAM
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2012
        </year>
        <volume>
         367
        </volume>
        <fpage>
         1814
        </fpage>
        <lpage>
         1820
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa1211721
        </pub-id>
        <pub-id pub-id-type="pmid">
         23075143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR39">
       <label>
        39.
       </label>
       <mixed-citation publication-type="other">
        Chinese Center for Disease Control and Prevention. 585 environmental samples from the South China Seafood Market in Wuhan, Hubei Province, China. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html">
         http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR40">
       <label>
        40.
       </label>
       <mixed-citation publication-type="other">
        Lu H, Tang CW, Tang Y. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Medl Virol. 2020; doi: 10.1002/jmv/25678.
       </mixed-citation>
      </ref>
      <ref id="CR41">
       <label>
        41.
       </label>
       <mixed-citation publication-type="other">
        Roujian L, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 10.1016/S0140-6736(20)30251-8.
       </mixed-citation>
      </ref>
      <ref id="CR42">
       <label>
        42.
       </label>
       <mixed-citation publication-type="other">
        Xu X, Chen P, Wang J, Feng J, Zhou H, Li X, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci Chin Life Sci. 2020; 10.1007/s11427-020-1637-5.
       </mixed-citation>
      </ref>
      <ref id="CR43">
       <label>
        43.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Pneumonia diagnosis and treatment of 2019-nCoV infection from Chinese NHC and CDC 2020. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf">
         http://www.nhc.gov.cn/xcs/zhengcwj/202001/4294563ed35b43209b31739bd0785e67/files/7a9309111267475a99d4306962c8bf78.pdf
        </ext-link>
        . Accessed 1 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR44">
       <label>
        44.
       </label>
       <mixed-citation publication-type="other">
        Zhang H, Kang Z, Gong H, Xu D, Wang J, Li Z, et al. The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes. bioRxiv. 2020; doi: 10.1101/2020.01.30.927806.
       </mixed-citation>
      </ref>
      <ref id="CR45">
       <label>
        45.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Pneumonia infected with novel coronavirus is included in the management of legal infectious diseases. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml">
         http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR46">
       <label>
        46.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on printing and distributing the technical guide for prevention and control of novel coronavirus infection in medical institutions (First Edition). 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/yzygj/s7659/202001/b91fdab7c304431eb082d67847d27e14.shtml">
         http://www.nhc.gov.cn/yzygj/s7659/202001/b91fdab7c304431eb082d67847d27e14.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR47">
       <label>
        47.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on printing and distributing the work plan for prevention and control of pneumonia caused by novel coronavirus infection in the near future. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/tigs/s7848/202001/808bbf75e5ce415aa19f74c78ddc653f.shtml">
         http://www.nhc.gov.cn/tigs/s7848/202001/808bbf75e5ce415aa19f74c78ddc653f.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR48">
       <label>
        48.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on further prevention and control of pneumonia caused by novel coronavirus infection in rural areas. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s3578/202001/f8d45f6af1d24ef18151c1d91cf8a028.shtml">
         http://www.nhc.gov.cn/jkj/s3578/202001/f8d45f6af1d24ef18151c1d91cf8a028.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR49">
       <label>
        49.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Notice on prevention and control of novel coronavirus infection pneumonia in the elderly people. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/lljks/tggg/202001/96e82ba8a14d41b283da990d39771493.shtml">
         http://www.nhc.gov.cn/lljks/tggg/202001/96e82ba8a14d41b283da990d39771493.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
      <ref id="CR50">
       <label>
        50.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wei
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <article-title>
         Disinfection measures for pneumonia foci infected by novel coronavirus in 2019
        </article-title>
        <source>
         Chin J Disinfect
        </source>
        <year>
         2020
        </year>
        <volume>
         37
        </volume>
        <fpage>
         59
        </fpage>
        <lpage>
         62
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR51">
       <label>
        51.
       </label>
       <mixed-citation publication-type="other">
        World Health Organization. International clinical trials registry platform. 2020.
        <ext-link ext-link-type="uri" xlink:href="https://apps.who.int/trialsearch/default.aspx">
         https://apps.who.int/trialsearch/default.aspx
        </ext-link>
        . Accessed 23 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR52">
       <label>
        52.
       </label>
       <mixed-citation publication-type="other">
        Chinese Clinical Trial Registry. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn">
         http://www.chictr.org.cn
        </ext-link>
        . Accessed 23 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR53">
       <label>
        53.
       </label>
       <mixed-citation publication-type="other">
        Bin C, Fang X, Chen H. Application effect of disaster vulnerability analysis in coping with the transmission of new coronavirus in non-closed hematology ward. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/14.1272.R.20200131.1909.002.html">
         http://kns.cnki.net/kcms/detail/14.1272.R.20200131.1909.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR54">
       <label>
        54.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Investigation on the psychological status of the first batch of clinical first-line support nurses to fight against pneumonia caused by novel coronavirus
        </article-title>
        <source>
         Chin Nurs Res
        </source>
        <year>
         2020
        </year>
        <volume>
         34
        </volume>
        <fpage>
         1
        </fpage>
        <lpage>
         3
        </lpage>
       </element-citation>
      </ref>
      <ref id="CR55">
       <label>
        55.
       </label>
       <mixed-citation publication-type="other">
        Ou F, Wu H, Yang Y, Tan W, Zhang J, Gu J. Countermeasures for rapid spread of new coronavirus pneumonia in Wuhan. Chin General Pract Nurs. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://kns.cnki.net/kcms/detail/14.1349.R.20200131.1319.002.html">
         http://kns.cnki.net/kcms/detail/14.1349.R.20200131.1319.002.html
        </ext-link>
        . Accessed 2 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR56">
       <label>
        56.
       </label>
       <mixed-citation publication-type="other">
        WHO. Advice on the use of masks in the community, during home care and in health care settings in the context of the novel coronavirus 2019-nCoV outbreak (Interim guidance). 2020. WHO/nCov/IPC_Masks/2020. Accessed 3 Feb 2020.
       </mixed-citation>
      </ref>
      <ref id="CR57">
       <label>
        57.
       </label>
       <mixed-citation publication-type="other">
        National Health Commission of People’s Republic of China. Guidelines for public protection against novel coronavirus infection. 2020.
        <ext-link ext-link-type="uri" xlink:href="http://www.nhc.gov.cn/jkj/s7915/202001/bc661e49b5bc487dba182f5c49ac445b.shtml">
         http://www.nhc.gov.cn/jkj/s7915/202001/bc661e49b5bc487dba182f5c49ac445b.shtml
        </ext-link>
        . Accessed 31 Jan 2020.
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Eur J Clin Microbiol Infect Dis
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Eur. J. Clin. Microbiol. Infect. Dis
      </journal-id>
      <journal-title-group>
       <journal-title>
        European Journal of Clinical Microbiology &amp; Infectious Diseases
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0934-9723
      </issn>
      <issn pub-type="epub">
       1435-4373
      </issn>
      <publisher>
       <publisher-name>
        Springer-Verlag
       </publisher-name>
       <publisher-loc>
        Berlin/Heidelberg
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       18449585
      </article-id>
      <article-id pub-id-type="pmc">
       7088151
      </article-id>
      <article-id pub-id-type="publisher-id">
       495
      </article-id>
      <article-id pub-id-type="doi">
       10.1007/s10096-008-0495-5
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        siRNA silencing of angiotensin-converting enzyme 2 reduced severe acute respiratory syndrome-associated coronavirus replications in Vero E6 cells
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Lu
         </surname>
         <given-names>
          C.-Y.
         </given-names>
        </name>
        <address>
         <phone>
          +886-2-23123456
         </phone>
         <fax>
          +886-2-23934749
         </fax>
         <email>
          cylu@ntuh.gov.tw
         </email>
        </address>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          H.-Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Yang
         </surname>
         <given-names>
          T.-H.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Chang
         </surname>
         <given-names>
          L.-Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Lee
         </surname>
         <given-names>
          C.-Y.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Huang
         </surname>
         <given-names>
          L.-M.
         </given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">
        </xref>
       </contrib>
       <aff id="Aff1">
        <institution-wrap>
         <institution-id institution-id-type="GRID">
          grid.412094.a
         </institution-id>
         <institution-id institution-id-type="ISNI">
          0000000405727815
         </institution-id>
         <institution>
          Department of Pediatrics,
         </institution>
         <institution>
          National Taiwan University Hospital,
         </institution>
        </institution-wrap>
        No. 7, Chung-Shan South Road, Taipei, Taiwan
       </aff>
      </contrib-group>
      <pub-date pub-type="epub">
       <day>
        1
       </day>
       <month>
        5
       </month>
       <year>
        2008
       </year>
      </pub-date>
      <pub-date pub-type="ppub">
       <year>
        2008
       </year>
      </pub-date>
      <volume>
       27
      </volume>
      <issue>
       8
      </issue>
      <fpage>
       709
      </fpage>
      <lpage>
       715
      </lpage>
      <history>
       <date date-type="received">
        <day>
         8
        </day>
        <month>
         10
        </month>
        <year>
         2007
        </year>
       </date>
       <date date-type="accepted">
        <day>
         15
        </day>
        <month>
         2
        </month>
        <year>
         2008
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © Springer-Verlag 2008
       </copyright-statement>
       <license>
        <license-p>
         This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
        </license-p>
       </license>
      </permissions>
      <abstract id="Abs1">
       <p>
        The outbreak of severe acute respiratory syndrome (SARS) in 2002–2003 has had a significant impact worldwide. No effective prophylaxis or treatment for SARS is available up to now. Angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for SARS-associated coronavirus (SARS-CoV). By expressing a U6 promoter-driven small interfering RNA containing sequences homologous to part of ACE2 mRNA, we successfully silenced ACE2 expression in Vero E6 cells. By detecting negative strand SARS-CoV RNA and measuring RNA copy numbers of SARS-CoV by real-time reverse transcription polymerase chain reaction (RT-PCR), we demonstrated that SARS-CoV infection was reduced in the ACE2-silenced cell lines. These findings support the involvement of ACE2 in SARS-CoV infections and provide a basis for further studies on potential use of siRNA targeting ACE2 as a preventive or therapeutic strategy for SARS.
       </p>
      </abstract>
      <kwd-group xml:lang="en">
       <title>
        Keywords
       </title>
       <kwd>
        Reverse Transcription Polymerase Chain Reaction
       </kwd>
       <kwd>
        Severe Acute Respiratory Syndrome
       </kwd>
       <kwd>
        Severe Acute Respiratory Syndrome
       </kwd>
       <kwd>
        Quantitative Reverse Transcription Polymerase Chain Reaction
       </kwd>
       <kwd>
        Severe Acute Respiratory Syndrome Patient
       </kwd>
      </kwd-group>
      <custom-meta-group>
       <custom-meta>
        <meta-name>
         issue-copyright-statement
        </meta-name>
        <meta-value>
         © Springer-Verlag 2008
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
    </front>
    <sec id="Sec1" sec-type="introduction">
     <title>
      Introduction
     </title>
     <p>
      The outbreak of severe acute respiratory syndrome (SARS) in 2002–2003 affected over 8,000 individuals and was responsible for almost 800 deaths (WHO, 2004). It also caused significant psychological and economic impacts worldwide [
      <xref ref-type="bibr" rid="CR1">
       1
      </xref>
      ,
      <xref ref-type="bibr" rid="CR2">
       2
      </xref>
      ]. Although the SARS epidemic was stopped in mid-2003, the potential threat of SARS will remain high as long as no effective prevention or treatment for SARS is available.
     </p>
     <p>
      Spike proteins of SARS-associated coronaviruses (SARS-CoV) interact with cellular receptors to mediate the infection of their target cells [
      <xref ref-type="bibr" rid="CR3">
       3
      </xref>
      ]. By using immunoprecipitation, Li et al. identified a metallopeptidase, angiotensin-converting enzyme 2 (ACE2), as the cellular receptor for SARS-CoV [
      <xref ref-type="bibr" rid="CR4">
       4
      </xref>
      ]. ACE2 is expressed mainly in the heart and kidneys but is also found in the bronchi and lungs [
      <xref ref-type="bibr" rid="CR5">
       5
      </xref>
      ,
      <xref ref-type="bibr" rid="CR6">
       6
      </xref>
      ], where the major pathology of SARS resides.
     </p>
     <p>
      RNA interference (RNAi) is a cellular process wherein short, double-stranded RNAs called small interfering RNAs (siRNAs) activate ribonucleases to target homologous mRNA [
      <xref ref-type="bibr" rid="CR7">
       7
      </xref>
      ,
      <xref ref-type="bibr" rid="CR8">
       8
      </xref>
      ]. It has been used as a powerful tool for gene silencing. RNAi is also regarded as an antiviral strategy used by plants and probably other organisms [
      <xref ref-type="bibr" rid="CR9">
       9
      </xref>
      ]. Moreover, applications of RNAi technologies in the treatment or prevention of infectious diseases are being tested extensively.
     </p>
     <p>
      The African green monkey kidney cell line Vero E6 expresses ACE2 and permits the replication of SARS-CoV [
      <xref ref-type="bibr" rid="CR10">
       10
      </xref>
      ]. In this study, we tested the hypothesis that RNAi technology can effectively eliminate ACE2, the cellular receptor for SARS-CoV, from Vero E6 cells and block SARS-CoV infections in these cells.
     </p>
    </sec>
    <sec id="Sec2">
     <title>
      Material and methods
     </title>
     <sec id="Sec3">
      <title>
       Plasmids
      </title>
      <p>
       Plasmids generating small hairpin RNAs that target ACE2 mRNA were constructed using the vector p
       <italic>
        Silencer 2.1-U6 neo
       </italic>
       (Ambion, Austin, TX, USA). The mRNA of ACE2 (accession no. NM021804) was scanned for sequences of the AAN
       <sub>
        19
       </sub>
       TT pattern. These sequences were all analyzed by BLAST search of the GenBank database. Sequences with more than 16–17 contiguous base pairs of homology to other coding sequences were excluded. Two mutually complementary 64 oligonucleotides encoding small hairpin sequences targeting position 200–222 of human ACE2 mRNA (5′-GATCCGCCACGAAGCCGAAGACCTGTTCAAGAGA CAGGTCTTCGGCTTCGTGGTTTTTTGGAAA-3′ and 5′-AGCTTTTCCAAAAAACCACGAAGCCGAAGACCTGTCTCTTGAACAGGTCTTCGGCTTCGTGGCG-3′) were synthesized, annealed, and ligated to the BamHI/HindIII sites of p
       <italic>
        Silencer 2.1-U6 neo
       </italic>
       to make p
       <italic>
        Silencer-ACE2
       </italic>
       . The inserted sequences were confirmed by direct sequencing.
      </p>
     </sec>
     <sec id="Sec4">
      <title>
       Establishment of ACE2-silenced stable cell lines
      </title>
      <p>
       The African green monkey kidney cell Vero E6 (CRL-1587) was purchased from the American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in minimal essential medium with Earle’s balance salts (EMEM, JRH Biosciences, Lenexa, KS, USA) with 10% fetal bovine serum (FBS, Biological Industries, Kibbutz Bet Haemek, Israel). Vero E6 cells (3 × 10
       <sup>
        5
       </sup>
       cells/well) were seeded into 6-well plates in EMEM with 10% fetal calf serum 1 day before transfection in order to get a 70% confluence at transfection. p
       <italic>
        Silencer-ACE2
       </italic>
       plasmids were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) with a ratio of 4 ug DNA mix to 10 ul Lipofectamine 2000 per well, according to the manufacturer’s instructions. Transfection of the same plasmids was repeated once 48 h later. The cells were subcultured 24 h after the transfections, and then every 2–3 days in complete medium containing 2 mg/ml G418 (Sigma, St. Louis, MO, USA). The concentration of G418 was reduced to 1 mg/ml 14 days later. The cells were then diluted and single colonies were picked for further experiments.
      </p>
     </sec>
     <sec id="Sec5">
      <title>
       SARS virus infection
      </title>
      <p>
       The SARS-CoV strain TW1 [
       <xref ref-type="bibr" rid="CR2">
        2
       </xref>
       ], which was isolated from a confirmed SARS patient in the National Taiwan University Hospital, was used for infection. The stock virus was grown in Vero E6 cells, titered, and frozen in aliquots at −80°C. For quantitative analysis of SARS replication experiments, cells were grown to 80–90% confluence (~6 × 10
       <sup>
        5
       </sup>
       cells) in 12-well culture plates and inoculated with serially diluted SARS-CoV at multiplicity of infection (MOI) of 1, 10
       <sup>
        –1
       </sup>
       , 10
       <sup>
        –2
       </sup>
       , and 10
       <sup>
        –3
       </sup>
       . During the infection process, G418 was removed from the medium for the ACE2-silenced cells. For observation of cytopathic effects, 10
       <sup>
        –1
       </sup>
       MOI of SARS viruses were inoculated to Vero E6 in 6-well plates. The virus were left in 200 ul EMEM with 2% FBS for 1 h for adsorption. Then, the cells were washed and re-fed with EMEM containing 10% FBS. Cytopathic effects were observed and RNA extraction was done at different time points after infection. All experiments associated with infectious SARS-CoV were carried out in a biosafety level 3 laboratory in the National Taiwan University.
      </p>
     </sec>
     <sec id="Sec6">
      <title>
       Western blotting
      </title>
      <p>
       Cell lysates were colleted by cell lysis buffer (10 mM Tris, 150 mM NaCl, 5 mM ethylenediaminetetraacetate, 1% NP40) premixed with protease inhibitor cocktail tablets (Roche, Penzberg, Germany), resolved by electrophoresis with 8% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane. Blocking was done with 5% skim milk. Goat anti-ACE2 antibody (AF933, R&amp;D Systems, Minneapolis, MN, USA) in 1:100 dilution was used as the primary antibody and rabbit anti-goat horseradish peroxidase(HRP) (Chemicon, Temecula, CA, USA) in 1:5,000 dilution was used as the secondary antibody. The bands were visualized by using the enhanced chemiluminescence system (PerkinElmer, Boston, MA, USA). Quantitative analysis of chemiluminescence was done by using Kodak Image Station 2000R with Kodak 1D image analysis software (Rochester, NY, USA). ACE2 expressions were compared in different cells after normalization by β-actin expressions.
      </p>
     </sec>
     <sec id="Sec7">
      <title>
       Flow cytometry analysis
      </title>
      <p>
       Vero E6 and other cells were trypsinized and washed with 1% bovine serum albumin (BSA, Sigma, St. Louis, MO, USA) in phosphate-buffered saline (PBS). Aliquots of 10
       <sup>
        6
       </sup>
       cells were incubated in 100 ul PBS with or without 5 ug of ACE2 antibody for 60 min at 4°C. The cells were washed with 1% BSA/PBS and then incubated with fluorescein isothiocyanate (FITC)-conjugated rabbit anti-goat secondary antibody for 30 min at 4°C. The cells were then fixed with 2% formaldehyde and stored at 4°C until analysis. Data were acquired by the BD FACSCalibur system and analysis by Cell Quest (BD Bioscience, Franklin Lakes, NJ, USA).
      </p>
     </sec>
     <sec id="Sec8">
      <title>
       Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
      </title>
      <p>
       Supernatants of cell cultures infected with the SARS-CoV were used for RNA extraction according to the mini spin protocol of the QIAamp virus RNA mini kit (Qiagen, Hilden, Germany). The extracted RNA was eluted in 50 µl RNase-free water, treated with deoxyribonuclease I (Life Technologies, Carlsbad, CA, USA) to digest genomic DNA, and stored at −80°C before use. Quantitative RT-PCR for SARS-CoV RNA was done by using the RealArt HPA-coronavirus LC RT-PCR Reagent (Artus Biotech, Hamburg, Germany) on a LightCycler instrument from Roche Diagnostics (Mannheim, Germany). Serial dilutions of the SARS-CoV stock were used as a standard.
      </p>
      <p>
       Real-time RT-PCR was also done to quantify the amount of ACE2 mRNA. A primer pair that extends over two exons of ACE2 (1528-AAAGTGGTGGGAGATGAAGC and 1572-GTTTCATCATGGGGCACA) was used to amplify an amplicon of 63 nucleotides. A fluorophore and quencher dual-labeled probe (Human #77 from Exiqon, Vedbaek, Denmark) was used on the Roche LightCycler (Roche Diagnostics, Mannheim, Germany). GADPH mRNA was also amplified as an internal control and used for normalization with the primer pair CTCATGACCACAGTCCATGC (left) and CCCTGTTGCTGTAGCCAAAT (right).
      </p>
     </sec>
     <sec id="Sec9">
      <title>
       Negative strand-specific RT-PCR
      </title>
      <p>
       Negative strand-specific reverse transcription for SARS-CoV RNA was carried out with 0.1 ug of total RNA, 20 units of AMV reverse transcriptase (Roche Diagnostics, Indianapolis, IN, USA), and the sense primer (BNIoutS2: ATGAATTACCAAGTCAATGGTTAC) [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ] at 42°C for 60 min. PCR with the primer pair ATGAATTACCAAGTCAATGGTTAC (BNIoutS2) and CATAACCAG TCGGTACAGCTA (BNIoutAs) [
       <xref ref-type="bibr" rid="CR11">
        11
       </xref>
       ] was then performed with universal cycle conditions (10 min at 95°C, 45 cycles of 10 s at 95°C, 10 s at 55°C, and 5 s at 72°C) on a LightCycler (Roche Diagnostics, Penzberg, Germany). The products were visualized by ethidium bromide staining after separating by 2–3% agarose gel electrophoresis. Again, GADPH mRNA was also amplified by PCR as an internal control with the primer pair CTCATGACCACAGTCCATGC (left) and CCCTGTTGCTGTAGCCAAAT (right).
      </p>
     </sec>
    </sec>
    <sec id="Sec10" sec-type="results">
     <title>
      Results
     </title>
     <sec id="Sec11">
      <title>
       ACE2 expression was silenced in Vero E6 cells by siRNA
      </title>
      <p>
       After two consecutive Lipofectamine transfections of p
       <italic>
        Silencer-ACE2
       </italic>
       , Vero E6 cells grew normally (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       b), with significantly reduced ACE2 expression. Western blotting showed different degrees of ACE2 expressions in various clones. Clones A4 and C4 both had &gt;99% reductions in ACE2 expressions by Western blotting and were used for further experiments (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       a). Quantitative RT-PCR also revealed 96.2–96.7% reductions in ACE2 mRNA in both clones (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       b). Flow cytometry further confirmed that ACE2 expression was significantly reduced in clone A4 (Fig.
       <xref ref-type="fig" rid="Fig1">
        1
       </xref>
       c). Repeated Western blotting for ACE2 expression after removal of G418 proved that ACE2 of these cells were stably silenced (data not shown).
       <fig id="Fig1">
        <label>
         Fig. 1
        </label>
        <caption>
         <p>
          ACE2 was silenced by siRNA in Vero E6.
          <bold>
           a
          </bold>
          Western blotting of ACE2 in various clones of Vero E6 stably transfected with p
          <italic>
           Silencer-ACE2
          </italic>
          , which expressed siRNA targeting ACE2 (
          <italic>
           lower panel
          </italic>
          ). Relative levels of ACE2 expression determined by quantitative analysis of chemiluminescence and normalized by β-actin expressions are shown in the
          <italic>
           upper panel
          </italic>
          . Clones A4 and C4 showed the lowest levels of ACE2 expression.
          <bold>
           b
          </bold>
          Quantitative RT-PCR of ACE2 mRNA. The
          <italic>
           numbers over the bars
          </italic>
          denote relative copy numbers of ACE2 mRNA normalized by GAPDH copy numbers. Clones A4 and C4 showed less than 4% of ACE2 mRNA left in comparison to the original Vero E6 cells.
          <bold>
           c
          </bold>
          Expressions of ACE2 in Vero E6 and clone A4 were determined by flow cytometry. The
          <italic>
           thin dotted line
          </italic>
          represents unstained control. ACE2 expression was hardly detectable in the majority of A4 cells
         </p>
        </caption>
        <graphic id="MO1" xlink:href="10096_2008_495_Fig1_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
     <sec id="Sec12">
      <title>
       Replication of SARS-CoV was blocked in ACE2-silenced cells
      </title>
      <p>
       Infections of SARS-CoV were done for Vero E6, A4, and C4 cells in a parallel fashion. Figure
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       a and b show morphology of Vero E6 and A4 cells, respectively. Vero E6 showed good susceptibility to SARS-CoV. Almost all Vero E6 cells rounded up and died 16 h after inoculation (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       d). On the other hand, A4 and C4 cells remained grossly healthy at 16 h post-inoculation, except for a few foci of typical cytopathic effects (Fig.
       <xref ref-type="fig" rid="Fig2">
        2
       </xref>
       e).
       <fig id="Fig2">
        <label>
         Fig. 2
        </label>
        <caption>
         <p>
          Inoculation of SARS-CoV resulted in typical cytopathic effects in Vero E6 but not A4 cells. Microscopic pictures of Vero E6 cells and its ACE2-silenced clone (A4) were taken before (
          <bold>
           a
          </bold>
          ,
          <bold>
           b
          </bold>
          ) and 16 h after (
          <bold>
           c
          </bold>
          ,
          <bold>
           d
          </bold>
          ,
          <bold>
           e
          </bold>
          ) inoculation (
          <italic>
           h.p.i.
          </italic>
          ) with SARS-CoV. Vero E6 cells inoculated with medium alone remained healthy and grew into a high density (
          <bold>
           c
          </bold>
          ). At 16 h post-inoculation of SARS-CoV, almost all Vero E6 cells rounded up and died (
          <bold>
           d
          </bold>
          ), while only a few foci of typical cytopathic effects (
          <italic>
           arrow
          </italic>
          in
          <bold>
           e
          </bold>
          ) were shown in ACE2-silenced A4 cells (
          <bold>
           e
          </bold>
          )
         </p>
        </caption>
        <graphic id="MO2" xlink:href="10096_2008_495_Fig2_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       By using a negative strand RNA-specific primer, the cDNA of the negative strand RNA of SARS-CoV RNA was synthesized and amplified. A product of 189 base pairs in size was detected in the Vero E6 but not in A4 or C4 cells (Fig.
       <xref ref-type="fig" rid="Fig3">
        3
       </xref>
       ). SARS-CoV is a positive-stranded RNA virus. Replication of SARS-CoV required synthesis of a negative strand of SARS-CoV. Inability to detect a negative strand RNA in ACE2-silenced A4 and C4 cells confirmed the lack of SARS-CoV replication in these cells.
       <fig id="Fig3">
        <label>
         Fig. 3
        </label>
        <caption>
         <p>
          Negative strand of SARS-CoV RNA was detected in Vero E6 cells but not in ACE2-silenced A4 or C4 cells. RT-PCR using negative strand SARS-CoV RNA-specific primer for was done at 0 and 24 h after inoculation for Vero E6, A4, and C4 cells. A positive result for negative strand RNA of SARS-CoV was shown for Vero E6 cells at 24 h after inoculation. A4 and C4 cells whose ACE2 had been silenced showed no negative strand of SARS-CoV. GAPDH was amplified as an internal control
         </p>
        </caption>
        <graphic id="MO3" xlink:href="10096_2008_495_Fig3_HTML">
        </graphic>
       </fig>
      </p>
      <p>
       Production of SARS-CoV was compared between Vero E6 and A4 cells by determining SARS-CoV RNA copy numbers with qRT-PCR at various time points after inoculation (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       ). With the inoculation dose of 1 MOI, SARS-CoV viral loads increased robustly to the same plateau in both Vero E6 and A4 cells. (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       a). When the inoculation dose decreased, the velocity of viral amplification also decreased. At inoculation doses of 10
       <sup>
        –1
       </sup>
       or 10
       <sup>
        –2
       </sup>
       MOI, SARS-CoV replication was significantly delayed in A4 cells. Lower viral loads were demonstrated in A4 than in Vero E6 at 24–48 h post-infection. However, the viral loads reached comparable levels in both cells at 72 h post-infection (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       b,c). When the inoculation dose was further decreased to 10
       <sup>
        –3
       </sup>
       MOI, the virus did not replicate in A4 cells up to 72 h post-infection (Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       d). The experiment was repeated twice with varied viral load readout but the same trends. The results shown in Fig.
       <xref ref-type="fig" rid="Fig4">
        4
       </xref>
       were representative of the two independent experiments.
       <fig id="Fig4">
        <label>
         Fig. 4
        </label>
        <caption>
         <p>
          Replication of SARS-CoV was blocked in ACE2-silenced A4 cells at low inoculation doses. Viral loads of SARS-CoV were determined by real-time RT-PCR in Vero E6 and A4 cells with different inoculation doses at different time points.
          <bold>
           a
          </bold>
          At the inoculation dose of 1 MOI, no difference in viral loads was noted between Vero E6 and A4 cells at various time points. The velocities of SARS-CoV replication were significantly lower in A4 cells than in Vero E6 with the inoculation doses of 10
          <sup>
           –1
          </sup>
          MOI (
          <bold>
           b
          </bold>
          ) and 10
          <sup>
           –2
          </sup>
          MOI (
          <bold>
           c
          </bold>
          ). When the inoculation dose was decreased to 10
          <sup>
           –3
          </sup>
          MOI, no increase in viral load was noted in A4 cells, while viral load increased to normal levels at 72 h in Vero E6 (
          <bold>
           d
          </bold>
          )
         </p>
        </caption>
        <graphic id="MO4" xlink:href="10096_2008_495_Fig4_HTML">
        </graphic>
       </fig>
      </p>
     </sec>
    </sec>
    <sec id="Sec13" sec-type="discussion">
     <title>
      Discussion
     </title>
     <p>
      The discovery of RNAi, together with development of methods for their generation and delivery, has led to potential application of RNAi as a novel antiviral approach. Reports regarding inhibition of SARS-CoV by RNAi are accumulating [
      <xref ref-type="bibr" rid="CR12">
       12
      </xref>
      –
      <xref ref-type="bibr" rid="CR21">
       21
      </xref>
      ] and reviewed elsewhere [
      <xref ref-type="bibr" rid="CR22">
       22
      </xref>
      ,
      <xref ref-type="bibr" rid="CR23">
       23
      </xref>
      ]. Using viral receptors or coreceptors as targets in inhibiting viral replication has also been tested for certain viruses, such as human immunodeficiency virus (HIV) [
      <xref ref-type="bibr" rid="CR24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="CR25">
       25
      </xref>
      ]. To our knowledge, however, this is the first study to test the feasibility of blocking SARS-CoV infections by siRNA targeting its cellular receptor, ACE2.
     </p>
     <p>
      In several earlier studies testing the susceptibility of various permanent and primary eukaryotic cell lines to SARS-CoV, ACE2 mRNA could be detected in all of the susceptible cell lines and its abundance correlated with SARS-CoV susceptibility [
      <xref ref-type="bibr" rid="CR26">
       26
      </xref>
      –
      <xref ref-type="bibr" rid="CR28">
       28
      </xref>
      ]. On the other hand, refractory cell lines were made permissive to SARS-CoV by the exogenous expression of ACE2 [
      <xref ref-type="bibr" rid="CR29">
       29
      </xref>
      ]. Our study extended these observations by showing that SARS-CoV susceptibility was reduced in Vero E6 cells as the ACE2 mRNA was reduced by siRNA.
     </p>
     <p>
      Although successful silencing of ACE2 and reduction of susceptibility to SARS-CoV were shown in the current study, obstacles exist in clinical usage of RNAi-mediated ACE2 silencing as a preventive or therapeutic modality for SARS-CoV infections. The blocking effects of ACE2 silencing appeared to be modest. In our experiments with an inoculation dose of 10
      <sup>
       –1
      </sup>
      to 10
      <sup>
       –2
      </sup>
      MOI, viral loads reached nearly normal levels 72 h post-inoculation (Fig.
      <xref ref-type="fig" rid="Fig4">
       4
      </xref>
      b,c), suggesting as low as 4% of ACE2 expression (Fig.
      <xref ref-type="fig" rid="Fig1">
       1
      </xref>
      ) is sufficient to support entry of SARS-CoV particles adequate to produce equivalent viral loads at 72 h. The presence of some other cellular receptor(s) for SARS-CoV is another possible explanation for the failure in blocking SARS-CoV replication at higher inoculations. CD209L was reported to be a minor receptor for SARS-CoV and has proved the possibility [
      <xref ref-type="bibr" rid="CR30">
       30
      </xref>
      ].
     </p>
     <p>
      The efficacy of ACE2 silencing could theoretically be enhanced by choosing different targets, or using a “multiple-hit” approach by incorporating several siRNAs targeting various RNA sequences of SARS-CoV and its receptor(s) at the same time might be useful. Synergistic effects of more than one siRNA targeting different genes of SARS-CoV have been observed [
      <xref ref-type="bibr" rid="CR31">
       31
      </xref>
      ]. Besides, a recent study showed that interleukin (IL)-4 and interferon (IFN)-gamma can downregulate ACE2 expression on the cell surface and inhibit SARS-CoV replication [
      <xref ref-type="bibr" rid="CR32">
       32
      </xref>
      ]. “Cocktail” approaches by coadministration of RNAi and non-RNAi strategies to suppress ACE2 expression might maximize clinical effectiveness and hence have potential therapeutic applications.
     </p>
     <p>
      Another concern about translating the current results to a clinically relevant context is that ACE2 was reported to be an essential regulator of cardiac function [
      <xref ref-type="bibr" rid="CR33">
       33
      </xref>
      ,
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. ACE2 knockout mice showed cardiac dysfunction [
      <xref ref-type="bibr" rid="CR34">
       34
      </xref>
      ]. Selective elimination of ACE2 in organs vulnerable to SARS-CoV has never been tested in vivo and could possibly lead to unexpected consequences.
     </p>
     <p>
      In summary, through siRNA technology, we have specifically silenced ACE2, the cellular receptor for SARS-CoV, in Vero E6 cells. Replication of SARS-CoV was reduced in these ACE2-silenced cells. The hypothesis that eliminating ACE2 can reduce or block SARS-CoV infections was proved to be true. However, considering the modest effect observed and concerns raised above, applying siRNA technology for SARS prevention or therapy requires further efforts.
     </p>
    </sec>
    <back>
     <fn-group>
      <fn>
       <p>
        Part of the results was presented at the 184th Scientific Meeting of the Taiwan Pediatric Association (Taipei, 2006) and the 7th Annual Meeting of the Infectious Disease Society of Taiwan (Taipei, 2006).
       </p>
      </fn>
     </fn-group>
     <ack>
      <p>
       This study was supported by research grant from the National Taiwan University Hospital (NTUH94A16). The funding source had no involvement in study design; collection, analysis, and interpretation of data; the writing of the report; and the decision to submit the paper for publication.
      </p>
      <sec id="d29e607">
       <title>
        Conflict of interest statement
       </title>
       <p>
        All authors declare no conflict of interest.
       </p>
      </sec>
     </ack>
     <ref-list id="Bib1">
      <title>
       References
      </title>
      <ref id="CR1">
       <label>
        1.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Groneberg
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Poutanen
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Low
          </surname>
          <given-names>
           DE
          </given-names>
         </name>
         <name>
          <surname>
           Lode
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Welte
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Zabel
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment and vaccines for severe acute respiratory syndrome
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <year>
         2005
        </year>
        <volume>
         5
        </volume>
        <fpage>
         147
        </fpage>
        <lpage>
         155
        </lpage>
        <pub-id pub-id-type="pmid">
         15766649
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR2">
       <label>
        2.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hsueh
          </surname>
          <given-names>
           PR
          </given-names>
         </name>
         <name>
          <surname>
           Hsiao
          </surname>
          <given-names>
           CH
          </given-names>
         </name>
         <name>
          <surname>
           Yeh
          </surname>
          <given-names>
           SH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Microbiologic characteristics, serologic responses, and clinical manifestations in severe acute respiratory syndrome, Taiwan
        </article-title>
        <source>
         Emerg Infect Dis
        </source>
        <year>
         2003
        </year>
        <volume>
         9
        </volume>
        <fpage>
         1163
        </fpage>
        <lpage>
         1167
        </lpage>
        <pub-id pub-id-type="pmid">
         14519257
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR3">
       <label>
        3.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           TM
          </given-names>
         </name>
         <name>
          <surname>
           Buchmeier
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronavirus spike proteins in viral entry and pathogenesis
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2001
        </year>
        <volume>
         279
        </volume>
        <fpage>
         371
        </fpage>
        <lpage>
         374
        </lpage>
        <pub-id pub-id-type="doi">
         10.1006/viro.2000.0757
        </pub-id>
        <pub-id pub-id-type="pmid">
         11162792
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR4">
       <label>
        4.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Moore
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Vasilieva
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2003
        </year>
        <volume>
         426
        </volume>
        <fpage>
         450
        </fpage>
        <lpage>
         454
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature02145
        </pub-id>
        <pub-id pub-id-type="pmid">
         14647384
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR5">
       <label>
        5.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Donoghue
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Hsieh
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Baronas
          </surname>
          <given-names>
           E
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9
        </article-title>
        <source>
         Circ Res
        </source>
        <year>
         2000
        </year>
        <volume>
         87
        </volume>
        <fpage>
         E1
        </fpage>
        <lpage>
         E9
        </lpage>
        <pub-id pub-id-type="pmid">
         10969042
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR6">
       <label>
        6.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Harmer
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Gilbert
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Borman
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme
        </article-title>
        <source>
         FEBS Lett
        </source>
        <year>
         2002
        </year>
        <volume>
         532
        </volume>
        <fpage>
         107
        </fpage>
        <lpage>
         110
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0014-5793(02)03640-2
        </pub-id>
        <pub-id pub-id-type="pmid">
         12459472
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR7">
       <label>
        7.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Dasaradhi
          </surname>
          <given-names>
           PV
          </given-names>
         </name>
         <name>
          <surname>
           Mohmmed
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Malhotra
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Bhatnagar
          </surname>
          <given-names>
           RK
          </given-names>
         </name>
         <name>
          <surname>
           Mukherjee
          </surname>
          <given-names>
           SK
          </given-names>
         </name>
        </person-group>
        <article-title>
         RNA interference: biology, mechanism, and applications
        </article-title>
        <source>
         Microbiol Mol Biol Rev
        </source>
        <year>
         2003
        </year>
        <volume>
         67
        </volume>
        <fpage>
         657
        </fpage>
        <lpage>
         685
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/MMBR.67.4.657-685.2003
        </pub-id>
        <pub-id pub-id-type="pmid">
         14665679
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR8">
       <label>
        8.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Fire
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Montgomery
          </surname>
          <given-names>
           MK
          </given-names>
         </name>
         <name>
          <surname>
           Kostas
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Driver
          </surname>
          <given-names>
           SE
          </given-names>
         </name>
         <name>
          <surname>
           Mello
          </surname>
          <given-names>
           CC
          </given-names>
         </name>
        </person-group>
        <article-title>
         Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
        </article-title>
        <source>
         Nature
        </source>
        <year>
         1998
        </year>
        <volume>
         391
        </volume>
        <fpage>
         806
        </fpage>
        <lpage>
         811
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/35888
        </pub-id>
        <pub-id pub-id-type="pmid">
         9486653
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR9">
       <label>
        9.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Voinnet
          </surname>
          <given-names>
           O
          </given-names>
         </name>
        </person-group>
        <article-title>
         Induction and suppression of RNA silencing: insights from viral infections
        </article-title>
        <source>
         Nat Rev Genet
        </source>
        <year>
         2005
        </year>
        <volume>
         6
        </volume>
        <fpage>
         206
        </fpage>
        <lpage>
         220
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nrg1555
        </pub-id>
        <pub-id pub-id-type="pmid">
         15703763
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR10">
       <label>
        10.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           TG
          </given-names>
         </name>
         <name>
          <surname>
           Erdman
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Goldsmith
          </surname>
          <given-names>
           CS
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         A novel coronavirus associated with severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1953
        </fpage>
        <lpage>
         1966
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030781
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690092
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR11">
       <label>
        11.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Drosten
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Gunther
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Preiser
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Identification of a novel coronavirus in patients with severe acute respiratory syndrome
        </article-title>
        <source>
         N Engl J Med
        </source>
        <year>
         2003
        </year>
        <volume>
         348
        </volume>
        <fpage>
         1967
        </fpage>
        <lpage>
         1976
        </lpage>
        <pub-id pub-id-type="doi">
         10.1056/NEJMoa030747
        </pub-id>
        <pub-id pub-id-type="pmid">
         12690091
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR12">
       <label>
        12.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         siRNA targeting the leader sequence of SARS-CoV inhibits virus replication
        </article-title>
        <source>
         Gene Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         12
        </volume>
        <fpage>
         751
        </fpage>
        <lpage>
         761
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.gt.3302479
        </pub-id>
        <pub-id pub-id-type="pmid">
         15772689
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR13">
       <label>
        13.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           ZL
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           XL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Silencing of SARS-CoV spike gene by small interfering RNA in HEK 293T cells
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2004
        </year>
        <volume>
         324
        </volume>
        <fpage>
         1186
        </fpage>
        <lpage>
         1193
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.09.180
        </pub-id>
        <pub-id pub-id-type="pmid">
         15504339
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR14">
       <label>
        14.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Fu
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference
        </article-title>
        <source>
         FEBS Lett
        </source>
        <year>
         2004
        </year>
        <volume>
         560
        </volume>
        <fpage>
         141
        </fpage>
        <lpage>
         146
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/S0014-5793(04)00087-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         14988013
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR15">
       <label>
        15.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <name>
          <surname>
           Xiong
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Jin
          </surname>
          <given-names>
           YX
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs
        </article-title>
        <source>
         Cell Res
        </source>
        <year>
         2005
        </year>
        <volume>
         15
        </volume>
        <fpage>
         193
        </fpage>
        <lpage>
         200
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/sj.cr.7290286
        </pub-id>
        <pub-id pub-id-type="pmid">
         15780182
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR16">
       <label>
        16.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qin
          </surname>
          <given-names>
           ZL
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           MM
          </given-names>
         </name>
         <name>
          <surname>
           Qi
          </surname>
          <given-names>
           ZT
          </given-names>
         </name>
        </person-group>
        <article-title>
         siRNAs targeting terminal sequences of the SARS-associated coronavirus membrane gene inhibit M protein expression through degradation of M mRNA
        </article-title>
        <source>
         J Virol Methods
        </source>
        <year>
         2007
        </year>
        <volume>
         145
        </volume>
        <fpage>
         146
        </fpage>
        <lpage>
         154
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.jviromet.2007.05.017
        </pub-id>
        <pub-id pub-id-type="pmid">
         17590445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR17">
       <label>
        17.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Ren
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2004
        </year>
        <volume>
         78
        </volume>
        <fpage>
         7523
        </fpage>
        <lpage>
         7527
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.78.14.7523-7527.2004
        </pub-id>
        <pub-id pub-id-type="pmid">
         15220426
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR18">
       <label>
        18.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of replication and infection of severe acute respiratory syndrome-associated coronavirus with plasmid-mediated interference RNA
        </article-title>
        <source>
         Antivir Ther
        </source>
        <year>
         2005
        </year>
        <volume>
         10
        </volume>
        <fpage>
         527
        </fpage>
        <lpage>
         533
        </lpage>
        <pub-id pub-id-type="pmid">
         16038478
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR19">
       <label>
        19.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Akerstrom
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Mirazimi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           YJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a/7b, 3a/3b and S
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2007
        </year>
        <volume>
         73
        </volume>
        <fpage>
         219
        </fpage>
        <lpage>
         227
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2006.10.008
        </pub-id>
        <pub-id pub-id-type="pmid">
         17112601
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR20">
       <label>
        20.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           HW
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           CY
          </given-names>
         </name>
         <name>
          <surname>
           Hong
          </surname>
          <given-names>
           CF
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Inhibition of SARS-CoV replication by siRNA
        </article-title>
        <source>
         Antiviral Res
        </source>
        <year>
         2005
        </year>
        <volume>
         65
        </volume>
        <fpage>
         45
        </fpage>
        <lpage>
         48
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.antiviral.2004.09.005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15652970
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR21">
       <label>
        21.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2005
        </year>
        <volume>
         11
        </volume>
        <fpage>
         944
        </fpage>
        <lpage>
         951
        </lpage>
        <pub-id pub-id-type="pmid">
         16116432
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR22">
       <label>
        22.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           YL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antiviral applications of RNAi for coronavirus
        </article-title>
        <source>
         Expert Opin Investig Drugs
        </source>
        <year>
         2006
        </year>
        <volume>
         15
        </volume>
        <fpage>
         89
        </fpage>
        <lpage>
         97
        </lpage>
        <pub-id pub-id-type="doi">
         10.1517/13543784.15.2.89
        </pub-id>
        <pub-id pub-id-type="pmid">
         16433589
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR23">
       <label>
        23.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Babiuk
          </surname>
          <given-names>
           LA
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <article-title>
         Therapeutic and prophylactic potential of small interfering RNAs against severe acute respiratory syndrome: progress to date
        </article-title>
        <source>
         BioDrugs
        </source>
        <year>
         2007
        </year>
        <volume>
         21
        </volume>
        <fpage>
         9
        </fpage>
        <lpage>
         15
        </lpage>
        <pub-id pub-id-type="doi">
         10.2165/00063030-200721010-00002
        </pub-id>
        <pub-id pub-id-type="pmid">
         17263585
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR24">
       <label>
        24.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Anderson
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Akkina
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <article-title>
         CXCR4 and CCR5 shRNA transgenic CD34+ cell derived macrophages are functionally normal and resist HIV-1 infection
        </article-title>
        <source>
         Retrovirology
        </source>
        <year>
         2005
        </year>
        <volume>
         2
        </volume>
        <fpage>
         53
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1742-4690-2-53
        </pub-id>
        <pub-id pub-id-type="pmid">
         16109172
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR25">
       <label>
        25.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Novina
          </surname>
          <given-names>
           CD
          </given-names>
         </name>
         <name>
          <surname>
           Murray
          </surname>
          <given-names>
           MF
          </given-names>
         </name>
         <name>
          <surname>
           Dykxhoorn
          </surname>
          <given-names>
           DM
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         siRNA-directed inhibition of HIV-1 infection
        </article-title>
        <source>
         Nat Med
        </source>
        <year>
         2002
        </year>
        <volume>
         8
        </volume>
        <fpage>
         681
        </fpage>
        <lpage>
         686
        </lpage>
        <pub-id pub-id-type="pmid">
         12042777
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR26">
       <label>
        26.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hattermann
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Muller
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Nitsche
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Wendt
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Donoso Mantke
          </surname>
          <given-names>
           O
          </given-names>
         </name>
         <name>
          <surname>
           Niedrig
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <article-title>
         Susceptibility of different eukaryotic cell lines to SARS-coronavirus
        </article-title>
        <source>
         Arch Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         150
        </volume>
        <fpage>
         1023
        </fpage>
        <lpage>
         1031
        </lpage>
        <pub-id pub-id-type="doi">
         10.1007/s00705-004-0461-1
        </pub-id>
        <pub-id pub-id-type="pmid">
         15645376
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR27">
       <label>
        27.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Hofmann
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Geier
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Marzi
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2004
        </year>
        <volume>
         319
        </volume>
        <fpage>
         1216
        </fpage>
        <lpage>
         1221
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.05.114
        </pub-id>
        <pub-id pub-id-type="pmid">
         15194496
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR28">
       <label>
        28.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Nie
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Highly infectious SARS-CoV pseudotyped virus reveals the cell tropism and its correlation with receptor expression
        </article-title>
        <source>
         Biochem Biophys Res Commun
        </source>
        <year>
         2004
        </year>
        <volume>
         321
        </volume>
        <fpage>
         994
        </fpage>
        <lpage>
         1000
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.bbrc.2004.07.060
        </pub-id>
        <pub-id pub-id-type="pmid">
         15358126
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR29">
       <label>
        29.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mossel
          </surname>
          <given-names>
           EC
          </given-names>
         </name>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Narayanan
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Makino
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Tesh
          </surname>
          <given-names>
           RB
          </given-names>
         </name>
         <name>
          <surname>
           Peters
          </surname>
          <given-names>
           CJ
          </given-names>
         </name>
        </person-group>
        <article-title>
         Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication
        </article-title>
        <source>
         J Virol
        </source>
        <year>
         2005
        </year>
        <volume>
         79
        </volume>
        <fpage>
         3846
        </fpage>
        <lpage>
         3850
        </lpage>
        <pub-id pub-id-type="doi">
         10.1128/JVI.79.6.3846-3850.2005
        </pub-id>
        <pub-id pub-id-type="pmid">
         15731278
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR30">
       <label>
        30.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jeffers
          </surname>
          <given-names>
           SA
          </given-names>
         </name>
         <name>
          <surname>
           Tusell
          </surname>
          <given-names>
           SM
          </given-names>
         </name>
         <name>
          <surname>
           Gillim-Ross
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus
        </article-title>
        <source>
         Proc Natl Acad Sci USA
        </source>
        <year>
         2004
        </year>
        <volume>
         101
        </volume>
        <fpage>
         15748
        </fpage>
        <lpage>
         15753
        </lpage>
        <pub-id pub-id-type="doi">
         10.1073/pnas.0403812101
        </pub-id>
        <pub-id pub-id-type="pmid">
         15496474
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR31">
       <label>
        31.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           He
          </surname>
          <given-names>
           ML
          </given-names>
         </name>
         <name>
          <surname>
           Zheng
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus
        </article-title>
        <source>
         FEBS Lett
        </source>
        <year>
         2006
        </year>
        <volume>
         580
        </volume>
        <fpage>
         2414
        </fpage>
        <lpage>
         2420
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.febslet.2006.03.066
        </pub-id>
        <pub-id pub-id-type="pmid">
         16638566
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR32">
       <label>
        32.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Lang
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           BL
          </given-names>
         </name>
        </person-group>
        <article-title>
         Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells
        </article-title>
        <source>
         Virology
        </source>
        <year>
         2006
        </year>
        <volume>
         353
        </volume>
        <fpage>
         474
        </fpage>
        <lpage>
         481
        </lpage>
        <pub-id pub-id-type="doi">
         10.1016/j.virol.2006.06.011
        </pub-id>
        <pub-id pub-id-type="pmid">
         16860835
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR33">
       <label>
        33.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Goulter
          </surname>
          <given-names>
           AB
          </given-names>
         </name>
         <name>
          <surname>
           Goddard
          </surname>
          <given-names>
           MJ
          </given-names>
         </name>
         <name>
          <surname>
           Allen
          </surname>
          <given-names>
           JC
          </given-names>
         </name>
         <name>
          <surname>
           Clark
          </surname>
          <given-names>
           KL
          </given-names>
         </name>
        </person-group>
        <article-title>
         ACE2 gene expression is up-regulated in the human failing heart
        </article-title>
        <source>
         BMC Med
        </source>
        <year>
         2004
        </year>
        <volume>
         2
        </volume>
        <fpage>
         19
        </fpage>
        <pub-id pub-id-type="doi">
         10.1186/1741-7015-2-19
        </pub-id>
        <pub-id pub-id-type="pmid">
         15151696
        </pub-id>
       </element-citation>
      </ref>
      <ref id="CR34">
       <label>
        34.
       </label>
       <element-citation publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crackower
          </surname>
          <given-names>
           MA
          </given-names>
         </name>
         <name>
          <surname>
           Sarao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Oudit
          </surname>
          <given-names>
           GY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <article-title>
         Angiotensin-converting enzyme 2 is an essential regulator of heart function
        </article-title>
        <source>
         Nature
        </source>
        <year>
         2002
        </year>
        <volume>
         417
        </volume>
        <fpage>
         822
        </fpage>
        <lpage>
         828
        </lpage>
        <pub-id pub-id-type="doi">
         10.1038/nature00786
        </pub-id>
        <pub-id pub-id-type="pmid">
         12075344
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       PLoS One
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       PLoS ONE
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       plos
      </journal-id>
      <journal-id journal-id-type="pmc">
       plosone
      </journal-id>
      <journal-title-group>
       <journal-title>
        PLoS ONE
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       1932-6203
      </issn>
      <publisher>
       <publisher-name>
        Public Library of Science
       </publisher-name>
       <publisher-loc>
        San Francisco, CA USA
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       26379044
      </article-id>
      <article-id pub-id-type="pmc">
       4574978
      </article-id>
      <article-id pub-id-type="doi">
       10.1371/journal.pone.0138380
      </article-id>
      <article-id pub-id-type="publisher-id">
       PONE-D-15-21790
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Research Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        TMPRSS2 Isoform 1 Activates Respiratory Viruses and Is Expressed in Viral Target Cells
       </article-title>
       <alt-title alt-title-type="running-head">
        Viral Activation by TMPRSS2 Isoform 1
       </alt-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Zmora
         </surname>
         <given-names>
          Pawel
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Moldenhauer
         </surname>
         <given-names>
          Anna-Sophie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Hofmann-Winkler
         </surname>
         <given-names>
          Heike
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff001">
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          Stefan
         </given-names>
        </name>
        <xref ref-type="corresp" rid="cor001">
         *
        </xref>
        <xref ref-type="aff" rid="aff001">
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff001">
       <addr-line>
        Infection Biology Unit, German Primate Center, Göttingen, Germany
       </addr-line>
      </aff>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Munster
         </surname>
         <given-names>
          Vincent Jacobus
         </given-names>
        </name>
        <role>
         Editor
        </role>
        <xref ref-type="aff" rid="edit1">
        </xref>
       </contrib>
      </contrib-group>
      <aff id="edit1">
       <addr-line>
        NIH, UNITED STATES
       </addr-line>
      </aff>
      <author-notes>
       <fn fn-type="COI-statement" id="coi001">
        <p>
         <bold>
          Competing Interests:
         </bold>
         The authors have declared that no competing interests exist.
        </p>
       </fn>
       <fn fn-type="con" id="contrib001">
        <p>
         Conceived and designed the experiments: PZ HHW SP. Performed the experiments: PZ ASM. Analyzed the data: PZ SP. Contributed reagents/materials/analysis tools: HHW. Wrote the paper: PZ SP.
        </p>
       </fn>
       <corresp id="cor001">
        * E-mail:
        <email>
         spoehlmann@dpz.eu
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="epub">
       <day>
        17
       </day>
       <month>
        9
       </month>
       <year>
        2015
       </year>
      </pub-date>
      <pub-date pub-type="collection">
       <year>
        2015
       </year>
      </pub-date>
      <volume>
       10
      </volume>
      <issue>
       9
      </issue>
      <elocation-id>
       e0138380
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         11
        </day>
        <month>
         6
        </month>
        <year>
         2015
        </year>
       </date>
       <date date-type="accepted">
        <day>
         28
        </day>
        <month>
         8
        </month>
        <year>
         2015
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2015 Zmora et al
       </copyright-statement>
       <copyright-year>
        2015
       </copyright-year>
       <copyright-holder>
        Zmora et al
       </copyright-holder>
       <license xlink:href="http://creativecommons.org/licenses/by/4.0/">
        <license-p>
         This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
        </license-p>
       </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="pone.0138380.pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        The cellular protease TMPRSS2 cleaves and activates the influenza virus hemagglutinin (HA) and TMPRSS2 expression is essential for viral spread and pathogenesis in mice. Moreover, severe acute respiratory syndrome coronavirus (SARS-CoV) and other respiratory viruses are activated by TMPRSS2. However, previous studies on viral activation by TMPRSS2 focused on a 492 amino acids comprising form of the protein (isoform 2) while other TMPRSS2 isoforms, generated upon alternative splicing of the tmprss2 mRNA, have not been characterized. Here, we show that the mRNA encoding a TMPRSS2 isoform with an extended N-terminal cytoplasmic domain (isoform 1) is expressed in lung-derived cell lines and tissues. Moreover, we demonstrate that TMPRSS2 isoform 1 colocalizes with HA and cleaves and activates HA. Finally, we show that isoform 1 activates the SARS-CoV spike protein for cathepsin L-independent entry into target cells. Our results indicate that TMPRSS2 isoform 1 is expressed in viral target cells and might contribute to viral activation in the host.
       </p>
      </abstract>
      <funding-group>
       <funding-statement>
        This work was supported by DFG (PO 716/6-1) and the Gӧttingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences (DFG Grant GSC 226/1 and DFG Grant GSC 226/2).
       </funding-statement>
      </funding-group>
      <counts>
       <fig-count count="5">
       </fig-count>
       <table-count count="0">
       </table-count>
       <page-count count="14">
       </page-count>
      </counts>
      <custom-meta-group>
       <custom-meta id="data-availability">
        <meta-name>
         Data Availability
        </meta-name>
        <meta-value>
         All relevant data are presented in the paper.
        </meta-value>
       </custom-meta>
      </custom-meta-group>
     </article-meta>
     <notes>
      <title>
       Data Availability
      </title>
      <p>
       All relevant data are presented in the paper.
      </p>
     </notes>
    </front>
    <sec id="sec001" sec-type="intro">
     <title>
      Introduction
     </title>
     <p>
      Respiratory viruses pose a significant threat to human health. In particular, annual influenza epidemics are associated with several hundred thousand deaths every year, and interspersed pandemics may wreck even greater havoc [
      <xref ref-type="bibr" rid="pone.0138380.ref001">
       1
      </xref>
      ], as documented by the 1918 Spanish influenza, which caused 30 to 50 million deaths [
      <xref ref-type="bibr" rid="pone.0138380.ref002">
       2
      </xref>
      ]. Antiviral drugs against influenza are available but their effectiveness is compromised by frequent acquisition of viral resistance. Moreover, no drugs with broad antiviral activity are available to combat emerging and highly virulent respiratory viruses, including severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome (MERS) CoV. In order to close this gap, novel antiviral strategies are being sought, which allow inhibition of a broad spectrum of viruses and which are associated with a high barrier against resistance development. Host cell factors which are essential for viral spread but dispensable for cellular survival are attractive targets for such approaches to antiviral therapy.
     </p>
     <p>
      The surface proteins of influenza A viruses (FLUAV) and coronaviruses, termed hemagglutinin (HA) and spike (S), respectively, facilitate viral binding to host cells and fusion of the viral envelope with a host cell membrane [
      <xref ref-type="bibr" rid="pone.0138380.ref003">
       3
      </xref>
      ]. These proteins are synthesized as inactive precursors and are converted by host cell proteases into their active forms [
      <xref ref-type="bibr" rid="pone.0138380.ref004">
       4
      </xref>
      ], a process referred to as activation in the remainder of the manuscript. Activation is essential for viral infectivity and the responsible enzymes are potential targets for antiviral therapy. Recent work indicated that several respiratory viruses hijack the type II transmembrane serine protease (TTSP) TMPRSS2 for their activation. Thus, TMPRSS2 was shown to cleave and activate the HA proteins of diverse FLUAV in culture [
      <xref ref-type="bibr" rid="pone.0138380.ref005">
       5
      </xref>
      –
      <xref ref-type="bibr" rid="pone.0138380.ref008">
       8
      </xref>
      ] and studies with tmprss2-deficient mice indicated that TMPRSS2 expression is essential for spread and pathogenesis of FLUAV [
      <xref ref-type="bibr" rid="pone.0138380.ref009">
       9
      </xref>
      –
      <xref ref-type="bibr" rid="pone.0138380.ref011">
       11
      </xref>
      ]. Moreover, augmented TMPRSS2 expression was found to be associated with increased risk of severe influenza upon infection with the 2009 H1N1 pandemic virus and with increased susceptibility to H7N9 FLUAV infection [
      <xref ref-type="bibr" rid="pone.0138380.ref012">
       12
      </xref>
      ]. Finally, TMPRSS2 was shown to activate diverse CoVs [
      <xref ref-type="bibr" rid="pone.0138380.ref013">
       13
      </xref>
      –
      <xref ref-type="bibr" rid="pone.0138380.ref016">
       16
      </xref>
      ], parainfluenza virus [
      <xref ref-type="bibr" rid="pone.0138380.ref017">
       17
      </xref>
      ], human metapneumovirus [
      <xref ref-type="bibr" rid="pone.0138380.ref018">
       18
      </xref>
      ] and hepatitis C virus [
      <xref ref-type="bibr" rid="pone.0138380.ref019">
       19
      </xref>
      ] in cell culture and might contribute to viral spread in the host. Remarkably, the absence of TMPRSS2 does not compromise development or homeostasis [
      <xref ref-type="bibr" rid="pone.0138380.ref020">
       20
      </xref>
      ], indicating that TMPRSS2-specific inhibitors might exert broad antiviral activity without causing substantial unwanted side effects.
     </p>
     <p>
      Alternative splicing of the messenger RNAs produced from several TTSP genes has been reported [
      <xref ref-type="bibr" rid="pone.0138380.ref021">
       21
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref022">
       22
      </xref>
      ], and may result in the production of isoforms with different functional properties. For instance, the presence of an alternative first exon in the corin mRNA can alter surface localization of the protein and conversion of the zymogen form into the mature enzyme [
      <xref ref-type="bibr" rid="pone.0138380.ref021">
       21
      </xref>
      ]. It has been suggested that the tmprss2 transcript can be alternatively spliced [
      <xref ref-type="bibr" rid="pone.0138380.ref023">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref024">
       24
      </xref>
      ], which may result in the production of two isoforms which differ only in the N-terminal, cytoplasmic tail: Isoform 1 contains 37 amino acids in its tail which are not present in isoform 2. However, previous analyses of TMPRSS2 in the context of viral infections have exclusively focused on isoform 2 while expression of isoform 1and its ability to cleave and activate the surface proteins of respiratory viruses has not been assessed.
     </p>
     <p>
      Here, we show that mRNA encoding isoform 1 is expressed in certain lung-derived cell lines and tissues and that the protein can activate FLUAV and the S proteins of SARS-CoV and MERS-CoV (SARS-S, MERS-S), suggesting that isoform 1 could promote viral spread in the infected host.
     </p>
    </sec>
    <sec id="sec002" sec-type="materials|methods">
     <title>
      Materials and Methods
     </title>
     <sec id="sec003">
      <title>
       Bioinformatic analysis
      </title>
      <p>
       Nucleotide and amino acid sequences were analyzed using the BLAST server at NCBI. The alignment of the amino acid sequences of the N-termini of TMPRSS2 isoform 1 (NP_001128571.1) and isoform 2 (NP_005647.3) was constructed using the Clustal Omega software.
      </p>
     </sec>
     <sec id="sec004">
      <title>
       Plasmid construction
      </title>
      <p>
       Expression plasmids for H1 and H3 FLUAV HA, SARS-S, MERS-S, ACE2 and DESC1 have been described previously [
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ]. For construction of the plasmids containing TMPRSS3 and TMPRSS2 isoform 2, the indicated genes were PCR-amplified from previously described plasmids and cloned into pCAGGS via the EcoRI and XhoI restriction sites. To PCR-amplify TMPRSS2 transcript variant 1, an oligonucleotide (Sigma Aldrich) encoding the extended N-terminal sequences, 5’-ATGCCCCCTGCCCCGCCCGGAGGTGAAAGCGGGTGTGAGGAGCGCGGCGCGGCAGGTCATATTGAACATTCCAGATACCTATCATTACTCGATGCTGTTGATAAAGCAAG-3’ was employed as 5’ primer and TMPRSS2 transcript variant 2 was used as template. Subsequently, the PCR-amplificate was cloned into pCAGGS via the EcoRI and XhoI restriction sites. Expression plasmids for proteases with an N-terminal myc-tag were generated by PCR using the above-described plasmids as templates, as reported previously [
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ]. The identity of all PCR-amplified sequences was verified by automated sequence analysis.
      </p>
     </sec>
     <sec id="sec005">
      <title>
       Cells and viruses
      </title>
      <p>
       The cell lines 293T (ATCC CRL-3216), Calu-3 (ATCC HTB-55), Caco-2 (ATCC HTB-37), EA-hy (ATCC CRL-2922), BEAS-2b (ATCC CRL-9609), NCI-H292 (ATCC CRL-184), NCI-H727 (ATCC CRL-5815), A549 (ATCC CCL-185) and COS-7 (ATCC CRL-1651) were grown in Dulbecco’s modified Eagle’s medium (DMEM, PAN Biotech), while LNCaP (ATCC CRL-1740) and NCI-H358 cells (ATCC CRL-5807) were propagated in RPMI-1640 medium (PAN Biotech), and MDCK cells (ATCC CRL-2936) were grown in minimum essential medium (Gibco). All media were supplemented with 10% fetal bovine serum (Biochrome), 100 U/ml penicillin and streptomycin (PAN Biotech). The cells were cultured in humidified atmosphere containing 5% CO
       <sub>
        2
       </sub>
       . All cell lines were obtained from collaborators and were regularly checked for mycoplasma contamination. The FLUAV A/PR/8/34 (H1N1) and A/Panama/2007/99 (H3N2) were propagated in the chorioallantoic cavities of 10-days-old embryonated hen eggs (Valo BioMedia, Germany) for 48 h at 37°C. Thereafter, the eggs were euthanized by an overnight incubation at 4°C and the allantoic fluid was harvested. Before propagation in eggs, the FLUAV A/Panama/2007/99 was recovered from a reverse genetics system [
       <xref ref-type="bibr" rid="pone.0138380.ref026">
        26
       </xref>
       ]. The amount of infectious units within the chorioallantoic fluid was determined by focus formation assay, as described previously [
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ]. In brief, serial 10-fold dilutions of samples were prepared and added onto MDCK cells. After 1 h of incubation, the medium was replaced by infection medium containing Avicel overlay and 2.5 μg/ml N-acetylated trypsin (Sigma). After an incubation period of 24 h, the cells were fixed with 4% formalin in PBS and incubated for 1 h with anti-FLUAV polyclonal antibody from goat (Millipore). Subsequently, the cells were washed and incubated for 1 h with anti-goat-HRP antibodies (KPL), washed again and incubated for 10 min with True Blue substrate (KPL). Finally, foci were counted and viral titers were calculated as focus forming units (FFU) per ml of culture supernatant.
      </p>
     </sec>
     <sec id="sec006">
      <title>
       Analysis of mRNA expression in tissues and cells
      </title>
      <p>
       Total RNA was isolated from human cell lines with RNeasy Mini Kit (Qiagen), as recommended by the manufacturer. The Human MTC™ Panel I (Clonetech) cDNA was used to analyze mRNA expression in human organs. This cDNA was obtained from pooled tissue samples from 1–15 Caucasian donors aged 18–69 and representing both sexes. Using a Cloned AMV First-Strand cDNA synthesis kit (Invitrogen) and random hexamers, the first strand cDNA synthesis was performed from 1 μg of total RNA, previously treated with DNaseI (Roche), according to the manufacturer’s protocol. The subsequent PCR was performed with Taq polymerase (New England Biolabs) using gene-specific primers for tmprss2 transcript variant 1 (forward 5’ GTG AAA GCG GGT GTG AGG A 3’ and reverse 5’CTG TGC GGG ATA GGG GTT TT 3’), tmprss2 transcript variant 2 (forward 5’GCG AGG GGC GGG GAG CGC C 3’ and reverse 5’ GGT AGT ACT GAG CCG GAT GC 3’) and GAPDH (forward 5’ ATG GGG AAG GTG AAG GTC GG 3’ and reverse 5’ ATA CTT CTC ATG GTT CAC AC 3’). All PCRs were run for 40 cycles of 30 sec denaturation at 95°C, 30 sec annealing at 58°C, and 30 sec elongation at 72°C. Amplicons were analyzed by agarose gel electrophoresis.
      </p>
     </sec>
     <sec id="sec007">
      <title>
       Western blot analysis
      </title>
      <p>
       For analysis of the expression of the TMPRSS2 isoforms, 293T cells were seeded into 6-well plates at a density of 2.8 x10
       <sup>
        5
       </sup>
       cells/well, cultivated for 24 h and then transfected with plasmids encoding the proteases equipped with an N-terminal myc tag or transfected with empty plasmid as control. After overnight incubation, the medium was replaced with fresh DMEM, and at 48 h post transfection the cells were washed with phosphate-buffered saline (PBS), resuspended in 100 μl of 2 x sodium dodecyl sulphate (SDS) loading buffer per well and then heated at 95°C for 30 min. Protein samples were separated by SDS-PAGE and blotted onto a nitrocellulose membrane (Hartenstein). TMPRSS2 isoforms were detected using a mouse anti-myc antibody (Biomol) as the primary antibody and a horseradish peroxidase (HRP)-coupled antibody (Dianova) as the secondary antibody. Expression of β-actin, detected with anti-β-actin antibody (Sigma Aldrich), served as a loading control. Bound antibodies were detected using ECL Prime Western blotting detection kit (Amersham), according to the manufacturer’s instructions. Image acquisition was performed with a ChemoCam Imager (Intas). For analysis of TMPRSS2 isoform expression by flow cytometry, 293T cells were transfected with plasmids encoding TMPRSS2 isoforms, as described above. At 48 h post transfection, the cells were detached, incubated with ice-cold ethanol for 10 min and stained with anti-TMPRSS2 antibody (Santa Cruz Biotechnology) diluted in 1% saponin for 30 min. The mouse IgG1 (R&amp;D Systems) served as isotype-matched control. Thereafter, the cells were washed three times with PBS and incubated with an AlexaFluor647-coupled anti-mouse antibody (Dianova) diluted in 1% saponin. After 30 min of incubation with secondary antibody, the cells were washed two times with PBS and then fixed with 2% paraformaldehyde. The staining was analyzed with an LSRII flow cytometer (BD Biosciences) and FCS Express 4 Flow Research Edition software (DeNovo Software).
      </p>
     </sec>
     <sec id="sec008">
      <title>
       Analysis of SARS-S and FLUAV HA cleavage by TMPRSS2 isoforms
      </title>
      <p>
       To determine cleavage of viral glycoproteins mediated by TMPRSS2 isoforms, 293T cells were seeded in 6-well plates at 2.8 x10
       <sup>
        5
       </sup>
       cells/well, cultured for 24 h and then cotransfected with 6 μg of plasmid encoding FLUAV HA of the H1 or H3 subtype or SARS-S with a C-terminal V5 tag and 0.1 μg of plasmid encoding the indicated proteases, employing the calcium phosphate transfection protocol. At 48 h post transfection, the cells were harvested in PBS and treated with PBS or 250 μg/ml tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK) trypsin (Sigma Aldrich) for 10 min at 37°C and processed for Western blot analysis as described above. The SARS-S protein with a C-terminal V5 tag was detected by staining with mouse monoclonal antibody reactive against the V5 tag (Invitrogen), followed by incubation with an HRP-coupled anti-mouse secondary antibody (Dianova). The FLUAV HA cleavage was detected by staining with a goat anti-FLUAV polyclonal antibody (Millipore) for H1 subtype or with a rabbit anti-H3 HA serum (Immune Technology) and HRP-coupled anti-goat or anti-rabbit antibodies (Dianova), respectively. As a loading control, the expression of β-actin was detected with anti-β-actin antibodies (Sigma Aldrich).
      </p>
     </sec>
     <sec id="sec009">
      <title>
       Activation of SARS-S- and MERS-S-mediated virus-cell fusion by TMPRSS2 isoforms
      </title>
      <p>
       For the analysis of the activation of SARS-S and MERS-S for virus-cell fusion, we employed a previously described retroviral pseudotyping system [
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref027">
        27
       </xref>
       ]. Briefly, 293T cells were seeded in T25 cell culture flasks at a density of 7.0 x10
       <sup>
        5
       </sup>
       cells/flask, cultured for 24 h and then transfected by calcium phosphate precipitation with plasmids encoding for MLV gag-pol (3 μg), a firefly-luciferase harboring MLV vector (6 μg), and a plasmid encoding for SARS-S (3 μg). The transfection medium was replaced by fresh DMEM after overnight incubation, and vector-containing supernatants were harvested at 48 h post transfection by filtration through 0.45 μm filters, aliquoted and stored at -80°C. For analysis of SARS-S-/MERS-S-mediated entry, 293T cells were transiently cotransfected with plasmids encoding ACE2 or DPP4 (2 μg), respectively, and the indicated proteases (0.3 μg) or an empty plasmid as a control. The transfection medium was changed after overnight incubation, the cells were resuspended in fresh DMEM and seeded into 96-well plates. At 48 h post transfection, the cells were preincubated with dimethyl sulfoxide (DMSO) or 10 μM cathepsin B and L inhibitor MDL 28170 (Calbiochem) for 1 h and then incubated with 50 μl of infectivity-normalized pseudotypes for 8 h. Thereafter, 50 μl of fresh medium was added and the luciferase activities in cell lysate were determined at 72 h post transduction using a commercially available kit (Beetle Juice (PJK)).
      </p>
     </sec>
     <sec id="sec010">
      <title>
       Proteolytic activation of influenza A viruses mediated by TMPRSS2 isoforms
      </title>
      <p>
       To determine whether the TMPRSS2 isoforms can activate FLUAV, 293T cells were seeded in 6-well plates at a density of 2.8 x10
       <sup>
        5
       </sup>
       cells/well and cultured for 24 h. Then, the cells were transiently transfected with 6 μg of plasmids encoding the proteases or empty plasmid, which served as a control, using the calcium phosphate transfection method. After overnight incubation, the medium was replaced by fresh DMEM. At 24 h post transfection, the cells were gently washed with PBS and then incubated with DPBS with Mg
       <sup>
        2+
       </sup>
       and Ca
       <sup>
        2+
       </sup>
       (PAN Biotech) supplemented with 0.2% bovine serum albumine (BSA) (MACS Miltenyi Biotec) containing FLUAV A/PR/8/34 or A/Panama/2007/99 at a multiplicity of infection (MOI) of 0.01 or 0.1, respectively. After 1 h of incubation at 37°C in a humidified atmosphere, the cells were gently washed with PBS, and fresh infection medium (DMEM supplemented with 0.2% BSA, penicillin and streptomycin) was added. To analyze virus release, the culture supernatants were collected at 48 h post infection. The amount of infectious units within the culture supernatants was determined by focus formation assay, as described above.
      </p>
     </sec>
     <sec id="sec011">
      <title>
       Cellular localization of TMPRSS2 isoforms
      </title>
      <p>
       To analyze the cellular localization of TMPRSS2 isoforms, COS-7 cells were transiently transfected with 6 μg of plasmids encoding TMPRSS2 isoforms or empty plasmid as control. After overnight incubation, the transfection medium was replaced with fresh DMEM. At 24 h post transfection, the cells were washed with PBS, and incubated for 1 h with DPBS with Ca
       <sup>
        2+
       </sup>
       and Mg
       <sup>
        2+
       </sup>
       , supplemented with 0.2% BSA, containing FLUAV at an MOI of 0.5. Thereafter, the cells were washed with PBS and fresh infection medium was added. At 24 h post infection, the cells were fixed with ice cold methanol, blocked with 3% BSA for 1 h, and then stained with mouse anti-TMPRSS2 and rabbit-anti-PR8 HA antibodies (Santa Cruz and Sino Biological, respectively). After 1 h of incubation with primary antibodies, the cells were washed three times with PBS, and incubated for 1 h with anti-mouse and anti-rabbit secondary antibodies, coupled to Rhodamine Red-X and FITC (Dianova), respectively. After three final washing steps, the cells were stained with Vectashield mounting medium (Vector Laboratories) and analyzed with a Zeiss LSM 5 laser scanning microscope. Image capture was performed with Pascal Software (Zeiss) and Fiji software was used for image analysis and calculation of Pearson Correlation Coefficient.
      </p>
     </sec>
    </sec>
    <sec id="sec012" sec-type="results">
     <title>
      Results
     </title>
     <sec id="sec013">
      <title>
       Expression and autocatalytic activation of TMPRSS2 isoforms in transfected cells
      </title>
      <p>
       Alternative splicing of the tmprss2 transcript is believed to generate mRNAs encoding for at least two different isoforms of the protein, isoforms 1 and 2 [
       <xref ref-type="bibr" rid="pone.0138380.ref023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref024">
        24
       </xref>
       ]: Both isoforms contain identical transmembrane and extracellular domains but isoform 1 exhibits an extended N-terminal cytoplasmic domain, harboring a 37 amino acids comprising sequence which is not present in isoform 2 (
       <xref ref-type="fig" rid="pone.0138380.g001">
        Fig 1A
       </xref>
       ). Isoform 2 has been shown to activate the envelope proteins of several viruses while it is at present unknown whether isoform 1 can also act as a viral activator. Moreover, it is unknown whether the isoforms are differentially expressed in viral target cells. To address these questions, we cloned the transcript variants encoding for each individual isoform and analyzed whether the proteins are efficiently expressed in transfected cells. The expression levels of TMPRSS2 isoforms 1 and 2 were comparable as determined by Western blot (
       <xref ref-type="fig" rid="pone.0138380.g001">
        Fig 1B
       </xref>
       ) and flow cytometry (
       <xref ref-type="fig" rid="pone.0138380.g001">
        Fig 1C
       </xref>
       ) and unprocessed isoform 1 exhibited a slightly higher molecular weight than its counterpart (
       <xref ref-type="fig" rid="pone.0138380.g001">
        Fig 1B
       </xref>
       ), in keeping with expectations (expected molecular weight isoform 1, 57.7 kDa; expected molecular weight isoform 2, 53.9 kDa). Both proteins were autocatalytically activated (i.e. the inactive zymogen form was cleaved between the C-terminal protease domain and the remainder of the protein, which allows the protease domain to undergo conformational changes and to transit into an active state), as evidenced by the presence of N-terminal cleavage products. A single N-terminal fragment was observed for isoform 2 while two fragments were detected for isoform 1 (
       <xref ref-type="fig" rid="pone.0138380.g001">
        Fig 1B
       </xref>
       ), suggesting that the presence of an extended N-terminus in isoform 1 does not alter the efficiency of TMPRSS2 auto-activation but might change cleavage specificity.
      </p>
      <fig id="pone.0138380.g001" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1371/journal.pone.0138380.g001
       </object-id>
       <label>
        Fig 1
       </label>
       <caption>
        <title>
         Expression of TMPRSS2 isoforms 1 and 2.
        </title>
        <p>
         (A) Sequence alignment of the N-termini of TMPRSS2 isoforms 1 and 2. Identical amino acids are marked with stars. Amino acids absent in isoform 2 are marked with ‘–‘. (B) Plasmids encoding TMPRSS2 isoform 1 and isoform 2, both equipped with an N-terminal myc tag, were transiently transfected into 293T cells. Empty plasmid (pCAGGS) served as a negative control. Protease expression in cell lysates was detected via Western blotting with anti-myc antibody. The β-actin expression served as a loading control. Black-filled arrowheads indicate the zymogen forms, while grey-filled arrowheads highlight cleavage products resulting from protease activation. (C) 293T cells were transfected as described for panel B but protease expression was determined using flow cytometry with an anti-TMPRSS2 antibody. The geometric mean channel fluorescence (GMCF) measured in a representative experiment performed with triplicate samples is shown. Error bars indicate standard deviations. Similar results were obtained in two independent experiments.
        </p>
       </caption>
       <graphic xlink:href="pone.0138380.g001">
       </graphic>
      </fig>
     </sec>
     <sec id="sec014">
      <title>
       Transcript variant 1 is expressed in influenza A virus target cell lines and organs
      </title>
      <p>
       We next determined whether transcript variant 1 (which encodes isoform 1) is expressed in tissues and cell lines. For this, we employed RT-PCR with primer sets specific for tmprss2 transcript variant 1 and 2, respectively. Primers specific for variant 1 amplified their target sequence from a plasmid encoding isoform 1 but not isoform 2, confirming that the PCR was specific. Similarly, the PCR designed to amplify transcript variant 2 was negative when a plasmid encoding isoform 1 was used as template but generated the expected amplificate from cDNA prepared from several cell lines and tissues, indicating that also this PCR was specific. In this context, it should be noted that the forward primer used for detection of transcript variant 2 binds to a 5’-untranslated region which is absent from the plasmid encoding isoform 2. Therefore, the respective PCR was negative.
      </p>
      <p>
       The investigation of tissue samples revealed robust expression of transcript variant 1 in lung, kidney, liver and pancreas, which were reported to express tmprss2 mRNA (isoforms were not discriminated in previous studies) [
       <xref ref-type="bibr" rid="pone.0138380.ref023">
        23
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref028">
        28
       </xref>
       ] (
       <xref ref-type="fig" rid="pone.0138380.g002">
        Fig 2
       </xref>
       , left panel). In contrast, mRNA levels in muscle and placenta were reduced and no expression of transcript variant 1 was detected in heart and brain. A similar result was obtained when expression in cell lines was determined (
       <xref ref-type="fig" rid="pone.0138380.g002">
        Fig 2
       </xref>
       , right panel): Transcript variant 1 was expressed in several but not all cell lines tested, including the lung-derived cell line Calu-3 and the colon-derived cell line Caco-2, which were previously shown to produce TMPRSS2 protein [
       <xref ref-type="bibr" rid="pone.0138380.ref005">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref006">
        6
       </xref>
       ]. The expression pattern of transcript variant 2 was similar but not identical to that of variant 1. Thus, all organs and cell lines positive for transcript variant 1 also expressed variant 2 except for muscle tissue, which was negative for variant 2. Conversely, heart tissue and the cell lines A549 and EA-hy were negative for transcript variant 1 but expressed variant 2. Collectively, tmprss2 transcript variant 1 and variant 2 exhibit an overlapping but not identical expression pattern. Moreover, our results indicate that both isoforms are expressed in lung tissue and several lung-derived cell lines (including Calu-3 and NCIH292) and are thus present in FLUAV targets.
      </p>
      <fig id="pone.0138380.g002" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1371/journal.pone.0138380.g002
       </object-id>
       <label>
        Fig 2
       </label>
       <caption>
        <title>
         Expression of tmprss2 transcript variants in human organs and cell lines.
        </title>
        <p>
         RT-PCR analysis of the expression of tmprss2 transcript variants 1 and 2 in organ samples from adult men (left panel) or from cell lines of human origin (right panel). Expression of GAPDH was assessed in parallel. Plasmids encoding isoform 1 and 2 (left panel) or a mix of both plasmids (right panel) served as positive control. Similar results were obtained in two separate experiments.
        </p>
       </caption>
       <graphic xlink:href="pone.0138380.g002">
       </graphic>
      </fig>
     </sec>
     <sec id="sec015">
      <title>
       TMPRSS2 isoform 1 and 2 colocalize with the influenza A virus hemagglutinin
      </title>
      <p>
       Activation of FLUAV by TMPRSS2 in infected cells requires that HA comes into contact with the protease. In order to address whether HA and TMPRSS2 isoform 1 colocalize, immunofluorescence staining and Fiji analysis of COS-7 cells transiently expressing TMPRSS2 isoforms and infected with FLUAV was employed. We observed colocalization of HA with both TMPRSS2 isoforms in infected cells (
       <xref ref-type="fig" rid="pone.0138380.g003">
        Fig 3A and 3B
       </xref>
       ). However, we also noted differences in the cellular localization of isoform 1 and 2: although both isoforms were found at or near the cell surface, where they colocalized with FLUAV HA, more cytoplasmic puncta were observed in cells expressing isoform 1 as compared to isoform 2, which was more homogenously distributed within the cells (
       <xref ref-type="fig" rid="pone.0138380.g003">
        Fig 3A
       </xref>
       ). Thus, the presence of an extended N-terminus in isoform 1 does not interfere with HA colocalization but might modestly alter the intracellular localization of TMPRSS2.
      </p>
      <fig id="pone.0138380.g003" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1371/journal.pone.0138380.g003
       </object-id>
       <label>
        Fig 3
       </label>
       <caption>
        <title>
         TMPRSS2 isoforms 1 and 2 colocalize with hemagglutinin.
        </title>
        <p>
         (A) COS-7 cells were transfected with plasmids encoding TMPRSS2 isoform 1 or isoform 2 or with empty plasmid which served as negative control. Subsequently, the cells were infected with FLUAV A/PR/8/34 (H1N1) at an MOI 0.5. At 24 h post infection, the cells were stained for FLUAV-HA (green) and TMPRSS2 isoforms (red) and images were taken at 63 x magnification. White squares show examples of colocalization of HA and TMPRSS2 (yellow signals) and were digitally magnified 2.5x from the original images. Similar results were obtained in three separate experiments. (B) Images obtained in (A) were analyzed with Fiji software, which allows calculation of the Pearson Correlation Coefficient (PCC), a measure for colocalization. The average PCC measured in three separate experiments is shown. For each experiment, 6–8 cells were analyzed. Error bars indicate standard error of the mean (SEM).
        </p>
       </caption>
       <graphic xlink:href="pone.0138380.g003">
       </graphic>
      </fig>
     </sec>
     <sec id="sec016">
      <title>
       TMPRSS2 isoform 1 cleaves and activates the glycoproteins of influenza A viruses
      </title>
      <p>
       In order to determine whether TMPRSS2 isoform 1 can activate FLUAV, we first assessed cleavage of FLUAV HA. For this purpose, we coexpressed the HA proteins of FLUAV A/South Carolina/1/1918 (H1N1) or FLUAV A/Hong Kong/1/1968 (H3N2) and proteases. Cleavage of the HA precursor, HA
       <sub>
        0
       </sub>
       , was observed upon treatment of cells with trypsin and upon coexpression of DESC1 and TMPRSS2 isoform 2, in keeping with previous reports [
       <xref ref-type="bibr" rid="pone.0138380.ref005">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ] (
       <xref ref-type="fig" rid="pone.0138380.g004">
        Fig 4A
       </xref>
       ). Additionally, HA proteolysis was detected upon coexpression of TMPRSS2 isoform 1. In contrast, the proteolytic cleavage products were not observed upon treatment of cells with PBS or upon coexpression of TMPRSS3 (
       <xref ref-type="fig" rid="pone.0138380.g004">
        Fig 4A
       </xref>
       ), as expected [
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ].
      </p>
      <fig id="pone.0138380.g004" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1371/journal.pone.0138380.g004
       </object-id>
       <label>
        Fig 4
       </label>
       <caption>
        <title>
         TMPRSS2 isoform 1 cleaves and activates the influenza virus hemagglutinin.
        </title>
        <p>
         (A) Expression plasmids encoding FLUAV HA subtypes H1 (left) and H3 (right) and the indicated proteases or empty plasmid (pCAGGS) were transiently cotransfected into 293T cells. At 48 h post transfection the cells were treated with PBS or trypsin, and HA cleavage was determined by Western blotting. Similar results were obtained in three independent experiments. The HA
         <sub>
          0
         </sub>
         precursor (upper arrow) and the HA
         <sub>
          1
         </sub>
         (middle arrow) and HA
         <sub>
          2
         </sub>
         (lower arrow) subunits are indicated. (B) The indicated proteases were transiently expressed in 293T cells and the cells infected with FLUAV A/PR/8/34 (H1N1) at an MOI 0.01 (left) or FLUAV A/Panama/2007/99 (H3N2) at an MOI of 0.1 (right) and treated with either trypsin or PBS. At 48 h post infection, the virus release was measured by determination of infectious particles (ffu/ml) in the culture supernatant. The results of representative experiments performed with triplicate samples are shown. Error bars indicate standard deviations. Similar results were obtained in three independent experiments. ffu, focus forming units.
        </p>
       </caption>
       <graphic xlink:href="pone.0138380.g004">
       </graphic>
      </fig>
      <p>
       We next asked whether cleavage results in HA activation. To this end, we determined the spread of FLUAV A/PR/8/34 (H1N1) and FLUAV A/Panama/2007/99 (H3N2) in 293T cells transfected to express the indicated proteases. Treatment of cells with PBS or expression of TMPRSS3 did not promote viral spread (
       <xref ref-type="fig" rid="pone.0138380.g004">
        Fig 4B
       </xref>
       ), as expected [
       <xref ref-type="bibr" rid="pone.0138380.ref005">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ]. In contrast, expression of TMPRSS2 isoform 2 and DESC1 or treatment of the cells with trypsin boosted viral spread (
       <xref ref-type="fig" rid="pone.0138380.g004">
        Fig 4B
       </xref>
       ), again in keeping with published findings [
       <xref ref-type="bibr" rid="pone.0138380.ref005">
        5
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ]. Finally, expression of TMPRSS2 isoform 1 markedly increased viral spread to levels observed in the presence of isoform 2, and spread was markedly reduced by camostat mesylate (not shown), a serine protease inhibitor known to be active against TMPRSS2. In sum, these results indicate that isoform 1 and isoform 2 can efficiently cleave and activate FLUAV HA.
      </p>
     </sec>
     <sec id="sec017">
      <title>
       TMPRSS2 isoform 1 cleaves and activates the spike protein of SARS- and MERS-coronavirus
      </title>
      <p>
       Apart from FLUAV, several respiratory viruses hijack TMPRSS2 to facilitate activation of their envelope glycoprotein, including the emerging SARS-CoV [
       <xref ref-type="bibr" rid="pone.0138380.ref014">
        14
       </xref>
       –
       <xref ref-type="bibr" rid="pone.0138380.ref016">
        16
       </xref>
       ] and MERS-CoV [
       <xref ref-type="bibr" rid="pone.0138380.ref029">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref030">
        30
       </xref>
       ]. Activation of SARS-S and MERS-S by TMPRSS2 isoform 2 occurs during viral entry into target cells and renders this process independent from the activity of cathepsin L [
       <xref ref-type="bibr" rid="pone.0138380.ref014">
        14
       </xref>
       –
       <xref ref-type="bibr" rid="pone.0138380.ref016">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref029">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref030">
        30
       </xref>
       ], an endosomal cysteine protease which can activate SARS-S and MERS-S for entry into TMPRSS2-negative cells [
       <xref ref-type="bibr" rid="pone.0138380.ref029">
        29
       </xref>
       –
       <xref ref-type="bibr" rid="pone.0138380.ref031">
        31
       </xref>
       ]. We investigated whether TMPRSS2 isoform 1 can also activate SARS-S and MERS-S. Western blot analysis of protease and SARS-S or MERS-S transfected cells revealed that both TMPRSS2 isoforms processed the S proteins comparably (
       <xref ref-type="fig" rid="pone.0138380.g005">
        Fig 5A
       </xref>
       and data not shown). Moreover, SARS-S- and MERS-S-driven entry into control cells was markedly reduced by pre-incubation of cells with MDL28170, a cathepsin B and L inhibitor, and this effect was rescued by TMPRSS2 isoform 2 and DESC1 but not TMPRSS3 (
       <xref ref-type="fig" rid="pone.0138380.g005">
        Fig 5B and 5C
       </xref>
       ), in keeping with published data [
       <xref ref-type="bibr" rid="pone.0138380.ref014">
        14
       </xref>
       –
       <xref ref-type="bibr" rid="pone.0138380.ref016">
        16
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref025">
        25
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref029">
        29
       </xref>
       ,
       <xref ref-type="bibr" rid="pone.0138380.ref030">
        30
       </xref>
       ]. Similarly, rescue was observed upon expression of isoform 1 (
       <xref ref-type="fig" rid="pone.0138380.g005">
        Fig 5B and 5C
       </xref>
       ), indicating that the extended N-terminus is compatible with coronavirus S protein activation during entry.
      </p>
      <fig id="pone.0138380.g005" orientation="portrait" position="float">
       <object-id pub-id-type="doi">
        10.1371/journal.pone.0138380.g005
       </object-id>
       <label>
        Fig 5
       </label>
       <caption>
        <title>
         TMPRSS2 isoform 1 cleaves and activates the SARS-coronavirus spike protein.
        </title>
        <p>
         (A) 293T cells were cotransfected with plasmid encoding SARS-S with a C-terminal V5 tag and plasmids encoding the indicated proteases. At 48 h post transfection, the cells were treated with PBS or trypsin, and SARS-S cleavage was analyzed by Western blotting with a V5-specific antibody. The expression of β-actin served as a loading control. The results are representative of three independent experiments with different plasmid preparations. Black-filled arrowhead, uncleaved SARS-S; gray-filled arrowhead, S2 subunit generated by trypsin digest; white-filled arrowheads, C-terminal cleavage fragments generated by TMPRSS2. (B) To analyze SARS-S-driven virus-cell fusion, 293T cells were transiently transfected with plasmids encoding the indicated proteases and ACE2. At 24 h post transfection, the cells were pretreated with medium supplemented with DMSO or 10 μM cathepsin B/L inhibitor MDL 28170, and transduced with pseudotypes bearing SARS-S. The luciferase activities in cell lysates were analyzed at 72 h post transduction. The results of a representative experiments performed with triplicate samples are shown. Error bars indicate standard deviations. Similar results were obtained in two separate experiments. (C) MERS-S-driven virus-cell fusion was analyzed as described for panel B but 293T cells transfected to express DPP4 were used as targets. The results of a representative experiment performed with triplicate samples are shown. Error bars indicate standard deviations. Similar results were obtained in three independent experiments. c.p.s., counts per second.
        </p>
       </caption>
       <graphic xlink:href="pone.0138380.g005">
       </graphic>
      </fig>
     </sec>
    </sec>
    <sec id="sec018" sec-type="conclusions">
     <title>
      Discussion
     </title>
     <p>
      Several host cell proteases can activate FLUAV HA in cell culture and it has thus been assumed that respiratory viruses can employ redundant proteolytic systems to ensure their activation in the host [
      <xref ref-type="bibr" rid="pone.0138380.ref004">
       4
      </xref>
      ]. In stark contrast, recent studies indicated a central role for TMPRSS2 in viral activation: The protease was found to activate FLUAV and other respiratory viruses upon directed and upon endogenous expression in cell lines [
      <xref ref-type="bibr" rid="pone.0138380.ref004">
       4
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref006">
       6
      </xref>
      –
      <xref ref-type="bibr" rid="pone.0138380.ref008">
       8
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref014">
       14
      </xref>
      –
      <xref ref-type="bibr" rid="pone.0138380.ref018">
       18
      </xref>
      ] and was shown to be expressed in viral target cells in the human aerodigestive tract [
      <xref ref-type="bibr" rid="pone.0138380.ref032">
       32
      </xref>
      ]. Moreover, and more importantly, TMPRSS2 expression was required for spread and pathogenesis of FLUAV in mice [
      <xref ref-type="bibr" rid="pone.0138380.ref009">
       9
      </xref>
      –
      <xref ref-type="bibr" rid="pone.0138380.ref011">
       11
      </xref>
      ]. Thus, TMPRSS2 is an important host factor for FLUAV and potentially other respiratory viruses and constitutes a potential target for antiviral intervention.
     </p>
     <p>
      The
      <italic>
       tmprss2
      </italic>
      gene is located on chromosome 21 and comprises 14 exons and 13 introns [
      <xref ref-type="bibr" rid="pone.0138380.ref023">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref024">
       24
      </xref>
      ]. It has been suggested that tmprss2 mRNA may be alternatively spliced [
      <xref ref-type="bibr" rid="pone.0138380.ref023">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref024">
       24
      </xref>
      ] and two transcript variants were documented at NCBI, which only differ in the first exon. The encoded proteins are identical except for the presence of an extended cytoplasmic domain in isoform 1 and the impact of this extension on expression and function was unknown. The present study shows that isoform 1 is efficiently expressed in transfected cells and, in keeping with expectations, exhibits a slightly increased molecular weight relative to isoform 2. Thus, the enzymatically inactive zymogen form of isoform 1 migrated slower than its counterpart in isoform 2 (the two bands observed might be the result of differential glycosylation) and differences were also observed for the N-terminal fragment of the protease, which is generated upon autocatalytic activation. Notably, two prominent N-terminal fragments were consistently observed for isoform 1 but not for isoform 2. Thus, the extended cytoplasmic domain might give rise to the expression of different glycoforms or, maybe more likely, might alter the specificity of autocatalytic cleavage, which is essential for the enzymatic activity of TMPRSS2. In fact, an impact of the cytoplasmic domain on the autocatalytic activation has previously been reported for the TTSP corin, in which the presence of a shortened cytoplasmic tail, due to the use of an alternative exon 1, reduces plasma membrane localization and autocatalytic activation [
      <xref ref-type="bibr" rid="pone.0138380.ref021">
       21
      </xref>
      ].
     </p>
     <p>
      An RT-PCR designed for the amplification of a sequence specific to transcript variant 1 showed that this transcript is expressed in cell lines and tissues susceptible to FLUAV infection and previously found to be positive for tmprss2 mRNA and or protein, including lung and liver [
      <xref ref-type="bibr" rid="pone.0138380.ref023">
       23
      </xref>
      ,
      <xref ref-type="bibr" rid="pone.0138380.ref028">
       28
      </xref>
      ]. In general, the expression patterns of transcript variant 1 and 2 were similar but not identical, suggesting that in certain tissues only isoform 1 might be available for viral activation. Whether the mRNA expression data match the expression of protein remains to be determined and such studies are complicated by the absence of isoform-specific antibodies. No major differences in the cellular localization of the two isoforms were observed, although distribution of isoform 2 at or close to the cell surface was more homogenous than that of isoform 1, which was frequently detected within speckles. Thus, the extended cytoplasmic tail of isoform 1 slightly impacts protein localization in transfected cells and this impact might be more pronounced in cells endogenously expressing this isoform.
     </p>
     <p>
      Our mRNA expression data suggest that at least a fraction of the TMPRSS2 molecules present in FLUAV target cells correspond to isoform 1, raising the question whether they contribute to viral activation. Our study provides an affirmative answer: Both isoform 1 and 2 colocalized with HA in transfected cells, cleaved HA upon coexpression and activated authentic FLUAV of different subtypes. Moreover, isoform 1, like isoform 2, activated SARS-S and MERS-S for entry into target cells. Thus, the presence of an extended N-terminus does not seem to alter the ability of TMPRSS2 to activate respiratory viruses, although one should take into account that transfected cells might not mirror all aspects of cells endogenously expressing isoform 1.
     </p>
     <p>
      Collectively, our results indicate that isoform 1 of TMPRSS2 can be produced in viral target cells and likely contributes to viral activation. Therefore, approaches to suppress HA activation for influenza therapy must target both isoforms and our initial results obtained with camostat mesylate indicate that this is feasible. However, it remains to be determined whether subtle differences in cellular localization and autocatalytic activation of TMPRSS2 isoforms observed here impact sensitivity to protease inhibitors in cells endogenously expressing these isoforms.
     </p>
    </sec>
    <back>
     <ack>
      <p>
       We thank M. Winkler for helpful discussion.
      </p>
     </ack>
     <ref-list>
      <title>
       References
      </title>
      <ref id="pone.0138380.ref001">
       <label>
        1
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Taubenberger
         </surname>
         <given-names>
          JK
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kash
         </surname>
         <given-names>
          JC
         </given-names>
        </name>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Influenza virus evolution, host adaptation, and pandemic formation
        </article-title>
        .
        <source>
         Cell Host Microbe
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         440
        </fpage>
        –
        <lpage>
         451
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1016/j.chom.2010.05.009
        </pub-id>
        <pub-id pub-id-type="pmid">
         20542248
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref002">
       <label>
        2
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Morens
         </surname>
         <given-names>
          DM
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Taubenberger
         </surname>
         <given-names>
          JK
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Harvey
         </surname>
         <given-names>
          HA
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Memoli
         </surname>
         <given-names>
          MJ
         </given-names>
        </name>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         The 1918 influenza pandemic: lessons for 2009 and the future
        </article-title>
        .
        <source>
         Crit Care Med
        </source>
        <volume>
         38
        </volume>
        :
        <fpage>
         e10
        </fpage>
        –
        <lpage>
         e20
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1097/CCM.0b013e3181ceb25b
        </pub-id>
        <pub-id pub-id-type="pmid">
         20048675
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref003">
       <label>
        3
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Edinger
         </surname>
         <given-names>
          TO
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Pohl
         </surname>
         <given-names>
          MO
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Stertz
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         Entry of influenza A virus: host factors and antiviral targets
        </article-title>
        .
        <source>
         J Gen Virol
        </source>
        <volume>
         95
        </volume>
        :
        <fpage>
         263
        </fpage>
        –
        <lpage>
         277
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1099/vir.0.059477-0
        </pub-id>
        <pub-id pub-id-type="pmid">
         24225499
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref004">
       <label>
        4
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Steffen
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kühl
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Novel insights into proteolytic cleavage of influenza virus hemagglutinin
        </article-title>
        .
        <source>
         Rev Med Virol
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         298
        </fpage>
        –
        <lpage>
         310
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1002/rmv.657
        </pub-id>
        <pub-id pub-id-type="pmid">
         20629046
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref005">
       <label>
        5
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Blazejewska
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Soilleux
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Allen
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Danisch
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         84
        </volume>
        :
        <fpage>
         10016
        </fpage>
        –
        <lpage>
         10025
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.00239-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20631123
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref006">
       <label>
        6
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Böttcher-Friebertshauser
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Stein
         </surname>
         <given-names>
          DA
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Klenk
         </surname>
         <given-names>
          HD
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Garten
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         85
        </volume>
        :
        <fpage>
         1554
        </fpage>
        –
        <lpage>
         1562
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01294-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         21123387
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref007">
       <label>
        7
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Böttcher
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Matrosovich
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Beyerle
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Klenk
         </surname>
         <given-names>
          HD
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Garten
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Matrosovich
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         80
        </volume>
        :
        <fpage>
         9896
        </fpage>
        –
        <lpage>
         9898
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16973594
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref008">
       <label>
        8
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Chaipan
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kobasa
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Steffen
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Tsegaye
         </surname>
         <given-names>
          TS
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2009
        </year>
        )
        <article-title>
         Proteolytic activation of the 1918 influenza virus hemagglutinin
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         83
        </volume>
        :
        <fpage>
         3200
        </fpage>
        –
        <lpage>
         3211
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.02205-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         19158246
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref009">
       <label>
        9
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Hatesuer
         </surname>
         <given-names>
          B
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Mehnert
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Bahgat
         </surname>
         <given-names>
          MM
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          PS
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Tmprss2 Is Essential for Influenza H1N1 Virus Pathogenesis in Mice
        </article-title>
        .
        <source>
         PLoS Pathog
        </source>
        <volume>
         9
        </volume>
        :
        <fpage>
         e1003774
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.ppat.1003774
        </pub-id>
        <pub-id pub-id-type="pmid">
         24348248
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref010">
       <label>
        10
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Sakai
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Ami
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Tahara
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kubota
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Anraku
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Abe
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         The host protease TMPRSS2 plays a major role in in vivo replication of emerging H7N9 and seasonal influenza viruses
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         5608
        </fpage>
        –
        <lpage>
         5616
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.03677-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24600012
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref011">
       <label>
        11
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Tarnow
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Engels
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Arendt
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Schwalm
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Sediri
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Preuss
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of H7N9 influenza A virus in mice
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         4744
        </fpage>
        –
        <lpage>
         4751
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.03799-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24522916
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref012">
       <label>
        12
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Cheng
         </surname>
         <given-names>
          Z
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Zhou
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        ,
        <name>
         <surname>
          To
         </surname>
         <given-names>
          KK
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Chu
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Wang
         </surname>
         <given-names>
          D
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         The identification of TMPRSS2 as the susceptible gene for severe illness of 2009 pandemic A(H1N1) influenza and infection of A(H7N9) influenza
        </article-title>
        .
        <source>
         J Infect Dis
        </source>
        .
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref013">
       <label>
        13
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Dijkman
         </surname>
         <given-names>
          R
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Habjan
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Heurich
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Gierer
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         6150
        </fpage>
        –
        <lpage>
         6160
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.03372-12
        </pub-id>
        <pub-id pub-id-type="pmid">
         23536651
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref014">
       <label>
        14
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          MA
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Allen
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Soilleux
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Pfefferle
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         85
        </volume>
        :
        <fpage>
         4122
        </fpage>
        –
        <lpage>
         4134
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.02232-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         21325420
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref015">
       <label>
        15
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Matsuyama
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Nagata
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Shirato
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kawase
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Takeda
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Taguchi
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        (
        <year>
         2010
        </year>
        )
        <article-title>
         Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         84
        </volume>
        :
        <fpage>
         12658
        </fpage>
        –
        <lpage>
         12664
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01542-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         20926566
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref016">
       <label>
        16
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Shulla
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Heald-Sargent
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Subramanya
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Zhao
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Perlman
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Gallagher
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         85
        </volume>
        :
        <fpage>
         873
        </fpage>
        –
        <lpage>
         882
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.02062-10
        </pub-id>
        <pub-id pub-id-type="pmid">
         21068237
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref017">
       <label>
        17
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Abe
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Tahara
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Sakai
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Yamaguchi
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kanou
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Shirato
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         TMPRSS2 is an activating protease for respiratory parainfluenza viruses
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         11930
        </fpage>
        –
        <lpage>
         11935
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01490-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23966399
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref018">
       <label>
        18
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Shirogane
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Takeda
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Iwasaki
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Ishiguro
         </surname>
         <given-names>
          N
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Takeuchi
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Nakatsu
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2008
        </year>
        )
        <article-title>
         Efficient multiplication of human metapneumovirus in Vero cells expressing the transmembrane serine protease TMPRSS2
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         82
        </volume>
        :
        <fpage>
         8942
        </fpage>
        –
        <lpage>
         8946
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.00676-08
        </pub-id>
        <pub-id pub-id-type="pmid">
         18562527
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref019">
       <label>
        19
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Esumi
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Ishibashi
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Yamaguchi
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Nakajima
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Tai
         </surname>
         <given-names>
          Y
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kikuta
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2015
        </year>
        )
        <article-title>
         Transmembrane serine protease TMPRSS2 activates hepatitis C virus infection
        </article-title>
        .
        <source>
         Hepatology
        </source>
        <volume>
         61
        </volume>
        :
        <fpage>
         438
        </fpage>
        –
        <lpage>
         447
        </lpage>
        .
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref020">
       <label>
        20
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          TS
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Heinlein
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Hackman
         </surname>
         <given-names>
          RC
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Nelson
         </surname>
         <given-names>
          PS
         </given-names>
        </name>
        (
        <year>
         2006
        </year>
        )
        <article-title>
         Phenotypic analysis of mice lacking the Tmprss2-encoded protease
        </article-title>
        .
        <source>
         Mol Cell Biol
        </source>
        <volume>
         26
        </volume>
        :
        <fpage>
         965
        </fpage>
        –
        <lpage>
         975
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16428450
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref021">
       <label>
        21
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Qi
         </surname>
         <given-names>
          X
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Jiang
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Zhu
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        (
        <year>
         2011
        </year>
        )
        <article-title>
         Human corin isoforms with different cytoplasmic tails that alter cell surface targeting
        </article-title>
        .
        <source>
         J Biol Chem
        </source>
        <volume>
         286
        </volume>
        :
        <fpage>
         20963
        </fpage>
        –
        <lpage>
         20969
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1074/jbc.M110.217570
        </pub-id>
        <pub-id pub-id-type="pmid">
         21518754
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref022">
       <label>
        22
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Lapointe
         </surname>
         <given-names>
          J
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kim
         </surname>
         <given-names>
          YH
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Miller
         </surname>
         <given-names>
          MA
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Li
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kaygusuz
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        ,
        <name>
         <surname>
          van de Rijn
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2007
        </year>
        )
        <article-title>
         A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis
        </article-title>
        .
        <source>
         Mod Pathol
        </source>
        <volume>
         20
        </volume>
        :
        <fpage>
         467
        </fpage>
        –
        <lpage>
         473
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         17334351
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref023">
       <label>
        23
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Jacquinet
         </surname>
         <given-names>
          E
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Rao
         </surname>
         <given-names>
          NV
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Rao
         </surname>
         <given-names>
          GV
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Zhengming
         </surname>
         <given-names>
          W
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Albertine
         </surname>
         <given-names>
          KH
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Hoidal
         </surname>
         <given-names>
          JR
         </given-names>
        </name>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Cloning and characterization of the cDNA and gene for human epitheliasin
        </article-title>
        .
        <source>
         Eur J Biochem
        </source>
        <volume>
         268
        </volume>
        :
        <fpage>
         2687
        </fpage>
        –
        <lpage>
         2699
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11322890
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref024">
       <label>
        24
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Paoloni-Giacobino
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Chen
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Peitsch
         </surname>
         <given-names>
          MC
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Rossier
         </surname>
         <given-names>
          C
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Antonarakis
         </surname>
         <given-names>
          SE
         </given-names>
        </name>
        (
        <year>
         1997
        </year>
        )
        <article-title>
         Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3
        </article-title>
        .
        <source>
         Genomics
        </source>
        <volume>
         44
        </volume>
        :
        <fpage>
         309
        </fpage>
        –
        <lpage>
         320
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         9325052
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref025">
       <label>
        25
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Zmora
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Blazejewska
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Moldenhauer
         </surname>
         <given-names>
          AS
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Welsch
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Nehlmeier
         </surname>
         <given-names>
          I
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Wu
         </surname>
         <given-names>
          Q
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         DESC1 and MSPL activate influenza A viruses and emerging coronaviruses for host cell entry
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         88
        </volume>
        :
        <fpage>
         12087
        </fpage>
        –
        <lpage>
         12097
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01427-14
        </pub-id>
        <pub-id pub-id-type="pmid">
         25122802
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref026">
       <label>
        26
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Matthaei
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Budt
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Wolff
         </surname>
         <given-names>
          T
         </given-names>
        </name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Highly pathogenic H5N1 influenza A virus strains provoke heterogeneous IFN-alpha/beta responses that distinctively affect viral propagation in human cells
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <volume>
         8
        </volume>
        :
        <fpage>
         e56659
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0056659
        </pub-id>
        <pub-id pub-id-type="pmid">
         23451066
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref027">
       <label>
        27
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Wrensch
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Winkler
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        (
        <year>
         2014
        </year>
        )
        <article-title>
         IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms
        </article-title>
        .
        <source>
         Viruses
        </source>
        <volume>
         6
        </volume>
        :
        <fpage>
         3683
        </fpage>
        –
        <lpage>
         3698
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.3390/v6093683
        </pub-id>
        <pub-id pub-id-type="pmid">
         25256397
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref028">
       <label>
        28
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Vaarala
         </surname>
         <given-names>
          MH
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Porvari
         </surname>
         <given-names>
          KS
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kellokumpu
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kyllonen
         </surname>
         <given-names>
          AP
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Vihko
         </surname>
         <given-names>
          PT
         </given-names>
        </name>
        (
        <year>
         2001
        </year>
        )
        <article-title>
         Expression of transmembrane serine protease TMPRSS2 in mouse and human tissues
        </article-title>
        .
        <source>
         J Pathol
        </source>
        <volume>
         193
        </volume>
        :
        <fpage>
         134
        </fpage>
        –
        <lpage>
         140
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         11169526
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref029">
       <label>
        29
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Gierer
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kaup
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Wrensch
         </surname>
         <given-names>
          F
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Heurich
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kramer-Kühl
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         5502
        </fpage>
        –
        <lpage>
         5511
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.00128-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         23468491
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref030">
       <label>
        30
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Shirato
         </surname>
         <given-names>
          K
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Kawase
         </surname>
         <given-names>
          M
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Matsuyama
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        (
        <year>
         2013
        </year>
        )
        <article-title>
         Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2
        </article-title>
        .
        <source>
         J Virol
        </source>
        <volume>
         87
        </volume>
        :
        <fpage>
         12552
        </fpage>
        –
        <lpage>
         12561
        </lpage>
        .
        <pub-id pub-id-type="doi">
         10.1128/JVI.01890-13
        </pub-id>
        <pub-id pub-id-type="pmid">
         24027332
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref031">
       <label>
        31
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Simmons
         </surname>
         <given-names>
          G
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Gosalia
         </surname>
         <given-names>
          DN
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Rennekamp
         </surname>
         <given-names>
          AJ
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Reeves
         </surname>
         <given-names>
          JD
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Diamond
         </surname>
         <given-names>
          SL
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Bates
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        (
        <year>
         2005
        </year>
        )
        <article-title>
         Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
        </article-title>
        .
        <source>
         Proc Natl Acad Sci U S A
        </source>
        <volume>
         102
        </volume>
        :
        <fpage>
         11876
        </fpage>
        –
        <lpage>
         11881
        </lpage>
        .
        <pub-id pub-id-type="pmid">
         16081529
        </pub-id>
       </mixed-citation>
      </ref>
      <ref id="pone.0138380.ref032">
       <label>
        32
       </label>
       <mixed-citation publication-type="journal">
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Heurich
         </surname>
         <given-names>
          A
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Lavender
         </surname>
         <given-names>
          H
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Gierer
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Danisch
         </surname>
         <given-names>
          S
         </given-names>
        </name>
        ,
        <name>
         <surname>
          Perin
         </surname>
         <given-names>
          P
         </given-names>
        </name>
        ,
        <etal>
         et al
        </etal>
        (
        <year>
         2012
        </year>
        )
        <article-title>
         Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts
        </article-title>
        .
        <source>
         PLoS One
        </source>
        <volume>
         7
        </volume>
        :
        <fpage>
         e35876
        </fpage>
        <pub-id pub-id-type="doi">
         10.1371/journal.pone.0035876
        </pub-id>
        <pub-id pub-id-type="pmid">
         22558251
        </pub-id>
       </mixed-citation>
      </ref>
     </ref-list>
    </back>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       One Health
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       One Health
      </journal-id>
      <journal-title-group>
       <journal-title>
        One Health
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2352-7714
      </issn>
      <publisher>
       <publisher-name>
        Elsevier
       </publisher-name>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       28616501
      </article-id>
      <article-id pub-id-type="pmc">
       5454147
      </article-id>
      <article-id pub-id-type="publisher-id">
       S2352-7714(16)30082-9
      </article-id>
      <article-id pub-id-type="doi">
       10.1016/j.onehlt.2017.03.001
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Article
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Searching for animal models and potential target species for emerging pathogens: Experience gained from Middle East respiratory syndrome (MERS) coronavirus
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author" id="au0005">
        <name>
         <surname>
          Vergara-Alert
         </surname>
         <given-names>
          Júlia
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0010">
        <name>
         <surname>
          Vidal
         </surname>
         <given-names>
          Enric
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0015">
        <name>
         <surname>
          Bensaid
         </surname>
         <given-names>
          Albert
         </given-names>
        </name>
        <xref ref-type="aff" rid="af0005">
         a
        </xref>
       </contrib>
       <contrib contrib-type="author" id="au0020">
        <name>
         <surname>
          Segalés
         </surname>
         <given-names>
          Joaquim
         </given-names>
        </name>
        <email>
         joaquim.segales@irta.cat
        </email>
        <xref ref-type="aff" rid="af0010">
         b
        </xref>
        <xref ref-type="aff" rid="af0015">
         c
        </xref>
        <xref ref-type="corresp" rid="cr0005">
         ⁎
        </xref>
       </contrib>
      </contrib-group>
      <aff id="af0005">
       <label>
        a
       </label>
       IRTA, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
      </aff>
      <aff id="af0010">
       <label>
        b
       </label>
       UAB, Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
      </aff>
      <aff id="af0015">
       <label>
        c
       </label>
       Departament de Sanitat i Anatomia Animals, Facultat de Veterinària, UAB, 08193 Bellaterra, Barcelona, Spain
      </aff>
      <author-notes>
       <corresp id="cr0005">
        <label>
         ⁎
        </label>
        Corresponding author at: Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, 08193 Bellaterra (Cerdanyola del Vallès), Spain.
        <email>
         joaquim.segales@irta.cat
        </email>
       </corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
      <pub-date pub-type="ppub">
       <month>
        6
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <pub-date pub-type="epub">
       <day>
        3
       </day>
       <month>
        3
       </month>
       <year>
        2017
       </year>
      </pub-date>
      <volume>
       3
      </volume>
      <fpage>
       34
      </fpage>
      <lpage>
       40
      </lpage>
      <history>
       <date date-type="received">
        <day>
         15
        </day>
        <month>
         12
        </month>
        <year>
         2016
        </year>
       </date>
       <date date-type="rev-recd">
        <day>
         10
        </day>
        <month>
         2
        </month>
        <year>
         2017
        </year>
       </date>
       <date date-type="accepted">
        <day>
         2
        </day>
        <month>
         3
        </month>
        <year>
         2017
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        © 2017 The Authors
       </copyright-statement>
       <copyright-year>
        2017
       </copyright-year>
       <license>
        <license-p>
         Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
        </license-p>
       </license>
      </permissions>
      <abstract id="ab0005">
       <p>
        Emerging and re-emerging pathogens represent a substantial threat to public health, as demonstrated with numerous outbreaks over the past years, including the 2013–2016 outbreak of Ebola virus in western Africa. Coronaviruses are also a threat for humans, as evidenced in 2002/2003 with infection by the severe acute respiratory syndrome coronavirus (SARS-CoV), which caused more than 8000 human infections with 10% fatality rate in 37 countries. Ten years later, a novel human coronavirus (Middle East respiratory syndrome coronavirus, MERS-CoV), associated with severe pneumonia, arose in the Kingdom of Saudi Arabia. Until December 2016, MERS has accounted for more than 1800 cases and 35% fatality rate. Finding an animal model of disease is key to develop vaccines or antivirals against such emerging pathogens and to understand its pathogenesis. Knowledge of the potential role of domestic livestock and other animal species in the transmission of pathogens is of importance to understand the epidemiology of the disease. Little is known about MERS-CoV animal host range. In this paper, experimental data on potential hosts for MERS-CoV is reviewed. Advantages and limitations of different animal models are evaluated in relation to viral pathogenesis and transmission studies. Finally, the relevance of potential new target species is discussed.
       </p>
      </abstract>
      <kwd-group id="ks0005">
       <title>
        Keywords
       </title>
       <kwd>
        Animal model
       </kwd>
       <kwd>
        Coronavirus (CoV)
       </kwd>
       <kwd>
        Emerging pathogen
       </kwd>
       <kwd>
        Middle East respiratory syndrome (MERS)
       </kwd>
       <kwd>
        Reservoir
       </kwd>
      </kwd-group>
      <kwd-group id="ks0010">
       <title>
        Abbreviations
       </title>
       <kwd>
        BSL, biosafety level
       </kwd>
       <kwd>
        DPP4, dipeptidyl peptidase-4
       </kwd>
       <kwd>
        FDA, Food and Drug Administration
       </kwd>
       <kwd>
        HCoV, human coronaviruses
       </kwd>
       <kwd>
        hDPP4, human dipeptidyl peptidase-4
       </kwd>
       <kwd>
        MERS-CoV, Middle East respiratory syndrome coronavirus
       </kwd>
       <kwd>
        NHP, Nonhuman primates
       </kwd>
       <kwd>
        PI, post-inoculation
       </kwd>
       <kwd>
        RDB, receptor binding domain
       </kwd>
       <kwd>
        SARS-CoV, severe acute respiratory syndrome coronavirus
       </kwd>
       <kwd>
        URT, upper respiratory tract
       </kwd>
       <kwd>
        WHO, World Health Organization
       </kwd>
      </kwd-group>
     </article-meta>
    </front>
    <sec id="s0005">
     <label>
      1
     </label>
     <title>
      Introduction
     </title>
     <p id="p0185">
      Over the past years, outbreaks of zoonotic diseases and growing resistance against antibiotics have emphasized the need for interdisciplinary collaboration between human health, veterinary medicine and environmental sciences, a concept commonly known as “One health”
      <xref ref-type="bibr" rid="bb0005">
       [1]
      </xref>
      . Most of emerging diseases are zoonotic
      <xref ref-type="bibr" rid="bb0010">
       [2]
      </xref>
      . For instance, the human flu pandemics have originated in domestic animals and wildlife, and have been driven by ecological, behavioral, or socioeconomic changes
      <xref ref-type="bibr" rid="bb0015">
       [3]
      </xref>
      . In these cases, the reaction time between detection of a new outbreak and application of medical countermeasures are critical in terms of epidemic control. To understand the potential role that animal sources could play in virus dissemination and the epidemiology of the disease, surveillance studies, as well as experimental infections in potential target species, are required. Furthermore, after having identified the novel or re-emerged virus responsible of the outbreak, it is important to rapidly provide an accurate diagnosis as a basis for quarantine measures. It is also imperative to focus on the search for new vaccines and treatments for highly pathogenic viruses, especially for those that represent a threat to human and animal health, particularly livestock.
     </p>
     <p id="p0190">
      Until the beginning of the last decade, human coronaviruses (HCoV) infections were considered to be restricted to the upper respiratory tract (URT), with low mortality rate, and recognized as the second ranked cause of the common cold after rhinoviruses
      <xref ref-type="bibr" rid="bb0020">
       [4]
      </xref>
      . However, in the late-2002, the severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in China. It rapidly spread worldwide with more than 8000 causalities and a lethality rate of 10%
      <xref ref-type="bibr" rid="bb0025">
       [5]
      </xref>
      . Ten years later, a novel HCoV associated with severe pneumonia emerged in the Kingdom of Saudi Arabia
      <xref ref-type="bibr" rid="bb0030">
       [6]
      </xref>
      . The new CoV was named Middle East respiratory syndrome coronavirus (MERS-CoV), and by March 2014, a total of 207 cases and 45% fatalities were recorded. One month later, only in April 2014, an increase in human cases was registered with at least 217 more infected people and 38 fatalities. More recently, as of December 2016, 1842 cases of MERS-CoV have been reported to the World Health Organization (WHO), including at least 652 deaths
      <xref ref-type="bibr" rid="bb0035">
       [7]
      </xref>
      .
     </p>
     <p id="p0195">
      Besides coronaviruses, highly pathogenic viruses belonging to other families represent a threat to either human or animal health, or both. One of the most recent examples is the outbreak of Ebola virus (
      <italic>
       Filoviridae
      </italic>
      ) in West Africa, which started in December of 2013 in Guinea and evolved as the largest Ebola outbreak recorded with more than 28,600 cases
      <xref ref-type="bibr" rid="bb0040">
       [8]
      </xref>
      . Furthermore, during recent years, outbreaks caused by other emerging viral pathogens from
      <italic>
       Arenaviridae, Bunyaviridae,
      </italic>
      and
      <italic>
       Flaviviridae
      </italic>
      families among others, disturbed public and private health, social networks and the economies of the affected countries
      <xref ref-type="bibr" rid="bb0045">
       [9]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0050">
       [10]
      </xref>
      . Prevention and control of emerging and reemerging viral diseases is efficient when several actions are combined: i.e. creating diagnostic networks and surveillance programs, training medical and veterinary staff, informing the population about sanitary measures, and also promoting research on prophylaxis, treatments and on the causative agent pathogenesis. Regarding the last point, animal models are crucial to study the viral and host factors contributing to the disease as well as transmission outcomes of virus infection and to allow pre-clinical testing of antiviral drugs and vaccines. Non-human primates (NHP) are the preferred models for pathogenesis studies, and potential vaccine and treatment testing, as they better translate to humans
      <xref ref-type="bibr" rid="bb0055">
       [11]
      </xref>
      . However, working with NHP is costly, with limited availability, and raises ethical problems. Therefore small-animal models are usually the first choice for drug screening. The United States Food and Drug Administration's (FDA) Animal Rule provides guidelines concerning the appropriateness of animal models for licensing purposes
      <xref ref-type="bibr" rid="bb0060">
       [12]
      </xref>
      . Additionally, by controlling the disease in animal reservoirs and/or in intermediate hosts, virus transmission to humans can be significantly reduced
      <xref ref-type="bibr" rid="bb0065">
       [13]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0070">
       [14]
      </xref>
      . This is particularly true for domestic or feral animals for which efficient vaccines and vaccination strategies can be implemented
      <xref ref-type="bibr" rid="bb0075">
       [15]
      </xref>
      . Therefore, in cases of new pathogenic virus outbreaks, the search for natural hosts or potential target animals (as opposed to laboratory animals) seems to be relevant not only to implement prophylactic solutions but also to improve the preparedness for an eventual global extension of diseases. Nowadays, this task is rendered possible by the availability of improved biosafety levels 3 and 4 (BSL3 and 4) animal facilities, which can accommodate large animal experimentation with such highly virulent pathogens
      <xref ref-type="bibr" rid="bb0080">
       [16]
      </xref>
      .
     </p>
     <p id="p0200">
      In this article, the current situation of comprehension on potential hosts for MERS-CoV is reviewed. Based on the coronaviruses experience, benefits and limitations of these species as animal models and transmission studies are discussed.
     </p>
    </sec>
    <sec id="s0010">
     <label>
      2
     </label>
     <title>
      Animal models for MERS research
     </title>
     <p id="p0205">
      Several review articles have described and discussed animal models for MERS-CoV infection
      <xref ref-type="bibr" rid="bb0085">
       [17]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0090">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0095">
       [19]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0100">
       [20]
      </xref>
      . In this section, the current status of animal models for MERS disease reproduction is briefly summarized.
     </p>
     <p id="p0210">
      After the identification of MERS-CoV in 2012
      <xref ref-type="bibr" rid="bb0030">
       [6]
      </xref>
      , the efforts were directed to develop an animal model to study pathogenesis and to test the efficacy of vaccines and/or treatments in vivo. Similar to SARS-CoV, rhesus macaques have demonstrated susceptibility to MERS-CoV
      <xref ref-type="bibr" rid="bb0105">
       [21]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0110">
       [22]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0115">
       [23]
      </xref>
      . A work led by Munster demonstrated that the common marmoset is also suitable as a MERS-CoV model
      <xref ref-type="bibr" rid="bb0120">
       [24]
      </xref>
      . They showed that this model recapitulates the disease observed in humans; therefore, findings in the evaluation of potential therapeutic strategies might be implemented in humans. However, small animals are required for controlled, large and comprehensive studies. While, at first, experiences with SARS-CoV turned out to be very helpful for the research on MERS-CoV, the development of a small animal model for MERS was a more difficult task
      <xref ref-type="bibr" rid="bb0090">
       [18]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0095">
       [19]
      </xref>
      . Raj and collaborators rapidly identified dipeptidyl peptidase-4 (DPP4) as the functional receptor for MERS-CoV
      <xref ref-type="bibr" rid="bb0125">
       [25]
      </xref>
      , and DPP4 is present in lung cells of many rodents. Thus, rodents were expected to be susceptible for MERS-CoV. However, and as predicted by the crystal structure analysis of the MERS-CoV receptor binding domain (RBD) with the human DPP4 (hDDP4) extracellular domain
      <xref ref-type="bibr" rid="bb0130">
       [26]
      </xref>
      , so far, no rodent model is naturally permissive for MERS-CoV infection. In Syrian hamster, the DPP4 receptor was shown to be expressed on bronchiolar epithelium, but inoculation of MERS-CoV via aerosols or intratracheal routes with different doses did not lead to productive infection
      <xref ref-type="bibr" rid="bb0135">
       [27]
      </xref>
      . Wild type and immune-deficient mice were also tested for MERS-CoV infection without success
      <xref ref-type="bibr" rid="bb0140">
       [28]
      </xref>
      . Since then, several groups have been focused on new strategies to develop a small animal model susceptible to MERS-CoV infection. It was found that mouse cells could be made permissive for MERS-CoV when expressing hDPP4. Consequently, the hDPP4 was transduced into mouse lungs using an adenovirus vector, which resulted in animals susceptible to MERS-CoV infection. These mice exhibited pneumonia and extensive inflammatory-cell infiltration with the presence of virus in the lungs
      <xref ref-type="bibr" rid="bb0145">
       [29]
      </xref>
      . Recently, a transgenic mice model expressing hDPP4, highly susceptible to MERS-CoV infection and able to display systemic lesions, has been developed
      <xref ref-type="bibr" rid="bb0150">
       [30]
      </xref>
      . As demonstrated for several diseases, transgenic animal models have become an important tool to improve medical research
      <xref ref-type="bibr" rid="bb0155">
       [31]
      </xref>
      . On the other hand, glycosylation of the murine DPP4 is a major factor impacting the receptor function by blocking the binding to MERS-CoV
      <xref ref-type="bibr" rid="bb0160">
       [32]
      </xref>
      . Therefore, the modification of the mouse genome to match the sequence in the hDPP4 made this species susceptible to MERS-CoV infection
      <xref ref-type="bibr" rid="bb0165">
       [33]
      </xref>
      . Accordingly, these newly established mice models are useful to evaluate the efficacy of vaccines and therapeutic agents against MERS-CoV infection
      <xref ref-type="bibr" rid="bb0150">
       [30]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0170">
       [34]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0175">
       [35]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0180">
       [36]
      </xref>
      . VelocImmune and VelociGene technologies have been used to develop a humanized mouse model for MERS-CoV infection
      <xref ref-type="bibr" rid="bb0180">
       [36]
      </xref>
      ; these methodologies can be also applied for other pathogens in future emerging epidemics.
     </p>
    </sec>
    <sec id="s0015">
     <label>
      3
     </label>
     <title>
      MERS-CoV animal reservoir and the role of domestic animals
     </title>
     <p id="p0215">
      Researchers worldwide have identified several animal species which could have a role in the transmission of MERS-CoV to humans (summarized in
      <xref ref-type="fig" rid="f0005">
       Fig. 1
      </xref>
      ). Bats have been suggested to be the reservoir for MERS-CoV, but RNA of MERS-like CoVs (and no MERS-CoV) has been found in several bat families (
      <italic>
       Vespertillionidae, Molosidae, Nycteridae
      </italic>
      and
      <italic>
       Emballonuridae
      </italic>
      ) in Africa, America, Asia and Europe
      <xref ref-type="bibr" rid="bb0185">
       [37]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0190">
       [38]
      </xref>
      . Recently, an experimental infection with Jamaican fruit bats (
      <italic>
       Artibeus jamaicensis
      </italic>
      ) confirmed that MERS-CoV can replicate in bats
      <xref ref-type="bibr" rid="bb0195">
       [39]
      </xref>
      . However, MERS-CoV strains causing disease in humans have not been so far identified in bats. The presence of MERS-CoV neutralizing antibodies has been reported in dromedary camels (
      <italic>
       Camelus dromedaries
      </italic>
      )
      <xref ref-type="bibr" rid="bb0200">
       [40]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0205">
       [41]
      </xref>
      and, more recently, a link between MERS-CoV infection in camels and a human infection in Qatar has been suggested
      <xref ref-type="bibr" rid="bb0210">
       [42]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0215">
       [43]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0220">
       [44]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0225">
       [45]
      </xref>
      . Most importantly, the MERS-CoV strain that caused the 2015 human outbreak was found in dromedary camels; in fact, phylogenetic analyses indicate that MERS-CoV was generated in this species by recombination
      <xref ref-type="bibr" rid="bb0230">
       [46]
      </xref>
      . In addition, Adney and collaborators have provided experimental evidence to support the role of dromedary camels as a MERS-CoV reservoir
      <xref ref-type="bibr" rid="bb0235">
       [47]
      </xref>
      . Recently, evidence was provided that other members of the
      <italic>
       Camelidae
      </italic>
      family such as alpaca (
      <italic>
       Vicugna pacos
      </italic>
      ) and llama (
      <italic>
       Lama glama
      </italic>
      ), are also susceptible to MERS-CoV infection
      <xref ref-type="bibr" rid="bb0240">
       [48]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0245">
       [49]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0250">
       [50]
      </xref>
      . Field studies with alpacas performed in Qatar confirmed this finding
      <xref ref-type="bibr" rid="bb0255">
       [51]
      </xref>
      . A recently published experimental study has demonstrated that domestic pigs are also susceptible to MERS-CoV infection, suggesting the possibility of MERS-CoV circulation in other unsuspected animal species such suidae
      <xref ref-type="bibr" rid="bb0250">
       [50]
      </xref>
      . While DPP4 in silico predictions and in vitro studies suggested that other livestock species such as goats, sheep, or horses could be susceptible to MERS-CoV infection, experimental data suggested the opposite
      <xref ref-type="bibr" rid="bb0250">
       [50]
      </xref>
      . Each natural and potential host for MERS-CoV infection is discussed below in detail and summarized in
      <xref ref-type="table" rid="t0005">
       Table 1
      </xref>
      ,
      <xref ref-type="table" rid="t0010">
       Table 2
      </xref>
      .
      <fig id="f0005">
       <label>
        Fig. 1
       </label>
       <caption>
        <p>
         Illustration of the known and potential host range of Middle East respiratory syndrome coronavirus (MERS-CoV). Dromedary camel is a demonstrated reservoir of MERS-CoV, but other species might act as hosts. In red: reported MERS-CoV-seropositive species and/or species in which virus has been naturally detected. In orange: other animal species that might be considered potential hosts since they are experimentally susceptible to MERS-CoV infection. Alpacas fit into both scenarios (red and orange). In black: animals (bats, to date) in which RNA of different sequences of MERS-CoV-like viruses have been found. Continuous arrows represent already described intra- and inter-species transmission events. Discontinuous arrows represent potential inter-species transmission.
        </p>
       </caption>
       <alt-text id="al0005">
        Fig. 1
       </alt-text>
       <graphic xlink:href="gr1_lrg">
       </graphic>
      </fig>
      <table-wrap id="t0005" position="float">
       <label>
        Table 1
       </label>
       <caption>
        <p>
         Summary of MERS-CoV shedding and presence of virus in different tissues in the potential animal reservoirs for MERS-CoV after experimental inoculation.
        </p>
       </caption>
       <alt-text id="al0010">
        Table 1
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th>
           Species
          </th>
          <th>
           Route and dose of inoculation
          </th>
          <th>
           MERS-CoV shedding
          </th>
          <th>
           MERS-CoV RNA in tissues
           <break>
           </break>
           MERS-CoV antigen in tissues
          </th>
          <th>
           Infectious MERS-CoV in tissues
          </th>
          <th>
           References
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td rowspan="3">
           Camelids
          </td>
          <td>
           Dromedary camels
           <italic>
            (Camelus dromedarius)
           </italic>
          </td>
          <td>
           IT, IN, conjunctival or IN only; 10
           <sup>
            7
           </sup>
           TCID
           <sub>
            50
           </sub>
          </td>
          <td>
           Viral RNA in NS (1 to 13 dpi)
           <break>
           </break>
           Infectious virus in NS (1 to 6 dpi)
          </td>
          <td>
           URT, LRT, tracheal LN, pulmonary LN, cervical LN, tonsil, PSG, intestine, liver, spleen, kidney, heart, adrenal
           <break>
           </break>
           Nasal respiratory epithelial cells
          </td>
          <td>
           URT, trachea, large bronchus, tracheal LN
          </td>
          <td>
           <break>
           </break>
           <xref ref-type="bibr" rid="bb0235">
            [47]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0265">
            [53]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Alpacas (
           <italic>
            Vicugna pacos
           </italic>
           )
          </td>
          <td>
           IN; 10
           <sup>
            7
           </sup>
           PFU in 3 mL saline solution
          </td>
          <td>
           Infectious virus in NS (1 to 5 dpi)
          </td>
          <td>
           URT, trachea
           <break>
           </break>
           Nasal respiratory epithelial cells
          </td>
          <td>
           ND
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0240">
            [48]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0245">
            [49]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Llamas (
           <italic>
            Lama glama
           </italic>
           )
          </td>
          <td>
           IN; 10
           <sup>
            7
           </sup>
           TCID
           <sub>
            50
           </sub>
           in 3 mL saline solution
          </td>
          <td>
           Viral RNA in NS (1 to 15 dpi)
           <break>
           </break>
           Infectious virus in NS (1 to 7 dpi)
          </td>
          <td>
           URT, trachea and bronchus
           <break>
           </break>
           Nasal respiratory epithelial cells
          </td>
          <td>
           ND
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0250">
            [50]
           </xref>
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           Non-camelid domestic species
          </td>
          <td>
           Domestic pig (
           <italic>
            Sus scrofa domesticus
           </italic>
           )
          </td>
          <td>
           IN; 10
           <sup>
            7
           </sup>
           TCID
           <sub>
            50
           </sub>
           in 3 mL saline solution
          </td>
          <td>
           Viral RNA in NS (1 to 10 dpi)
           <break>
           </break>
           Infectious virus in NS (1 to 4 dpi)
          </td>
          <td>
           URT, trachea and bronchus
           <break>
           </break>
           Nasal respiratory epithelial cells
          </td>
          <td>
           ND
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0250">
            [50]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Rabbit (
           <italic>
            Oryctolagus cuniculus
           </italic>
           )
          </td>
          <td>
           IN (1 × 10
           <sup>
            6
           </sup>
           TCID
           <sub>
            50
           </sub>
           ), IT (4 × 10
           <sup>
            6
           </sup>
           TCID
           <sub>
            50
           </sub>
           )
          </td>
          <td>
           Viral RNA in NS (1 to 10 dpi)
           <break>
           </break>
           Infectious virus in NS (1 to 7 dpi)
          </td>
          <td>
           Mainly in URT, LRT
           <break>
           </break>
           Nasal respiratory and bronchiolar epithelial cells
          </td>
          <td>
           ND
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0270">
            [54]
           </xref>
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           NHP
          </td>
          <td>
           Rhesus macaques
           <italic>
            (Macaca mulatta)
           </italic>
          </td>
          <td>
           IT, OC, oral, IN; 7 × 10
           <sup>
            6
           </sup>
           TCID
           <sub>
            50
           </sub>
           /IT, 6,5 × 10
           <sup>
            7
           </sup>
           TCID
           <sub>
            50
           </sub>
          </td>
          <td>
           Viral RNA in NS, BAL samples, and few OS
          </td>
          <td>
           URT, lung, mediastinal LN
           <break>
           </break>
           Type I and II pneumocytes, alveolar MΦ
          </td>
          <td>
           Lung
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0105">
            [21]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0110">
            [22]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0115">
            [23]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Common marmoset
           <italic>
            (Callithrix jacchus)
           </italic>
          </td>
          <td>
           OC, oral, IT, IN; 5 × 10
           <sup>
            6
           </sup>
           /IT, 5 × 10
           <sup>
            7
           </sup>
           TCID
           <sub>
            50
           </sub>
          </td>
          <td>
           Viral RNA in NS and OS
          </td>
          <td>
           URT, lung, mediastinal LN, blood
           <break>
           </break>
           Type I pneumocytes, alveolar MΦ
          </td>
          <td>
           Nasal mucosa, trachea, lung
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0120">
            [24]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0275">
            [55]
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Abbreviations: BAL, bronchoalveolar lavages; dpi, days post inoculation; IN, intranasal; IT, intratracheal; LN, lymph node; LRT, lower respiratory tract; MΦ, macrophages; ND, non-determined; NHP, non-human primates; NS, nasal swabs; OC, ocular; OS, oropharyngeal swabs; PFU, plaque-forming units; PSG, parotid salivary gland; RNA, ribonucleic acid; TCID
          <sub>
           50
          </sub>
          , 50% tissue culture infectious dose; URT, upper respiratory tract.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
      <table-wrap id="t0010" position="float">
       <label>
        Table 2
       </label>
       <caption>
        <p>
         Summary of clinical signs, pathological findings and target cells in tissues of natural and potential reservoir hosts for MERS-CoV infection as experimental animal models.
        </p>
       </caption>
       <alt-text id="al0015">
        Table 2
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th>
           Species
          </th>
          <th>
           Clinical signs
          </th>
          <th>
           Gross findings
          </th>
          <th>
           Histopathological lesions
          </th>
          <th>
           Target cells in tissues
          </th>
          <th>
           References
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td rowspan="3">
           Camelids
          </td>
          <td>
           Dromedary camels
           <italic>
            (Camelus dromedarius)
           </italic>
          </td>
          <td>
           Mild respiratory disease, nasal discharge
          </td>
          <td>
           Not present
          </td>
          <td>
           Multifocal moderate rhinitis, tracheitis and bronchitis with epithelial necrosis. Hyperplasia of lymph nodes and tonsil
          </td>
          <td>
           Respiratory epithelial cells in the URT
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0235">
            [47]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0265">
            [53]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Alpacas (
           <italic>
            Vicugna pacos
           </italic>
           )
          </td>
          <td>
           Not observable
          </td>
          <td>
           Not present
          </td>
          <td>
           Squamous metaplasia of the epithelium of the turbinate. Hypertrophy and hyperplasia of lymph nodes
          </td>
          <td>
           Respiratory epithelial cells in the URT
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0240">
            [48]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0245">
            [49]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Llamas (
           <italic>
            Lama glama
           </italic>
           )
          </td>
          <td>
           Mild mucus secretion in one nostril
          </td>
          <td>
           Not present
          </td>
          <td>
           Mild to severe rhinitis
          </td>
          <td>
           Respiratory epithelial cells in the URT
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0250">
            [50]
           </xref>
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           Non-camelid domestic species
          </td>
          <td>
           Domestic pig (
           <italic>
            Sus scrofa domesticus
           </italic>
           )
          </td>
          <td>
           Mild excretion of mucus in the nose
          </td>
          <td>
           Not present
          </td>
          <td>
           Mild to severe rhinitis
          </td>
          <td>
           Respiratory epithelial cells in the URT
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0250">
            [50]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Rabbit (
           <italic>
            Oryctolagus cuniculus
           </italic>
           )
          </td>
          <td>
           Not observable
          </td>
          <td>
           Not present
          </td>
          <td>
           Focal mild to moderate rhinitis with necrosis
          </td>
          <td>
           Respiratory epithelial cells in the URT
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0270">
            [54]
           </xref>
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           NHP
          </td>
          <td>
           Rhesus macaques
           <xref ref-type="table-fn" rid="tf0005">
            a
           </xref>
           <italic>
            (Macaca mulatta)
           </italic>
          </td>
          <td>
           Fever, mild to moderate respiratory disease
          </td>
          <td>
           Lung congestion and nodules in lung
           <break>
           </break>
           No extra pulmonary lesions
          </td>
          <td>
           Multifocal mild-to-moderate interstitial pneumonia
          </td>
          <td>
           Type I and II pneumocytes and alveolar macrophages
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0105">
            [21]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0110">
            [22]
           </xref>
           ,
           <xref ref-type="bibr" rid="bb0115">
            [23]
           </xref>
          </td>
         </tr>
         <tr>
          <td>
           Common marmoset
           <xref ref-type="table-fn" rid="tf0005">
            a
           </xref>
           <italic>
            (Callithrix jacchus)
           </italic>
          </td>
          <td>
           Mild to severe respiratory disease
          </td>
          <td>
           Congestion of bronchioles
          </td>
          <td>
           Diffuse interstitial infiltration in lower lung lobes, bronchointerstitial pneumonia
          </td>
          <td>
           Type I pneumocytes and alveolar macrophages
          </td>
          <td>
           <xref ref-type="bibr" rid="bb0120">
            [24]
           </xref>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Abbreviations: NHP, non-human primates; URT, upper respiratory tract.
         </p>
        </fn>
       </table-wrap-foot>
       <table-wrap-foot>
        <fn id="tf0005">
         <label>
          a
         </label>
         <p id="np0005">
          Also animal models of disease (translation to human).
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <sec id="s0020">
      <label>
       3.1
      </label>
      <title>
       Camelids
      </title>
      <p id="p0220">
       Dromedary camels are the main source of MERS-CoV zoonotic transmission (reviewed in
       <xref ref-type="bibr" rid="bb0260">
        [52]
       </xref>
       ). In experimental intranasal inoculations with MERS-CoV, only mild clinical signs (i.e. nasal discharge) with URT infection were observed. Viral RNA was detected in nasal swabs, in upper and lower respiratory tracts, and also in extra-pulmonary tissues (i.e. lymph nodes, tonsil, intestine, liver, adrenal gland, etc.). In contrast, infectious virus was only detected in the URT, trachea, large bronchus and tracheobronchial lymph node. Gross lesions were not observed in dromedary camels, but inflammation in the nasal cavity, trachea and bronchus was present. The virus replication in dromedaries was only detected in epithelial cells in the URT
       <xref ref-type="bibr" rid="bb0235">
        [47]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0265">
        [53]
       </xref>
       .
      </p>
      <p id="p0225">
       Llamas and alpacas, also known as domestic new world camelids, developed a similar clinical-pathological picture to that of dromedaries after experimental MERS-CoV infection. In both species the virus was inoculated via intranasal route, and either no clinical signs (alpacas) or mild mucus secretion (llamas) was observed. MERS-CoV was detected in nasal swabs, and in the URT and trachea of both llamas and alpacas. None of the species showed lesions macroscopically, but microscopically mild to severe rhinitis was detected in alpacas as well as metaplasia of the epithelium of the turbinate in alpacas. Similar to dromedaries, the epithelial cells in the URT were the main target cells for virus replication. Concomitant to an antibody response, the virus was cleared from the URT 7 to 10 days after experimental infection
       <xref ref-type="bibr" rid="bb0240">
        [48]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0245">
        [49]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0250">
        [50]
       </xref>
       .
      </p>
     </sec>
     <sec id="s0025">
      <label>
       3.2
      </label>
      <title>
       Non-camelid domestic species
      </title>
      <p id="p0230">
       After intranasal inoculation of MERS-CoV, only mild excretion of mucus was observed in 6 to 8-week old domestic pigs
       <xref ref-type="bibr" rid="bb0250">
        [50]
       </xref>
       . Viral RNA was detected in nasal swabs, in the URT, trachea and bronchus. Although gross lesions were not present in pigs, they showed mild to moderate rhinitis, with virus replication observed in the epithelial cells in the URT. Shedding of MERS-CoV was detected in nasal swabs from days 1 to 10 PI, but infectious virus was only detected until day 4 PI. Viral RNA was also detected in the URT, trachea and bronchus
       <xref ref-type="bibr" rid="bb0250">
        [50]
       </xref>
       .
      </p>
      <p id="p0235">
       New Zealand white rabbits did not exhibit clinical signs or significant gross lesions at necropsy after experimental MERS-CoV inoculation; thus, they were considered an animal model of asymptomatic infection
       <xref ref-type="bibr" rid="bb0270">
        [54]
       </xref>
       . Similar to pigs, mild to moderate rhinitis with necrosis was observed, and respiratory epithelial cells in the URT were identified as the target cells for MERS-CoV replication. Viral RNA was present in nasal swabs, and upper and lower respiratory tracts. Infectious virus was also detected in nasal swabs up to 7 days PI
       <xref ref-type="bibr" rid="bb0270">
        [54]
       </xref>
       .
      </p>
     </sec>
     <sec id="s0030">
      <label>
       3.3
      </label>
      <title>
       Non-human primates
      </title>
      <p id="p0240">
       The rhesus macaque was used as the first animal model developed for MERS-CoV infection, showing mild to moderate respiratory disease from day 1 to 4 PI after intratracheal inoculation
       <xref ref-type="bibr" rid="bb0105">
        [21]
       </xref>
       . Gross lesions were present only in the lung, consisting in congestion and presence of nodules, and the main observed microscopical lesion was interstitial pneumonia. Although MERS-CoV RNA was detected in nasal swabs, bronchoalveolar lavage samples, oropharyngeal swabs, and also in some upper and lower respiratory tract tissue samples, infectious virus was only isolated from the lungs. MERS-CoV replication occurred in type I and II pneumocytes, and viral antigen co-localized with sites of pneumonia
       <xref ref-type="bibr" rid="bb0105">
        [21]
       </xref>
       . Macaques represent a useful model to study mild MERS-CoV infection because they develop a transient respiratory disease similar to humans.
      </p>
      <p id="p0245">
       On the other hand, common marmosets exhibited moderate to severe respiratory disease from 1 to 13 days after inoculation of MERS-CoV through multiple routes (ocular, oral, intratracheal and intranasal)
       <xref ref-type="bibr" rid="bb0120">
        [24]
       </xref>
       . Similar to macaques, gross findings were present only in the lung and correlated with moderate to severe bronchointerstitial pneumonia. MERS-CoV antigen was detected by immunohistochemistry in both type I and II pneumocytes and alveolar macrophages, but the virus replicated only in type I pneumocytes and macrophages. Similar results were observed in marmosets after inoculation of MERS-CoV only via intratracheal route
       <xref ref-type="bibr" rid="bb0275">
        [55]
       </xref>
       . However, the outcome of MERS-CoV infection in marmosets has been controversial after the publication of a recent study by Johnson and collaborators, which demonstrated no lethality after intratracheal inoculation
       <xref ref-type="bibr" rid="bb0280">
        [56]
       </xref>
       . The outcome of experimental infections in both species is reviewed in recent publications
       <xref ref-type="bibr" rid="bb0085">
        [17]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0090">
        [18]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0095">
        [19]
       </xref>
       ,
       <xref ref-type="bibr" rid="bb0100">
        [20]
       </xref>
       .
      </p>
     </sec>
    </sec>
    <sec id="s0035">
     <label>
      4
     </label>
     <title>
      Advantages and disadvantages of animal hosts used for MERS-CoV experimental infection
     </title>
     <p id="p0250">
      As described in the previous section, a number of animal species have been described as either natural reservoir (dromedary camel) or potential intermediate hosts of MERS-CoV, each one with its benefits and limitations (
      <xref ref-type="table" rid="t0015">
       Table 3
      </xref>
      ) when used as experimental infection models. Camelids (dromedary camels, alpacas and llamas), non-camelid domestic species (pigs and rabbits), and NHP (rhesus macaques and common marmosets) have been experimentally demonstrated to be susceptible to MERS-CoV infection, but with differences among them
      <xref ref-type="bibr" rid="bb0105">
       [21]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0110">
       [22]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0115">
       [23]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0120">
       [24]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0235">
       [47]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0240">
       [48]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0245">
       [49]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0250">
       [50]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0265">
       [53]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0270">
       [54]
      </xref>
      . Experiments with dromedary camels, the natural MERS-CoV host, and probably the first target for controlling MERS through vaccination
      <xref ref-type="bibr" rid="bb0265">
       [53]
      </xref>
      , are costly and represent a high security risk for animal caretakers because of the difficulty in handling these animals under appropriate biosafety conditions. The main advantages of using the llama or alpaca models are that both belong to the family
      <italic>
       Camelidae
      </italic>
      , have smaller size, more gentle behavior, and are more available at a commercial level than dromedary camels; importantly, specific reagents for immune monitoring have been developed for new world camelids
      <xref ref-type="bibr" rid="bb0285">
       [57]
      </xref>
      . Therefore, they may be useful surrogates for dromedaries under experimental conditions. However, both models are also quite expensive and require large and complex BSL3 facilities. In contrast to camelids, other domestic species such as pigs and rabbits are readily available, with lower cost and easier handling. Additionally, an extensive panel of specific-immunological reagents is available for these species. When compared to camelids, however, lower MERS-CoV titers were detected in nasal cavities and tissue samples of pigs and rabbits during the infection. Furthermore their usefulness as animal models for transmission studies has not yet been addressed.
      <table-wrap id="t0015" position="float">
       <label>
        Table 3
       </label>
       <caption>
        <p>
         Advantages and limitations of natural and potential intermediate hosts for MERS-CoV infection as experimental animal models as well as for transmission studies.
        </p>
       </caption>
       <alt-text id="al0020">
        Table 3
       </alt-text>
       <table frame="hsides" rules="groups">
        <thead>
         <tr>
          <th>
          </th>
          <th>
           Species
          </th>
          <th>
           Advantages
          </th>
          <th>
           Limitations
          </th>
         </tr>
        </thead>
        <tbody>
         <tr>
          <td rowspan="3">
           Camelids
          </td>
          <td>
           Dromedary camels
           <italic>
            (Camelus dromedarius)
           </italic>
          </td>
          <td>
           <list id="l0005" list-type="simple">
            <list-item id="li0005">
             <label>
              •
             </label>
             <p id="p0005">
              Natural host for MERS-CoV
             </p>
            </list-item>
            <list-item id="li0010">
             <label>
              •
             </label>
             <p id="p0010">
              Efficient animal-to-animal transmission (field studies)
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0010" list-type="simple">
            <list-item id="li0015">
             <label>
              •
             </label>
             <p id="p0015">
              Expensive and limited availability
             </p>
            </list-item>
            <list-item id="li0020">
             <label>
              •
             </label>
             <p id="p0020">
              Complex husbandry requirements (large BSL3 facilities)
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Alpacas (
           <italic>
            Vicugna pacos
           </italic>
           )
          </td>
          <td>
           <list id="l0015" list-type="simple">
            <list-item id="li0025">
             <label>
              •
             </label>
             <p id="p0025">
              Potential surrogates for dromedaries under experimental conditions (potential hosts for MERS-CoV)
             </p>
            </list-item>
            <list-item id="li0030">
             <label>
              •
             </label>
             <p id="p0030">
              Efficient animal-to-animal transmission (experimental)
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0020" list-type="simple">
            <list-item id="li0035">
             <label>
              •
             </label>
             <p id="p0035">
              Expensive and limited availability
             </p>
            </list-item>
            <list-item id="li0040">
             <label>
              •
             </label>
             <p id="p0040">
              Complex husbandry requirements (large BSL3 facilities)
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Llamas (
           <italic>
            Lama glama
           </italic>
           )
          </td>
          <td>
           <list id="l0025" list-type="simple">
            <list-item id="li0045">
             <label>
              •
             </label>
             <p id="p0045">
              Potential surrogates for dromedaries under experimental conditions (potential hosts for MERS-CoV)
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0030" list-type="simple">
            <list-item id="li0050">
             <label>
              •
             </label>
             <p id="p0050">
              Expensive and limited availability
             </p>
            </list-item>
            <list-item id="li0055">
             <label>
              •
             </label>
             <p id="p0055">
              Complex husbandry requirements (large BSL3 facilities)
             </p>
            </list-item>
            <list-item id="li0060">
             <label>
              •
             </label>
             <p id="p0060">
              No animal-to-animal transmission studies available
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           Non-camelid domestic species
          </td>
          <td>
           Domestic pig (
           <italic>
            Sus scrofa domesticus
           </italic>
           )
          </td>
          <td>
           <list id="l0035" list-type="simple">
            <list-item id="li0065">
             <label>
              •
             </label>
             <p id="p0065">
              Relative low cost and readily available
             </p>
            </list-item>
            <list-item id="li0070">
             <label>
              •
             </label>
             <p id="p0070">
              Ease handling
             </p>
            </list-item>
            <list-item id="li0075">
             <label>
              •
             </label>
             <p id="p0075">
              Potential surrogates for dromedaries under experimental conditions (potential hosts for MERS-CoV)
             </p>
            </list-item>
            <list-item id="li0080">
             <label>
              •
             </label>
             <p id="p0080">
              Animal-to-animal transmission (experimental)
             </p>
            </list-item>
            <list-item id="li0085">
             <label>
              •
             </label>
             <p id="p0085">
              Pig-specific immunological reagents are available
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0040" list-type="simple">
            <list-item id="li0090">
             <label>
              •
             </label>
             <p id="p0090">
              Complex husbandry requirements (large BSL3 facilities)
             </p>
            </list-item>
            <list-item id="li0095">
             <label>
              •
             </label>
             <p id="p0095">
              Limited transmission (only via direct contact, and during few days)
             </p>
            </list-item>
            <list-item id="li0100">
             <label>
              •
             </label>
             <p id="p0100">
              Lower viral titers in NS and tissues upon infection
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Rabbit (
           <italic>
            Oryctolagus cuniculus
           </italic>
           )
          </td>
          <td>
           <list id="l0045" list-type="simple">
            <list-item id="li0105">
             <label>
              •
             </label>
             <p id="p0105">
              Low cost and readily available
             </p>
            </list-item>
            <list-item id="li0110">
             <label>
              •
             </label>
             <p id="p0110">
              Ease handling
             </p>
            </list-item>
            <list-item id="li0115">
             <label>
              •
             </label>
             <p id="p0115">
              Potential surrogates for dromedaries under experimental conditions (potential hosts for MERS-CoV)
             </p>
            </list-item>
            <list-item id="li0120">
             <label>
              •
             </label>
             <p id="p0120">
              Rabbit-specific immunological reagents are available
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0050" list-type="simple">
            <list-item id="li0125">
             <label>
              •
             </label>
             <p id="p0125">
              No animal-to-animal transmission studies available
             </p>
            </list-item>
            <list-item id="li0130">
             <label>
              •
             </label>
             <p id="p0130">
              Lower viral titers in NS and tissues upon infection
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td rowspan="2">
           NHP
          </td>
          <td>
           Rhesus macaques
           <italic>
            (Macaca mulatta)
           </italic>
          </td>
          <td>
           <list id="l0055" list-type="simple">
            <list-item id="li0135">
             <label>
              •
             </label>
             <p id="p0135">
              Human-specific immunological reagents are widely available
             </p>
            </list-item>
            <list-item id="li0140">
             <label>
              •
             </label>
             <p id="p0140">
              Clinical disease similar to humans: translational research (for intra species transmission)
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0060" list-type="simple">
            <list-item id="li0145">
             <label>
              •
             </label>
             <p id="p0145">
              Expensive and limited availability
             </p>
            </list-item>
            <list-item id="li0150">
             <label>
              •
             </label>
             <p id="p0150">
              Complex husbandry requirements (large BSL3 facilities)
             </p>
            </list-item>
            <list-item id="li0155">
             <label>
              •
             </label>
             <p id="p0155">
              No animal-to-animal transmission studies available
             </p>
            </list-item>
           </list>
          </td>
         </tr>
         <tr>
          <td>
           Common marmoset
           <italic>
            (Callithrix jacchus)
           </italic>
          </td>
          <td>
           <list id="l0065" list-type="simple">
            <list-item id="li0160">
             <label>
              •
             </label>
             <p id="p0160">
              Some human-specific immunological reagents cross-react
             </p>
            </list-item>
            <list-item id="li0165">
             <label>
              •
             </label>
             <p id="p0165">
              Clinical disease similar to humans: translational research (for intra species transmission)
             </p>
            </list-item>
           </list>
          </td>
          <td>
           <list id="l0070" list-type="simple">
            <list-item id="li0170">
             <label>
              •
             </label>
             <p id="p0170">
              Expensive and limited availability
             </p>
            </list-item>
            <list-item id="li0175">
             <label>
              •
             </label>
             <p id="p0175">
              Complex husbandry requirements (large BSL3 facilities);
             </p>
            </list-item>
            <list-item id="li0180">
             <label>
              •
             </label>
             <p id="p0180">
              No animal-to-animal transmission studies available
             </p>
            </list-item>
           </list>
          </td>
         </tr>
        </tbody>
       </table>
       <table-wrap-foot>
        <fn>
         <p>
          Abbreviations: BSL3, biosafety level 3; MERS-CoV, Middle East respiratory syndrome; NHP, non-human primates; NS, nasal swabs.
         </p>
        </fn>
       </table-wrap-foot>
      </table-wrap>
     </p>
     <p id="p0255">
      Contrary to the mentioned species, both macaques and common marmosets develop clinical disease relatively similar to humans. In that respect, phylogenetically-related species as baboons
      <xref ref-type="bibr" rid="bb0290">
       [58]
      </xref>
      , which live in Africa and Arabic Peninsula, might also play a role in the transmission of the virus. However, little attention has been paid to these species since no sero-epidemiology has been documented. There are important limitations when working with NHP models, namely the complex husbandry requirements that lead to substantially increased costs, some controversy results among different groups. Besides practical considerations, human-specific immunological reagents cross-react with NHP species and are widely available.
     </p>
    </sec>
    <sec id="s0040">
     <label>
      5
     </label>
     <title>
      Conclusion and future steps
     </title>
     <p id="p0260">
      As summarized in this review, several species of animals are susceptible to experimental MERS-CoV infection; thus, they might act as potential intermediate hosts of the disease. However, the presence of viral RNA and/or specific antibodies against the virus has been only demonstrated in the field in dromedaries and alpacas
      <xref ref-type="bibr" rid="bb0205">
       [41]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0255">
       [51]
      </xref>
      . At the light of recent experimental studies, it seems that the list of potential host targets for MERS-CoV is not closed. MERS surveillance programs should be implemented in endemic areas in animal species for which experimental evidence of susceptibility has been provided and species closely related to them.
     </p>
     <p id="p0265">
      SARS and MERS outbreaks taught us many lessons, and one of the most important is that, even in the absence of an overt threat, there is the possibility of the re-emergence of a virus or other similar viruses. On the other hand, and since the first case of MERS, continuous new cases have been described in different countries around the world
      <xref ref-type="bibr" rid="bb0295">
       [59]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0300">
       [60]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0305">
       [61]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0310">
       [62]
      </xref>
      . This underlines the importance of the development of animal models closer to the natural host targets. The key role of domestic animals and wildlife in the transmission of MERS-CoV should be further elucidated; meanwhile, countermeasures against deadly coronaviruses must be further explored since the risk of a global outbreak is not negligible. Noteworthy, after more than a decade of SARS and five years of MERS epidemics, there are still no licensed preventive or therapeutic drugs available that could be used in case of an eventual re-emergence of SARS or MERS. This scenario is not the outcome of technical issues, since effective vaccine prototypes against those pathogens are already available
      <xref ref-type="bibr" rid="bb0265">
       [53]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0315">
       [63]
      </xref>
      ,
      <xref ref-type="bibr" rid="bb0320">
       [64]
      </xref>
      . In case of MERS-CoV, vaccination of dromedary camels, the main source of zoonotic transmission, might be useful to control the spread of MERS
      <xref ref-type="bibr" rid="bb0265">
       [53]
      </xref>
      . However, when developing a vaccine, besides testing the protection efficacy, researchers need to think about social problems such as the reticence of camel owners to vaccinate their animals. Thus, the development of a dual vaccine able to protect against both, MERS-CoV and camelpox virus (an endemic disease in the Middle East, Africa and Asia) might be an ideal solution
      <xref ref-type="bibr" rid="bb0265">
       [53]
      </xref>
      . Recently, another dual-vaccine for humans and animals against MERS-CoV and rabies virus has been designed
      <xref ref-type="bibr" rid="bb0325">
       [65]
      </xref>
      . Political aspects have also a key role in the release of a vaccine into the market. Unless the requirements and timings for vaccine licensing procedures are facilitated, pharmaceutical companies will unlikely invest in their development taking into account the current market demand. Moreover, fragmentation of intellectual property rights may also adversely affect the development of vaccines to combat those infections
      <xref ref-type="bibr" rid="bb0330">
       [66]
      </xref>
      .
     </p>
    </sec>
    <sec id="s0045">
     <title>
      Conflicts of interest
     </title>
     <p id="p0270">
      None.
     </p>
    </sec>
    <back>
     <ref-list id="bi0005">
      <title>
       References
      </title>
      <ref id="bb0005">
       <label>
        1
       </label>
       <element-citation id="rf0005" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Rubin
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Stokes
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Dunham
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Harris
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lautner
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Review of institute of medicine and national research council recommendations for one health initiative
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         12
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1913
        </fpage>
        <lpage>
         1917
        </lpage>
        <pub-id pub-id-type="pmid">
         24274461
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0010">
       <label>
        2
       </label>
       <element-citation id="rf0010" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Jones
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Patel
          </surname>
          <given-names>
           N.G.
          </given-names>
         </name>
         <name>
          <surname>
           Levy
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Storeygard
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Balk
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Gittleman
          </surname>
          <given-names>
           J.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Global trends in emerging infectious diseases
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         451
        </volume>
        <issue>
         7181
        </issue>
        <year>
         2008
        </year>
        <fpage>
         990
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="pmid">
         18288193
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0015">
       <label>
        3
       </label>
       <element-citation id="rf0015" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Morse
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.A.K.
          </given-names>
         </name>
         <name>
          <surname>
           Woolhouse
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Parrish
          </surname>
          <given-names>
           C.R.
          </given-names>
         </name>
         <name>
          <surname>
           Carroll
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Karesh
          </surname>
          <given-names>
           W.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Prediction and prevention of the next pandemic zoonosis
        </article-title>
        <source>
         Lancet
        </source>
        <volume>
         380
        </volume>
        <issue>
         9857
        </issue>
        <year>
         2012
        </year>
        <fpage>
         1956
        </fpage>
        <lpage>
         1965
        </lpage>
        <pub-id pub-id-type="pmid">
         23200504
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0020">
       <label>
        4
       </label>
       <element-citation id="rf0020" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mäkelä
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Puhakka
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Ruuskanen
          </surname>
          <given-names>
           O.
          </given-names>
         </name>
         <name>
          <surname>
           Leinonen
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Saikku
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Kimpimäki
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Viruses and bacteria in the etiology of the common cold
        </article-title>
        <source>
         J. Clin. Microbiol.
        </source>
        <volume>
         36
        </volume>
        <issue>
         2
        </issue>
        <year>
         1998
        </year>
        <fpage>
         539
        </fpage>
        <lpage>
         542
        </lpage>
        <pub-id pub-id-type="pmid">
         9466772
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0025">
       <label>
        5
       </label>
       <element-citation id="rf0025" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization, WHO
          </surname>
         </name>
        </person-group>
        <ext-link ext-link-type="uri" id="ir0005" xlink:href="http://www.who.int/csr/don/2016_">
         http://www.who.int/csr/don/2016_
        </ext-link>
        <year>
         2014
        </year>
        <comment>
         (Accessed on December 15, 2016)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0030">
       <label>
        6
       </label>
       <element-citation id="rf0030" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Bermingham
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Chand
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           C.S.
          </given-names>
         </name>
         <name>
          <surname>
           Aarons
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Langrish
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe respiratory illness caused by a novel coronavirus, in a patient transferred to United Kingdom from the Middle East, September 2012
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <volume>
         17
        </volume>
        <issue>
         40
        </issue>
        <year>
         2012
        </year>
        <fpage>
         20290
        </fpage>
        <pub-id pub-id-type="pmid">
         23078800
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0035">
       <label>
        7
       </label>
       <element-citation id="rf0035" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization, WHO
          </surname>
         </name>
        </person-group>
        <ext-link ext-link-type="uri" id="ir0010" xlink:href="http://www.who.int/emergencies/mers-cov/en/">
         http://www.who.int/emergencies/mers-cov/en/
        </ext-link>
        <year>
         2016
        </year>
        <comment>
         (Accessed on December 15, 2016)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0040">
       <label>
        8
       </label>
       <element-citation id="rf0040" publication-type="other">
        <person-group person-group-type="author">
         <name>
          <surname>
           World Health Organization, WHO
          </surname>
         </name>
        </person-group>
        <ext-link ext-link-type="uri" id="ir0015" xlink:href="https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/">
         https://www.cdc.gov/vhf/ebola/outbreaks/2014-west-africa/
        </ext-link>
        <year>
         2014
        </year>
        <comment>
         (Accessed on December 15, 2016)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0045">
       <label>
        9
       </label>
       <element-citation id="rf0045" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Paweska
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
         <name>
          <surname>
           Sewlall
          </surname>
          <given-names>
           N.H.
          </given-names>
         </name>
         <name>
          <surname>
           Ksiazek
          </surname>
          <given-names>
           T.G.
          </given-names>
         </name>
         <name>
          <surname>
           Blumberg
          </surname>
          <given-names>
           L.H.
          </given-names>
         </name>
         <name>
          <surname>
           Hale
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Lipkin
          </surname>
          <given-names>
           W.I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Nosocomial outbreak of novel arenavirus infection, southern Africa
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         15
        </volume>
        <issue>
         10
        </issue>
        <year>
         2009
        </year>
        <fpage>
         1598
        </fpage>
        <lpage>
         1602
        </lpage>
        <pub-id pub-id-type="pmid">
         19861052
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0050">
       <label>
        10
       </label>
       <element-citation id="rf0050" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           X.J.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           M.F.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.Y.
          </given-names>
         </name>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           J.D.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           Y.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Fever with thrombocytopenia associated with a novel bunyavirus in China
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         364
        </volume>
        <issue>
         16
        </issue>
        <year>
         2011
        </year>
        <fpage>
         1523
        </fpage>
        <lpage>
         1532
        </lpage>
        <pub-id pub-id-type="pmid">
         21410387
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0055">
       <label>
        11
       </label>
       <element-citation id="rf0055" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Safronetz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Geisbert
          </surname>
          <given-names>
           T.W.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal models for highly pathogenic emerging viruses
        </article-title>
        <source>
         Curr. Opin. Virol.
        </source>
        <volume>
         3
        </volume>
        <issue>
         2
        </issue>
        <year>
         2013
        </year>
        <fpage>
         205
        </fpage>
        <lpage>
         209
        </lpage>
        <pub-id pub-id-type="pmid">
         23403208
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0060">
       <label>
        12
       </label>
       <element-citation id="rf0060" publication-type="book">
        <person-group person-group-type="author">
         <name>
          <surname>
           Food and Drug Administration, FDA
          </surname>
         </name>
        </person-group>
        <chapter-title>
         Guidance for industry product development under the animal rule
        </chapter-title>
        <source>
         US Department of Health and Human Services
        </source>
        <edition>
         May 2014 ed.
        </edition>
        <year>
         2014
        </year>
        <publisher-name>
         FDA
        </publisher-name>
        <publisher-loc>
         Silver Spring, MD
        </publisher-loc>
       </element-citation>
      </ref>
      <ref id="bb0065">
       <label>
        13
       </label>
       <element-citation id="rf0065" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Plumb
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Babiuk
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Mazet
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Olsen
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Rupprecht
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Pastoret
          </surname>
          <given-names>
           P.P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vaccination in conservation medicine
        </article-title>
        <source>
         Rev. Sci. Tech.
        </source>
        <volume>
         26
        </volume>
        <issue>
         1
        </issue>
        <year>
         2007
        </year>
        <fpage>
         229
        </fpage>
        <lpage>
         241
        </lpage>
        <pub-id pub-id-type="pmid">
         17633305
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0070">
       <label>
        14
       </label>
       <element-citation id="rf0070" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adams
          </surname>
          <given-names>
           L.G.
          </given-names>
         </name>
         <name>
          <surname>
           Khare
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Lawhon
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Rossetti
          </surname>
          <given-names>
           C.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lewin
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Lipton
          </surname>
          <given-names>
           M.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: linking systems biology with vaccine development
        </article-title>
        <source>
         Vaccine
        </source>
        <volume>
         29
        </volume>
        <issue>
         41
        </issue>
        <year>
         2011
        </year>
        <fpage>
         7197
        </fpage>
        <lpage>
         7206
        </lpage>
        <pub-id pub-id-type="pmid">
         21651944
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0075">
       <label>
        15
       </label>
       <element-citation id="rf0075" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Alharbi
          </surname>
          <given-names>
           N.K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Vaccines against Middle East respiratory syndrome coronavirus for humans and camels
        </article-title>
        <source>
         Rev. Med. Virol.
        </source>
        <year>
         2016 Oct 27
        </year>
        <comment>
         (Epub ahead of print)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0080">
       <label>
        16
       </label>
       <element-citation id="rf0080" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Lowenthal
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Overview of the CSIRO Australian Animal Health Laboratory
        </article-title>
        <source>
         J. Infect. Public Health
        </source>
        <volume>
         9
        </volume>
        <issue>
         3
        </issue>
        <year>
         2016 May–Jun
        </year>
        <fpage>
         236
        </fpage>
        <lpage>
         239
        </lpage>
        <pub-id pub-id-type="pmid">
         27118215
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0085">
       <label>
        17
       </label>
       <element-citation id="rf0085" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.J.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.P.
          </given-names>
         </name>
         <name>
          <surname>
           Rosenke
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An acute immune response to Middle East respiratory syndrome coronavirus replication contributes to viral pathogenicity
        </article-title>
        <source>
         Am. J. Pathol.
        </source>
        <volume>
         186
        </volume>
        <issue>
         3
        </issue>
        <year>
         2016
        </year>
        <fpage>
         630
        </fpage>
        <lpage>
         638
        </lpage>
        <pub-id pub-id-type="pmid">
         26724387
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0090">
       <label>
        18
       </label>
       <element-citation id="rf0090" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Animal models of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         122
        </volume>
        <year>
         2015
        </year>
        <fpage>
         28
        </fpage>
        <lpage>
         38
        </lpage>
        <pub-id pub-id-type="pmid">
         26192750
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0095">
       <label>
        19
       </label>
       <element-citation id="rf0095" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sutton
          </surname>
          <given-names>
           T.C.
          </given-names>
         </name>
         <name>
          <surname>
           Subbarao
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         479–480
        </volume>
        <year>
         2015
        </year>
        <fpage>
         247
        </fpage>
        <lpage>
         258
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0100">
       <label>
        20
       </label>
       <element-citation id="rf0100" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A comparative review of animal models of Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         Vet. Pathol.
        </source>
        <volume>
         53
        </volume>
        <issue>
         3
        </issue>
        <year>
         2016
        </year>
        <fpage>
         521
        </fpage>
        <lpage>
         531
        </lpage>
        <pub-id pub-id-type="pmid">
         26869154
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0105">
       <label>
        21
       </label>
       <element-citation id="rf0105" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Brining
          </surname>
          <given-names>
           D.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         110
        </volume>
        <issue>
         41
        </issue>
        <year>
         2013
        </year>
        <fpage>
         16598
        </fpage>
        <lpage>
         16603
        </lpage>
        <pub-id pub-id-type="pmid">
         24062443
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0110">
       <label>
        22
       </label>
       <element-citation id="rf0110" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pneumonia from human coronavirus in a macaque model
        </article-title>
        <source>
         N. Engl. J. Med.
        </source>
        <volume>
         368
        </volume>
        <issue>
         16
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1560
        </fpage>
        <lpage>
         1562
        </lpage>
       </element-citation>
      </ref>
      <ref id="bb0115">
       <label>
        23
       </label>
       <element-citation id="rf0115" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Lv
          </surname>
          <given-names>
           Q.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         209
        </volume>
        <issue>
         2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         236
        </fpage>
        <lpage>
         242
        </lpage>
        <pub-id pub-id-type="pmid">
         24218506
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0120">
       <label>
        24
       </label>
       <element-citation id="rf0120" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Falzarano
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Feldmann
          </surname>
          <given-names>
           F.
          </given-names>
         </name>
         <name>
          <surname>
           Rasmussen
          </surname>
          <given-names>
           A.L.
          </given-names>
         </name>
         <name>
          <surname>
           Okumura
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection with MERS-CoV causes lethal pneumonia in the common marmoset
        </article-title>
        <source>
         PLoS Pathog.
        </source>
        <volume>
         10
        </volume>
        <issue>
         8
        </issue>
        <year>
         2014
        </year>
        <fpage>
         e1004250
        </fpage>
        <pub-id pub-id-type="pmid">
         25144235
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0125">
       <label>
        25
       </label>
       <element-citation id="rf0125" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Mou
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
         <name>
          <surname>
           Dekkers
          </surname>
          <given-names>
           D.H.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Dijkman
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
        </article-title>
        <source>
         Nature
        </source>
        <volume>
         495
        </volume>
        <issue>
         7440
        </issue>
        <year>
         2013
        </year>
        <fpage>
         251
        </fpage>
        <lpage>
         254
        </lpage>
        <pub-id pub-id-type="pmid">
         23486063
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0130">
       <label>
        26
       </label>
       <element-citation id="rf0130" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Tong
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4
        </article-title>
        <source>
         Cell Res.
        </source>
        <volume>
         23
        </volume>
        <issue>
         8
        </issue>
        <year>
         2013
        </year>
        <fpage>
         986
        </fpage>
        <lpage>
         993
        </lpage>
        <pub-id pub-id-type="pmid">
         23835475
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0135">
       <label>
        27
       </label>
       <element-citation id="rf0135" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Prescott
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Baseler
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Thomas
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Lackemeyer
          </surname>
          <given-names>
           M.G.
          </given-names>
         </name>
        </person-group>
        <article-title>
         The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters
        </article-title>
        <source>
         PLoS One
        </source>
        <volume>
         8
        </volume>
        <issue>
         7
        </issue>
        <year>
         2013
        </year>
        <fpage>
         e69127
        </fpage>
        <pub-id pub-id-type="pmid">
         23844250
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0140">
       <label>
        28
       </label>
       <element-citation id="rf0140" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Matthews
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Goicochea
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Frieman
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         J. Gen. Virol.
        </source>
        <volume>
         95
        </volume>
        <issue>
         Pt 2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         408
        </fpage>
        <lpage>
         412
        </lpage>
        <pub-id pub-id-type="pmid">
         24197535
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0145">
       <label>
        29
       </label>
       <element-citation id="rf0145" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlford-Lenane
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Agnihothramn
          </surname>
          <given-names>
           S.S.
          </given-names>
         </name>
         <name>
          <surname>
           Fett
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Rapid generation of a mouse model for Middle East respiratory syndrome
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         111
        </volume>
        <issue>
         13
        </issue>
        <year>
         2014
        </year>
        <fpage>
         4970
        </fpage>
        <lpage>
         4975
        </lpage>
        <pub-id pub-id-type="pmid">
         24599590
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0150">
       <label>
        30
       </label>
       <element-citation id="rf0150" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Agrawal
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Garron
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Wakamiya
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         7
        </issue>
        <year>
         2015
        </year>
        <fpage>
         3659
        </fpage>
        <lpage>
         3670
        </lpage>
        <pub-id pub-id-type="pmid">
         25589660
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0155">
       <label>
        31
       </label>
       <element-citation id="rf0155" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Houdebine
          </surname>
          <given-names>
           L.M.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Transgenic animal models in biomedical research
        </article-title>
        <source>
         Methods Mol. Biol.
        </source>
        <volume>
         360
        </volume>
        <year>
         2007
        </year>
        <fpage>
         163
        </fpage>
        <lpage>
         202
        </lpage>
        <pub-id pub-id-type="pmid">
         17172731
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0160">
       <label>
        32
       </label>
       <element-citation id="rf0160" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Peck
          </surname>
          <given-names>
           K.M.
          </given-names>
         </name>
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Baric
          </surname>
          <given-names>
           R.S.
          </given-names>
         </name>
         <name>
          <surname>
           Heise
          </surname>
          <given-names>
           M.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Glycosylation of mouse DPP4 plays a role in inhibiting Middle East respiratory syndrome coronavirus infection
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         8
        </issue>
        <year>
         2015
        </year>
        <fpage>
         4696
        </fpage>
        <lpage>
         4699
        </lpage>
        <pub-id pub-id-type="pmid">
         25653445
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0165">
       <label>
        33
       </label>
       <element-citation id="rf0165" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cockrell
          </surname>
          <given-names>
           A.S.
          </given-names>
         </name>
         <name>
          <surname>
           Yount
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Scobey
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Jensen
          </surname>
          <given-names>
           K.
          </given-names>
         </name>
         <name>
          <surname>
           Douglas
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Beall
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
        </article-title>
        <source>
         Nat Microbiol.
        </source>
        <volume>
         2
        </volume>
        <year>
         2016
        </year>
        <fpage>
         16226
        </fpage>
        <pub-id pub-id-type="pmid">
         27892925
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0170">
       <label>
        34
       </label>
       <element-citation id="rf0170" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Zhao
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tao
          </surname>
          <given-names>
           X.
          </given-names>
         </name>
        </person-group>
        <article-title>
         A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         499
        </volume>
        <year>
         2016
        </year>
        <fpage>
         375
        </fpage>
        <lpage>
         382
        </lpage>
        <pub-id pub-id-type="pmid">
         27750111
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0175">
       <label>
        35
       </label>
       <element-citation id="rf0175" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Qiu
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Xiao
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Feng
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Tai
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection
        </article-title>
        <source>
         Antivir. Res.
        </source>
        <volume>
         132
        </volume>
        <year>
         2016
        </year>
        <fpage>
         141
        </fpage>
        <lpage>
         148
        </lpage>
        <pub-id pub-id-type="pmid">
         27312105
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0180">
       <label>
        36
       </label>
       <element-citation id="rf0180" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Pascal
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Mujica
          </surname>
          <given-names>
           A.O.
          </given-names>
         </name>
         <name>
          <surname>
           Kamat
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Badithe
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Fairhurst
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection
        </article-title>
        <source>
         Proc. Natl. Acad. Sci. U. S. A.
        </source>
        <volume>
         112
        </volume>
        <issue>
         28
        </issue>
        <year>
         2015
        </year>
        <fpage>
         8738
        </fpage>
        <lpage>
         8743
        </lpage>
        <pub-id pub-id-type="pmid">
         26124093
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0185">
       <label>
        37
       </label>
       <element-citation id="rf0185" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           de Benedictis
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Marciano
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Scaravelli
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Priori
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Zecchin
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Capua
          </surname>
          <given-names>
           I.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Alpha and lineage C beta CoV infections in Italian bats
        </article-title>
        <source>
         Virus Genes
        </source>
        <volume>
         48
        </volume>
        <issue>
         2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         366
        </fpage>
        <lpage>
         371
        </lpage>
        <pub-id pub-id-type="pmid">
         24242847
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0190">
       <label>
        38
       </label>
       <element-citation id="rf0190" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
         <name>
          <surname>
           Mishra
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Olival
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Fagbo
          </surname>
          <given-names>
           S.F.
          </given-names>
         </name>
         <name>
          <surname>
           Kapoor
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Epstein
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in bats, Saudi Arabia
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         19
        </volume>
        <issue>
         11
        </issue>
        <year>
         2013
        </year>
        <fpage>
         1819
        </fpage>
        <lpage>
         1823
        </lpage>
        <pub-id pub-id-type="pmid">
         24206838
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0195">
       <label>
        39
       </label>
       <element-citation id="rf0195" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Munster
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           V.R.
          </given-names>
         </name>
         <name>
          <surname>
           Miazgowicz
          </surname>
          <given-names>
           K.L.
          </given-names>
         </name>
         <name>
          <surname>
           Milne-Price
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in Jamaican fruit bats (
         <italic>
          Artibeus jamaicensis
         </italic>
         )
        </article-title>
        <source>
         Sci. Rep.
        </source>
        <volume>
         6
        </volume>
        <year>
         2016
        </year>
        <fpage>
         21878
        </fpage>
        <pub-id pub-id-type="pmid">
         26899616
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0200">
       <label>
        40
       </label>
       <element-citation id="rf0200" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Jores
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Younan
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Liljander
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Said
          </surname>
          <given-names>
           M.Y.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Antibodies against MERS coronavirus in dromedary camels, Kenya, 1992–2013
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <issue>
         8
        </issue>
        <year>
         2014
        </year>
        <fpage>
         1319
        </fpage>
        <lpage>
         1322
        </lpage>
        <pub-id pub-id-type="pmid">
         25075637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0205">
       <label>
        41
       </label>
       <element-citation id="rf0205" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Gutierrez
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Godeke
          </surname>
          <given-names>
           G.J.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         13
        </volume>
        <issue>
         10
        </issue>
        <year>
         2013
        </year>
        <fpage>
         859
        </fpage>
        <lpage>
         866
        </lpage>
        <pub-id pub-id-type="pmid">
         23933067
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0210">
       <label>
        42
       </label>
       <element-citation id="rf0210" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Al Dhahiry
          </surname>
          <given-names>
           S.H.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Galiano
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Myers
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         14
        </volume>
        <issue>
         2
        </issue>
        <year>
         2014
        </year>
        <fpage>
         140
        </fpage>
        <lpage>
         145
        </lpage>
        <pub-id pub-id-type="pmid">
         24355866
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0215">
       <label>
        43
       </label>
       <element-citation id="rf0215" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Müller
          </surname>
          <given-names>
           M.A.
          </given-names>
         </name>
         <name>
          <surname>
           Meyer
          </surname>
          <given-names>
           B.
          </given-names>
         </name>
         <name>
          <surname>
           Corman
          </surname>
          <given-names>
           V.M.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Masri
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Turkestani
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Ritz
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study
        </article-title>
        <source>
         Lancet Infect. Dis.
        </source>
        <volume>
         15
        </volume>
        <issue>
         5
        </issue>
        <year>
         2015
        </year>
        <fpage>
         559
        </fpage>
        <lpage>
         564
        </lpage>
        <pub-id pub-id-type="pmid">
         25863564
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0220">
       <label>
        44
       </label>
       <element-citation id="rf0220" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           Mohran
          </surname>
          <given-names>
           K.A.
          </given-names>
         </name>
         <name>
          <surname>
           Stalin Raj
          </surname>
          <given-names>
           V.
          </given-names>
         </name>
         <name>
          <surname>
           Pas
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014
        </article-title>
        <source>
         Infect. Ecol. Epidemiol.
        </source>
        <volume>
         5
        </volume>
        <year>
         2015 Jul 15
        </year>
        <fpage>
         28305
        </fpage>
        <pub-id pub-id-type="pmid">
         26183160
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0225">
       <label>
        45
       </label>
       <element-citation id="rf0225" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Lamers
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Pas
          </surname>
          <given-names>
           S.D.
          </given-names>
         </name>
         <name>
          <surname>
           Voermans
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <issue>
         8
        </issue>
        <year>
         2014 Aug
        </year>
        <fpage>
         1339
        </fpage>
        <lpage>
         1342
        </lpage>
        <pub-id pub-id-type="pmid">
         25075761
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0230">
       <label>
        46
       </label>
       <element-citation id="rf0230" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Sabir
          </surname>
          <given-names>
           J.S.
          </given-names>
         </name>
         <name>
          <surname>
           Lam
          </surname>
          <given-names>
           T.T.
          </given-names>
         </name>
         <name>
          <surname>
           Ahmed
          </surname>
          <given-names>
           M.M.
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Shen
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Abo-Aba
          </surname>
          <given-names>
           S.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <issue>
         6268
        </issue>
        <year>
         2016
        </year>
        <fpage>
         81
        </fpage>
        <lpage>
         84
        </lpage>
        <pub-id pub-id-type="pmid">
         26678874
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0235">
       <label>
        47
       </label>
       <element-citation id="rf0235" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
         <name>
          <surname>
           Brown
          </surname>
          <given-names>
           V.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
         <name>
          <surname>
           Scott
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           de Wit
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         20
        </volume>
        <issue>
         12
        </issue>
        <year>
         2014
        </year>
        <fpage>
         1999
        </fpage>
        <lpage>
         2005
        </lpage>
        <pub-id pub-id-type="pmid">
         25418529
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0240">
       <label>
        48
       </label>
       <element-citation id="rf0240" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Adney
          </surname>
          <given-names>
           D.R.
          </given-names>
         </name>
         <name>
          <surname>
           Bielefeldt-Ohmann
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Hartwig
          </surname>
          <given-names>
           A.E.
          </given-names>
         </name>
         <name>
          <surname>
           Bowen
          </surname>
          <given-names>
           R.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Infection, replication, and transmission of Middle East respiratory syndrome coronavirus in alpacas
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         22
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         1031
        </fpage>
        <lpage>
         1037
        </lpage>
        <pub-id pub-id-type="pmid">
         27070385
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0245">
       <label>
        49
       </label>
       <element-citation id="rf0245" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Crameri
          </surname>
          <given-names>
           G.
          </given-names>
         </name>
         <name>
          <surname>
           Durr
          </surname>
          <given-names>
           P.A.
          </given-names>
         </name>
         <name>
          <surname>
           Klein
          </surname>
          <given-names>
           R.
          </given-names>
         </name>
         <name>
          <surname>
           Foord
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Riddell
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Experimental infection and response to rechallenge of alpacas with Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         22
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         1071
        </fpage>
        <lpage>
         1074
        </lpage>
        <pub-id pub-id-type="pmid">
         27070733
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0250">
       <label>
        50
       </label>
       <element-citation id="rf0250" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Vergara-Alert
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Widagdo
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Muñoz
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Livestock susceptibility to infection with Middle East respiratory syndrome coronavirus
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         15
        </volume>
        <year>
         2017 Feb
        </year>
        <fpage>
         23(2)
        </fpage>
        <comment>
         (Epub ahead of print)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0255">
       <label>
        51
       </label>
       <element-citation id="rf0255" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Reusken
          </surname>
          <given-names>
           C.B.
          </given-names>
         </name>
         <name>
          <surname>
           Schilp
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           De Bruin
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Kohl
          </surname>
          <given-names>
           R.H.
          </given-names>
         </name>
         <name>
          <surname>
           Farag
          </surname>
          <given-names>
           E.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         MERS-CoV infection of alpaca in a region where MERS-CoV is endemic
        </article-title>
        <source>
         Emerg. Infect. Dis.
        </source>
        <volume>
         22
        </volume>
        <issue>
         6
        </issue>
        <year>
         2016
        </year>
        <fpage>
         1129
        </fpage>
        <lpage>
         1131
        </lpage>
        <pub-id pub-id-type="pmid">
         27070501
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0260">
       <label>
        52
       </label>
       <element-citation id="rf0260" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Mohd
          </surname>
          <given-names>
           H.A.
          </given-names>
         </name>
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Middle East respiratory syndrome coronavirus (MERS-CoV) origin and animal reservoir
        </article-title>
        <source>
         Virol. J.
        </source>
        <volume>
         13
        </volume>
        <year>
         2016
        </year>
        <fpage>
         87
        </fpage>
        <pub-id pub-id-type="pmid">
         27255185
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0265">
       <label>
        53
       </label>
       <element-citation id="rf0265" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Volz
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Wohlsein
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Smits
          </surname>
          <given-names>
           S.L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
        </article-title>
        <source>
         Science
        </source>
        <volume>
         351
        </volume>
        <issue>
         6268
        </issue>
        <year>
         2016
        </year>
        <fpage>
         77
        </fpage>
        <lpage>
         81
        </lpage>
        <pub-id pub-id-type="pmid">
         26678878
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0270">
       <label>
        54
       </label>
       <element-citation id="rf0270" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Haagmans
          </surname>
          <given-names>
           B.L.
          </given-names>
         </name>
         <name>
          <surname>
           van den Brand
          </surname>
          <given-names>
           J.M.
          </given-names>
         </name>
         <name>
          <surname>
           Provacia
          </surname>
          <given-names>
           L.B.
          </given-names>
         </name>
         <name>
          <surname>
           Raj
          </surname>
          <given-names>
           V.S.
          </given-names>
         </name>
         <name>
          <surname>
           Stittelaar
          </surname>
          <given-names>
           K.J.
          </given-names>
         </name>
         <name>
          <surname>
           Getu
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         11
        </issue>
        <year>
         2015
        </year>
        <fpage>
         6131
        </fpage>
        <lpage>
         6135
        </lpage>
        <pub-id pub-id-type="pmid">
         25810539
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0275">
       <label>
        55
       </label>
       <element-citation id="rf0275" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Chan
          </surname>
          <given-names>
           J.F.
          </given-names>
         </name>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Yeung
          </surname>
          <given-names>
           M.L.
          </given-names>
         </name>
         <name>
          <surname>
           Deng
          </surname>
          <given-names>
           W.
          </given-names>
         </name>
         <name>
          <surname>
           Bao
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Jia
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset
        </article-title>
        <source>
         J. Infect. Dis.
        </source>
        <volume>
         212
        </volume>
        <issue>
         12
        </issue>
        <year>
         2015
        </year>
        <fpage>
         1904
        </fpage>
        <lpage>
         1913
        </lpage>
        <pub-id pub-id-type="pmid">
         26198719
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0280">
       <label>
        56
       </label>
       <element-citation id="rf0280" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Johnson
          </surname>
          <given-names>
           R.F.
          </given-names>
         </name>
         <name>
          <surname>
           Via
          </surname>
          <given-names>
           L.E.
          </given-names>
         </name>
         <name>
          <surname>
           Kumar
          </surname>
          <given-names>
           M.R.
          </given-names>
         </name>
         <name>
          <surname>
           Cornish
          </surname>
          <given-names>
           J.P.
          </given-names>
         </name>
         <name>
          <surname>
           Yellayi
          </surname>
          <given-names>
           S.
          </given-names>
         </name>
         <name>
          <surname>
           Huzella
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease
        </article-title>
        <source>
         Virology
        </source>
        <volume>
         485
        </volume>
        <year>
         2015
        </year>
        <fpage>
         422
        </fpage>
        <lpage>
         430
        </lpage>
        <pub-id pub-id-type="pmid">
         26342468
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0285">
       <label>
        57
       </label>
       <element-citation id="rf0285" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Davis
          </surname>
          <given-names>
           W.C.
          </given-names>
         </name>
         <name>
          <surname>
           Heirman
          </surname>
          <given-names>
           L.R.
          </given-names>
         </name>
         <name>
          <surname>
           Hamilton
          </surname>
          <given-names>
           M.J.
          </given-names>
         </name>
         <name>
          <surname>
           Parish
          </surname>
          <given-names>
           S.M.
          </given-names>
         </name>
         <name>
          <surname>
           Barrington
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Loftis
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Flow cytometric analysis of an immunodeficiency disorder affecting juvenile llamas
        </article-title>
        <source>
         Vet. Immunol. Immunopathol.
        </source>
        <volume>
         74
        </volume>
        <issue>
         1–2
        </issue>
        <year>
         2000
        </year>
        <fpage>
         103
        </fpage>
        <lpage>
         120
        </lpage>
        <pub-id pub-id-type="pmid">
         10760393
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0290">
       <label>
        58
       </label>
       <element-citation id="rf0290" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Eichler
          </surname>
          <given-names>
           E.E.
          </given-names>
         </name>
         <name>
          <surname>
           DeJong
          </surname>
          <given-names>
           P.J.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Biomedical applications and studies of molecular evolution: a proposal for a primate genomic library resource
        </article-title>
        <source>
         Genome Res.
        </source>
        <volume>
         12
        </volume>
        <issue>
         5
        </issue>
        <year>
         2002
        </year>
        <fpage>
         673
        </fpage>
        <lpage>
         678
        </lpage>
        <pub-id pub-id-type="pmid">
         11997334
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0295">
       <label>
        59
       </label>
       <element-citation id="rf0295" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Cowling
          </surname>
          <given-names>
           B.J.
          </given-names>
         </name>
         <name>
          <surname>
           Park
          </surname>
          <given-names>
           M.
          </given-names>
         </name>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           V.J.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P.
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           G.M.
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <volume>
         20
        </volume>
        <issue>
         25
        </issue>
        <year>
         2015
        </year>
        <fpage>
         7
        </fpage>
        <lpage>
         13
        </lpage>
        <pub-id pub-id-type="pmid">
         26132767
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0300">
       <label>
        60
       </label>
       <element-citation id="rf0300" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           J.
          </given-names>
         </name>
         <name>
          <surname>
           Yi
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zou
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Zhong
          </surname>
          <given-names>
           H.
          </given-names>
         </name>
         <name>
          <surname>
           Liang
          </surname>
          <given-names>
           L.
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           T.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Imported case of MERS-CoV infection identified in China, May 2015: detection and lesson learned
        </article-title>
        <source>
         Euro Surveill.
        </source>
        <volume>
         20
        </volume>
        <issue>
         24
        </issue>
        <year>
         2015
        </year>
        <comment>
         (pii: 21158)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0305">
       <label>
        61
       </label>
       <element-citation id="rf0305" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Korean Society of Infectious Diseases
          </surname>
         </name>
         <name>
          <surname>
           Korean Society for Healthcare-associated Infection Control and Prevention
          </surname>
         </name>
        </person-group>
        <article-title>
         The Same Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) yet Different Outbreak Patterns and Public Health Impacts on the Far East Expert Opinion from the Rapid Response Team of the Republic of Korea
        </article-title>
        <source>
         Infect. Chemother.
        </source>
        <volume>
         47
        </volume>
        <issue>
         4
        </issue>
        <year>
         2015
        </year>
        <fpage>
         247
        </fpage>
        <lpage>
         251
        </lpage>
        <pub-id pub-id-type="pmid">
         26788408
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0310">
       <label>
        62
       </label>
       <element-citation id="rf0310" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Al-Tawfiq
          </surname>
          <given-names>
           J.A.
          </given-names>
         </name>
         <name>
          <surname>
           Zumla
          </surname>
          <given-names>
           A.
          </given-names>
         </name>
         <name>
          <surname>
           Memish
          </surname>
          <given-names>
           Z.A.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Coronaviruses: severe acute respiratory syndrome coronavirus and Middle East respiratorysyndrome coronavirus in travelers
        </article-title>
        <source>
         Curr. Opin. Infect. Dis.
        </source>
        <volume>
         27
        </volume>
        <issue>
         5
        </issue>
        <year>
         2014
        </year>
        <fpage>
         411
        </fpage>
        <lpage>
         417
        </lpage>
        <pub-id pub-id-type="pmid">
         25033169
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0315">
       <label>
        63
       </label>
       <element-citation id="rf0315" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Roper
          </surname>
          <given-names>
           R.L.
          </given-names>
         </name>
         <name>
          <surname>
           Rehm
          </surname>
          <given-names>
           K.E.
          </given-names>
         </name>
        </person-group>
        <article-title>
         SARS vaccines: where are we?
        </article-title>
        <source>
         Expert Rev. Vaccines
        </source>
        <volume>
         8
        </volume>
        <issue>
         7
        </issue>
        <year>
         2009
        </year>
        <fpage>
         887
        </fpage>
        <lpage>
         898
        </lpage>
        <pub-id pub-id-type="pmid">
         19538115
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0320">
       <label>
        64
       </label>
       <element-citation id="rf0320" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Honda-Okubo
          </surname>
          <given-names>
           Y.
          </given-names>
         </name>
         <name>
          <surname>
           Barnard
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Ong
          </surname>
          <given-names>
           C.H.
          </given-names>
         </name>
         <name>
          <surname>
           Peng
          </surname>
          <given-names>
           B.H.
          </given-names>
         </name>
         <name>
          <surname>
           Tseng
          </surname>
          <given-names>
           C.T.
          </given-names>
         </name>
         <name>
          <surname>
           Petrovsky
          </surname>
          <given-names>
           N.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         89
        </volume>
        <issue>
         6
        </issue>
        <year>
         2015
        </year>
        <fpage>
         2995
        </fpage>
        <lpage>
         3007
        </lpage>
        <pub-id pub-id-type="pmid">
         25520500
        </pub-id>
       </element-citation>
      </ref>
      <ref id="bb0325">
       <label>
        65
       </label>
       <element-citation id="rf0325" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Wirblich
          </surname>
          <given-names>
           C.
          </given-names>
         </name>
         <name>
          <surname>
           Coleman
          </surname>
          <given-names>
           C.M.
          </given-names>
         </name>
         <name>
          <surname>
           Kurup
          </surname>
          <given-names>
           D.
          </given-names>
         </name>
         <name>
          <surname>
           Abraham
          </surname>
          <given-names>
           T.S.
          </given-names>
         </name>
         <name>
          <surname>
           Bernbaum
          </surname>
          <given-names>
           J.G.
          </given-names>
         </name>
         <name>
          <surname>
           Jahrling
          </surname>
          <given-names>
           P.B.
          </given-names>
         </name>
        </person-group>
        <article-title>
         One-health: a safe, efficient, dual-use vaccine for humans and animals against Middle East respiratory syndrome coronavirus and rabies virus
        </article-title>
        <source>
         J. Virol.
        </source>
        <volume>
         91
        </volume>
        <issue>
         2
        </issue>
        <year>
         2017 Jan 3
        </year>
        <comment>
         (pii: e02040-16)
        </comment>
       </element-citation>
      </ref>
      <ref id="bb0330">
       <label>
        66
       </label>
       <element-citation id="rf0330" publication-type="journal">
        <person-group person-group-type="author">
         <name>
          <surname>
           Simon
          </surname>
          <given-names>
           J.H.
          </given-names>
         </name>
         <name>
          <surname>
           Claassen
          </surname>
          <given-names>
           E.
          </given-names>
         </name>
         <name>
          <surname>
           Correa
          </surname>
          <given-names>
           C.E.
          </given-names>
         </name>
         <name>
          <surname>
           Osterhaus
          </surname>
          <given-names>
           A.D.
          </given-names>
         </name>
        </person-group>
        <article-title>
         Managing severe acute respiratory syndrome (SARS) intellectual property rights: the possible role of patent pooling
        </article-title>
        <source>
         Bull. World Health Organ.
        </source>
        <volume>
         83
        </volume>
        <issue>
         9
        </issue>
        <year>
         2005
        </year>
        <fpage>
         707
        </fpage>
        <lpage>
         710
        </lpage>
        <pub-id pub-id-type="pmid">
         16211163
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
     <ack id="ac0005">
      <title>
       Acknowledgements
      </title>
      <p>
       This review work was performed as part of the Zoonotic Anticipation and Preparedness Initiative (ZAPI project) [
       <funding-source id="gts0005">
        Innovative Medicines Initiative
       </funding-source>
       (IMI) grant 115760] with assistance and financial support from
       <funding-source id="gts0010">
        IMI
       </funding-source>
       and the
       <funding-source id="gts0015">
        European Commission
       </funding-source>
       and contributions from EFPIA partners. The funding from
       <funding-source id="gts0020">
        CERCA Programme/Generalitat de Catalunya
       </funding-source>
       to
       <funding-source id="gts0025">
        IRTA
       </funding-source>
       is also acknowledged.
      </p>
     </ack>
    </back>
   </article>
   <article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       J Virol
      </journal-id>
      <journal-id journal-id-type="hwp">
       jvi
      </journal-id>
      <journal-id journal-id-type="pmc">
       jvi
      </journal-id>
      <journal-id journal-id-type="publisher-id">
       JVI
      </journal-id>
      <journal-title-group>
       <journal-title>
        Journal of Virology
       </journal-title>
      </journal-title-group>
      <issn pub-type="ppub">
       0022-538X
      </issn>
      <issn pub-type="epub">
       1098-5514
      </issn>
      <publisher>
       <publisher-name>
        American Society for Microbiology
       </publisher-name>
       <publisher-loc>
        1752 N St., N.W., Washington, DC
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       21325420
      </article-id>
      <article-id pub-id-type="pmc">
       3126222
      </article-id>
      <article-id pub-id-type="publisher-id">
       2232-10
      </article-id>
      <article-id pub-id-type="doi">
       10.1128/JVI.02232-10
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Pathogenesis and Immunity
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune Response
        <xref ref-type="fn" rid="FN2">
         <sup>
          ▿
         </sup>
        </xref>
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="author">
        <name>
         <surname>
          Glowacka
         </surname>
         <given-names>
          Ilona
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Bertram
         </surname>
         <given-names>
          Stephanie
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="author-notes" rid="FN1">
         †
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Müller
         </surname>
         <given-names>
          Marcel A.
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Allen
         </surname>
         <given-names>
          Paul
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Soilleux
         </surname>
         <given-names>
          Elizabeth
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff3">
         <sup>
          3
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pfefferle
         </surname>
         <given-names>
          Susanne
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff4">
         <sup>
          4
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Steffen
         </surname>
         <given-names>
          Imke
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Tsegaye
         </surname>
         <given-names>
          Theodros Solomon
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          He
         </surname>
         <given-names>
          Yuxian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff5">
         <sup>
          5
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Gnirss
         </surname>
         <given-names>
          Kerstin
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Niemeyer
         </surname>
         <given-names>
          Daniela
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Schneider
         </surname>
         <given-names>
          Heike
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff6">
         <sup>
          6
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Drosten
         </surname>
         <given-names>
          Christian
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff2">
         <sup>
          2
         </sup>
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Pöhlmann
         </surname>
         <given-names>
          Stefan
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff1">
         <sup>
          1
         </sup>
        </xref>
        <xref ref-type="aff" rid="aff7">
         <sup>
          7
         </sup>
        </xref>
        <xref ref-type="corresp" rid="cor1">
         *
        </xref>
       </contrib>
       <aff id="aff1">
        <label>
         1
        </label>
        Institute of Virology, Hannover Medical School, 30625 Hannover, Germany
       </aff>
       <aff id="aff2">
        <label>
         2
        </label>
        Institute of Virology, University of Bonn Medical Centre, 53127 Bonn, Germany
       </aff>
       <aff id="aff3">
        <label>
         3
        </label>
        Department of Cellular Pathology, John Radcliffe Hospital, Oxford OX3 9DU, England
       </aff>
       <aff id="aff4">
        <label>
         4
        </label>
        Bernhard Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany
       </aff>
       <aff id="aff5">
        <label>
         5
        </label>
        Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 1007302, China
       </aff>
       <aff id="aff6">
        <label>
         6
        </label>
        Institute for Physiological Chemistry, Hannover Medical School, 30625 Hannover, Germany
       </aff>
       <aff id="aff7">
        <label>
         7
        </label>
        German Primate Center, Kellnerweg 4, 37077 Göttingen, Germany
       </aff>
      </contrib-group>
      <author-notes>
       <corresp id="cor1">
        <label>
         *
        </label>
        Corresponding author. Mailing address:
        <addr-line>
         Infection Biology Unit, German Primate Center, Kellnerweg 4, 37077 Göttingen, Germany
        </addr-line>
        . Phone:
        <phone>
         49 551 3851 150
        </phone>
        . Fax:
        <fax>
         49 551 3851 184
        </fax>
        . E-mail:
        <email>
         s.poehlmann@dpz.eu
        </email>
        .
       </corresp>
       <fn fn-type="equal" id="FN1">
        <label>
         †
        </label>
        <p>
         I.G. and S.B. contributed equally to this work.
        </p>
       </fn>
      </author-notes>
      <pub-date pub-type="ppub">
       <month>
        5
       </month>
       <year>
        2011
       </year>
      </pub-date>
      <volume>
       85
      </volume>
      <issue>
       9
      </issue>
      <fpage>
       4122
      </fpage>
      <lpage>
       4134
      </lpage>
      <history>
       <date date-type="received">
        <day>
         25
        </day>
        <month>
         10
        </month>
        <year>
         2010
        </year>
       </date>
       <date date-type="accepted">
        <day>
         27
        </day>
        <month>
         1
        </month>
        <year>
         2011
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2011, American Society for Microbiology
       </copyright-statement>
       <copyright-year>
        2011
       </copyright-year>
       <copyright-holder>
        American Society for Microbiology
       </copyright-holder>
      </permissions>
      <self-uri xlink:href="zjv00911004122.pdf" xlink:title="pdf" xlink:type="simple">
      </self-uri>
      <abstract>
       <p>
        The spike (S) protein of the severe acute respiratory syndrome coronavirus (SARS-CoV) can be proteolytically activated by cathepsins B and L upon viral uptake into target cell endosomes. In contrast, it is largely unknown whether host cell proteases located in the secretory pathway of infected cells and/or on the surface of target cells can cleave SARS S. We along with others could previously show that the type II transmembrane protease TMPRSS2 activates the influenza virus hemagglutinin and the human metapneumovirus F protein by cleavage. Here, we assessed whether SARS S is proteolytically processed by TMPRSS2. Western blot analysis revealed that SARS S was cleaved into several fragments upon coexpression of TMPRSS2 (
        <italic>
         cis
        </italic>
        -cleavage) and upon contact between SARS S-expressing cells and TMPRSS2-positive cells (
        <italic>
         trans
        </italic>
        -cleavage).
        <italic>
         cis
        </italic>
        -cleavage resulted in release of SARS S fragments into the cellular supernatant and in inhibition of antibody-mediated neutralization, most likely because SARS S fragments function as antibody decoys.
        <italic>
         trans
        </italic>
        -cleavage activated SARS S on effector cells for fusion with target cells and allowed efficient SARS S-driven viral entry into targets treated with a lysosomotropic agent or a cathepsin inhibitor. Finally, ACE2, the cellular receptor for SARS-CoV, and TMPRSS2 were found to be coexpressed by type II pneumocytes, which represent important viral target cells, suggesting that SARS S is cleaved by TMPRSS2 in the lung of SARS-CoV-infected individuals. In summary, we show that TMPRSS2 might promote viral spread and pathogenesis by diminishing viral recognition by neutralizing antibodies and by activating SARS S for cell-cell and virus-cell fusion.
       </p>
      </abstract>
     </article-meta>
    </front>
   </article>
   <article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
    <?properties open_access?>
    <front>
     <journal-meta>
      <journal-id journal-id-type="nlm-ta">
       Cureus
      </journal-id>
      <journal-id journal-id-type="iso-abbrev">
       Cureus
      </journal-id>
      <journal-id journal-id-type="issn">
       2168-8184
      </journal-id>
      <journal-title-group>
       <journal-title>
        Cureus
       </journal-title>
      </journal-title-group>
      <issn pub-type="epub">
       2168-8184
      </issn>
      <publisher>
       <publisher-name>
        Cureus
       </publisher-name>
       <publisher-loc>
        Palo Alto (CA)
       </publisher-loc>
      </publisher>
     </journal-meta>
     <article-meta>
      <article-id pub-id-type="pmid">
       32269893
      </article-id>
      <article-id pub-id-type="pmc">
       7138423
      </article-id>
      <article-id pub-id-type="doi">
       10.7759/cureus.7560
      </article-id>
      <article-categories>
       <subj-group subj-group-type="heading">
        <subject>
         Infectious Disease
        </subject>
       </subj-group>
       <subj-group>
        <subject>
         Other
        </subject>
       </subj-group>
       <subj-group>
        <subject>
         Epidemiology/Public Health
        </subject>
       </subj-group>
      </article-categories>
      <title-group>
       <article-title>
        A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19)
       </article-title>
      </title-group>
      <contrib-group>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Muacevic
         </surname>
         <given-names>
          Alexander
         </given-names>
        </name>
       </contrib>
       <contrib contrib-type="editor">
        <name>
         <surname>
          Adler
         </surname>
         <given-names>
          John R
         </given-names>
        </name>
       </contrib>
      </contrib-group>
      <contrib-group>
       <contrib contrib-type="author" corresp="yes">
        <name>
         <surname>
          Kakodkar
         </surname>
         <given-names>
          Pramath
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff-1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Kaka
         </surname>
         <given-names>
          Nagham
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff-1">
         1
        </xref>
       </contrib>
       <contrib contrib-type="author">
        <name>
         <surname>
          Baig
         </surname>
         <given-names>
          MN
         </given-names>
        </name>
        <xref ref-type="aff" rid="aff-2">
         2
        </xref>
       </contrib>
      </contrib-group>
      <aff id="aff-1">
       <label>
        1
       </label>
       Medicine, National University of Ireland Galway, Galway, IRL
      </aff>
      <aff id="aff-2">
       <label>
        2
       </label>
       Orthopaedics, University Hospital Galway, Galway, IRL
      </aff>
      <author-notes>
       <corresp id="cor1">
        Pramath Kakodkar
        <email>
         p.kakodkar1@nuigalway.ie
        </email>
       </corresp>
      </author-notes>
      <pub-date date-type="pub" publication-format="electronic">
       <day>
        6
       </day>
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <pub-date date-type="collection" publication-format="electronic">
       <month>
        4
       </month>
       <year>
        2020
       </year>
      </pub-date>
      <volume>
       12
      </volume>
      <issue>
       4
      </issue>
      <elocation-id>
       e7560
      </elocation-id>
      <history>
       <date date-type="received">
        <day>
         24
        </day>
        <month>
         3
        </month>
        <year>
         2020
        </year>
       </date>
       <date date-type="accepted">
        <day>
         6
        </day>
        <month>
         4
        </month>
        <year>
         2020
        </year>
       </date>
      </history>
      <permissions>
       <copyright-statement>
        Copyright © 2020, Kakodkar et al.
       </copyright-statement>
       <copyright-year>
        2020
       </copyright-year>
       <copyright-holder>
        Kakodkar et al.
       </copyright-holder>
       <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/">
        <license-p>
         This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
        </license-p>
       </license>
      </permissions>
      <self-uri xlink:href="https://www.cureus.com/articles/29670-a-comprehensive-literature-review-on-the-clinical-presentation-and-management-of-the-pandemic-coronavirus-disease-2019-covid-19">
       This article is available from https://www.cureus.com/articles/29670-a-comprehensive-literature-review-on-the-clinical-presentation-and-management-of-the-pandemic-coronavirus-disease-2019-covid-19
      </self-uri>
      <abstract>
       <p>
        Coronavirus disease 2019 (COVID-19) is a declared global pandemic. There are multiple parameters of the clinical course and management of the COVID-19 that need optimization. A hindrance to this development is the vast amount of misinformation present due to scarcely sourced manuscript preprints and social media. This literature review aims to presents accredited and the most current studies pertaining to the basic sciences of SARS-CoV-2, clinical presentation and disease course of COVID-19, public health interventions, and current epidemiological developments.
       </p>
       <p>
        The review on basic sciences aims to clarify the jargon in virology, describe the virion structure of SARS-CoV-2 and present pertinent details relevant to clinical practice. Another component discussed is the brief history on the series of experiments used to explore the origins and evolution of the phylogeny of the viral genome of SARS-CoV-2. Additionally, the clinical and epidemiological differences between COVID-19 and other infections causing outbreaks (SARS, MERS, H1N1) are elucidated.
       </p>
       <p>
        Emphasis is placed on evidence-based medicine to evaluate the frequency of presentation of various symptoms to create a stratification system of the most important epidemiological risk factors for COVID-19. These can be used to triage and expedite risk assessment. Furthermore, the limitations and statistical strength of the diagnostic tools currently in clinical practice are evaluated. Criteria on rapid screening, discharge from hospital and discontinuation of self-quarantine are clarified. Epidemiological factors influencing the rapid rate of spread of the SARS-CoV-2 virus are described. Accurate information pertinent to improving prevention strategies is also discussed.
       </p>
       <p>
        The penultimate portion of the review aims to explain the involvement of micronutrients such as vitamin C and vitamin D in COVID19 treatment and prophylaxis. Furthermore, the biochemistry of the major candidates for novel therapies is briefly reviewed and a summary of their current status in the clinical trials is presented. Lastly, the current scientific data and status of governing bodies such as the Center of Disease Control (CDC) and the WHO on the usage of controversial therapies such as angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) (Ibuprofen), and corticosteroids usage in COVID-19 are discussed.
       </p>
       <p>
        The composite collection of accredited studies on each of these subtopics of COVID-19 within this review will enable clarification and focus on the current status and direction in the planning of the management of this global pandemic.
       </p>
      </abstract>
      <kwd-group kwd-group-type="author">
       <kwd>
        covid-19
       </kwd>
       <kwd>
        sars-cov-2
       </kwd>
       <kwd>
        severe acute respiratory infection
       </kwd>
       <kwd>
        pandemic
       </kwd>
       <kwd>
        mrna-1273 vaccine
       </kwd>
       <kwd>
        remdesivir (gs-5734)
       </kwd>
       <kwd>
        chloroquine
       </kwd>
       <kwd>
        ards
       </kwd>
       <kwd>
        ace2
       </kwd>
       <kwd>
        lopinavir and ritonavir
       </kwd>
      </kwd-group>
     </article-meta>
     <notes>
      <p content-type="disclaimer">
       The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.
      </p>
     </notes>
    </front>
    <sec sec-type="intro">
     <title>
      Introduction and background
     </title>
     <p>
      History of the outbreak
     </p>
     <p>
      On 31st December 2019, Wuhan health commission in the Hubei province of the Republic of China notified the National Health Commission, China CDC and WHO of a cluster of 27 cases of pneumonia of unknown etiology [
      <xref ref-type="bibr" rid="REF1">
       1
      </xref>
      ]. These patients presented with a constellation of symptoms such as fever, dyspnea, dry cough, and radiological findings showed bilateral lung glassy opacities. Furthermore, the public health office traced all these 27 cases to Huanan Seafood Wholesale Market which trades live species of bats, snakes, pangolins, and badgers [
      <xref ref-type="bibr" rid="REF1">
       1
      </xref>
      ]. Multiple intrinsic variables led to rapid early transmission dynamics, and this made Wuhan the flashpoint of the pandemic. In 2018, Wuhan had a documented population of 11.08 million, this made Wuhan one of the top five most populated cities in China [
      <xref ref-type="bibr" rid="REF2">
       2
      </xref>
      ]. Wuhan’s large population density and proximity of the marketplace that sold live animals made it the epicenter for the human-animal interface. Additionally, the lack of early containment due to the inability to accurately trace the history of exposure in the early patient cases contributed to the rapid rate of spread in Wuhan. This eventually precipitated into the WHO declaring this viral pneumonia as an outbreak on 30th January 2020. On 11th March 2020, due to the global logarithmic expansion of the cases the coronavirus disease 2019 (COVID-19) was declared as a pandemic by the WHO.
     </p>
     <p>
      Virology
     </p>
     <p>
      On the 7th January 2020, the China CDC discovered the virus called novel coronavirus 2019 (2019-nCoV) which was colloquially noted as the “Wuhan Coronavirus”. The WHO renamed it to SARS-CoV-2 to destigmatize the association of the virus with any geographic location or nationality and relate it to the disease symptomatology. The SARS-CoV-2 virus is genetically similar to the SARS Coronavirus of 2002 (SARS-CoV-1). There are a myriad of other coronaviruses that cause the common cold. These coronaviruses can become infective when they attain an animal reservoir that provides an adequate cellular environment wherein the virus can multiply and acquire a series of advantageous genetic mutations. These mutations can then enable the virus to cross-species and infect and multiply within human hosts effectively.
     </p>
     <p>
      The virion structure and pathophysiology of infection
     </p>
     <p>
      SARS-CoV2 is from the beta Coronavirus family, it is a positive-sense, single-stranded RNA, enveloped virus that is 50-200 nm in diameter [
      <xref ref-type="bibr" rid="REF3">
       3
      </xref>
      ]. The genomic RNA is 30 Kb, one vital encoded structural protein is the Spike Glycoprotein (S) that consists of three S1-S2 heterodimers that bind to angiotensin-converting enzyme 2 (ACE2) receptor on type II pneumocyte [
      <xref ref-type="bibr" rid="REF3">
       3
      </xref>
      ,
      <xref ref-type="bibr" rid="REF4">
       4
      </xref>
      ]. The other surface protein such as the hemagglutinin-esterase (HE) dimer is shown in Figure
      <xref ref-type="fig" rid="FIG1">
       1
      </xref>
      . The entry of SARS-CoV-2 into the type II pneumocyte is via endocytosis and then multiplies in the cytoplasm. The high protein manufacturing stress induced upon the type II pneumocytes leads to apoptosis. Additionally, the RNA from the SARS-CoV-2 acts as a pathogen-associated molecular pattern (PAMP) and will be recognized by the pattern recognition receptor or toll-like receptors. This leads to a chemokine surge which causes neutrophil migration and activation. This leads to the destruction of the alveolar-capillary walls. At a microscopic level, this leads to a loss in the interface between the intra-alveolar space and the surrounding stroma. Therefore, fluid leaks through and fills into the alveolar sacs.
     </p>
     <fig fig-type="figure" id="FIG1" orientation="portrait" position="float">
      <label>
       Figure 1
      </label>
      <caption>
       <title>
        3-D model of the SARS-CoV-2 virion and a schematic diagram of its structural proteins and genome.
       </title>
       <p>
        Image component modified from CDC Public Health Image Library (ID 23312: Alissa Eckert and Dan Higgins)
       </p>
      </caption>
      <graphic xlink:href="cureus-0012-00000007560-i01">
      </graphic>
     </fig>
     <p>
      Origin of SARS-CoV-2
     </p>
     <p>
      The origin of the SARS-CoV-2 genome has been linked to bats akin to the SARS-CoV-1 and MERS-CoV viruses [
      <xref ref-type="bibr" rid="REF5">
       5
      </xref>
      ]. Interestingly, the SARS-CoV-2 whole-genome aligned with the genomes of viruses (Bat-CoV and Bat-CoV RaTG13) in Rhinolophus affinis species of Yunnan province with 96% similarity [
      <xref ref-type="bibr" rid="REF6">
       6
      </xref>
      ]. As seen previously in SARS-CoV-1 and MERS-CoV viruses that undertake residence in the intermediate hosts shown in Figure
      <xref ref-type="fig" rid="FIG2">
       2
      </xref>
      , it was suspected that in SARS-CoV-2 pangolins were the natural reservoir. This was based on the analysis of the genome contig alignment of SARS-CoV-2 like CoV (Renamed: Pangolin-CoV) harbored in the lung tissue of two dead Malayan pangolins [
      <xref ref-type="bibr" rid="REF7">
       7
      </xref>
      ]. This Pangolin-CoV’s whole genome had 91.02% similarity with SARS-CoV-2 and 90.55% similarity with Bat-CoV RaTG13 [
      <xref ref-type="bibr" rid="REF8">
       8
      </xref>
      ]. Proteomic analysis revealed that the S1 subunit of Spike glycoprotein (S) was more closely related to that of SARS-CoV-2 compared to BaT-CoV RaTG13. Furthermore, five amino acid residues of the S protein of SARS-CoV-2 interacting with the ACE2 receptor are identical in Pangolin-CoV [
      <xref ref-type="bibr" rid="REF8">
       8
      </xref>
      ]. Contrastingly, only four amino acid residues are identical in the S protein of BaT-CoV RaTG13. Interestingly, both Pangolin-CoV and BaT-CoV RaTG13 have lost the furin recognition motif, vital to the S1/S2 cleavage [
      <xref ref-type="bibr" rid="REF8">
       8
      </xref>
      ]. This putative furin recognition sequence is still intact within the SARS-CoV-2. A compilation of all these findings portrays that pangolins are the intermediate hosts for SARS-CoV-2.
     </p>
     <fig fig-type="figure" id="FIG2" orientation="portrait" position="float">
      <label>
       Figure 2
      </label>
      <caption>
       <title>
        Summary of the natural reservoir, intermediate host and target in major coronaviruses.
       </title>
      </caption>
      <graphic xlink:href="cureus-0012-00000007560-i02">
      </graphic>
     </fig>
     <p>
      Evolution of SARS-CoV-2
     </p>
     <p>
      The phylogenetic analysis by Tang et al. of 103 genomes with SARS-CoV-2 indicated that the two major lineages co-exist. These lineages are designated as L-type (T28,144 is in the codon of Leucine) and S-type (C28,144 is in the codon of Serine) and these are defined by the significant linkage (r2 = 0.954, and LOD = 50.13) of their SNPs at positions 8782 (orf1ab: T8517C, synonymous) and 28144 (ORF8: C251T, S84L) [
      <xref ref-type="bibr" rid="REF9">
       9
      </xref>
      ]. Furthermore, the S-type (28.7%, n = 29 out of 101) is indicated as the ancestral strain which attained a single-nucleotide polymorphism (SNP) that led to the formation of the L-type (71.9%, n = 72 out of 101). The resultant amino acids from the SNPs in the open reading frame (ORF8) have an undefined functional role in the SARS-CoV-2 life cycle and virulence. Therefore, Tang et al.’s initial labeling of the L-type as the aggressive lineage based on its higher frequency was misleading. This aggressive lineage label has now been removed in their current addendum and the L-type is only defined as having a higher frequency. It must be noted that the 30% and 70% frequencies of the S-type and L-type correspond to patients in Wuhan. Moreover, although the S-type is ancestral lineage it was surprising that the majority of the early cases in Wuhan were of the L-type lineage and globally the S-type is more prominent. One patient (USA_2020/01/21.a, GISAID ID: EPI_ISL_404253) in the USA tested positive for coinfection with S-type and L-type SARS-CoV-2, but it is unclear if this will cause any significant clinical severity due to the coinfection. It is also notable that there is no current evidence indicating that immunity against one of the lineages will provide cross-reactivity against the other lineage. This implies that a patient recovering from one COVID-19 lineage can sustain another separate COVID-19 infection from the other strain. Therefore, future vaccines must target a conserved region in both lineages. Alternatively, a separate vaccine for each lineage must be designed.
     </p>
     <p>
      Mode of transmission
     </p>
     <p>
      Modes of transmission traced in an imported case are through droplet transmission, fecal-oral route, conjunctiva and fomites [
      <xref ref-type="bibr" rid="REF10">
       10
      </xref>
      ,
      <xref ref-type="bibr" rid="REF11">
       11
      </xref>
      ]. Additionally, local transmission can be traced back to the patient’s bodily fluids such as respiratory droplets, saliva, feces, and urine [
      <xref ref-type="bibr" rid="REF11">
       11
      </xref>
      ]. The virion is stabilized at lower temperatures, i.e., 4°C has higher survival than 22°C [
      <xref ref-type="bibr" rid="REF12">
       12
      </xref>
      ,
      <xref ref-type="bibr" rid="REF13">
       13
      </xref>
      ]. As SARS-CoV-2 virions are shed throughout the clinical course, patients with COVID-19 can spread the infection prior to symptom presentation, during the symptomatic course and during the clinical recovery period. Additional considerations must be made regarding the residence time of the SARS-CoV-2 virion on surfaces. The half-life of SARS-CoV-2 in aerosols, copper, cardboard, stainless steel, and plastic are 1.5 h, 1 h, 3.4 h, 5.6 h, and 6.8 h, respectively. The viable residence time of SARS-CoV-1 in aerosols, copper, cardboard, stainless steel, and plastic are 3 h, 4 h, 24 h, 48 h, and 72 h, respectively [
      <xref ref-type="bibr" rid="REF14">
       14
      </xref>
      ].
     </p>
     <p>
      Differences between COVID-19, common cold, and flu
     </p>
     <p>
      Common cold is caused by a myriad of viruses. Majority of which are Rhinoviruses, and benign forms of coronaviruses. Common cold and COVID-19 both have a gradual course to symptom presentation in comparison to the flu which is caused by the various strains of Influenza (Orthomyxovirus family). Pyrexia is rare in the common cold but is the most notable symptom in both COVID-19 and flu [
      <xref ref-type="bibr" rid="REF15">
       15
      </xref>
      ]. Presentation of cough and fatigue is rare in the common cold. Coryzal symptoms such as rhinorrhea and nasal congestion are predominant in the common cold and are rare in flu and COVID-19.
     </p>
     <p>
      COVID-19 presents similar to Influenza flu as both these are diseases of the respiratory system. In both diseases, the clinical presentation can vary from asymptomatic to severe pneumonia. Furthermore, both COVID-19 and Influenza are transmitted by contact, droplets, and fomites. Therefore, similar hand hygiene techniques and respiratory etiquettes will be beneficial in preventing the spread. Another factor that influences the rate of spread of any infection is the Basic Reproduction Number (Rₒ). The influenza virus has an Rₒ of ~1.3 whereas the SARS-CoV-2 virus has an Rₒ of ~2.3. Therefore, each COVID-19 patient can spread 1.8-fold more new contacts compared to influenza patients.
     </p>
     <p>
      In comparison to SARS (caused by SARS-CoV-1 virus), some patients with COVID-19 (caused by SARS-CoV-2 virus) can be infectious during their incubation period even in their asymptomatic stage [
      <xref ref-type="bibr" rid="REF14">
       14
      </xref>
      ]. The time elapsed from the advent of exposure to a pathogen to clinical manifestation of the disease is termed as the incubation period. Table
      <xref ref-type="table" rid="TAB1">
       1
      </xref>
      shows the variance in the incubation periods of each coronavirus and common orthomyxovirus. The larger incubation for the manifestation of COVID along with the ability to transmit infection during this period explains how rapid the potential spread of SARS-CoV-2 can be.
     </p>
     <table-wrap id="TAB1" orientation="portrait" position="float">
      <label>
       Table 1
      </label>
      <caption>
       <title>
        Summary of incubation times of various coronaviruses and orthomyxovirus.
       </title>
      </caption>
      <table frame="hsides" rules="groups">
       <tbody>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          Virus Family
         </td>
         <td colspan="1" rowspan="1">
          Virus (Disease)
         </td>
         <td colspan="1" rowspan="1">
          Incubation Period
         </td>
         <td colspan="1" rowspan="1">
          References
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="3">
          Coronavirus
         </td>
         <td colspan="1" rowspan="1">
          SARS-CoV-2 (COVID-19)
         </td>
         <td colspan="1" rowspan="1">
          2-14 days
         </td>
         <td colspan="1" rowspan="1">
          [
          <xref ref-type="bibr" rid="REF16">
           16
          </xref>
          ]
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          SARS-CoV-1 (SARS)
         </td>
         <td colspan="1" rowspan="1">
          2-7 days
         </td>
         <td colspan="1" rowspan="1">
          [
          <xref ref-type="bibr" rid="REF17">
           17
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          MERS-CoV (MERS)
         </td>
         <td colspan="1" rowspan="1">
          5 days
         </td>
         <td colspan="1" rowspan="1">
          [
          <xref ref-type="bibr" rid="REF18">
           18
          </xref>
          ]
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="2">
          Orthomyxovirus
         </td>
         <td colspan="1" rowspan="1">
          H1N1 Influenza A (swine flu)
         </td>
         <td colspan="1" rowspan="1">
          1-4 days
         </td>
         <td colspan="1" rowspan="1">
          [
          <xref ref-type="bibr" rid="REF19">
           19
          </xref>
          ]
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Influenza A (Seasonal flu)
         </td>
         <td colspan="1" rowspan="1">
          2 days
         </td>
         <td colspan="1" rowspan="1">
          [
          <xref ref-type="bibr" rid="REF15">
           15
          </xref>
          ]
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
    </sec>
    <sec sec-type="review">
     <title>
      Review
     </title>
     <p>
      Clinical presentation of COVID-19
     </p>
     <p>
      The infection caused by the virus SARS-CoV-2 is termed as Coronavirus Disease 2019 (COVID-19). The symptomatology of COVID-19 was extensively discussed in WHO-China joint report on COVID-19 (n = 55,924) [
      <xref ref-type="bibr" rid="REF16">
       16
      </xref>
      ]. Patients with COVID-19 present with pyrexia in 85% of cases during their illness course, but only 45% are febrile on early presentation [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      ]. Moreover, cough is seen in 67.7% of patients and sputum is produced in 33.4%. Respiratory symptoms such as dyspnea, sore throat, and nasal congestion present in 18.6%, 13.9%, and 4.8% of cases, respectively [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      ]. Constitutional symptoms such as muscle or bone aches, chills, and headache are seen in 14.8%, 11.4% and 13.6% of the cases, respectively [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      ]. Gastrointestinal (GI) symptoms such as nausea or vomiting and diarrhea are seen in 5% and 3.7% of the cases, respectively. These clinical manifestations of COVID-19 were consistent in other similar studies on COVID-19 patients in China (n = 41, n = 81, n = 99, n = 138) [
      <xref ref-type="bibr" rid="REF21">
       21
      </xref>
      -
      <xref ref-type="bibr" rid="REF24">
       24
      </xref>
      ].
     </p>
     <p>
      More severe insult on the lung tissue can result in acute respiratory distress syndrome (ARDS) which can further precipitate septic shock. These two complications are the major contributors to intensive care unit (ICU) care and mortality from COVID-19 in patients older than 60 years, with smoking history, and comorbid medical conditions. Smoking and older age group patients tend to have a higher density of ACE2 receptors. A list of chronic medical conditions affecting the clinical course of COVID-19 is summarized in Table
      <xref ref-type="table" rid="TAB2">
       2
      </xref>
      . Our overall analysis (N = 1458) showed that the leading comorbid conditions include hypertension, cardiovascular and cerebrovascular disease, and diabetes.
     </p>
     <table-wrap id="TAB2" orientation="portrait" position="float">
      <label>
       Table 2
      </label>
      <caption>
       <title>
        Summary of co-morbidity history from COVID-19 patients in China.
       </title>
       <p>
        CAD: Coronary artery disease; CVA: Cerebrovascular accident; GI: Gastrointestinal; CNS: Central nervous system; COPD: Chronic obstructive pulmonary disease; CRF: Chronic renal failure.
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <tbody>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
          Guan et al. (N = 1099) [
          <xref ref-type="bibr" rid="REF20">
           20
          </xref>
          ]
         </td>
         <td colspan="1" rowspan="1">
          Wang et al. (N = 138) [
          <xref ref-type="bibr" rid="REF21">
           21
          </xref>
          ]
         </td>
         <td colspan="1" rowspan="1">
          Chen et al. (N = 99) [
          <xref ref-type="bibr" rid="REF22">
           22
          </xref>
          ]
         </td>
         <td colspan="1" rowspan="1">
          Shi et al. (N = 81) [
          <xref ref-type="bibr" rid="REF23">
           23
          </xref>
          ]
         </td>
         <td colspan="1" rowspan="1">
          Huang et al. (N = 41) [
          <xref ref-type="bibr" rid="REF24">
           24
          </xref>
          ]
         </td>
         <td colspan="1" rowspan="1">
          Analysis N = 1458
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Comorbidity
         </td>
         <td colspan="1" rowspan="1">
          23.7% (n = 261)
         </td>
         <td colspan="1" rowspan="1">
          46.4% (n = 64)
         </td>
         <td colspan="1" rowspan="1">
          51% (n = 50)
         </td>
         <td colspan="1" rowspan="1">
          26% (n = 21)
         </td>
         <td colspan="1" rowspan="1">
          32% (n = 13)
         </td>
         <td colspan="1" rowspan="1">
          28% (n = 409)
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          CAD and CVA
         </td>
         <td colspan="1" rowspan="1">
          3.9% (n = 42)
         </td>
         <td colspan="1" rowspan="1">
          19.6% (n = 27)
         </td>
         <td colspan="1" rowspan="1">
          40% (n = 40)
         </td>
         <td colspan="1" rowspan="1">
          17% (n = 14)
         </td>
         <td colspan="1" rowspan="1">
          15% (n = 6)
         </td>
         <td colspan="1" rowspan="1">
          31.5% (n = 129)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Hypertension
         </td>
         <td colspan="1" rowspan="1">
          15% (n = 165)
         </td>
         <td colspan="1" rowspan="1">
          31.2% (n = 43)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          15% (n = 12)
         </td>
         <td colspan="1" rowspan="1">
          15% (n = 6)
         </td>
         <td colspan="1" rowspan="1">
          55.3% (n = 226)
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          GI disease
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          11% (n = 11)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          2.7% (n = 11)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Diabetes
         </td>
         <td colspan="1" rowspan="1">
          7.4% (n = 81)
         </td>
         <td colspan="1" rowspan="1">
          10.1% (n = 14)
         </td>
         <td colspan="1" rowspan="1">
          12% (n = 12)
         </td>
         <td colspan="1" rowspan="1">
          12% (n = 10)
         </td>
         <td colspan="1" rowspan="1">
          20% (n = 8)
         </td>
         <td colspan="1" rowspan="1">
          30.6% (n = 125)
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          Malignancy
         </td>
         <td colspan="1" rowspan="1">
          0.9% (n = 10)
         </td>
         <td colspan="1" rowspan="1">
          7.2% (n = 10)
         </td>
         <td colspan="1" rowspan="1">
          1% (n = 1)
         </td>
         <td colspan="1" rowspan="1">
          5% (n = 4)
         </td>
         <td colspan="1" rowspan="1">
          2% (n = 1)
         </td>
         <td colspan="1" rowspan="1">
          6.4% (n = 26)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          CNS diseases
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          1% (n = 1)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          0.2% (n = 1)
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          COPD
         </td>
         <td colspan="1" rowspan="1">
          1.1% (n = 12)
         </td>
         <td colspan="1" rowspan="1">
          2.9% (n = 4)
         </td>
         <td colspan="1" rowspan="1">
          1% (n = 1)
         </td>
         <td colspan="1" rowspan="1">
          11% (n = 9)
         </td>
         <td colspan="1" rowspan="1">
          2% (n = 1)
         </td>
         <td colspan="1" rowspan="1">
          6.6% (n = 27)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          CRF
         </td>
         <td colspan="1" rowspan="1">
          0.7% (n = 8)
         </td>
         <td colspan="1" rowspan="1">
          2.9% (n = 4)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          4% (n = 3)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          3.7% (n = 15)
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          Immunodeficiency
         </td>
         <td colspan="1" rowspan="1">
          0.2% (n = 2)
         </td>
         <td colspan="1" rowspan="1">
          1.4% (n = 2)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          1% (n = 4)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Hepatitis/ Liver Cirrhosis
         </td>
         <td colspan="1" rowspan="1">
          21% (n = 23)
         </td>
         <td colspan="1" rowspan="1">
          2.9% (n = 4)
         </td>
         <td colspan="1" rowspan="1">
          -
         </td>
         <td colspan="1" rowspan="1">
          9% (n = 7)
         </td>
         <td colspan="1" rowspan="1">
          2% (n = 1)
         </td>
         <td colspan="1" rowspan="1">
          8.6% (n = 35)
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      In the largest study (n = 1099), the median age of the patients with COVID-19 is 47 years [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      ]. The presentation of COVID-19 is predominantly mild and asymptomatic in the age group &lt;14. There is no explanation for this phenomenon yet. Perhaps the ACE2 receptor is not highly expressed in this age group. A preliminary unpublished single-cell transcriptomics study suggested that Asian cell donors have higher ACE2 receptor density than Caucasian and African American donors. This variance in distribution could explain the higher susceptibility of the Asian population to the SARS-nCoV-2 virus.
     </p>
     <p>
      Clinical disease course of COVID-19
     </p>
     <p>
      The official incubation period for SARS-CoV-2 is 2-14 days and therefore 14 days is the chosen cut-off for self-quarantine. Guan et al. (n = 1324) estimated that the mean incubation period is three days [95% CI: 2 to 7 days] and that in 95% of all COVID-19 patients developed illness onset within 10 days [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      ]. Outlier cases have been found wherein the incubation period has been 19, 24, and 27 days.
     </p>
     <p>
      Wang et al. (n = 138) showed that the median time from preliminary symptoms to dyspnea, hospital admission and ARDS was 5, 7, and 8 days, respectively. The median hospital stay was 10 days in patients that were discharged [
      <xref ref-type="bibr" rid="REF21">
       21
      </xref>
      ].
     </p>
     <p>
      Figure
      <xref ref-type="fig" rid="FIG3">
       3
      </xref>
      shows a comprehensive summary of the clinical course of COVID-19 patients (n = 191) and this is stratified based on survivors and non-survivors [
      <xref ref-type="bibr" rid="REF25">
       25
      </xref>
      ]. Zhou et al. showed that the survivors group developed ARDS and sepsis on days 9 and 10, respectively. Conversely, the non-survivors group developed ARDS and sepsis later, on days 10 and 12, respectively. Furthermore, the non-survivors group developed more complications such as acute kidney injury (AKI) and secondary infection by days 15 and 17, respectively. Lastly, the survivor groups were discharged from the hospital by day 22 and the non-survivor groups died by day 19.
     </p>
     <fig fig-type="figure" id="FIG3" orientation="portrait" position="float">
      <label>
       Figure 3
      </label>
      <caption>
       <title>
        Summary of the clinical course of COVID-19 patients. The solid colors and cross-hatched patterns indicate the survivors (n = 137) and non-survivors (n = 54), respectively.
       </title>
      </caption>
      <graphic xlink:href="cureus-0012-00000007560-i03">
      </graphic>
     </fig>
     <p>
      Epidemiology
     </p>
     <p>
      As of March 21, there have been 304,900 cases of which 94,793 have recovered and 13,001 have died [
      <xref ref-type="bibr" rid="REF26">
       26
      </xref>
      ]. Therefore, the worldwide case fatality rate (CFR) within this time period is 12%. The current estimate of COVID-19 Rₒ is 2-2.5 [
      <xref ref-type="bibr" rid="REF16">
       16
      </xref>
      ,
      <xref ref-type="bibr" rid="REF27">
       27
      </xref>
      ]. This can be interpreted as every case of COVID-19 can spread to two to three new people. Table
      <xref ref-type="table" rid="TAB3">
       3
      </xref>
      shows a comparison between the epidemiological parameters of the major infectious outbreaks from 2000-2020 [
      <xref ref-type="bibr" rid="REF19">
       19
      </xref>
      ,
      <xref ref-type="bibr" rid="REF28">
       28
      </xref>
      ,
      <xref ref-type="bibr" rid="REF29">
       29
      </xref>
      ].
     </p>
     <table-wrap id="TAB3" orientation="portrait" position="float">
      <label>
       Table 3
      </label>
      <caption>
       <title>
        Summary of cases, mortality rate, and basic reproductive number of major outbreaks from 2000-2020.
       </title>
       <p>
        *Accurate as of March 22, 2020
       </p>
      </caption>
      <table frame="hsides" rules="groups">
       <tbody>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          Virus (Disease)
         </td>
         <td colspan="1" rowspan="1">
          Cases
         </td>
         <td colspan="1" rowspan="1">
          Mortality Rate
         </td>
         <td colspan="1" rowspan="1">
          Rₒ
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          SARS-CoV-2 (COVID-19)
         </td>
         <td colspan="1" rowspan="1">
          304,900*
         </td>
         <td colspan="1" rowspan="1">
          3.4% estimated from WHO on March 3, 2020
         </td>
         <td colspan="1" rowspan="1">
          2-2.5
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          SARS-CoV-1 (SARS 2020)
         </td>
         <td colspan="1" rowspan="1">
          8,098
         </td>
         <td colspan="1" rowspan="1">
          9.6%
         </td>
         <td colspan="1" rowspan="1">
          2-5
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          MERS-CoV (MERS 2012)
         </td>
         <td colspan="1" rowspan="1">
          2,494
         </td>
         <td colspan="1" rowspan="1">
          34%
         </td>
         <td colspan="1" rowspan="1">
          0.3-0.8
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          H1N1 Influenza A (Swine flu 2009)
         </td>
         <td colspan="1" rowspan="1">
          60.8 million
         </td>
         <td colspan="1" rowspan="1">
          0.02%
         </td>
         <td colspan="1" rowspan="1">
          1.4-1.6
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      As shown in Figure
      <xref ref-type="fig" rid="FIG4">
       4
      </xref>
      , a total of 188 countries and territories along with the Diamond Princess cruise ship (currently harbored in Japan) have been affected [
      <xref ref-type="bibr" rid="REF26">
       26
      </xref>
      ,
      <xref ref-type="bibr" rid="REF30">
       30
      </xref>
      ]. The major cluster of active cases has been in the USA, Italy, Spain, Germany, and France.
     </p>
     <fig fig-type="figure" id="FIG4" orientation="portrait" position="float">
      <label>
       Figure 4
      </label>
      <caption>
       <title>
        Illustration of the geographical spread of active COVID-19.
       </title>
       <p>
        This data is accurate as of 22nd March 2020. The image is modified from the source [
        <xref ref-type="bibr" rid="REF30">
         30
        </xref>
        ].
       </p>
      </caption>
      <graphic xlink:href="cureus-0012-00000007560-i04">
      </graphic>
     </fig>
     <p>
      Countries with the highest mortality rates are Italy, Spain, Iran, France, and the USA [
      <xref ref-type="bibr" rid="REF30">
       30
      </xref>
      ]. Mortality rate increases in the 60 years and above cohort to 8.8% in comparison to 0.46% for patients under 60 years old [
      <xref ref-type="bibr" rid="REF16">
       16
      </xref>
      ]. The mortality rate has a predilection for the male gender (M:F = 1.7:1). Furthermore, the mortality rate also increases in patients with additional comorbidities. The cardiovascular, diabetes and hypertension leading the cohort with mortality rates of 13.2%, 9.2%, and 8.4%, respectively [
      <xref ref-type="bibr" rid="REF31">
       31
      </xref>
      ].
     </p>
     <p>
      Screening tool
     </p>
     <p>
      There are two prominent screening tools, one developed by the CDC and the other by the WHO. Both criteria charts have evolved over the progression of the outbreak. Table
      <xref ref-type="table" rid="TAB4">
       4
      </xref>
      is the most updated COVID-19 screening tool developed by the CDC [
      <xref ref-type="bibr" rid="REF32">
       32
      </xref>
      ].
     </p>
     <table-wrap id="TAB4" orientation="portrait" position="float">
      <label>
       Table 4
      </label>
      <caption>
       <title>
        Summary of CDC COVID-19 screening criteria.
       </title>
      </caption>
      <table frame="hsides" rules="groups">
       <tbody>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          Clinical Features
         </td>
         <td colspan="1" rowspan="1">
         </td>
         <td colspan="1" rowspan="1">
          Epidemiologic Risk (within 14 days of symptom onset)
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Pyrexia OR Respiratory symptoms (cough, dyspnea, sore throat, and nasal congestion)
         </td>
         <td colspan="1" rowspan="1">
          AND
         </td>
         <td colspan="1" rowspan="1">
          Close contact with RT-PCR confirmed COVID-19 patient
         </td>
        </tr>
        <tr style="background-color:#ccc">
         <td colspan="1" rowspan="1">
          Pyrexia AND Respiratory symptoms (cough, dyspnea, sore throat, and nasal congestion) requiring hospitalization
         </td>
         <td colspan="1" rowspan="1">
          AND
         </td>
         <td colspan="1" rowspan="1">
          History of travel to CDC flagged areas
         </td>
        </tr>
        <tr>
         <td colspan="1" rowspan="1">
          Pyrexia AND Severe Respiratory illness (pneumonia, ARDS) requiring hospitalization AND without any alternative diagnosis
         </td>
         <td colspan="1" rowspan="1">
          AND
         </td>
         <td colspan="1" rowspan="1">
          No discernment of exposure history
         </td>
        </tr>
       </tbody>
      </table>
     </table-wrap>
     <p>
      Diagnostic tools
     </p>
     <p>
      On 12th January 2020, the China CDC shared the genetic sequence of the SARS-CoV-2. This enabled countries to develop primers against the SARS-CoV-2 genome and utilize reverse transcriptase polymerase chain reaction (RT-PCR) assays to make a diagnosis of COVID-19. Therefore, RT-PCR has become the gold standard for the diagnosis of COVID-19, but it is only 66-80% sensitive [
      <xref ref-type="bibr" rid="REF33">
       33
      </xref>
      ]. Essentially, this means that 20-34% of patients with COVID-19 out of 100 would test negative despite being infected. This variance in the sensitivity can be attributed to the patients being tested early in the disease course wherein the viral load is beneath detection level or due to lack of automation in sample preparation for RT-PCR. Furthermore, a single negative RT-PCR does not rule out COVID-19, hence a repeat RT-PCR must be performed. The concern rises regarding the timeframe of the repeat RT-PCR, the ideal window lies between 24 to 72 hours of the negative test.
     </p>
     <p>
      The largest study (n = 1014) showed that CT-chest had a 95% sensitivity in making an early diagnosis of COVID-19 through the identification of ground-glass opacities [
      <xref ref-type="bibr" rid="REF33">
       33
      </xref>
      ]. This can be interpreted as five out of 100 tested will be falsely ruled out. This finding was also consistent in a case series of 51 COVID-19 patients wherein the sensitivity of CT was 98% and RT-PCR was 71% (p &lt; 0.001) for patients investigated with imaging and assay within three days of admission [
      <xref ref-type="bibr" rid="REF33">
       33
      </xref>
      ]. The utilization of the CT scan would prevent an infected patient from being discharged back to the community. The cons of increased CT usage are the huge economic burden on the healthcare resources and the potential to contaminate the CT scanners. In the management algorithm, CT radiology can be used to stratify patients into those that require further investigation and isolation. Utilization of radiology can be directive for management plans in hospitals with ease of accessibility to CT radiology and lack of access to laboratory services or in countries that utilize a centralized laboratory service with large turnaround time.
     </p>
     <p>
      Contrastingly, chest X-rays have poor sensitivity, but if there are ground-glass opacities then the patient must be isolated. The pathophysiology of this radiological finding is that the SARS-CoV-2 virus induces an inflammatory response in the alveolar sacs leading to the accumulation of exudative fluid. In the severe progression of the disease, this moves to the lobes and the radiological finding is a solid white consolidation.
     </p>
     <p>
      Laboratory examination
     </p>
     <p>
      Standard blood investigations revealed that most patients with COVID-19 have normal or decreased leucocytes, and lymphocytopenia. Furthermore, there is a systemic elevation of the pyrogenic cytokines such as IL-6, IL-10, and TNF-α [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      -
      <xref ref-type="bibr" rid="REF24">
       24
      </xref>
      ]. In critical COVID-19 patients, neutrophilia, elevated D-dimer, increase in plasma blood urea nitrogen (BUN) and creatinine are also documented [
      <xref ref-type="bibr" rid="REF20">
       20
      </xref>
      -
      <xref ref-type="bibr" rid="REF24">
       24
      </xref>
      ,
      <xref ref-type="bibr" rid="REF33">
       33
      </xref>
      ]. Patients admitted to the ICU will also have elevated plasma levels of the interleukins (IL-2, IL-7, and IL-10), and other chemokines such as Granulocyte Colony Stimulating Factor, 10 kD Interferon-gamma-induced-protein-10, Monocyte Chemoattractant Protein-1, and Macrophage Inflammatory Protein 1-α [
      <xref ref-type="bibr" rid="REF24">
       24
      </xref>
      ].
     </p>
     <p>
      Management
     </p>
     <p>
      The management of viral pneumonia is predominantly supportive amidst the absence of validated antiviral drugs. The most primary symptoms managed in COVID-19 are fever and non-productive cough, therefore the first-line antipyretic agent is Paracetamol and antitussive of choice is guaifenesin [
      <xref ref-type="bibr" rid="REF21">
       21
      </xref>
      ]. Supplementary oxygen at 5 L/min must be administered for patients that require management of severe respiratory distress and the oxygen saturation (SaO2) target must be ≥92-95% in pregnant patients and ≥90% in all other patients [
      <xref ref-type="bibr" rid="REF34">
       34
      </xref>
      ]. Complications such as septic shock and AKI should be managed with sepsis protocol and renal replacement therapy (RRT) respectively. Renal function tests and fluid balance measurements will enable the identification of patients indicated for RRT [
      <xref ref-type="bibr" rid="REF21">
       21
      </xref>
      ]. Some patients may develop superimposed bacterial or fungal infection in the middle to later course of COVID-19, as such appropriate empiric antimicrobial coverage must be provided. The latest version (6th edition) of the Guidelines for the Prevention, Diagnosis, and Treatment of COVID-19 by the National Health Commission (NHC) of China has recommended a combination regimen of protease inhibitors (lopinavir and ritonavir) with INF-α. The rationale for this combination treatment is based on experience with this regimen in reducing the mortality rates in SARS. The WHO recommends usage of extracorporeal membrane oxygenation (ECMO) in patients that sustain hypoxia refractory to supplementary oxygen [
      <xref ref-type="bibr" rid="REF31">
       31
      </xref>
      ]. Alternatively, convalescent plasma and IgG are used as rescue therapy in critical cases but there is no robust evidence for this practice.
     </p>
     <p>
      In the majority of the cases, public health measures are vital for the management of the spread of COVID-19. If public health measures for containment are not adequate, then there will be a patient burden that supersedes the capacity of available ICU beds and mechanical ventilation, as seen in the crisis taking place in Italy. Therefore, the entire objective of the COVID-19 management rests on the premise of social distancing to suppress the rapid emergence influx of new cases in a short time frame. This epidemiological concept is referred to as the “flattening of the curve”. The mainstay of public health must be to identify the infective cases, isolate these cases, attain contact tracing and isolate contacts that present with symptoms.
     </p>
     <p>
      Discharge criteria and quarantine discontinuation
     </p>
     <p>
      Four major discharge criteria exist, and these are from Italy (Ministero della salute, Consiglio Superiore di Sanità), China (China CDC), USA (CDC), and Singapore (National Centre for Infectious Diseases). These models differ only in their cutoffs.
     </p>
     <p>
      The China CDC discharge criteria state that all four conditions must be met to satisfy a discharge from the hospital [
      <xref ref-type="bibr" rid="REF35">
       35
      </xref>
      ].
     </p>
     <p>
      1. A patient must remain apyrexic for at least three consecutive days.
     </p>
     <p>
      2. All respiratory symptoms (cough, dyspnea, sore throat, and nasal congestion) must be resolved.
     </p>
     <p>
      3. Chest CT must demonstrate marked resolution of the exudative lesion.
     </p>
     <p>
      4. Two serial RT-PCRs must be negative for SARS-CoV-2 RNA from the nasopharyngeal collection, these assays must be spaced by 24 hours.
     </p>
     <p>
      Quarantine discontinuation criteria
     </p>
     <p>
      Two separate quarantine discontinuation criteria for COVID patients in self-quarantined at home have been developed by Italy (Ministero della salute, Consiglio Superiore di Sanità) and USA (CDC).
     </p>
     <p>
      The CDC quarantine discontinuation criteria state that both conditions must be met to satisfy the criteria [
      <xref ref-type="bibr" rid="REF35">
       35
      </xref>
      ].
     </p>
     <p>
      1. At least two serial RT-PCRs must be negative for SARS-CoV-2 RNA. These swabs must be nasopharyngeal collections, these assays must be spaced by 24 hours.
     </p>
     <p>
      2. The patient must remain apyrexic for at least 72 hrs without antipyretic medication use, and resolution of respiratory signs and symptoms. A minimum of seven days have passed since the preliminary symptom appeared.
     </p>
     <p>
      Prevention strategies
     </p>
     <p>
      Self-Protection
     </p>
     <p>
      Hand washing for at least 20 seconds after visiting public spaces. Soap or hand sanitizer with at least 60% of ethanol is recommended [
      <xref ref-type="bibr" rid="REF36">
       36
      </xref>
      ]. It is also recommended to avoid touching the denoted facial T-zone (eyes, nose, mouth) as this is the access point for virions into the upper respiratory tract [
      <xref ref-type="bibr" rid="REF36">
       36
      </xref>
      ]. Avoiding contact with people who are already presenting with symptoms, as well as avoiding gathering or crowded places. Travel to outbreak areas must be prohibited. A healthy individual must maintain at least six feet distance from individuals presenting with symptoms [
      <xref ref-type="bibr" rid="REF36">
       36
      </xref>
      ]. The sterilization of frequently handled surfaces is beneficial.
     </p>
     <p>
      All healthcare workers managing COVID-19 patients require full personal protective equipment (PPE) containing surgical masks, double gloves, full-sleeved procedural gowns, and eye shield [
      <xref ref-type="bibr" rid="REF36">
       36
      </xref>
      ]. The N95 masks which prevent 95% of the droplets from entering the mask must be exclusively dawned prior to performing procedures associated with a higher risk for aerosol exposure such as tracheostomy, tracheal intubation, bronchoscopy, cardiopulmonary resuscitation (CPR), and noninvasive ventilation (NIV) [
      <xref ref-type="bibr" rid="REF36">
       36
      </xref>
      ]. These procedures have the potential to aerosolize the virus.
     </p>
     <p>
      Containment of community transmissions is achieved by the closure of educational institutions, businesses, airspace, and sports events. High-risk individuals such as those older than 65 or having chronic comorbidities without any symptoms are also required to self-quarantine to decrease the likelihood of COVID-19 contraction [
      <xref ref-type="bibr" rid="REF36">
       36
      </xref>
      ].
     </p>
     <p>
      Herd Protection
     </p>
     <p>
      On the development of any symptoms, the potential patient should remain quarantined in self-isolation away in a separate room with a separate bathroom for at least 14 days. This self-isolation must be extended to pets as well, as there is a recorded case of a human-to-dog transmission [
      <xref ref-type="bibr" rid="REF31">
       31
      </xref>
      ]. If there are any further concerns about COVID-19, then immediate contact with the public health hotline or general practice clinic via telemedicine must be established to attain a potential diagnosis. Face masks (N95) are needed for COVID-19 patients to prevent droplet spread [
      <xref ref-type="bibr" rid="REF31">
       31
      </xref>
      ].
     </p>
     <p>
      Role of vitamins
     </p>
     <p>
      Vitamin C
     </p>
     <p>
      Vitamin C (L-ascorbic acid) has a pleiotropic physiological role, but there is evidence supporting the protective effect of high dose intravenous vitamin C (HDIVC) during sepsis-induced ARDS. Vitamin C reinforces the maintenance of the alveolar epithelial barrier and transcriptionally upregulates the protein channels (CFTR, aquaporin-5, ENaC, and Na+/K+ ATPase) regulating the alveolar fluid clearance [
      <xref ref-type="bibr" rid="REF37">
       37
      </xref>
      ]. HDIVC has been implicated in reducing plasma cell-free DNA formed from the neutrophil extracellular trap (NET) which is the facilitator of systemic inflammation in sepsis-induced multi-organ failure [
      <xref ref-type="bibr" rid="REF38">
       38
      </xref>
      ,
      <xref ref-type="bibr" rid="REF39">
       39
      </xref>
      ]. Interestingly, elevated levels of syndecan-1 in the plasma correlate with increased mortality in severe sepsis and ARDS, and this endothelial glycocalyx can be reduced significantly by HDIVC [
      <xref ref-type="bibr" rid="REF39">
       39
      </xref>
      ]. As of 14 February 2020, there is a randomized controlled trial (RCT) undertaken at the Zhongnan Hospital (NCT04264533) that aims to evaluate the clinical efficacy and safety of vitamin C in viral pneumonia from SARS-CoV-2. They hypothesize that vitamin C infusion can improve the prognosis of severe acute respiratory tract infections. The treatment arm includes a 12 g vitamin C infusion (q12h) for seven days and the primary outcome measures the ventilation-free days. The estimated completion time is September 2020.
     </p>
     <p>
      Vitamin D
     </p>
     <p>
      Vitamin D is known to mitigate the scope of acquired immunity and regenerate endothelial lining. This may be beneficial in minimizing the alveolar damage caused in ARDS. Level I evidence (N = 11,321) showed that there is a 12% overall protective effect of vitamin D supplementation against bacterial and viral acute respiratory tract infection (adjusted OD = 0.88, p &lt; 0.001) [
      <xref ref-type="bibr" rid="REF40">
       40
      </xref>
      ]. These protective effects increased to 19% in those individuals on the daily or weekly regimen of vitamin D compared to those dosing on a monthly bolus of vitamin D (adjusted OD = 0.81, p &lt; 0.001). Furthermore, there is a 70% protective effect when vitamin D deficiency is corrected with supplementation (adjusted OD = 0.30, p = 0.006) [
      <xref ref-type="bibr" rid="REF40">
       40
      </xref>
      ]. This result is pertinent to the majority of individuals residing in the northern latitudes that experience vitamin D deficiency (serum 25-hydroxyVitamin D &lt;25 nmol/L) due to extended periods of lack of sunlight.
     </p>
     <p>
      Vaccination
     </p>
     <p>
      Unfortunately, there is no approved vaccine against COVID-19 as of March 2020. One of the leading candidates is the mRNA-1273 vaccine manufactured by ModernaTx Inc (Cambridge, MA, USA). The mRNA-1273 is encapsulated within a lipid nanoparticle and encodes for a full-length, prefusion stabilized spike glycoprotein (S) of the SARS-CoV-2 virus. This vaccine is currently in Phase I, Open-Label, Dose-Ranging, clinical trial (NCT04283461) to evaluate the safety profile, reactogenicity, and immunogenicity in healthy subjects. The estimated completion time is June 2021.
     </p>
     <p>
      Novel therapeutics
     </p>
     <p>
      Currently, multiple avenues for therapies are being explored. Summarized below are some of the more prominent candidates.
     </p>
     <p>
      Remdesivir
     </p>
     <p>
      Remdesivir (GS-5734) is a nucleoside inhibitor that is the strongest candidate from COVID-19 treatment. Remdesivir is a monophosphoramide prodrug that causes premature termination of viral RNA replication and was originally developed against Ebola, MERS-CoV, and SARS-CoV. Furthermore, an in vitro study on human cell line (human liver cancer Huh-7 cells) showed potent interference of remdesivir with the NSP12 polymerase of SARS-CoV-2 despite intact ExoN proofreading activity [
      <xref ref-type="bibr" rid="REF41">
       41
      </xref>
      ]. There are eight clinical trials currently underway in China (NCT04252664, NCT04257656), France (NCT04314817, NCT04315948) and the USA (NCT04315948, NCT04292730, NCT04280705, NCT04302766). The suggested dosing is for a 10-day course, IV 200 mg for the first day and then IV 100 mg for nine following days.
     </p>
     <p>
      Lopinavir and Ritonavir
     </p>
     <p>
      The protease inhibitors lopinavir and ritonavir combination is usually a part of the HAART regimen to treat HIV. The lopinavir and ritonavir combination has also been shown to be effective against SARS in vitro [
      <xref ref-type="bibr" rid="REF42">
       42
      </xref>
      ]. The current Chinese guidelines for COVID-19 treatment include a PO 50 mg-200 mg dose BID for a duration of 10 days [
      <xref ref-type="bibr" rid="REF43">
       43
      </xref>
      ]. The lopinavir and ritonavir are used as a regimen single-agent or combination with either ribavirin or interferon-α. Currently, an RCT (Chinese Clinical Trial Register number: ChiCTR 2000029308) with 199 patients in Wuhan aims to evaluate the safety and efficacy of lopinavir and ritonavir regimen in severe COVID-19 patients. This was a two-arm study comparing lopinavir-ritonavir (n = 99) to standard care (n = 100). There was a statistically significant difference in the time to clinical improvement between the two groups on day 14 but this result was not statistically significant on day 28. The mortality at 28 days reduced by 5.8% and the length of stay in the ICU reduced by five days with the lopinavir-ritonavir treatment [
      <xref ref-type="bibr" rid="REF44">
       44
      </xref>
      ]. There are 12 clinical trials currently underway in South Korea (NCT04307693), Thailand (NCT04303299), and China (NCT04286503, NCT04255017, NCT04261907, NCT04261907, NCT04295551, NCT04315948, NCT04275388, NCT04251871, NCT04276688, NCT04291729, NCT04306497).
     </p>
     <p>
      Umifenovir
     </p>
     <p>
      Umifenovir is a non-nucleoside broad-spectrum antiviral licensed for influenza treatment and prophylaxis in Russia and China. It has not received FDA approval yet. Umifenovir is a membrane fusion inhibitor. Current regimens of Umifenovir used in China include a PO dose of 200 mg TDS for a duration of 10 days [
      <xref ref-type="bibr" rid="REF43">
       43
      </xref>
      ]. One large Chinese RCT (GDCT0379047) aims to evaluate the safety and efficacy of combination treatment of Umifenovir with immunostimulatory recombinant cytokine gene-derived protein. Another Chinese RCT (NCT04246242) aims to evaluate the safety and efficacy of single-agent treatment of Umifenovir.
     </p>
     <p>
      Chloroquine
     </p>
     <p>
      Chloroquine is an anti-malarial medication. In viruses, chloroquine can inhibit pH-dependent stages of replication. Furthermore, chloroquine’s immunomodulation is dependent on the suppression of cytokines (IL-6 and TNF-α) production and dissemination. Moreover, experiments with monkey cell line (Vero E6) showed that chloroquine interferes with the receptor glycosylation and thereby affects the entry mechanism of SARS-CoV-2. This treatment was especially successful in the in vitro experiments with SARS-CoV-2 infection of a human cell line (human liver cancer Huh-7 cells) [
      <xref ref-type="bibr" rid="REF41">
       41
      </xref>
      ]. Interestingly, pharmacological modeling utilizing dosing from another in vitro study showed that hydroxychloroquine has a higher potency than chloroquine at inhibiting the SARS-CoV-2 infection. The suggested dosing from this study was PO hydroxychloroquine 400 mg BID for the first day and then 200 mg BID for the following four days [
      <xref ref-type="bibr" rid="REF45">
       45
      </xref>
      ].
     </p>
     <p>
      Secondary COVID-19 rates can be minimized with pre-exposure prophylaxis and post-exposure prophylaxis in an individual with document exposure to SARS-CoV-2. Therefore, hydroxychloroquine has been hypothesized to be an adequate chemoprophylaxis candidate to reduce secondary COVID-19. There are six clinical trials currently underway in Mexico (NCT04315896), South Korea (NCT04307693), China (NCT04261517, NCT04307693), Spain (NCT04304053), Norway (NCT04316377), and USA (NCT04308668). The first Chinese study (NCT04261517) has shown positive outcomes in its preliminary data. Although the sample size is small (n = 30), this is still promising. The current Chinese guidelines recommend dosing of chloroquine as PO 300 mg or 500 mg (Chloroquine phosphate) BID for a duration of 10 days [
      <xref ref-type="bibr" rid="REF43">
       43
      </xref>
      ].
     </p>
     <p>
      ACE Inhibitor (ACEi) and Angiotensin Receptor-1 Blocker (ARBs)
     </p>
     <p>
      SARS-CoV-2 enters the type II pneumocytes via the ACE2 receptor, and this is also a functional receptor. The functional role of the ACE2 receptor has a reciprocal physiological action to ACE1, it converts the angiotensin II back into angiotensin I. Therefore, patients taking ARBs will have an increased plasma level of angiotensin II. Contrastingly, patients taking ACEi will have low levels of angiotensin II. There is an upregulation of ACE2 receptors in the kidney and heart in response to ACEi or ARB dosing in rats and humans [
      <xref ref-type="bibr" rid="REF46">
       46
      </xref>
      -
      <xref ref-type="bibr" rid="REF48">
       48
      </xref>
      ]. There is no data available on its effect in the alveolar tissue. If there is a similar upregulation of ACE2 receptors then there will be heightened infectivity of SARS-CoV-2 along with subsequent clinical illness severity. Discontinuation of ACEi or ARBs is not recommended yet as hypertension is an acute risk of discontinuation and can exacerbate the clinical course and increase mortality of COVID-19 if infected by SARS-CoV-2. This view of not discontinuing ACEi and ARBs has been supported by the council on hypertension from the European Society of Cardiology.
     </p>
     <p>
      Antipyretics
     </p>
     <p>
      Ibuprofen has shown to upregulate ACE2 receptors [
      <xref ref-type="bibr" rid="REF49">
       49
      </xref>
      ]. There is no current evidence indicating that ibuprofen worsens the clinical course of COVID-1. The current standpoint of the WHO is to continue the use of ibuprofen as antipyretic agent. The first-line antipyretic remains to be acetaminophen.
     </p>
     <p>
      Systemic Corticosteroids
     </p>
     <p>
      The use of systemic corticosteroids such as glucocorticoid in the management of ARDS secondary to viral pneumonia is controversial. The rationale behind this approach is that the corticosteroids prolong the viral shedding time and maintain a systemic anti-inflammatory state that will minimize the precipitation of ARDS, dyspnea, and severe pneumonia. The WHO states that the use of corticosteroid is not recommended outside of clinical trials (NCT04273321) or otherwise indicated [
      <xref ref-type="bibr" rid="REF31">
       31
      </xref>
      ]. Moreover, the MERS patients that received systemic corticosteroids had a higher likelihood of receiving invasive mechanical ventilation and a raised mortality rate at day 90 [
      <xref ref-type="bibr" rid="REF50">
       50
      </xref>
      ].
     </p>
    </sec>
    <sec sec-type="conclusions">
     <title>
      Conclusions
     </title>
     <p>
      This COVID-19 pandemic is a reminder of the volatility in the ongoing planning to manage the primary and secondary infection of SARS-CoV-2. This planning can be improved by accurate modeling of current data and by eliminating the misinformation in our era of data surplus. Additional variables that can strengthen countermeasure to this pandemic are rapidly updating surveillance data, availability of robust accredited information, and a multidisciplinary approach that bridges the gap in knowledge between basic sciences and clinical sciences.
     </p>
     <p>
      This literature review comprehensively summarizes the most relevant study relating to the individual parameters that influence the clinical course and management of COVID-19. Due to the lack of available and validated therapeutics, most of the countermeasures rely on the usage of public health containment and quarantine approaches. Primary learning points from this COVID-19 pandemic are to upheld transparency to prevent delays in threat identification. Secondly, delays in travel restriction and self-quarantine measures led to a logarithmic expansion of cases. Lastly, there is a need to increase investments towards research and development in COVID-19.
     </p>
    </sec>
    <back>
     <fn-group content-type="competing-interests">
      <fn fn-type="COI-statement">
       <p>
        The authors have declared that no competing interests exist.
       </p>
      </fn>
     </fn-group>
     <ack>
      <p>
       This paper is dedicated to Dr. Li Wenliang (died: February 7, 2020) and his team that was the first to courageously alert the authorities of a SARS-like outbreak in Wuhan.
      </p>
     </ack>
     <ref-list>
      <title>
       References
      </title>
      <ref id="REF1">
       <label>
        1
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle
        </article-title>
        <source>
         J Med Virol
        </source>
        <person-group>
         <name>
          <surname>
           Lu
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Stratton
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <fpage>
         401
        </fpage>
        <lpage>
         402
        </lpage>
        <volume>
         92
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         31950516
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF2">
       <label>
        2
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
        </article-title>
        <source>
         N Engl J Med
        </source>
        <person-group>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         1199
        </fpage>
        <lpage>
         1207
        </lpage>
        <volume>
         382
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         31995857
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF3">
       <label>
        3
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission
        </article-title>
        <source>
         Sci China Life Sci
        </source>
        <person-group>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         457
        </fpage>
        <lpage>
         460
        </lpage>
        <volume>
         63
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32009228
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF4">
       <label>
        4
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2
        </article-title>
        <source>
         PLOS Pathog
        </source>
        <person-group>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Gui
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Xiang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
        </person-group>
        <fpage>
         0
        </fpage>
        <volume>
         14
        </volume>
        <year>
         2018
        </year>
       </element-citation>
      </ref>
      <ref id="REF5">
       <label>
        5
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Bats are natural reservoirs of SARS-like coronaviruses
        </article-title>
        <source>
         Science
        </source>
        <person-group>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         676
        </fpage>
        <lpage>
         679
        </lpage>
        <volume>
         310
        </volume>
        <year>
         2005
        </year>
        <pub-id pub-id-type="pmid">
         16195424
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF6">
       <label>
        6
       </label>
       <element-citation publication-type="journal">
        <article-title>
         A pneumonia outbreak associated with a new coronavirus of probable bat origin
        </article-title>
        <source>
         Nature
        </source>
        <person-group>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           X-L
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           X-G
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         270
        </fpage>
        <lpage>
         273
        </lpage>
        <volume>
         579
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32015507
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF7">
       <label>
        7
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Viral metagenomics revealed Sendai virus and coronavirus infection of Malayan pangolins (Manis javanica)
        </article-title>
        <source>
         Viruses
        </source>
        <person-group>
         <name>
          <surname>
           Liu
          </surname>
          <given-names>
           P
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           J-P
          </given-names>
         </name>
        </person-group>
        <fpage>
         979
        </fpage>
        <volume>
         11
        </volume>
        <year>
         2019
        </year>
       </element-citation>
      </ref>
      <ref id="REF8">
       <label>
        8
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak
        </article-title>
        <source>
         Curr Biol
        </source>
        <person-group>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           Q
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
        </person-group>
        <fpage>
         1
        </fpage>
        <lpage>
         6
        </lpage>
        <volume>
         30
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         31839447
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF9">
       <label>
        9
       </label>
       <element-citation publication-type="journal">
        <article-title>
         On the origin and continuing evolution of SARS-CoV-2
        </article-title>
        <source>
         Nat Sci Rev
        </source>
        <person-group>
         <name>
          <surname>
           Tang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         36
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF10">
       <label>
        10
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang, China
        </article-title>
        <source>
         medRxiv
        </source>
        <person-group>
         <name>
          <surname>
           Xu
          </surname>
          <given-names>
           l
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Song
          </surname>
          <given-names>
           W
          </given-names>
         </name>
         <name>
          <surname>
           Sun
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Mu
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           B
          </given-names>
         </name>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF11">
       <label>
        11
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient
        </article-title>
        <source>
         JAMA
        </source>
        <person-group>
         <name>
          <surname>
           Ong
          </surname>
          <given-names>
           SWX
          </given-names>
         </name>
         <name>
          <surname>
           Tan
          </surname>
          <given-names>
           YK
          </given-names>
         </name>
         <name>
          <surname>
           Chia
          </surname>
          <given-names>
           PY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF12">
       <label>
        12
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <person-group>
         <name>
          <surname>
           Kampf
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Todt
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Pfaender
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Steinmann
          </surname>
          <given-names>
           E
          </given-names>
         </name>
        </person-group>
        <fpage>
         246
        </fpage>
        <lpage>
         251
        </lpage>
        <volume>
         104
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32035997
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF13">
       <label>
        13
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination
        </article-title>
        <source>
         J Hosp Infect
        </source>
        <person-group>
         <name>
          <surname>
           Otter
          </surname>
          <given-names>
           JA
          </given-names>
         </name>
         <name>
          <surname>
           Donskey
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Yezli
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Douthwaite
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Goldenberg
          </surname>
          <given-names>
           SD
          </given-names>
         </name>
         <name>
          <surname>
           Weber
          </surname>
          <given-names>
           DJ
          </given-names>
         </name>
        </person-group>
        <fpage>
         235
        </fpage>
        <lpage>
         250
        </lpage>
        <volume>
         92
        </volume>
        <year>
         2016
        </year>
        <pub-id pub-id-type="pmid">
         26597631
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF14">
       <label>
        14
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1
        </article-title>
        <source>
         N Engl J Med
        </source>
        <person-group>
         <name>
          <surname>
           van Doremalen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Bushmaker
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Morris
          </surname>
          <given-names>
           DH
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF15">
       <label>
        15
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Understanding the symptoms of the common cold and influenza
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <person-group>
         <name>
          <surname>
           Eccles
          </surname>
          <given-names>
           R
          </given-names>
         </name>
        </person-group>
        <fpage>
         718
        </fpage>
        <lpage>
         725
        </lpage>
        <volume>
         5
        </volume>
        <year>
         2005
        </year>
        <pub-id pub-id-type="pmid">
         16253889
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF16">
       <label>
        16
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19)
        </article-title>
        <source>
         Disease
        </source>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <volume>
         2020
        </volume>
        <year>
         2020
        </year>
        <uri xlink:href="https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf">
         https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
        </uri>
       </element-citation>
      </ref>
      <ref id="REF17">
       <label>
        17
       </label>
       <element-citation publication-type="website">
        <article-title>
         Preliminary clinical description of severe acute respiratory syndrome
        </article-title>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2004
        </year>
        <uri xlink:href="https://www.who.int/csr/sars/clinical/en/">
         https://www.who.int/csr/sars/clinical/en/
        </uri>
       </element-citation>
      </ref>
      <ref id="REF18">
       <label>
        18
       </label>
       <element-citation publication-type="website">
        <article-title>
         MERS clinical features
        </article-title>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2019
        </year>
        <uri xlink:href="https://www.cdc.gov/coronavirus/mers/clinical-features.html">
         https://www.cdc.gov/coronavirus/mers/clinical-features.html
        </uri>
       </element-citation>
      </ref>
      <ref id="REF19">
       <label>
        19
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1)
        </article-title>
        <source>
         BMC Med
        </source>
        <person-group>
         <name>
          <surname>
           Coburn
          </surname>
          <given-names>
           BJ
          </given-names>
         </name>
         <name>
          <surname>
           Wagner
          </surname>
          <given-names>
           BG
          </given-names>
         </name>
         <name>
          <surname>
           Blower
          </surname>
          <given-names>
           S
          </given-names>
         </name>
        </person-group>
        <fpage>
         30
        </fpage>
        <volume>
         7
        </volume>
        <year>
         2009
        </year>
        <pub-id pub-id-type="pmid">
         19545404
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF20">
       <label>
        20
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Clinical characteristics of coronavirus disease 2019 in China
        </article-title>
        <source>
         N Engl J Med
        </source>
        <person-group>
         <name>
          <surname>
           Guan
          </surname>
          <given-names>
           W-j
          </given-names>
         </name>
         <name>
          <surname>
           Ni
          </surname>
          <given-names>
           Z-y
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF21">
       <label>
        21
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
        </article-title>
        <source>
         JAMA
        </source>
        <person-group>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         1061
        </fpage>
        <lpage>
         1069
        </lpage>
        <volume>
         323
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF22">
       <label>
        22
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet
        </source>
        <person-group>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         507
        </fpage>
        <lpage>
         513
        </lpage>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32007143
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF23">
       <label>
        23
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study
        </article-title>
        <source>
         Lancet Infect Dis
        </source>
        <person-group>
         <name>
          <surname>
           Shi
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Han
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Jiang
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         425
        </fpage>
        <lpage>
         434
        </lpage>
        <volume>
         20
        </volume>
        <year>
         2020
        </year>
        <uri xlink:href="https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30086-4/fulltext">
         https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30086-4/fulltext
        </uri>
        <pub-id pub-id-type="pmid">
         32105637
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF24">
       <label>
        24
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
        </article-title>
        <source>
         Lancet
        </source>
        <person-group>
         <name>
          <surname>
           Huang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Li
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         497
        </fpage>
        <lpage>
         506
        </lpage>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         31986264
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF25">
       <label>
        25
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
        </article-title>
        <source>
         Lancet
        </source>
        <person-group>
         <name>
          <surname>
           Zhou
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Yu
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Du
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         1054
        </fpage>
        <lpage>
         1062
        </lpage>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32171076
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF26">
       <label>
        26
       </label>
       <element-citation publication-type="website">
        <article-title>
         Novel coronavirus (COVID-19) situation
        </article-title>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2020
        </year>
        <uri xlink:href="https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd">
         https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd
        </uri>
       </element-citation>
      </ref>
      <ref id="REF27">
       <label>
        27
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China
        </article-title>
        <source>
         Nat Med
        </source>
        <person-group>
         <name>
          <surname>
           Wu
          </surname>
          <given-names>
           JT
          </given-names>
         </name>
         <name>
          <surname>
           Leung
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <name>
          <surname>
           Bushman
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF28">
       <label>
        28
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures
        </article-title>
        <source>
         Am J Epidemiol
        </source>
        <person-group>
         <name>
          <surname>
           Wallinga
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Teunis
          </surname>
          <given-names>
           P
          </given-names>
         </name>
        </person-group>
        <fpage>
         509
        </fpage>
        <lpage>
         516
        </lpage>
        <volume>
         160
        </volume>
        <year>
         2004
        </year>
        <pub-id pub-id-type="pmid">
         15353409
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF29">
       <label>
        29
       </label>
       <element-citation publication-type="journal">
        <article-title>
         The role of superspreading in Middle East respiratory syndrome coronavirus (MERS-CoV) transmission
        </article-title>
        <source>
         Euro Surveill
        </source>
        <person-group>
         <name>
          <surname>
           Kucharski
          </surname>
          <given-names>
           AJ
          </given-names>
         </name>
         <name>
          <surname>
           Althaus
          </surname>
          <given-names>
           CL
          </given-names>
         </name>
        </person-group>
        <fpage>
         21167
        </fpage>
        <volume>
         20
        </volume>
        <year>
         2015
        </year>
        <uri xlink:href="https://boris.unibe.ch/70121/7/Kucharski%20EuroSurveill%202015.pdf">
         https://boris.unibe.ch/70121/7/Kucharski%20EuroSurveill%202015.pdf
        </uri>
        <pub-id pub-id-type="pmid">
         26132768
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF30">
       <label>
        30
       </label>
       <element-citation publication-type="website">
        <article-title>
         Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)
        </article-title>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2020
        </year>
        <uri xlink:href="https://coronavirus.jhu.edu/map.html">
         https://coronavirus.jhu.edu/map.html
        </uri>
       </element-citation>
      </ref>
      <ref id="REF31">
       <label>
        31
       </label>
       <element-citation publication-type="website">
        <article-title>
         Clinical management of severe acute respiratory infection when COVID-19 is suspected: interim guidance
        </article-title>
        <source>
         Communications WDo 2020
        </source>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2020
        </year>
        <uri xlink:href="https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected">
         https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected
        </uri>
       </element-citation>
      </ref>
      <ref id="REF32">
       <label>
        32
       </label>
       <element-citation publication-type="website">
        <article-title>
         Evaluating and testing persons for coronavirus disease 2019 (COVID-19)
        </article-title>
        <source>
         Evaluating and Testing Persons for Coronavirus Disease
        </source>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2020
        </year>
        <uri xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html">
         https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
        </uri>
       </element-citation>
      </ref>
      <ref id="REF33">
       <label>
        33
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Correlation of chest CT and RT-PCR testing in Coronavirus Disease 2019 (COVID-19) in China: a report of 1014 cases
        </article-title>
        <source>
         Radiology
        </source>
        <person-group>
         <name>
          <surname>
           Ai
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <name>
          <surname>
           Yang
          </surname>
          <given-names>
           Z
          </given-names>
         </name>
         <name>
          <surname>
           Hou
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF34">
       <label>
        34
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records
        </article-title>
        <source>
         Lancet
        </source>
        <person-group>
         <name>
          <surname>
           Chen
          </surname>
          <given-names>
           H
          </given-names>
         </name>
         <name>
          <surname>
           Guo
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           C
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         809
        </fpage>
        <lpage>
         815
        </lpage>
        <volume>
         395
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32151335
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF35">
       <label>
        35
       </label>
       <element-citation publication-type="website">
        <article-title>
         Discharge criteria for confirmed COVID-19 cases - When is it safe to discharge COVID-19 cases from the hospital or end home isolation?
        </article-title>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2020
        </year>
        <uri xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-Discharge-criteria.pdf">
         https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-Discharge-criteria.pdf
        </uri>
       </element-citation>
      </ref>
      <ref id="REF36">
       <label>
        36
       </label>
       <element-citation publication-type="website">
        <article-title>
         Updated IPAC recommendations for use of personal protective equipment for care of individuals with suspect or confirmed COVID-19
        </article-title>
        <date-in-citation content-type="access-date">
         <month>
          3
         </month>
         <year>
          2020
         </year>
        </date-in-citation>
        <year>
         2020
        </year>
        <uri xlink:href="https://www.publichealthontario.ca/-/media/documents/ncov/updated-ipac-measures-covid-19.pdf?la=en">
         https://www.publichealthontario.ca/-/media/documents/ncov/updated-ipac-measures-covid-19.pdf?la=en
        </uri>
       </element-citation>
      </ref>
      <ref id="REF37">
       <label>
        37
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat
        </article-title>
        <source>
         PLoS ONE
        </source>
        <person-group>
         <name>
          <surname>
           da Silva
          </surname>
          <given-names>
           MR
          </given-names>
         </name>
         <name>
          <surname>
           Schapochnik
          </surname>
          <given-names>
           A
          </given-names>
         </name>
         <name>
          <surname>
           Leal
          </surname>
          <given-names>
           MP
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         205535
        </fpage>
        <volume>
         13
        </volume>
        <year>
         2018
        </year>
       </element-citation>
      </ref>
      <ref id="REF38">
       <label>
        38
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Neutrophil extracellular traps are elevated in patients with pneumonia-related acute respiratory distress syndrome
        </article-title>
        <source>
         Anesthesiology
        </source>
        <person-group>
         <name>
          <surname>
           Bendib
          </surname>
          <given-names>
           I
          </given-names>
         </name>
         <name>
          <surname>
           De Chaisemartin
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Granger
          </surname>
          <given-names>
           V
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         581
        </fpage>
        <lpage>
         591
        </lpage>
        <volume>
         130
        </volume>
        <year>
         2019
        </year>
        <pub-id pub-id-type="pmid">
         30676417
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF39">
       <label>
        39
       </label>
       <element-citation publication-type="journal">
        <article-title>
         The emerging role of vitamin C as a treatment for sepsis
        </article-title>
        <source>
         Nutrients
        </source>
        <person-group>
         <name>
          <surname>
           Kashiouris
          </surname>
          <given-names>
           MG
          </given-names>
         </name>
         <name>
          <surname>
           L'Heureux
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cable
          </surname>
          <given-names>
           CA
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         292
        </fpage>
        <volume>
         12
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF40">
       <label>
        40
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
        </article-title>
        <source>
         BMJ
        </source>
        <person-group>
         <name>
          <surname>
           Martineau
          </surname>
          <given-names>
           AR
          </given-names>
         </name>
         <name>
          <surname>
           Jolliffe
          </surname>
          <given-names>
           DA
          </given-names>
         </name>
         <name>
          <surname>
           Hooper
          </surname>
          <given-names>
           RL
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         0
        </fpage>
        <volume>
         356
        </volume>
        <year>
         2017
        </year>
       </element-citation>
      </ref>
      <ref id="REF41">
       <label>
        41
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
        </article-title>
        <source>
         Cell Res
        </source>
        <person-group>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           R
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         269
        </fpage>
        <lpage>
         271
        </lpage>
        <volume>
         30
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32020029
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF42">
       <label>
        42
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
        </article-title>
        <source>
         Thorax
        </source>
        <person-group>
         <name>
          <surname>
           Chu
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
         <name>
          <surname>
           Cheng
          </surname>
          <given-names>
           VCC
          </given-names>
         </name>
         <name>
          <surname>
           Hung
          </surname>
          <given-names>
           IFN
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         252
        </fpage>
        <lpage>
         256
        </lpage>
        <volume>
         59
        </volume>
        <year>
         2004
        </year>
        <pub-id pub-id-type="pmid">
         14985565
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF43">
       <label>
        43
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Discovering drugs to treat coronavirus disease 2019 (COVID-19)
        </article-title>
        <source>
         Drug Discov Ther
        </source>
        <person-group>
         <name>
          <surname>
           Dong
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Hu
          </surname>
          <given-names>
           S
          </given-names>
         </name>
         <name>
          <surname>
           Gao
          </surname>
          <given-names>
           J
          </given-names>
         </name>
        </person-group>
        <fpage>
         58
        </fpage>
        <lpage>
         60
        </lpage>
        <volume>
         14
        </volume>
        <year>
         2020
        </year>
        <pub-id pub-id-type="pmid">
         32147628
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF44">
       <label>
        44
       </label>
       <element-citation publication-type="journal">
        <article-title>
         A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19
        </article-title>
        <source>
         N Engl J Med
        </source>
        <person-group>
         <name>
          <surname>
           Cao
          </surname>
          <given-names>
           B
          </given-names>
         </name>
         <name>
          <surname>
           Wang
          </surname>
          <given-names>
           Y
          </given-names>
         </name>
         <name>
          <surname>
           Wen
          </surname>
          <given-names>
           D
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF45">
       <label>
        45
       </label>
       <element-citation publication-type="journal">
        <article-title>
         In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
        </article-title>
        <source>
         Clin Infect Dis
        </source>
        <person-group>
         <name>
          <surname>
           Yao
          </surname>
          <given-names>
           X
          </given-names>
         </name>
         <name>
          <surname>
           Ye
          </surname>
          <given-names>
           F
          </given-names>
         </name>
         <name>
          <surname>
           Zhang
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF46">
       <label>
        46
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors
        </article-title>
        <source>
         Hypertension
        </source>
        <person-group>
         <name>
          <surname>
           Ishiyama
          </surname>
          <given-names>
           EY
          </given-names>
         </name>
         <name>
          <surname>
           Gallagher
          </surname>
          <given-names>
           BP
          </given-names>
         </name>
         <name>
          <surname>
           Averill
          </surname>
          <given-names>
           AD
          </given-names>
         </name>
         <name>
          <surname>
           Tallant
          </surname>
          <given-names>
           EA
          </given-names>
         </name>
         <name>
          <surname>
           Brosnihan
          </surname>
          <given-names>
           KB
          </given-names>
         </name>
         <name>
          <surname>
           Ferrario
          </surname>
          <given-names>
           CM
          </given-names>
         </name>
        </person-group>
        <fpage>
         970
        </fpage>
        <lpage>
         976
        </lpage>
        <volume>
         43
        </volume>
        <year>
         2004
        </year>
        <pub-id pub-id-type="pmid">
         15007027
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF47">
       <label>
        47
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats
        </article-title>
        <source>
         J Cell Mol Med
        </source>
        <person-group>
         <name>
          <surname>
           Klimas
          </surname>
          <given-names>
           J
          </given-names>
         </name>
         <name>
          <surname>
           Olvedy
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Ochodnicka‐Mackovicova
          </surname>
          <given-names>
           K
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         1965
        </fpage>
        <lpage>
         1974
        </lpage>
        <volume>
         19
        </volume>
        <year>
         2015
        </year>
        <pub-id pub-id-type="pmid">
         25766467
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF48">
       <label>
        48
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Urinary angiotensin‐converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker
        </article-title>
        <source>
         Am J Hypertens
        </source>
        <person-group>
         <name>
          <surname>
           Furuhashi
          </surname>
          <given-names>
           M
          </given-names>
         </name>
         <name>
          <surname>
           Moniwa
          </surname>
          <given-names>
           N
          </given-names>
         </name>
         <name>
          <surname>
           Mita
          </surname>
          <given-names>
           T
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         15
        </fpage>
        <lpage>
         21
        </lpage>
        <volume>
         28
        </volume>
        <year>
         2015
        </year>
        <pub-id pub-id-type="pmid">
         24842388
        </pub-id>
       </element-citation>
      </ref>
      <ref id="REF49">
       <label>
        49
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
        </article-title>
        <source>
         Lancet Respir Med
        </source>
        <person-group>
         <name>
          <surname>
           Fang
          </surname>
          <given-names>
           L
          </given-names>
         </name>
         <name>
          <surname>
           Karakiulakis
          </surname>
          <given-names>
           G
          </given-names>
         </name>
         <name>
          <surname>
           Roth
          </surname>
          <given-names>
           M
          </given-names>
         </name>
        </person-group>
        <volume>
         [Published online ahead of print]
        </volume>
        <year>
         2020
        </year>
       </element-citation>
      </ref>
      <ref id="REF50">
       <label>
        50
       </label>
       <element-citation publication-type="journal">
        <article-title>
         Critically ill patients with the Middle East respiratory syndrome: a multicenter retrospective cohort study
        </article-title>
        <source>
         Crit Care Med
        </source>
        <person-group>
         <name>
          <surname>
           Arabi
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <name>
          <surname>
           Al-Omari
          </surname>
          <given-names>
           AA
          </given-names>
         </name>
         <name>
          <surname>
           Mandourah
          </surname>
          <given-names>
           MY
          </given-names>
         </name>
         <etal>
         </etal>
        </person-group>
        <fpage>
         1683
        </fpage>
        <lpage>
         1695
        </lpage>
        <volume>
         45
        </volume>
        <year>
         2017
        </year>
        <pub-id pub-id-type="pmid">
         28787295
        </pub-id>
       </element-citation>
      </ref>
     </ref-list>
    </back>
   </article>
  </pmc-articleset>
 </body>
</html>